comp_molregno,act_standard_units,act_standard_type,act_activity_comment,act_bao_endpoint,act_type,ass_assay_id,ass_description,ass_expert_selection,ass_assay_type,ass_assay_category,ass_chembl_id,doc_doi,doc_pubmed_id,doc_chembl_id,doc_title,doc_doc_type,doc_abstract,doc_patent_id,coms_canonical_smiles,comp_full_molformula,mold_chembl_id,act_0,act_1,act_2,act_3,act_4,act_5,act_6,act_7,act_8,act_9,act_10,act_11,act_12,act_13,act_14,act_15,act_16,act_17,act_18,act_19,act_20,act_21,act_22,act_23,act_24,act_25,act_26,act_27,act_28,act_29,act_30,act_31,act_32,act_33,act_34,act_35,act_36,act_37,act_38,act_39,act_40,act_41,act_42,act_43,act_44,act_45,act_46,act_47,act_48,act_49,act_50,act_51,act_52,act_53,act_54,act_std,act_min,act_mean,act_median,act_max,log_act_mean,log_act_median,log_act_min,pIC50_mean,pIC50_median,pIC50_min,meas_count,class_activity_mean_1000,class_activity_median_1000,class_activity_min_1000,class_activity_max_1000,class_activity_mean_2000,class_activity_median_2000,class_activity_min_2000,class_activity_max_2000,class_activity_mean_3000,class_activity_median_3000,class_activity_min_3000,class_activity_max_3000,class_activity_mean_4000,class_activity_median_4000,class_activity_min_4000,class_activity_max_4000,class_activity_mean_5000,class_activity_median_5000,class_activity_min_5000,class_activity_max_5000,act_mean_expert,act_median_expert,act_min_expert,act_max_expert,pIC50_expert_mean,pIC50_expert_median,pIC50_expert_min,pIC50_expert_max,class_activity_mean_expert_1000,class_activity_median_expert_1000,class_activity_min_expert_1000,class_activity_mean_expert_2000,class_activity_median_expert_2000,class_activity_min_expert_2000,class_activity_mean_expert_3000,class_activity_median_expert_3000,class_activity_min_expert_3000,class_activity_mean_expert_4000,class_activity_median_expert_4000,class_activity_min_expert_4000,class_activity_mean_expert_5000,class_activity_median_expert_5000,class_activity_min_expert_5000,source
716,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,C15H14F3NO2,CHEMBL6843,1.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,1.0,5.5,5.5,10.0,0.740362689,0.740362689,0.0,8.259637311,8.259637311,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.5,5.5,1.0,10.0,8.259637310505756,8.259637310505756,9.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
717,nM,IC50,325861.0,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, Entry 8: BAO_0000190, Entry 9: BAO_0000190, Entry 10: BAO_0000190, Entry 11: BAO_0000190, Entry 12: BAO_0000190, Entry 13: BAO_0000190, Entry 14: BAO_0000190, Entry 15: BAO_0000190, Entry 16: BAO_0000190, Entry 17: BAO_0000190, Entry 18: BAO_0000190, Entry 19: BAO_0000190, Entry 20: BAO_0000190, Entry 21: BAO_0000190, Entry 22: BAO_0000190, Entry 23: BAO_0000190, Entry 24: BAO_0000190, Entry 25: BAO_0000190, Entry 26: BAO_0000190, Entry 27: BAO_0000190, Entry 28: BAO_0000190, Entry 29: BAO_0000190, Entry 30: BAO_0000190, Entry 31: BAO_0000190, Entry 32: BAO_0000190, Entry 33: BAO_0000190, Entry 34: BAO_0000190, Entry 35: BAO_0000190, Entry 36: BAO_0000190, Entry 37: BAO_0000190, Entry 38: BAO_0000190, Entry 39: BAO_0000190, Entry 40: BAO_0000190, Entry 41: BAO_0000190, Entry 42: BAO_0000190, Entry 43: BAO_0000190, Entry 44: BAO_0000190, Entry 45: BAO_0000190, Entry 46: BAO_0000190, Entry 47: BAO_0000190, Entry 48: BAO_0000190, Entry 49: BAO_0000190, Entry 50: BAO_0000190, Entry 51: BAO_0000190, Entry 52: BAO_0000190, Entry 53: BAO_0000190, Entry 54: BAO_0000190, ",mix,"Entry 0: 36100, Entry 1: 36107, Entry 2: 36115, Entry 3: 36117, Entry 4: 36124, Entry 5: 305503, Entry 6: 312479, Entry 7: 312709, Entry 8: 312710, Entry 9: 312787, Entry 10: 312999, Entry 11: 317578, Entry 12: 327103, Entry 13: 312372, Entry 14: 432232, Entry 15: 432234, Entry 16: 438255, Entry 17: 449391, Entry 18: 449393, Entry 19: 464721, Entry 20: 467616, Entry 21: 467618, Entry 22: 479688, Entry 23: 629229, Entry 24: 643541, Entry 25: 643543, Entry 26: 629235, Entry 27: 663713, Entry 28: 687028, Entry 29: 687031, Entry 30: 796524, Entry 31: 796525, Entry 32: 796526, Entry 33: 805648, Entry 34: 805650, Entry 35: 805651, Entry 36: 796600, Entry 37: 796601, Entry 38: 933427, Entry 39: 944550, Entry 40: 944551, Entry 41: 944552, Entry 42: 944553, Entry 43: 966507, Entry 44: 993095, Entry 45: 993096, Entry 46: 1468250, Entry 47: 1468251, Entry 48: 1519755, Entry 49: 1640502, Entry 50: 1648028, Entry 51: 2101892, Entry 52: 2227402, Entry 53: 2227440, Entry 54: 2227483, ","Entry 0: Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell, Entry 1: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 2: In vitro agonistic activity against human androgen receptor (hAR) expressed in CV-1 cells; not active, Entry 3: In vitro binding affinity at human androgen receptor transfected into COS cells., Entry 4: Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells, Entry 5: Inhibition of androgen receptor in human MDA-453 cells, Entry 6: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 7: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 8: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 9: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 10: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, Entry 11: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, Entry 12: Inhibition of AR mediated transcriptional activation using reporter assay, Entry 13: In vitro antagonistic activity against androgen receptor of MDA-453 cells, Entry 14: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 15: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, Entry 16: Antagonist activity at human androgen receptor expressed in CV1 cells, Entry 17: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 18: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, Entry 19: Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay, Entry 20: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 21: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, Entry 22: Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay, Entry 23: Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, Entry 24: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 25: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, Entry 26: Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days, Entry 27: Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay, Entry 28: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 29: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, Entry 30: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 31: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 32: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 33: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 34: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 35: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 36: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 37: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 38: Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days, Entry 39: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 40: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 41: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 42: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, Entry 43: Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay, Entry 44: Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay, Entry 45: Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in human LNCAP cells assessed as inhibition of DHT-induced cell growth after 6 days by WST-8 assay, Entry 46: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 47: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, Entry 48: Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay, Entry 49: Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer., Entry 50: Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay, Entry 51: Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay, Entry 52: Binding affinity to Androgen receptor (unknown origin), Entry 53: Antagonist activity at Androgen receptor (unknown origin) in African green monkey COS-1 cells, Entry 54: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of Binding Function 3 (BF3) of AR measured by luciferase assay, ","0,1,2,3,4,5,7,12,13,16,22,24,25,43,","Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: B, Entry 4: F, Entry 5: B, Entry 6: F, Entry 7: F, Entry 8: F, Entry 9: F, Entry 10: F, Entry 11: B, Entry 12: F, Entry 13: F, Entry 14: B, Entry 15: F, Entry 16: F, Entry 17: B, Entry 18: F, Entry 19: F, Entry 20: F, Entry 21: B, Entry 22: F, Entry 23: B, Entry 24: F, Entry 25: F, Entry 26: F, Entry 27: F, Entry 28: F, Entry 29: F, Entry 30: B, Entry 31: B, Entry 32: F, Entry 33: B, Entry 34: F, Entry 35: F, Entry 36: F, Entry 37: F, Entry 38: B, Entry 39: B, Entry 40: B, Entry 41: B, Entry 42: B, Entry 43: B, Entry 44: B, Entry 45: B, Entry 46: B, Entry 47: B, Entry 48: B, Entry 49: B, Entry 50: B, Entry 51: B, Entry 52: B, Entry 53: B, Entry 54: B, ",,"Entry 0: CHEMBL884023, Entry 1: CHEMBL648072, Entry 2: CHEMBL648080, Entry 3: CHEMBL648082, Entry 4: CHEMBL649556, Entry 5: CHEMBL831105, Entry 6: CHEMBL833228, Entry 7: CHEMBL837992, Entry 8: CHEMBL837993, Entry 9: CHEMBL833436, Entry 10: CHEMBL873340, Entry 11: CHEMBL877304, Entry 12: CHEMBL863517, Entry 13: CHEMBL836730, Entry 14: CHEMBL914604, Entry 15: CHEMBL914606, Entry 16: CHEMBL887361, Entry 17: CHEMBL899659, Entry 18: CHEMBL899661, Entry 19: CHEMBL933064, Entry 20: CHEMBL930491, Entry 21: CHEMBL930493, Entry 22: CHEMBL933552, Entry 23: CHEMBL1121343, Entry 24: CHEMBL1212405, Entry 25: CHEMBL1212407, Entry 26: CHEMBL1121349, Entry 27: CHEMBL1250613, Entry 28: CHEMBL1291499, Entry 29: CHEMBL1291551, Entry 30: CHEMBL1937839, Entry 31: CHEMBL1937840, Entry 32: CHEMBL1937841, Entry 33: CHEMBL1960482, Entry 34: CHEMBL1960484, Entry 35: CHEMBL1960485, Entry 36: CHEMBL1937915, Entry 37: CHEMBL1937916, Entry 38: CHEMBL2318839, Entry 39: CHEMBL2339066, Entry 40: CHEMBL2339067, Entry 41: CHEMBL2339068, Entry 42: CHEMBL2339069, Entry 43: CHEMBL2399205, Entry 44: CHEMBL2446445, Entry 45: CHEMBL2446446, Entry 46: CHEMBL3411793, Entry 47: CHEMBL3411794, Entry 48: CHEMBL3624234, Entry 49: CHEMBL3887225, Entry 50: CHEMBL3997084, Entry 51: CHEMBL4810288, Entry 52: CHEMBL5140915, Entry 53: CHEMBL5140953, Entry 54: CHEMBL5140996, ","Entry 0: 10.1016/s0960-894x(98)00107-3, Entry 1: 10.1021/jm970699s, Entry 2: 10.1016/s0960-894x(99)00118-3, Entry 3: 10.1016/s0960-894x(99)00118-3, Entry 4: 10.1016/s0960-894x(00)00010-x, Entry 5: 10.1016/j.bmcl.2004.10.085, Entry 6: 10.1016/j.bmcl.2004.09.049, Entry 7: 10.1016/j.bmcl.2004.10.051, Entry 8: 10.1016/j.bmcl.2004.10.051, Entry 9: 10.1016/j.bmcl.2004.10.085, Entry 10: 10.1016/j.bmcl.2004.10.051, Entry 11: 10.1016/j.bmcl.2004.10.085, Entry 12: 10.1021/jm050293c, Entry 13: 10.1016/j.bmcl.2004.09.049, Entry 14: 10.1016/j.bmc.2006.09.072, Entry 15: 10.1016/j.bmc.2006.09.072, Entry 16: 10.1016/j.bmcl.2007.01.007, Entry 17: 10.1016/j.bmcl.2007.07.090, Entry 18: 10.1016/j.bmcl.2007.07.090, Entry 19: 10.1016/j.bmcl.2008.02.006, Entry 20: 10.1016/j.bmcl.2008.03.085, Entry 21: 10.1016/j.bmcl.2008.03.085, Entry 22: 10.1016/j.bmcl.2008.03.062, Entry 23: 10.1016/j.bmc.2010.03.036, Entry 24: 10.1016/j.bmcl.2010.06.034, Entry 25: 10.1016/j.bmcl.2010.06.034, Entry 26: 10.1016/j.bmc.2010.03.036, Entry 27: 10.1016/j.bmc.2010.08.029, Entry 28: 10.1016/j.bmc.2010.10.023, Entry 29: 10.1016/j.bmc.2010.10.023, Entry 30: 10.1016/j.bmc.2011.10.067, Entry 31: 10.1016/j.bmc.2011.10.067, Entry 32: 10.1016/j.bmc.2011.10.067, Entry 33: 10.1016/j.bmc.2012.02.005, Entry 34: 10.1016/j.bmc.2012.02.005, Entry 35: 10.1016/j.bmc.2012.02.005, Entry 36: 10.1016/j.bmc.2011.10.067, Entry 37: 10.1016/j.bmc.2011.10.067, Entry 38: 10.1021/jm3015712, Entry 39: 10.1016/j.bmc.2012.11.001, Entry 40: 10.1016/j.bmc.2012.11.001, Entry 41: 10.1016/j.bmc.2012.11.001, Entry 42: 10.1016/j.bmc.2012.11.001, Entry 43: 10.1016/j.bmcl.2013.04.065, Entry 44: 10.1021/ml4001744, Entry 45: 10.1021/ml4001744, Entry 46: 10.1021/jm501995n, Entry 47: 10.1021/jm501995n, Entry 48: 10.1021/acsmedchemlett.5b00173, Entry 49: 10.1016/j.bmcl.2017.01.065, Entry 50: 10.1021/acs.jmedchem.1c00439, Entry 51: 10.1021/acs.jmedchem.2c00716, Entry 52: 10.1021/acs.jmedchem.2c00716, Entry 53: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 9871534, Entry 1: 9484511, Entry 2: 10230628, Entry 3: 10230628, Entry 4: 10743937, Entry 5: 15603938, Entry 6: 15546739, Entry 7: 15603960, Entry 8: 15603960, Entry 9: 15603938, Entry 10: 15603960, Entry 11: 15603938, Entry 12: 16420057, Entry 13: 15546739, Entry 14: 17064916, Entry 15: 17064916, Entry 16: 17257838, Entry 17: 17804229, Entry 18: 17804229, Entry 19: 18291644, Entry 20: 18442912, Entry 21: 18442912, Entry 22: 18400499, Entry 23: 20381361, Entry 24: 20584610, Entry 25: 20584610, Entry 26: 20381361, Entry 27: 20826091, Entry 28: 21050768, Entry 29: 21050768, Entry 30: 22094279, Entry 31: 22094279, Entry 32: 22094279, Entry 33: 22391033, Entry 34: 22391033, Entry 35: 22391033, Entry 36: 22094279, Entry 37: 22094279, Entry 38: 23301637, Entry 39: 23199477, Entry 40: 23199477, Entry 41: 23199477, Entry 42: 23199477, Entry 43: 23727044, Entry 44: 24900588, Entry 45: 24900588, Entry 46: 25646649, Entry 47: 25646649, Entry 48: 26288692, Entry 49: 28162857, Entry 50: 34269581, Entry 51: 35786895, Entry 52: 35786895, Entry 53: 35786895, ","Entry 0: CHEMBL1130772, Entry 1: CHEMBL1131477, Entry 2: CHEMBL1132082, Entry 3: CHEMBL1132082, Entry 4: CHEMBL1133046, Entry 5: CHEMBL1142826, Entry 6: CHEMBL1138730, Entry 7: CHEMBL1144249, Entry 8: CHEMBL1144249, Entry 9: CHEMBL1142826, Entry 10: CHEMBL1144249, Entry 11: CHEMBL1142826, Entry 12: CHEMBL1147729, Entry 13: CHEMBL1138730, Entry 14: CHEMBL1144524, Entry 15: CHEMBL1144524, Entry 16: CHEMBL1144605, Entry 17: CHEMBL1137463, Entry 18: CHEMBL1137463, Entry 19: CHEMBL1142249, Entry 20: CHEMBL1143080, Entry 21: CHEMBL1143080, Entry 22: CHEMBL1145608, Entry 23: CHEMBL1158555, Entry 24: CHEMBL1208719, Entry 25: CHEMBL1208719, Entry 26: CHEMBL1158555, Entry 27: CHEMBL1250541, Entry 28: CHEMBL1287756, Entry 29: CHEMBL1287756, Entry 30: CHEMBL1932924, Entry 31: CHEMBL1932924, Entry 32: CHEMBL1932924, Entry 33: CHEMBL1955860, Entry 34: CHEMBL1955860, Entry 35: CHEMBL1955860, Entry 36: CHEMBL1932924, Entry 37: CHEMBL1932924, Entry 38: CHEMBL2311268, Entry 39: CHEMBL2331321, Entry 40: CHEMBL2331321, Entry 41: CHEMBL2331321, Entry 42: CHEMBL2331321, Entry 43: CHEMBL2396586, Entry 44: CHEMBL2439974, Entry 45: CHEMBL2439974, Entry 46: CHEMBL3407333, Entry 47: CHEMBL3407333, Entry 48: CHEMBL3621143, Entry 49: CHEMBL3886221, Entry 50: CHEMBL3994642, Entry 51: CHEMBL4808211, Entry 52: CHEMBL5137058, Entry 53: CHEMBL5137058, Entry 54: CHEMBL5137058, ","Entry 0: New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone., Entry 1: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 2: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 3: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 4: Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines., Entry 5: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 6: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 7: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 8: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 9: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 10: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 11: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 12: (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist., Entry 13: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 14: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 15: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 16: Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones., Entry 17: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 18: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 19: Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists., Entry 20: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 21: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 22: Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity., Entry 23: Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Entry 24: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 25: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 26: Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Entry 27: 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth., Entry 28: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 29: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 30: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 31: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 32: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 33: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 34: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 35: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 36: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 37: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 38: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., Entry 39: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 40: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 41: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 42: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 43: Discovery of non-LBD inhibitor for androgen receptor by structure-guide design., Entry 44: Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists., Entry 45: Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists., Entry 46: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 47: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 48: Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer., Entry 49: Treatment of hyperproliferative disorders with diarylhydantoin compounds, Entry 50: Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents., Entry 51: Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer., Entry 52: Therapeutic Strategies to Target the Androgen Receptor., Entry 53: Therapeutic Strategies to Target the Androgen Receptor., Entry 54: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, Entry 8: PUBLICATION, Entry 9: PUBLICATION, Entry 10: PUBLICATION, Entry 11: PUBLICATION, Entry 12: PUBLICATION, Entry 13: PUBLICATION, Entry 14: PUBLICATION, Entry 15: PUBLICATION, Entry 16: PUBLICATION, Entry 17: PUBLICATION, Entry 18: PUBLICATION, Entry 19: PUBLICATION, Entry 20: PUBLICATION, Entry 21: PUBLICATION, Entry 22: PUBLICATION, Entry 23: PUBLICATION, Entry 24: PUBLICATION, Entry 25: PUBLICATION, Entry 26: PUBLICATION, Entry 27: PUBLICATION, Entry 28: PUBLICATION, Entry 29: PUBLICATION, Entry 30: PUBLICATION, Entry 31: PUBLICATION, Entry 32: PUBLICATION, Entry 33: PUBLICATION, Entry 34: PUBLICATION, Entry 35: PUBLICATION, Entry 36: PUBLICATION, Entry 37: PUBLICATION, Entry 38: PUBLICATION, Entry 39: PUBLICATION, Entry 40: PUBLICATION, Entry 41: PUBLICATION, Entry 42: PUBLICATION, Entry 43: PUBLICATION, Entry 44: PUBLICATION, Entry 45: PUBLICATION, Entry 46: PUBLICATION, Entry 47: PUBLICATION, Entry 48: PUBLICATION, Entry 49: PATENT, Entry 50: PUBLICATION, Entry 51: PUBLICATION, Entry 52: PUBLICATION, Entry 53: PUBLICATION, Entry 54: PUBLICATION, ",,US-9126941-B2,CC(O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C18H14F4N2O4S,CHEMBL409,10.0,54.0,54.0,54.0,86.9,86.9,117.0,120.0,120.0,120.23,140.0,140.0,157.0,157.0,162.0,162.0,162.0,170.0,173.0,173.0,173.0,173.0,173.0,200.0,200.0,200.0,200.0,232.0,248.0,270.0,270.0,300.0,330.0,330.0,330.0,338.0,400.0,400.0,400.0,400.0,470.0,470.0,470.0,550.0,600.0,725.0,725.0,889.0,890.0,940.0,1300.0,4600.0,10000.0,44260.0,100000.0,14480.47941,10.0,3179.546,232.0,100000.0,3.502365113,2.365487985,1.0,5.497634887,6.634512015,8.0,55,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,147.4857142857143,138.5,10.0,550.0,6.8312500441424255,6.858550226599533,8.0,6.259637310505756,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
790,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,C15H14F3NO2,CHEMBL266473,1.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,1.0,5.5,5.5,10.0,0.740362689,0.740362689,0.0,8.259637311,8.259637311,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.5,5.5,1.0,10.0,8.259637310505756,8.259637310505756,9.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
791,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CC1(C)CCc2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,C15H14F3NO2,CHEMBL7289,1.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,1.0,5.5,5.5,10.0,0.740362689,0.740362689,0.0,8.259637311,8.259637311,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.5,5.5,1.0,10.0,8.259637310505756,8.259637310505756,9.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
799,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3,C13H10F3NO2,CHEMBL268098,1.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,1.0,5.5,5.5,10.0,0.740362689,0.740362689,0.0,8.259637311,8.259637311,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.5,5.5,1.0,10.0,8.259637310505756,8.259637310505756,9.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
809,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3C(F)(F)F,C14H9F6NO2,CHEMBL267270,2.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,2.0,6.0,6.0,10.0,0.77815125,0.77815125,0.301029996,8.22184875,8.22184875,8.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,6.0,6.0,2.0,10.0,8.221848749616356,8.221848749616356,8.698970004336019,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
819,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,O=c1cc(C(F)(F)F)c2cc3c(cc2o1)NCCC3C(F)(F)C(F)(F)F,C15H9F8NO2,CHEMBL266928,5.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.5,5.0,7.5,7.5,10.0,0.875061263,0.875061263,0.698970004,8.124938737,8.124938737,8.301029996,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.5,7.5,5.0,10.0,8.1249387366083,8.1249387366083,8.301029995663981,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
824,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1CCN(C)c2cc3oc(=O)cc(C(F)(F)F)c3cc21,C16H16F3NO2,CHEMBL6530,10.0,276.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,133.0,10.0,143.0,143.0,276.0,2.155336037,2.155336037,1.0,6.844663963,6.844663963,8.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,143.0,143.0,10.0,276.0,6.844663962534939,6.844663962534939,8.0,6.559090917934783,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
828,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCCC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,C16H16F3NO2,CHEMBL6855,5.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.5,5.0,7.5,7.5,10.0,0.875061263,0.875061263,0.698970004,8.124938737,8.124938737,8.301029996,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.5,7.5,5.0,10.0,8.1249387366083,8.1249387366083,8.301029995663981,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
864,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1Nc2cc3oc(=O)cc(C(F)(F)F)c3cc2CC1C,C16H16F3NO2,CHEMBL6654,7.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5,7.0,8.5,8.5,10.0,0.929418926,0.929418926,0.84509804,8.070581074,8.070581074,8.15490196,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,8.5,8.5,7.0,10.0,8.070581074285707,8.070581074285707,8.154901959985743,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1029,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1CC(C)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,C16H16F3NO2,CHEMBL269305,10.0,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.5,10.0,10.5,10.5,11.0,1.021189299,1.021189299,1.0,7.978810701,7.978810701,8.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.5,10.5,10.0,11.0,7.978810700930062,7.978810700930062,8.0,7.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1030,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CC1CCNc2cc3oc(=O)cc(C(F)(F)F)c3cc21,C14H12F3NO2,CHEMBL415289,1.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,1.0,5.5,5.5,10.0,0.740362689,0.740362689,0.0,8.259637311,8.259637311,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.5,5.5,1.0,10.0,8.259637310505756,8.259637310505756,9.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1061,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CCC1CC(CC)c2cc3c(C(F)(F)F)cc(=O)oc3cc2N1,C17H18F3NO2,CHEMBL6721,7.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.5,7.0,8.5,8.5,10.0,0.929418926,0.929418926,0.84509804,8.070581074,8.070581074,8.15490196,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,8.5,8.5,7.0,10.0,8.070581074285707,8.070581074285707,8.154901959985743,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1347,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(CC)CC,C19H23F3N2O,CHEMBL267471,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,48.0,48.0,48.0,48.0,1.681241237,1.681241237,1.681241237,7.318758763,7.318758763,7.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1348,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,C17H19F3N2O,CHEMBL7421,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1385,nM,IC50,,BAO_0000190,IC50,36104,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cells; no data,0,F,,CHEMBL648069,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1C[C@@H](C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H17F3N2O,CHEMBL427957,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1446,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CCC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,C18H21F3N2O,CHEMBL7231,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1462,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,C15H15F3N2O,CHEMBL7058,74.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,74.0,74.0,74.0,74.0,1.86923172,1.86923172,1.86923172,7.13076828,7.13076828,7.13076828,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,74.0,74.0,74.0,74.0,7.130768280269024,7.130768280269024,7.130768280269024,7.130768280269024,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1479,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,C16H17F3N2O,CHEMBL266269,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1480,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,C16H17F3N2O,CHEMBL7053,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1490,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC(C)[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C16H17F3N2O,CHEMBL267850,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25.0,25.0,25.0,25.0,1.397940009,1.397940009,1.397940009,7.602059991,7.602059991,7.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,25.0,25.0,25.0,25.0,7.6020599913279625,7.6020599913279625,7.6020599913279625,7.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1497,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,C[C@@H]1C[C@H](C)c2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C15H15F3N2O,CHEMBL268326,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,15.0,15.0,15.0,15.0,1.176091259,1.176091259,1.176091259,7.823908741,7.823908741,7.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,15.0,15.0,15.0,15.0,7.823908740944319,7.823908740944319,7.823908740944319,7.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1500,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,C16H17F3N2O,CHEMBL267907,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,24.0,24.0,24.0,24.0,1.380211242,1.380211242,1.380211242,7.619788758,7.619788758,7.619788758,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,24.0,24.0,24.0,24.0,7.619788758288394,7.619788758288394,7.619788758288394,7.619788758288394,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1501,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@H]1C,C16H17F3N2O,CHEMBL7089,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,15.0,15.0,15.0,15.0,1.176091259,1.176091259,1.176091259,7.823908741,7.823908741,7.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,15.0,15.0,15.0,15.0,7.823908740944319,7.823908740944319,7.823908740944319,7.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1512,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2CC1(C)C,C17H19F3N2O,CHEMBL6689,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.0,42.0,42.0,42.0,1.62324929,1.62324929,1.62324929,7.37675071,7.37675071,7.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.0,42.0,42.0,42.0,7.376750709602099,7.376750709602099,7.376750709602099,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1531,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CCC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C16H17F3N2O,CHEMBL268569,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32.0,32.0,32.0,32.0,1.505149978,1.505149978,1.505149978,7.494850022,7.494850022,7.494850022,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,C[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C14H13F3N2O,CHEMBL267141,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1564,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,C15H10O5,CHEMBL28,5200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5200.0,5200.0,5200.0,5200.0,3.716003344,3.716003344,3.716003344,5.283996656,5.283996656,5.283996656,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5200.0,5200.0,5200.0,5200.0,5.2839966563652006,5.2839966563652006,5.2839966563652006,5.2839966563652006,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1572,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 36103, Entry 1: 36107, Entry 2: 36124, Entry 3: 1869960, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines, Entry 1: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 2: Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells, Entry 3: Inhibition of human androgen receptor, ","0,1,2,3","Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: B, ",,"Entry 0: CHEMBL648068, Entry 1: CHEMBL648072, Entry 2: CHEMBL649556, Entry 3: CHEMBL4371127, ","Entry 0: 10.1016/s0960-894x(99)00119-5, Entry 1: 10.1021/jm970699s, Entry 2: 10.1016/s0960-894x(00)00010-x, Entry 3: 10.1021/acs.jmedchem.7b01788, ","Entry 0: 10230629, Entry 1: 9484511, Entry 2: 10743937, Entry 3: 29400967, ","Entry 0: CHEMBL1132083, Entry 1: CHEMBL1131477, Entry 2: CHEMBL1133046, Entry 3: CHEMBL4371002, ","Entry 0: Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone., Entry 1: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 2: Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines., Entry 3: Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay., Entry 1: A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases., Entry 2: A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background., Entry 3: The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the methyl group while also acting as a functional mimetic of the carbonyl, carbinol, and nitrile moieties. In this context, fluorine substitution can influence the potency, conformation, metabolism, membrane permeability, and P-gp recognition of a molecule and temper inhibition of the hERG channel by basic amines. However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated molecular construction that broadens biological mimesis. In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a molecule are summarized., ",,CC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C15H15F3N2O,CHEMBL6874,27.0,27.0,27.0,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1575,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1CC,C17H19F3N2O,CHEMBL6959,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1587,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@@H]1CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C15H15F3N2O,CHEMBL7177,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11.0,11.0,11.0,11.0,1.041392685,1.041392685,1.041392685,7.958607315,7.958607315,7.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,11.0,11.0,11.0,11.0,7.958607314841775,7.958607314841775,7.958607314841775,7.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1589,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,C[C@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N[C@@H]1C,C15H15F3N2O,CHEMBL6983,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,33.0,33.0,33.0,33.0,1.51851394,1.51851394,1.51851394,7.48148606,7.48148606,7.48148606,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,33.0,33.0,33.0,33.0,7.481486060122113,7.481486060122113,7.481486060122113,7.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1668,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C[C@@H]1C,C16H17F3N2O,CHEMBL7455,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11.0,11.0,11.0,11.0,1.041392685,1.041392685,1.041392685,7.958607315,7.958607315,7.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,11.0,11.0,11.0,11.0,7.958607314841775,7.958607314841775,7.958607314841775,7.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1704,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@@H]1C[C@H](C)c2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C16H17F3N2O,CHEMBL7373,137.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,137.0,137.0,137.0,137.0,2.136720567,2.136720567,2.136720567,6.863279433,6.863279433,6.863279433,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,137.0,137.0,137.0,137.0,6.863279432843593,6.863279432843593,6.863279432843593,6.863279432843593,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1705,nM,IC50,,BAO_0000190,IC50,36104,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cells; no data,0,F,,CHEMBL648069,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC[C@@H]1C[C@H](CC)c2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C17H19F3N2O,CHEMBL7383,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2658,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=c1c(-c2ccc(O)cc2)coc2cc(O)cc(O)c12,C15H10O5,CHEMBL44,1300000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1300000.0,1300000.0,1300000.0,1300000.0,6.113943352,6.113943352,6.113943352,2.886056648,2.886056648,2.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,1300000.0,1300000.0,1300000.0,1300000.0,2.886056647693163,2.886056647693163,2.886056647693163,2.886056647693163,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
3784,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 791027, Entry 1: 791030, Entry 2: 791031, ","Entry 0: Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis, Entry 1: Displacement of [3H]DHT from human androgen receptor expressed in Escherichia coli BL21 cells, Entry 2: Displacement of 5-iodoacetamidofluorescein labeled SRC23 peptide CKENALLRYLLDKDD human androgen receptor AF2 site expressed in Escherichia coli BL21 cells by fluorescence polarization assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL1925688, Entry 1: CHEMBL1925691, Entry 2: CHEMBL1925692, ","Entry 0: 10.1021/jm201098n, Entry 1: 10.1021/jm201098n, Entry 2: 10.1021/jm201098n, ","Entry 0: 22047606, Entry 1: 22047606, Entry 2: 22047606, ","Entry 0: CHEMBL1921777, Entry 1: CHEMBL1921777, Entry 2: CHEMBL1921777, ","Entry 0: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 1: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 2: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 1: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 2: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., ",,CC(Cc1ccc(O)c(O)c1)C(C)Cc1ccc(O)c(O)c1,C18H22O4,CHEMBL52,10000.0,38800.0,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16848.60693,10000.0,32933.33333,38800.0,50000.0,4.51763569,4.588831726,4.0,4.48236431,4.411168274,5.0,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
5155,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, Entry 2: 501560, Entry 3: 501561, Entry 4: 538003, Entry 5: 538004, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, Entry 2: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 3: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, Entry 4: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 5: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, Entry 4: B, Entry 5: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, Entry 2: CHEMBL987689, Entry 3: CHEMBL987690, Entry 4: CHEMBL1032459, Entry 5: CHEMBL1032460, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, Entry 2: 10.1016/j.bmcl.2009.02.104, Entry 3: 10.1016/j.bmcl.2009.02.104, Entry 4: 10.1021/jm8009316, Entry 5: 10.1021/jm8009316, ","Entry 0: 17766112, Entry 1: 17766112, Entry 2: 19286380, Entry 3: 19286380, Entry 4: 18921992, Entry 5: 18921992, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, Entry 2: CHEMBL1153981, Entry 3: CHEMBL1153981, Entry 4: CHEMBL1142535, Entry 5: CHEMBL1142535, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 2: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 4: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 5: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 2: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 3: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 4: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 5: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=O)N1CCCCO,C17H18F3N3O3,CHEMBL9337,15.9,16.0,16.0,31.1,32.0,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.625082972,15.9,25.16666667,23.55,40.0,1.400825697,1.371990911,1.201397124,7.599174303,7.628009089,7.798602876,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
6284,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=C1CC(c2ccccc2)Oc2ccccc21,C15H12O2,CHEMBL274318,20000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20000.0,20000.0,20000.0,20000.0,4.301029996,4.301029996,4.301029996,4.698970004,4.698970004,4.698970004,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,20000.0,20000.0,20000.0,20000.0,4.698970004336019,4.698970004336019,4.698970004336019,4.698970004336019,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
6787,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, Entry 8: BAO_0000190, Entry 9: BAO_0000190, Entry 10: BAO_0000190, Entry 11: BAO_0000190, Entry 12: BAO_0000190, Entry 13: BAO_0000190, Entry 14: BAO_0000190, Entry 15: BAO_0000190, Entry 16: BAO_0000190, Entry 17: BAO_0000190, ",mix,"Entry 0: 36107, Entry 1: 36124, Entry 2: 305503, Entry 3: 312709, Entry 4: 432232, Entry 5: 432234, Entry 6: 449391, Entry 7: 449393, Entry 8: 464721, Entry 9: 487550, Entry 10: 513497, Entry 11: 620577, Entry 12: 854887, Entry 13: 942995, Entry 14: 993098, Entry 15: 1520318, Entry 16: 1520320, Entry 17: 1989103, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 1: Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells, Entry 2: Inhibition of androgen receptor in human MDA-453 cells, Entry 3: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 4: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 5: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, Entry 6: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 7: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, Entry 8: Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay, Entry 9: Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method, Entry 10: Antagonist activity at human androgen receptor expressed in mouse NIH3T3 cells assessed as inhibition of DHT-induced transcriptional activation after 24 hrs by androgen response element-mediated luciferase reporter gene assay, Entry 11: Antagonist activity at androgen receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay, Entry 12: Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay, Entry 13: Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay, Entry 14: Displacement of [3H]-DHT from human GST-tagged androgen receptor LBD (627 to 919) expressed in Escherichia coli HB-101 after 15 hrs by liquid scintillation counting analysis, Entry 15: Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay, Entry 16: Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay, Entry 17: Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay, ","0,1,2,3,11,","Entry 0: F, Entry 1: F, Entry 2: B, Entry 3: F, Entry 4: B, Entry 5: F, Entry 6: B, Entry 7: F, Entry 8: F, Entry 9: F, Entry 10: F, Entry 11: B, Entry 12: B, Entry 13: B, Entry 14: B, Entry 15: B, Entry 16: B, Entry 17: B, ",,"Entry 0: CHEMBL648072, Entry 1: CHEMBL649556, Entry 2: CHEMBL831105, Entry 3: CHEMBL837992, Entry 4: CHEMBL914604, Entry 5: CHEMBL914606, Entry 6: CHEMBL899659, Entry 7: CHEMBL899661, Entry 8: CHEMBL933064, Entry 9: CHEMBL1013144, Entry 10: CHEMBL975403, Entry 11: CHEMBL1111210, Entry 12: CHEMBL2162624, Entry 13: CHEMBL2343831, Entry 14: CHEMBL2446673, Entry 15: CHEMBL3626368, Entry 16: CHEMBL3626370, Entry 17: CHEMBL4622650, ","Entry 0: 10.1021/jm970699s, Entry 1: 10.1016/s0960-894x(00)00010-x, Entry 2: 10.1016/j.bmcl.2004.10.085, Entry 3: 10.1016/j.bmcl.2004.10.051, Entry 4: 10.1016/j.bmc.2006.09.072, Entry 5: 10.1016/j.bmc.2006.09.072, Entry 6: 10.1016/j.bmcl.2007.07.090, Entry 7: 10.1016/j.bmcl.2007.07.090, Entry 8: 10.1016/j.bmcl.2008.02.006, Entry 9: 10.1016/j.bmc.2008.05.063, Entry 10: 10.1016/j.bmc.2008.07.055, Entry 11: 10.1021/np9004882, Entry 12: 10.1021/jm300233k, Entry 13: 10.1016/j.bmc.2013.01.060, Entry 14: 10.1021/ml4001744, Entry 15: 10.1016/j.ejmech.2015.08.002, Entry 16: 10.1016/j.ejmech.2015.08.002, Entry 17: 10.1021/acs.jmedchem.0c00939, ","Entry 0: 9484511, Entry 1: 10743937, Entry 2: 15603938, Entry 3: 15603960, Entry 4: 17064916, Entry 5: 17064916, Entry 6: 17804229, Entry 7: 17804229, Entry 8: 18291644, Entry 9: 18571420, Entry 10: 18707892, Entry 11: 19863083, Entry 12: 22746350, Entry 13: 23462715, Entry 14: 24900588, Entry 15: 26295173, Entry 16: 26295173, Entry 17: 32847363, ","Entry 0: CHEMBL1131477, Entry 1: CHEMBL1133046, Entry 2: CHEMBL1142826, Entry 3: CHEMBL1144249, Entry 4: CHEMBL1144524, Entry 5: CHEMBL1144524, Entry 6: CHEMBL1137463, Entry 7: CHEMBL1137463, Entry 8: CHEMBL1142249, Entry 9: CHEMBL1155056, Entry 10: CHEMBL1140043, Entry 11: CHEMBL1154793, Entry 12: CHEMBL2157978, Entry 13: CHEMBL2331115, Entry 14: CHEMBL2439974, Entry 15: CHEMBL3621051, Entry 16: CHEMBL3621051, Entry 17: CHEMBL4619820, ","Entry 0: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 1: Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 3: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 4: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 5: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 6: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 7: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 8: Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists., Entry 9: 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor., Entry 10: Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring., Entry 11: The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144., Entry 12: Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators., Entry 13: Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange., Entry 14: Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists., Entry 15: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., Entry 16: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., Entry 17: Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, Entry 8: PUBLICATION, Entry 9: PUBLICATION, Entry 10: PUBLICATION, Entry 11: PUBLICATION, Entry 12: PUBLICATION, Entry 13: PUBLICATION, Entry 14: PUBLICATION, Entry 15: PUBLICATION, Entry 16: PUBLICATION, Entry 17: PUBLICATION, ","Entry 0: A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases., Entry 1: A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 3: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 4: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 5: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 6: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 7: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 8: A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model., Entry 9: Various 4-(anilino)pyrrole-2-carboxamides were designed and synthesized as novel androgen receptor (AR) antagonists without steroidal or anilide structure, based on our strategy for developing full antagonists of nuclear receptors. Introduction of a bulky N-alkyl group, such as a cyclohexylmethyl or benzyl group, increased the binding affinity for wild-type AR and the potency for growth inhibition of androgen-dependent SC-3 cells. Among the compounds obtained, N-[4-[(benzyl)(4-nitrophenyl)amino]-1-methylpyrrole-2-carbonyl]pyrrolidine (22) is as potent an AR antagonist as the typical anilide-type AR antagonists hydroxyflutamide and bicalutamide. Further, compound 22 had potent binding affinity for T877A mutated AR, and dose-dependently inhibited the testosterone-induced production of prostate-specific antigen in LNCaP cells bearing T877A AR., Entry 10: We previously developed carborane-containing potent AR antagonists, BA321 and BA341, on the basis of our hypothesis that the carborane cage would be an excellent hydrophobic pharmacophore in place of steroidal C and D rings. As an extension of that work, we designed and synthesized carborane-containing AR antagonist candidates with a pyridine ring. Compound 6b, which has a pyridine ring directly bound to the p-carborane cage at the 3-position, exhibited potent AR-antagonistic activity in transcriptional activation assay using NIH3T3 cells transfected with a hAR-expression plasmid. In addition, it showed more potent antiandrogenic activity than that of the well-known antiandrogen flutamide and comparable activity to that of (R)-bicalutamide in SC-3 cell proliferation assay., Entry 11: Four new indolosesquiterpenes, lecanindoles A-D (1-4), were isolated from fermentations of the terrestrial fungus Verticillium lecanii 6144. The structures of compounds 1-4 were elucidated from analysis of spectroscopic data. Compound 2 was reduced to give 4 and its isomer 5. Compound 4 was found to be a potent and selective progesterone receptor agonist with an EC50 of 1.1 +/- 0.4 nM in a cell-based luciferase reporter assay., Entry 12: We report here the design, preparation, and systematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen receptor (AR) modulators. Cycloalkane[d]isoxazoles form new core structures that interact with the hydrophobic region of the AR ligand-binding domain. To systematize and rationalize the structure-activity relationship of the new fragment, we used molecular modeling to design a molecular library containing over 40 cycloalkane[d]isoxazole derivatives. The most potent compound, 4-(3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile (6a), exhibits antiandrogenic activity significantly greater than that of the most widely used antiandrogenic prostate cancer drugs bicalutamide (1) and hydroxyflutamide (2) in reporter gene assays measuring the transcriptional activity of AR (decreasing approximately 90% of the total AR activity) and in competitive AR ligand-binding assays (showing over four times higher potency to inhibit radioligand binding in comparison to bicalutamide). Notably, 6a maintains its antiandrogenic activity with AR mutants W741L and T877A commonly observed and activated by bicalutamide and hydroxyflutamide, respectively, in prostate cancer patients., Entry 13: We previously reported that bis-phenol derivatives, including LG190178 (3a), possess not only vitamin D receptor (VDR) agonistic activity, but also androgen receptor (AR) antagonistic activity. Here, we describe the design, synthesis and evaluation of silicon-containing bis-phenol derivatives, with the objective of obtaining increased selectivity toward VDR or AR. We found that replacement of the quaternary carbon in the bis-phenol skeleton with silicon increased AR-antagonistic activity and reduced VDR-agonistic activity, that is, the AR selectivity of the silicon-containing compounds was higher than that of corresponding carbon compounds. To our knowledge, this is the first report of nuclear receptor (NR) selectivity switching by sila-substitution (C/Si exchange). Among the compounds synthesized, AR-selective ligand (S,R)-3b exhibited more potent anti-androgenic activity (IC50=0.072 M) than hydroxyflutamide, a well-known androgen antagonist (IC50=1.4 M), in SC-3 cell proliferation assay. These results suggest that sila-substitution is a useful approach for structural development of selective AR ligands., Entry 14: We report the design and synthesis of novel 4-(4-benzoylaminophenoxy)phenol derivatives that bind to the androgen receptor (AR) ligand-binding domain and exhibit potent androgen-antagonistic activity. Compound 22 is one of the most potent of these derivatives, inhibiting the dihydrotestosterone-promoted growth of SC-3 cell line bearing wild-type AR (IC50 0.75 M), LNCaP cell line bearing T877A-mutated AR (IC50 0.043 M), and 22Rv1 cell line bearing H874Y-mutated AR (IC50 0.22 M). Structure-activity relationship studies confirmed that the pharmacophore of these novel AR antagonists is distinct from the nitro- or cyano-substituted anilide substructure of other nonsteroidal AR antagonists. This novel pharmacophore is expected to provide a basis for designing new antiprostate cancer agents., Entry 15: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., Entry 16: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., Entry 17: Aldo-keto reductase (AKR) 1C3 catalyzes the synthesis of active androgens that promote the progression of prostate cancer. AKR1C3 also contributes to androgen-independent cell proliferation and survival through the metabolism of prostaglandins and reactive aldehydes. Because of its elevation in castration-resistant prostate cancer (CRPC) tissues, AKR1C3 is a promising therapeutic target for CRPC. In this study, we found a novel potent AKR1C3 inhibitor, <i>N</i>-(4-fluorophenyl)-8-hydroxy-2-imino-2<i>H</i>-chromene-3-carboxamide (<b>2d</b>), and synthesized its derivatives with IC<sub>50</sub> values of 25-56 nM and >220-fold selectivity over other AKRs (1C1, 1C2, and 1C4). The structural factors for the inhibitory potency were elucidated by crystallographic study of AKR1C3 complexes with <b>2j</b> and <b>2l</b>. The inhibitors suppressed proliferation of prostate cancer 22Rv1 and PC3 cells through both androgen-dependent and androgen-independent mechanisms. Additionally, <b>2j</b> and <b>2l</b> prevented prostate tumor growth in a xenograft mouse model. Furthermore, the inhibitors significantly augmented apoptotic cell death induced by anti-CRPC drugs (abiraterone or enzalutamide)., ",,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C11H11F3N2O4,CHEMBL491,15.0,25.0,26.0,26.0,26.0,31.0,31.0,43.0,67.0,180.0,200.0,200.0,223.87,230.0,300.0,350.0,7100.0,7690.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2289.74193,15.0,931.3261111,123.5,7690.0,2.969101779,2.091666958,1.176091259,6.030898221,6.908333042,7.823908741,18,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,58.4,26.0,15.0,200.0,7.2335871528876,7.585026652029182,7.823908740944319,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
12825,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 36108, Entry 1: 44194, Entry 2: 36120, Entry 3: 36122, Entry 4: 35971, Entry 5: 1847878, ","Entry 0: Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay., Entry 1: Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells, Entry 2: Inhibition of human androgen receptor at 10e-12 to 10e-5 M, Entry 3: Inhibitory activity against human Androgen receptor, Entry 4: Antagonist activity against Androgen receptor, Entry 5: Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay, ","0,1,","Entry 0: F, Entry 1: F, Entry 2: B, Entry 3: B, Entry 4: F, Entry 5: B, ",,"Entry 0: CHEMBL648073, Entry 1: CHEMBL654135, Entry 2: CHEMBL647746, Entry 3: CHEMBL647748, Entry 4: CHEMBL646935, Entry 5: CHEMBL4348419, ","Entry 0: 10.1021/jm9705768, Entry 1: 10.1021/jm980366a, Entry 2: 10.1021/jm020477g, Entry 3: 10.1021/jm950747d, Entry 4: 10.1016/s0960-894x(03)00255-5, Entry 5: 10.1016/j.ejmech.2019.03.041, ","Entry 0: 9464360, Entry 1: 9784110, Entry 2: 12954062, Entry 3: 8627601, Entry 4: 12781197, Entry 5: 30925341, ","Entry 0: CHEMBL1131454, Entry 1: CHEMBL1131161, Entry 2: CHEMBL1145087, Entry 3: CHEMBL1129561, Entry 4: CHEMBL1136068, Entry 5: CHEMBL4346686, ","Entry 0: 5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists., Entry 1: 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists., Entry 2: 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators., Entry 3: Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether., Entry 4: Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators., Entry 5: Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats., Entry 1: A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats., Entry 2: A series of 5-benylidene-1,2-dihydrochromeno[3,4-f]quinolines (4) were synthesized and tested in bioassays to evaluate their progestational activities, receptor- and tissue-selectivity profiles as selective progesterone receptor modulators (SPRMs). Most of the new analogues exhibited as highly potent progestins with more than 100-fold receptor selectivity over other steroid hormone receptors and LG120920 (7b) demonstrated tissue selectivity toward uterus and vagina versus breasts in a rodent model after oral administration., Entry 3: A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor., Entry 4: A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position., Entry 5: Prostate cancer (PC) is the second most common malignancy in men worldwide. Among current therapies, two antiandrogens, Abiraterone Acetate and Enzalutamide (Enza) have become the standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we designed and synthesized a new series of nonsteroidal compounds deriving from the hybridization of Abiraterone (Abi) and Enzalutamide, among which compound 4a featuring the diphenylamine scaffold was identified as a potent and cell selective androgen receptor (AR) antagonist. In cell proliferation assays, compound 4a exhibited better antiproliferative activities than Enzalutamide against AR-overexpressing VCaP cells and 22Rv1 cells bearing H874Y-mutated AR. In addition, 4a suppressed the activity of AR-F876L mutant that confers resistance to Enzalutamide and efficiently blocked R1881-induced PSA and FKBP5 gene expression. In competitive binding assay, compound 4a displayed higher binding affinity to AR than Enzalutamide. These results suggest compound 4a as a potential candidate to treat Enza-resistant CRPC., ",,CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,C21H30O2,CHEMBL103,13.7,37.0,37.0,37.0,37.0,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.683397313,13.7,33.11666667,37.0,37.0,1.520046617,1.568201724,1.136720567,7.479953383,7.431798276,7.863279433,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,25.35,25.35,13.7,37.0,7.596022036330645,7.596022036330645,7.863279432843593,7.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
17928,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,COc1cccc2oc(-c3ccccc3)cc(=O)c12,C16H12O3,CHEMBL16685,8700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8700.0,8700.0,8700.0,8700.0,3.939519253,3.939519253,3.939519253,5.060480747,5.060480747,5.060480747,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8700.0,8700.0,8700.0,8700.0,5.060480747381382,5.060480747381382,5.060480747381382,5.060480747381382,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
18024,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,Cc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C16H12O3,CHEMBL16972,11100.0,11220.18,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60.09,11100.0,11160.09,11160.09,11220.18,4.047667697,4.047667697,4.045322979,4.952332303,4.952332303,4.954677021,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11160.09,11160.09,11100.0,11220.18,4.952332303037708,4.952332303037708,4.954677021213342,4.950000175844591,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
18033,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",mix,"Entry 0: 580463, Entry 1: 962459, Entry 2: 962459, ","Entry 0: Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 2: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1,2","Entry 0: F, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL1052490, Entry 1: CHEMBL2390352, Entry 2: CHEMBL2390352, ","Entry 0: 10.1016/j.bmcl.2009.06.073, Entry 1: 10.1016/j.bmc.2013.03.060, Entry 2: 10.1016/j.bmc.2013.03.060, ","Entry 0: 19592245, Entry 1: 23611768, Entry 2: 23611768, ","Entry 0: CHEMBL1153076, Entry 1: CHEMBL2385078, Entry 2: CHEMBL2385078, ","Entry 0: Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 2: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 2: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccccc2)oc2cccc(O)c12,C15H10O3,CHEMBL16807,300.0,831.76,840.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,252.6386517,300.0,657.2533333,831.76,840.0,2.817732797,2.919998031,2.477121255,6.182267203,6.080001969,6.522878745,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,657.2533333333333,831.76,300.0,840.0,6.182267202643278,6.0800019690359814,6.522878745280337,6.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
18145,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 580463, Entry 1: 580463, ","Entry 0: Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay, Entry 1: Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1052490, Entry 1: CHEMBL1052490, ","Entry 0: 10.1016/j.bmcl.2009.06.073, Entry 1: 10.1016/j.bmcl.2009.06.073, ","Entry 0: 19592245, Entry 1: 19592245, ","Entry 0: CHEMBL1153076, Entry 1: CHEMBL1153076, ","Entry 0: Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay., Entry 1: Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR., Entry 1: The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR., ",,O=c1cc(-c2ccccc2)oc2ccccc12,C15H10O2,CHEMBL275638,5900.0,5900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5900.0,5900.0,5900.0,5900.0,3.770852012,3.770852012,3.770852012,5.229147988,5.229147988,5.229147988,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5900.0,5900.0,5900.0,5900.0,5.229147988357856,5.229147988357856,5.229147988357856,5.229147988357856,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
18151,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(Cl)cc2)oc2cccc(O)c12,C15H9ClO3,CHEMBL274471,457.09,460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.455,457.09,458.545,458.545,460.0,2.661381962,2.661381962,2.66000172,6.338618038,6.338618038,6.33999828,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,458.54499999999996,458.54499999999996,457.09,460.0,6.338618037763423,6.338618037763423,6.339998279897117,6.337242168318426,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
27626,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 332775, Entry 1: 455548, Entry 2: 458140, ","Entry 0: Inhibitory activity against AR, Entry 1: Binding affinity to androgen receptor, Entry 2: Binding affinity at AR, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL859226, Entry 1: CHEMBL886327, Entry 2: CHEMBL925473, ","Entry 0: 10.1016/j.bmcl.2005.11.014, Entry 1: 10.1016/j.bmcl.2006.12.053, Entry 2: 10.1016/j.bmcl.2007.09.001, ","Entry 0: 16309907, Entry 1: 17448656, Entry 2: 17890084, ","Entry 0: CHEMBL1149417, Entry 1: CHEMBL1139947, Entry 2: CHEMBL1140529, ","Entry 0: Androstenediol analogs as ER-beta-selective SERMs., Entry 1: Bridged androstenediol analogs as ER-beta selective SERMs., Entry 2: Androstene-3,5-dienes as ER-beta selective SERMs., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta., Entry 1: A series of bridged androstenediol derivatives was prepared. The bridged compounds exhibited reduced ER-beta selectivity relative to uncyclized analogs., Entry 2: A series of androstene-3,5-diene derivatives were prepared. Despite lacking the C-3 hydroxyl previously believed necessary for ER activity, some of the analogs retained surprising affinity for ER-beta. For example, diene 4 retained excellent selectivity and potency as an ER-beta agonist and was more selective for ER-beta over the androgen receptor (AR)., ",,C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,C18H24O2,CHEMBL135,19.1,19.1,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.252691193,19.1,21.4,19.1,26.0,1.330413773,1.281033367,1.281033367,7.669586227,7.718966633,7.718966633,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.1,19.1,19.1,19.1,7.718966632752273,7.718966632752273,7.718966632752273,7.718966632752273,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
29860,nM,IC50,,BAO_0000190,IC50,791027,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,0,B,,CHEMBL1925688,10.1021/jm201098n,22047606,CHEMBL1921777,Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.,PUBLICATION,"The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms.",,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,C14H10F3NO2,CHEMBL23588,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
31213,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 624727, Entry 1: 624727, ","Entry 0: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, Entry 1: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1113403, Entry 1: CHEMBL1113403, ","Entry 0: 10.1016/j.bmcl.2010.02.059, Entry 1: 10.1016/j.bmcl.2010.02.059, ","Entry 0: 20226658, Entry 1: 20226658, ","Entry 0: CHEMBL1156958, Entry 1: CHEMBL1156958, ","Entry 0: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., Entry 1: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., Entry 1: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., ",,COc1cc(CCC(C)=O)ccc1O,C11H14O3,CHEMBL25894,151356.12,153000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,821.94,151356.12,152178.06,152178.06,153000.0,5.182352043,5.182352043,5.179999986,3.817647957,3.817647957,3.820000014,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,151356.12,151356.12,151356.12,151356.12,3.8200000138980688,3.8200000138980688,3.8200000138980688,3.8200000138980688,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
34608,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 44193, Entry 1: 36120, ","Entry 0: Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells, Entry 1: Inhibition of human androgen receptor at 10e-12 to 10e-5 M, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL653492, Entry 1: CHEMBL647746, ","Entry 0: 10.1021/jm980366a, Entry 1: 10.1021/jm020477g, ","Entry 0: 9784110, Entry 1: 12954062, ","Entry 0: CHEMBL1131161, Entry 1: CHEMBL1145087, ","Entry 0: 5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists., Entry 1: 5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats., Entry 1: A series of 5-benylidene-1,2-dihydrochromeno[3,4-f]quinolines (4) were synthesized and tested in bioassays to evaluate their progestational activities, receptor- and tissue-selectivity profiles as selective progesterone receptor modulators (SPRMs). Most of the new analogues exhibited as highly potent progestins with more than 100-fold receptor selectivity over other steroid hormone receptors and LG120920 (7b) demonstrated tissue selectivity toward uterus and vagina versus breasts in a rodent model after oral administration., ",,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,C24H34O4,CHEMBL717,6.1,6.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6.1,6.1,6.1,6.1,0.785329835,0.785329835,0.785329835,8.214670165,8.214670165,8.214670165,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,6.1,6.1,6.1,6.1,8.214670164989233,8.214670164989233,8.214670164989233,8.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
35703,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1(CC)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C17H19F3N2O,CHEMBL282866,73.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,73.0,73.0,73.0,73.0,1.86332286,1.86332286,1.86332286,7.13667714,7.13667714,7.13667714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,73.0,73.0,73.0,73.0,7.136677139879544,7.136677139879544,7.136677139879544,7.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
35704,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC1(C)CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C15H15F3N2O,CHEMBL281028,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.0,16.0,16.0,16.0,1.204119983,1.204119983,1.204119983,7.795880017,7.795880017,7.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
35705,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3c1cc(C(F)(F)F)cc(C(F)(F)F)c1,C21H13F9N2O,CHEMBL285602,251.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,251.0,251.0,251.0,251.0,2.399673721,2.399673721,2.399673721,6.600326279,6.600326279,6.600326279,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,251.0,251.0,251.0,251.0,6.600326278518962,6.600326278518962,6.600326278518962,6.600326278518962,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
36141,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCCC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H17F3N2O,CHEMBL280865,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36246,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC[C@@H]1CCCC[C@H]31,C17H17F3N2O,CHEMBL431493,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36285,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC[C@@H]1CCC[C@H]31,C16H15F3N2O,CHEMBL27812,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36578,nM,IC50,,BAO_0000190,IC50,36106,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells was determined as a function of maximal inhibition of dihydrotestosterone using cotransfection assay,0,F,,CHEMBL648071,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1CCN(C=O)c2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H15F3N2O2,CHEMBL27372,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36627,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C14H13F3N2O,CHEMBL283449,259.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,259.0,259.0,259.0,259.0,2.413299764,2.413299764,2.413299764,6.586700236,6.586700236,6.586700236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,259.0,259.0,259.0,259.0,6.586700235918748,6.586700235918748,6.586700235918748,6.586700235918748,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
36628,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC(C)C1CCNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H17F3N2O,CHEMBL27276,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36688,nM,IC50,,BAO_0000190,IC50,36106,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells was determined as a function of maximal inhibition of dihydrotestosterone using cotransfection assay,0,F,,CHEMBL648071,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,C[C@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2C1CCC(F)(F)F,C17H16F6N2O,CHEMBL281945,61.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,61.0,61.0,61.0,61.0,1.785329835,1.785329835,1.785329835,7.214670165,7.214670165,7.214670165,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,61.0,61.0,61.0,61.0,7.214670164989233,7.214670164989233,7.214670164989233,7.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
36689,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,C16H17F3N2O,CHEMBL418198,2710.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2710.0,2710.0,2710.0,2710.0,3.432969291,3.432969291,3.432969291,5.567030709,5.567030709,5.567030709,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2710.0,2710.0,2710.0,2710.0,5.567030709125595,5.567030709125595,5.567030709125595,5.567030709125595,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
36690,nM,IC50,,BAO_0000190,IC50,36106,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells was determined as a function of maximal inhibition of dihydrotestosterone using cotransfection assay,0,F,,CHEMBL648071,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@H]1C,C15H15F3N2O,CHEMBL282204,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
36706,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1CCN(C)c2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H17F3N2O,CHEMBL27945,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
37371,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCCC3,C13H11F3N2O,CHEMBL286684,12.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,12.0,12.0,12.0,12.0,1.079181246,1.079181246,1.079181246,7.920818754,7.920818754,7.920818754,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,12.0,12.0,12.0,12.0,7.920818753952375,7.920818753952375,7.920818753952375,7.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
37372,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1CCN(C)c2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,C17H19F3N2O,CHEMBL27413,216.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,216.0,216.0,216.0,216.0,2.334453751,2.334453751,2.334453751,6.665546249,6.665546249,6.665546249,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,216.0,216.0,216.0,216.0,6.665546248849069,6.665546248849069,6.665546248849069,6.665546248849069,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
37373,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CCC1CCNc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,C16H17F3N2O,CHEMBL27297,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
42644,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 332775, Entry 1: 458140, ","Entry 0: Inhibitory activity against AR, Entry 1: Binding affinity at AR, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL859226, Entry 1: CHEMBL925473, ","Entry 0: 10.1016/j.bmcl.2005.11.014, Entry 1: 10.1016/j.bmcl.2007.09.001, ","Entry 0: 16309907, Entry 1: 17890084, ","Entry 0: CHEMBL1149417, Entry 1: CHEMBL1140529, ","Entry 0: Androstenediol analogs as ER-beta-selective SERMs., Entry 1: Androstene-3,5-dienes as ER-beta selective SERMs., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta., Entry 1: A series of androstene-3,5-diene derivatives were prepared. Despite lacking the C-3 hydroxyl previously believed necessary for ER activity, some of the analogs retained surprising affinity for ER-beta. For example, diene 4 retained excellent selectivity and potency as an ER-beta agonist and was more selective for ER-beta over the androgen receptor (AR)., ",,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C19H30O2,CHEMBL440283,212.0,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,212.0,221.0,221.0,230.0,2.344392274,2.344392274,2.326335861,6.655607726,6.655607726,6.673664139,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,212.0,212.0,212.0,212.0,6.673664139071248,6.673664139071248,6.673664139071248,6.673664139071248,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
46884,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=c1c(O)c(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,C15H10O6,CHEMBL150,9700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9700.0,9700.0,9700.0,9700.0,3.986771734,3.986771734,3.986771734,5.013228266,5.013228266,5.013228266,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9700.0,9700.0,9700.0,9700.0,5.013228265733755,5.013228265733755,5.013228265733755,5.013228265733755,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
49963,nM,IC50,,BAO_0000190,IC50,44194,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,0,F,,CHEMBL654135,10.1021/jm980366a,9784110,CHEMBL1131161,"5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cccc(F)c1)Oc1ccccc1-3,C26H22FNO,CHEMBL32812,795.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,795.0,795.0,795.0,795.0,2.900367129,2.900367129,2.900367129,6.099632871,6.099632871,6.099632871,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,795.0,795.0,795.0,795.0,6.0996328713435295,6.0996328713435295,6.0996328713435295,6.0996328713435295,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
50050,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)cc1)Oc1ccccc1-3,C25H22ClNO,CHEMBL286595,1550.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1550.0,1550.0,1550.0,1550.0,3.190331698,3.190331698,3.190331698,5.809668302,5.809668302,5.809668302,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1550.0,1550.0,1550.0,1550.0,5.809668301829708,5.809668301829708,5.809668301829708,5.809668301829708,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
52087,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, ",IC50,"Entry 0: 36123, Entry 1: 306281, Entry 2: 487550, Entry 3: 513497, Entry 4: 540647, Entry 5: 624727, Entry 6: 663713, ","Entry 0: Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate, Entry 1: Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate, Entry 2: Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method, Entry 3: Antagonist activity at human androgen receptor expressed in mouse NIH3T3 cells assessed as inhibition of DHT-induced transcriptional activation after 24 hrs by androgen response element-mediated luciferase reporter gene assay, Entry 4: Antiandrogenic activity in human MDA-MB-453 cells expressing androgen receptor assessed as inhibition of DHT-induced androgen-dependent transcription by luciferase reporter gene assay, Entry 5: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, Entry 6: Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay, ","3,4,5,6","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: B, Entry 5: F, Entry 6: F, ",,"Entry 0: CHEMBL647749, Entry 1: CHEMBL828424, Entry 2: CHEMBL1013144, Entry 3: CHEMBL975403, Entry 4: CHEMBL1023897, Entry 5: CHEMBL1113403, Entry 6: CHEMBL1250613, ","Entry 0: 10.1021/jm0303305, Entry 1: 10.1021/jm0495226, Entry 2: 10.1016/j.bmc.2008.05.063, Entry 3: 10.1016/j.bmc.2008.07.055, Entry 4: 10.1016/j.bmcl.2008.12.075, Entry 5: 10.1016/j.bmcl.2010.02.059, Entry 6: 10.1016/j.bmc.2010.08.029, ","Entry 0: 14613328, Entry 1: 15509168, Entry 2: 18571420, Entry 3: 18707892, Entry 4: 19131248, Entry 5: 20226658, Entry 6: 20826091, ","Entry 0: CHEMBL1145911, Entry 1: CHEMBL1138810, Entry 2: CHEMBL1155056, Entry 3: CHEMBL1140043, Entry 4: CHEMBL1136843, Entry 5: CHEMBL1156958, Entry 6: CHEMBL1250541, ","Entry 0: Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate., Entry 1: Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera., Entry 2: 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor., Entry 3: Design and synthesis of carborane-containing androgen receptor (AR) antagonist bearing a pyridine ring., Entry 4: N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1)., Entry 5: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., Entry 6: 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, ","Entry 0: The synthesis and preliminary evaluation of a doxorubicin-formaldehyde conjugate tethered to the nonsteroidal antiandrogen, cyanonilutamide (RU 56279), for the treatment of prostate cancer are reported. The relative ability of the targeting group to bind to the human androgen receptor was studied as a function of tether. The tether served to attach the antiandrogen to the doxorubicin-formaldehyde conjugate via an N-Mannich base of a salicylamide derivative. The salicylamide was selected to serve as a trigger release mechanism to separate the doxorubicin-formaldehyde conjugate from the targeting group after it has bound to the androgen receptor. The remaining part of the tether consisted of a linear group that spanned from the 5-position of the salicylamide to the 3'-position of cyanonilutamide. The structures explored for the linear region of the tether were derivatives of di(ethylene glycol), tri(ethylene glycol), N,N'-disubstituted-piperazine, and 2-butyne-1,4-diol. Relative binding affinity of the tethers bound to the targeting group for human androgen receptor were measured using a (3)H-Mibolerone competition assay and varied from 18% of nilutamide binding for the butynediol-based linear region to less than 1% for one of the piperazine derivatives. The complete targeted drug with the butynediol-based linear region has a relative binding affinity of 10%. This relative binding affinity is encouraging in light of the cocrystal structure of human androgen receptor ligand binding domain bound to the steroid Metribolone which predicts very limited space for a tether connecting the antiandrogen on the inside to the cytotoxin on the outside., Entry 1: The synthesis of a doxorubicin-formaldehyde conjugate bound to the nonsteroidal anti-androgen cyanonilutamide, via a cleavable tether, and binding of the construct to cell free androgen receptor (AR) as a function of tether design were previously reported. Cyanonilutamide bearing a linear alkyne tether bound to the AR better than other designs. Fluorescence microscopy studies of binding of the lead targeted drug, as well as various tethered cyanonilutamides, to the AR and subsequent trafficking of the resulting AR complex in live PC3 prostate cancer cells transfected with AR-green fluorescent protein (GFP) chimera are now described. Cyanonilutamide and cyanonilutamide bonded to a linear alkyne tether caused translocation of AR-GFP to the nucleus. In general, the ability of tethered cyanonilutamides to cause translocation paralleled their binding affinity for the AR. However, a noncleavable form of the lead cyanonilutamide-doxorubicin-formaldehyde conjugate bound to AR-GFP but the resulting complex did not translocate to the nucleus. Binding was apparent from the drugs inhibition of Mibolerone-induced translocation. Direct observation of anthraquinone fluorescence of targeted drug in PC3 cells showed initial cytosolic localization, independent of AR expression, with predominant nuclear localization after sufficient time for release of drug from the targeting moiety. The results indicate that doxorubicin-formaldehyde conjugate bonded to cyanonilutamide via a cleavable linear tether enters PC3 cells, resides in cytosol, binds to the AR if present, and ultimately releases doxorubicin or a doxorubicin derivative to the nucleus., Entry 2: Various 4-(anilino)pyrrole-2-carboxamides were designed and synthesized as novel androgen receptor (AR) antagonists without steroidal or anilide structure, based on our strategy for developing full antagonists of nuclear receptors. Introduction of a bulky N-alkyl group, such as a cyclohexylmethyl or benzyl group, increased the binding affinity for wild-type AR and the potency for growth inhibition of androgen-dependent SC-3 cells. Among the compounds obtained, N-[4-[(benzyl)(4-nitrophenyl)amino]-1-methylpyrrole-2-carbonyl]pyrrolidine (22) is as potent an AR antagonist as the typical anilide-type AR antagonists hydroxyflutamide and bicalutamide. Further, compound 22 had potent binding affinity for T877A mutated AR, and dose-dependently inhibited the testosterone-induced production of prostate-specific antigen in LNCaP cells bearing T877A AR., Entry 3: We previously developed carborane-containing potent AR antagonists, BA321 and BA341, on the basis of our hypothesis that the carborane cage would be an excellent hydrophobic pharmacophore in place of steroidal C and D rings. As an extension of that work, we designed and synthesized carborane-containing AR antagonist candidates with a pyridine ring. Compound 6b, which has a pyridine ring directly bound to the p-carborane cage at the 3-position, exhibited potent AR-antagonistic activity in transcriptional activation assay using NIH3T3 cells transfected with a hAR-expression plasmid. In addition, it showed more potent antiandrogenic activity than that of the well-known antiandrogen flutamide and comparable activity to that of (R)-bicalutamide in SC-3 cell proliferation assay., Entry 4: A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors., Entry 5: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., Entry 6: Here, the synthesis and the evaluation of novel 20-aminosteroids on androgen receptor (AR) activity is reported. Compounds 11 and 18 of the series inhibit both the wild type and the T877A mutant AR-mediated transactivation indicating AR antagonistic function. Interestingly, minor structural changes such as stereoisomers of the amino lactame moiety exhibit preferences for antagonism among wild type and mutant AR. Other tested nuclear receptors are only weakly or not affected. In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited. Further, the expression of the prostate specific antigen used as a diagnostic marker is also repressed. Finally steroid 18 enhances cellular senescence that might explain in part the growth inhibition mediated by this derivative. Steroids 11 and 18 are the first steroids that act as complete AR antagonists and exhibit AR specificity., ",,CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C11H11F3N2O3,CHEMBL806,154.0,154.0,580.0,1000.0,2000.0,4200.0,110000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38043.04519,154.0,16869.71429,1000.0,110000.0,4.227107727,3.0,2.187520721,4.772892273,6.0,6.812479279,7,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,29300.0,3100.0,1000.0,110000.0,4.533132379645891,5.508638306165727,6.0,3.958607314841775,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,IC50
60268,nM,IC50,,BAO_0000190,IC50,791027,Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis,0,B,,CHEMBL1925688,10.1021/jm201098n,22047606,CHEMBL1921777,Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening.,PUBLICATION,"The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms.",,O=C(O)Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1,C14H9I3O4,CHEMBL41632,34800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34800.0,34800.0,34800.0,34800.0,4.541579244,4.541579244,4.541579244,4.458420756,4.458420756,4.458420756,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,34800.0,34800.0,34800.0,34800.0,4.458420756053419,4.458420756053419,4.458420756053419,4.458420756053419,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
62815,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 624727, Entry 1: 624727, ","Entry 0: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, Entry 1: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1113403, Entry 1: CHEMBL1113403, ","Entry 0: 10.1016/j.bmcl.2010.02.059, Entry 1: 10.1016/j.bmcl.2010.02.059, ","Entry 0: 20226658, Entry 1: 20226658, ","Entry 0: CHEMBL1156958, Entry 1: CHEMBL1156958, ","Entry 0: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., Entry 1: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., Entry 1: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., ",,C=CCc1ccc(O)c(OC)c1,C10H12O2,CHEMBL42710,19000.0,19054.61,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27.305,19000.0,19027.305,19027.305,19054.61,4.27937728,4.27937728,4.278753601,4.72062272,4.72062272,4.721246399,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,19027.305,19027.305,19000.0,19054.61,4.720622720200282,4.720622720200282,4.721246399047171,4.719999935717911,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
63252,nM,IC50,,BAO_0000190,IC50,942995,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,0,B,,CHEMBL2343831,10.1016/j.bmc.2013.01.060,23462715,CHEMBL2331115,Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.,PUBLICATION,"We previously reported that bis-phenol derivatives, including LG190178 (3a), possess not only vitamin D receptor (VDR) agonistic activity, but also androgen receptor (AR) antagonistic activity. Here, we describe the design, synthesis and evaluation of silicon-containing bis-phenol derivatives, with the objective of obtaining increased selectivity toward VDR or AR. We found that replacement of the quaternary carbon in the bis-phenol skeleton with silicon increased AR-antagonistic activity and reduced VDR-agonistic activity, that is, the AR selectivity of the silicon-containing compounds was higher than that of corresponding carbon compounds. To our knowledge, this is the first report of nuclear receptor (NR) selectivity switching by sila-substitution (C/Si exchange). Among the compounds synthesized, AR-selective ligand (S,R)-3b exhibited more potent anti-androgenic activity (IC50=0.072 M) than hydroxyflutamide, a well-known androgen antagonist (IC50=1.4 M), in SC-3 cell proliferation assay. These results suggest that sila-substitution is a useful approach for structural development of selective AR ligands.",,C=C1/C(=C\C=C2/CCC[C@]3(C)[C@@H]([C@H](C)CCCC(C)(C)O)CC[C@@H]23)C[C@@H](O)C[C@@H]1O,C27H44O3,CHEMBL846,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
77181,nM,IC50,,BAO_0000190,IC50,36122,Inhibitory activity against human Androgen receptor,0,B,,CHEMBL647748,10.1021/jm950747d,8627601,CHEMBL1129561,Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.,PUBLICATION,"A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor.",,C=C1CC[C@@H](Br)C(C)(C)[C@@H]1Cc1cc(OC)c(Br)cc1O,C17H22Br2O2,CHEMBL51639,238.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,238.0,238.0,238.0,238.0,2.376576957,2.376576957,2.376576957,6.623423043,6.623423043,6.623423043,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,238.0,238.0,238.0,238.0,6.623423042943488,6.623423042943488,6.623423042943488,6.623423042943488,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
77234,nM,IC50,,BAO_0000190,IC50,36122,Inhibitory activity against human Androgen receptor,0,B,,CHEMBL647748,10.1021/jm950747d,8627601,CHEMBL1129561,Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.,PUBLICATION,"A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor.",,C=C1CC[C@@H](Br)C(C)(C)[C@H]1Cc1cc(OC)c(Br)cc1O,C17H22Br2O2,CHEMBL51093,449.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,449.0,449.0,449.0,449.0,2.652246341,2.652246341,2.652246341,6.347753659,6.347753659,6.347753659,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,449.0,449.0,449.0,449.0,6.347753658996677,6.347753658996677,6.347753658996677,6.347753658996677,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
77352,nM,IC50,,BAO_0000190,IC50,36122,Inhibitory activity against human Androgen receptor,0,B,,CHEMBL647748,10.1021/jm950747d,8627601,CHEMBL1129561,Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.,PUBLICATION,"A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor.",,C=C1C=C(C)CC(C)(C)C1Cc1ccc([N+](=O)[O-])cc1,C17H21NO2,CHEMBL50023,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,250.0,250.0,250.0,250.0,2.397940009,2.397940009,2.397940009,6.602059991,6.602059991,6.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.0,250.0,250.0,250.0,6.6020599913279625,6.6020599913279625,6.6020599913279625,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
77492,nM,IC50,,BAO_0000190,IC50,36122,Inhibitory activity against human Androgen receptor,0,B,,CHEMBL647748,10.1021/jm950747d,8627601,CHEMBL1129561,Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether.,PUBLICATION,"A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor.",,C=C1CCCC(C)(C)[C@H]1Cc1cc(OC)c(Br)cc1O,C17H23BrO2,CHEMBL417729,377.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,377.0,377.0,377.0,377.0,2.57634135,2.57634135,2.57634135,6.42365865,6.42365865,6.42365865,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,377.0,377.0,377.0,377.0,6.423658649794207,6.423658649794207,6.423658649794207,6.423658649794207,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
86618,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=c1c(O)c(-c2ccccc2)oc2ccccc12,C15H10O3,CHEMBL294009,23500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23500.0,23500.0,23500.0,23500.0,4.371067862,4.371067862,4.371067862,4.628932138,4.628932138,4.628932138,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,23500.0,23500.0,23500.0,23500.0,4.628932137728264,4.628932137728264,4.628932137728264,4.628932137728264,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
99969,nM,IC50,,BAO_0000190,IC50,36099,Antagonist activity against human Androgen receptor,0,F,,CHEMBL647321,10.1016/s0960-894x(03)00255-5,12781197,CHEMBL1136068,"Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.",PUBLICATION,"A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position.",,CC/C(C)=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,C23H24FNO,CHEMBL62981,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,250.0,250.0,250.0,250.0,2.397940009,2.397940009,2.397940009,6.602059991,6.602059991,6.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.0,250.0,250.0,250.0,6.6020599913279625,6.6020599913279625,6.6020599913279625,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100044,nM,IC50,,BAO_0000190,IC50,35972,Antagonist activity against Androgen receptor; not active,0,F,,CHEMBL646936,10.1016/s0960-894x(03)00255-5,12781197,CHEMBL1136068,"Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.",PUBLICATION,"A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position.",,CC(C)=C/C=C1\Oc2ccc(F)cc2-c2ccc3c(c21)C(C)=CC(C)(C)N3,C24H24FNO,CHEMBL65690,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100045,nM,IC50,,BAO_0000190,IC50,44193,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,0,F,,CHEMBL653492,10.1021/jm980366a,9784110,CHEMBL1131161,"5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1C)Oc1ccccc1-3,C27H25NO,CHEMBL302362,1062.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1062.0,1062.0,1062.0,1062.0,3.026124517,3.026124517,3.026124517,5.973875483,5.973875483,5.973875483,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1062.0,1062.0,1062.0,1062.0,5.97387548325455,5.97387548325455,5.97387548325455,5.97387548325455,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100605,nM,IC50,,BAO_0000190,IC50,36099,Antagonist activity against human Androgen receptor,0,F,,CHEMBL647321,10.1016/s0960-894x(03)00255-5,12781197,CHEMBL1136068,"Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.",PUBLICATION,"A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(=C1SCCCS1)Oc1ccc(F)cc1-3,C23H22FNOS2,CHEMBL65929,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,180.0,180.0,180.0,180.0,2.255272505,2.255272505,2.255272505,6.744727495,6.744727495,6.744727495,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,180.0,180.0,180.0,180.0,6.7447274948966935,6.7447274948966935,6.7447274948966935,6.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100660,nM,IC50,,BAO_0000190,IC50,35971,Antagonist activity against Androgen receptor,0,F,,CHEMBL646935,10.1016/s0960-894x(03)00255-5,12781197,CHEMBL1136068,"Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.",PUBLICATION,"A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position.",,CC(=O)C[C@]1(C(C)=O)CC[C@H]2C3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,C25H36O3,CHEMBL292284,6.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6.1,6.1,6.1,6.1,0.785329835,0.785329835,0.785329835,8.214670165,8.214670165,8.214670165,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,6.1,6.1,6.1,6.1,8.214670164989233,8.214670164989233,8.214670164989233,8.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100661,nM,IC50,,BAO_0000190,IC50,35971,Antagonist activity against Androgen receptor,0,F,,CHEMBL646935,10.1016/s0960-894x(03)00255-5,12781197,CHEMBL1136068,"Synthesis and biological activity of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators.",PUBLICATION,"A series of 5-methylidene 1,2-dihydrochromeno[3,4-f]quinoline derivatives were synthesized and tested in biological assays to evaluate scope and limitations of the nonsteroidal SPRM pharmacophore (3). A number of orally available highly potent nonsteroidal modulators were identified by modification of the substituents at 5-methylidene position.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/Br)Oc1ccc(F)cc1-3,C20H17BrFNO,CHEMBL62700,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,250.0,250.0,250.0,250.0,2.397940009,2.397940009,2.397940009,6.602059991,6.602059991,6.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.0,250.0,250.0,250.0,6.6020599913279625,6.6020599913279625,6.6020599913279625,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100829,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(F)cc1-3,C19H18FNO,CHEMBL65079,1248.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1248.0,1248.0,1248.0,1248.0,3.096214585,3.096214585,3.096214585,5.903785415,5.903785415,5.903785415,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1248.0,1248.0,1248.0,1248.0,5.903785414653595,5.903785414653595,5.903785414653595,5.903785414653595,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100862,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Br)cc1-3,C19H18BrNO,CHEMBL63870,395.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,395.0,395.0,395.0,395.0,2.596597096,2.596597096,2.596597096,6.403402904,6.403402904,6.403402904,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,395.0,395.0,395.0,395.0,6.403402904373539,6.403402904373539,6.403402904373539,6.403402904373539,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100949,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,C19H18N2O3,CHEMBL64294,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
100977,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Br)cc1-3,C19H17BrFNO,CHEMBL62761,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,90.0,90.0,90.0,90.0,1.954242509,1.954242509,1.954242509,7.045757491,7.045757491,7.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,90.0,90.0,90.0,90.0,7.045757490560675,7.045757490560675,7.045757490560675,7.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101051,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(C#N)cc1-3,C20H17FN2O,CHEMBL62227,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101147,nM,IC50,,BAO_0000190,IC50,36126,Inhibition of antagonist activity towards human androgen receptor,0,F,,CHEMBL649558,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,C19H19F2NO,CHEMBL63788,147.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,147.0,147.0,147.0,147.0,2.167317335,2.167317335,2.167317335,6.832682665,6.832682665,6.832682665,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,147.0,147.0,147.0,147.0,6.8326826652518236,6.8326826652518236,6.8326826652518236,6.8326826652518236,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101149,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1ccc(Cl)cc1-3,C19H18ClNO,CHEMBL64123,788.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,788.0,788.0,788.0,788.0,2.896526217,2.896526217,2.896526217,6.103473783,6.103473783,6.103473783,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,788.0,788.0,788.0,788.0,6.103473782510445,6.103473782510445,6.103473782510445,6.103473782510445,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101289,nM,IC50,,BAO_0000190,IC50,36127,Inhibition of antagonist activity towards human Androgen receptor,0,F,,CHEMBL649559,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(F)cc1-3,C19H17F2NO,CHEMBL418684,644.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,644.0,644.0,644.0,644.0,2.808885867,2.808885867,2.808885867,6.191114133,6.191114133,6.191114133,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,644.0,644.0,644.0,644.0,6.1911141326401875,6.1911141326401875,6.1911141326401875,6.1911141326401875,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101405,nM,IC50,,BAO_0000190,IC50,36125,Inhibition of antagonist activity towards Androgen receptor,0,F,,CHEMBL649557,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1CC(C)(C)Nc2ccc3c(c21)COc1ccc([N+](=O)[O-])cc1-3,C19H20N2O3,CHEMBL293409,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,63.0,63.0,63.0,63.0,1.799340549,1.799340549,1.799340549,7.200659451,7.200659451,7.200659451,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,63.0,63.0,63.0,63.0,7.200659450546419,7.200659450546419,7.200659450546419,7.200659450546419,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
101712,nM,IC50,,BAO_0000190,IC50,36127,Inhibition of antagonist activity towards human Androgen receptor,0,F,,CHEMBL649559,10.1016/s0960-894x(03)00256-7,12781198,CHEMBL1144945,"Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore.",PUBLICATION,"A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring.",,CC1=CC(C)(C)Nc2ccc3c(c21)COc1c(F)cc(Cl)cc1-3,C19H17ClFNO,CHEMBL65743,428.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,428.0,428.0,428.0,428.0,2.631443769,2.631443769,2.631443769,6.368556231,6.368556231,6.368556231,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,428.0,428.0,428.0,428.0,6.368556230986828,6.368556230986828,6.368556230986828,6.368556230986828,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
102911,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, Entry 8: BAO_0000190, Entry 9: BAO_0000190, ",mix,"Entry 0: 441967, Entry 1: 446573, Entry 2: 441969, Entry 3: 487550, Entry 4: 854887, Entry 5: 1520321, Entry 6: 1591302, Entry 7: 1648028, Entry 8: 1909470, Entry 9: 2230827, ","Entry 0: Agonist activity at human AR, Entry 1: Antagonist activity at human androgen receptor by luciferase reporter gene assay, Entry 2: Antagonist activity at human AR, Entry 3: Antagonist activity at wild type human recombinant androgen receptor assessed as inhibition of testosterone-induced growth of mouse androgen dependent SC3 cells by WST-1 method, Entry 4: Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay, Entry 5: Antagonist activity at AR T877A mutant expressed in human LNCaP cells assessed as inhibition of 10 nM DHT-stimulated cell proliferation after 6 days by WST-8 assay, Entry 6: Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay, Entry 7: Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay, Entry 8: Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay, Entry 9: Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay, ","0,1,2","Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: F, Entry 4: B, Entry 5: B, Entry 6: B, Entry 7: B, Entry 8: B, Entry 9: B, ",,"Entry 0: CHEMBL891111, Entry 1: CHEMBL896867, Entry 2: CHEMBL891113, Entry 3: CHEMBL1013144, Entry 4: CHEMBL2162624, Entry 5: CHEMBL3626371, Entry 6: CHEMBL3829948, Entry 7: CHEMBL3997084, Entry 8: CHEMBL4411916, Entry 9: CHEMBL5144599, ","Entry 0: 10.1016/j.bmcl.2007.01.001, Entry 1: 10.1021/jm070231h, Entry 2: 10.1016/j.bmcl.2007.01.001, Entry 3: 10.1016/j.bmc.2008.05.063, Entry 4: 10.1021/jm300233k, Entry 5: 10.1016/j.ejmech.2015.08.002, Entry 6: 10.1016/j.bmcl.2016.06.001, Entry 7: 10.1016/j.bmcl.2017.01.065, Entry 8: 10.1021/acs.jmedchem.8b00973, Entry 9: 10.1016/j.bmcl.2021.128441, ","Entry 0: 17267219, Entry 1: 17887661, Entry 2: 17267219, Entry 3: 18571420, Entry 4: 22746350, Entry 5: 26295173, Entry 6: 27301368, Entry 7: 28162857, Entry 8: 30525603, Entry 9: 34767912, ","Entry 0: CHEMBL1147033, Entry 1: CHEMBL1148826, Entry 2: CHEMBL1147033, Entry 3: CHEMBL1155056, Entry 4: CHEMBL2157978, Entry 5: CHEMBL3621051, Entry 6: CHEMBL3826911, Entry 7: CHEMBL3994642, Entry 8: CHEMBL4411271, Entry 9: CHEMBL5143530, ","Entry 0: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., Entry 1: Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators., Entry 2: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., Entry 3: 4-(Anilino)pyrrole-2-carboxamides: Novel non-steroidal/non-anilide type androgen antagonists effective upon human prostate tumor LNCaP cells with mutated nuclear androgen receptor., Entry 4: Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators., Entry 5: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., Entry 6: Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety., Entry 7: Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents., Entry 8: New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity., Entry 9: Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, Entry 8: PUBLICATION, Entry 9: PUBLICATION, ","Entry 0: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., Entry 1: The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis., Entry 2: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., Entry 3: Various 4-(anilino)pyrrole-2-carboxamides were designed and synthesized as novel androgen receptor (AR) antagonists without steroidal or anilide structure, based on our strategy for developing full antagonists of nuclear receptors. Introduction of a bulky N-alkyl group, such as a cyclohexylmethyl or benzyl group, increased the binding affinity for wild-type AR and the potency for growth inhibition of androgen-dependent SC-3 cells. Among the compounds obtained, N-[4-[(benzyl)(4-nitrophenyl)amino]-1-methylpyrrole-2-carbonyl]pyrrolidine (22) is as potent an AR antagonist as the typical anilide-type AR antagonists hydroxyflutamide and bicalutamide. Further, compound 22 had potent binding affinity for T877A mutated AR, and dose-dependently inhibited the testosterone-induced production of prostate-specific antigen in LNCaP cells bearing T877A AR., Entry 4: We report here the design, preparation, and systematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen receptor (AR) modulators. Cycloalkane[d]isoxazoles form new core structures that interact with the hydrophobic region of the AR ligand-binding domain. To systematize and rationalize the structure-activity relationship of the new fragment, we used molecular modeling to design a molecular library containing over 40 cycloalkane[d]isoxazole derivatives. The most potent compound, 4-(3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile (6a), exhibits antiandrogenic activity significantly greater than that of the most widely used antiandrogenic prostate cancer drugs bicalutamide (1) and hydroxyflutamide (2) in reporter gene assays measuring the transcriptional activity of AR (decreasing approximately 90% of the total AR activity) and in competitive AR ligand-binding assays (showing over four times higher potency to inhibit radioligand binding in comparison to bicalutamide). Notably, 6a maintains its antiandrogenic activity with AR mutants W741L and T877A commonly observed and activated by bicalutamide and hydroxyflutamide, respectively, in prostate cancer patients., Entry 5: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., Entry 6: Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target. Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations. Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified., Entry 7: The structural modification and molecular docking-based screening approaches on thiazole-based isoindolinediones were imposed to find the novel 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives. The best fit compounds (6a-n) were synthesized and evaluated their antiproliferative activities on the prostate cancer cell lines (PC-3 & LNCaP). Among them, the compound, 6m exhibited good activity, particularly on LNCaP (IC50=5.961.6M), moderately active against PC-3 cell lines as compared to bicalutamide. The compound, 6m decreased the androgen-mediated transcription of ARE-mRNA in PSA, TMPRSS2, c-myc and cyclin D1 than R-bicalutamide. The compounds, 6e and 6f were reconfirmed through single crystal XRD analysis. The ADME profiling of the test compounds was evaluated to find the drug-likeness and pharmacokinetic parameters. These findings may provide vital information for the development of anti-prostate cancer agents., Entry 8: In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed., Entry 9: The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window., ",,C[C@](O)(CS(=O)(=O)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C18H14F4N2O4S,CHEMBL63560,120.23,128.0,162.0,248.0,270.0,350.0,490.0,850.0,10000.0,27710.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8405.260696,120.23,4032.823,310.0,27710.0,3.605609161,2.491361694,2.080012847,5.394390839,6.508638306,6.919987153,10,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,136.74333333333334,128.0,120.23,162.0,6.864093837697436,6.892790030352131,6.919987152892072,6.790484985457369,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
109571,nM,IC50,,BAO_0000190,IC50,36585,Antagonist activity for androgen receptor,0,F,,CHEMBL654202,10.1016/j.bmcl.2004.02.054,15081005,CHEMBL1147554,Novel pyrrole-containing progesterone receptor modulators.,PUBLICATION,"A series of 1,4-dihydro-2H-[d][3,1]-benzoxazin-2-one and 1,3-dihydro-[3H]-indol-2-one containing 6- or 5-, respectively, appended substituted pyrrole moieties were synthesized and evaluated for their ability to modulate the activity of the progesterone receptor (PR). Key structural changes to the pyrrole moieties of these molecules were shown to have a predictive influence as to whether the compounds behaved as PR agonists or antagonists. Compounds with the 5(')-cyano-2(')-pyrrole moiety (e.g., 32, 33, and 38) were shown to be potent PR agonists (EC(50)'s of 1.1, 1.8, and 2.8 nM, respectively). Compounds with the 5(')-nitro-2(')-pyrrole moiety (e.g., 34 and 36) were shown to be PR antagonists (IC(50)'s of 180 and 36 nM, respectively).",,N#Cc1cccc(-c2ccc3c(c2)C2(CCCCC2)C(=O)N3)c1,C20H18N2O,CHEMBL308938,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
118793,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,O=C1CC(c2ccccc2O)Oc2ccccc21,C15H12O3,CHEMBL75897,1000.0,6400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2700.0,1000.0,3700.0,3700.0,6400.0,3.568201724,3.568201724,3.0,5.431798276,5.431798276,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,3700.0,3700.0,1000.0,6400.0,5.431798275933005,5.431798275933005,6.0,5.1938200260161125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
155592,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CC(C)(c1ccc(O)cc1)c1ccc(O)cc1,C15H16O2,CHEMBL418971,5900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5900.0,5900.0,5900.0,5900.0,3.770852012,3.770852012,3.770852012,5.229147988,5.229147988,5.229147988,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5900.0,5900.0,5900.0,5900.0,5.229147988357856,5.229147988357856,5.229147988357856,5.229147988357856,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
167051,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Cl)c1)Oc1ccccc1-3,C25H22ClNO,CHEMBL320690,253.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,253.0,253.0,253.0,253.0,2.403120521,2.403120521,2.403120521,6.596879479,6.596879479,6.596879479,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,253.0,253.0,253.0,253.0,6.5968794788241825,6.5968794788241825,6.5968794788241825,6.5968794788241825,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167472,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cc(Cl)cc(Cl)c1)Oc1ccccc1-3,C25H21Cl2NO,CHEMBL102541,1089.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1089.0,1089.0,1089.0,1089.0,3.03702788,3.03702788,3.03702788,5.96297212,5.96297212,5.96297212,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1089.0,1089.0,1089.0,1089.0,5.962972120244225,5.962972120244225,5.962972120244225,5.962972120244225,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167762,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccccc1)Oc1ccccc1-3,C25H23NO,CHEMBL101914,745.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,745.0,745.0,745.0,745.0,2.872156273,2.872156273,2.872156273,6.127843727,6.127843727,6.127843727,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,745.0,745.0,745.0,745.0,6.127843727251707,6.127843727251707,6.127843727251707,6.127843727251707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167770,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(C)cc1)Oc1ccccc1-3,C26H25NO,CHEMBL102403,1239.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1239.0,1239.0,1239.0,1239.0,3.093071306,3.093071306,3.093071306,5.906928694,5.906928694,5.906928694,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1239.0,1239.0,1239.0,1239.0,5.906928693623937,5.906928693623937,5.906928693623937,5.906928693623937,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167801,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(C(F)(F)F)c1)Oc1ccccc1-3,C26H22F3NO,CHEMBL318513,315.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,315.0,315.0,315.0,315.0,2.498310554,2.498310554,2.498310554,6.501689446,6.501689446,6.501689446,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,315.0,315.0,315.0,315.0,6.501689446210399,6.501689446210399,6.501689446210399,6.501689446210399,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167863,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(F)c1)Oc1ccccc1-3,C25H21ClFNO,CHEMBL102754,2205.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2205.0,2205.0,2205.0,2205.0,3.343408594,3.343408594,3.343408594,5.656591406,5.656591406,5.656591406,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2205.0,2205.0,2205.0,2205.0,5.656591406196143,5.656591406196143,5.656591406196143,5.656591406196143,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167880,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cccc(Br)c1)Oc1ccccc1-3,C25H22BrNO,CHEMBL430855,401.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,401.0,401.0,401.0,401.0,2.603144373,2.603144373,2.603144373,6.396855627,6.396855627,6.396855627,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,401.0,401.0,401.0,401.0,6.396855627379818,6.396855627379818,6.396855627379818,6.396855627379818,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167900,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1cc(C)cc(Br)c1)Oc1ccccc1-3,C26H24BrNO,CHEMBL101907,1236.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1236.0,1236.0,1236.0,1236.0,3.092018471,3.092018471,3.092018471,5.907981529,5.907981529,5.907981529,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1236.0,1236.0,1236.0,1236.0,5.907981529247203,5.907981529247203,5.907981529247203,5.907981529247203,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167910,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Br)cc1)Oc1ccccc1-3,C25H22BrNO,CHEMBL103232,481.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,481.0,481.0,481.0,481.0,2.682145076,2.682145076,2.682145076,6.317854924,6.317854924,6.317854924,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,481.0,481.0,481.0,481.0,6.317854923626168,6.317854923626168,6.317854923626168,6.317854923626168,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167917,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(C)c(F)c1)Oc1ccccc1-3,C26H24FNO,CHEMBL103092,1220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1220.0,1220.0,1220.0,1220.0,3.086359831,3.086359831,3.086359831,5.913640169,5.913640169,5.913640169,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1220.0,1220.0,1220.0,1220.0,5.913640169325252,5.913640169325252,5.913640169325252,5.913640169325252,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167918,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(C)c1)Oc1ccccc1-3,C26H24ClNO,CHEMBL102720,1426.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1426.0,1426.0,1426.0,1426.0,3.154119526,3.154119526,3.154119526,5.845880474,5.845880474,5.845880474,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1426.0,1426.0,1426.0,1426.0,5.8458804744841535,5.8458804744841535,5.8458804744841535,5.8458804744841535,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
167919,nM,IC50,,BAO_0000190,IC50,36108,Antagonistic activity was determined in Human androgen receptor(hAR) of CV-1 cells in cotransfection assay.,0,F,,CHEMBL648073,10.1021/jm9705768,9464360,CHEMBL1131454,"5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines: a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"The development of a novel class of nonsteroidal human progesterone receptor (hPR) agonists, 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines 2, is described. The introduction of a 5-aryl group into the 1,2-dihydrocoumarino[3,4-f]quinoline core 1 is the key for progestational activities. The structure-activity relationship (SAR) studies of the 5-aryl substituents generated a series of potent hPR agonists, which exhibited similar biological activity (EC50 = 8-30 nM) to the natural hormone progesterone (EC50 = 2.9 nM) in cell-based assays with efficacies ranging from 28% to 96%. Most of the analogues displayed similar or greater binding affinity (Ki = 0.41-3.6 nM) than progesterone (Ki = 3.5 nM). Three representative analogues (13, 15, and 24) demonstrated in vivo activities in mammary gland morphology/uterine wet weight assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)C(c1ccc(Cl)c(Cl)c1)Oc1ccccc1-3,C25H21Cl2NO,CHEMBL317921,946.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,946.0,946.0,946.0,946.0,2.975891136,2.975891136,2.975891136,6.024108864,6.024108864,6.024108864,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,946.0,946.0,946.0,946.0,6.024108863598207,6.024108863598207,6.024108863598207,6.024108863598207,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
171837,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 624727, Entry 1: 624727, ","Entry 0: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, Entry 1: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1113403, Entry 1: CHEMBL1113403, ","Entry 0: 10.1016/j.bmcl.2010.02.059, Entry 1: 10.1016/j.bmcl.2010.02.059, ","Entry 0: 20226658, Entry 1: 20226658, ","Entry 0: CHEMBL1156958, Entry 1: CHEMBL1156958, ","Entry 0: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., Entry 1: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., Entry 1: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., ",,CC(=O)CCc1ccc(O)cc1,C10H12O2,CHEMBL105912,251188.64,252000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,405.68,251188.64,251594.32,251594.32,252000.0,5.400700832,5.400700832,5.399999995,3.599299168,3.599299168,3.600000005,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,251594.32,251594.32,251188.64,252000.0,3.5992991677597663,3.5992991677597663,3.6000000054478725,3.598599459218456,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
219275,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1=CC(C)(C)Nc2cc3nc(Cl)cc(C(F)(F)F)c3cc21,C16H14ClF3N2,CHEMBL133331,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219277,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1=CC(C)(C)Nc2cc3nc(F)cc(C(F)(F)F)c3cc21,C16H14F4N2,CHEMBL132803,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,31.0,31.0,31.0,31.0,1.491361694,1.491361694,1.491361694,7.508638306,7.508638306,7.508638306,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,31.0,31.0,31.0,31.0,7.508638306165727,7.508638306165727,7.508638306165727,7.508638306165727,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219312,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(Cl)nc3cc2N1,C15H14ClF3N2,CHEMBL133792,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219313,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,Cc1c2c(cc3c(C(F)(F)F)cc(Cl)nc13)C(C)CC(C)(C)N2,C17H18ClF3N2,CHEMBL131963,675.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,675.0,675.0,675.0,675.0,2.829303773,2.829303773,2.829303773,6.170696227,6.170696227,6.170696227,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,675.0,675.0,675.0,675.0,6.170696227168975,6.170696227168975,6.170696227168975,6.170696227168975,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219369,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(Br)nc3cc2N1,C15H14BrF3N2,CHEMBL134140,72.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,72.0,72.0,72.0,72.0,1.857332496,1.857332496,1.857332496,7.142667504,7.142667504,7.142667504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,72.0,72.0,72.0,72.0,7.142667503568732,7.142667503568732,7.142667503568732,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219402,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,Cc1c2c(cc3c(C(F)(F)F)cc(Br)nc13)C(C)CC(C)(C)N2,C17H18BrF3N2,CHEMBL134056,785.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,785.0,785.0,785.0,785.0,2.894869657,2.894869657,2.894869657,6.105130343,6.105130343,6.105130343,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,785.0,785.0,785.0,785.0,6.105130343254747,6.105130343254747,6.105130343254747,6.105130343254747,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219403,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(F)nc3cc2N1,C15H14F4N2,CHEMBL133503,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219589,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C16H17F3N2S,CHEMBL134242,751.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,751.0,751.0,751.0,751.0,2.875639937,2.875639937,2.875639937,6.124360063,6.124360063,6.124360063,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,751.0,751.0,751.0,751.0,6.124360062995832,6.124360062995832,6.124360062995832,6.124360062995832,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219626,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(C#N)nc3cc2N1,C16H14F3N3,CHEMBL335316,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9.0,9.0,9.0,9.0,0.954242509,0.954242509,0.954242509,8.045757491,8.045757491,8.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,9.0,9.0,9.0,9.0,8.045757490560675,8.045757490560675,8.045757490560675,8.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219627,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)ccnc3cc2N1,C15H15F3N2,CHEMBL338922,212.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,212.0,212.0,212.0,212.0,2.326335861,2.326335861,2.326335861,6.673664139,6.673664139,6.673664139,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,212.0,212.0,212.0,212.0,6.673664139071248,6.673664139071248,6.673664139071248,6.673664139071248,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219663,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,Cc1c2c(cc3c(C(F)(F)F)ccnc13)C(C)CC(C)(C)N2,C17H19F3N2,CHEMBL133054,244.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,244.0,244.0,244.0,244.0,2.387389826,2.387389826,2.387389826,6.612610174,6.612610174,6.612610174,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,244.0,244.0,244.0,244.0,6.61261017366127,6.61261017366127,6.61261017366127,6.61261017366127,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219839,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(NS(C)(=O)=O)nc3cc2N1,C16H18F3N3O2S,CHEMBL134180,503.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,503.0,503.0,503.0,503.0,2.701567985,2.701567985,2.701567985,6.298432015,6.298432015,6.298432015,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,503.0,503.0,503.0,503.0,6.298432014944073,6.298432014944073,6.298432014944073,6.298432014944073,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219840,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(N)nc3cc2N1,C15H16F3N3,CHEMBL133329,1159.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1159.0,1159.0,1159.0,1159.0,3.064083436,3.064083436,3.064083436,5.935916564,5.935916564,5.935916564,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1159.0,1159.0,1159.0,1159.0,5.935916564036404,5.935916564036404,5.935916564036404,5.935916564036404,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219842,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,COc1ccc(CNc2cc(C(F)(F)F)c3cc4c(cc3n2)NC(C)(C)CC4)cc1,C23H24F3N3O,CHEMBL134117,3217.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3217.0,3217.0,3217.0,3217.0,3.507451061,3.507451061,3.507451061,5.492548939,5.492548939,5.492548939,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3217.0,3217.0,3217.0,3217.0,5.49254893909803,5.49254893909803,5.49254893909803,5.49254893909803,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219853,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,C[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C16H17F3N2OS,CHEMBL134209,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,63.0,63.0,63.0,63.0,1.799340549,1.799340549,1.799340549,7.200659451,7.200659451,7.200659451,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,63.0,63.0,63.0,63.0,7.200659450546419,7.200659450546419,7.200659450546419,7.200659450546419,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219854,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(SCC(F)(F)F)nc3cc2N1,C17H16F6N2S,CHEMBL132354,889.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,889.0,889.0,889.0,889.0,2.948901761,2.948901761,2.948901761,6.051098239,6.051098239,6.051098239,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,889.0,889.0,889.0,889.0,6.051098239029787,6.051098239029787,6.051098239029787,6.051098239029787,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219866,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN1c2cc3nccc(C(F)(F)F)c3cc2CCC1(C)C,C16H17F3N2,CHEMBL132609,725.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,725.0,725.0,725.0,725.0,2.860338007,2.860338007,2.860338007,6.139661993,6.139661993,6.139661993,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,725.0,725.0,725.0,725.0,6.139661993429006,6.139661993429006,6.139661993429006,6.139661993429006,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219869,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN1c2cc3nc(Br)cc(C(F)(F)F)c3cc2CCC1(C)C,C16H16BrF3N2,CHEMBL133167,72.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,72.0,72.0,72.0,72.0,1.857332496,1.857332496,1.857332496,7.142667504,7.142667504,7.142667504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,72.0,72.0,72.0,72.0,7.142667503568732,7.142667503568732,7.142667503568732,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219876,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(S(C)(=O)=O)nc3cc2N1,C16H17F3N2O2S,CHEMBL132635,479.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,479.0,479.0,479.0,479.0,2.680335513,2.680335513,2.680335513,6.319664487,6.319664487,6.319664487,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,479.0,479.0,479.0,479.0,6.319664486585437,6.319664486585437,6.319664486585437,6.319664486585437,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219905,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN1c2cc3nc(F)cc(C(F)(F)F)c3cc2CCC1(C)C,C16H16F4N2,CHEMBL133465,172.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,172.0,172.0,172.0,172.0,2.235528447,2.235528447,2.235528447,6.764471553,6.764471553,6.764471553,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,172.0,172.0,172.0,172.0,6.764471553092451,6.764471553092451,6.764471553092451,6.764471553092451,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219906,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN1c2cc3nc(Cl)cc(C(F)(F)F)c3cc2CCC1(C)C,C16H16ClF3N2,CHEMBL133289,251.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,251.0,251.0,251.0,251.0,2.399673721,2.399673721,2.399673721,6.600326279,6.600326279,6.600326279,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,251.0,251.0,251.0,251.0,6.600326278518962,6.600326278518962,6.600326278518962,6.600326278518962,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
219949,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CCCC[S+]([O-])c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C19H23F3N2OS,CHEMBL132295,335.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,335.0,335.0,335.0,335.0,2.525044807,2.525044807,2.525044807,6.474955193,6.474955193,6.474955193,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,335.0,335.0,335.0,335.0,6.474955192963154,6.474955192963154,6.474955192963154,6.474955192963154,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220010,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(C(F)(F)F)nc3cc2N1,C16H14F6N2,CHEMBL132205,467.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,467.0,467.0,467.0,467.0,2.669316881,2.669316881,2.669316881,6.330683119,6.330683119,6.330683119,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,467.0,467.0,467.0,467.0,6.330683119433888,6.330683119433888,6.330683119433888,6.330683119433888,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220048,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN(C)c1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C17H20F3N3,CHEMBL132131,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
220050,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CCCCSc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C19H23F3N2S,CHEMBL133715,1866.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1866.0,1866.0,1866.0,1866.0,3.270911639,3.270911639,3.270911639,5.729088361,5.729088361,5.729088361,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1866.0,1866.0,1866.0,1866.0,5.729088360589519,5.729088360589519,5.729088360589519,5.729088360589519,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220092,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1=CC(C)(C)N(C)c2cc3nc(Cl)cc(C(F)(F)F)c3cc21,C17H16ClF3N2,CHEMBL132516,336.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,336.0,336.0,336.0,336.0,2.526339277,2.526339277,2.526339277,6.473660723,6.473660723,6.473660723,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,336.0,336.0,336.0,336.0,6.473660722610156,6.473660722610156,6.473660722610156,6.473660722610156,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220354,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,COc1ccc(-c2coc3cc(O)cc(O)c3c2=O)cc1,C16H12O5,CHEMBL131921,1600000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1600000.0,1600000.0,1600000.0,1600000.0,6.204119983,6.204119983,6.204119983,2.795880017,2.795880017,2.795880017,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,1600000.0,1600000.0,1600000.0,1600000.0,2.795880017344075,2.795880017344075,2.795880017344075,2.795880017344075,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
220457,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CC1(C)CCc2cc3c(C(F)(F)F)cc(N(S(C)(=O)=O)S(C)(=O)=O)nc3cc2N1,C17H20F3N3O4S2,CHEMBL134303,636.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,636.0,636.0,636.0,636.0,2.803457116,2.803457116,2.803457116,6.196542884,6.196542884,6.196542884,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,636.0,636.0,636.0,636.0,6.196542884351586,6.196542884351586,6.196542884351586,6.196542884351586,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220498,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,Cc1c2c(cc3c(C(F)(F)F)cc(F)nc13)C(C)CC(C)(C)N2,C17H18F4N2,CHEMBL133825,1448.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1448.0,1448.0,1448.0,1448.0,3.160768562,3.160768562,3.160768562,5.839231438,5.839231438,5.839231438,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1448.0,1448.0,1448.0,1448.0,5.839231438138872,5.839231438138872,5.839231438138872,5.839231438138872,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
220499,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CNc1cc(C(F)(F)F)c2cc3c(cc2n1)NC(C)(C)CC3,C16H18F3N3,CHEMBL335948,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
220600,nM,IC50,,BAO_0000190,IC50,36124,Inhibitory concentration against human androgen receptor (AR) dependent transcriptional activity in co-transfected mammalian CV-1 cells,0,F,,CHEMBL649556,10.1016/s0960-894x(00)00010-x,10743937,CHEMBL1133046,"Effects of isosteric pyridone replacements in androgen receptor antagonists based on 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethyl-8-pyridono[5,6-g]quin olines.",PUBLICATION,"A series of nonsteroidal human androgen receptor (hAR) antagonists based on 8-substituted 1,2-dihydro- and 1,2,3,4-tetrahydro-2,2-dimethyl-6-trifluoromethylpyrido[3,2-g]quin olines was synthesized. Compounds in this series were tested for the ability to bind to hAR and inhibit hAR-dependent transcription in a mammalian cellular background.",,CN1c2cc3nc(C#N)cc(C(F)(F)F)c3cc2CCC1(C)C,C17H16F3N3,CHEMBL132427,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,45.0,45.0,45.0,45.0,1.653212514,1.653212514,1.653212514,7.346787486,7.346787486,7.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
226190,nM,IC50,,BAO_0000190,IC50,44195,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,0,B,,CHEMBL654136,10.1021/jm980366a,9784110,CHEMBL1131161,"5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1cc(F)ccc1F)Oc1ccccc1-3,C26H21F2NO,CHEMBL137103,1600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1600.0,1600.0,1600.0,1600.0,3.204119983,3.204119983,3.204119983,5.795880017,5.795880017,5.795880017,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1600.0,1600.0,1600.0,1600.0,5.795880017344075,5.795880017344075,5.795880017344075,5.795880017344075,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
226650,nM,IC50,,BAO_0000190,IC50,44194,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,0,F,,CHEMBL654135,10.1021/jm980366a,9784110,CHEMBL1131161,"5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccccc1)Oc1ccccc1-3,C26H23NO,CHEMBL134421,650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,650.0,650.0,650.0,650.0,2.812913357,2.812913357,2.812913357,6.187086643,6.187086643,6.187086643,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,650.0,650.0,650.0,650.0,6.187086643357144,6.187086643357144,6.187086643357144,6.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
227145,nM,IC50,,BAO_0000190,IC50,44195,Inhibitory activity (IC50) against human androgen receptor expressed in CV-1 cells,0,B,,CHEMBL654136,10.1021/jm980366a,9784110,CHEMBL1131161,"5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists.",PUBLICATION,"A novel series of nonsteroidal progestins, 5-benzylidene-1, 2-dihydrochromeno[3,4-f]quinolines (2), was discovered, and a preliminary structure-activity relationship study around the 5-benzylidene ring generated several potent human progesterone receptor agonists (compounds 8, 16). These new progestins showed biological activities (EC50 = 5.7 and 7.6 nM) similar to progesterone (EC50 = 2.9 nM) in the cotransfection assay with high efficacy (132% and 166%) and binding affinity (Ki = 0.66 and 0.83 nM) similar to medroxyprogesterone acetate (MPA) (Ki = 0.34 nM). A representative analogue, 8, demonstrated similar oral potency to MPA in the uterine wet weight/mammary gland morphology assay in ovariectomized rats.",,CC1=CC(C)(C)Nc2ccc3c(c21)/C(=C/c1ccc(F)c(F)c1)Oc1ccccc1-3,C26H21F2NO,CHEMBL342426,916.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,916.0,916.0,916.0,916.0,2.961895474,2.961895474,2.961895474,6.038104526,6.038104526,6.038104526,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,916.0,916.0,916.0,916.0,6.03810452633215,6.03810452633215,6.03810452633215,6.03810452633215,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
227747,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36112, Entry 1: 1735708, ","Entry 0: Antagonist activity against the Androgen Receptor (AR), Entry 1: Antagonist activity at human AR assessed as reduction in DHT-induced transactivation, ",0,"Entry 0: F, Entry 1: A, ",,"Entry 0: CHEMBL648077, Entry 1: CHEMBL4151244, ","Entry 0: 10.1021/jm025555e, Entry 1: 10.1021/acsmedchemlett.8b00058, ","Entry 0: 12238914, Entry 1: 30034593, ","Entry 0: CHEMBL1135816, Entry 1: CHEMBL4145662, ","Entry 0: 6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists., Entry 1: Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Novel 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones were synthesized and tested as progesterone receptor (PR) antagonists. These compounds were potent and showed good selectivity for PR over other steroid receptors such as the glucocorticoid and androgen receptors (e.g., greater than 80-fold selectivity at PR for 4h). Numerous 6-aryl benzoxazinones (e.g., 4h-j) were active orally in the uterine decidualization and component C3 assays in the rats. In these in vivo models,4h had potencies comparable to mifepristone., Entry 1: The progesterone receptor (PR) plays an important role in various physiological systems, including female reproduction and the central nervous system, and PR antagonists are thought to be effective not only as contraceptive agents and abortifacients but also in the treatment of various diseases, including hormone-dependent cancers and endometriosis. Here, we identified phenanthridin-6(5H)-one derivatives as a new class of PR antagonists and investigated their structure-activity relationships. Among the synthesized compounds, 37, 40, and 46 exhibited very potent PR antagonistic activity with high selectivity for PR over other nuclear receptors. These compounds are structurally distinct from other nonsteroidal PR antagonists, including cyanoaryl derivatives, and should be useful for further studies of the clinical utility of PR antagonists., ",,CC1(C)OC(=O)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,C17H13FN2O2,CHEMBL136322,1292.0,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,1292.0,1296.0,1296.0,1300.0,3.112605002,3.112605002,3.111262514,5.887394998,5.887394998,5.888737486,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1292.0,1292.0,1292.0,1292.0,5.8887374863409345,5.8887374863409345,5.8887374863409345,5.8887374863409345,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
227909,nM,IC50,,BAO_0000190,IC50,36112,Antagonist activity against the Androgen Receptor (AR),0,F,,CHEMBL648077,10.1021/jm025555e,12238914,CHEMBL1135816,"6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.",PUBLICATION,"Novel 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones were synthesized and tested as progesterone receptor (PR) antagonists. These compounds were potent and showed good selectivity for PR over other steroid receptors such as the glucocorticoid and androgen receptors (e.g., greater than 80-fold selectivity at PR for 4h). Numerous 6-aryl benzoxazinones (e.g., 4h-j) were active orally in the uterine decidualization and component C3 assays in the rats. In these in vivo models,4h had potencies comparable to mifepristone.",,CC1(C)OC(=O)Nc2ccc(-c3ccc(F)c(Cl)c3)cc21,C16H13ClFNO2,CHEMBL343306,207.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,207.0,207.0,207.0,207.0,2.315970345,2.315970345,2.315970345,6.684029655,6.684029655,6.684029655,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,207.0,207.0,207.0,207.0,6.684029654543083,6.684029654543083,6.684029654543083,6.684029654543083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
228475,nM,IC50,,BAO_0000190,IC50,36112,Antagonist activity against the Androgen Receptor (AR),0,F,,CHEMBL648077,10.1021/jm025555e,12238914,CHEMBL1135816,"6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.",PUBLICATION,"Novel 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones were synthesized and tested as progesterone receptor (PR) antagonists. These compounds were potent and showed good selectivity for PR over other steroid receptors such as the glucocorticoid and androgen receptors (e.g., greater than 80-fold selectivity at PR for 4h). Numerous 6-aryl benzoxazinones (e.g., 4h-j) were active orally in the uterine decidualization and component C3 assays in the rats. In these in vivo models,4h had potencies comparable to mifepristone.",,CC1(C)OC(=O)Nc2ccc(-c3coc(C#N)c3)cc21,C15H12N2O3,CHEMBL138059,129.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,129.0,129.0,129.0,129.0,2.11058971,2.11058971,2.11058971,6.88941029,6.88941029,6.88941029,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,129.0,129.0,129.0,129.0,6.889410289700751,6.889410289700751,6.889410289700751,6.889410289700751,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
228503,nM,IC50,,BAO_0000190,IC50,36112,Antagonist activity against the Androgen Receptor (AR),0,F,,CHEMBL648077,10.1021/jm025555e,12238914,CHEMBL1135816,"6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists.",PUBLICATION,"Novel 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones were synthesized and tested as progesterone receptor (PR) antagonists. These compounds were potent and showed good selectivity for PR over other steroid receptors such as the glucocorticoid and androgen receptors (e.g., greater than 80-fold selectivity at PR for 4h). Numerous 6-aryl benzoxazinones (e.g., 4h-j) were active orally in the uterine decidualization and component C3 assays in the rats. In these in vivo models,4h had potencies comparable to mifepristone.",,CC1(C)OC(=O)Nc2ccc(-c3csc(C#N)c3)cc21,C15H12N2O2S,CHEMBL139749,280.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,280.0,280.0,280.0,280.0,2.447158031,2.447158031,2.447158031,6.552841969,6.552841969,6.552841969,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,280.0,280.0,280.0,280.0,6.552841968657781,6.552841968657781,6.552841968657781,6.552841968657781,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
236019,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36107, Entry 1: 2160327, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 1: Antagonist activity at human AR AF2 assessed as inhibition of fluorescent-labelled D11-FxxLF peptide Co-activator to receptor by TR-FRET assay, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648072, Entry 1: CHEMBL5045077, ","Entry 0: 10.1021/jm970699s, Entry 1: 10.1021/acs.jmedchem.1c01938, ","Entry 0: 9484511, Entry 1: 35077161, ","Entry 0: CHEMBL1131477, Entry 1: CHEMBL5042532, ","Entry 0: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 1: Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases., Entry 1: Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment., ",,CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)[C@@H]5C[C@@H]5[C@]4(C)[C@H]3CC[C@@]21C,C24H29ClO4,CHEMBL139835,23.0,258.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,117.8,23.0,140.8,140.8,258.6,2.148602655,2.148602655,1.361727836,6.851397345,6.851397345,7.638272164,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
242493,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,O=c1cc(-c2ccccc2O)oc2ccccc12,C15H10O3,CHEMBL144278,1000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4500.0,1000.0,5500.0,5500.0,10000.0,3.740362689,3.740362689,3.0,5.259637311,5.259637311,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
243360,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,COc1cccc2oc(-c3ccc(F)cc3)cc(=O)c12,C16H11FO3,CHEMBL143978,1610.0,1621.81,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.905,1610.0,1615.905,1615.905,1621.81,3.208415825,3.208415825,3.206825876,5.791584175,5.791584175,5.793174124,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1615.905,1615.905,1610.0,1621.81,5.791584175237514,5.791584175237514,5.79317412396815,5.790000026071145,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
244434,nM,IC50,,BAO_0000190,IC50,144886,In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor,0,F,,CHEMBL749959,10.1021/jm001000c,11150172,CHEMBL1133568,"Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist.",PUBLICATION,"Herein we describe the chemical synthesis and pharmacological characterization of a novel, highly potent progesterone receptor (PR) antagonist, ZK 230211. The introduction of a 17alpha-pentafluorethyl side chain in the D-ring of the steroid skeleton allowed the combination of high antiprogestagenic activity with little or no other endocrinological effects. In contrast to many other antiprogestins, ZK 230211 did not convert to an agonist in the presence of protein kinase A (PKA) activators and showed high antiprogestagenic activity on both PR isoforms PR-A and PR-B. This high antiprogestagenic activity could also be demonstrated in several in vivo models. Furthermore, this compound displayed only marginal antiglucocorticoid effects. In tumor models ZK 230211 exhibited strong antiproliferative action. The pharmacological properties of ZK 230211 may prove useful in the treatment of endometriosis, leiomyomas, breast cancer, and in hormone replacement therapy.",,CC(=O)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C(F)(F)C(F)(F)F)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,C28H29F5O3,CHEMBL146032,54.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,54.0,54.0,54.0,54.0,1.73239376,1.73239376,1.73239376,7.26760624,7.26760624,7.26760624,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,54.0,54.0,54.0,54.0,7.267606240177032,7.267606240177032,7.267606240177032,7.267606240177032,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
249414,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 36123, Entry 1: 306281, Entry 2: 2027527, Entry 3: 2214674, ","Entry 0: Inhibition of 1.0 nM [3H]mibolerone binding to human androgen receptor of PC3/AR cell lysate, Entry 1: Inhibition of [3H]mibolerone binding to human Androgen receptor of PC3/AR Cell Lysate, Entry 2: Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay, Entry 3: Inhibition of Androgen receptor (unknown origin), ","2,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL647749, Entry 1: CHEMBL828424, Entry 2: CHEMBL4681685, Entry 3: CHEMBL5127806, ","Entry 0: 10.1021/jm0303305, Entry 1: 10.1021/jm0495226, Entry 2: 10.1021/acs.jmedchem.6b01410, Entry 3: 10.1016/j.ejmech.2022.114119, ","Entry 0: 14613328, Entry 1: 15509168, Entry 2: 27933964, Entry 3: 35063736, ","Entry 0: CHEMBL1145911, Entry 1: CHEMBL1138810, Entry 2: CHEMBL4680100, Entry 3: CHEMBL5126525, ","Entry 0: Rational design and synthesis of androgen receptor-targeted nonsteroidal anti-androgen ligands for the tumor-specific delivery of a doxorubicin-formaldehyde conjugate., Entry 1: Studies of targeting and intracellular trafficking of an anti-androgen doxorubicin-formaldehyde conjugate in PC-3 prostate cancer cells bearing androgen receptor-GFP chimera., Entry 2: Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978)., Entry 3: Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The synthesis and preliminary evaluation of a doxorubicin-formaldehyde conjugate tethered to the nonsteroidal antiandrogen, cyanonilutamide (RU 56279), for the treatment of prostate cancer are reported. The relative ability of the targeting group to bind to the human androgen receptor was studied as a function of tether. The tether served to attach the antiandrogen to the doxorubicin-formaldehyde conjugate via an N-Mannich base of a salicylamide derivative. The salicylamide was selected to serve as a trigger release mechanism to separate the doxorubicin-formaldehyde conjugate from the targeting group after it has bound to the androgen receptor. The remaining part of the tether consisted of a linear group that spanned from the 5-position of the salicylamide to the 3'-position of cyanonilutamide. The structures explored for the linear region of the tether were derivatives of di(ethylene glycol), tri(ethylene glycol), N,N'-disubstituted-piperazine, and 2-butyne-1,4-diol. Relative binding affinity of the tethers bound to the targeting group for human androgen receptor were measured using a (3)H-Mibolerone competition assay and varied from 18% of nilutamide binding for the butynediol-based linear region to less than 1% for one of the piperazine derivatives. The complete targeted drug with the butynediol-based linear region has a relative binding affinity of 10%. This relative binding affinity is encouraging in light of the cocrystal structure of human androgen receptor ligand binding domain bound to the steroid Metribolone which predicts very limited space for a tether connecting the antiandrogen on the inside to the cytotoxin on the outside., Entry 1: The synthesis of a doxorubicin-formaldehyde conjugate bound to the nonsteroidal anti-androgen cyanonilutamide, via a cleavable tether, and binding of the construct to cell free androgen receptor (AR) as a function of tether design were previously reported. Cyanonilutamide bearing a linear alkyne tether bound to the AR better than other designs. Fluorescence microscopy studies of binding of the lead targeted drug, as well as various tethered cyanonilutamides, to the AR and subsequent trafficking of the resulting AR complex in live PC3 prostate cancer cells transfected with AR-green fluorescent protein (GFP) chimera are now described. Cyanonilutamide and cyanonilutamide bonded to a linear alkyne tether caused translocation of AR-GFP to the nucleus. In general, the ability of tethered cyanonilutamides to cause translocation paralleled their binding affinity for the AR. However, a noncleavable form of the lead cyanonilutamide-doxorubicin-formaldehyde conjugate bound to AR-GFP but the resulting complex did not translocate to the nucleus. Binding was apparent from the drugs inhibition of Mibolerone-induced translocation. Direct observation of anthraquinone fluorescence of targeted drug in PC3 cells showed initial cytosolic localization, independent of AR expression, with predominant nuclear localization after sufficient time for release of drug from the targeting moiety. The results indicate that doxorubicin-formaldehyde conjugate bonded to cyanonilutamide via a cleavable linear tether enters PC3 cells, resides in cytosol, binds to the AR if present, and ultimately releases doxorubicin or a doxorubicin derivative to the nucleus., Entry 2: The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins., Entry 3: Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated., ",,CC1(C)NC(=O)N(c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)C1=O,C12H10F3N3O4,CHEMBL1274,9.0,9.0,600.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2089.837374,9.0,1404.5,304.5,5000.0,3.147521744,2.483587297,0.954242509,5.852478256,6.516412703,8.045757491,4,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,2800.0,2800.0,600.0,5000.0,5.552841968657781,5.552841968657781,6.221848749616356,5.301029995663981,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262064,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N1CCCC1(C)CC3,C18H19F3N2O,CHEMBL157407,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262065,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NC1(CCCCC1)CC3,C18H19F3N2O,CHEMBL345854,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,35.0,35.0,35.0,35.0,1.544068044,1.544068044,1.544068044,7.455931956,7.455931956,7.455931956,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,35.0,35.0,35.0,35.0,7.455931955649724,7.455931955649724,7.455931955649724,7.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262352,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NC(C)(C)CC3,C16H17F3N2O,CHEMBL346827,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,36.0,36.0,36.0,36.0,1.556302501,1.556302501,1.556302501,7.443697499,7.443697499,7.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,36.0,36.0,36.0,36.0,7.443697499232713,7.443697499232713,7.443697499232713,7.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262354,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,Cc1c2c(cc3c(C(F)(F)F)cc(=O)n(C)c13)C(C)CC(C)(C)N2,C18H21F3N2O,CHEMBL352002,31.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,31.0,31.0,31.0,31.0,1.491361694,1.491361694,1.491361694,7.508638306,7.508638306,7.508638306,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,31.0,31.0,31.0,31.0,7.508638306165727,7.508638306165727,7.508638306165727,7.508638306165727,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262355,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)Nc2c1cc1c(C(F)(F)F)cc(=O)n(C)c1c2C,C18H19F3N2O,CHEMBL160923,2413.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2413.0,2413.0,2413.0,2413.0,3.382557322,3.382557322,3.382557322,5.617442678,5.617442678,5.617442678,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2413.0,2413.0,2413.0,2413.0,5.617442678091214,5.617442678091214,5.617442678091214,5.617442678091214,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262426,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36107, Entry 1: 438255, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 1: Antagonist activity at human androgen receptor expressed in CV1 cells, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL648072, Entry 1: CHEMBL887361, ","Entry 0: 10.1021/jm970699s, Entry 1: 10.1016/j.bmcl.2007.01.007, ","Entry 0: 9484511, Entry 1: 17257838, ","Entry 0: CHEMBL1131477, Entry 1: CHEMBL1144605, ","Entry 0: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 1: Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases., Entry 1: A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays., ",,CC1(C)C=Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C15H13F3N2O,CHEMBL350877,27.0,58.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.5,27.0,42.5,42.5,58.0,1.62838893,1.62838893,1.431363764,7.37161107,7.37161107,7.568636236,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.5,42.5,27.0,58.0,7.371611069949688,7.371611069949688,7.568636235841013,7.236572006437063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262456,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,C[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC(C)(C)[C@H]1C,C17H19F3N2O,CHEMBL156641,164.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,164.0,164.0,164.0,164.0,2.214843848,2.214843848,2.214843848,6.785156152,6.785156152,6.785156152,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,164.0,164.0,164.0,164.0,6.785156151952302,6.785156151952302,6.785156151952302,6.785156151952302,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262457,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=C(C)C(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C17H17F3N2O,CHEMBL349539,68.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,68.0,68.0,68.0,68.0,1.832508913,1.832508913,1.832508913,7.167491087,7.167491087,7.167491087,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,68.0,68.0,68.0,68.0,7.167491087293763,7.167491087293763,7.167491087293763,7.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262629,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C16H17F3N2O,CHEMBL351148,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23.0,23.0,23.0,23.0,1.361727836,1.361727836,1.361727836,7.638272164,7.638272164,7.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262646,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1(CC)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C17H19F3N2O,CHEMBL160250,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262664,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC12CCCN1c1cc3nc(O)cc(C(F)(F)F)c3cc1CC2,C17H17F3N2O,CHEMBL156312,325.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,325.0,325.0,325.0,325.0,2.511883361,2.511883361,2.511883361,6.488116639,6.488116639,6.488116639,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,325.0,325.0,325.0,325.0,6.488116639021126,6.488116639021126,6.488116639021126,6.488116639021126,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262666,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1CC(C)(C)Nc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,C17H19F3N2O,CHEMBL156278,73.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,73.0,73.0,73.0,73.0,1.86332286,1.86332286,1.86332286,7.13667714,7.13667714,7.13667714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,73.0,73.0,73.0,73.0,7.136677139879544,7.136677139879544,7.136677139879544,7.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262686,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,Cc1c2c(cc3c(C(F)(F)F)cc(O)nc13)C(C)CC(C)(C)N2,C17H19F3N2O,CHEMBL347910,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262707,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NC(C)(C)C=C3C,C18H19F3N2O,CHEMBL160239,692.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,692.0,692.0,692.0,692.0,2.840106094,2.840106094,2.840106094,6.159893906,6.159893906,6.159893906,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,692.0,692.0,692.0,692.0,6.1598939055432425,6.1598939055432425,6.1598939055432425,6.1598939055432425,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262709,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,C[C@@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC(C)(C)[C@H]1C,C17H19F3N2O,CHEMBL160257,7042.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7042.0,7042.0,7042.0,7042.0,3.847696021,3.847696021,3.847696021,5.152303979,5.152303979,5.152303979,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7042.0,7042.0,7042.0,7042.0,5.1523039792658345,5.1523039792658345,5.1523039792658345,5.1523039792658345,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
262740,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCCC1(C)CCc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C17H19F3N2O,CHEMBL160713,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.0,42.0,42.0,42.0,1.62324929,1.62324929,1.62324929,7.37675071,7.37675071,7.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.0,42.0,42.0,42.0,7.376750709602099,7.376750709602099,7.376750709602099,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262741,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)N(C)c2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,C18H19F3N2O,CHEMBL345342,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,46.0,46.0,46.0,46.0,1.662757832,1.662757832,1.662757832,7.337242168,7.337242168,7.337242168,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,46.0,46.0,46.0,46.0,7.337242168318426,7.337242168318426,7.337242168318426,7.337242168318426,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262754,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC(C)(C)C1(C)C,C18H21F3N2O,CHEMBL157344,57.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,57.0,57.0,57.0,57.0,1.755874856,1.755874856,1.755874856,7.244125144,7.244125144,7.244125144,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,57.0,57.0,57.0,57.0,7.2441251443275085,7.2441251443275085,7.2441251443275085,7.2441251443275085,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262756,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC(C)C1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C18H21F3N2O,CHEMBL156751,159.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,159.0,159.0,159.0,159.0,2.201397124,2.201397124,2.201397124,6.798602876,6.798602876,6.798602876,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,159.0,159.0,159.0,159.0,6.798602875679548,6.798602875679548,6.798602875679548,6.798602875679548,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262773,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)Nc2cc3c(cc21)c(C(F)(F)F)cc(=O)n3C,C17H17F3N2O,CHEMBL160386,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34.0,34.0,34.0,34.0,1.531478917,1.531478917,1.531478917,7.468521083,7.468521083,7.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,34.0,34.0,34.0,34.0,7.468521082957745,7.468521082957745,7.468521082957745,7.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262786,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1(C)Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,C17H19F3N2O,CHEMBL156806,83.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,83.0,83.0,83.0,83.0,1.919078092,1.919078092,1.919078092,7.080921908,7.080921908,7.080921908,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,83.0,83.0,83.0,83.0,7.080921907623926,7.080921907623926,7.080921907623926,7.080921907623926,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262833,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C17H19F3N2O,CHEMBL156982,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262835,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,C17H19F3N2O,CHEMBL350465,46.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,46.0,46.0,46.0,46.0,1.662757832,1.662757832,1.662757832,7.337242168,7.337242168,7.337242168,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,46.0,46.0,46.0,46.0,7.337242168318426,7.337242168318426,7.337242168318426,7.337242168318426,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262872,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2NC1(C)C,C16H17F3N2O,CHEMBL160665,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262899,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)Nc2c1cc1c(C(F)(F)F)cc(O)nc1c2C,C17H17F3N2O,CHEMBL157703,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23.0,23.0,23.0,23.0,1.361727836,1.361727836,1.361727836,7.638272164,7.638272164,7.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262934,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H15F3N2O,CHEMBL160451,28.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,28.0,28.0,28.0,28.0,1.447158031,1.447158031,1.447158031,7.552841969,7.552841969,7.552841969,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,28.0,28.0,28.0,28.0,7.552841968657781,7.552841968657781,7.552841968657781,7.552841968657781,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262980,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1CC(C)(C)Nc2cc3nc(O)cc(C(F)(F)F)c3cc21,C16H17F3N2O,CHEMBL156142,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26.0,26.0,26.0,26.0,1.414973348,1.414973348,1.414973348,7.585026652,7.585026652,7.585026652,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,26.0,26.0,26.0,26.0,7.585026652029182,7.585026652029182,7.585026652029182,7.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
262981,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)Nc2cc3nc(O)cc(C)c3cc21,C16H18N2O,CHEMBL346487,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,36.0,36.0,36.0,36.0,1.556302501,1.556302501,1.556302501,7.443697499,7.443697499,7.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,36.0,36.0,36.0,36.0,7.443697499232713,7.443697499232713,7.443697499232713,7.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
263511,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1(C)CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N1C,C18H21F3N2O,CHEMBL160230,24.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,24.0,24.0,24.0,24.0,1.380211242,1.380211242,1.380211242,7.619788758,7.619788758,7.619788758,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,24.0,24.0,24.0,24.0,7.619788758288394,7.619788758288394,7.619788758288394,7.619788758288394,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
263512,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CN1c2cc3c(cc2CCC1(C)C)c(C(F)(F)F)cc(=O)n3C,C17H19F3N2O,CHEMBL435651,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
263604,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CC1=CC(C)(C)N(C)c2cc3nc(O)cc(C(F)(F)F)c3cc21,C17H17F3N2O,CHEMBL347870,156.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,156.0,156.0,156.0,156.0,2.193124598,2.193124598,2.193124598,6.806875402,6.806875402,6.806875402,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,156.0,156.0,156.0,156.0,6.806875401645539,6.806875401645539,6.806875401645539,6.806875401645539,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
263634,nM,IC50,,BAO_0000190,IC50,36107,Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells.,0,F,,CHEMBL648072,10.1021/jm970699s,9484511,CHEMBL1131477,"Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines.",PUBLICATION,"A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases.",,CCC1(C)CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N1,C17H19F3N2O,CHEMBL422707,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,48.0,48.0,48.0,48.0,1.681241237,1.681241237,1.681241237,7.318758763,7.318758763,7.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272428,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@@H]1Cc2cc3c(C(F)(F)F)cc(O)nc3cc2N1,C13H11F3N2O,CHEMBL351465,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.0,7.0,7.0,7.0,0.84509804,0.84509804,0.84509804,8.15490196,8.15490196,8.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.0,7.0,7.0,7.0,8.154901959985743,8.154901959985743,8.154901959985743,8.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272451,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CCCN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,C20H23F3N2O,CHEMBL165912,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272452,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CCn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)N[C@@H]1CCCC[C@H]31,C18H19F3N2O,CHEMBL352456,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,230.0,230.0,230.0,230.0,2.361727836,2.361727836,2.361727836,6.638272164,6.638272164,6.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,230.0,230.0,230.0,230.0,6.638272163982407,6.638272163982407,6.638272163982407,6.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272478,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CN1c2cc3c(cc2[C@H]2CCCC[C@H]21)c(C(F)(F)F)cc(=O)n3C,C18H19F3N2O,CHEMBL161892,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,36.0,36.0,36.0,36.0,1.556302501,1.556302501,1.556302501,7.443697499,7.443697499,7.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,36.0,36.0,36.0,36.0,7.443697499232713,7.443697499232713,7.443697499232713,7.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272495,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@H]1N(C)c2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,C17H19F3N2O,CHEMBL349631,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,56.0,56.0,56.0,56.0,1.748188027,1.748188027,1.748188027,7.251811973,7.251811973,7.251811973,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,56.0,56.0,56.0,56.0,7.251811972993799,7.251811972993799,7.251811972993799,7.251811972993799,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272496,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@H]1Nc2cc3c(cc2C1(C)C)c(C(F)(F)F)cc(=O)n3C,C16H17F3N2O,CHEMBL351519,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272497,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@H]1Nc2cc3nc(O)cc(C(F)(F)F)c3cc2C1(C)C,C15H15F3N2O,CHEMBL165219,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,48.0,48.0,48.0,48.0,1.681241237,1.681241237,1.681241237,7.318758763,7.318758763,7.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272515,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@H]1CC[C@@H]2[C@H](C1)c1cc3c(C(F)(F)F)cc(=O)n(C)c3cc1N2C,C19H21F3N2O,CHEMBL161980,54.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,54.0,54.0,54.0,54.0,1.73239376,1.73239376,1.73239376,7.26760624,7.26760624,7.26760624,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,54.0,54.0,54.0,54.0,7.267606240177032,7.267606240177032,7.267606240177032,7.267606240177032,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272548,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@H]1CC[C@H]2Nc3cc4c(cc3[C@H]2C1)c(C(F)(F)F)cc(=O)n4C,C18H19F3N2O,CHEMBL165803,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,48.0,48.0,48.0,48.0,1.681241237,1.681241237,1.681241237,7.318758763,7.318758763,7.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272661,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CN1CCc2cc3c(C(F)(F)F)cc(=O)n(C)c3cc21,C14H13F3N2O,CHEMBL162103,197.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,197.0,197.0,197.0,197.0,2.294466226,2.294466226,2.294466226,6.705533774,6.705533774,6.705533774,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,197.0,197.0,197.0,197.0,6.705533773838407,6.705533773838407,6.705533773838407,6.705533773838407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272662,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CN1c2cc3c(cc2[C@H]2CCCC(C)(C)[C@H]21)c(C(F)(F)F)cc(=O)n3C,C20H23F3N2O,CHEMBL163142,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272663,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CC1(C)CCC[C@@H]2c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@@H]21,C18H19F3N2O,CHEMBL162368,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26.0,26.0,26.0,26.0,1.414973348,1.414973348,1.414973348,7.585026652,7.585026652,7.585026652,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,26.0,26.0,26.0,26.0,7.585026652029182,7.585026652029182,7.585026652029182,7.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272664,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,Cn1c(=O)cc(C(F)(F)F)c2cc3c(cc21)NCC3,C13H11F3N2O,CHEMBL162503,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,56.0,56.0,56.0,56.0,1.748188027,1.748188027,1.748188027,7.251811973,7.251811973,7.251811973,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,56.0,56.0,56.0,56.0,7.251811972993799,7.251811972993799,7.251811972993799,7.251811972993799,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
272859,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,C[C@@H]1c2cc3c(C(F)(F)F)cc(=O)n(C)c3cc2N[C@@H]1C,C15H15F3N2O,CHEMBL348918,9182.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9182.0,9182.0,9182.0,9182.0,3.962937288,3.962937288,3.962937288,5.037062712,5.037062712,5.037062712,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9182.0,9182.0,9182.0,9182.0,5.037062711569998,5.037062711569998,5.037062711569998,5.037062711569998,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
272891,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CC1(C)CNc2cc3nc(O)cc(C(F)(F)F)c3cc21,C14H13F3N2O,CHEMBL351022,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
273132,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CC1(C)CCC[C@]2(C)c3cc4c(C(F)(F)F)cc(O)nc4cc3N[C@H]12,C19H21F3N2O,CHEMBL423620,51.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,51.0,51.0,51.0,51.0,1.707570176,1.707570176,1.707570176,7.292429824,7.292429824,7.292429824,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,51.0,51.0,51.0,51.0,7.292429823902063,7.292429823902063,7.292429823902063,7.292429823902063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
273168,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,CN1c2cc3c(cc2[C@@]2(C)CCCC[C@@H]12)c(C(F)(F)F)cc(=O)n3C,C19H21F3N2O,CHEMBL163143,53.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,53.0,53.0,53.0,53.0,1.72427587,1.72427587,1.72427587,7.27572413,7.27572413,7.27572413,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,53.0,53.0,53.0,53.0,7.275724130399211,7.275724130399211,7.275724130399211,7.275724130399211,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
273200,nM,IC50,,BAO_0000190,IC50,36100,Antagonistic activity (IC50) against human androgen receptor (hAR) in co-transfected CV-1 cell,0,F,,CHEMBL884023,10.1016/s0960-894x(98)00107-3,9871534,CHEMBL1130772,"New nonsteroidal androgen receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone.",PUBLICATION,"A series of 2(1H)-pyrrolidino[3,2-g]quinolinones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g]quinolinone, displayed moderate interaction with hAR, but more substituted analogues, particularly 6,7-disubstituted compounds, were potent hAR agonists in vitro.",,Oc1cc(C(F)(F)F)c2cc3c(cc2n1)NCC3,C12H9F3N2O,CHEMBL166323,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23.0,23.0,23.0,23.0,1.361727836,1.361727836,1.361727836,7.638272164,7.638272164,7.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300069,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C16H12F3NO2,CHEMBL178469,35.0,410.0,744.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,289.6093154,35.0,396.3333333,410.0,744.0,2.5980606,2.612783857,1.544068044,6.4019394,6.387216143,7.455931956,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,35.0,35.0,35.0,35.0,7.455931955649724,7.455931955649724,7.455931955649724,7.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300081,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312709, Entry 2: 312710, Entry 3: 312710, Entry 4: 312999, Entry 5: 464721, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 2: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 3: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 4: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, Entry 5: Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay, ","0,1","Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: F, Entry 4: F, Entry 5: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837992, Entry 2: CHEMBL837993, Entry 3: CHEMBL837993, Entry 4: CHEMBL873340, Entry 5: CHEMBL933064, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, Entry 3: 10.1016/j.bmcl.2004.10.051, Entry 4: 10.1016/j.bmcl.2004.10.051, Entry 5: 10.1016/j.bmcl.2008.02.006, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, Entry 3: 15603960, Entry 4: 15603960, Entry 5: 18291644, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, Entry 3: CHEMBL1144249, Entry 4: CHEMBL1144249, Entry 5: CHEMBL1142249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 3: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 4: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 5: Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 3: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 4: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 5: A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model., ",,O=C1[C@@H]2C3CCC(C3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C16H14F3NO2,CHEMBL367364,7.0,12.0,127.0,152.0,205.0,317.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,107.9145753,7.0,136.6666667,139.5,317.0,2.135662602,2.144574208,0.84509804,6.864337398,6.855425792,8.15490196,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,9.5,9.5,7.0,12.0,8.022276394711152,8.022276394711152,8.154901959985743,7.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300127,nM,IC50,,BAO_0000190,IC50,312709,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,0,F,,CHEMBL837992,10.1016/j.bmcl.2004.10.051,15603960,CHEMBL1144249,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines.",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C16H11F3N2O4,CHEMBL368906,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,119.0,119.0,119.0,119.0,2.075546961,2.075546961,2.075546961,6.924453039,6.924453039,6.924453039,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,119.0,119.0,119.0,119.0,6.924453038607469,6.924453038607469,6.924453038607469,6.924453038607469,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300144,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312709, Entry 2: 312709, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 2: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, ","0,1,2","Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL837992, Entry 2: CHEMBL837992, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603938, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3CCC(C3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C16H13F3N2O4,CHEMBL178333,12.0,12.0,114.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,48.08326112,12.0,46.0,12.0,114.0,1.662757832,1.079181246,1.079181246,7.337242168,7.920818754,7.920818754,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,46.0,12.0,12.0,114.0,7.337242168318426,7.920818753952375,7.920818753952375,6.943095148663527,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300196,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc(O)c2ncccc12,C18H14N2O3,CHEMBL369509,418.0,1790.0,3639.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1319.765383,418.0,1949.0,1790.0,3639.0,3.289811839,3.252853031,2.621176282,5.710188161,5.747146969,6.378823718,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,418.0,418.0,418.0,418.0,6.3788237182249645,6.3788237182249645,6.3788237182249645,6.3788237182249645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300202,nM,IC50,,BAO_0000190,IC50,312709,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,0,F,,CHEMBL837992,10.1016/j.bmcl.2004.10.051,15603960,CHEMBL1144249,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines.",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C19H14N2O4,CHEMBL181571,5.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5.0,5.0,5.0,5.0,0.698970004,0.698970004,0.698970004,8.301029996,8.301029996,8.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,5.0,5.0,5.0,5.0,8.301029995663981,8.301029995663981,8.301029995663981,8.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300226,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1cc(C(F)(F)F)cc(C(F)(F)F)c1,C17H11F6NO2,CHEMBL178957,72.0,198.0,1746.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,761.1727793,72.0,672.0,198.0,1746.0,2.827369273,2.29666519,1.857332496,6.172630727,6.70333481,7.142667504,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,72.0,72.0,72.0,72.0,7.142667503568732,7.142667503568732,7.142667503568732,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300270,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1cc(Cl)cc(Cl)c1,C15H11Cl2NO2,CHEMBL178886,41.0,180.0,307.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,108.6308735,41.0,176.0,180.0,307.0,2.245512668,2.255272505,1.612783857,6.754487332,6.744727495,7.387216143,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,41.0,41.0,41.0,41.0,7.3872161432802645,7.3872161432802645,7.3872161432802645,7.3872161432802645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300280,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3CCC(C3)[C@@H]2C(=O)N1c1ccc2ccccc2c1,C19H17NO2,CHEMBL359911,84.0,265.0,1200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,489.0401029,84.0,516.3333333,265.0,1200.0,2.712930163,2.423245874,1.924279286,6.287069837,6.576754126,7.075720714,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.0,84.0,84.0,84.0,7.075720713938118,7.075720713938118,7.075720713938118,7.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300281,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])cc1,C15H12N2O4,CHEMBL182186,30.0,179.0,664.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,270.6744662,30.0,291.0,179.0,664.0,2.463892989,2.252853031,1.477121255,6.536107011,6.747146969,7.522878745,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300282,nM,IC50,,BAO_0000190,IC50,312709,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,0,F,,CHEMBL837992,10.1016/j.bmcl.2004.10.051,15603960,CHEMBL1144249,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines.",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc(Br)c(C(F)(F)F)c1,C16H11BrF3NO2,CHEMBL361222,146.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,146.0,146.0,146.0,146.0,2.164352856,2.164352856,2.164352856,6.835647144,6.835647144,6.835647144,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,146.0,146.0,146.0,146.0,6.835647144215563,6.835647144215563,6.835647144215563,6.835647144215563,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300283,nM,IC50,,BAO_0000190,IC50,312709,Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay,0,F,,CHEMBL837992,10.1016/j.bmcl.2004.10.051,15603960,CHEMBL1144249,"Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines.",,Cc1cc(N2C(=O)[C@@H]3C4C=CC(C4)[C@@H]3C2=O)ccc1Br,C16H14BrNO2,CHEMBL182236,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300291,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc2cccnc2c1,C18H14N2O2,CHEMBL181722,52.0,234.0,1038.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,428.3996058,52.0,441.3333333,234.0,1038.0,2.64476673,2.369215857,1.716003344,6.35523327,6.630784143,7.283996656,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,52.0,52.0,52.0,52.0,7.2839966563652006,7.2839966563652006,7.2839966563652006,7.2839966563652006,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300298,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc2ccccc2c1,C19H15NO2,CHEMBL181674,84.0,265.0,1210.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,493.700539,84.0,519.6666667,265.0,1210.0,2.71572486,2.423245874,1.924279286,6.28427514,6.576754126,7.075720714,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.0,84.0,84.0,84.0,7.075720713938118,7.075720713938118,7.075720713938118,7.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300311,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc(F)c(Cl)c1,C15H11ClFNO2,CHEMBL180859,33.0,132.0,517.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,208.7747324,33.0,227.3333333,132.0,517.0,2.35666312,2.120573931,1.51851394,6.64333688,6.879426069,7.48148606,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,33.0,33.0,33.0,33.0,7.481486060122113,7.481486060122113,7.481486060122113,7.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
300312,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 312709, Entry 1: 312710, Entry 2: 312999, ","Entry 0: Inhibition of human androgen receptor of breast carcinoma MDA-453 cells in reporter gene assay, Entry 1: Inhibition of T877A androgen receptor of human prostate cancer cells in reporter gene assay, Entry 2: Inhibition of L701H/T877A mutant androgen receptor of human prostate cancer MDAMB-PCa2b cell proliferation, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL837992, Entry 1: CHEMBL837993, Entry 2: CHEMBL873340, ","Entry 0: 10.1016/j.bmcl.2004.10.051, Entry 1: 10.1016/j.bmcl.2004.10.051, Entry 2: 10.1016/j.bmcl.2004.10.051, ","Entry 0: 15603960, Entry 1: 15603960, Entry 2: 15603960, ","Entry 0: CHEMBL1144249, Entry 1: CHEMBL1144249, Entry 2: CHEMBL1144249, ","Entry 0: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 1: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., Entry 2: Identification of a novel class of androgen receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). SAR around this series revealed dramatic differences in binding and function in mutant variants (MT) of the AR as compared to the wild type (WT) receptor. Optimization of the aniline portion revealed substitution patterns, which yielded potent antagonist activity against the WT AR as well as the MT AR found in the LNCaP and PCa2b human prostate tumor cell lines., ",,Cc1ccc(N2C(=O)[C@@H]3C4C=CC(C4)[C@@H]3C2=O)cc1C,C17H17NO2,CHEMBL366924,10.0,96.0,2014.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,925.0907463,10.0,706.6666667,96.0,2014.0,2.849214606,1.982271233,1.0,6.150785394,7.017728767,8.0,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305180,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312787, Entry 2: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 2: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL833436, Entry 2: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, Entry 2: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, Entry 2: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, Entry 2: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,CN1C(=O)C2C=CC1[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)[C@H]21,C20H15N3O5,CHEMBL183173,631.0,4030.0,8460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3205.400686,631.0,4373.666667,4030.0,8460.0,3.640845681,3.605305046,2.800029359,5.359154319,5.394694954,6.199970641,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,631.0,631.0,631.0,631.0,6.199970640755866,6.199970640755866,6.199970640755866,6.199970640755866,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305233,nM,IC50,,BAO_0000190,IC50,305503,Inhibition of androgen receptor in human MDA-453 cells,0,B,,CHEMBL831105,10.1016/j.bmcl.2004.10.085,15603938,CHEMBL1142826,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.",,O=C1[C@@H]2C3C=CC([C@H]4C[C@@H]34)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C21H16N2O4,CHEMBL367375,786.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,786.0,786.0,786.0,786.0,2.895422546,2.895422546,2.895422546,6.104577454,6.104577454,6.104577454,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,786.0,786.0,786.0,786.0,6.104577453960592,6.104577453960592,6.104577453960592,6.104577453960592,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305258,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312787, Entry 2: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 2: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL833436, Entry 2: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, Entry 2: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, Entry 2: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, Entry 2: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,O=C1[C@@H]2C3C=CC([C@H]4C[C@@H]34)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C18H14F3NO2,CHEMBL182993,30.0,148.0,1700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,760.959044,30.0,626.0,148.0,1700.0,2.796574333,2.170261715,1.477121255,6.203425667,6.829738285,7.522878745,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305273,nM,IC50,,BAO_0000190,IC50,305503,Inhibition of androgen receptor in human MDA-453 cells,0,B,,CHEMBL831105,10.1016/j.bmcl.2004.10.085,15603938,CHEMBL1142826,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.",,Cc1cc(N2C(=O)[C@@H]3C4C=CC(CC4)[C@@H]3C2=O)ccc1Br,C17H16BrNO2,CHEMBL180681,68.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,68.0,68.0,68.0,68.0,1.832508913,1.832508913,1.832508913,7.167491087,7.167491087,7.167491087,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,68.0,68.0,68.0,68.0,7.167491087293763,7.167491087293763,7.167491087293763,7.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305278,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,Cc1cc(N2C(=O)[C@@H]3C4C=CC([C@H](O)[C@@H]4O)[C@@H]3C2=O)ccc1Br,C17H16BrNO4,CHEMBL427502,59.0,5240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2590.5,59.0,2649.5,2649.5,5240.0,3.423163924,3.423163924,1.770852012,5.576836076,5.576836076,7.229147988,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,59.0,59.0,59.0,59.0,7.229147988357856,7.229147988357856,7.229147988357856,7.229147988357856,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305294,nM,IC50,,BAO_0000190,IC50,305503,Inhibition of androgen receptor in human MDA-453 cells,0,B,,CHEMBL831105,10.1016/j.bmcl.2004.10.085,15603938,CHEMBL1142826,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.",,O=C1[C@@H]2C3C=CC(CC3)[C@@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,C16H13Cl2NO2,CHEMBL184981,150.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,150.0,150.0,150.0,150.0,2.176091259,2.176091259,2.176091259,6.823908741,6.823908741,6.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,150.0,150.0,150.0,150.0,6.823908740944319,6.823908740944319,6.823908740944319,6.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305315,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312787, Entry 2: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 2: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL833436, Entry 2: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, Entry 2: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, Entry 2: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, Entry 2: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,O=C1[C@@H]2C3C=CC(C3)[C@@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,C15H11Cl2NO2,CHEMBL182593,41.0,180.0,307.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,108.6308735,41.0,176.0,180.0,307.0,2.245512668,2.255272505,1.612783857,6.754487332,6.744727495,7.387216143,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,41.0,41.0,41.0,41.0,7.3872161432802645,7.3872161432802645,7.3872161432802645,7.3872161432802645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305331,nM,IC50,,BAO_0000190,IC50,305503,Inhibition of androgen receptor in human MDA-453 cells,0,B,,CHEMBL831105,10.1016/j.bmcl.2004.10.085,15603938,CHEMBL1142826,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.",,O=C1[C@@H]2C3C=CC(CC3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C20H16N2O4,CHEMBL361445,224.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,224.0,224.0,224.0,224.0,2.350248018,2.350248018,2.350248018,6.649751982,6.649751982,6.649751982,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,224.0,224.0,224.0,224.0,6.649751981665837,6.649751981665837,6.649751981665837,6.649751981665837,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305351,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312787, Entry 2: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 2: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL833436, Entry 2: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, Entry 2: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, Entry 2: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, Entry 2: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,O=C1[C@@H]2C3C=CC(CC3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C17H14F3NO2,CHEMBL182412,0.4,66.0,196.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,81.28326328,0.4,87.46666667,66.0,196.0,1.941842576,1.819543936,-0.397940009,7.058157424,7.180456064,9.397940009,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.4,0.4,0.4,0.4,9.397940008672037,9.397940008672037,9.397940008672037,9.397940008672037,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305366,nM,IC50,,BAO_0000190,IC50,305503,Inhibition of androgen receptor in human MDA-453 cells,0,B,,CHEMBL831105,10.1016/j.bmcl.2004.10.085,15603938,CHEMBL1142826,"Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists.",PUBLICATION,"A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule.",,O=C1[C@@H]2C3C=CC(CCC3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C21H18N2O4,CHEMBL369542,49.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,49.0,49.0,49.0,49.0,1.69019608,1.69019608,1.69019608,7.30980392,7.30980392,7.30980392,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,49.0,49.0,49.0,49.0,7.309803919971486,7.309803919971486,7.309803919971486,7.309803919971486,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
305378,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 305503, Entry 1: 312787, Entry 2: 317578, ","Entry 0: Inhibition of androgen receptor in human MDA-453 cells, Entry 1: Inhibition of androgen dependent human prostate cancer cell MDA-MB-PCa2b proliferation, Entry 2: Inhibition of mutant T877A Androgen receptor in human LNCaP cells, ",0,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL831105, Entry 1: CHEMBL833436, Entry 2: CHEMBL877304, ","Entry 0: 10.1016/j.bmcl.2004.10.085, Entry 1: 10.1016/j.bmcl.2004.10.085, Entry 2: 10.1016/j.bmcl.2004.10.085, ","Entry 0: 15603938, Entry 1: 15603938, Entry 2: 15603938, ","Entry 0: CHEMBL1142826, Entry 1: CHEMBL1142826, Entry 2: CHEMBL1142826, ","Entry 0: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 1: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., Entry 2: Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 1: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., Entry 2: A novel series of isoindoledione based compounds were identified as potent antagonists of the androgen receptor (AR). Co-crystallization of members of this family of inhibitors was successfully accomplished with the T877A AR LBD. A working model of how this class of compounds functions to antagonize the AR was created. Based on this model, it was proposed that expanding the bicyclic portion of the molecule should result in analogs which function as effective antagonists against a variety of AR isoforms. In contrast to what was predicted by the model, SAR around this new series was dictated by the aniline portion rather than the bicyclic portion of the molecule., ",,O=C1[C@@H]2C3CCCC(CC3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C18H18F3NO2,CHEMBL183882,23.0,179.0,658.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,270.185533,23.0,286.6666667,179.0,658.0,2.457377197,2.252853031,1.361727836,6.542622803,6.747146969,7.638272164,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
306817,nM,IC50,,BAO_0000190,IC50,306071,Inhibition of human androgen receptor,0,B,,CHEMBL833026,10.1021/jm050205o,16078847,CHEMBL1141148,Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.,PUBLICATION,"Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2-alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA(1c), triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.",,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccc(Oc2cccc(OCCCC(=O)NCCCC(=O)O)c2)cc1,C36H41N3O7S,CHEMBL185265,1600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1600.0,1600.0,1600.0,1600.0,3.204119983,3.204119983,3.204119983,5.795880017,5.795880017,5.795880017,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1600.0,1600.0,1600.0,1600.0,5.795880017344075,5.795880017344075,5.795880017344075,5.795880017344075,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
312856,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 306188, Entry 1: 306232, Entry 2: 312581, ","Entry 0: Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor, Entry 1: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 2: Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation, ",0,"Entry 0: B, Entry 1: B, Entry 2: F, ",,"Entry 0: CHEMBL830982, Entry 1: CHEMBL874560, Entry 2: CHEMBL835247, ","Entry 0: 10.1021/jm0342515, Entry 1: 10.1021/jm0342515, Entry 2: 10.1021/jm0342515, ","Entry 0: 15456242, Entry 1: 15456242, Entry 2: 15456242, ","Entry 0: CHEMBL1137214, Entry 1: CHEMBL1137214, Entry 2: CHEMBL1137214, ","Entry 0: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 1: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 2: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 1: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 2: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., ",,CCCCCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,C26H40O2,CHEMBL186467,0.9,6.6,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.665499898,0.9,8.166666667,6.6,17.0,0.91204483,0.819543936,-0.045757491,8.08795517,8.180456064,9.045757491,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.9,0.9,0.9,0.9,9.045757490560675,9.045757490560675,9.045757490560675,9.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
312891,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 306188, Entry 1: 306232, Entry 2: 312581, ","Entry 0: Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor, Entry 1: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 2: Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation, ",0,"Entry 0: B, Entry 1: B, Entry 2: F, ",,"Entry 0: CHEMBL830982, Entry 1: CHEMBL874560, Entry 2: CHEMBL835247, ","Entry 0: 10.1021/jm0342515, Entry 1: 10.1021/jm0342515, Entry 2: 10.1021/jm0342515, ","Entry 0: 15456242, Entry 1: 15456242, Entry 2: 15456242, ","Entry 0: CHEMBL1137214, Entry 1: CHEMBL1137214, Entry 2: CHEMBL1137214, ","Entry 0: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 1: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 2: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 1: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 2: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., ",,CCCCCCCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,C28H44O2,CHEMBL186254,0.8,17.0,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36.47842589,0.8,34.26666667,17.0,85.0,1.53487186,1.230448921,-0.096910013,7.46512814,7.769551079,9.096910013,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.8,0.8,0.8,0.8,9.096910013008056,9.096910013008056,9.096910013008056,9.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
312949,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 306188, Entry 1: 306232, Entry 2: 312581, ","Entry 0: Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor, Entry 1: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 2: Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation, ",0,"Entry 0: B, Entry 1: B, Entry 2: F, ",,"Entry 0: CHEMBL830982, Entry 1: CHEMBL874560, Entry 2: CHEMBL835247, ","Entry 0: 10.1021/jm0342515, Entry 1: 10.1021/jm0342515, Entry 2: 10.1021/jm0342515, ","Entry 0: 15456242, Entry 1: 15456242, Entry 2: 15456242, ","Entry 0: CHEMBL1137214, Entry 1: CHEMBL1137214, Entry 2: CHEMBL1137214, ","Entry 0: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 1: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 2: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 1: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 2: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., ",,CC(=O)O[C@]1(C(C)=O)CCC2C3C=C(Cl)C4=CC(=O)[C@@H]5CC5[C@]4(C)C3CC[C@@]21C,C24H29ClO4,CHEMBL361245,4.7,22.0,61.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23.54659683,4.7,29.23333333,22.0,61.0,1.465878339,1.342422681,0.672097858,7.534121661,7.657577319,8.327902142,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4.7,4.7,4.7,4.7,8.327902142064282,8.327902142064282,8.327902142064282,8.327902142064282,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
313080,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 306188, Entry 1: 306232, Entry 2: 312581, ","Entry 0: Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor, Entry 1: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 2: Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation, ",0,"Entry 0: B, Entry 1: B, Entry 2: F, ",,"Entry 0: CHEMBL830982, Entry 1: CHEMBL874560, Entry 2: CHEMBL835247, ","Entry 0: 10.1021/jm0342515, Entry 1: 10.1021/jm0342515, Entry 2: 10.1021/jm0342515, ","Entry 0: 15456242, Entry 1: 15456242, Entry 2: 15456242, ","Entry 0: CHEMBL1137214, Entry 1: CHEMBL1137214, Entry 2: CHEMBL1137214, ","Entry 0: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 1: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 2: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 1: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 2: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., ",,CCCCC[C@H]1C[C@@]2(C)C(CC[C@@H]2O)C2CCC3=CC(=O)CCC3=C21,C23H34O2,CHEMBL184313,0.009,0.1,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.988271695,0.009,5.703,0.1,17.0,0.756103372,-1.0,-2.045757491,8.243896628,10.0,11.04575749,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.009,0.009,0.009,0.009,11.045757490560675,11.045757490560675,11.045757490560675,11.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314458,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc([N+](=O)[O-])cc4)C(=O)N32)cc1,C24H24N4O5,CHEMBL365482,60.0,4750.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2345.0,60.0,2405.0,2405.0,4750.0,3.381115081,3.381115081,1.77815125,5.618884919,5.618884919,7.22184875,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4750.0,4750.0,4750.0,4750.0,5.323306390375134,5.323306390375134,5.323306390375134,5.323306390375134,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314560,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,O=C1[C@H]2[C@@H]3C[C@@H](CN3C(=O)Oc3ccc(F)cc3)N2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C24H17FN4O6,CHEMBL426623,340.0,30000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,14830.0,340.0,15170.0,15170.0,30000.0,4.180985581,4.180985581,2.531478917,4.819014419,4.819014419,6.468521083,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,30000.0,30000.0,30000.0,30000.0,4.522878745280337,4.522878745280337,4.522878745280337,4.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314643,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)c4ccccc4)N3C2=O)cc1C(F)(F)F,C22H15F3N4O3,CHEMBL189600,300.0,2600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1150.0,300.0,1450.0,1450.0,2600.0,3.161368002,3.161368002,2.477121255,5.838631998,5.838631998,6.522878745,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2600.0,2600.0,2600.0,2600.0,5.585026652029182,5.585026652029182,5.585026652029182,5.585026652029182,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314669,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@]1(C)C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,C21H21F3N4O4,CHEMBL188261,780.0,10400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4810.0,780.0,5590.0,5590.0,10400.0,3.747411808,3.747411808,2.892094603,5.252588192,5.252588192,6.107905397,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10400.0,10400.0,10400.0,10400.0,4.982966660701219,4.982966660701219,4.982966660701219,4.982966660701219,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314681,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,C20H19F3N4O4,CHEMBL414845,640.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2180.0,640.0,2820.0,2820.0,5000.0,3.450249108,3.450249108,2.806179974,5.549750892,5.549750892,6.193820026,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314728,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)N32)cc1,C26H23F3N4O3,CHEMBL447184,17900.0,33700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7900.0,17900.0,25800.0,25800.0,33700.0,4.411619706,4.411619706,4.252853031,4.588380294,4.588380294,4.747146969,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,33700.0,33700.0,33700.0,33700.0,4.4723700991286615,4.4723700991286615,4.4723700991286615,4.4723700991286615,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314771,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)N21,C22H22N4O6,CHEMBL188129,3320.0,4430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,555.0,3320.0,3875.0,3875.0,4430.0,3.588271707,3.588271707,3.521138084,5.411728293,5.411728293,5.478861916,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4430.0,4430.0,4430.0,4430.0,5.3535962737769305,5.3535962737769305,5.3535962737769305,5.3535962737769305,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314799,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CCCCc1ccc(C(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc(C#N)cc4)C(=O)N32)cc1,C25H24N4O3,CHEMBL371392,580.0,6800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3110.0,580.0,3690.0,3690.0,6800.0,3.567026366,3.567026366,2.763427994,5.432973634,5.432973634,6.236572006,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,6800.0,6800.0,6800.0,6800.0,5.167491087293763,5.167491087293763,5.167491087293763,5.167491087293763,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314825,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,O=C1[C@@H]2[C@@H]3CC[C@@H](C3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C16H13F3N2O4,CHEMBL188297,10.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2495.0,10.0,2505.0,2505.0,5000.0,3.39880773,3.39880773,1.0,5.60119227,5.60119227,8.0,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
314861,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, Entry 2: 2227423, Entry 3: 2227424, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, Entry 2: Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay, Entry 3: Antagonist activity at Androgen receptor in human LNCaP cells measured by SEAP reporter gene assay, ","1,2,3","Entry 0: F, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, Entry 2: CHEMBL5140936, Entry 3: CHEMBL5140937, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 15546739, Entry 1: 15546739, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)Oc4ccc(F)cc4)N3C2=O)cc1C(F)(F)F,C22H14F4N4O4,CHEMBL362566,200.0,350.0,3920.0,3920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1823.271442,200.0,2097.5,2135.0,3920.0,3.32170197,3.329397879,2.301029996,5.67829803,5.670602121,6.698970004,4,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2730.0,3920.0,350.0,3920.0,5.5638373529592435,5.406713932979542,6.455931955649724,5.406713932979542,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314863,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,N#Cc1ccc(N2C(=O)[C@H]3[C@@H]4C[C@@H](CN4C(=O)Oc4ccc(F)cc4)N3C2=O)c2ccccc12,C25H17FN4O4,CHEMBL365921,580.0,1870.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,645.0,580.0,1225.0,1225.0,1870.0,3.088136089,3.088136089,2.763427994,5.911863911,5.911863911,6.236572006,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1870.0,1870.0,1870.0,1870.0,5.728158393463501,5.728158393463501,5.728158393463501,5.728158393463501,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314978,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312372, Entry 1: 312479, ","Entry 0: In vitro antagonistic activity against androgen receptor of MDA-453 cells, Entry 1: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL836730, Entry 1: CHEMBL833228, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,C20H19F3N4O4,CHEMBL187605,770.0,4380.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1805.0,770.0,2575.0,2575.0,4380.0,3.410777233,3.410777233,2.886490725,5.589222767,5.589222767,6.113509275,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4380.0,4380.0,4380.0,4380.0,5.3585258894959,5.3585258894959,5.3585258894959,5.3585258894959,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
314979,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,O=C1[C@H]2[C@@H]3C[C@@H](CN3C(=O)c3ccccc3)N2C(=O)N1c1ccc([N+](=O)[O-])cc1,C20H16N4O5,CHEMBL365650,2540.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1230.0,2540.0,3770.0,3770.0,5000.0,3.57634135,3.57634135,3.404833717,5.42365865,5.42365865,5.595166283,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
315024,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@H]2C[C@@H]1[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,C20H19F3N4O4,CHEMBL188681,5000.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
315044,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,O=C1[C@H]2[C@H]3CC[C@H](C3)N2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C18H15N3O4,CHEMBL185880,1300.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1850.0,1300.0,3150.0,3150.0,5000.0,3.498310554,3.498310554,3.113943352,5.501689446,5.501689446,5.886056648,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
315066,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc(C#N)cc3)C(=O)N21,C19H20N4O4,CHEMBL188857,3510.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,745.0,3510.0,4255.0,4255.0,5000.0,3.628899564,3.628899564,3.545307116,5.371100436,5.371100436,5.454692884,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
315095,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@H]1C(=O)N(c3ccc([N+](=O)[O-])c4ccccc34)C(=O)N21,C22H22N4O6,CHEMBL188545,1330.0,5860.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2265.0,1330.0,3595.0,3595.0,5860.0,3.555698895,3.555698895,3.123851641,5.444301105,5.444301105,5.876148359,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5860.0,5860.0,5860.0,5860.0,5.23210238398191,5.23210238398191,5.23210238398191,5.23210238398191,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
315280,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1[C@@H]1C(=O)N(c3ccc(C#N)cc3)C(=O)N21,C19H20N4O4,CHEMBL188803,2540.0,4970.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1215.0,2540.0,3755.0,3755.0,4970.0,3.574609941,3.574609941,3.404833717,5.425390059,5.425390059,5.595166283,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4970.0,4970.0,4970.0,4970.0,5.303643611266668,5.303643611266668,5.303643611266668,5.303643611266668,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
315455,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 312479, Entry 1: 312372, ","Entry 0: In vitro antagonistic activity against mutant androgen receptor of LNCap cells, Entry 1: In vitro antagonistic activity against androgen receptor of MDA-453 cells, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL833228, Entry 1: CHEMBL836730, ","Entry 0: 10.1016/j.bmcl.2004.09.049, Entry 1: 10.1016/j.bmcl.2004.09.049, ","Entry 0: 15546739, Entry 1: 15546739, ","Entry 0: CHEMBL1138730, Entry 1: CHEMBL1138730, ","Entry 0: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., Entry 1: The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., Entry 1: A novel series of [2.2.1]-azahydantoins has been designed and synthesized in an enantiospecific manner. The ability of these compounds to act as antagonists to the androgen receptor was investigated and several were found to have potent activity in vitro., ",,CC(C)(C)OC(=O)N1C[C@H]2C[C@@H]1[C@H]1C(=O)N(c3ccc([N+](=O)[O-])cc3)C(=O)N21,C18H20N4O6,CHEMBL364393,250.0,2390.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1070.0,250.0,1320.0,1320.0,2390.0,3.120573931,3.120573931,2.397940009,5.879426069,5.879426069,6.602059991,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2390.0,2390.0,2390.0,2390.0,5.621602099051862,5.621602099051862,5.621602099051862,5.621602099051862,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
318437,nM,IC50,,BAO_0000190,IC50,306071,Inhibition of human androgen receptor,0,B,,CHEMBL833026,10.1021/jm050205o,16078847,CHEMBL1141148,Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.,PUBLICATION,"Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2-alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA(1c), triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(Cc4ccc(C)cc4)C3=CC[C@@]21C,C29H34O2,CHEMBL363151,6500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6500.0,6500.0,6500.0,6500.0,3.812913357,3.812913357,3.812913357,5.187086643,5.187086643,5.187086643,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6500.0,6500.0,6500.0,6500.0,5.187086643357144,5.187086643357144,5.187086643357144,5.187086643357144,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
318439,nM,IC50,,BAO_0000190,IC50,306071,Inhibition of human androgen receptor,0,B,,CHEMBL833026,10.1021/jm050205o,16078847,CHEMBL1141148,Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.,PUBLICATION,"Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2-alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA(1c), triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.",,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccc(Oc2ccc(Cl)c(OCC(=O)O)c2)cc1)Cc1ccc(F)cc1F,C30H27ClF2N2O6S,CHEMBL190109,3600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3600.0,3600.0,3600.0,3600.0,3.556302501,3.556302501,3.556302501,5.443697499,5.443697499,5.443697499,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3600.0,3600.0,3600.0,3600.0,5.443697499232713,5.443697499232713,5.443697499232713,5.443697499232713,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
318470,nM,IC50,,BAO_0000190,IC50,306071,Inhibition of human androgen receptor,0,B,,CHEMBL833026,10.1021/jm050205o,16078847,CHEMBL1141148,Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators.,PUBLICATION,"Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2-alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA(1c), triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents.",,Cc1c(NS(C)(=O)=O)cccc1N(Cc1ccccc1)Cc1ccc(Oc2ccc(OCC(=O)O)cc2)cc1,C30H30N2O6S,CHEMBL190225,11700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11700.0,11700.0,11700.0,11700.0,4.068185862,4.068185862,4.068185862,4.931814138,4.931814138,4.931814138,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11700.0,11700.0,11700.0,11700.0,4.931814138253839,4.931814138253839,4.931814138253839,4.931814138253839,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
328120,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,O=C1CC(c2ccccc2)Oc2ccc(O)cc21,C15H12O3,CHEMBL195033,3300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3300.0,3300.0,3300.0,3300.0,3.51851394,3.51851394,3.51851394,5.48148606,5.48148606,5.48148606,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3300.0,3300.0,3300.0,3300.0,5.481486060122113,5.481486060122113,5.481486060122113,5.481486060122113,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
328201,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 649966, Entry 1: 792912, Entry 2: 974217, Entry 3: 1438887, Entry 4: 1497343, Entry 5: 2222791, ","Entry 0: Antagonist activity at androgen receptor, Entry 1: Displacement of [3H]testosterone from AR, Entry 2: Antagonist activity at androgen receptor (unknown origin) by NH Pro assay, Entry 3: Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting, Entry 4: Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay, Entry 5: Displacement of [3H]-methyltrienolene from human androgen receptor incubated overnight by liquid scintillation counting analysis, ",0,"Entry 0: F, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, Entry 5: B, ",,"Entry 0: CHEMBL1219664, Entry 1: CHEMBL1929758, Entry 2: CHEMBL2411351, Entry 3: CHEMBL3381812, Entry 4: CHEMBL3579176, Entry 5: CHEMBL5136125, ","Entry 0: 10.1021/jm100505n, Entry 1: 10.1021/jm2011645, Entry 2: 10.1016/j.bmcl.2013.05.077, Entry 3: 10.1016/j.bmc.2014.07.038, Entry 4: 10.1021/acsmedchemlett.5b00010, Entry 5: 10.1021/acs.jmedchem.2c00402, ","Entry 0: 20672822, Entry 1: 22074142, Entry 2: 23777778, Entry 3: 25187277, Entry 4: 25941555, Entry 5: 35652647, ","Entry 0: CHEMBL1212897, Entry 1: CHEMBL1926625, Entry 2: CHEMBL2407028, Entry 3: CHEMBL3351638, Entry 4: CHEMBL3576820, Entry 5: CHEMBL5131538, ","Entry 0: Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy., Entry 1: Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists., Entry 2: Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists., Entry 3: Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists., Entry 4: Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists., Entry 5: Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies., Entry 1: Mineralocorticoid receptor (MR) blockade has come into focus as a promising approach for the treatment of cardiovascular diseases such as hypertension and congestive heart failure. In order to identify a novel class of nonsteroidal MR antagonists that exhibit significant potency and good selectivity over other steroidal hormone receptors, we designed a novel series of benzoxazin-3-one derivatives and synthesized them from 6-(7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)-2H-1,4-benzoxazin-3(4H)-one (1a), high-throughput screening (HTS) hit compound. Our design was based on a crystal structure of an MR/compound complex and a docking model. In the course of lead generation from 1a, a 1,2-diaryl framework was characterized as a key structure with high binding affinity. On the basis of scaffold hopping and optimization studies, benzoxazin-3-one derivatives possessing 1-phenyl-3-trifluoromethylpyrazol-5-yl moiety at the 6-position were identified as a novel series of potent and selective MR antagonists. Among these compounds, 6-[1-(4-fluoro-2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2H-1,4-benzoxazin-3(4H)-one (14n) showed highly potent activity and good selectivity and also exhibited a significant antihypertensive effect in deoxycorticosterone acetate-salt hypertensive rats. On the basis of these results, compound 14n was progressed for further pharmacological evaluation., Entry 2: Novel oxazolidinedione analogs were discovered as potent and selective mineralocorticoid receptor (MR) antagonists. Structure-activity relationship (SAR) studies were focused on improving the potency and microsomal stability. Selected compounds demonstrated excellent MR activity, reasonable nuclear hormone receptor selectivity, and acceptable rat pharmacokinetics., Entry 3: In the course of our study on selective nonsteroidal mineralocorticoid receptor (MR) antagonists, a series of novel benzoxazine derivatives possessing an azole ring as the core scaffold was designed for the purpose of attenuating the partial agonistic activity of the previously reported dihydropyrrol-2-one derivatives. Screening of alternative azole rings identified 1,3-dimethyl pyrazole 6a as a lead compound with reduced partial agonistic activity. Subsequent replacement of the 1-methyl group of the pyrazole ring with larger lipophilic side chains or polar side chains targeting Arg817 and Gln776 increased MR binding activity while maintaining the agonistic response at the lower level. Among these compounds, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (37a) showed highly potent in vitro activity, high selectivity versus other steroid hormone receptors, and good pharmacokinetic profiles. Oral administration of 37a in deoxycorticosterone acetate-salt hypertensive rats showed a significant blood pressure-lowering effect with no signs of antiandrogenic effects., Entry 4: Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization., Entry 5: Overactivation of the mineralocorticoid receptor (MR) is involved in many diseases, such as hypertension, kidney disease, and heart failure. Thus, MR antagonists (MRAs) are expected to be beneficial to patients with these diseases. In order to identify novel nonsteroidal MRAs that overcome the issues of already marketed steroidal MRAs, we searched for new compounds guided by our hypothesis that T-shaped compounds with a hydrophobic core structure, two polar functional groups at both extremities able to interact with MR, and a bulky substituent that can interfere with the folding of the C-terminal helix 12 may exhibit antagonist activity toward MR. We discovered that the novel 1,4-benzoxazin-3-one derivative <b>19</b> (apararenone: MT-3995) acted as a highly selective and potent nonsteroidal MRA. Apararenone exhibited a more potent antihypertensive and organ-protective activity than steroidal MRA eplerenone in a primary aldosteronism rat model obtained by infusing aldosterone in uninephrectomized rats., ",,CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@H]12,C24H32O4S,CHEMBL1393,48.0,120.0,120.0,523.0,670.0,670.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,268.1105183,48.0,358.5,321.5,670.0,2.55448916,2.507180977,1.681241237,6.44551084,6.492819023,7.318758763,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
330210,nM,IC50,,BAO_0000190,IC50,942995,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,0,B,,CHEMBL2343831,10.1016/j.bmc.2013.01.060,23462715,CHEMBL2331115,Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.,PUBLICATION,"We previously reported that bis-phenol derivatives, including LG190178 (3a), possess not only vitamin D receptor (VDR) agonistic activity, but also androgen receptor (AR) antagonistic activity. Here, we describe the design, synthesis and evaluation of silicon-containing bis-phenol derivatives, with the objective of obtaining increased selectivity toward VDR or AR. We found that replacement of the quaternary carbon in the bis-phenol skeleton with silicon increased AR-antagonistic activity and reduced VDR-agonistic activity, that is, the AR selectivity of the silicon-containing compounds was higher than that of corresponding carbon compounds. To our knowledge, this is the first report of nuclear receptor (NR) selectivity switching by sila-substitution (C/Si exchange). Among the compounds synthesized, AR-selective ligand (S,R)-3b exhibited more potent anti-androgenic activity (IC50=0.072 M) than hydroxyflutamide, a well-known androgen antagonist (IC50=1.4 M), in SC-3 cell proliferation assay. These results suggest that sila-substitution is a useful approach for structural development of selective AR ligands.",,CCC(CC)(c1ccc(OCC(=O)C(C)(C)C)c(C)c1)c1ccc(OCC(=O)C(C)(C)C)c(C)c1,C31H44O4,CHEMBL197946,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
330241,nM,IC50,,BAO_0000190,IC50,942995,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,0,B,,CHEMBL2343831,10.1016/j.bmc.2013.01.060,23462715,CHEMBL2331115,Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.,PUBLICATION,"We previously reported that bis-phenol derivatives, including LG190178 (3a), possess not only vitamin D receptor (VDR) agonistic activity, but also androgen receptor (AR) antagonistic activity. Here, we describe the design, synthesis and evaluation of silicon-containing bis-phenol derivatives, with the objective of obtaining increased selectivity toward VDR or AR. We found that replacement of the quaternary carbon in the bis-phenol skeleton with silicon increased AR-antagonistic activity and reduced VDR-agonistic activity, that is, the AR selectivity of the silicon-containing compounds was higher than that of corresponding carbon compounds. To our knowledge, this is the first report of nuclear receptor (NR) selectivity switching by sila-substitution (C/Si exchange). Among the compounds synthesized, AR-selective ligand (S,R)-3b exhibited more potent anti-androgenic activity (IC50=0.072 M) than hydroxyflutamide, a well-known androgen antagonist (IC50=1.4 M), in SC-3 cell proliferation assay. These results suggest that sila-substitution is a useful approach for structural development of selective AR ligands.",,CCC(CC)(c1ccc(OCC(O)CO)c(C)c1)c1ccc(OCC(O)C(C)(C)C)c(C)c1,C28H42O5,CHEMBL197589,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
336214,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,Cc1ncccc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,C21H22F3N5O,CHEMBL199284,680.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,680.0,680.0,680.0,680.0,2.832508913,2.832508913,2.832508913,6.167491087,6.167491087,6.167491087,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,680.0,680.0,680.0,680.0,6.167491087293763,6.167491087293763,6.167491087293763,6.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336306,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,COc1ncccc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,C21H22F3N5O2,CHEMBL201077,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,190.0,190.0,190.0,190.0,2.278753601,2.278753601,2.278753601,6.721246399,6.721246399,6.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.0,190.0,190.0,190.0,6.721246399047171,6.721246399047171,6.721246399047171,6.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336316,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,COc1ccncc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,C21H22F3N5O2,CHEMBL197648,1200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1200.0,1200.0,1200.0,1200.0,3.079181246,3.079181246,3.079181246,5.920818754,5.920818754,5.920818754,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1200.0,1200.0,1200.0,1200.0,5.920818753952375,5.920818753952375,5.920818753952375,5.920818753952375,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336317,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,COc1cncc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)c1,C21H22F3N5O2,CHEMBL381558,440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,440.0,440.0,440.0,440.0,2.643452676,2.643452676,2.643452676,6.356547324,6.356547324,6.356547324,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,440.0,440.0,440.0,440.0,6.356547323513812,6.356547323513812,6.356547323513812,6.356547323513812,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336362,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1cncnc1,C19H19F3N6O,CHEMBL203423,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336365,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,COc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,C21H22F3N5O2,CHEMBL381253,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,170.0,170.0,170.0,170.0,2.230448921,2.230448921,2.230448921,6.769551079,6.769551079,6.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336366,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,CSc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,C21H22F3N5OS,CHEMBL201069,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336371,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(C#N)nc1,C21H19F3N6O,CHEMBL200973,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,200.0,200.0,200.0,200.0,2.301029996,2.301029996,2.301029996,6.698970004,6.698970004,6.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,200.0,200.0,200.0,200.0,6.698970004336019,6.698970004336019,6.698970004336019,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336375,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(O)nc1,C20H20F3N5O2,CHEMBL382426,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
336381,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,CC1CN(c2ccc(C#N)c(C(F)(F)F)c2)C(C)CN1C(=O)Nc1ccc(C(F)(F)F)nc1,C21H19F6N5O,CHEMBL202660,210.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,210.0,210.0,210.0,210.0,2.322219295,2.322219295,2.322219295,6.677780705,6.677780705,6.677780705,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336400,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(N)nc1,C20H21F3N6O,CHEMBL379465,370.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,370.0,370.0,370.0,370.0,2.568201724,2.568201724,2.568201724,6.431798276,6.431798276,6.431798276,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,370.0,370.0,370.0,370.0,6.431798275933005,6.431798275933005,6.431798275933005,6.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336401,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(Cl)nc1,C20H19ClF3N5O,CHEMBL202710,730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,730.0,730.0,730.0,730.0,2.86332286,2.86332286,2.86332286,6.13667714,6.13667714,6.13667714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,730.0,730.0,730.0,730.0,6.136677139879544,6.136677139879544,6.136677139879544,6.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336411,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,COC(=O)c1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,C22H22F3N5O3,CHEMBL201327,470.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,470.0,470.0,470.0,470.0,2.672097858,2.672097858,2.672097858,6.327902142,6.327902142,6.327902142,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,470.0,470.0,470.0,470.0,6.327902142064283,6.327902142064283,6.327902142064283,6.327902142064283,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336418,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,CC(=O)c1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,C22H22F3N5O2,CHEMBL381358,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336440,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1cccnc1,C20H20F3N5O,CHEMBL439685,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,120.0,120.0,120.0,120.0,2.079181246,2.079181246,2.079181246,6.920818754,6.920818754,6.920818754,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,120.0,120.0,120.0,120.0,6.920818753952375,6.920818753952375,6.920818753952375,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336447,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccncc1,C20H20F3N5O,CHEMBL199899,140.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,140.0,140.0,140.0,140.0,2.146128036,2.146128036,2.146128036,6.853871964,6.853871964,6.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336467,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 327103, Entry 1: 2227442, ","Entry 0: Inhibition of AR mediated transcriptional activation using reporter assay, Entry 1: Antagonist activity at human Androgen receptor measured by AR-mediated transcriptional activation assay, ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL863517, Entry 1: CHEMBL5140955, ","Entry 0: 10.1021/jm050293c, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 16420057, Entry 1: 35786895, ","Entry 0: CHEMBL1147729, Entry 1: CHEMBL5137058, ","Entry 0: (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(F)cc1F,C21H19F5N4O,CHEMBL202990,200.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,200.0,200.0,200.0,200.0,2.301029996,2.301029996,2.301029996,6.698970004,6.698970004,6.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,200.0,200.0,200.0,200.0,6.698970004336019,6.698970004336019,6.698970004336019,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336471,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc[n+]([O-])c1,C20H20F3N5O2,CHEMBL201126,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
336475,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccccn1,C20H20F3N5O,CHEMBL201167,7800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7800.0,7800.0,7800.0,7800.0,3.892094603,3.892094603,3.892094603,5.107905397,5.107905397,5.107905397,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7800.0,7800.0,7800.0,7800.0,5.107905397309519,5.107905397309519,5.107905397309519,5.107905397309519,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
336509,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ncccn1,C19H19F3N6O,CHEMBL265785,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
336510,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccncn1,C19H19F3N6O,CHEMBL203085,4600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4600.0,4600.0,4600.0,4600.0,3.662757832,3.662757832,3.662757832,5.337242168,5.337242168,5.337242168,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4600.0,4600.0,4600.0,4600.0,5.337242168318426,5.337242168318426,5.337242168318426,5.337242168318426,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336634,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 327103, Entry 1: 2227442, ","Entry 0: Inhibition of AR mediated transcriptional activation using reporter assay, Entry 1: Antagonist activity at human Androgen receptor measured by AR-mediated transcriptional activation assay, ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL863517, Entry 1: CHEMBL5140955, ","Entry 0: 10.1021/jm050293c, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 16420057, Entry 1: 35786895, ","Entry 0: CHEMBL1147729, Entry 1: CHEMBL5137058, ","Entry 0: (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,C[C@@H]1CN(c2ccc(C#N)c(C(F)(F)F)c2)[C@@H](C)CN1C(=O)Nc1ccc(C(F)(F)F)nc1,C21H19F6N5O,CHEMBL197595,110.0,110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,110.0,110.0,110.0,110.0,2.041392685,2.041392685,2.041392685,6.958607315,6.958607315,6.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336635,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,C[C@@H]1CN(C(=O)Nc2ccc(C(F)(F)F)nc2)[C@@H](C)CN1c1ccc(C#N)c(C(F)(F)F)c1,C21H19F6N5O,CHEMBL372390,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1300.0,1300.0,1300.0,1300.0,3.113943352,3.113943352,3.113943352,5.886056648,5.886056648,5.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336650,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,Cc1ccncc1NC(=O)N1C[C@H](C)N(c2ccc(C#N)c(C(F)(F)F)c2)C[C@H]1C,C21H22F3N5O,CHEMBL201757,330.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,330.0,330.0,330.0,330.0,2.51851394,2.51851394,2.51851394,6.48148606,6.48148606,6.48148606,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,330.0,330.0,330.0,330.0,6.481486060122113,6.481486060122113,6.481486060122113,6.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336661,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,Cc1cncc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)c1,C21H22F3N5O,CHEMBL381776,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,250.0,250.0,250.0,250.0,2.397940009,2.397940009,2.397940009,6.602059991,6.602059991,6.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.0,250.0,250.0,250.0,6.6020599913279625,6.6020599913279625,6.6020599913279625,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
336662,nM,IC50,,BAO_0000190,IC50,327103,Inhibition of AR mediated transcriptional activation using reporter assay,0,F,,CHEMBL863517,10.1021/jm050293c,16420057,CHEMBL1147729,"(+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3- yl]piperazine-1-carboxamide (YM580) as an orally potent and peripherally selective nonsteroidal androgen receptor antagonist.",PUBLICATION,"A novel series of trans-N-aryl-2,5-dimethylpiperazine-1-carboxamide derivatives was synthesized and their androgen receptor (AR) antagonist activities and in vivo antiandrogenic effects were evaluated. Pharmacological assays indicated that compound 33 was a potent AR antagonist, and subsequent optical resolution provided (+)-(2R,5S)-4-[4-cyano-3-(trifluoromethyl)phenyl]-2,5-dimethyl-N-[6-(trifluoromethyl)pyridin-3-yl]piperazine-1-carboxamide (33a, YM580) which exhibited the most potent antiandrogenic activity. Unlike bicalutamide, compound 33a decreased the weight of rat ventral prostate in a dose-dependent manner (ED(50) = 2.2 mg/kg/day), and induced the maximum antiandrogenic effect, comparable to that of surgical castration, without significantly affecting serum testosterone levels. Compound 33a is a promising clinical candidate for prostate cancer monotherapy.",,Cc1ccc(NC(=O)N2C[C@H](C)N(c3ccc(C#N)c(C(F)(F)F)c3)C[C@H]2C)cn1,C21H22F3N5O,CHEMBL201242,130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,130.0,130.0,130.0,130.0,2.113943352,2.113943352,2.113943352,6.886056648,6.886056648,6.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,130.0,130.0,130.0,130.0,6.886056647693163,6.886056647693163,6.886056647693163,6.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338284,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/Cl)C1CC[C@@H]2O,C20H29ClO2,CHEMBL370236,1436.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1436.0,1436.0,1436.0,1436.0,3.15715444,3.15715444,3.15715444,5.84284556,5.84284556,5.84284556,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1436.0,1436.0,1436.0,1436.0,5.842845560093719,5.842845560093719,5.842845560093719,5.842845560093719,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338367,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C=C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C20H30O2,CHEMBL373019,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,33.0,33.0,33.0,33.0,1.51851394,1.51851394,1.51851394,7.48148606,7.48148606,7.48148606,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,33.0,33.0,33.0,33.0,7.481486060122113,7.481486060122113,7.481486060122113,7.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338580,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/F)C1CC[C@@H]2O,C20H29FO2,CHEMBL202400,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,85.0,85.0,85.0,85.0,1.929418926,1.929418926,1.929418926,7.070581074,7.070581074,7.070581074,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,85.0,85.0,85.0,85.0,7.070581074285707,7.070581074285707,7.070581074285707,7.070581074285707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338586,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\Cl)C1CC[C@@H]2O,C20H29ClO2,CHEMBL201569,172.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,172.0,172.0,172.0,172.0,2.235528447,2.235528447,2.235528447,6.764471553,6.764471553,6.764471553,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,172.0,172.0,172.0,172.0,6.764471553092451,6.764471553092451,6.764471553092451,6.764471553092451,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338620,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\F)C1CC[C@@H]2O,C20H29FO2,CHEMBL202007,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11.0,11.0,11.0,11.0,1.041392685,1.041392685,1.041392685,7.958607315,7.958607315,7.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,11.0,11.0,11.0,11.0,7.958607314841775,7.958607314841775,7.958607314841775,7.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338717,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C/C=C/[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H32O2,CHEMBL202415,843.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,843.0,843.0,843.0,843.0,2.925827575,2.925827575,2.925827575,6.074172425,6.074172425,6.074172425,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,843.0,843.0,843.0,843.0,6.074172425375258,6.074172425375258,6.074172425375258,6.074172425375258,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338718,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CC/C=C\[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C22H34O2,CHEMBL369991,3767.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3767.0,3767.0,3767.0,3767.0,3.57599562,3.57599562,3.57599562,5.42400438,5.42400438,5.42400438,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3767.0,3767.0,3767.0,3767.0,5.424004379796733,5.424004379796733,5.424004379796733,5.424004379796733,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338860,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C#C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C20H28O2,CHEMBL437065,1761.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1761.0,1761.0,1761.0,1761.0,3.245759356,3.245759356,3.245759356,5.754240644,5.754240644,5.754240644,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1761.0,1761.0,1761.0,1761.0,5.754240644032723,5.754240644032723,5.754240644032723,5.754240644032723,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338866,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CC#C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H30O2,CHEMBL201809,3733.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3733.0,3733.0,3733.0,3733.0,3.57205799,3.57205799,3.57205799,5.42794201,5.42794201,5.42794201,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3733.0,3733.0,3733.0,3733.0,5.4279420100736955,5.4279420100736955,5.4279420100736955,5.4279420100736955,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338936,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43CC=O)C1CC[C@@H]2O,C20H30O3,CHEMBL201364,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
338945,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C=CC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H32O2,CHEMBL369979,1768.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1768.0,1768.0,1768.0,1768.0,3.247482261,3.247482261,3.247482261,5.752517739,5.752517739,5.752517739,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1768.0,1768.0,1768.0,1768.0,5.752517739322946,5.752517739322946,5.752517739322946,5.752517739322946,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338946,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C20H32O2,CHEMBL382097,33.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,33.0,33.0,33.0,33.0,1.51851394,1.51851394,1.51851394,7.48148606,7.48148606,7.48148606,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,33.0,33.0,33.0,33.0,7.481486060122113,7.481486060122113,7.481486060122113,7.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
338947,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CCC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H34O2,CHEMBL201517,1769.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1769.0,1769.0,1769.0,1769.0,3.247727833,3.247727833,3.247727833,5.752272167,5.752272167,5.752272167,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1769.0,1769.0,1769.0,1769.0,5.752272167090277,5.752272167090277,5.752272167090277,5.752272167090277,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339121,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CO/C=C\[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H32O3,CHEMBL380876,1402.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1402.0,1402.0,1402.0,1402.0,3.146748014,3.146748014,3.146748014,5.853251986,5.853251986,5.853251986,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1402.0,1402.0,1402.0,1402.0,5.85325198636936,5.85325198636936,5.85325198636936,5.85325198636936,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339129,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,CO/C=C/[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H32O3,CHEMBL204389,4617.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4617.0,4617.0,4617.0,4617.0,3.664359875,3.664359875,3.664359875,5.335640125,5.335640125,5.335640125,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4617.0,4617.0,4617.0,4617.0,5.335640125448859,5.335640125448859,5.335640125448859,5.335640125448859,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339130,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C/C=C\[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H32O2,CHEMBL383253,718.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,718.0,718.0,718.0,718.0,2.856124444,2.856124444,2.856124444,6.143875556,6.143875556,6.143875556,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,718.0,718.0,718.0,718.0,6.1438755557577,6.1438755557577,6.1438755557577,6.1438755557577,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339131,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43CO)C1CC[C@@H]2O,C19H30O3,CHEMBL382632,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
339140,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43C=O)C1CC[C@@H]2O,C19H28O3,CHEMBL380978,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
339141,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C=C[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@]2(C)O,C21H32O2,CHEMBL204642,169.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,169.0,169.0,169.0,169.0,2.227886705,2.227886705,2.227886705,6.772113295,6.772113295,6.772113295,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,169.0,169.0,169.0,169.0,6.772113295386326,6.772113295386326,6.772113295386326,6.772113295386326,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339142,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C#C[C@]1(O)CCC2C3CC=C4C[C@@H](O)CC[C@]4(C=C)C3CC[C@@]21C,C22H30O2,CHEMBL381566,287.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,287.0,287.0,287.0,287.0,2.457881897,2.457881897,2.457881897,6.542118103,6.542118103,6.542118103,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,287.0,287.0,287.0,287.0,6.542118103266008,6.542118103266008,6.542118103266008,6.542118103266008,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339191,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C\Br)C1CC[C@@H]2O,C20H29BrO2,CHEMBL379441,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339198,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C[C@]12CCC3C(CC=C4C[C@@H](O)CC[C@@]43/C=C/Br)C1CC[C@@H]2O,C20H29BrO2,CHEMBL204317,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,120.0,120.0,120.0,120.0,2.079181246,2.079181246,2.079181246,6.920818754,6.920818754,6.920818754,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,120.0,120.0,120.0,120.0,6.920818753952375,6.920818753952375,6.920818753952375,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339320,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C=C[C@]12CCC(=O)C=C1CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C20H28O2,CHEMBL203748,7.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.9,7.9,7.9,7.9,0.897627091,0.897627091,0.897627091,8.102372909,8.102372909,8.102372909,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.9,7.9,7.9,7.9,8.102372908709558,8.102372908709558,8.102372908709558,8.102372908709558,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
339321,nM,IC50,,BAO_0000190,IC50,332775,Inhibitory activity against AR,0,B,,CHEMBL859226,10.1016/j.bmcl.2005.11.014,16309907,CHEMBL1149417,Androstenediol analogs as ER-beta-selective SERMs.,PUBLICATION,A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta.,,C#CC[C@]12CC[C@H](O)CC1=CCC1C2CC[C@@]2(C)C1CC[C@@H]2O,C21H30O2,CHEMBL203561,1717.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1717.0,1717.0,1717.0,1717.0,3.234770295,3.234770295,3.234770295,5.765229705,5.765229705,5.765229705,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1717.0,1717.0,1717.0,1717.0,5.765229704839084,5.765229704839084,5.765229704839084,5.765229704839084,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
347303,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1520318, Entry 1: 1520320, Entry 2: 1520321, ","Entry 0: Antagonist activity at wild type AR expressed in human SC cells assessed as inhibition of 1 nM DHT-induced cell proliferation after 3 days by WST-8 assay, Entry 1: Displacement of [3H]-DHT from human GST fused AR-LBD (627 to 919 amino acids) transfected in Escherichia coli HB 101 after 15 hrs by liquid scintillation counting assay, Entry 2: Antagonist activity at AR T877A mutant expressed in human LNCaP cells assessed as inhibition of 10 nM DHT-stimulated cell proliferation after 6 days by WST-8 assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3626368, Entry 1: CHEMBL3626370, Entry 2: CHEMBL3626371, ","Entry 0: 10.1016/j.ejmech.2015.08.002, Entry 1: 10.1016/j.ejmech.2015.08.002, Entry 2: 10.1016/j.ejmech.2015.08.002, ","Entry 0: 26295173, Entry 1: 26295173, Entry 2: 26295173, ","Entry 0: CHEMBL3621051, Entry 1: CHEMBL3621051, Entry 2: CHEMBL3621051, ","Entry 0: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., Entry 1: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., Entry 2: Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., Entry 1: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., Entry 2: The androgen receptor (AR) plays important roles in multiple physiological functions, including differentiation, growth, and maintenance of male reproductive organs, and also has effects on hair and skin. In this paper, we report the synthesis of nonsteroidal AR antagonists having a 4-benzyl-1-(2H)-phthalazinone skeleton. Among the synthesized compounds, 11c with two ortho-substituents on the phenyl group potently inhibited SC-3 cell proliferation (IC50: 0.18 M) and showed high wt AR-binding affinity (IC50: 10.9 M), comparable to that of hydroxyflutamide (3). Compound 11c also inhibited proliferation of LNCaP cells containing T877A-mutated AR. Docking study of 11c with the AR ligand-binding domain indicated that the benzyl group is important for the antagonism. These phthalazinone derivatives may be useful for investigating potential clinical applications of AR antagonists., ",,Oc1nnc(Cc2ccccc2Cl)c2ccccc12,C15H11ClN2O,CHEMBL378274,860.0,1260.0,85400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,39758.59264,860.0,29173.33333,1260.0,85400.0,4.464986054,3.100370545,2.934498451,4.535013946,5.899629455,6.065501549,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,860.0,860.0,860.0,860.0,6.0655015487564325,6.0655015487564325,6.0655015487564325,6.0655015487564325,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360119,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,CN(C)c1ccc2nc(O)cc(C(F)(F)F)c2c1,C12H11F3N2O,CHEMBL217168,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34.0,34.0,34.0,34.0,1.531478917,1.531478917,1.531478917,7.468521083,7.468521083,7.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,34.0,34.0,34.0,34.0,7.468521082957745,7.468521082957745,7.468521082957745,7.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360120,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 414681, Entry 1: 441969, ","Entry 0: Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay, Entry 1: Antagonist activity at human AR, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL911188, Entry 1: CHEMBL891113, ","Entry 0: 10.1021/jm060792t, Entry 1: 10.1016/j.bmcl.2007.01.001, ","Entry 0: 17034117, Entry 1: 17267219, ","Entry 0: CHEMBL1137374, Entry 1: CHEMBL1147033, ","Entry 0: Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator., Entry 1: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators., Entry 1: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., ",,CCN(CC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,C14H15F3N2O,CHEMBL277378,1000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4500.0,1000.0,5500.0,5500.0,10000.0,3.740362689,3.740362689,3.0,5.259637311,5.259637311,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5500.0,5500.0,1000.0,10000.0,5.259637310505756,5.259637310505756,6.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
360121,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 414681, Entry 1: 441969, Entry 2: 446573, ","Entry 0: Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay, Entry 1: Antagonist activity at human AR, Entry 2: Antagonist activity at human androgen receptor by luciferase reporter gene assay, ","0,1,2","Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL911188, Entry 1: CHEMBL891113, Entry 2: CHEMBL896867, ","Entry 0: 10.1021/jm060792t, Entry 1: 10.1016/j.bmcl.2007.01.001, Entry 2: 10.1021/jm070231h, ","Entry 0: 17034117, Entry 1: 17267219, Entry 2: 17887661, ","Entry 0: CHEMBL1137374, Entry 1: CHEMBL1147033, Entry 2: CHEMBL1148826, ","Entry 0: Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator., Entry 1: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., Entry 2: Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators., Entry 1: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., Entry 2: The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis., ",,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C14H9F9N2O,CHEMBL436784,10000.0,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
360216,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,CCCCN(CCCC)c1ccc2nc(O)cc(C(F)(F)F)c2c1,C18H23F3N2O,CHEMBL216949,29.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,29.5,29.5,29.5,29.5,1.469822016,1.469822016,1.469822016,7.530177984,7.530177984,7.530177984,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,29.5,29.5,29.5,29.5,7.530177984021837,7.530177984021837,7.530177984021837,7.530177984021837,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360223,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,CCN(c1ccc2nc(O)cc(C(F)(F)F)c2c1)C(C)C,C15H17F3N2O,CHEMBL217402,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
360232,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,Oc1cc(C(F)(F)F)c2cc(N(CC3CC3)CC3CC3)ccc2n1,C18H19F3N2O,CHEMBL217324,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
360238,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 414681, Entry 1: 438255, ","Entry 0: Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay, Entry 1: Antagonist activity at human androgen receptor expressed in CV1 cells, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL911188, Entry 1: CHEMBL887361, ","Entry 0: 10.1021/jm060792t, Entry 1: 10.1016/j.bmcl.2007.01.007, ","Entry 0: 17034117, Entry 1: 17257838, ","Entry 0: CHEMBL1137374, Entry 1: CHEMBL1144605, ","Entry 0: Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator., Entry 1: Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators., Entry 1: A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays., ",,Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,C10H7F3N2O,CHEMBL385509,26.0,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26.0,26.0,26.0,26.0,1.414973348,1.414973348,1.414973348,7.585026652,7.585026652,7.585026652,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,26.0,26.0,26.0,26.0,7.585026652029182,7.585026652029182,7.585026652029182,7.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360239,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,CCCNc1ccc2nc(O)cc(C(F)(F)F)c2c1,C13H13F3N2O,CHEMBL405835,27.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.5,27.5,27.5,27.5,1.439332694,1.439332694,1.439332694,7.560667306,7.560667306,7.560667306,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.5,27.5,27.5,27.5,7.560667306169737,7.560667306169737,7.560667306169737,7.560667306169737,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360240,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 414681, Entry 1: 441969, ","Entry 0: Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay, Entry 1: Antagonist activity at human AR, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL911188, Entry 1: CHEMBL891113, ","Entry 0: 10.1021/jm060792t, Entry 1: 10.1016/j.bmcl.2007.01.001, ","Entry 0: 17034117, Entry 1: 17267219, ","Entry 0: CHEMBL1137374, Entry 1: CHEMBL1147033, ","Entry 0: Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator., Entry 1: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators., Entry 1: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., ",,CCN(CC(F)(F)F)c1ccc2nc(O)cc(C(F)(F)F)c2c1,C14H12F6N2O,CHEMBL217769,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
360246,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,CC(C)Nc1ccc2nc(O)cc(C(F)(F)F)c2c1,C13H13F3N2O,CHEMBL217428,16.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.5,16.5,16.5,16.5,1.217483944,1.217483944,1.217483944,7.782516056,7.782516056,7.782516056,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.5,16.5,16.5,16.5,7.782516055786094,7.782516055786094,7.782516055786094,7.782516055786094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
360247,nM,IC50,,BAO_0000190,IC50,414681,Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay,0,F,,CHEMBL911188,10.1021/jm060792t,17034117,CHEMBL1137374,"Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator.",PUBLICATION,"The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators.",,Oc1cc(C(F)(F)F)c2cc(N(CC3CC3)CC(F)(F)F)ccc2n1,C16H14F6N2O,CHEMBL267260,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
364520,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, ",mix,"Entry 0: 306232, Entry 1: 332775, Entry 2: 455548, Entry 3: 458140, Entry 4: 687675, Entry 5: 854887, Entry 6: 1468250, Entry 7: 1468251, ","Entry 0: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 1: Inhibitory activity against AR, Entry 2: Binding affinity to androgen receptor, Entry 3: Binding affinity at AR, Entry 4: Binding affinity to androgen receptor by fluorescence binding assay, Entry 5: Displacement of [3H]R1881 from wild type human androgen receptor expressed in COS-1 cells co-transfected with pSG5 after 15 mins by scintillation assay, Entry 6: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 7: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",1,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, Entry 5: B, Entry 6: B, Entry 7: B, ",,"Entry 0: CHEMBL874560, Entry 1: CHEMBL859226, Entry 2: CHEMBL886327, Entry 3: CHEMBL925473, Entry 4: CHEMBL1291059, Entry 5: CHEMBL2162624, Entry 6: CHEMBL3411793, Entry 7: CHEMBL3411794, ","Entry 0: 10.1021/jm0342515, Entry 1: 10.1016/j.bmcl.2005.11.014, Entry 2: 10.1016/j.bmcl.2006.12.053, Entry 3: 10.1016/j.bmcl.2007.09.001, Entry 4: 10.1016/j.bmcl.2010.09.140, Entry 5: 10.1021/jm300233k, Entry 6: 10.1021/jm501995n, Entry 7: 10.1021/jm501995n, ","Entry 0: 15456242, Entry 1: 16309907, Entry 2: 17448656, Entry 3: 17890084, Entry 4: 21036041, Entry 5: 22746350, Entry 6: 25646649, Entry 7: 25646649, ","Entry 0: CHEMBL1137214, Entry 1: CHEMBL1149417, Entry 2: CHEMBL1139947, Entry 3: CHEMBL1140529, Entry 4: CHEMBL1287721, Entry 5: CHEMBL2157978, Entry 6: CHEMBL3407333, Entry 7: CHEMBL3407333, ","Entry 0: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 1: Androstenediol analogs as ER-beta-selective SERMs., Entry 2: Bridged androstenediol analogs as ER-beta selective SERMs., Entry 3: Androstene-3,5-dienes as ER-beta selective SERMs., Entry 4: Synthesis of potent, substituted carbazoles as selective androgen receptor modulators (SARMs)., Entry 5: Design, synthesis, and biological evaluation of nonsteroidal cycloalkane[d]isoxazole-containing androgen receptor modulators., Entry 6: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 7: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, ","Entry 0: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 1: A series of 19-substituted androstenediol derivatives was prepared. Some of the novel analogs were surprisingly potent and selective ligands for ER-beta., Entry 2: A series of bridged androstenediol derivatives was prepared. The bridged compounds exhibited reduced ER-beta selectivity relative to uncyclized analogs., Entry 3: A series of androstene-3,5-diene derivatives were prepared. Despite lacking the C-3 hydroxyl previously believed necessary for ER activity, some of the analogs retained surprising affinity for ER-beta. For example, diene 4 retained excellent selectivity and potency as an ER-beta agonist and was more selective for ER-beta over the androgen receptor (AR)., Entry 4: The synthesis and in vitro binding affinity for a novel series of potent androgen receptor modulators is described. One of the more potent compounds (17, RAD35010) was further characterized in vivo where it restored levator ani weight in castrated male rats to near sham level while having no significant effect on prostate weight., Entry 5: We report here the design, preparation, and systematic evaluation of a novel cycloalkane[d]isoxazole pharmacophoric fragment-containing androgen receptor (AR) modulators. Cycloalkane[d]isoxazoles form new core structures that interact with the hydrophobic region of the AR ligand-binding domain. To systematize and rationalize the structure-activity relationship of the new fragment, we used molecular modeling to design a molecular library containing over 40 cycloalkane[d]isoxazole derivatives. The most potent compound, 4-(3a,4,5,6,7,7a-hexahydrobenzo[d]isoxazol-3-yl)-2-(trifluoromethyl)benzonitrile (6a), exhibits antiandrogenic activity significantly greater than that of the most widely used antiandrogenic prostate cancer drugs bicalutamide (1) and hydroxyflutamide (2) in reporter gene assays measuring the transcriptional activity of AR (decreasing approximately 90% of the total AR activity) and in competitive AR ligand-binding assays (showing over four times higher potency to inhibit radioligand binding in comparison to bicalutamide). Notably, 6a maintains its antiandrogenic activity with AR mutants W741L and T877A commonly observed and activated by bicalutamide and hydroxyflutamide, respectively, in prostate cancer patients., Entry 6: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 7: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C19H28O2,CHEMBL386630,2.7,2.7,3.0,3.9,4.17,4.27,5.0,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.770116703,2.7,6.876375,4.035,30.0,0.837359553,0.605843539,0.431363764,8.162640447,8.394156461,8.568636236,8,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2.7,2.7,2.7,2.7,8.568636235841012,8.568636235841012,8.568636235841012,8.568636235841012,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
364605,nM,IC50,,BAO_0000190,IC50,422453,Activity against human androgen receptor expressed in HepG2 cells assessed as luciferase reporter gene activation,0,B,,CHEMBL911023,10.1021/jm060713d,17149866,CHEMBL1137300,"Identification of the brominated flame retardant 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane as an androgen agonist.",PUBLICATION,"To investigate androgen receptor (AR) activation by exogenous compounds, we used a combination of experimental analysis and theoretical modeling to compare a set of brominated flame retardants (BFRs) to dihydrotestosterone (DHT) with regard to ligand docking, AR binding, and AR activation in human hepatocellular liver carcinoma cells, as well as interacting energy analysis. Modeling of receptor docking was found to be a useful first step in predicting the potential to translocate to the ligand pocket of the receptor, and the computed interaction energy was found to correlate with the observed binding affinity. Flexible alignment studies of the BFR compounds demonstrated that 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane (BCH) closely overlap DHT. Combining the theoretical modeling with in vitro ligand-binding and receptor-activation assays, we show that BCH binds to and activates the human AR. The remaining BFRs did not successfully interact with the ligand pocket, were not able to replace a synthetic androgen from the receptor, and failed to activate the receptor.",,BrCC(Br)C1CCC(Br)C(Br)C1,C8H12Br4,CHEMBL375107,42.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.7,42.7,42.7,42.7,1.630427875,1.630427875,1.630427875,7.369572125,7.369572125,7.369572125,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.7,42.7,42.7,42.7,7.369572124974976,7.369572124974976,7.369572124974976,7.369572124974976,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
366274,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(S(N)(=O)=O)cc21,C10H16N2O4S3,CHEMBL218490,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,65.0,65.0,65.0,65.0,1.812913357,1.812913357,1.812913357,7.187086643,7.187086643,7.187086643,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,65.0,65.0,65.0,65.0,7.187086643357144,7.187086643357144,7.187086643357144,7.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375721,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CC(C)N(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C31H53NO3,CHEMBL224414,420.0,430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.0,420.0,425.0,425.0,430.0,2.62838893,2.62838893,2.62324929,6.37161107,6.37161107,6.37675071,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,430.0,430.0,430.0,430.0,6.366531544420414,6.366531544420414,6.366531544420414,6.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375727,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C30H51NO3,CHEMBL390071,420.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,120.0,420.0,540.0,540.0,660.0,2.73239376,2.73239376,2.62324929,6.26760624,6.26760624,6.37675071,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375734,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C29H49NO3,CHEMBL389277,190.0,260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,190.0,225.0,225.0,260.0,2.352182518,2.352182518,2.278753601,6.647817482,6.647817482,6.721246399,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,260.0,260.0,260.0,260.0,6.585026652029182,6.585026652029182,6.585026652029182,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375738,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCN(CC)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C31H53NO3,CHEMBL224352,120.0,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.0,120.0,210.0,210.0,300.0,2.322219295,2.322219295,2.079181246,6.677780705,6.677780705,6.920818754,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375746,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CCC(=O)C[C@@H]1CC(CCCCCCCC(=O)N1CCOCC1)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C31H51NO4,CHEMBL224654,730.0,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,285.0,730.0,1015.0,1015.0,1300.0,3.006466042,3.006466042,2.86332286,5.993533958,5.993533958,6.13667714,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375754,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CCC(=O)C[C@@H]1CC(CCCCCCCC(=O)N1CCCC1)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C31H51NO3,CHEMBL427243,300.0,350.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,25.0,300.0,325.0,325.0,350.0,2.511883361,2.511883361,2.477121255,6.488116639,6.488116639,6.522878745,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,350.0,350.0,350.0,350.0,6.455931955649724,6.455931955649724,6.455931955649724,6.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375760,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CCC(=O)C[C@@H]1CC(CCCCCCCC(=O)N1CCCCC1)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C32H53NO3,CHEMBL224707,120.0,490.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,185.0,120.0,305.0,305.0,490.0,2.484299839,2.484299839,2.079181246,6.515700161,6.515700161,6.920818754,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,490.0,490.0,490.0,490.0,6.309803919971486,6.309803919971486,6.309803919971486,6.309803919971486,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375771,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CCC(=O)C[C@@H]1CC(CCCCCCCC(N)=O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C27H45NO3,CHEMBL224733,260.0,450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95.0,260.0,355.0,355.0,450.0,2.550228353,2.550228353,2.414973348,6.449771647,6.449771647,6.585026652,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,450.0,450.0,450.0,450.0,6.346787486224656,6.346787486224656,6.346787486224656,6.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375772,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C28H47NO3,CHEMBL427078,480.0,710.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,115.0,480.0,595.0,595.0,710.0,2.774516966,2.774516966,2.681241237,6.225483034,6.225483034,6.318758763,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,710.0,710.0,710.0,710.0,6.1487416512809245,6.1487416512809245,6.1487416512809245,6.1487416512809245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375779,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C29H49NO3,CHEMBL387651,940.0,1500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,280.0,940.0,1220.0,1220.0,1500.0,3.086359831,3.086359831,2.973127854,5.913640169,5.913640169,6.026872146,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1500.0,1500.0,1500.0,1500.0,5.823908740944319,5.823908740944319,5.823908740944319,5.823908740944319,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375786,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C30H51NO3,CHEMBL224734,1600.0,1800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.0,1600.0,1700.0,1700.0,1800.0,3.230448921,3.230448921,3.204119983,5.769551079,5.769551079,5.795880017,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1800.0,1800.0,1800.0,1800.0,5.7447274948966935,5.7447274948966935,5.7447274948966935,5.7447274948966935,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375792,nM,IC50,,BAO_0000190,IC50,432234,Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay,0,F,,CHEMBL914606,10.1016/j.bmc.2006.09.072,17064916,CHEMBL1144524,Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships.,PUBLICATION,"A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities.",,CCCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C31H53NO3,CHEMBL276621,6300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6300.0,6300.0,6300.0,6300.0,3.799340549,3.799340549,3.799340549,5.200659451,5.200659451,5.200659451,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6300.0,6300.0,6300.0,6300.0,5.200659450546418,5.200659450546418,5.200659450546418,5.200659450546418,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375795,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C29H45F5O3S,CHEMBL224736,6800.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1600.0,6800.0,8400.0,8400.0,10000.0,3.924279286,3.924279286,3.832508913,5.075720714,5.075720714,5.167491087,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375796,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C31H49F5O3S,CHEMBL387850,960.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4520.0,960.0,5480.0,5480.0,10000.0,3.738780558,3.738780558,2.982271233,5.261219442,5.261219442,6.017728767,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375797,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C33H53F5O3S,CHEMBL224015,110.0,2900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1395.0,110.0,1505.0,1505.0,2900.0,3.1775365,3.1775365,2.041392685,5.8224635,5.8224635,6.958607315,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2900.0,2900.0,2900.0,2900.0,5.5376020021010435,5.5376020021010435,5.5376020021010435,5.5376020021010435,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375798,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C35H57F5O3S,CHEMBL388724,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375799,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCCCNC(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C33H57NO3,CHEMBL224047,2100.0,6600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2250.0,2100.0,4350.0,4350.0,6600.0,3.638489257,3.638489257,3.322219295,5.361510743,5.361510743,5.677780705,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,6600.0,6600.0,6600.0,6600.0,5.180456064458132,5.180456064458132,5.180456064458132,5.180456064458132,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375806,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,C[C@]12CC[C@H]3[C@@H]([C@H](CCCCCCCCCCCCC[S+]([O-])CCCC(F)(F)C(F)(F)F)CC4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,C37H61F5O3S,CHEMBL224278,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375807,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C32H55NO3,CHEMBL223813,280.0,340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30.0,280.0,310.0,310.0,340.0,2.491361694,2.491361694,2.447158031,6.508638306,6.508638306,6.552841969,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,340.0,340.0,6.468521082957745,6.468521082957745,6.468521082957745,6.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375808,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CN(C)C(=O)CCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C28H47NO3,CHEMBL225147,110.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.0,110.0,155.0,155.0,200.0,2.190331698,2.190331698,2.041392685,6.809668302,6.809668302,6.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,200.0,200.0,200.0,200.0,6.698970004336019,6.698970004336019,6.698970004336019,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375812,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C33H57NO3,CHEMBL389631,550.0,3400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1425.0,550.0,1975.0,1975.0,3400.0,3.2955671,3.2955671,2.740362689,5.7044329,5.7044329,6.259637311,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3400.0,3400.0,3400.0,3400.0,5.468521082957745,5.468521082957745,5.468521082957745,5.468521082957745,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375813,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCN(CC)C(=O)CCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C30H51NO3,CHEMBL376182,330.0,530.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.0,330.0,430.0,430.0,530.0,2.633468456,2.633468456,2.51851394,6.366531544,6.366531544,6.48148606,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,530.0,530.0,530.0,530.0,6.275724130399211,6.275724130399211,6.275724130399211,6.275724130399211,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375821,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C34H59NO3,CHEMBL224779,570.0,1800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,615.0,570.0,1185.0,1185.0,1800.0,3.07371835,3.07371835,2.755874856,5.92628165,5.92628165,6.244125144,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1800.0,1800.0,1800.0,1800.0,5.7447274948966935,5.7447274948966935,5.7447274948966935,5.7447274948966935,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375822,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C35H61NO3,CHEMBL375675,1300.0,1900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,300.0,1300.0,1600.0,1600.0,1900.0,3.204119983,3.204119983,3.113943352,5.795880017,5.795880017,5.886056648,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1900.0,1900.0,1900.0,1900.0,5.721246399047171,5.721246399047171,5.721246399047171,5.721246399047171,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375823,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCCCCCC[C@@H]1CC2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C36H63NO3,CHEMBL373460,3500.0,9900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3200.0,3500.0,6700.0,6700.0,9900.0,3.826074803,3.826074803,3.544068044,5.173925197,5.173925197,5.455931956,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,9900.0,9900.0,9900.0,9900.0,5.00436480540245,5.00436480540245,5.00436480540245,5.00436480540245,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375824,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CN(Cc1ccccc1)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C35H53NO3,CHEMBL223355,820.0,1600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,390.0,820.0,1210.0,1210.0,1600.0,3.08278537,3.08278537,2.913813852,5.91721463,5.91721463,6.086186148,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1600.0,1600.0,1600.0,1600.0,5.795880017344075,5.795880017344075,5.795880017344075,5.795880017344075,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375825,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCCCN(CCCCCC)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C39H69NO3,CHEMBL224216,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
375835,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C32H55NO3,CHEMBL224770,280.0,340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,30.0,280.0,310.0,310.0,340.0,2.491361694,2.491361694,2.447158031,6.508638306,6.508638306,6.552841969,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,340.0,340.0,6.468521082957745,6.468521082957745,6.468521082957745,6.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
375842,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 432232, Entry 1: 432234, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL914604, Entry 1: CHEMBL914606, ","Entry 0: 10.1016/j.bmc.2006.09.072, Entry 1: 10.1016/j.bmc.2006.09.072, ","Entry 0: 17064916, Entry 1: 17064916, ","Entry 0: CHEMBL1144524, Entry 1: CHEMBL1144524, ","Entry 0: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., Entry 1: Discovery of 7alpha-substituted dihydrotestosterones as androgen receptor pure antagonists and their structure-activity relationships., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., Entry 1: A series of 7alpha-substituted dihydrotestosterone derivatives were synthesized and evaluated for androgen receptor (AR) pure antagonistic activity. From reporter gene assay (RGA), the compound with a side chain containing N-n-butyl-N-methyl amide (19a) showed pure antagonistic activity (IC(50)=340nM, FI(5)>10,000nM), whereas known AR antagonists showed partial agonistic activities. The optimization of 19a led to compound 23 (CH4892280), which showed more potent pure antagonistic activity (IC(50)=190nM, FI(5)>10,000nM). The SARs of tested compounds suggested that the length of the side chain and the substituents on the amide nitrogen are important for pure antagonistic activities., ",,CCCN(C)C(=O)CCCCCCCC1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C31H53NO3,CHEMBL375282,300.0,1100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,400.0,300.0,700.0,700.0,1100.0,2.84509804,2.84509804,2.477121255,6.15490196,6.15490196,6.522878745,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1100.0,1100.0,1100.0,1100.0,5.958607314841775,5.958607314841775,5.958607314841775,5.958607314841775,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
377718,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,C20H29FO3,CHEMBL1445,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377719,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 36105, Entry 1: 36114, Entry 2: 434683, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay, Entry 1: Antagonist activity against Human Androgen receptor expressed in CV-1 cells, Entry 2: Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay, ","0,1,2","Entry 0: F, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL648070, Entry 1: CHEMBL648079, Entry 2: CHEMBL916637, ","Entry 0: 10.1016/s0960-894x(99)00186-9, Entry 1: 10.1021/jm9806648, Entry 2: 10.1021/jm061329j, ","Entry 0: 10340624, Entry 1: 9925725, Entry 2: 17439112, ","Entry 0: CHEMBL1132051, Entry 1: CHEMBL1132152, Entry 2: CHEMBL1139861, ","Entry 0: 4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists., Entry 1: Discovery of a potent, orally active, nonsteroidal androgen receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6- (trifluoromethyl)-8-pyridono[5,6-g]- quinoline (LG121071)., Entry 2: Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy., Entry 1: Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy., ",,CCC1CCNc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,C15H15F3N2O,CHEMBL390728,4580.0,7481.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2214.536872,4580.0,7353.666667,7481.0,10000.0,3.86650394,3.873959655,3.660865478,5.13349606,5.126040345,5.339134522,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,7353.666666666667,7481.0,4580.0,10000.0,5.13349606009515,5.126040345256647,5.33913452199613,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
377725,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3,C12H9F3N2O2,CHEMBL390754,296.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,296.0,296.0,296.0,296.0,2.471291711,2.471291711,2.471291711,6.528708289,6.528708289,6.528708289,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,296.0,296.0,296.0,296.0,6.528708288941061,6.528708288941061,6.528708288941061,6.528708288941061,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
377726,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,C13H11F3N2O2,CHEMBL227030,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377728,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CCN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,C14H13F3N2O2,CHEMBL224204,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377746,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CCCN1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,C15H15F3N2O2,CHEMBL227590,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377748,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CC(C)(C)N1CCOc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc21,C16H17F3N2O2,CHEMBL375907,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377752,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3CC(F)(F)F,C14H10F6N2O2,CHEMBL227783,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377753,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3CC1CC1,C16H15F3N2O2,CHEMBL227784,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377758,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OCCN3Cc1ccccc1,C19H15F3N2O2,CHEMBL390577,224.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,224.0,224.0,224.0,224.0,2.350248018,2.350248018,2.350248018,6.649751982,6.649751982,6.649751982,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,224.0,224.0,224.0,224.0,6.649751981665837,6.649751981665837,6.649751981665837,6.649751981665837,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
377765,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 434683, Entry 1: 434683, ","Entry 0: Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay, Entry 1: Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL916637, Entry 1: CHEMBL916637, ","Entry 0: 10.1021/jm061329j, Entry 1: 10.1021/jm061329j, ","Entry 0: 17439112, Entry 1: 17439112, ","Entry 0: CHEMBL1139861, Entry 1: CHEMBL1139861, ","Entry 0: Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones., Entry 1: Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy., Entry 1: Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy., ",,CC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,C15H12F6N2O2,CHEMBL227408,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377766,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CCC1CN(C)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,C15H15F3N2O2,CHEMBL227463,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,67.0,67.0,67.0,67.0,1.826074803,1.826074803,1.826074803,7.173925197,7.173925197,7.173925197,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,67.0,67.0,67.0,67.0,7.173925197299173,7.173925197299173,7.173925197299173,7.173925197299173,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
377767,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CCC1CN(CC)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,C16H17F3N2O2,CHEMBL388831,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377773,nM,IC50,,BAO_0000190,IC50,434683,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL916637,10.1021/jm061329j,17439112,CHEMBL1139861,"Novel series of potent, nonsteroidal, selective androgen receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones.",PUBLICATION,"Recent interest in orally available androgens has fueled the search for new androgens for use in hormone replacement therapy and as anabolic agents. In pursuit of this, we have discovered a series of novel androgen receptor modulators derived from 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. These compounds were synthesized and evaluated in competitive binding assays and an androgen receptor transcriptional activation assay. A number of compounds from the series demonstrated single-digit nanomolar agonist activity in vitro. In addition, lead compound (R)-16e was orally active in established rodent models that measure androgenic and anabolic properties of these agents. In this assay, (R)-16e demonstrated full efficacy in muscle and only partially stimulated the prostate at 100 mg/kg. These data suggest that these compounds may be utilized as selective androgen receptor modulators or SARMs. This series represents a novel class of compounds for use in androgen replacement therapy.",,CCC1CN(CC(F)(F)F)c2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2O1,C16H14F6N2O2,CHEMBL376360,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
377825,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457221, Entry 1: 479688, ","Entry 0: Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay, Entry 1: Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL940822, Entry 1: CHEMBL933552, ","Entry 0: 10.1016/j.bmcl.2007.07.034, Entry 1: 10.1016/j.bmcl.2008.03.062, ","Entry 0: 17703938, Entry 1: 18400499, ","Entry 0: CHEMBL1139788, Entry 1: CHEMBL1145608, ","Entry 0: Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones., Entry 1: Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action., Entry 1: Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay., ",,C[C@@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,C15H12F6N2O2,CHEMBL224263,70.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4965.0,70.0,5035.0,5035.0,10000.0,3.701999475,3.701999475,1.84509804,5.298000525,5.298000525,7.15490196,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5035.0,5035.0,70.0,10000.0,5.298000525110363,5.298000525110363,7.154901959985743,5.0,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
389437,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,O=c1cc(C(F)(F)F)c2cc(N3CCCC3)ccc2[nH]1,C14H13F3N2O,CHEMBL446191,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25.0,25.0,25.0,25.0,1.397940009,1.397940009,1.397940009,7.602059991,7.602059991,7.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,25.0,25.0,25.0,25.0,7.6020599913279625,7.6020599913279625,7.6020599913279625,7.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
389439,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,CC1CCCN1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H15F3N2O,CHEMBL244895,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
389441,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@H](C)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H17F3N2O,CHEMBL244896,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
389443,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@@H](C)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H17F3N2O,CHEMBL243251,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
389445,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@H](CO)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H17F3N2O2,CHEMBL243252,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
389447,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@H](CCl)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H16ClF3N2O,CHEMBL395992,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396161,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 414681, Entry 1: 441969, ","Entry 0: Antagonist activity against human androgen receptor in CV1 cells measured as inhibition of DHT-stimulated luciferase reporter gene activity by cotransfection assay, Entry 1: Antagonist activity at human AR, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL911188, Entry 1: CHEMBL891113, ","Entry 0: 10.1021/jm060792t, Entry 1: 10.1016/j.bmcl.2007.01.001, ","Entry 0: 17034117, Entry 1: 17267219, ","Entry 0: CHEMBL1137374, Entry 1: CHEMBL1147033, ","Entry 0: Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino- 4-trifluoromethylquinolin-2(1H)-one as a novel selective androgen receptor modulator., Entry 1: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor is a member of the extended family of nuclear receptors and is widely distributed throughout the body. Androgen therapy is used to compensate for low levels of the natural hormones testosterone (T) and dihydrotestosterone and consists of administration of T, prodrugs thereof, or synthetic androgens. However, currently available androgens have many drawbacks. We identified 6-dialkylamino-4-trifluoromethylquinolin-2(1H)-ones as orally available tissue-selective androgen receptor modulators., Entry 1: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., ",,CCCN(CCC)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H19F3N2O,CHEMBL442240,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396162,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)F)ccc2[nH]1,C14H11F7N2O,CHEMBL237045,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396163,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)(F)Cl)ccc2[nH]1,C14H10ClF7N2O,CHEMBL393664,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396164,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C13H10F6N2O,CHEMBL237259,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396166,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CCCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H14F6N2O,CHEMBL237261,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396167,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CCCCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H16F6N2O,CHEMBL393864,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396168,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CC(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H14F6N2O,CHEMBL237262,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396169,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CC(C)(C)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C17H18F6N2O,CHEMBL237472,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396170,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CC(C)(C)CCN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C18H20F6N2O,CHEMBL237473,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396171,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CCC(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H16F6N2O,CHEMBL393865,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396172,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CC(F)F)CC(F)(F)F)ccc2[nH]1,C14H10F8N2O,CHEMBL440980,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396173,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CCCl)CC(F)(F)F)ccc2[nH]1,C14H11ClF6N2O,CHEMBL237474,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396174,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CC(Cl)Cl)CC(F)(F)F)ccc2[nH]1,C14H10Cl2F6N2O,CHEMBL428026,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396175,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CCC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C15H11F9N2O,CHEMBL391940,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396176,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)C(F)(F)F)ccc2[nH]1,C15H9F11N2O,CHEMBL237681,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396177,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(CCO)CC(F)(F)F)ccc2[nH]1,C14H12F6N2O2,CHEMBL237682,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396184,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1ccc2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C13H10F6N2O,CHEMBL391798,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,9.0,9.0,9.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1.0,1.0,1.0,1.0,9.0,9.0,9.0,9.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
396185,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,Cc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,C14H12F6N2O,CHEMBL238122,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396186,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CCc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,C15H14F6N2O,CHEMBL238123,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396187,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 441967, Entry 1: 441969, ","Entry 0: Agonist activity at human AR, Entry 1: Antagonist activity at human AR, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL891111, Entry 1: CHEMBL891113, ","Entry 0: 10.1016/j.bmcl.2007.01.001, Entry 1: 10.1016/j.bmcl.2007.01.001, ","Entry 0: 17267219, Entry 1: 17267219, ","Entry 0: CHEMBL1147033, Entry 1: CHEMBL1147033, ","Entry 0: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., Entry 1: Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., Entry 1: A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity., ",,CCCc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,C16H16F6N2O,CHEMBL392004,36.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4982.0,36.0,5018.0,5018.0,10000.0,3.700530657,3.700530657,1.556302501,5.299469343,5.299469343,7.443697499,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5018.0,5018.0,36.0,10000.0,5.299469343021408,5.299469343021408,7.443697499232713,5.0,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
396188,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CC(C)c1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,C16H16F6N2O,CHEMBL238124,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2.0,2.0,2.0,2.0,0.301029996,0.301029996,0.301029996,8.698970004,8.698970004,8.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2.0,2.0,2.0,2.0,8.698970004336019,8.698970004336019,8.698970004336019,8.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
396189,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)F)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C14H10F8N2O,CHEMBL238330,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396190,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(Cl)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C13H9ClF6N2O,CHEMBL238331,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396191,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(Br)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C13H9BrF6N2O,CHEMBL238332,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396192,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,COc1cc(=O)[nH]c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc12,C14H12F6N2O2,CHEMBL393280,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,15.0,15.0,15.0,15.0,1.176091259,1.176091259,1.176091259,7.823908741,7.823908741,7.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,15.0,15.0,15.0,15.0,7.823908740944319,7.823908740944319,7.823908740944319,7.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
396193,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(O)c2cc(N(CC(F)(F)F)CC(F)(F)F)ccc2[nH]1,C13H10F6N2O2,CHEMBL235126,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.0,7.0,7.0,7.0,0.84509804,0.84509804,0.84509804,8.15490196,8.15490196,8.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.0,7.0,7.0,7.0,8.154901959985743,8.154901959985743,8.154901959985743,8.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
396194,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,C[C@@H](N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,C15H11F9N2O,CHEMBL235127,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396195,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,C[C@H](N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,C15H11F9N2O,CHEMBL235128,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
396196,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,C[C@H](CCl)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H13ClF6N2O,CHEMBL394194,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396197,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,C[C@@H](CCl)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H13ClF6N2O,CHEMBL235347,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
396198,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,Cc1cc(=O)[nH]c2ccc(N(CC(C)C)CC(F)(F)F)cc12,C16H19F3N2O,CHEMBL235346,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
399096,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C[C@@H]1C[C@@H](CCCCCCCCC(CCCC(F)(F)C(F)(F)F)C(=O)O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C34H53F5O4,CHEMBL236699,410.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4795.0,410.0,5205.0,5205.0,10000.0,3.716420734,3.716420734,2.612783857,5.283579266,5.283579266,6.387216143,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
399097,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C[C@@H]1C[C@@H](CCCCCCCCCC(=O)O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C29H48O4,CHEMBL393319,350.0,920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,285.0,350.0,635.0,635.0,920.0,2.802773725,2.802773725,2.544068044,6.197226275,6.197226275,6.455931956,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,920.0,920.0,920.0,920.0,6.036212172654444,6.036212172654444,6.036212172654444,6.036212172654444,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399099,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C[C@@H]1C[C@@H](CCCCCCCC(=O)O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](O)CC[C@@H]12,C27H44O4,CHEMBL235003,660.0,730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,660.0,695.0,695.0,730.0,2.841984805,2.841984805,2.819543936,6.158015195,6.158015195,6.180456064,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,730.0,730.0,730.0,730.0,6.136677139879544,6.136677139879544,6.136677139879544,6.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399102,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,CN(C)C(=O)CCCCCCC[C@@H]1C[C@H]2CC(=O)CC[C@]2(C)[C@H]2CC[C@]3(C)[C@@H](O)CC[C@H]3[C@H]12,C29H49NO3,CHEMBL393320,190.0,260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,190.0,225.0,225.0,260.0,2.352182518,2.352182518,2.278753601,6.647817482,6.647817482,6.721246399,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,260.0,260.0,260.0,260.0,6.585026652029182,6.585026652029182,6.585026652029182,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399107,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCCCCCCC(=O)O)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C30H48O4,CHEMBL391648,600.0,2000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,700.0,600.0,1300.0,1300.0,2000.0,3.113943352,3.113943352,2.77815125,5.886056648,5.886056648,6.22184875,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2000.0,2000.0,2000.0,2000.0,5.698970004336019,5.698970004336019,5.698970004336019,5.698970004336019,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399109,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCc1ccc(OCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C32H44O5,CHEMBL235661,170.0,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65.0,170.0,235.0,235.0,300.0,2.371067862,2.371067862,2.230448921,6.628932138,6.628932138,6.769551079,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399111,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCc1ccc(OCCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C33H46O5,CHEMBL428021,430.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,115.0,430.0,545.0,545.0,660.0,2.736396502,2.736396502,2.633468456,6.263603498,6.263603498,6.366531544,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399115,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCc1ccc(OCCCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C34H48O5,CHEMBL237999,300.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,180.0,300.0,480.0,480.0,660.0,2.681241237,2.681241237,2.477121255,6.318758763,6.318758763,6.522878745,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399117,nM,IC50,,BAO_0000190,IC50,449393,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,0,F,,CHEMBL899661,10.1016/j.bmcl.2007.07.090,17804229,CHEMBL1137463,Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.,PUBLICATION,"Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified.",,C[C@]12CCC(=O)C=C1C[C@@H](CCCc1cccc(OCCCC(=O)O)c1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C33H46O5,CHEMBL237971,5800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5800.0,5800.0,5800.0,5800.0,3.763427994,3.763427994,3.763427994,5.236572006,5.236572006,5.236572006,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5800.0,5800.0,5800.0,5800.0,5.236572006437063,5.236572006437063,5.236572006437063,5.236572006437063,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
399120,nM,IC50,,BAO_0000190,IC50,449393,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,0,F,,CHEMBL899661,10.1016/j.bmcl.2007.07.090,17804229,CHEMBL1137463,Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.,PUBLICATION,"Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified.",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1ccc(OCCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C34H48O5,CHEMBL238000,850.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,850.0,850.0,850.0,850.0,2.929418926,2.929418926,2.929418926,6.070581074,6.070581074,6.070581074,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,850.0,850.0,850.0,850.0,6.070581074285707,6.070581074285707,6.070581074285707,6.070581074285707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399121,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1ccc(OCCCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C35H50O5,CHEMBL238001,96.0,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77.0,96.0,173.0,173.0,250.0,2.238046103,2.238046103,1.982271233,6.761953897,6.761953897,7.017728767,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.0,250.0,250.0,250.0,6.6020599913279625,6.6020599913279625,6.6020599913279625,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399126,nM,IC50,,BAO_0000190,IC50,449393,Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay,0,F,,CHEMBL899661,10.1016/j.bmcl.2007.07.090,17804229,CHEMBL1137463,Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists.,PUBLICATION,"Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified.",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1ccc(OCCCCCC(=O)O)cc1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C36H52O5,CHEMBL235445,420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,420.0,420.0,420.0,420.0,2.62324929,2.62324929,2.62324929,6.37675071,6.37675071,6.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,420.0,420.0,420.0,420.0,6.376750709602099,6.376750709602099,6.376750709602099,6.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399130,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1cccc(OCCCC(=O)O)c1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C34H48O5,CHEMBL235871,670.0,920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,125.0,670.0,795.0,795.0,920.0,2.900367129,2.900367129,2.826074803,6.099632871,6.099632871,6.173925197,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,920.0,920.0,920.0,920.0,6.036212172654444,6.036212172654444,6.036212172654444,6.036212172654444,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399133,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1cccc(OCCCCC(=O)O)c1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C35H50O5,CHEMBL235811,330.0,350.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10.0,330.0,340.0,340.0,350.0,2.531478917,2.531478917,2.51851394,6.468521083,6.468521083,6.48148606,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,350.0,350.0,350.0,350.0,6.455931955649724,6.455931955649724,6.455931955649724,6.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399136,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449391, Entry 1: 449393, ","Entry 0: Displacement of [3H]mibolerone from human androgen receptor expressed in CHOK1 cells, Entry 1: Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899659, Entry 1: CHEMBL899661, ","Entry 0: 10.1016/j.bmcl.2007.07.090, Entry 1: 10.1016/j.bmcl.2007.07.090, ","Entry 0: 17804229, Entry 1: 17804229, ","Entry 0: CHEMBL1137463, Entry 1: CHEMBL1137463, ","Entry 0: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., Entry 1: Discovery and structure-activity relationships of new steroidal compounds bearing a carboxy-terminal side chain as androgen receptor pure antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., Entry 1: Lead optimization of CH4892280 (4), an androgen receptor (AR) pure antagonist, was investigated. Compounds 6 and 7, which have a carboxylic acid at the end of the side chain at the position 7alpha of dihydrotestosterone (DHT), showed partial agonistic activities in reporter gene assay (RGA). Conversion of the steroidal core structure to 17alpha-methyltestosterone gave compound 14, which showed weak pure antagonistic activity. Optimization of the side chain by the insertion of a phenyl ring led to compounds 22 and 28-30, which showed pure antagonistic activities at submicromolar concentrations. The structure-activity relationships were clarified., ",,C[C@]12CCC(=O)C=C1C[C@@H](CCCCc1cccc(OCCCCCC(=O)O)c1)[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C36H52O5,CHEMBL235872,120.0,530.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,205.0,120.0,325.0,325.0,530.0,2.511883361,2.511883361,2.079181246,6.488116639,6.488116639,6.920818754,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,530.0,530.0,530.0,530.0,6.275724130399211,6.275724130399211,6.275724130399211,6.275724130399211,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399817,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,COc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NO,CHEMBL238366,20.1,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.45,20.1,28.55,28.55,37.0,1.455606113,1.455606113,1.303196057,7.544393887,7.544393887,7.696803943,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,37.0,37.0,37.0,37.0,7.431798275933005,7.431798275933005,7.431798275933005,7.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399819,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,COc1cccc(-c2ccc(C#N)c(C(F)(F)F)c2)c1,C15H10F3NO,CHEMBL443579,140.0,955.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,407.5,140.0,547.5,547.5,955.0,2.738384124,2.738384124,2.146128036,6.261615876,6.261615876,6.853871964,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,955.0,955.0,955.0,955.0,6.019996628416254,6.019996628416254,6.019996628416254,6.019996628416254,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399821,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,COc1ccc(-c2ccc(C#N)c(C(F)(F)F)c2)cc1,C15H10F3NO,CHEMBL235159,0.8,56.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27.95,0.8,28.75,28.75,56.7,1.458637849,1.458637849,-0.096910013,7.541362151,7.541362151,9.096910013,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,56.7,56.7,56.7,56.7,7.246416941107094,7.246416941107094,7.246416941107094,7.246416941107094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399822,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, Entry 2: 538003, Entry 3: 538004, Entry 4: 2227383, Entry 5: 2227458, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, Entry 2: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 3: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, Entry 4: Binding affinity to human Androgen receptor, Entry 5: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, Entry 4: B, Entry 5: B, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, Entry 2: CHEMBL1032459, Entry 3: CHEMBL1032460, Entry 4: CHEMBL5140896, Entry 5: CHEMBL5140971, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, Entry 2: 10.1021/jm8009316, Entry 3: 10.1021/jm8009316, Entry 4: 10.1021/acs.jmedchem.2c00716, Entry 5: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 17764935, Entry 1: 17764935, Entry 2: 18921992, Entry 3: 18921992, Entry 4: 35786895, Entry 5: 35786895, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, Entry 2: CHEMBL1142535, Entry 3: CHEMBL1142535, Entry 4: CHEMBL5137058, Entry 5: CHEMBL5137058, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 2: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 3: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 4: Therapeutic Strategies to Target the Androgen Receptor., Entry 5: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 2: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 3: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 4: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 5: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,N#Cc1ccc(-c2ccccc2O)cc1C(F)(F)F,C14H8F3NO,CHEMBL391548,0.02,0.02,0.0,39.9,39.9,39.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,19.91009041,0.02,19.99,20.05,39.9,1.300812794,1.302114377,-1.698970004,7.699187206,7.697885623,10.69897,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.02,0.02,0.02,0.02,10.698970004336019,10.698970004336019,10.698970004336019,10.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399826,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,N#Cc1ccc(-c2ccc(O)cc2)cc1C(F)(F)F,C14H8F3NO,CHEMBL235378,11.9,61.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24.65,11.9,36.55,36.55,61.2,1.562887381,1.562887381,1.075546961,7.437112619,7.437112619,7.924453039,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,61.2,61.2,61.2,61.2,7.213248577854439,7.213248577854439,7.213248577854439,7.213248577854439,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399828,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,Cc1ccccc1-c1ccc(C#N)c(C(F)(F)F)c1,C15H10F3N,CHEMBL235379,146.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,427.0,146.0,573.0,573.0,1000.0,2.758154622,2.758154622,2.164352856,6.241845378,6.241845378,6.835647144,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399832,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,Cc1ccc(-c2ccc(C#N)c(C(F)(F)F)c2)cc1,C15H10F3N,CHEMBL392827,200.0,843.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,321.5,200.0,521.5,521.5,843.0,2.717254313,2.717254313,2.301029996,6.282745687,6.282745687,6.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,843.0,843.0,843.0,843.0,6.074172425375258,6.074172425375258,6.074172425375258,6.074172425375258,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399834,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,N#Cc1ccc(-c2ccccc2C(F)(F)F)cc1C(F)(F)F,C15H7F6N,CHEMBL396656,1.0,10.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.95,1.0,5.95,5.95,10.9,0.774516966,0.774516966,0.0,8.225483034,8.225483034,9.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.9,10.9,10.9,10.9,7.962573502059376,7.962573502059376,7.962573502059376,7.962573502059376,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
399835,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 449233, Entry 1: 449234, ","Entry 0: Displacement of [3H]DHT from human recombinant AR expressed in Sf9 cells, Entry 1: Antagonist activity at human AR in MDA-MB453-MMTV-luci cells by functional assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL899495, Entry 1: CHEMBL899496, ","Entry 0: 10.1016/j.bmcl.2007.08.034, Entry 1: 10.1016/j.bmcl.2007.08.034, ","Entry 0: 17764935, Entry 1: 17764935, ","Entry 0: CHEMBL1137443, Entry 1: CHEMBL1137443, ","Entry 0: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., Entry 1: Preparation of 4-aryl-2-trifluoromethylbenzonitrile derivatives as androgen receptor antagonists for topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., Entry 1: A series of substituted 4-aryl-2-trifluoromethylbenzonitrile analogs were evaluated in the human androgen receptor binding and cellular functional assays. Analogs with sufficient in vitro binding and cellular potency (IC(50)<200 nM) were tested in the progesterone receptor binding assay for selectivity and in the Golden Syrian hamster ear model for in vivo efficacy. Within the series, compound 4 e was identified to be the most active analog in vivo (wax ester inhibition=86%)., ",,COc1cccc(OC)c1-c1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO2,CHEMBL427678,14.7,399.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,192.15,14.7,206.85,206.85,399.0,2.315655525,2.315655525,1.167317335,6.684344475,6.684344475,7.832682665,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,399.0,399.0,399.0,399.0,6.399027104313252,6.399027104313252,6.399027104313252,6.399027104313252,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
405280,nM,IC50,,BAO_0000190,IC50,448904,Antagonist activity at androgen receptor expressed in A549 cells by HRE-tk luciferase assay,0,F,,CHEMBL898139,10.1016/j.bmc.2007.07.011,17681796,CHEMBL1149694,"5-(3-Cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile: A novel, highly potent, selective, and orally active non-steroidal progesterone receptor agonist.",PUBLICATION,"We have recently discovered 5-(3-cyclopentyl-2-thioxo-2,3-dihydro-1H-benzimidazol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (14) as a potent, selective, and orally active non-steroidal progesterone receptor (PR) agonist. Compound 14 and its analog 13 possessed sub-nanomolar in vitro potency (EC(50) 0.1-0.5nM) in the T47D alkaline phosphatase assay, similar to that of the steroidal PR agonist medroxyprogesterone acetate (MPA). In contrast to MPA, 14 was highly selective (>500-fold) for the PR over both glucocorticoid and androgen receptors. In the rat uterine decidualization and complement component C3 models, 14 had oral ED(50) values of 0.02 and 0.003mg/kg, respectively, and was from 6- to 20-fold more potent than MPA. In the monkey ovulation inhibition model, compound 14 was also highly efficacious and potent with an oral ED(100) of 0.03mg/kg.",,Cn1c(C#N)ccc1-c1ccc2[nH]c(=S)n(C3CCCC3)c2c1,C18H18N4S,CHEMBL239957,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
407035,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 791027, Entry 1: 791031, ","Entry 0: Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis, Entry 1: Displacement of 5-iodoacetamidofluorescein labeled SRC23 peptide CKENALLRYLLDKDD human androgen receptor AF2 site expressed in Escherichia coli BL21 cells by fluorescence polarization assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL1925688, Entry 1: CHEMBL1925692, ","Entry 0: 10.1021/jm201098n, Entry 1: 10.1021/jm201098n, ","Entry 0: 22047606, Entry 1: 22047606, ","Entry 0: CHEMBL1921777, Entry 1: CHEMBL1921777, ","Entry 0: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 1: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 1: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., ",,O=C(CSc1nc(O)c2ccccc2n1)c1ccc(O)c(O)c1,C16H12N2O4S,CHEMBL240331,50000.0,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
413873,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CCCN(CCC)c1cc(C(F)(F)F)c(C#N)cn1,C13H16F3N3,CHEMBL248868,78.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,461.0,78.0,539.0,539.0,1000.0,2.731588765,2.731588765,1.892094603,6.268411235,6.268411235,7.107905397,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413874,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CCCN(CC1CC1)c1cc(C(F)(F)F)c(C#N)cn1,C14H16F3N3,CHEMBL398431,0.8,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,499.6,0.8,500.4,500.4,1000.0,2.699317301,2.699317301,-0.096910013,6.300682699,6.300682699,9.096910013,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413875,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CCC(C)N(C)c1cc(C(F)(F)F)c(C#N)cn1,C12H14F3N3,CHEMBL249070,7.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,496.5,7.0,503.5,503.5,1000.0,2.701999475,2.701999475,0.84509804,6.298000525,6.298000525,8.15490196,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413876,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CCCCN(C)c1cc(C(F)(F)F)c(C#N)cn1,C12H14F3N3,CHEMBL249071,3.8,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,498.1,3.8,501.9,501.9,1000.0,2.700617196,2.700617196,0.579783597,6.299382804,6.299382804,8.420216403,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413877,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,N#Cc1cnc(N2CCCCC2)cc1C(F)(F)F,C12H12F3N3,CHEMBL398432,209.0,422.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,106.5,209.0,315.5,315.5,422.0,2.498999364,2.498999364,2.320146286,6.501000636,6.501000636,6.679853714,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,422.0,422.0,422.0,422.0,6.374687549038327,6.374687549038327,6.374687549038327,6.374687549038327,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413878,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CC1CCN(c2cc(C(F)(F)F)c(C#N)cn2)CC1,C13H14F3N3,CHEMBL249072,73.0,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,31.5,73.0,104.5,104.5,136.0,2.01911629,2.01911629,1.86332286,6.98088371,6.98088371,7.13667714,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,136.0,136.0,136.0,136.0,6.866461091629782,6.866461091629782,6.866461091629782,6.866461091629782,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413879,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,N#Cc1cnc(N2CCC3CCCCC3C2)cc1C(F)(F)F,C16H18F3N3,CHEMBL248841,169.0,260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.5,169.0,214.5,214.5,260.0,2.331427297,2.331427297,2.227886705,6.668572703,6.668572703,6.772113295,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,260.0,260.0,260.0,260.0,6.585026652029182,6.585026652029182,6.585026652029182,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413880,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, ","Entry 0: 17766112, Entry 1: 17766112, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,CC(c1ccccc1)N(C)c1cc(C(F)(F)F)c(C#N)cn1,C16H14F3N3,CHEMBL399876,123.0,229.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,53.0,123.0,176.0,176.0,229.0,2.245512668,2.245512668,2.089905111,6.754487332,6.754487332,6.910094889,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,229.0,229.0,229.0,229.0,6.640164517660112,6.640164517660112,6.640164517660112,6.640164517660112,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
413881,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 457372, Entry 1: 457373, Entry 2: 538003, Entry 3: 538004, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in MDA-MB-453 cells, Entry 2: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 3: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, ",,"Entry 0: CHEMBL940963, Entry 1: CHEMBL940964, Entry 2: CHEMBL1032459, Entry 3: CHEMBL1032460, ","Entry 0: 10.1016/j.bmcl.2007.07.059, Entry 1: 10.1016/j.bmcl.2007.07.059, Entry 2: 10.1021/jm8009316, Entry 3: 10.1021/jm8009316, ","Entry 0: 17766112, Entry 1: 17766112, Entry 2: 18921992, Entry 3: 18921992, ","Entry 0: CHEMBL1139813, Entry 1: CHEMBL1139813, Entry 2: CHEMBL1142535, Entry 3: CHEMBL1142535, ","Entry 0: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 1: Synthesis and biological evaluation of amino-pyridines as androgen receptor antagonists for stimulating hair growth and reducing sebum production., Entry 2: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 3: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: A series of amino-pyridines were synthesized and evaluated for androgen antagonist activities. Among these compounds, (R)-(+)-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile was the most active example of this class. This compound displayed potent androgen receptor antagonist activity as well as favorable pharmacokinetic characteristics for a potential topical agent. It also demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 2: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 3: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., ",,C[C@H](c1ccccc1)N(C)c1cc(C(F)(F)F)c(C#N)cn1,C16H14F3N3,CHEMBL248690,20.0,20.0,45.0,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.5,20.0,32.5,32.5,45.0,1.511883361,1.511883361,1.301029996,7.488116639,7.488116639,7.698970004,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415260,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,C[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC(F)(F)F,C15H12F6N2O2,CHEMBL395596,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415261,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)NCCO3,C12H9F3N2O2,CHEMBL247785,1500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1500.0,1500.0,1500.0,1500.0,3.176091259,3.176091259,3.176091259,5.823908741,5.823908741,5.823908741,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1500.0,1500.0,1500.0,1500.0,5.823908740944319,5.823908740944319,5.823908740944319,5.823908740944319,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415262,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,C[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,C13H11F3N2O2,CHEMBL247786,72.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,72.0,72.0,72.0,72.0,1.857332496,1.857332496,1.857332496,7.142667504,7.142667504,7.142667504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,72.0,72.0,72.0,72.0,7.142667503568732,7.142667503568732,7.142667503568732,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415267,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,C14H13F3N2O2,CHEMBL246607,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,84.0,84.0,84.0,84.0,1.924279286,1.924279286,1.924279286,7.075720714,7.075720714,7.075720714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.0,84.0,84.0,84.0,7.075720713938118,7.075720713938118,7.075720713938118,7.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415268,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N[C@H](c1ccccc1)CO3,C18H13F3N2O2,CHEMBL250083,1480.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1480.0,1480.0,1480.0,1480.0,3.170261715,3.170261715,3.170261715,5.829738285,5.829738285,5.829738285,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1480.0,1480.0,1480.0,1480.0,5.8297382846050425,5.8297382846050425,5.8297382846050425,5.8297382846050425,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415269,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CCC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1,C15H15F3N2O2,CHEMBL250084,113.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,113.0,113.0,113.0,113.0,2.053078443,2.053078443,2.053078443,6.946921557,6.946921557,6.946921557,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,113.0,113.0,113.0,113.0,6.94692155651658,6.94692155651658,6.94692155651658,6.94692155651658,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415281,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC,C16H17F3N2O2,CHEMBL250702,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415283,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC(F)(F)F,C16H14F6N2O2,CHEMBL250897,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415285,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,C=CCN1c2ccc3[nH]c(=O)cc(C(F)(F)F)c3c2OC[C@H]1CC,C17H17F3N2O2,CHEMBL440958,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415287,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CCCN1c2ccc3[nH]c(=O)cc(C(F)(F)F)c3c2OC[C@H]1CC,C17H19F3N2O2,CHEMBL394504,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415288,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC(C)C,C18H21F3N2O2,CHEMBL247633,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415290,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC(C)(C)O,C18H21F3N2O3,CHEMBL394505,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415295,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CCN1c2ccc3[nH]c(=O)cc(C(F)(F)F)c3c2OC[C@H]1C(C)C,C17H19F3N2O2,CHEMBL247993,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415296,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,CC(C)[C@@H]1COc2c(ccc3[nH]c(=O)cc(C(F)(F)F)c23)N1CC(F)(F)F,C17H16F6N2O2,CHEMBL397561,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415297,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,C=CCN1c2ccc3[nH]c(=O)cc(C(F)(F)F)c3c2OC[C@H]1C(C)C,C18H19F3N2O2,CHEMBL247994,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415298,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC(F)(F)F)[C@H](Cc1ccccc1)CO3,C21H16F6N2O2,CHEMBL247995,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415301,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC(F)(F)F)[C@H](c1ccccc1)CO3,C20H14F6N2O2,CHEMBL247453,65.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,65.0,65.0,65.0,65.0,1.812913357,1.812913357,1.812913357,7.187086643,7.187086643,7.187086643,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,65.0,65.0,65.0,65.0,7.187086643357144,7.187086643357144,7.187086643357144,7.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415302,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC1CC1)[C@H](c1ccccc1)CO3,C22H19F3N2O2,CHEMBL397563,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,45.0,45.0,45.0,45.0,1.653212514,1.653212514,1.653212514,7.346787486,7.346787486,7.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
415303,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC1CC1)[C@@H](c1ccccc1)CO3,C22H19F3N2O2,CHEMBL247454,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
415306,nM,IC50,,BAO_0000190,IC50,457221,Antagonist activity at human androgen receptor expressed in CV1 cells by transcriptional activation assay,0,F,,CHEMBL940822,10.1016/j.bmcl.2007.07.034,17703938,CHEMBL1139788,"Potent, nonsteroidal selective androgen receptor modulators (SARMs) based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones.",PUBLICATION,"A series of androgen receptor modulators based on 8H-[1,4]oxazino[2,3-f]quinolin-8-ones was synthesized and evaluated in an androgen receptor transcriptional activation assay. The most potent analogues from the series exhibited single-digit nanomolar potency in vitro. Compound 18h demonstrated full efficacy in the maintenance of muscle weight, at 10 mg/kg, with reduced activity in prostate weight in an in vivo model of androgen action.",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)N(CC1CC1)C(c1ccccc1)CO3,C22H19F3N2O2,CHEMBL247637,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
417347,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457595, Entry 1: 457596, ","Entry 0: Displacement of [3H]DHT from androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at androgen receptor expressed in MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced response in reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL923796, Entry 1: CHEMBL923797, ","Entry 0: 10.1016/j.bmcl.2007.07.075, Entry 1: 10.1016/j.bmcl.2007.07.075, ","Entry 0: 17827000, Entry 1: 17827000, ","Entry 0: CHEMBL1140457, Entry 1: CHEMBL1140457, ","Entry 0: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., Entry 1: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,N#Cc1ccc(OC2CCCCC2C#N)cc1C(F)(F)F,C15H13F3N2O,CHEMBL251552,13.0,58.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.5,13.0,35.5,35.5,58.0,1.550228353,1.550228353,1.113943352,7.449771647,7.449771647,7.886056648,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,58.0,58.0,58.0,58.0,7.236572006437063,7.236572006437063,7.236572006437063,7.236572006437063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
417348,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 457595, Entry 1: 457596, Entry 2: 538003, Entry 3: 538004, Entry 4: 2227383, Entry 5: 2227458, ","Entry 0: Displacement of [3H]DHT from androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at androgen receptor expressed in MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced response in reporter gene assay, Entry 2: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 3: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, Entry 4: Binding affinity to human Androgen receptor, Entry 5: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, Entry 4: B, Entry 5: B, ",,"Entry 0: CHEMBL923796, Entry 1: CHEMBL923797, Entry 2: CHEMBL1032459, Entry 3: CHEMBL1032460, Entry 4: CHEMBL5140896, Entry 5: CHEMBL5140971, ","Entry 0: 10.1016/j.bmcl.2007.07.075, Entry 1: 10.1016/j.bmcl.2007.07.075, Entry 2: 10.1021/jm8009316, Entry 3: 10.1021/jm8009316, Entry 4: 10.1021/acs.jmedchem.2c00716, Entry 5: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 17827000, Entry 1: 17827000, Entry 2: 18921992, Entry 3: 18921992, Entry 4: 35786895, Entry 5: 35786895, ","Entry 0: CHEMBL1140457, Entry 1: CHEMBL1140457, Entry 2: CHEMBL1142535, Entry 3: CHEMBL1142535, Entry 4: CHEMBL5137058, Entry 5: CHEMBL5137058, ","Entry 0: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., Entry 1: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., Entry 2: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 3: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 4: Therapeutic Strategies to Target the Androgen Receptor., Entry 5: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 2: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 3: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 4: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 5: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,N#Cc1ccc(O[C@@H]2CCCC[C@H]2C#N)cc1C(F)(F)F,C15H13F3N2O,CHEMBL399887,12.0,12.0,12.0,60.0,60.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24.0,12.0,36.0,36.0,60.0,1.556302501,1.556302501,1.079181246,7.443697499,7.443697499,7.920818754,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,12.0,12.0,12.0,12.0,7.920818753952375,7.920818753952375,7.920818753952375,7.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
417391,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 457595, Entry 1: 457596, ","Entry 0: Displacement of [3H]DHT from androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at androgen receptor expressed in MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced response in reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL923796, Entry 1: CHEMBL923797, ","Entry 0: 10.1016/j.bmcl.2007.07.075, Entry 1: 10.1016/j.bmcl.2007.07.075, ","Entry 0: 17827000, Entry 1: 17827000, ","Entry 0: CHEMBL1140457, Entry 1: CHEMBL1140457, ","Entry 0: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., Entry 1: (1R,2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile, a potent androgen receptor antagonist for stimulating hair growth and reducing sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., Entry 1: Synthesis, pharmacology, and pharmacokinetic profiles of (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile are reported. This compound demonstrated remarkable potency for stimulating hair growth in a male C3H mouse model as well as reducing sebum production in the male Syrian hamster ear model., ",,N#Cc1ccc(O[C@H]2CCCC[C@@H]2C#N)cc1C(F)(F)F,C15H13F3N2O,CHEMBL399439,43.0,196.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,76.5,43.0,119.5,119.5,196.0,2.077367905,2.077367905,1.633468456,6.922632095,6.922632095,7.366531544,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,196.0,196.0,196.0,196.0,6.707743928643524,6.707743928643524,6.707743928643524,6.707743928643524,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
419995,nM,IC50,,BAO_0000190,IC50,321242,Inhibitory concentration against Androgen receptor,0,B,,CHEMBL881777,10.1021/jm0505056,16250653,CHEMBL1140376,Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.,PUBLICATION,"Guggulsterone 1, the active principle of guggulipid, has been used in ethnic medicine for thousands of years for its antinflammatory and antilipidemic activities. The activities of 1 are apparently mediated by its interaction with an array of nuclear receptors, including endocrine steroid receptors and metabolic lipid receptors. Although relatively weak, the activity at the metabolic farnesoid X receptor (FXR) is particularly intriguing, as 1 is, so far, the only antagonist known for this receptor, with a peculiar ability of gene selective modulation. We report here a systematic study aimed at identifying the potential binding pocket of 1 at FXR. Although 1 could be docked into the canonical binding site, we identified a novel, so far undescribed binding pocket, localized near the loop region between helix 1 and helix 2. This novel binding pocket may explain some of the peculiar characteristics of 1 when acting at FXR.",,C/C=C1/C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,C21H28O2,CHEMBL402063,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425738,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1OC2,C18H12F3NO3,CHEMBL402136,78.0,477.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,199.5,78.0,277.5,277.5,477.0,2.443262987,2.443262987,1.892094603,6.556737013,6.556737013,7.107905397,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,78.0,78.0,78.0,78.0,7.107905397309519,7.107905397309519,7.107905397309519,7.107905397309519,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425785,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1ccccc1CO3,C17H10F3NO2,CHEMBL450334,40.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4980.0,40.0,5020.0,5020.0,10000.0,3.700703717,3.700703717,1.602059991,5.299296283,5.299296283,7.397940009,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,40.0,40.0,40.0,40.0,7.3979400086720375,7.3979400086720375,7.3979400086720375,7.3979400086720375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425830,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,O=c1cc(C(F)(F)F)c2c(ccc3c2oc(=O)c2cccc(O)c23)[nH]1,C17H8F3NO4,CHEMBL257751,22.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4989.0,22.0,5011.0,5011.0,10000.0,3.699924403,3.699924403,1.342422681,5.300075597,5.300075597,7.657577319,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425832,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c(=O)oc3c(ccc4[nH]c(=O)cc(C(F)(F)F)c43)c12,C18H10F3NO4,CHEMBL403219,89.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4955.5,89.0,5044.5,5044.5,10000.0,3.702818126,3.702818126,1.949390007,5.297181874,5.297181874,7.050609993,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,89.0,89.0,89.0,89.0,7.050609993355087,7.050609993355087,7.050609993355087,7.050609993355087,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425925,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,O=c1cc(C(F)(F)F)c2c3c(ccc2[nH]1)-c1c(O)cccc1OC3,C17H10F3NO3,CHEMBL253535,1.1,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4999.45,1.1,5000.55,5000.55,10000.0,3.699017774,3.699017774,0.041392685,5.300982226,5.300982226,8.958607315,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,1.1,1.1,1.1,1.1,8.958607314841775,8.958607314841775,8.958607314841775,8.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425928,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C(F)(F)F)c3c1CO2,C18H12F3NO3,CHEMBL401629,14.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4993.0,14.0,5007.0,5007.0,10000.0,3.699577591,3.699577591,1.146128036,5.300422409,5.300422409,7.853871964,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,14.0,14.0,14.0,14.0,7.853871964321762,7.853871964321762,7.853871964321762,7.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
425972,nM,IC50,,BAO_0000190,IC50,467616,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,0,F,,CHEMBL930491,10.1016/j.bmcl.2008.03.085,18442912,CHEMBL1143080,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,PUBLICATION,"A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide.",,C=CCC1Oc2cccc(OC)c2-c2ccc3[nH]c(=O)cc(C)c3c21,C21H19NO3,CHEMBL258384,144.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,144.0,144.0,144.0,144.0,2.158362492,2.158362492,2.158362492,6.841637508,6.841637508,6.841637508,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,144.0,144.0,144.0,144.0,6.841637507904751,6.841637507904751,6.841637507904751,6.841637507904751,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426017,nM,IC50,,BAO_0000190,IC50,467616,Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay,0,F,,CHEMBL930491,10.1016/j.bmcl.2008.03.085,18442912,CHEMBL1143080,Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones.,PUBLICATION,"A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide.",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(C)O2,C19H17NO3,CHEMBL253744,62.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,62.0,62.0,62.0,62.0,1.792391689,1.792391689,1.792391689,7.207608311,7.207608311,7.207608311,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,62.0,62.0,62.0,62.0,7.2076083105017466,7.2076083105017466,7.2076083105017466,7.2076083105017466,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426020,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(OC)O2,C19H17NO4,CHEMBL253746,19.0,112.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,46.5,19.0,65.5,65.5,112.0,1.8162413,1.8162413,1.278753601,7.1837587,7.1837587,7.721246399,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426060,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1c(O)ccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,C18H15NO4,CHEMBL427731,1.2,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.9,1.2,10.1,10.1,19.0,1.004321374,1.004321374,0.079181246,7.995678626,7.995678626,8.920818754,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1.2,1.2,1.2,1.2,8.920818753952375,8.920818753952375,8.920818753952375,8.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426061,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1C(O)O2,C18H15NO4,CHEMBL258190,50.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4975.0,50.0,5025.0,5025.0,10000.0,3.701136066,3.701136066,1.698970004,5.298863934,5.298863934,7.301029996,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,50.0,50.0,50.0,50.0,7.301029995663981,7.301029995663981,7.301029995663981,7.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426063,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2c1-c1ccc3[nH]c(=O)cc(C)c3c1CO2,C18H15NO3,CHEMBL256947,12.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4994.0,12.0,5006.0,5006.0,10000.0,3.699490845,3.699490845,1.079181246,5.300509155,5.300509155,7.920818754,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,12.0,12.0,12.0,12.0,7.920818753952375,7.920818753952375,7.920818753952375,7.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426064,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,Cc1cc(=O)[nH]c2ccc3c(c12)COc1cccc(CO)c1-3,C18H15NO3,CHEMBL257151,0.3,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4999.85,0.3,5000.15,5000.15,10000.0,3.698983033,3.698983033,-0.522878745,5.301016967,5.301016967,9.522878745,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,0.3,0.3,0.3,0.3,9.522878745280337,9.522878745280337,9.522878745280337,9.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426100,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1c(OC(C)C)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,C21H19NO5,CHEMBL256768,2.8,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.6,2.8,11.4,11.4,20.0,1.056904851,1.056904851,0.447158031,7.943095149,7.943095149,8.552841969,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2.8,2.8,2.8,2.8,8.55284196865778,8.55284196865778,8.55284196865778,8.55284196865778,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426102,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1c(C(=O)OC(F)(F)F)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,C20H12F3NO6,CHEMBL256769,0.2,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4999.9,0.2,5000.1,5000.1,10000.0,3.69897869,3.69897869,-0.698970004,5.30102131,5.30102131,9.698970004,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,0.2,0.2,0.2,0.2,9.698970004336019,9.698970004336019,9.698970004336019,9.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426103,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,CCOc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1OC,C20H17NO5,CHEMBL256977,10.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4995.0,10.0,5005.0,5005.0,10000.0,3.699404082,3.699404082,1.0,5.300595918,5.300595918,8.0,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426105,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1c(O)ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,C18H13NO5,CHEMBL427898,0.2,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4999.9,0.2,5000.1,5000.1,10000.0,3.69897869,3.69897869,-0.698970004,5.30102131,5.30102131,9.698970004,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,0.2,0.2,0.2,0.2,9.698970004336019,9.698970004336019,9.698970004336019,9.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426143,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,Cc1cc(=O)[nH]c2ccc3c4c(C(=O)OC(C)(C)C)cccc4oc(=O)c3c12,C22H19NO5,CHEMBL401711,1.9,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4999.05,1.9,5000.95,5000.95,10000.0,3.699052512,3.699052512,0.278753601,5.300947488,5.300947488,8.721246399,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,1.9,1.9,1.9,1.9,8.721246399047171,8.721246399047171,8.721246399047171,8.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426145,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1ccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c2c1,C18H13NO4,CHEMBL258397,0.8,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23.6,0.8,24.4,24.4,48.0,1.387389826,1.387389826,-0.096910013,7.612610174,7.612610174,9.096910013,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.8,0.8,0.8,0.8,9.096910013008056,9.096910013008056,9.096910013008056,9.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426146,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,COc1cccc2oc(=O)c3c(ccc4[nH]c(=O)cc(C)c43)c12,C18H13NO4,CHEMBL450933,21.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4989.5,21.0,5010.5,5010.5,10000.0,3.699881066,3.699881066,1.322219295,5.300118934,5.300118934,7.677780705,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,21.0,21.0,21.0,21.0,7.6777807052660805,7.6777807052660805,7.6777807052660805,7.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426190,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 467616, Entry 1: 467618, ","Entry 0: Antagonist activity at human androgen receptor african green monkey CV1 cells by cotransfection assay, Entry 1: Activity at androgen receptor in human Saos2 cells assessed as IL6 repression, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL930491, Entry 1: CHEMBL930493, ","Entry 0: 10.1016/j.bmcl.2008.03.085, Entry 1: 10.1016/j.bmcl.2008.03.085, ","Entry 0: 18442912, Entry 1: 18442912, ","Entry 0: CHEMBL1143080, Entry 1: CHEMBL1143080, ","Entry 0: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., Entry 1: Discovery of a novel series of nonsteroidal androgen receptor modulators: 5- or 6-oxachrysen-2-ones., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., Entry 1: A novel oxachrysenone series (2) of nonsteroidal selective androgen receptor modulators (SARM) was developed based on the 6-aryl-2-quinolinones (1). Synthesis and preliminary SAR results based on in vitro assays are discussed. In the cotransfection assay, lead compound 5d showed AR agonist activity more potent than dihydrotestosterone (DHT), whereas compound 17b was a potent antagonist similar to bicalutamide., ",,Cc1cc(=O)[nH]c2ccc3c4cc(F)ccc4oc(=O)c3c12,C17H10FNO3,CHEMBL258241,27.0,101.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.0,27.0,64.0,64.0,101.0,1.806179974,1.806179974,1.431363764,7.193820026,7.193820026,7.568636236,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426302,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](CF)N3CC(F)(F)F,C15H11F7N2O2,CHEMBL254798,199.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,199.0,199.0,199.0,199.0,2.298853076,2.298853076,2.298853076,6.701146924,6.701146924,6.701146924,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,199.0,199.0,199.0,199.0,6.701146923590294,6.701146923590294,6.701146923590294,6.701146923590294,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426349,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,CSCC1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,C16H14F6N2O2S,CHEMBL255918,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25.0,25.0,25.0,25.0,1.397940009,1.397940009,1.397940009,7.602059991,7.602059991,7.602059991,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,25.0,25.0,25.0,25.0,7.6020599913279625,7.6020599913279625,7.6020599913279625,7.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426455,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,COC[C@H]1COc2cc3[nH]c(=O)cc(C(F)(F)F)c3cc2N1CC(F)(F)F,C16H14F6N2O3,CHEMBL404568,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,17.0,17.0,17.0,17.0,1.230448921,1.230448921,1.230448921,7.769551079,7.769551079,7.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,17.0,17.0,17.0,17.0,7.769551078621726,7.769551078621726,7.769551078621726,7.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426557,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@H](CO)N3CC(F)(F)F,C15H12F6N2O3,CHEMBL436644,165.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,165.0,165.0,165.0,165.0,2.217483944,2.217483944,2.217483944,6.782516056,6.782516056,6.782516056,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,165.0,165.0,165.0,165.0,6.782516055786093,6.782516055786093,6.782516055786093,6.782516055786093,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426560,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](CO)N3CC(F)(F)F,C15H12F6N2O3,CHEMBL404512,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426843,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](C(F)(F)F)N3CC(F)(F)F,C15H9F9N2O2,CHEMBL257988,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34.0,34.0,34.0,34.0,1.531478917,1.531478917,1.531478917,7.468521083,7.468521083,7.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,34.0,34.0,34.0,34.0,7.468521082957745,7.468521082957745,7.468521082957745,7.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426888,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,Cc1ccc([C@H]2COc3cc4[nH]c(=O)cc(C(F)(F)F)c4cc3N2CC(F)(F)F)cc1,C21H16F6N2O2,CHEMBL256329,44.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,44.0,44.0,44.0,44.0,1.643452676,1.643452676,1.643452676,7.356547324,7.356547324,7.356547324,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,44.0,44.0,44.0,44.0,7.356547323513813,7.356547323513813,7.356547323513813,7.356547323513813,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426935,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,Cc1cccc([C@H]2COc3cc4[nH]c(=O)cc(C(F)(F)F)c4cc3N2CC(F)(F)F)c1,C21H16F6N2O2,CHEMBL257387,574.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,574.0,574.0,574.0,574.0,2.758911892,2.758911892,2.758911892,6.241088108,6.241088108,6.241088108,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,574.0,574.0,574.0,574.0,6.241088107602026,6.241088107602026,6.241088107602026,6.241088107602026,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426936,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@H](c1ccccc1)N3CC(F)(F)F,C20H14F6N2O2,CHEMBL404222,340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,340.0,340.0,340.0,340.0,2.531478917,2.531478917,2.531478917,6.468521083,6.468521083,6.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,340.0,340.0,6.468521082957745,6.468521082957745,6.468521082957745,6.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
426979,nM,IC50,,BAO_0000190,IC50,479688,Antagonist activity at human androgen receptor in CV1 cells by transcriptional activation assay,0,F,,CHEMBL933552,10.1016/j.bmcl.2008.03.062,18400499,CHEMBL1145608,"Selective androgen receptor modulators based on a series of 7H-[1,4]oxazino[3,2-g]quinolin-7-ones with improved in vivo activity.",PUBLICATION,"Modification on a lead series of [1,4]oxazino[3,2-g]quinolin-7-ones at the 2-position led to selective androgen receptor modulators with improved in vivo activity. The most potent analog (-)-33a exhibited full maintenance of levator ani muscle at 3mg/kg and reduced activity on ventral prostate weight in a 2-week orally-dosed and orchidectomized rat maintenance assay.",,O=c1cc(C(F)(F)F)c2cc3c(cc2[nH]1)OC[C@@H](Cc1ccccc1)N3CC(F)(F)F,C21H16F6N2O2,CHEMBL256082,51.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,51.0,51.0,51.0,51.0,1.707570176,1.707570176,1.707570176,7.292429824,7.292429824,7.292429824,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,51.0,51.0,51.0,51.0,7.292429823902063,7.292429823902063,7.292429823902063,7.292429823902063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
428318,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 475674, Entry 1: 475674, ","Entry 0: Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation by CAT reporter gene assay, Entry 1: Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation by CAT reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL937560, Entry 1: CHEMBL937560, ","Entry 0: 10.1073/pnas.0609752104, Entry 1: 10.1073/pnas.0609752104, ","Entry 0: 17606915, Entry 1: 17606915, ","Entry 0: CHEMBL1145525, Entry 1: CHEMBL1145525, ","Entry 0: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs., Entry 1: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico ""drug repurposing"" procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics., Entry 1: Finding good drug leads de novo from large chemical libraries, real or virtual, is not an easy task. High-throughput screening is often plagued by low hit rates and many leads that are toxic or exhibit poor bioavailability. Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles. Here, we describe an efficient computational methodology to discover leads to a protein target from safe marketed drugs. We applied an in silico ""drug repurposing"" procedure for identification of nonsteroidal antagonists against the human androgen receptor (AR), using multiple predicted models of an antagonist-bound receptor. The library of marketed oral drugs was then docked into the best-performing models, and the 11 selected compounds with the highest docking score were tested in vitro for AR binding and antagonism of dihydrotestosterone-induced AR transactivation. The phenothiazine derivatives acetophenazine, fluphenazine, and periciazine, used clinically as antipsychotic drugs, were identified as weak AR antagonists. This in vitro biological activity correlated well with endocrine side effects observed in individuals taking these medications. Further computational optimization of phenothiazines, combined with in vitro screening, led to the identification of a nonsteroidal antiandrogen with improved AR antagonism and marked reduction in affinity for dopaminergic and serotonergic receptors that are the primary target of phenothiazine antipsychotics., ",,O=C(CN1c2ccccc2Sc2ccc(C(F)(F)F)cc21)c1cccc2ccccc12,C25H16F3NOS,CHEMBL263660,250.0,251.19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.595,250.0,250.595,250.595,251.19,2.398972401,2.398972401,2.397940009,6.601027599,6.601027599,6.602059991,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.595,250.595,250.0,251.19,6.6010275985217275,6.6010275985217275,6.6020599913279625,6.599997654072044,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
431456,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 474428, Entry 1: 887117, ","Entry 0: Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay, Entry 1: Antagonist activity at androgen receptor by cellular reporter gene assay, ","0,1","Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL934261, Entry 1: CHEMBL2214342, ","Entry 0: 10.1021/jm701080t, Entry 1: 10.1016/j.bmcl.2012.09.077, ","Entry 0: 18318463, Entry 1: 23079530, ","Entry 0: CHEMBL1144664, Entry 1: CHEMBL2203135, ","Entry 0: Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348)., Entry 1: Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et al. Biorg. Med. Chem. Lett. 2002, 12, 3487; 2003, 13, 1317 ). We herein report a new functional switch within the 5-(2-oxoindolin-5-yl)-1 H-pyrrole-2-carbonitrile class of compounds. We found that the size of the 3,3-dialkyl substituent is important for controlling the functional response; thus small groups (dimethyl) afford potent PR antagonists, whereas larger groups (spirocyclohexyl) are PR agonists. The product from our optimization activities in cell-based systems and also for kinetic properties in rodents and nonhuman primates was 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-1-methyl-1 H-pyrrole-2-carbonitrile 27 (WAY-255348), which demonstrated potent and robust activity on PR antagonist and contraceptive end points in the rat and also in cynomolgus and rhesus monkeys including ovulation inhibition, menses induction, and reproductive tract morphology., Entry 1: We have developed a new series of progesterone receptor modulators based upon the 4-aryl-phenylsulfonamide. Initial work in the series afforded potent compounds with good properties, however an advanced intermediate proved to be genotoxic in a non-GLP Ames assay following metabolic activation. We subsequently solved this problem and identified advanced leads which demonstrated oral efficacy in rhesus monkey pharmacodynamic and kinetics models., ",,COC[C@]1(OC)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(/C=N/O)cc3)C[C@@]21C,C28H35NO4,CHEMBL267431,6.1,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.45,6.1,7.55,7.55,9.0,0.877946952,0.877946952,0.785329835,8.122053048,8.122053048,8.214670165,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.55,7.55,6.1,9.0,8.122053048370812,8.122053048370812,8.214670164989233,8.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435485,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)n4nccc34)C(=O)[C@H]12,C18H16N4O3,CHEMBL255216,88.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,88.0,88.0,88.0,88.0,1.944482672,1.944482672,1.944482672,7.055517328,7.055517328,7.055517328,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,88.0,88.0,88.0,88.0,7.055517327849832,7.055517327849832,7.055517327849832,7.055517327849832,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435528,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3c(N)ccc4nccn34)C(=O)[C@H]12,C17H18N4O3,CHEMBL271261,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,70.0,70.0,70.0,70.0,1.84509804,1.84509804,1.84509804,7.15490196,7.15490196,7.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,70.0,70.0,70.0,70.0,7.154901959985743,7.154901959985743,7.154901959985743,7.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435529,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)c4nsnc34)C(=O)[C@H]12,C17H14N4O3S,CHEMBL446626,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.0,16.0,16.0,16.0,1.204119983,1.204119983,1.204119983,7.795880017,7.795880017,7.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435530,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,COc1cc(N2C(=O)[C@@H]3[C@H](C2=O)C2(C)CCC3(C)O2)ccc1-c1cnco1,C20H20N2O5,CHEMBL403061,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435531,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3c(N)ccc4ncsc34)C(=O)[C@H]12,C17H17N3O3S,CHEMBL271262,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,120.0,120.0,120.0,120.0,2.079181246,2.079181246,2.079181246,6.920818754,6.920818754,6.920818754,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,120.0,120.0,120.0,120.0,6.920818753952375,6.920818753952375,6.920818753952375,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435570,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3cnc(C#N)c(Cl)c3)C(=O)[C@H]12,C16H14ClN3O3,CHEMBL403213,38.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,38.0,38.0,38.0,38.0,1.579783597,1.579783597,1.579783597,7.420216403,7.420216403,7.420216403,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,38.0,38.0,38.0,38.0,7.42021640338319,7.42021640338319,7.42021640338319,7.42021640338319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435572,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3cc(Cl)cc(Cl)c3)C(=O)[C@H]12,C16H15Cl2NO3,CHEMBL257668,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.0,16.0,16.0,16.0,1.204119983,1.204119983,1.204119983,7.795880017,7.795880017,7.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435573,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc([N+](=O)[O-])c(C(F)(F)F)c3)C(=O)[C@H]12,C17H15F3N2O5,CHEMBL403214,11.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11.0,11.0,11.0,11.0,1.041392685,1.041392685,1.041392685,7.958607315,7.958607315,7.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,11.0,11.0,11.0,11.0,7.958607314841775,7.958607314841775,7.958607314841775,7.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435613,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@H]12,C17H15IN2O3,CHEMBL403668,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.0,7.0,7.0,7.0,0.84509804,0.84509804,0.84509804,8.15490196,8.15490196,8.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.0,7.0,7.0,7.0,8.154901959985743,8.154901959985743,8.154901959985743,8.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435614,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CSc1cc(N2C(=O)[C@@H]3[C@H](C2=O)C2(C)CCC3(C)O2)ccc1C#N,C18H18N2O3S,CHEMBL272509,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435615,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C18H15F3N2O3,CHEMBL403669,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.0,7.0,7.0,7.0,0.84509804,0.84509804,0.84509804,8.15490196,8.15490196,8.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.0,7.0,7.0,7.0,8.154901959985743,8.154901959985743,8.154901959985743,8.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435616,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3cccc(C(F)(F)F)c3)C(=O)[C@H]12,C17H16F3NO3,CHEMBL272510,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,36.0,36.0,36.0,36.0,1.556302501,1.556302501,1.556302501,7.443697499,7.443697499,7.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,36.0,36.0,36.0,36.0,7.443697499232713,7.443697499232713,7.443697499232713,7.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435658,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1cccc(C(F)(F)F)c1,C15H12F3NO3,CHEMBL255157,11500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11500.0,11500.0,11500.0,11500.0,4.06069784,4.06069784,4.06069784,4.93930216,4.93930216,4.93930216,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11500.0,11500.0,11500.0,11500.0,4.939302159646388,4.939302159646388,4.939302159646388,4.939302159646388,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
435659,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(O1)[C@H]1C(=O)N(c3cccc(C(F)(F)F)c3)C(=O)[C@H]12,C16H14F3NO3,CHEMBL404506,343.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,343.0,343.0,343.0,343.0,2.53529412,2.53529412,2.53529412,6.46470588,6.46470588,6.46470588,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,343.0,343.0,343.0,343.0,6.464705879957229,6.464705879957229,6.464705879957229,6.464705879957229,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435660,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,N#Cc1ccc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)cc1C(F)(F)F,C16H11F3N2O3,CHEMBL427721,2860.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2860.0,2860.0,2860.0,2860.0,3.456366033,3.456366033,3.456366033,5.543633967,5.543633967,5.543633967,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2860.0,2860.0,2860.0,2860.0,5.543633966870957,5.543633966870957,5.543633966870957,5.543633966870957,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435751,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@H]2C3CCC(C3)N2C(=O)N1c1cccc(C(F)(F)F)c1,C15H13F3N2O2,CHEMBL255776,130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,130.0,130.0,130.0,130.0,2.113943352,2.113943352,2.113943352,6.886056648,6.886056648,6.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,130.0,130.0,130.0,130.0,6.886056647693163,6.886056647693163,6.886056647693163,6.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435752,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC(C)(C)OC(=O)N1CC2CC1[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)N21,C20H19F3N4O4,CHEMBL404315,774.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,774.0,774.0,774.0,774.0,2.888740961,2.888740961,2.888740961,6.111259039,6.111259039,6.111259039,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,774.0,774.0,774.0,774.0,6.111259039317107,6.111259039317107,6.111259039317107,6.111259039317107,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435796,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c([N+](=O)[O-])c1,C14H11ClN2O5,CHEMBL271924,1150.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1150.0,1150.0,1150.0,1150.0,3.06069784,3.06069784,3.06069784,5.93930216,5.93930216,5.93930216,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1150.0,1150.0,1150.0,1150.0,5.939302159646388,5.939302159646388,5.939302159646388,5.939302159646388,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435797,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c(C(F)(F)F)c1,C15H11ClF3NO3,CHEMBL271925,3310.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3310.0,3310.0,3310.0,3310.0,3.519827994,3.519827994,3.519827994,5.480172006,5.480172006,5.480172006,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3310.0,3310.0,3310.0,3310.0,5.480172006224281,5.480172006224281,5.480172006224281,5.480172006224281,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435837,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,Cc1cc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)ccc1Cl,C15H14ClNO3,CHEMBL255367,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435880,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,Cc1ccc(N2C(=O)[C@@H]3C4CCC(O4)[C@@H]3C2=O)cc1Cl,C15H14ClNO3,CHEMBL437214,2290.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2290.0,2290.0,2290.0,2290.0,3.359835482,3.359835482,3.359835482,5.640164518,5.640164518,5.640164518,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2290.0,2290.0,2290.0,2290.0,5.640164517660112,5.640164517660112,5.640164517660112,5.640164517660112,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435883,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Cl)c(Cl)c1,C14H11Cl2NO3,CHEMBL270450,480.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,480.0,480.0,480.0,480.0,2.681241237,2.681241237,2.681241237,6.318758763,6.318758763,6.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,480.0,480.0,480.0,480.0,6.318758762624412,6.318758762624412,6.318758762624412,6.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
435930,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(I)c(Cl)c1,C14H11ClINO3,CHEMBL270586,350.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,350.0,350.0,350.0,350.0,2.544068044,2.544068044,2.544068044,6.455931956,6.455931956,6.455931956,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,350.0,350.0,350.0,350.0,6.455931955649724,6.455931955649724,6.455931955649724,6.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
436027,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc(Br)c2ccccc12,C18H14BrNO3,CHEMBL402930,670.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,670.0,670.0,670.0,670.0,2.826074803,2.826074803,2.826074803,6.173925197,6.173925197,6.173925197,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,670.0,670.0,670.0,670.0,6.173925197299173,6.173925197299173,6.173925197299173,6.173925197299173,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
436078,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,O=C1[C@@H]2C3CCC(O3)[C@@H]2C(=O)N1c1ccc([N+](=O)[O-])c2ccccc12,C18H14N2O5,CHEMBL402807,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
436116,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12C[C@@H](O)C(C)(O1)[C@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@H]12,C17H15IN2O4,CHEMBL272574,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
436119,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12C[C@H](O)C(C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@@H]12,C17H15IN2O4,CHEMBL255331,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
436161,nM,IC50,,BAO_0000190,IC50,464721,Antagonist activity at human androgen receptor in MDA453 cells by alkaline phosphatase reporter gene assay,0,F,,CHEMBL933064,10.1016/j.bmcl.2008.02.006,18291644,CHEMBL1142249,Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.,PUBLICATION,"A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor. Molecular modeling and iterative drug design were applied to optimize this series. The lead compound [3aS-(3aalpha,4beta,5beta,7beta,7aalpha)]-4-(octahydro-5-hydroxy-4,7-dimethyl-1,3-dioxo-4,7-epoxy-2H-isoindol-2-yl)-2-iodobenzonitrile was shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model.",,CC12CCC(C)(O1)[C@H]1C(=O)N(c3ccc([N+](=O)[O-])c4c(Br)cccc34)C(=O)[C@H]12,C20H17BrN2O5,CHEMBL403039,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,40.0,40.0,40.0,40.0,1.602059991,1.602059991,1.602059991,7.397940009,7.397940009,7.397940009,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,40.0,40.0,40.0,40.0,7.3979400086720375,7.3979400086720375,7.3979400086720375,7.3979400086720375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
439461,nM,IC50,,BAO_0000190,IC50,321242,Inhibitory concentration against Androgen receptor,0,B,,CHEMBL881777,10.1021/jm0505056,16250653,CHEMBL1140376,Is antagonism of E/Z-guggulsterone at the farnesoid X receptor mediated by a noncanonical binding site? A molecular modeling study.,PUBLICATION,"Guggulsterone 1, the active principle of guggulipid, has been used in ethnic medicine for thousands of years for its antinflammatory and antilipidemic activities. The activities of 1 are apparently mediated by its interaction with an array of nuclear receptors, including endocrine steroid receptors and metabolic lipid receptors. Although relatively weak, the activity at the metabolic farnesoid X receptor (FXR) is particularly intriguing, as 1 is, so far, the only antagonist known for this receptor, with a peculiar ability of gene selective modulation. We report here a systematic study aimed at identifying the potential binding pocket of 1 at FXR. Although 1 could be docked into the canonical binding site, we identified a novel, so far undescribed binding pocket, localized near the loop region between helix 1 and helix 2. This novel binding pocket may explain some of the peculiar characteristics of 1 when acting at FXR.",,C/C=C1\C(=O)C[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,C21H28O2,CHEMBL410683,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,660.0,660.0,660.0,660.0,2.819543936,2.819543936,2.819543936,6.180456064,6.180456064,6.180456064,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
440257,nM,IC50,,BAO_0000190,IC50,474428,Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay,0,B,,CHEMBL934261,10.1021/jm701080t,18318463,CHEMBL1144664,"Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348).",PUBLICATION,"We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et al. Biorg. Med. Chem. Lett. 2002, 12, 3487; 2003, 13, 1317 ). We herein report a new functional switch within the 5-(2-oxoindolin-5-yl)-1 H-pyrrole-2-carbonitrile class of compounds. We found that the size of the 3,3-dialkyl substituent is important for controlling the functional response; thus small groups (dimethyl) afford potent PR antagonists, whereas larger groups (spirocyclohexyl) are PR agonists. The product from our optimization activities in cell-based systems and also for kinetic properties in rodents and nonhuman primates was 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-1-methyl-1 H-pyrrole-2-carbonitrile 27 (WAY-255348), which demonstrated potent and robust activity on PR antagonist and contraceptive end points in the rat and also in cynomolgus and rhesus monkeys including ovulation inhibition, menses induction, and reproductive tract morphology.",,Cn1c(C#N)ccc1-c1cc(F)c2c(c1)C(C)(C)C(=O)N2,C16H14FN3O,CHEMBL407848,196.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,196.0,196.0,196.0,196.0,2.292256071,2.292256071,2.292256071,6.707743929,6.707743929,6.707743929,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,196.0,196.0,196.0,196.0,6.707743928643524,6.707743928643524,6.707743928643524,6.707743928643524,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
455243,nM,IC50,,BAO_0000190,IC50,519424,Antagonist activity at gal-AR expressed in african green monkey CV1 cells co-expressing MH100 with GRIP1 co-factor by luciferase reporter gene assay,0,F,,CHEMBL949850,10.1021/jm8014124,19159286,CHEMBL1140941,"Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).",PUBLICATION,"Azepino[4,5-b]indoles have been identified as potent agonists of the farnesoid X receptor (FXR). In vitro and in vivo optimization has led to the discovery of 6m (XL335, WAY-362450) as a potent, selective, and orally bioavailable FXR agonist (EC(50) = 4 nM, Eff = 149%). Oral administration of 6m to LDLR(-/-) mice results in lowering of cholesterol and triglycerides. Chronic administration in an atherosclerosis model results in significant reduction in aortic arch lesions.",,CC(C)OC(=O)C1=CN(C(=O)c2ccc(F)c(F)c2)CC(C)(C)c2c1[nH]c1ccccc21,C25H24F2N2O3,CHEMBL454138,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
457061,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Sc2c(C)cc(C)cc2C)ccc1C#N,C17H17NOS,CHEMBL462022,39.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.0,39.0,54.0,54.0,69.0,1.73239376,1.73239376,1.591064607,7.26760624,7.26760624,7.408935393,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,69.0,69.0,69.0,69.0,7.161150909262744,7.161150909262744,7.161150909262744,7.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457062,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,CCCSc1ccc(C#N)c(OC)c1,C11H13NOS,CHEMBL443970,40.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,480.0,40.0,520.0,520.0,1000.0,2.716003344,2.716003344,1.602059991,6.283996656,6.283996656,7.397940009,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457063,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,CCCCSc1ccc(C#N)c(OC)c1,C12H15NOS,CHEMBL455566,66.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,66.0,75.0,75.0,84.0,1.875061263,1.875061263,1.819543936,7.124938737,7.124938737,7.180456064,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.0,84.0,84.0,84.0,7.075720713938118,7.075720713938118,7.075720713938118,7.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457064,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(SC(C)C)ccc1C#N,C11H13NOS,CHEMBL445429,10.0,29.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.5,10.0,19.5,19.5,29.0,1.290034611,1.290034611,1.0,7.709965389,7.709965389,8.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,29.0,29.0,29.0,29.0,7.5376020021010435,7.5376020021010435,7.5376020021010435,7.5376020021010435,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457065,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(SCC2CC2)ccc1C#N,C12H13NOS,CHEMBL504110,55.0,169.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,57.0,55.0,112.0,112.0,169.0,2.049218023,2.049218023,1.740362689,6.950781977,6.950781977,7.259637311,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,169.0,169.0,169.0,169.0,6.772113295386326,6.772113295386326,6.772113295386326,6.772113295386326,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457068,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,CCCSc1ccc(C#N)c(C(F)(F)F)c1,C11H10F3NS,CHEMBL462664,11.0,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.0,11.0,17.0,17.0,23.0,1.230448921,1.230448921,1.041392685,7.769551079,7.769551079,7.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457069,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,CCCCSc1ccc(C#N)c(C(F)(F)F)c1,C12H12F3NS,CHEMBL462665,49.0,838.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,394.5,49.0,443.5,443.5,838.0,2.646893624,2.646893624,1.69019608,6.353106376,6.353106376,7.30980392,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,838.0,838.0,838.0,838.0,6.076755981369724,6.076755981369724,6.076755981369724,6.076755981369724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457135,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,CC(C)Sc1ccc(C#N)c(C(F)(F)F)c1,C11H10F3NS,CHEMBL453740,20.0,89.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,34.5,20.0,54.5,54.5,89.0,1.736396502,1.736396502,1.301029996,7.263603498,7.263603498,7.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,89.0,89.0,89.0,89.0,7.050609993355087,7.050609993355087,7.050609993355087,7.050609993355087,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457265,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,N#Cc1ccc(SCC2CC2)cc1C(F)(F)F,C12H10F3NS,CHEMBL453623,35.0,133.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,49.0,35.0,84.0,84.0,133.0,1.924279286,1.924279286,1.544068044,7.075720714,7.075720714,7.455931956,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,133.0,133.0,133.0,133.0,6.876148359032914,6.876148359032914,6.876148359032914,6.876148359032914,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457266,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,N#Cc1ccc(SCC2CCC2)cc1C(F)(F)F,C13H12F3NS,CHEMBL453624,63.0,702.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,319.5,63.0,382.5,382.5,702.0,2.582631439,2.582631439,1.799340549,6.417368561,6.417368561,7.200659451,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,702.0,702.0,702.0,702.0,6.153662887870195,6.153662887870195,6.153662887870195,6.153662887870195,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457269,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,N#Cc1ccc(SC2CCC2)cc1C(F)(F)F,C12H10F3NS,CHEMBL449371,167.0,194.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,13.5,167.0,180.5,180.5,194.0,2.256477206,2.256477206,2.222716471,6.743522794,6.743522794,6.777283529,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,194.0,194.0,194.0,194.0,6.7121982700697735,6.7121982700697735,6.7121982700697735,6.7121982700697735,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457951,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, Entry 2: 566235, Entry 3: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, Entry 2: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 3: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, Entry 2: CHEMBL964136, Entry 3: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, Entry 2: 10.1016/j.bmcl.2009.01.063, Entry 3: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19286380, Entry 1: 19286380, Entry 2: 19201190, Entry 3: 19201190, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, Entry 2: CHEMBL1153273, Entry 3: CHEMBL1153273, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 2: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 3: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,Cc1ccccc1Oc1ccc(C#N)cc1Cl,C14H10ClNO,CHEMBL490955,46.0,46.0,64.0,64.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.0,46.0,55.0,55.0,64.0,1.740362689,1.740362689,1.662757832,7.259637311,7.259637311,7.337242168,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,46.0,46.0,46.0,46.0,7.337242168318426,7.337242168318426,7.337242168318426,7.337242168318426,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457952,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, Entry 2: 2227383, Entry 3: 2227458, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, Entry 2: Binding affinity to human Androgen receptor, Entry 3: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, Entry 2: CHEMBL5140896, Entry 3: CHEMBL5140971, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 19201190, Entry 1: 19201190, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1ccccc1Sc1ccc(C#N)cc1Cl,C14H10ClNS,CHEMBL490956,43.0,43.0,78.0,78.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.5,43.0,60.5,60.5,78.0,1.781755375,1.781755375,1.633468456,7.218244625,7.218244625,7.366531544,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,43.0,43.0,43.0,43.0,7.366531544420414,7.366531544420414,7.366531544420414,7.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457954,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Oc2ccccc2C)ccc1C#N,C15H13NO2,CHEMBL491493,24.0,81.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.5,24.0,52.5,52.5,81.0,1.720159303,1.720159303,1.380211242,7.279840697,7.279840697,7.619788758,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,81.0,81.0,81.0,81.0,7.0915149811213505,7.0915149811213505,7.0915149811213505,7.0915149811213505,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
457955,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Oc2cccc(C)c2)ccc1C#N,C15H13NO2,CHEMBL490957,57.0,197.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,70.0,57.0,127.0,127.0,197.0,2.103803721,2.103803721,1.755874856,6.896196279,6.896196279,7.244125144,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,197.0,197.0,197.0,197.0,6.705533773838407,6.705533773838407,6.705533773838407,6.705533773838407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458018,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Oc2ccc(C)cc2)ccc1C#N,C15H13NO2,CHEMBL501649,200.0,209.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.5,200.0,204.5,204.5,209.0,2.310693312,2.310693312,2.301029996,6.689306688,6.689306688,6.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,209.0,209.0,209.0,209.0,6.679853713888946,6.679853713888946,6.679853713888946,6.679853713888946,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458019,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(C#N)ccc1Oc1ccccc1C,C15H13NO2,CHEMBL449867,48.0,115.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,33.5,48.0,81.5,81.5,115.0,1.911157609,1.911157609,1.681241237,7.088842391,7.088842391,7.318758763,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,115.0,115.0,115.0,115.0,6.939302159646388,6.939302159646388,6.939302159646388,6.939302159646388,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458022,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, Entry 2: 566235, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, Entry 2: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, Entry 2: CHEMBL964136, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, Entry 2: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19286380, Entry 1: 19286380, Entry 2: 19201190, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, Entry 2: CHEMBL1153273, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 2: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,Cc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NO,CHEMBL499137,92.0,535.0,743.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,271.4803042,92.0,456.6666667,535.0,743.0,2.659599312,2.728353782,1.963787827,6.340400688,6.271646218,7.036212173,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,535.0,535.0,535.0,535.0,6.2716462179787715,6.2716462179787715,6.2716462179787715,6.2716462179787715,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458023,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 566235, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL964136, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19286380, Entry 1: 19201190, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153273, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,Cc1cccc(Oc2ccc(C#N)c(C(F)(F)F)c2)c1,C15H10F3NO,CHEMBL464764,770.0,1680.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,455.0,770.0,1225.0,1225.0,1680.0,3.088136089,3.088136089,2.886490725,5.911863911,5.911863911,6.113509275,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1680.0,1680.0,1680.0,1680.0,5.774690718274137,5.774690718274137,5.774690718274137,5.774690718274137,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458024,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 566235, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL964136, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19286380, Entry 1: 19201190, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153273, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,Cc1ccc(Oc2ccc(C#N)c(C(F)(F)F)c2)cc1,C15H10F3NO,CHEMBL465539,4000.0,5330.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,665.0,4000.0,4665.0,4665.0,5330.0,3.668851648,3.668851648,3.602059991,5.331148352,5.331148352,5.397940009,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5330.0,5330.0,5330.0,5330.0,5.273272790973428,5.273272790973428,5.273272790973428,5.273272790973428,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
458092,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,Cc1ccccc1Sc1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NS,CHEMBL462025,123.0,225.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,51.0,123.0,174.0,174.0,225.0,2.240549248,2.240549248,2.089905111,6.759450752,6.759450752,6.910094889,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,225.0,225.0,225.0,225.0,6.647817481888637,6.647817481888637,6.647817481888637,6.647817481888637,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458093,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, Entry 2: 634399, Entry 3: 634400, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, Entry 2: Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting, Entry 3: Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, Entry 2: CHEMBL1118176, Entry 3: CHEMBL1118177, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, Entry 2: 10.1021/jm9018004, Entry 3: 10.1021/jm9018004, ","Entry 0: 19201190, Entry 1: 19201190, Entry 2: 20462217, Entry 3: 20462217, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, Entry 2: CHEMBL1155517, Entry 3: CHEMBL1155517, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 3: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 2: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 3: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., ",,N#Cc1ccc(Sc2ccccc2F)cc1C(F)(F)F,C14H7F4NS,CHEMBL507671,54.0,54.0,184.0,184.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65.0,54.0,119.0,119.0,184.0,2.075546961,2.075546961,1.73239376,6.924453039,6.924453039,7.26760624,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,54.0,54.0,54.0,54.0,7.267606240177032,7.267606240177032,7.267606240177032,7.267606240177032,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458094,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1ccccc1Sc1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NOS,CHEMBL462026,37.0,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.5,37.0,46.5,46.5,56.0,1.667452953,1.667452953,1.568201724,7.332547047,7.332547047,7.431798276,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,56.0,56.0,56.0,56.0,7.251811972993799,7.251811972993799,7.251811972993799,7.251811972993799,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458097,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Sc2ccccc2OC)ccc1C#N,C15H13NO2S,CHEMBL510145,20.0,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.5,20.0,27.5,27.5,35.0,1.439332694,1.439332694,1.301029996,7.560667306,7.560667306,7.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,35.0,35.0,35.0,35.0,7.455931955649724,7.455931955649724,7.455931955649724,7.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
458098,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 566235, Entry 1: 566236, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB453 cells by luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL964136, Entry 1: CHEMBL964137, ","Entry 0: 10.1016/j.bmcl.2009.01.063, Entry 1: 10.1016/j.bmcl.2009.01.063, ","Entry 0: 19201190, Entry 1: 19201190, ","Entry 0: CHEMBL1153273, Entry 1: CHEMBL1153273, ","Entry 0: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: 4-(Alkylthio)- and 4-(arylthio)-benzonitrile derivatives as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., Entry 1: The first examples of thioether-substituted benzonitriles as potential soft-drug androgen receptor antagonists are reported. A number of 4-(alkylthio)- and of 4-(arylthio)-benzonitrile analogs were evaluated in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro binding and cellular activities were evaluated for topical in vivo efficacy in the Golden Syrian hamster ear model. Analogs from both the 4-(alkylthio)- and of 4-(arylthio)-benzonitrile series showed moderate reduction of wax esters in vivo., ",,COc1cc(Sc2c(C)cccc2C)ccc1C#N,C16H15NOS,CHEMBL448454,30.0,43.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.5,30.0,36.5,36.5,43.0,1.562292864,1.562292864,1.477121255,7.437707136,7.437707136,7.522878745,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,43.0,43.0,43.0,43.0,7.366531544420414,7.366531544420414,7.366531544420414,7.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
471130,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1ccc2nc(-c3ccncc3)ccc2c1,C14H10N2,CHEMBL452153,2260.0,4200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,970.0,2260.0,3230.0,3230.0,4200.0,3.509202522,3.509202522,3.354108439,5.490797478,5.490797478,5.645891561,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3230.0,3230.0,2260.0,4200.0,5.490797477668897,5.490797477668897,5.645891560852599,5.376750709602099,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
479591,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@H]([C@@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C17H16F6N2O2,CHEMBL467888,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
483886,nM,IC50,,BAO_0000190,IC50,580463,Antagonist activity at androgen receptor in human MDA-kb2 cells assessed as inhibition of DHT-induced luciferase activity by luciferase reporter gene assay,0,F,,CHEMBL1052490,10.1016/j.bmcl.2009.06.073,19592245,CHEMBL1153076,Effect of flavonoids on androgen and glucocorticoid receptors based on in vitro reporter gene assay.,PUBLICATION,"The effect of 32 flavonoids on androgen (AR) and glucocorticoid receptors (GR) was investigated using an MDA-kb2 human breast cancer cell line to predict potential AR and GR activities. Among them, 5-hydroxyflavone (7) had the highest AR antagonistic activity with an IC(50) value of 0.3 microM, whereas 6-methoxyflavone (11) had the highest induced luciferase activity with an EC(150) value of 0.7 microM. Genistein (2) and daizein (1) showed a sufficient increase of luciferase activities as their concentrations increased with EC(150) values of 4.4 and 10.1 microM, respectively. These findings provide evidence of a fundamental property of their structure-activity relationship with AR and/or GR.",,COc1ccc2c(c1)C(=O)CC(c1ccccc1)O2,C16H14O3,CHEMBL476292,39500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,39500.0,39500.0,39500.0,39500.0,4.596597096,4.596597096,4.596597096,4.403402904,4.403402904,4.403402904,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,39500.0,39500.0,39500.0,39500.0,4.403402904373539,4.403402904373539,4.403402904373539,4.403402904373539,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
483887,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccc2c(c1)C(=O)CC(c1ccccc1OC)O2,C17H16O4,CHEMBL507539,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
484695,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(O)cc2)oc2cccc(O)c12,C15H10O4,CHEMBL484662,851.14,860.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.43,851.14,855.57,855.57,860.0,2.932255548,2.932255548,2.930001001,6.067744452,6.067744452,6.069998999,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,855.5699999999999,855.5699999999999,851.14,860.0,6.067744452084238,6.067744452084238,6.069998998990925,6.0655015487564325,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
507649,nM,IC50,,BAO_0000190,IC50,553970,Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay,0,B,,CHEMBL965388,10.1016/j.bmc.2008.05.018,18504132,CHEMBL1157410,"7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.",PUBLICATION,"Novel 7-aryl benzo[1,4]oxazepin-2-ones were synthesized and evaluated as non-steroidal progesterone receptor (PR) modulators. The structure activity relationship of 7-aryl benzo[1,4]oxazepinones was examined using the T47D cell alkaline phosphatase assay. A number of 7-aryl benzo[1,4]oxazepinones such as 10j and 10v demonstrated good in vitro potency (IC(50) of 10-30 nM) and selectivity (over 100-fold) at PR over other steroidal receptors such as glucocorticoid and androgen receptors (GR and AR). Several 7-aryl benzo[1,4]oxazepinones were active in the rat uterine decidualization model. In this in vivo model, compounds 10j and 10u were active at 3 mg/kg when dosed orally.",,CC1(C)OCC(=O)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,C18H15FN2O2,CHEMBL487728,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
507762,nM,IC50,,BAO_0000190,IC50,553970,Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay,0,B,,CHEMBL965388,10.1016/j.bmc.2008.05.018,18504132,CHEMBL1157410,"7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.",PUBLICATION,"Novel 7-aryl benzo[1,4]oxazepin-2-ones were synthesized and evaluated as non-steroidal progesterone receptor (PR) modulators. The structure activity relationship of 7-aryl benzo[1,4]oxazepinones was examined using the T47D cell alkaline phosphatase assay. A number of 7-aryl benzo[1,4]oxazepinones such as 10j and 10v demonstrated good in vitro potency (IC(50) of 10-30 nM) and selectivity (over 100-fold) at PR over other steroidal receptors such as glucocorticoid and androgen receptors (GR and AR). Several 7-aryl benzo[1,4]oxazepinones were active in the rat uterine decidualization model. In this in vivo model, compounds 10j and 10u were active at 3 mg/kg when dosed orally.",,CCC1(c2ccco2)OCC(=O)Nc2ccc(-c3cc(F)cc(C#N)c3)cc21,C22H17FN2O3,CHEMBL501080,690.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,690.0,690.0,690.0,690.0,2.838849091,2.838849091,2.838849091,6.161150909,6.161150909,6.161150909,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,690.0,690.0,690.0,690.0,6.161150909262744,6.161150909262744,6.161150909262744,6.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
507763,nM,IC50,,BAO_0000190,IC50,553970,Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay,0,B,,CHEMBL965388,10.1016/j.bmc.2008.05.018,18504132,CHEMBL1157410,"7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists.",PUBLICATION,"Novel 7-aryl benzo[1,4]oxazepin-2-ones were synthesized and evaluated as non-steroidal progesterone receptor (PR) modulators. The structure activity relationship of 7-aryl benzo[1,4]oxazepinones was examined using the T47D cell alkaline phosphatase assay. A number of 7-aryl benzo[1,4]oxazepinones such as 10j and 10v demonstrated good in vitro potency (IC(50) of 10-30 nM) and selectivity (over 100-fold) at PR over other steroidal receptors such as glucocorticoid and androgen receptors (GR and AR). Several 7-aryl benzo[1,4]oxazepinones were active in the rat uterine decidualization model. In this in vivo model, compounds 10j and 10u were active at 3 mg/kg when dosed orally.",,N#Cc1cc(F)cc(-c2ccc3c(c2)C(c2ccco2)(c2ccco2)OCC(=O)N3)c1,C24H15FN2O4,CHEMBL487116,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
513227,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 538003, Entry 1: 538004, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1032459, Entry 1: CHEMBL1032460, ","Entry 0: 10.1021/jm8009316, Entry 1: 10.1021/jm8009316, ","Entry 0: 18921992, Entry 1: 18921992, ","Entry 0: CHEMBL1142535, Entry 1: CHEMBL1142535, ","Entry 0: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 1: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 1: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., ",,COc1cc(-c2ccccc2O)ccc1C#N,C14H11NO2,CHEMBL503575,20.1,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8.45,20.1,28.55,28.55,37.0,1.455606113,1.455606113,1.303196057,7.544393887,7.544393887,7.696803943,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,37.0,37.0,37.0,37.0,7.431798275933005,7.431798275933005,7.431798275933005,7.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
513229,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 538003, Entry 1: 538004, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1032459, Entry 1: CHEMBL1032460, ","Entry 0: 10.1021/jm8009316, Entry 1: 10.1021/jm8009316, ","Entry 0: 18921992, Entry 1: 18921992, ","Entry 0: CHEMBL1142535, Entry 1: CHEMBL1142535, ","Entry 0: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 1: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 1: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., ",,N#Cc1ccc(C2CCCCC2O)cc1C(F)(F)F,C14H14F3NO,CHEMBL501627,26.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32.0,26.0,58.0,58.0,90.0,1.763427994,1.763427994,1.414973348,7.236572006,7.236572006,7.585026652,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,90.0,90.0,90.0,90.0,7.045757490560675,7.045757490560675,7.045757490560675,7.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
513345,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 538003, Entry 1: 538004, Entry 2: 2227383, Entry 3: 2227458, ","Entry 0: Displacement of [3H]dihydrotestosterone from human androgen receptor expressed in Sf9 cells, Entry 1: Antagonist activity against human androgen receptor expressed in human MDA-MB-453 cells assessed as inhibition of dihydrotestosterone-induced effect by luciferase receptor gene assay, Entry 2: Binding affinity to human Androgen receptor, Entry 3: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL1032459, Entry 1: CHEMBL1032460, Entry 2: CHEMBL5140896, Entry 3: CHEMBL5140971, ","Entry 0: 10.1021/jm8009316, Entry 1: 10.1021/jm8009316, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 18921992, Entry 1: 18921992, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL1142535, Entry 1: CHEMBL1142535, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 1: Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 1: 4-((1 R,2 R)-2-Hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile [PF-0998425, (-)- 6a] is a novel, nonsteroidal androgen receptor antagonist for sebum control and treatment of androgenetic alopecia. It is potent, selective, and active in vivo. The compound is rapidly metabolized systemically, thereby reducing the risk of unwanted systemic side effects due to its primary pharmacology. (-)- 6a was tested negative in the 3T3 NRU assay, validating our rationale that reduction of conjugation might reduce potential phototoxicity., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,N#Cc1ccc([C@H]2CCCC[C@H]2O)cc1C(F)(F)F,C14H14F3NO,CHEMBL458084,26.0,37.0,43.0,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24.44381312,26.0,49.0,40.0,90.0,1.69019608,1.602059991,1.414973348,7.30980392,7.397940009,7.585026652,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,37.0,37.0,37.0,37.0,7.431798275933005,7.431798275933005,7.431798275933005,7.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
519560,nM,IC50,,BAO_0000190,IC50,540647,Antiandrogenic activity in human MDA-MB-453 cells expressing androgen receptor assessed as inhibition of DHT-induced androgen-dependent transcription by luciferase reporter gene assay,0,B,,CHEMBL1023897,10.1016/j.bmcl.2008.12.075,19131248,CHEMBL1136843,N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).,PUBLICATION,"A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors.",,COc1ccccc1CNC(=O)c1cc(C(F)(F)F)nn1-c1cccc(CNC(=O)[C@H](C)N)c1,C23H24F3N5O3,CHEMBL516241,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
519561,nM,IC50,,BAO_0000190,IC50,540647,Antiandrogenic activity in human MDA-MB-453 cells expressing androgen receptor assessed as inhibition of DHT-induced androgen-dependent transcription by luciferase reporter gene assay,0,B,,CHEMBL1023897,10.1016/j.bmcl.2008.12.075,19131248,CHEMBL1136843,N-Benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides as inhibitors of co-activator associated arginine methyltransferase 1 (CARM1).,PUBLICATION,"A series of N-benzyl-1-heteroaryl-3-(trifluoromethyl)-1H-pyrazole-5-carboxamides targeting co-activator associated arginine methyltransferase 1 (CARM1) have been designed and synthesized. The potency of these inhibitors was influenced by the nature of the heteroaryl fragment with the thiophene analogues being superior to thiazole, pyridine, isoindoline and benzofuran based inhibitors.",,COc1ccccc1CNC(=O)c1cc(C(F)(F)F)nn1-c1csc(CNC(=O)[C@H](C)N)c1,C21H22F3N5O3S,CHEMBL475503,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
520621,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2ccc(O)cc21,C15H12O4,CHEMBL485349,2730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2730.0,2730.0,2730.0,2730.0,3.436162647,3.436162647,3.436162647,5.563837353,5.563837353,5.563837353,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2730.0,2730.0,2730.0,2730.0,5.5638373529592435,5.5638373529592435,5.5638373529592435,5.5638373529592435,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521244,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, Entry 2: 2227383, Entry 3: 2227458, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, Entry 2: Binding affinity to human Androgen receptor, Entry 3: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, Entry 2: CHEMBL5140896, Entry 3: CHEMBL5140971, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 19286380, Entry 1: 19286380, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1ccccc1Oc1ccc(C#N)c(Cl)c1,C14H10ClNO,CHEMBL470204,30.0,57.0,57.0,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.18605761,30.0,51.0,57.0,60.0,1.707570176,1.755874856,1.477121255,7.292429824,7.244125144,7.522878745,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,57.0,57.0,57.0,57.0,7.2441251443275085,7.2441251443275085,7.2441251443275085,7.2441251443275085,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521318,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NO2,CHEMBL469380,72.0,83.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.5,72.0,77.5,77.5,83.0,1.889301703,1.889301703,1.857332496,7.110698297,7.110698297,7.142667504,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,83.0,83.0,83.0,83.0,7.080921907623926,7.080921907623926,7.080921907623926,7.080921907623926,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521397,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,CCc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO,CHEMBL513195,20.0,356.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,168.0,20.0,188.0,188.0,356.0,2.274157849,2.274157849,1.301029996,6.725842151,6.725842151,7.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,356.0,356.0,356.0,356.0,6.448550002027125,6.448550002027125,6.448550002027125,6.448550002027125,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521398,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,CCCc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C17H14F3NO,CHEMBL469602,202.0,303.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.5,202.0,252.5,252.5,303.0,2.402261382,2.402261382,2.305351369,6.597738618,6.597738618,6.694648631,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,303.0,303.0,303.0,303.0,6.518557371497695,6.518557371497695,6.518557371497695,6.518557371497695,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521471,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,Cc1cccc(C)c1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO,CHEMBL471644,10.0,681.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,335.5,10.0,345.5,345.5,681.0,2.538448052,2.538448052,1.0,6.461551948,6.461551948,8.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,681.0,681.0,681.0,681.0,6.166852888087215,6.166852888087215,6.166852888087215,6.166852888087215,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521472,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,Cc1cc(C)c(Oc2ccc(C#N)c(C(F)(F)F)c2)c(C)c1,C17H14F3NO,CHEMBL513768,198.0,812.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,307.0,198.0,505.0,505.0,812.0,2.703291378,2.703291378,2.29666519,6.296708622,6.296708622,6.70333481,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,812.0,812.0,812.0,812.0,6.090443970758825,6.090443970758825,6.090443970758825,6.090443970758825,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521473,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,N#Cc1ccc(Oc2ccccc2O)cc1C(F)(F)F,C14H8F3NO2,CHEMBL471645,34.0,97.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,31.5,34.0,65.5,65.5,97.0,1.8162413,1.8162413,1.531478917,7.1837587,7.1837587,7.468521083,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,97.0,97.0,97.0,97.0,7.013228265733755,7.013228265733755,7.013228265733755,7.013228265733755,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521474,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,CSc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C15H10F3NOS,CHEMBL504179,22.0,74.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26.0,22.0,48.0,48.0,74.0,1.681241237,1.681241237,1.342422681,7.318758763,7.318758763,7.657577319,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,74.0,74.0,74.0,74.0,7.130768280269024,7.130768280269024,7.130768280269024,7.130768280269024,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521475,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,CCOc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO2,CHEMBL449804,47.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36.5,47.0,83.5,83.5,120.0,1.921686475,1.921686475,1.672097858,7.078313525,7.078313525,7.327902142,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,120.0,120.0,120.0,120.0,6.920818753952375,6.920818753952375,6.920818753952375,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521476,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,CCSc1ccccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NOS,CHEMBL470395,229.0,545.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,158.0,229.0,387.0,387.0,545.0,2.587710965,2.587710965,2.359835482,6.412289035,6.412289035,6.640164518,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,545.0,545.0,545.0,545.0,6.2636034977233574,6.2636034977233574,6.2636034977233574,6.2636034977233574,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521549,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1cccc(OC)c1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO3,CHEMBL469333,157.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,421.5,157.0,578.5,578.5,1000.0,2.762303363,2.762303363,2.195899652,6.237696637,6.237696637,6.804100348,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521550,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1cc(C)ccc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO2,CHEMBL469334,69.0,299.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,115.0,69.0,184.0,184.0,299.0,2.264817823,2.264817823,1.838849091,6.735182177,6.735182177,7.161150909,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,299.0,299.0,299.0,299.0,6.52432881167557,6.52432881167557,6.52432881167557,6.52432881167557,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521551,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1ccc(C)cc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO2,CHEMBL512837,103.0,482.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,189.5,103.0,292.5,292.5,482.0,2.46612587,2.46612587,2.012837225,6.53387413,6.53387413,6.987162775,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,482.0,482.0,482.0,482.0,6.31695296176115,6.31695296176115,6.31695296176115,6.31695296176115,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521552,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1ccc(CO)cc1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H12F3NO3,CHEMBL451153,216.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,392.0,216.0,608.0,608.0,1000.0,2.783903579,2.783903579,2.334453751,6.216096421,6.216096421,6.665546249,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521631,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,Cc1ccc(O)c(Oc2ccc(C#N)c(C(F)(F)F)c2)c1,C15H10F3NO2,CHEMBL469982,127.0,811.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,342.0,127.0,469.0,469.0,811.0,2.671172843,2.671172843,2.103803721,6.328827157,6.328827157,6.896196279,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,811.0,811.0,811.0,811.0,6.090979145788844,6.090979145788844,6.090979145788844,6.090979145788844,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
521632,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 501560, Entry 1: 501561, ","Entry 0: Displacement of [3H]DHT from human cloned androgen receptor expressed in insect Sf9 cell system, Entry 1: Antagonist activity at human androgen receptor expressed in human MDA-MB-231 cells assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL987689, Entry 1: CHEMBL987690, ","Entry 0: 10.1016/j.bmcl.2009.02.104, Entry 1: 10.1016/j.bmcl.2009.02.104, ","Entry 0: 19286380, Entry 1: 19286380, ","Entry 0: CHEMBL1153981, Entry 1: CHEMBL1153981, ","Entry 0: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Diphenyl ethers as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., Entry 1: A series of diphenyl ethers was prepared and evaluated for androgen receptor antagonist activity in human androgen receptor binding and cellular functional assays. Analogs with potent in vitro activities were evaluated for topical in vivo efficacy in the Golden Syrian Hamster ear model. Several compounds showed reduction in wax esters in this validated animal model., ",,COc1cccc(F)c1Oc1ccc(C#N)c(C(F)(F)F)c1,C15H9F4NO2,CHEMBL469983,42.0,158.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,58.0,42.0,100.0,100.0,158.0,2.0,2.0,1.62324929,7.0,7.0,7.37675071,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,158.0,158.0,158.0,158.0,6.801342913045577,6.801342913045577,6.801342913045577,6.801342913045577,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
589663,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 766306, Entry 1: 766307, ","Entry 0: Displacement of SRC2-3 peptide from human AR ligand binding site expressed in Escherichia coli BL21 by AF2 FP assay, Entry 1: Inhibition of human AR AF2 site expressed in human LNCap cells coexpressing eGFP -ARR2PB assessed as inhibition of transcriptional activity, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL1826238, Entry 1: CHEMBL1826239, ","Entry 0: 10.1021/jm200532b, Entry 1: 10.1021/jm200532b, ","Entry 0: 21846139, Entry 1: 21846139, ","Entry 0: CHEMBL1821560, Entry 1: CHEMBL1821560, ","Entry 0: Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening., Entry 1: Inhibitors of androgen receptor activation function-2 (AF2) site identified through virtual screening., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) is one of the most studied drug targets for the treatment of prostate cancer. However, all current anti-androgens directly interact with the AR at the androgen binding site, which is prone to resistant mutations, calling for new strategies of the AR inhibition. The current study represents the first attempt to use virtual screening to identify inhibitors of activation function-2 (AF2) of the human AR. By combining large-scale docking with experimental approaches, we were able to identify several small molecules that interact with the AF2 and effectively prevent the transcriptional activation of the AR. The crystallographic structure of one of these inhibitors in complex with the AR provides critical insight into the corresponding protein-ligand interactions and suitable for future hit optimization. Taken together, our results provide a promising ground for development of novel anti-androgens that can help to address the problem of drug resistance in prostate cancer., Entry 1: The androgen receptor (AR) is one of the most studied drug targets for the treatment of prostate cancer. However, all current anti-androgens directly interact with the AR at the androgen binding site, which is prone to resistant mutations, calling for new strategies of the AR inhibition. The current study represents the first attempt to use virtual screening to identify inhibitors of activation function-2 (AF2) of the human AR. By combining large-scale docking with experimental approaches, we were able to identify several small molecules that interact with the AF2 and effectively prevent the transcriptional activation of the AR. The crystallographic structure of one of these inhibitors in complex with the AR provides critical insight into the corresponding protein-ligand interactions and suitable for future hit optimization. Taken together, our results provide a promising ground for development of novel anti-androgens that can help to address the problem of drug resistance in prostate cancer., ",,CCOc1cc(C2Nc3cccc4cccc(c34)N2)ccc1O,C19H18N2O2,CHEMBL591628,11100.0,31500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,10200.0,11100.0,21300.0,21300.0,31500.0,4.328379603,4.328379603,4.045322979,4.671620397,4.671620397,4.954677021,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,31500.0,31500.0,31500.0,31500.0,4.501689446210399,4.501689446210399,4.501689446210399,4.501689446210399,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
590516,nM,IC50,,BAO_0000190,IC50,603516,Antagonist activity at AR by reporter gene assay,0,F,,CHEMBL1068435,10.1016/j.bmcl.2009.10.111,19954971,CHEMBL1153171,Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.,PUBLICATION,The synthesis and SAR studies of 3- and 4-substituted 7-hydroxycoumarins as novel 17beta-HSD3 inhibitors are discussed. The most potent compounds from this series exhibited low nanomolar inhibitory activity with acceptable selectivity versus other 17beta-HSD isoenzymes and nuclear receptors.,,O=c1oc2cc(O)ccc2c(C(F)(F)F)c1Cc1ccccc1,C17H11F3O3,CHEMBL592043,6000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6000.0,6000.0,6000.0,6000.0,3.77815125,3.77815125,3.77815125,5.22184875,5.22184875,5.22184875,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6000.0,6000.0,6000.0,6000.0,5.221848749616356,5.221848749616356,5.221848749616356,5.221848749616356,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
590676,nM,IC50,,BAO_0000190,IC50,603516,Antagonist activity at AR by reporter gene assay,0,F,,CHEMBL1068435,10.1016/j.bmcl.2009.10.111,19954971,CHEMBL1153171,Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer.,PUBLICATION,The synthesis and SAR studies of 3- and 4-substituted 7-hydroxycoumarins as novel 17beta-HSD3 inhibitors are discussed. The most potent compounds from this series exhibited low nanomolar inhibitory activity with acceptable selectivity versus other 17beta-HSD isoenzymes and nuclear receptors.,,Cc1cccc(SCc2cc(=O)oc3cc(O)ccc23)n1,C16H13NO3S,CHEMBL589158,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
593739,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccccc1/C=C/C(=O)c1ccccc1O,C16H14O3,CHEMBL594854,3500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3500.0,3500.0,3500.0,3500.0,3.544068044,3.544068044,3.544068044,5.455931956,5.455931956,5.455931956,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3500.0,3500.0,3500.0,3500.0,5.455931955649724,5.455931955649724,5.455931955649724,5.455931955649724,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
612407,nM,IC50,,BAO_0000190,IC50,620577,Antagonist activity at androgen receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay,0,B,,CHEMBL1111210,10.1021/np9004882,19863083,CHEMBL1154793,"The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144.",PUBLICATION,"Four new indolosesquiterpenes, lecanindoles A-D (1-4), were isolated from fermentations of the terrestrial fungus Verticillium lecanii 6144. The structures of compounds 1-4 were elucidated from analysis of spectroscopic data. Compound 2 was reduced to give 4 and its isomer 5. Compound 4 was found to be a potent and selective progesterone receptor agonist with an EC50 of 1.1 +/- 0.4 nM in a cell-based luciferase reporter assay.",,CC1(C)C(=O)CC[C@]2(C)[C@@]3(C)c4[nH]c5ccccc5c4C[C@@H]3CC[C@@]12O,C23H29NO2,CHEMBL1087512,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
612409,nM,IC50,,BAO_0000190,IC50,620577,Antagonist activity at androgen receptor ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay,0,B,,CHEMBL1111210,10.1021/np9004882,19863083,CHEMBL1154793,"The lecanindoles, nonsteroidal progestins from the terrestrial fungus Verticillium lecanii 6144.",PUBLICATION,"Four new indolosesquiterpenes, lecanindoles A-D (1-4), were isolated from fermentations of the terrestrial fungus Verticillium lecanii 6144. The structures of compounds 1-4 were elucidated from analysis of spectroscopic data. Compound 2 was reduced to give 4 and its isomer 5. Compound 4 was found to be a potent and selective progesterone receptor agonist with an EC50 of 1.1 +/- 0.4 nM in a cell-based luciferase reporter assay.",,CC1(C)[C@H](O)CC[C@]2(C)[C@@]3(C)c4[nH]c5ccccc5c4C[C@@H]3CC[C@@]12O,C23H31NO2,CHEMBL1076438,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
621521,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 624727, Entry 1: 624727, ","Entry 0: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, Entry 1: Antagonist activity at AR in human MDA-kb2 cells co-transfected with MMTV-luc assessed as decrease in DHT-induced luciferase activity by reporter gene assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1113403, Entry 1: CHEMBL1113403, ","Entry 0: 10.1016/j.bmcl.2010.02.059, Entry 1: 10.1016/j.bmcl.2010.02.059, ","Entry 0: 20226658, Entry 1: 20226658, ","Entry 0: CHEMBL1156958, Entry 1: CHEMBL1156958, ","Entry 0: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., Entry 1: Effect of essential oils, such as raspberry ketone and its derivatives, on antiandrogenic activity based on in vitro reporter gene assay., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., Entry 1: The effect of essential oils, such as raspberry ketone, on androgen (AR) receptor was investigated using a MDA-kb2 human breast cancer cell line for predicting potential AR activity. Among them, eugenol had the highest AR antagonistic activity with its IC(50) value of 19 microM. Raspberry ketone, which has threefold higher anti-obese activity than that of capsaicin, also had AR antagonist activity with its IC(50) value of 252 microM. Based on these findings, a more precise CoMFA model was proposed as follows: pIC(50) [log (1/IC(50))]=3.77+[CoMFA field terms] (n=39, s=0.249, r(2)=0.834, s(cv)=0.507, q(2)=0.311 (three components)., ",,CC(=O)Cc1ccc(O)cc1,C9H10O2,CHEMBL1090553,416869.38,420000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1565.31,416869.38,418434.69,418434.69,420000.0,5.621627682,5.621627682,5.619999996,3.378372318,3.378372318,3.380000004,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,418434.69,418434.69,416869.38,420000.0,3.3783723178046063,3.3783723178046063,3.380000003615395,3.3767507096020997,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
625315,nM,IC50,,BAO_0000190,IC50,629570,Inhibition of androgen receptor,0,B,,CHEMBL1120988,10.1021/jm1002827,20408553,CHEMBL1157753,Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.,PUBLICATION,"A number of known 1,4-dihydropyridine CCBs were identified as having comparable potency to the steroidal MR antagonist eplerenone. Chiral resolution of mebudipine revealed that MR and CCB activity reside in opposite enantiomers. Small molecule X-ray crystal structures showed that the C4 stereochemistry of optimized selective MR analogues, e.g. 5, is consistent with MR-active mebudipine. Molecular modeling supports a binding pose consistent with that previously proposed for DHP diesters.",,CCCC1=C(C(=O)OCC)[C@H](c2ccnc3ccccc23)C(C#N)=C(C)N1,C22H23N3O2,CHEMBL1094797,730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,730.0,730.0,730.0,730.0,2.86332286,2.86332286,2.86332286,6.13667714,6.13667714,6.13667714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,730.0,730.0,730.0,730.0,6.136677139879544,6.136677139879544,6.136677139879544,6.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
626453,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 649966, Entry 1: 792912, Entry 2: 974217, Entry 3: 1438887, Entry 4: 2222791, ","Entry 0: Antagonist activity at androgen receptor, Entry 1: Displacement of [3H]testosterone from AR, Entry 2: Antagonist activity at androgen receptor (unknown origin) by NH Pro assay, Entry 3: Displacement of [3H]testosterone from androgen receptor (unknown origin) expressed in 293 cells after 16 hrs by scintillation counting, Entry 4: Displacement of [3H]-methyltrienolene from human androgen receptor incubated overnight by liquid scintillation counting analysis, ",2,"Entry 0: F, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, ",,"Entry 0: CHEMBL1219664, Entry 1: CHEMBL1929758, Entry 2: CHEMBL2411351, Entry 3: CHEMBL3381812, Entry 4: CHEMBL5136125, ","Entry 0: 10.1021/jm100505n, Entry 1: 10.1021/jm2011645, Entry 2: 10.1016/j.bmcl.2013.05.077, Entry 3: 10.1016/j.bmc.2014.07.038, Entry 4: 10.1021/acs.jmedchem.2c00402, ","Entry 0: 20672822, Entry 1: 22074142, Entry 2: 23777778, Entry 3: 25187277, Entry 4: 35652647, ","Entry 0: CHEMBL1212897, Entry 1: CHEMBL1926625, Entry 2: CHEMBL2407028, Entry 3: CHEMBL3351638, Entry 4: CHEMBL5131538, ","Entry 0: Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy., Entry 1: Identification of benzoxazin-3-one derivatives as novel, potent, and selective nonsteroidal mineralocorticoid receptor antagonists., Entry 2: Discovery of novel oxazolidinedione derivatives as potent and selective mineralocorticoid receptor antagonists., Entry 3: Discovery of 6-[5-(4-fluorophenyl)-3-methyl-pyrazol-4-yl]-benzoxazin-3-one derivatives as novel selective nonsteroidal mineralocorticoid receptor antagonists., Entry 4: Discovery of Apararenone (MT-3995) as a Highly Selective, Potent, and Novel Nonsteroidal Mineralocorticoid Receptor Antagonist., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies., Entry 1: Mineralocorticoid receptor (MR) blockade has come into focus as a promising approach for the treatment of cardiovascular diseases such as hypertension and congestive heart failure. In order to identify a novel class of nonsteroidal MR antagonists that exhibit significant potency and good selectivity over other steroidal hormone receptors, we designed a novel series of benzoxazin-3-one derivatives and synthesized them from 6-(7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazin-6-yl)-2H-1,4-benzoxazin-3(4H)-one (1a), high-throughput screening (HTS) hit compound. Our design was based on a crystal structure of an MR/compound complex and a docking model. In the course of lead generation from 1a, a 1,2-diaryl framework was characterized as a key structure with high binding affinity. On the basis of scaffold hopping and optimization studies, benzoxazin-3-one derivatives possessing 1-phenyl-3-trifluoromethylpyrazol-5-yl moiety at the 6-position were identified as a novel series of potent and selective MR antagonists. Among these compounds, 6-[1-(4-fluoro-2-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-5-yl]-2H-1,4-benzoxazin-3(4H)-one (14n) showed highly potent activity and good selectivity and also exhibited a significant antihypertensive effect in deoxycorticosterone acetate-salt hypertensive rats. On the basis of these results, compound 14n was progressed for further pharmacological evaluation., Entry 2: Novel oxazolidinedione analogs were discovered as potent and selective mineralocorticoid receptor (MR) antagonists. Structure-activity relationship (SAR) studies were focused on improving the potency and microsomal stability. Selected compounds demonstrated excellent MR activity, reasonable nuclear hormone receptor selectivity, and acceptable rat pharmacokinetics., Entry 3: In the course of our study on selective nonsteroidal mineralocorticoid receptor (MR) antagonists, a series of novel benzoxazine derivatives possessing an azole ring as the core scaffold was designed for the purpose of attenuating the partial agonistic activity of the previously reported dihydropyrrol-2-one derivatives. Screening of alternative azole rings identified 1,3-dimethyl pyrazole 6a as a lead compound with reduced partial agonistic activity. Subsequent replacement of the 1-methyl group of the pyrazole ring with larger lipophilic side chains or polar side chains targeting Arg817 and Gln776 increased MR binding activity while maintaining the agonistic response at the lower level. Among these compounds, 6-[1-(2,2-difluoro-3-hydroxypropyl)-5-(4-fluorophenyl)-3-methyl-1H-pyrazol-4-yl]-2H-1,4-benzoxazin-3(4H)-one (37a) showed highly potent in vitro activity, high selectivity versus other steroid hormone receptors, and good pharmacokinetic profiles. Oral administration of 37a in deoxycorticosterone acetate-salt hypertensive rats showed a significant blood pressure-lowering effect with no signs of antiandrogenic effects., Entry 4: Overactivation of the mineralocorticoid receptor (MR) is involved in many diseases, such as hypertension, kidney disease, and heart failure. Thus, MR antagonists (MRAs) are expected to be beneficial to patients with these diseases. In order to identify novel nonsteroidal MRAs that overcome the issues of already marketed steroidal MRAs, we searched for new compounds guided by our hypothesis that T-shaped compounds with a hydrophobic core structure, two polar functional groups at both extremities able to interact with MR, and a bulky substituent that can interfere with the folding of the C-terminal helix 12 may exhibit antagonist activity toward MR. We discovered that the novel 1,4-benzoxazin-3-one derivative <b>19</b> (apararenone: MT-3995) acted as a highly selective and potent nonsteroidal MRA. Apararenone exhibited a more potent antihypertensive and organ-protective activity than steroidal MRA eplerenone in a primary aldosteronism rat model obtained by infusing aldosterone in uninephrectomized rats., ",,COC(=O)[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@@]23O[C@@H]2C[C@@]2(C)[C@@H](CC[C@@]24CCC(=O)O4)[C@H]13,C24H30O6,CHEMBL1095097,10000.0,10000.0,10000.0,17000.0,20000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4270.831301,10000.0,13400.0,10000.0,20000.0,4.127104798,4.0,4.0,4.872895202,5.0,5.0,5,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
626455,nM,IC50,,BAO_0000190,IC50,629570,Inhibition of androgen receptor,0,B,,CHEMBL1120988,10.1021/jm1002827,20408553,CHEMBL1157753,Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.,PUBLICATION,"A number of known 1,4-dihydropyridine CCBs were identified as having comparable potency to the steroidal MR antagonist eplerenone. Chiral resolution of mebudipine revealed that MR and CCB activity reside in opposite enantiomers. Small molecule X-ray crystal structures showed that the C4 stereochemistry of optimized selective MR analogues, e.g. 5, is consistent with MR-active mebudipine. Molecular modeling supports a binding pose consistent with that previously proposed for DHP diesters.",,COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,C20H24N2O6,CHEMBL1099083,1270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1270.0,1270.0,1270.0,1270.0,3.103803721,3.103803721,3.103803721,5.896196279,5.896196279,5.896196279,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1270.0,1270.0,1270.0,1270.0,5.896196279044043,5.896196279044043,5.896196279044043,5.896196279044043,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
626549,nM,IC50,,BAO_0000190,IC50,629570,Inhibition of androgen receptor,0,B,,CHEMBL1120988,10.1021/jm1002827,20408553,CHEMBL1157753,Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.,PUBLICATION,"A number of known 1,4-dihydropyridine CCBs were identified as having comparable potency to the steroidal MR antagonist eplerenone. Chiral resolution of mebudipine revealed that MR and CCB activity reside in opposite enantiomers. Small molecule X-ray crystal structures showed that the C4 stereochemistry of optimized selective MR analogues, e.g. 5, is consistent with MR-active mebudipine. Molecular modeling supports a binding pose consistent with that previously proposed for DHP diesters.",,CC1=C(C#N)[C@@H](c2ccc(F)cc2Cl)C(C(=O)OC(C)(C)C)=C(C)N1,C19H20ClFN2O2,CHEMBL1097751,246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,246.0,246.0,246.0,246.0,2.390935107,2.390935107,2.390935107,6.609064893,6.609064893,6.609064893,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,246.0,246.0,246.0,246.0,6.609064892896621,6.609064892896621,6.609064892896621,6.609064892896621,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
626622,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 629229, Entry 1: 629233, Entry 2: 629235, Entry 3: 687028, Entry 4: 687031, Entry 5: 2227402, ","Entry 0: Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as effect on cell proliferation after 6 days, Entry 2: Antagonist activity at AR in bicalutamide-resistant human LNCAP cells assessed as effect on cell proliferation after 6 days, Entry 3: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 4: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, Entry 5: Binding affinity to Androgen receptor (unknown origin), ",3,"Entry 0: B, Entry 1: F, Entry 2: F, Entry 3: F, Entry 4: F, Entry 5: B, ",,"Entry 0: CHEMBL1121343, Entry 1: CHEMBL1121347, Entry 2: CHEMBL1121349, Entry 3: CHEMBL1291499, Entry 4: CHEMBL1291551, Entry 5: CHEMBL5140915, ","Entry 0: 10.1016/j.bmc.2010.03.036, Entry 1: 10.1016/j.bmc.2010.03.036, Entry 2: 10.1016/j.bmc.2010.03.036, Entry 3: 10.1016/j.bmc.2010.10.023, Entry 4: 10.1016/j.bmc.2010.10.023, Entry 5: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 20381361, Entry 1: 20381361, Entry 2: 20381361, Entry 3: 21050768, Entry 4: 21050768, Entry 5: 35786895, ","Entry 0: CHEMBL1158555, Entry 1: CHEMBL1158555, Entry 2: CHEMBL1158555, Entry 3: CHEMBL1287756, Entry 4: CHEMBL1287756, Entry 5: CHEMBL5137058, ","Entry 0: Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Entry 1: Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Entry 2: Structure-activity relationships of bioisosteric replacement of the carboxylic acid in novel androgen receptor pure antagonists., Entry 3: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 4: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 5: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently., Entry 2: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of hormone refractory prostate cancer. CH4933468 (32d) with a sulfonamide side chain not only exhibited antagonistic activity with no agonistic activity in the reporter gene assay but also inhibited the growth of bicalutamide-resistant cell lines. This compound also inhibited tumor growth of the LNCaP xenograft in mice dose-dependently., Entry 3: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 4: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 5: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1CCCS(N)(=O)=O,C15H17ClN4O3S2,CHEMBL1099086,10.0,12.0,200.0,410.0,440.0,440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,189.0855186,10.0,252.0,305.0,440.0,2.401400541,2.484299839,1.0,6.598599459,6.515700161,8.0,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,410.0,410.0,410.0,410.0,6.3872161432802645,6.3872161432802645,6.3872161432802645,6.3872161432802645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
630886,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, Entry 8: BAO_0000190, Entry 9: BAO_0000190, Entry 10: BAO_0000190, Entry 11: BAO_0000190, Entry 12: BAO_0000190, Entry 13: BAO_0000190, Entry 14: BAO_0000190, Entry 15: BAO_0000190, Entry 16: BAO_0000190, Entry 17: BAO_0000190, Entry 18: BAO_0000190, Entry 19: BAO_0000190, Entry 20: BAO_0000190, Entry 21: BAO_0000190, Entry 22: BAO_0000190, Entry 23: BAO_0000190, Entry 24: BAO_0000190, Entry 25: BAO_0000190, Entry 26: BAO_0000190, Entry 27: BAO_0000190, ",IC50,"Entry 0: 933427, Entry 1: 991860, Entry 2: 1591302, Entry 3: 1621367, Entry 4: 1726360, Entry 5: 1803383, Entry 6: 1803387, Entry 7: 1847878, Entry 8: 1909470, Entry 9: 2031517, Entry 10: 2031518, Entry 11: 2031846, Entry 12: 2022761, Entry 13: 2034916, Entry 14: 2055578, Entry 15: 2101892, Entry 16: 2111612, Entry 17: 2111625, Entry 18: 2119486, Entry 19: 2127796, Entry 20: 2172739, Entry 21: 2160328, Entry 22: 2172740, Entry 23: 2172741, Entry 24: 2194588, Entry 25: 2207001, Entry 26: 2207015, Entry 27: 2230827, ","Entry 0: Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days, Entry 1: Displacement of Fluormone AL Green from androgen receptor ligand binding domain (unknown origin) after 4 hrs by fluorescence polarization assay, Entry 2: Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay, Entry 3: Displacement of [18F]-FDHT from androgen receptor in human LNCAP/AR cells, Entry 4: Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay, Entry 5: Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay, Entry 6: Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay, Entry 7: Competitive displacement of [3H]R1881 from human AR-LBD expressed in LNCaP cells incubated for 24 hrs by scintillation counting method based radioligand competitive binding assay, Entry 8: Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay, Entry 9: Displacement of fluormone-AL green from GST-tagged androgen receptor LBD (unknown origin) measured after 4 hrs by fluorescence polarization assay, Entry 10: Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay, Entry 11: Antagonist activity at Androgen receptor (unknown origin) expressed in COS7 cells by dual luciferase reporter gene assay relative to control, Entry 12: Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay, Entry 13: Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay, Entry 14: Inhibition of androgen receptor (unknown origin), Entry 15: Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay, Entry 16: Displacement of [3H]methyltrienolone from wild-type androgen receptor in human LNCaP cells incubated for 24 hrs by scintillation counting analysis, Entry 17: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay, Entry 18: Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method, Entry 19: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay, Entry 20: Binding affinity to GST-tagged AR ligand binding domain (unknown origin) measured after 4 hrs by fluorescence polarization assay, Entry 21: Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay, Entry 22: Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay, Entry 23: Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP assessed as decrease in PSA level, Entry 24: Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay, Entry 25: Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay, Entry 26: Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay, Entry 27: Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay, ","11,13,17","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, Entry 5: B, Entry 6: B, Entry 7: B, Entry 8: B, Entry 9: B, Entry 10: B, Entry 11: B, Entry 12: B, Entry 13: B, Entry 14: B, Entry 15: B, Entry 16: B, Entry 17: B, Entry 18: B, Entry 19: B, Entry 20: B, Entry 21: B, Entry 22: B, Entry 23: B, Entry 24: B, Entry 25: B, Entry 26: B, Entry 27: B, ",,"Entry 0: CHEMBL2318839, Entry 1: CHEMBL2446110, Entry 2: CHEMBL3829948, Entry 3: CHEMBL3863650, Entry 4: CHEMBL4141638, Entry 5: CHEMBL4275675, Entry 6: CHEMBL4275679, Entry 7: CHEMBL4348419, Entry 8: CHEMBL4411916, Entry 9: CHEMBL4685675, Entry 10: CHEMBL4685676, Entry 11: CHEMBL4686004, Entry 12: CHEMBL4676574, Entry 13: CHEMBL4689074, Entry 14: CHEMBL4710579, Entry 15: CHEMBL4810288, Entry 16: CHEMBL4820462, Entry 17: CHEMBL4820475, Entry 18: CHEMBL4828552, Entry 19: CHEMBL4837141, Entry 20: CHEMBL5057873, Entry 21: CHEMBL5045078, Entry 22: CHEMBL5057874, Entry 23: CHEMBL5057875, Entry 24: CHEMBL5106948, Entry 25: CHEMBL5119709, Entry 26: CHEMBL5119723, Entry 27: CHEMBL5144599, ","Entry 0: 10.1021/jm3015712, Entry 1: 10.1021/jm301714s, Entry 2: 10.1016/j.bmcl.2016.06.001, Entry 3: 10.1016/j.bmcl.2016.09.058, Entry 4: 10.1016/j.ejmech.2017.10.031, Entry 5: 10.1016/j.ejmech.2018.08.059, Entry 6: 10.1016/j.ejmech.2018.08.059, Entry 7: 10.1016/j.ejmech.2019.03.041, Entry 8: 10.1021/acs.jmedchem.8b00973, Entry 9: 10.1016/j.ejmech.2020.112156, Entry 10: 10.1016/j.ejmech.2020.112156, Entry 11: 10.1016/j.ejmech.2020.112196, Entry 12: 10.1021/acs.jmedchem.0c00943, Entry 13: 10.1016/j.bmc.2020.115953, Entry 14: 10.1016/j.ejmech.2020.112667, Entry 15: 10.1021/acs.jmedchem.1c00439, Entry 16: 10.1021/acs.jmedchem.0c01563, Entry 17: 10.1021/acs.jmedchem.0c01563, Entry 18: 10.1021/acs.jmedchem.1c00681, Entry 19: 10.1021/acsmedchemlett.1c00032, Entry 20: 10.1021/acs.jmedchem.1c01287, Entry 21: 10.1021/acs.jmedchem.1c01938, Entry 22: 10.1021/acs.jmedchem.1c01287, Entry 23: 10.1021/acs.jmedchem.1c01287, Entry 24: 10.1021/acs.jmedchem.2c00912, Entry 25: 10.1021/acs.jmedchem.2c01164, Entry 26: 10.1021/acs.jmedchem.2c01164, Entry 27: 10.1016/j.bmcl.2021.128441, ","Entry 0: 23301637, Entry 1: 24044500, Entry 2: 27301368, Entry 3: 27717544, Entry 4: 29117897, Entry 5: 30193215, Entry 6: 30193215, Entry 7: 30925341, Entry 8: 30525603, Entry 9: 32114360, Entry 10: 32114360, Entry 11: 32169785, Entry 12: 33095584, Entry 13: 33388655, Entry 14: 32911308, Entry 15: 34269581, Entry 16: 33470111, Entry 17: 33470111, Entry 18: 34661404, Entry 19: 34422225, Entry 20: 34809430, Entry 21: 35077161, Entry 22: 34809430, Entry 23: 34809430, Entry 24: 36154033, Entry 25: 36070471, Entry 26: 36070471, Entry 27: 34767912, ","Entry 0: CHEMBL2311268, Entry 1: CHEMBL2440058, Entry 2: CHEMBL3826911, Entry 3: CHEMBL3862016, Entry 4: CHEMBL4138152, Entry 5: CHEMBL4270637, Entry 6: CHEMBL4270637, Entry 7: CHEMBL4346686, Entry 8: CHEMBL4411271, Entry 9: CHEMBL4680213, Entry 10: CHEMBL4680213, Entry 11: CHEMBL4680224, Entry 12: CHEMBL4673256, Entry 13: CHEMBL4680336, Entry 14: CHEMBL4706566, Entry 15: CHEMBL4808211, Entry 16: CHEMBL4819022, Entry 17: CHEMBL4819022, Entry 18: CHEMBL4825767, Entry 19: CHEMBL4834497, Entry 20: CHEMBL5055679, Entry 21: CHEMBL5042532, Entry 22: CHEMBL5055679, Entry 23: CHEMBL5055679, Entry 24: CHEMBL5104187, Entry 25: CHEMBL5113526, Entry 26: CHEMBL5113526, Entry 27: CHEMBL5143530, ","Entry 0: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., Entry 1: Synthesis and structure-activity relationship studies of novel dihydropyridones as androgen receptor modulators., Entry 2: Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety., Entry 3: Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors., Entry 4: Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents., Entry 5: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 6: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 7: Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer., Entry 8: New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity., Entry 9: Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation., Entry 10: Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation., Entry 11: Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists., Entry 12: Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer., Entry 13: Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer., Entry 14: New drug approvals for 2019: Synthesis and clinical applications., Entry 15: Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer., Entry 16: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 17: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 18: Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer., Entry 19: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 20: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., Entry 21: Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2., Entry 22: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., Entry 23: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., Entry 24: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 25: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer., Entry 26: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer., Entry 27: Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, Entry 8: PUBLICATION, Entry 9: PUBLICATION, Entry 10: PUBLICATION, Entry 11: PUBLICATION, Entry 12: PUBLICATION, Entry 13: PUBLICATION, Entry 14: PUBLICATION, Entry 15: PUBLICATION, Entry 16: PUBLICATION, Entry 17: PUBLICATION, Entry 18: PUBLICATION, Entry 19: PUBLICATION, Entry 20: PUBLICATION, Entry 21: PUBLICATION, Entry 22: PUBLICATION, Entry 23: PUBLICATION, Entry 24: PUBLICATION, Entry 25: PUBLICATION, Entry 26: PUBLICATION, Entry 27: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (  J. Med. Chem.     2011 .  54  ,   8563  ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines., Entry 1: A library of 3-hydroxy-2,3-dihydropyridones was synthesized, and their activities as antiandrogens were tested in the human prostate cancer cell line LNCaP. Structure-activity relationship (SAR) studies resulted in the identification of a potent compound whose activity is comparable to that of MDV3100. Homology modeling and molecular mechanics were used to build a structural model of the androgen receptor-ligand binding domain and to investigate the structural basis of the antagonism. The model is qualitatively consistent with the observed SAR. Moreover, the enrichment plot shows that screening with the model performs significantly better than random screening. Therefore, the model probably represents a realistic conformation of the antagonist form and can be utilized for structure-based design of novel antiandrogens., Entry 2: Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target. Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations. Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified., Entry 3: While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20-40% of patients have no response to these agents. It has been stipulated that the lack of response and the development of secondary resistance to these drugs may be due to the presence of AR splice variants. HDAC6 has a role in regulating the androgen receptor (AR) by modulating heat shock protein 90 (Hsp90) acetylation, which controls the nuclear localization and activation of the AR in androgen-dependent and independent scenarios. With dual-acting AR-HDAC6 inhibitors it should be possible to target patients who don't respond to enzalutamide. Herein, we describe the design, synthesis and biological evaluation of dual-acting compounds which target AR and are also specific towards HDAC6. Our efforts led to compound 10 which was found to have potent dual activity (HDAC6 IC50=0.0356M and AR binding IC50=<0.03M). Compound 10 was further evaluated for antagonist and other cell-based activities, in vitro stability and pharmacokinetics., Entry 4: Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising invitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists., Entry 5: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 6: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 7: Prostate cancer (PC) is the second most common malignancy in men worldwide. Among current therapies, two antiandrogens, Abiraterone Acetate and Enzalutamide (Enza) have become the standard of care for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we designed and synthesized a new series of nonsteroidal compounds deriving from the hybridization of Abiraterone (Abi) and Enzalutamide, among which compound 4a featuring the diphenylamine scaffold was identified as a potent and cell selective androgen receptor (AR) antagonist. In cell proliferation assays, compound 4a exhibited better antiproliferative activities than Enzalutamide against AR-overexpressing VCaP cells and 22Rv1 cells bearing H874Y-mutated AR. In addition, 4a suppressed the activity of AR-F876L mutant that confers resistance to Enzalutamide and efficiently blocked R1881-induced PSA and FKBP5 gene expression. In competitive binding assay, compound 4a displayed higher binding affinity to AR than Enzalutamide. These results suggest compound 4a as a potential candidate to treat Enza-resistant CRPC., Entry 8: In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed., Entry 9: Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics., Entry 10: Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics., Entry 11: Prostate cancer (PC) is the most diagnosed type of malignancy in men and the major frequently cause of cancer-related death worldwide. The androgen receptor (AR) has become a promising drug target for the treatment of PC. Here, we reported the design, optimization and evaluation of pyridine tetrahydroisoquinoline thiohydantoin derivatives with improved activity and safety as potent AR antagonists. The most promising compound 42f exhibited potent inhibitory activity on AR and strongly blocked AR nuclear translocation. Moreover, 42f displayed promising invitro antitumor activity toward AR-dependent prostate cancer cell lines (LNCaP) and also demonstrated therapeutic effects in LNCaP xenograft tumor model in mice (TGI: 79%) with no apparent toxicity observed invivo. More importantly, 42f showed negligible penetration of the brain-blood barrier (BBB) compared with enzalutamide. These results provide a foundation for the development of a new class of androgen receptor antagonists for potential therapeutics against PC with lower seizurogenic risk for patients., Entry 12: We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer., Entry 13: Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer., Entry 14: 48 new drugs including 38 chemical entities (33 new chemical entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.S. Food and Drug Administration (FDA) during 2019. These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biological targets and improved therapeutic efficacy. This review aims to provide an overview regarding the synthetic approaches of 33 new chemical entities approved by the FDA in 2019 and their clinical applications., Entry 15: A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers., Entry 16: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 17: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 18: Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics., Entry 19: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 20: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., Entry 21: Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment., Entry 22: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., Entry 23: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., Entry 24: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 25: Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients., Entry 26: Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients., Entry 27: The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window., ",,CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,C21H16F4N4O2S,CHEMBL1082407,14.0,21.0,25.0,36.0,38.0,50.0,70.0,75.0,80.0,90.0,112.0,117.0,117.0,216.0,216.0,216.0,219.0,361.0,450.0,480.0,492.0,647.0,1260.0,3030.0,3970.0,5336.0,5600.0,100000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,18462.8475,14.0,4404.935714,216.0,100000.0,3.643939575,2.334453751,1.146128036,5.356060425,6.665546249,7.853871964,28,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,231.33333333333334,216.0,117.0,361.0,6.635761784264807,6.665546248849069,6.931814138253839,6.442492798094342,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
630944,nM,IC50,,BAO_0000190,IC50,635293,Inhibition of androgen receptor,0,B,,CHEMBL1119491,10.1016/j.bmcl.2010.04.018,20430618,CHEMBL1155473,Optimisation of a pyrazole series of progesterone antagonists; Part 1.,PUBLICATION,The design and synthesis of a novel series of non-steroidal progesterone receptor antagonists is described. Ligand-lipophilicity efficiency (LLE) was used in the selection of a prototype agent for in vivo pharmacology studies.,,CCc1cn(CCO)c(CC)c1Oc1ccc(C#N)cc1,C17H20N2O2,CHEMBL1084770,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
631042,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccccc1,C19H14F3N3OS,CHEMBL1085883,100.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,100.0,150.0,150.0,200.0,2.176091259,2.176091259,2.0,6.823908741,6.823908741,7.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
631058,nM,IC50,,BAO_0000190,IC50,635293,Inhibition of androgen receptor,0,B,,CHEMBL1119491,10.1016/j.bmcl.2010.04.018,20430618,CHEMBL1155473,Optimisation of a pyrazole series of progesterone antagonists; Part 1.,PUBLICATION,The design and synthesis of a novel series of non-steroidal progesterone receptor antagonists is described. Ligand-lipophilicity efficiency (LLE) was used in the selection of a prototype agent for in vivo pharmacology studies.,,CNC(=O)Cn1cc(C2CC2)c(Oc2ccc(C#N)cc2)c1C1CC1,C20H21N3O2,CHEMBL1083754,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
632623,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 634399, Entry 1: 634400, Entry 2: 2227383, Entry 3: 2227458, ","Entry 0: Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting, Entry 1: Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response, Entry 2: Binding affinity to human Androgen receptor, Entry 3: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL1118176, Entry 1: CHEMBL1118177, Entry 2: CHEMBL5140896, Entry 3: CHEMBL5140971, ","Entry 0: 10.1021/jm9018004, Entry 1: 10.1021/jm9018004, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 20462217, Entry 1: 20462217, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL1155517, Entry 1: CHEMBL1155517, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 1: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 1: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC1(C)CN(Cc2ccccc2)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H19F3N2O2,CHEMBL1085593,38.0,38.0,100.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,31.0,38.0,69.0,69.0,100.0,1.838849091,1.838849091,1.579783597,7.161150909,7.161150909,7.420216403,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,38.0,38.0,38.0,38.0,7.42021640338319,7.42021640338319,7.42021640338319,7.42021640338319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
632624,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 634399, Entry 1: 634400, ","Entry 0: Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting, Entry 1: Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1118176, Entry 1: CHEMBL1118177, ","Entry 0: 10.1021/jm9018004, Entry 1: 10.1021/jm9018004, ","Entry 0: 20462217, Entry 1: 20462217, ","Entry 0: CHEMBL1155517, Entry 1: CHEMBL1155517, ","Entry 0: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 1: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 1: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., ",,N#Cc1ccc(Oc2ccc(F)cc2F)cc1C(F)(F)F,C14H6F5NO,CHEMBL1085594,60.0,488.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,214.0,60.0,274.0,274.0,488.0,2.437750563,2.437750563,1.77815125,6.562249437,6.562249437,7.22184875,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,488.0,488.0,488.0,488.0,6.311580177997289,6.311580177997289,6.311580177997289,6.311580177997289,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
632625,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 634399, Entry 1: 634400, ","Entry 0: Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting, Entry 1: Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1118176, Entry 1: CHEMBL1118177, ","Entry 0: 10.1021/jm9018004, Entry 1: 10.1021/jm9018004, ","Entry 0: 20462217, Entry 1: 20462217, ","Entry 0: CHEMBL1155517, Entry 1: CHEMBL1155517, ","Entry 0: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 1: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 1: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., ",,CC1(C)CN(Cc2ccccc2F)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H18F4N2O2,CHEMBL1085819,44.0,174.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,65.0,44.0,109.0,109.0,174.0,2.037426498,2.037426498,1.643452676,6.962573502,6.962573502,7.356547324,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,174.0,174.0,174.0,174.0,6.7594507517174005,6.7594507517174005,6.7594507517174005,6.7594507517174005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
632626,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 634399, Entry 1: 634400, ","Entry 0: Displacement of [3H]DHT from human AR expressed in baculovirus Sf9 cells system by scintillation counting, Entry 1: Antagonist activity at androgen receptor in human MDA-MB-453 cells coexpressing MMTV-ARE reporter gene assessed as inhibition of DHT-induced response, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1118176, Entry 1: CHEMBL1118177, ","Entry 0: 10.1021/jm9018004, Entry 1: 10.1021/jm9018004, ","Entry 0: 20462217, Entry 1: 20462217, ","Entry 0: CHEMBL1155517, Entry 1: CHEMBL1155517, ","Entry 0: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., Entry 1: Rational design of a topical androgen receptor antagonist for the suppression of sebum production with properties suitable for follicular delivery., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., Entry 1: A novel nonsteroidal androgen receptor antagonist, (R)-4-(1-benzyl-4,4-dimethyl-2-oxopyrrolidin-3-yloxy)-2-(trifluoromethyl)benzonitrile (1), for the topical control of sebum production is reported. This compound, which is potent, selective, and efficacious in the clinically validated golden Syrian hamster ear animal model, was designed to be delivered to the pilosebaceous unit, the site of action, preferentially by the follicular route., ",,CSc1ccc(CN2CC(C)(C)[C@@H](Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,C22H21F3N2O2S,CHEMBL1084843,28.0,316.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,144.0,28.0,172.0,172.0,316.0,2.235528447,2.235528447,1.447158031,6.764471553,6.764471553,7.552841969,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,316.0,316.0,316.0,316.0,6.5003129173815966,6.5003129173815966,6.5003129173815966,6.5003129173815966,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
645196,nM,IC50,,BAO_0000190,IC50,637933,Antagonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay,0,F,,CHEMBL1166289,10.1016/j.bmc.2010.04.092,20510622,CHEMBL1165993,Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists.,PUBLICATION,"A novel class of non-steroidal progesterone receptor antagonists with aromatic beta-amino-ketone scaffold have been synthesized and characterized with high binding affinity and great selectivity for the cognate receptors. Among them, compound 22 was shown to be the most potent progesterone receptor antagonist in cotransfection assay and a murine model of ligand-induced decidualization.",,Cc1ccc(C(=O)CC(Nc2ccc([N+](=O)[O-])cc2)c2cccc(F)c2)cc1,C22H19FN2O3,CHEMBL1163598,140.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,140.0,140.0,140.0,140.0,2.146128036,2.146128036,2.146128036,6.853871964,6.853871964,6.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
674387,nM,IC50,,BAO_0000190,IC50,2214674,Inhibition of Androgen receptor (unknown origin),0,B,,CHEMBL5127806,10.1016/j.ejmech.2022.114119,35063736,CHEMBL5126525,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,PUBLICATION,"Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated.",,C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,C19H30O3,CHEMBL1200436,0.808,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.808,0.808,0.808,0.808,-0.092588639,-0.092588639,-0.092588639,9.092588639,9.092588639,9.092588639,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.808,0.808,0.808,0.808,9.092588639225413,9.092588639225413,9.092588639225413,9.092588639225413,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
675254,nM,IC50,,BAO_0000190,IC50,2227484,Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of DNA binding domain of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay,0,B,,CHEMBL5140997,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1,C26H28N3+,CHEMBL1201303,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,190.0,190.0,190.0,190.0,2.278753601,2.278753601,2.278753601,6.721246399,6.721246399,6.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.0,190.0,190.0,190.0,6.721246399047171,6.721246399047171,6.721246399047171,6.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683711,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCCN1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C21H22F3N3O3,CHEMBL1209903,14.0,25.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.5,14.0,19.5,19.5,25.0,1.290034611,1.290034611,1.146128036,7.709965389,7.709965389,7.853871964,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.5,19.5,14.0,25.0,7.709965388637482,7.709965388637482,7.853871964321762,7.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683712,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C21H20F3N3O4,CHEMBL1209904,129.0,549.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,210.0,129.0,339.0,339.0,549.0,2.530199698,2.530199698,2.11058971,6.469800302,6.469800302,6.88941029,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,339.0,339.0,129.0,549.0,6.4698003017969175,6.4698003017969175,6.889410289700751,6.2604276555499085,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683713,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CC(C)C(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H22F3N3O4,CHEMBL1209905,215.0,1610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,697.5,215.0,912.5,912.5,1610.0,2.960232873,2.960232873,2.33243846,6.039767127,6.039767127,6.66756154,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,912.5,912.5,215.0,1610.0,6.039767126871488,6.039767126871488,6.667561540084395,5.79317412396815,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683714,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(C(=O)C3CC3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H20F3N3O4,CHEMBL1209906,69.0,404.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,167.5,69.0,236.5,236.5,404.0,2.373831145,2.373831145,1.838849091,6.626168855,6.626168855,7.161150909,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,236.5,236.5,69.0,404.0,6.62616885492617,6.62616885492617,7.161150909262744,6.393618634889395,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683778,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(C(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C25H20F3N3O4,CHEMBL1209970,54.0,177.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,61.5,54.0,115.5,115.5,177.0,2.062581984,2.062581984,1.73239376,6.937418016,6.937418016,7.26760624,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,115.5,115.5,54.0,177.0,6.937418015771837,6.937418015771837,7.267606240177032,6.752026733638194,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683779,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CC(C)NC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H23F3N4O4,CHEMBL1209971,876.0,4600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1862.0,876.0,2738.0,2738.0,4600.0,3.437433444,3.437433444,2.942504106,5.562566556,5.562566556,6.057495894,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2738.0,2738.0,876.0,4600.0,5.562566556202029,5.562566556202029,6.057495893831919,5.337242168318426,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683780,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(C(=O)Nc3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C25H21F3N4O4,CHEMBL1209972,16.0,123.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,53.5,16.0,69.5,69.5,123.0,1.841984805,1.841984805,1.204119983,7.158015195,7.158015195,7.795880017,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,69.5,69.5,16.0,123.0,7.158015195409886,7.158015195409886,7.795880017344075,6.910094888560602,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683781,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C21H20F3N3O5,CHEMBL1209973,65.0,590.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,262.5,65.0,327.5,327.5,590.0,2.515211304,2.515211304,1.812913357,6.484788696,6.484788696,7.187086643,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,327.5,327.5,65.0,590.0,6.484788695672198,6.484788695672198,7.187086643357144,6.229147988357856,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683842,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCCOC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H22F3N3O5,CHEMBL1210033,9.3,54.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.35,9.3,31.65,31.65,54.0,1.500373714,1.500373714,0.968482949,7.499626286,7.499626286,8.031517051,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,31.65,31.65,9.3,54.0,7.4996262856466265,7.4996262856466265,8.031517051446064,7.267606240177032,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683843,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(C(=O)Nc3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C25H20F4N4O4,CHEMBL1210034,39.0,104.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,32.5,39.0,71.5,71.5,104.0,1.854306042,1.854306042,1.591064607,7.145693958,7.145693958,7.408935393,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,71.5,71.5,39.0,104.0,7.14569395819892,7.14569395819892,7.4089353929735005,6.982966660701219,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683844,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(S(C)(=O)=O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C19H18F3N3O5S,CHEMBL1210035,205.0,3511.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1653.0,205.0,1858.0,1858.0,3511.0,3.26904571,3.26904571,2.311753861,5.73095429,5.73095429,6.688246139,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1858.0,1858.0,205.0,3511.0,5.730954290342377,5.730954290342377,6.688246138944246,5.454569170534649,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683845,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCS(=O)(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C20H20F3N3O5S,CHEMBL1210036,85.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,257.5,85.0,342.5,342.5,600.0,2.534660576,2.534660576,1.929418926,6.465339424,6.465339424,7.070581074,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,342.5,342.5,85.0,600.0,6.465339424171556,6.465339424171556,7.070581074285707,6.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683899,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(S(=O)(=O)c3ccccc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C24H20F3N3O5S,CHEMBL1210090,99.0,979.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,440.0,99.0,539.0,539.0,979.0,2.731588765,2.731588765,1.995635195,6.268411235,6.268411235,7.004364805,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,539.0,539.0,99.0,979.0,6.268411234813262,6.268411234813262,7.00436480540245,6.009217308196862,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683900,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(S(=O)(=O)c3ccc(F)cc3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C24H19F4N3O5S,CHEMBL1208805,54.0,685.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,315.5,54.0,369.5,369.5,685.0,2.567614443,2.567614443,1.73239376,6.432385557,6.432385557,7.26760624,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,369.5,369.5,54.0,685.0,6.432385557269155,6.432385557269155,7.267606240177032,6.164309428507575,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683901,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(S(=O)(=O)c3ccccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C23H19F3N4O5S,CHEMBL1210091,170.0,1241.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,535.5,170.0,705.5,705.5,1241.0,2.848497018,2.848497018,2.230448921,6.151502982,6.151502982,6.769551079,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,705.5,705.5,170.0,1241.0,6.151502981909633,6.151502981909633,6.769551078621726,5.90622821850127,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683960,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(c3cccc(S(N)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C24H21F3N4O5S,CHEMBL1210150,37.0,337.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,150.0,37.0,187.0,187.0,337.0,2.271841607,2.271841607,1.568201724,6.728158393,6.728158393,7.431798276,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,187.0,187.0,37.0,337.0,6.728158393463501,6.728158393463501,7.431798275933005,6.4723700991286615,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683961,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(c3cccc(S(C)(=O)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C25H22F3N3O5S,CHEMBL1210151,7.4,150.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,71.3,7.4,78.7,78.7,150.0,1.895974732,1.895974732,0.86923172,7.104025268,7.104025268,8.13076828,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,78.7,78.7,7.4,150.0,7.104025267640935,7.104025267640935,8.130768280269024,6.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
683962,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(c3cc(Cl)ncn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H17ClF3N5O3,CHEMBL1210152,11.0,104.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,46.5,11.0,57.5,57.5,104.0,1.759667845,1.759667845,1.041392685,7.240332155,7.240332155,7.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,57.5,57.5,11.0,104.0,7.2403321553103694,7.2403321553103694,7.958607314841775,6.982966660701219,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684025,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(c3ncccn3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H18F3N5O3,CHEMBL1210214,31.0,377.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,173.0,31.0,204.0,204.0,377.0,2.309630167,2.309630167,1.491361694,6.690369833,6.690369833,7.508638306,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,204.0,204.0,31.0,377.0,6.690369832574102,6.690369832574102,7.508638306165727,6.423658649794207,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684599,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(c3cccc(C(N)=O)c3)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C25H21F3N4O4,CHEMBL1210783,7.4,127.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,59.8,7.4,67.2,67.2,127.0,1.827369273,1.827369273,0.86923172,7.172630727,7.172630727,8.13076828,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,67.2,67.2,7.4,127.0,7.172630726946175,7.172630726946175,8.130768280269024,6.896196279044043,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684600,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CNC[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C18H16F3N3O3,CHEMBL1208812,128.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2436.0,128.0,2564.0,2564.0,5000.0,3.408918021,3.408918021,2.10720997,5.591081979,5.591081979,6.89279003,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,2564.0,2564.0,128.0,5000.0,5.59108197915322,5.59108197915322,6.892790030352131,5.301029995663981,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684657,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CN1C(=O)[C@]2(C)O[C@](C)(C1=O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C19H14F3N3O5,CHEMBL1210840,2144.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1428.0,2144.0,3572.0,3572.0,5000.0,3.55291145,3.55291145,3.331224781,5.44708855,5.44708855,5.668775219,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,3572.0,3572.0,2144.0,5000.0,5.4470885497834916,5.4470885497834916,5.668775218979268,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684658,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12O[C@](C)(C(=O)N(CC3CC3)C1=O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C22H18F3N3O5,CHEMBL1210841,873.0,3329.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1228.0,873.0,2101.0,2101.0,3329.0,3.322426052,3.322426052,2.941014244,5.677573948,5.677573948,6.058985756,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2101.0,2101.0,873.0,3329.0,5.677573947594047,5.677573947594047,6.0589857562944305,5.477686204843333,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684659,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CC(C)OC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H22F3N3O5,CHEMBL1210842,12.0,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,28.5,12.0,40.5,40.5,69.0,1.607455023,1.607455023,1.079181246,7.392544977,7.392544977,7.920818754,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,40.5,40.5,12.0,69.0,7.392544976785332,7.392544976785332,7.920818753952375,7.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684660,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CC(C)[N+]1([O-])C(=O)[C@]2(C)O[C@](C)(C1=O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C21H18F3N3O6,CHEMBL1210843,3900.0,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,550.0,3900.0,4450.0,4450.0,5000.0,3.648360011,3.648360011,3.591064607,5.351639989,5.351639989,5.408935393,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4450.0,4450.0,3900.0,5000.0,5.351639989019068,5.351639989019068,5.4089353929735005,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684693,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1803383, Entry 1: 1803384, Entry 2: 1803387, ","Entry 0: Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay, Entry 1: Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay, Entry 2: Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4275675, Entry 1: CHEMBL4275676, Entry 2: CHEMBL4275679, ","Entry 0: 10.1016/j.ejmech.2018.08.059, Entry 1: 10.1016/j.ejmech.2018.08.059, Entry 2: 10.1016/j.ejmech.2018.08.059, ","Entry 0: 30193215, Entry 1: 30193215, Entry 2: 30193215, ","Entry 0: CHEMBL4270637, Entry 1: CHEMBL4270637, Entry 2: CHEMBL4270637, ","Entry 0: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 1: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 2: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 1: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 2: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., ",,COc1ccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)cc1O,C22H14Cl2O3,CHEMBL1210876,340.0,1886.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4236.648466,340.0,4075.333333,1886.0,10000.0,3.610163137,3.275541688,2.531478917,5.389836863,5.724458312,6.468521083,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
684695,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1803383, Entry 1: 1803384, Entry 2: 1803387, ","Entry 0: Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay, Entry 1: Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay, Entry 2: Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4275675, Entry 1: CHEMBL4275676, Entry 2: CHEMBL4275679, ","Entry 0: 10.1016/j.ejmech.2018.08.059, Entry 1: 10.1016/j.ejmech.2018.08.059, Entry 2: 10.1016/j.ejmech.2018.08.059, ","Entry 0: 30193215, Entry 1: 30193215, Entry 2: 30193215, ","Entry 0: CHEMBL4270637, Entry 1: CHEMBL4270637, Entry 2: CHEMBL4270637, ","Entry 0: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 1: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 2: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 1: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 2: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., ",,COc1cccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)c1O,C22H14Cl2O3,CHEMBL1210878,730.0,1480.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4204.307315,730.0,4070.0,1480.0,10000.0,3.609594409,3.170261715,2.86332286,5.390405591,5.829738285,6.13667714,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
684725,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CCNC(=O)N1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C21H21F3N4O4,CHEMBL1210907,313.0,1456.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,571.5,313.0,884.5,884.5,1456.0,2.946697837,2.946697837,2.495544338,6.053302163,6.053302163,6.504455662,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,884.5,884.5,313.0,1456.0,6.0533021627542585,6.0533021627542585,6.504455662453552,5.836838625022982,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684726,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CC(C)N1C(=O)[C@]2(C)O[C@](C)(C1=O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C21H18F3N3O5,CHEMBL1210908,32.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,46.5,32.0,78.5,78.5,125.0,1.894869657,1.894869657,1.505149978,7.105130343,7.105130343,7.494850022,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,78.5,78.5,32.0,125.0,7.105130343254747,7.105130343254747,7.494850021680094,6.903089986991944,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684727,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,C[C@]12CN(O)C[C@](C)(O1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C18H16F3N3O4,CHEMBL1210909,182.0,1280.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,549.0,182.0,731.0,731.0,1280.0,2.863917377,2.863917377,2.260071388,6.136082623,6.136082623,6.739928612,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,731.0,731.0,182.0,1280.0,6.13608262304214,6.13608262304214,6.739928612014925,5.892790030352131,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684728,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 643541, Entry 1: 643543, ","Entry 0: Antagonist activity at human wild type AR expressed in human MDA-MB-435 cells by transactivation assay, Entry 1: Antagonist activity at wild type human AR expressed in human LNCAP cells by transactivation assay, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1212405, Entry 1: CHEMBL1212407, ","Entry 0: 10.1016/j.bmcl.2010.06.034, Entry 1: 10.1016/j.bmcl.2010.06.034, ","Entry 0: 20584610, Entry 1: 20584610, ","Entry 0: CHEMBL1208719, Entry 1: CHEMBL1208719, ","Entry 0: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., Entry 1: Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., Entry 1: A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo., ",,CON1C[C@@]2(C)O[C@@](C)(C1)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C19H18F3N3O4,CHEMBL1210910,24.0,179.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,77.5,24.0,101.5,101.5,179.0,2.006466042,2.006466042,1.380211242,6.993533958,6.993533958,7.619788758,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,101.5,101.5,24.0,179.0,6.993533957750769,6.993533957750769,7.619788758288394,6.747146969020107,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
684777,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1803383, Entry 1: 1803384, Entry 2: 1803387, ","Entry 0: Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay, Entry 1: Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay, Entry 2: Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4275675, Entry 1: CHEMBL4275676, Entry 2: CHEMBL4275679, ","Entry 0: 10.1016/j.ejmech.2018.08.059, Entry 1: 10.1016/j.ejmech.2018.08.059, Entry 2: 10.1016/j.ejmech.2018.08.059, ","Entry 0: 30193215, Entry 1: 30193215, Entry 2: 30193215, ","Entry 0: CHEMBL4270637, Entry 1: CHEMBL4270637, Entry 2: CHEMBL4270637, ","Entry 0: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 1: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 2: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 1: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 2: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., ",,COc1ccc(C=C2c3cccc(Cl)c3C(=O)c3c(Cl)cccc32)c(OC)c1O,C23H16Cl2O4,CHEMBL1210959,170.0,1135.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4424.029712,170.0,3768.333333,1135.0,10000.0,3.576149312,3.054995862,2.230448921,5.423850688,5.945004138,6.769551079,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
686696,nM,IC50,,BAO_0000190,IC50,649966,Antagonist activity at androgen receptor,0,F,,CHEMBL1219664,10.1021/jm100505n,20672822,CHEMBL1212897,"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.",PUBLICATION,"We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.",,N#Cc1ccc(N2N=C(c3ccc(C(=O)O)cc3)C[C@@H]2c2ccc(F)cc2)cc1Cl,C23H15ClFN3O2,CHEMBL1214839,8920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8920.0,8920.0,8920.0,8920.0,3.950364854,3.950364854,3.950364854,5.049635146,5.049635146,5.049635146,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8920.0,8920.0,8920.0,8920.0,5.049635145623877,5.049635145623877,5.049635145623877,5.049635145623877,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
686987,nM,IC50,,BAO_0000190,IC50,649966,Antagonist activity at androgen receptor,0,F,,CHEMBL1219664,10.1021/jm100505n,20672822,CHEMBL1212897,"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.",PUBLICATION,"We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.",,N#Cc1ccc(N2N=C(c3ccc(C(=O)O)cc3)C[C@@H]2C2CCCC2)cc1Cl,C22H20ClN3O2,CHEMBL1215127,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
686990,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 649966, Entry 1: 1349007, ","Entry 0: Antagonist activity at androgen receptor, Entry 1: Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL1219664, Entry 1: CHEMBL3266005, ","Entry 0: 10.1021/jm100505n, Entry 1: 10.1021/jm500206r, ","Entry 0: 20672822, Entry 1: 24738581, ","Entry 0: CHEMBL1212897, Entry 1: CHEMBL3259597, ","Entry 0: Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy., Entry 1: Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies., Entry 1: A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist., ",,COc1cc(C2=NN(c3ccc(C#N)c(Cl)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C23H22ClN3O3,CHEMBL1215130,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
687058,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 649966, Entry 1: 1349007, ","Entry 0: Antagonist activity at androgen receptor, Entry 1: Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL1219664, Entry 1: CHEMBL3266005, ","Entry 0: 10.1021/jm100505n, Entry 1: 10.1021/jm500206r, ","Entry 0: 20672822, Entry 1: 24738581, ","Entry 0: CHEMBL1212897, Entry 1: CHEMBL3259597, ","Entry 0: Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy., Entry 1: Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies., Entry 1: A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist., ",,CCOc1cc(C2=NN(c3ccc(C#N)c(Cl)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C24H24ClN3O3,CHEMBL1215197,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
687193,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 649966, Entry 1: 1349007, ","Entry 0: Antagonist activity at androgen receptor, Entry 1: Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay, ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL1219664, Entry 1: CHEMBL3266005, ","Entry 0: 10.1021/jm100505n, Entry 1: 10.1021/jm500206r, ","Entry 0: 20672822, Entry 1: 24738581, ","Entry 0: CHEMBL1212897, Entry 1: CHEMBL3259597, ","Entry 0: Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy., Entry 1: Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies., Entry 1: A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist., ",,N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1Cl,C24H22ClN3O2,CHEMBL1215331,8910.0,8910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8910.0,8910.0,8910.0,8910.0,3.949877704,3.949877704,3.949877704,5.050122296,5.050122296,5.050122296,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8910.0,8910.0,8910.0,8910.0,5.050122295963125,5.050122295963125,5.050122295963125,5.050122295963125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
687266,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(C)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C16H14ClFN2O2,CHEMBL1215403,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687269,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,CCCC1=C(C(=O)OC)C(c2ccccc2Cl)C(C#N)=C(C)N1,C18H19ClN2O2,CHEMBL1215406,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687345,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,CCCCC1=C(C(=O)OC)C(c2ccccc2Cl)C(C#N)=C(C)N1,C19H21ClN2O2,CHEMBL1215480,900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,900.0,900.0,900.0,900.0,2.954242509,2.954242509,2.954242509,6.045757491,6.045757491,6.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,900.0,900.0,900.0,900.0,6.045757490560675,6.045757490560675,6.045757490560675,6.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687350,nM,IC50,,BAO_0000190,IC50,649966,Antagonist activity at androgen receptor,0,F,,CHEMBL1219664,10.1021/jm100505n,20672822,CHEMBL1212897,"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.",PUBLICATION,"We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.",,N#Cc1ccc(N2N=C3c4ccc(C(=O)O)cc4CC[C@@H]3[C@@H]2C2CCCC2)cc1,C24H23N3O2,CHEMBL1215485,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
687415,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,CCCC1=C(C(=O)OC)C(c2ccc(F)cc2Cl)C(C#N)=C(C)N1,C18H18ClFN2O2,CHEMBL1215549,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,100.0,100.0,100.0,100.0,2.0,2.0,2.0,7.0,7.0,7.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687416,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(C(F)(F)F)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C16H11ClF4N2O2,CHEMBL1215550,800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,800.0,800.0,800.0,800.0,2.903089987,2.903089987,2.903089987,6.096910013,6.096910013,6.096910013,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,800.0,800.0,800.0,800.0,6.096910013008056,6.096910013008056,6.096910013008056,6.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687418,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(Cn2ccnc2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C19H16ClFN4O2,CHEMBL1215552,3900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3900.0,3900.0,3900.0,3900.0,3.591064607,3.591064607,3.591064607,5.408935393,5.408935393,5.408935393,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3900.0,3900.0,3900.0,3900.0,5.4089353929735005,5.4089353929735005,5.4089353929735005,5.4089353929735005,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687486,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(Cn2cccn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C19H16ClFN4O2,CHEMBL1215620,800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,800.0,800.0,800.0,800.0,2.903089987,2.903089987,2.903089987,6.096910013,6.096910013,6.096910013,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,800.0,800.0,800.0,800.0,6.096910013008056,6.096910013008056,6.096910013008056,6.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687487,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(Cn2cncn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C18H15ClFN5O2,CHEMBL1215621,4600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4600.0,4600.0,4600.0,4600.0,3.662757832,3.662757832,3.662757832,5.337242168,5.337242168,5.337242168,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4600.0,4600.0,4600.0,4600.0,5.337242168318426,5.337242168318426,5.337242168318426,5.337242168318426,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687488,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)C1c1ccc(F)cc1Cl,C17H14ClFN6O2,CHEMBL1215622,2700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2700.0,2700.0,2700.0,2700.0,3.431363764,3.431363764,3.431363764,5.568636236,5.568636236,5.568636236,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2700.0,2700.0,2700.0,2700.0,5.568636235841013,5.568636235841013,5.568636235841013,5.568636235841013,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687489,nM,IC50,,BAO_0000190,IC50,649877,Antagonist activity at androgen receptor LBD expressed in human HUH7 cells coexpressing GAL4 by luciferase reporter gene assay,0,F,,CHEMBL1219575,10.1021/jm100506y,20672820,CHEMBL1212896,Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists.,PUBLICATION,"A new 1,4-dihydropyridine 5a, containing a cyano group at the C3 position, was recently reported to possess excellent mineralocorticoid receptor (MR) antagonist in vitro potency and no calcium channel-blocker (CCB) activity. In the present study, we report the structure-activity relationships of this novel series of cyano ester dihydropyridines that resulted in R6 substituted analogues with improved metabolic stability while maintaining excellent MR antagonist activity and selectivity against other nuclear receptors. Further structure optimization with the introduction of five-membered ring heterocycles at R6 resulted in compounds with excellent MR antagonist potency and a suitable pharmacokinetic profile. In vivo studies of a promising tool compound in the Dahl salt-sensitive rat model of hypertension showed similar blood pressure (BP) reduction as the steroidal MR antagonist eplerenone, providing proof-of-concept (POC) for a nonsteroidal, orally efficacious MR antagonist.",,COC(=O)C1=C(Cn2cnnn2)NC(C)=C(C#N)[C@H]1c1ccc(F)cc1Cl,C17H14ClFN6O2,CHEMBL1215623,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
687493,nM,IC50,,BAO_0000190,IC50,649966,Antagonist activity at androgen receptor,0,F,,CHEMBL1219664,10.1021/jm100505n,20672822,CHEMBL1212897,"Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.",PUBLICATION,"We have discovered a novel class of nonsteroidal pyrazoline antagonists of the mineralocorticoid receptor (MR) that show excellent potency and selectivity against other nuclear receptors. Early analogues were poorly soluble and had a propensity to inhibit the hERG channel. Remarkably, both of these challenges were overcome by incorporation of a single carboxylate moiety. Structural modification of carboxylate-containing lead R-4g with a wide range of substituents at each position of the pyrazoline ring resulted in R-12o, which shows excellent activity against MR and reasonable pharmacokinetic profile. Introduction of conformational restriction led to a novel series characterized by exquisite potency and favorable steroid receptor selectivity and pharmacokinetic profile. Oral dosing of 3S,3aR-27d (PF-3882845) in the Dahl salt sensitive preclinical model of salt-induced hypertension and nephropathy showed blood pressure attenuation significantly greater than that with eplerenone, reduction in urinary albumin, and renal protection. As a result of these findings, 3S,3aR-27d was advanced to clinical studies.",,Cc1cc(N2N=C3c4ccc(C(=O)O)cc4CO[C@@H]3[C@@H]2C2CCCC2)ccc1C#N,C24H23N3O3,CHEMBL1215627,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
703288,nM,IC50,,BAO_0000190,IC50,663713,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,0,F,,CHEMBL1250613,10.1016/j.bmc.2010.08.029,20826091,CHEMBL1250541,20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.,PUBLICATION,"Here, the synthesis and the evaluation of novel 20-aminosteroids on androgen receptor (AR) activity is reported. Compounds 11 and 18 of the series inhibit both the wild type and the T877A mutant AR-mediated transactivation indicating AR antagonistic function. Interestingly, minor structural changes such as stereoisomers of the amino lactame moiety exhibit preferences for antagonism among wild type and mutant AR. Other tested nuclear receptors are only weakly or not affected. In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited. Further, the expression of the prostate specific antigen used as a diagnostic marker is also repressed. Finally steroid 18 enhances cellular senescence that might explain in part the growth inhibition mediated by this derivative. Steroids 11 and 18 are the first steroids that act as complete AR antagonists and exhibit AR specificity.",,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@]1(C)CC=CC(=O)N1,C25H37NO2,CHEMBL1253831,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
703289,nM,IC50,,BAO_0000190,IC50,663713,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,0,F,,CHEMBL1250613,10.1016/j.bmc.2010.08.029,20826091,CHEMBL1250541,20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.,PUBLICATION,"Here, the synthesis and the evaluation of novel 20-aminosteroids on androgen receptor (AR) activity is reported. Compounds 11 and 18 of the series inhibit both the wild type and the T877A mutant AR-mediated transactivation indicating AR antagonistic function. Interestingly, minor structural changes such as stereoisomers of the amino lactame moiety exhibit preferences for antagonism among wild type and mutant AR. Other tested nuclear receptors are only weakly or not affected. In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited. Further, the expression of the prostate specific antigen used as a diagnostic marker is also repressed. Finally steroid 18 enhances cellular senescence that might explain in part the growth inhibition mediated by this derivative. Steroids 11 and 18 are the first steroids that act as complete AR antagonists and exhibit AR specificity.",,C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@]1(C)CC=CC(=O)N1,C25H35NO2,CHEMBL1253832,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
704390,nM,IC50,,BAO_0000190,IC50,663713,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,0,F,,CHEMBL1250613,10.1016/j.bmc.2010.08.029,20826091,CHEMBL1250541,20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.,PUBLICATION,"Here, the synthesis and the evaluation of novel 20-aminosteroids on androgen receptor (AR) activity is reported. Compounds 11 and 18 of the series inhibit both the wild type and the T877A mutant AR-mediated transactivation indicating AR antagonistic function. Interestingly, minor structural changes such as stereoisomers of the amino lactame moiety exhibit preferences for antagonism among wild type and mutant AR. Other tested nuclear receptors are only weakly or not affected. In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited. Further, the expression of the prostate specific antigen used as a diagnostic marker is also repressed. Finally steroid 18 enhances cellular senescence that might explain in part the growth inhibition mediated by this derivative. Steroids 11 and 18 are the first steroids that act as complete AR antagonists and exhibit AR specificity.",,C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@@]1(C)CC=CC(=O)N1,C25H37NO2,CHEMBL1254922,2000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2000.0,2000.0,2000.0,2000.0,3.301029996,3.301029996,3.301029996,5.698970004,5.698970004,5.698970004,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2000.0,2000.0,2000.0,2000.0,5.698970004336019,5.698970004336019,5.698970004336019,5.698970004336019,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
704477,nM,IC50,,BAO_0000190,IC50,663713,Antagonist activity at human androgen receptor expressed in human CV1 cells assessed as inhibition of receptor-mediated transactivation by MMTV-luciferase reporter gene assay,0,F,,CHEMBL1250613,10.1016/j.bmc.2010.08.029,20826091,CHEMBL1250541,20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.,PUBLICATION,"Here, the synthesis and the evaluation of novel 20-aminosteroids on androgen receptor (AR) activity is reported. Compounds 11 and 18 of the series inhibit both the wild type and the T877A mutant AR-mediated transactivation indicating AR antagonistic function. Interestingly, minor structural changes such as stereoisomers of the amino lactame moiety exhibit preferences for antagonism among wild type and mutant AR. Other tested nuclear receptors are only weakly or not affected. In line with this, the prostate cancer cell growth of androgen-dependent but not of cancer cells lacking expression of the AR is inhibited. Further, the expression of the prostate specific antigen used as a diagnostic marker is also repressed. Finally steroid 18 enhances cellular senescence that might explain in part the growth inhibition mediated by this derivative. Steroids 11 and 18 are the first steroids that act as complete AR antagonists and exhibit AR specificity.",,C[C@]12CC[C@H]3[C@@H](CC=C4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2[C@@]1(C)CC=CC(=O)N1,C25H35NO2,CHEMBL1255008,2000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2000.0,2000.0,2000.0,2000.0,3.301029996,3.301029996,3.301029996,5.698970004,5.698970004,5.698970004,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2000.0,2000.0,2000.0,2000.0,5.698970004336019,5.698970004336019,5.698970004336019,5.698970004336019,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
712273,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, Entry 7: BAO_0000190, Entry 8: BAO_0000190, Entry 9: BAO_0000190, Entry 10: BAO_0000190, Entry 11: BAO_0000190, Entry 12: BAO_0000190, Entry 13: BAO_0000190, Entry 14: BAO_0000190, Entry 15: BAO_0000190, Entry 16: BAO_0000190, ",mix,"Entry 0: 36107, Entry 1: 36111, Entry 2: 36112, Entry 3: 36122, Entry 4: 36125, Entry 5: 144891, Entry 6: 306188, Entry 7: 306232, Entry 8: 306071, Entry 9: 312581, Entry 10: 474428, Entry 11: 535118, Entry 12: 553970, Entry 13: 634773, Entry 14: 637933, Entry 15: 645023, Entry 16: 1735708, ","Entry 0: Antagonistic activity against human androgen receptor (hAR) in co-transfected CV-1 cells., Entry 1: Displacement of [3H]mibolerone from human Androgen receptor, Entry 2: Antagonist activity against the Androgen Receptor (AR), Entry 3: Inhibitory activity against human Androgen receptor, Entry 4: Inhibition of antagonist activity towards Androgen receptor, Entry 5: In vitro antagonist potency in transactivation assay in CV-1 cells expressing androgen receptor, Entry 6: Inhibition of AR-dimerization in CHO-K1 cells expressing human androgen receptor, Entry 7: Inhibition of human androgen receptor expressed in Escherichia coli, Entry 8: Inhibition of human androgen receptor, Entry 9: Inhibition of human lymph node carcinoma of prostate (LNCaP) cell proliferation, Entry 10: Antagonist activity at human AR ligand binding domain expressed in african green monkey COS7 cells in presence of 5-alpha-dihydrotestosterone by Gal4 hybrid assay, Entry 11: Antagonist activity at androgen receptor by Gal4-DNA binding domain-hormone receptor LBD one-hybrid assay, Entry 12: Antagonist activity at cloned androgen receptor-ligand binding domain expressed in african green monkey COS7 cells by two hybrid luciferase assay, Entry 13: Binding affinity to AR, Entry 14: Antagonist activity at human androgen receptor expressed in african green monkey CV1 cells co-transfected with MMTV-Luc by luciferase reporter gene assay, Entry 15: Antagonist activity at androgen receptor ligand binding domain by two hybrid assay, Entry 16: Antagonist activity at human AR assessed as reduction in DHT-induced transactivation, ","0,2,3,4,5,12,16","Entry 0: F, Entry 1: B, Entry 2: F, Entry 3: B, Entry 4: F, Entry 5: F, Entry 6: B, Entry 7: B, Entry 8: B, Entry 9: F, Entry 10: B, Entry 11: B, Entry 12: B, Entry 13: B, Entry 14: F, Entry 15: B, Entry 16: A, ",,"Entry 0: CHEMBL648072, Entry 1: CHEMBL648076, Entry 2: CHEMBL648077, Entry 3: CHEMBL647748, Entry 4: CHEMBL649557, Entry 5: CHEMBL749964, Entry 6: CHEMBL830982, Entry 7: CHEMBL874560, Entry 8: CHEMBL833026, Entry 9: CHEMBL835247, Entry 10: CHEMBL934261, Entry 11: CHEMBL983681, Entry 12: CHEMBL965388, Entry 13: CHEMBL1119509, Entry 14: CHEMBL1166289, Entry 15: CHEMBL1211472, Entry 16: CHEMBL4151244, ","Entry 0: 10.1021/jm970699s, Entry 1: 10.1016/j.bmcl.2004.02.048, Entry 2: 10.1021/jm025555e, Entry 3: 10.1021/jm950747d, Entry 4: 10.1016/s0960-894x(03)00256-7, Entry 5: 10.1021/jm001000c, Entry 6: 10.1021/jm0342515, Entry 7: 10.1021/jm0342515, Entry 8: 10.1021/jm050205o, Entry 9: 10.1021/jm0342515, Entry 10: 10.1021/jm701080t, Entry 11: 10.1016/j.bmcl.2008.08.015, Entry 12: 10.1016/j.bmc.2008.05.018, Entry 13: 10.1021/jm100447c, Entry 14: 10.1016/j.bmc.2010.04.092, Entry 15: 10.1016/j.bmcl.2010.06.109, Entry 16: 10.1021/acsmedchemlett.8b00058, ","Entry 0: 9484511, Entry 1: 15080982, Entry 2: 12238914, Entry 3: 8627601, Entry 4: 12781198, Entry 5: 11150172, Entry 6: 15456242, Entry 7: 15456242, Entry 8: 16078847, Entry 9: 15456242, Entry 10: 18318463, Entry 11: 18722119, Entry 12: 18504132, Entry 13: 20469868, Entry 14: 20510622, Entry 15: 20638844, Entry 16: 30034593, ","Entry 0: CHEMBL1131477, Entry 1: CHEMBL1147539, Entry 2: CHEMBL1135816, Entry 3: CHEMBL1129561, Entry 4: CHEMBL1144945, Entry 5: CHEMBL1133568, Entry 6: CHEMBL1137214, Entry 7: CHEMBL1137214, Entry 8: CHEMBL1141148, Entry 9: CHEMBL1137214, Entry 10: CHEMBL1144664, Entry 11: CHEMBL1144156, Entry 12: CHEMBL1157410, Entry 13: CHEMBL1155531, Entry 14: CHEMBL1165993, Entry 15: CHEMBL1208786, Entry 16: CHEMBL4145662, ","Entry 0: Synthesis and biological activity of a novel series of nonsteroidal, peripherally selective androgen receptor antagonists derived from 1,2-dihydropyridono[5,6-g]quinolines., Entry 1: Synthesis and biological evaluation of novel, selective, nonsteroidal glucocorticoid receptor antagonists., Entry 2: 6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin- 2-ones: a novel class of potent, selective, and orally active nonsteroidal progesterone receptor antagonists., Entry 3: Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether., Entry 4: Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore., Entry 5: Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist., Entry 6: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 7: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 8: Antidiabetic activity of passive nonsteroidal glucocorticoid receptor modulators., Entry 9: 11beta-alkyl-Delta9-19-nortestosterone derivatives: high-affinity ligands and potent partial agonists of the androgen receptor., Entry 10: Design, synthesis, and SAR of new pyrrole-oxindole progesterone receptor modulators leading to 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1H-indol-5-yl)-1-methyl-1H-pyrrole-2-carbonitrile (WAY-255348)., Entry 11: 1,5-Dihydro-benzo[e][1,4]oxazepin-2(1H)-ones containing a 7-(5'-cyanopyrrol-2-yl) group as nonsteroidal progesterone receptor modulators., Entry 12: 7-aryl 1,5-dihydro-benzo[e][1,4]oxazepin-2-ones and analogs as non-steroidal progesterone receptor antagonists., Entry 13: Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists., Entry 14: Aromatic beta-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists., Entry 15: 1-Methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalene derivatives as non-steroidal progesterone receptor antagonists., Entry 16: Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, Entry 7: PUBLICATION, Entry 8: PUBLICATION, Entry 9: PUBLICATION, Entry 10: PUBLICATION, Entry 11: PUBLICATION, Entry 12: PUBLICATION, Entry 13: PUBLICATION, Entry 14: PUBLICATION, Entry 15: PUBLICATION, Entry 16: PUBLICATION, ","Entry 0: A new nonsteroidal antiandrogenic pharmacophore has been discovered using cell-based cotransfection assays with human androgen receptor (hAR). This series of AR antagonists is structurally characterized by a linear tricyclic 1,2-dihydropyridono[5,6-g]quinoline core. Analogues inhibit AR-mediated reporter gene expression and bind to AR as potently as or better than any known AR antagonists. Several analogues also showed excellent in vivo activity in classic rodent models of AR antagonism, inhibiting growth of rat ventral prostate and seminal vesicles, without accompanying increases in serum gonadotropin and testosterone levels, as is seen with other AR antagonists. Investigations of structure-activity relationships surrounding this pharmacophore resulted in molecules with complete specificity for AR, antagonist activity on an AR mutant commonly observed in prostate cancer patients, and improved in vivo efficacy. Molecules based on this series of compounds have the potential to provide unique and effective clinical opportunities for treatment of prostate cancer and other androgen-dependent diseases., Entry 1: We report the discovery of a novel class of glucocorticoid receptor (GR) antagonists based on the chromene molecular scaffold. The compounds exhibit good functional potency and an improved receptor selectivity profile for GR over other steroid receptors when compared to the classical steroidal GR-antagonist, RU-486., Entry 2: Novel 6-aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones were synthesized and tested as progesterone receptor (PR) antagonists. These compounds were potent and showed good selectivity for PR over other steroid receptors such as the glucocorticoid and androgen receptors (e.g., greater than 80-fold selectivity at PR for 4h). Numerous 6-aryl benzoxazinones (e.g., 4h-j) were active orally in the uterine decidualization and component C3 assays in the rats. In these in vivo models,4h had potencies comparable to mifepristone., Entry 3: A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor., Entry 4: A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring., Entry 5: Herein we describe the chemical synthesis and pharmacological characterization of a novel, highly potent progesterone receptor (PR) antagonist, ZK 230211. The introduction of a 17alpha-pentafluorethyl side chain in the D-ring of the steroid skeleton allowed the combination of high antiprogestagenic activity with little or no other endocrinological effects. In contrast to many other antiprogestins, ZK 230211 did not convert to an agonist in the presence of protein kinase A (PKA) activators and showed high antiprogestagenic activity on both PR isoforms PR-A and PR-B. This high antiprogestagenic activity could also be demonstrated in several in vivo models. Furthermore, this compound displayed only marginal antiglucocorticoid effects. In tumor models ZK 230211 exhibited strong antiproliferative action. The pharmacological properties of ZK 230211 may prove useful in the treatment of endometriosis, leiomyomas, breast cancer, and in hormone replacement therapy., Entry 6: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 7: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 8: Much has been learned about the consequences of glucocorticoid receptor antagonism by studying steroidal active antagonists such as RU-38486 (1). In the liver glucocorticoid receptor antagonism suppresses hepatic glucose production decreasing plasma glucose levels; however, extrahepatic antagonism produces several undesirable side effects including activation of the hypothalamic pituitary adrenal axis. A series of nonsteroidal passive N-(3-dibenzylamino-2-alkyl-phenyl)-methanesulfonamide glucocorticoid receptor modulators was discovered. Liver selective and systemically available members of this series were found and characterized in diabetes and side effect rodent models. A highly liver selective member of this series, acid 14, shows efficacy in the ob/ob model of diabetes. It lowers plasma glucose, cholesterol, and free fatty acid concentrations and reduces the rate of body weight gain. The structurally related systemically available passive modulator 12 lowers glucose, HbA(1c), triglyceride, free fatty acid, and cholesterol levels. Interestingly, it did not acutely activate the hypothalamic pituitary adrenal axis in unstressed CD-1 mice or have the abortive effects observed with 1. These results indicate that passive GR antagonists may have utility as antidiabetic agents., Entry 9: We report the synthesis of novel steroidal androgen receptor ligands comprising 11beta-alkyl-Delta(9)-derivatives of 19-nortestosterone. These compounds are structurally related to the antiprogestin, antiglucocorticoid, and antiandrogen drug mifepristone (RU486). Nortestosterone analogues bearing 11beta-octyl and 11beta-decyl side-chains bind tightly to recombinant AR protein (IC(50) = 6.6 nM and IC(50) = 0.8 nM), block AR dimerization, exhibit activity against LNCaP prostate cancer cells, and comprise partial AR agonists with low antiglucocorticoid activity., Entry 10: We have continued to explore the 3,3-dialkyl-5-aryloxindole series of progesterone receptor (PR) modulators looking for new agents to be used in female healthcare: contraception, fibroids, endometriosis, and certain breast cancers. Previously we reported that subtle structural changes with this and related templates produced functional switches between agonist and antagonist properties ( Fensome et al. Biorg. Med. Chem. Lett. 2002, 12, 3487; 2003, 13, 1317 ). We herein report a new functional switch within the 5-(2-oxoindolin-5-yl)-1 H-pyrrole-2-carbonitrile class of compounds. We found that the size of the 3,3-dialkyl substituent is important for controlling the functional response; thus small groups (dimethyl) afford potent PR antagonists, whereas larger groups (spirocyclohexyl) are PR agonists. The product from our optimization activities in cell-based systems and also for kinetic properties in rodents and nonhuman primates was 5-(7-fluoro-3,3-dimethyl-2-oxo-2,3-dihydro-1 H-indol-5-yl)-1-methyl-1 H-pyrrole-2-carbonitrile 27 (WAY-255348), which demonstrated potent and robust activity on PR antagonist and contraceptive end points in the rat and also in cynomolgus and rhesus monkeys including ovulation inhibition, menses induction, and reproductive tract morphology., Entry 11: A series of novel 7-(5'-cyanopyrrol-2-yl) substituted benzo[1,4]oxazepin-2-ones were prepared and tested for their progesterone receptor (PR) agonist or antagonist activity in the alkaline phosphatase assay using the human T47D breast carcinoma cell line. Both PR agonists and antagonists were achieved with an appropriate choice of 5-substitution. Several analogs were potent PR agonists (e.g., 12 and 13) or PR antagonists (e.g., 18) with good selectivity over other steroid receptors., Entry 12: Novel 7-aryl benzo[1,4]oxazepin-2-ones were synthesized and evaluated as non-steroidal progesterone receptor (PR) modulators. The structure activity relationship of 7-aryl benzo[1,4]oxazepinones was examined using the T47D cell alkaline phosphatase assay. A number of 7-aryl benzo[1,4]oxazepinones such as 10j and 10v demonstrated good in vitro potency (IC(50) of 10-30 nM) and selectivity (over 100-fold) at PR over other steroidal receptors such as glucocorticoid and androgen receptors (GR and AR). Several 7-aryl benzo[1,4]oxazepinones were active in the rat uterine decidualization model. In this in vivo model, compounds 10j and 10u were active at 3 mg/kg when dosed orally., Entry 13: Glucocorticoid receptor (GR) agonists have been used for more than half a century as the most effective treatment of acute and chronic inflammatory conditions despite serious side effects that accompany their extended use that include glucose intolerance, muscle wasting, skin thinning, and osteoporosis. As a starting point for the identification of GR ligands with an improved therapeutic index, we wished to discover selective nonsteroidal GR agonists and antagonists with simplified structure compared to known GR ligands to serve as starting points for the optimization of dissociated GR modulators. To do so, we selected multiple chemical series by structure guided docking studies and evaluated GR agonist activity. From these efforts we identified 5-arylindazole compounds that showed moderate binding to the glucocorticoid receptor (GR) with clear opportunities for further development. Structure guided optimization was used to design arrays that led to potent GR agonists and antagonists. Several in vitro and in vivo experiments were utilized to demonstrate that GR agonist 23a (GSK9027) had a profile similar to that of a classical steroidal GR agonist., Entry 14: A novel class of non-steroidal progesterone receptor antagonists with aromatic beta-amino-ketone scaffold have been synthesized and characterized with high binding affinity and great selectivity for the cognate receptors. Among them, compound 22 was shown to be the most potent progesterone receptor antagonist in cotransfection assay and a murine model of ligand-induced decidualization., Entry 15: Non-steroidal 1-methyl-1H-pyrrole-2-carbonitrile containing tetrahydronaphthalenes and acyclic derivatives were evaluated as novel series of progesterone receptor (PR) antagonists using the T47D cell alkaline phosphatase assay. Moderate to potent PR antagonists were achieved with these scaffolds. Several compounds (e.g., 15 and 20) demonstrated low nanomolar PR antagonist potency and good selectivity versus other steroid receptors., Entry 16: The progesterone receptor (PR) plays an important role in various physiological systems, including female reproduction and the central nervous system, and PR antagonists are thought to be effective not only as contraceptive agents and abortifacients but also in the treatment of various diseases, including hormone-dependent cancers and endometriosis. Here, we identified phenanthridin-6(5H)-one derivatives as a new class of PR antagonists and investigated their structure-activity relationships. Among the synthesized compounds, 37, 40, and 46 exhibited very potent PR antagonistic activity with high selectivity for PR over other nuclear receptors. These compounds are structurally distinct from other nonsteroidal PR antagonists, including cyanoaryl derivatives, and should be useful for further studies of the clinical utility of PR antagonists., ",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C29H35NO2,CHEMBL1276308,1.0,2.2,5.0,5.0,5.0,5.0,7.0,7.0,7.0,6.9,8.0,8.0,8.8,10.0,23.0,63.0,89.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,23.05247362,1.0,15.34117647,6.9,89.0,1.185858666,0.838849091,0.0,7.814141334,8.161150909,9.0,17,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.97142857142857,5.0,1.0,89.0,7.770281599369082,8.301029995663981,9.0,7.050609993355087,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716297,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1,C18H15ClN4O3S2,CHEMBL1289887,100.0,400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,150.0,100.0,250.0,250.0,400.0,2.397940009,2.397940009,2.0,6.602059991,6.602059991,7.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716411,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)c1,C19H15F3N4O3S2,CHEMBL1289999,100.0,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.0,100.0,200.0,200.0,300.0,2.301029996,2.301029996,2.0,6.698970004,6.698970004,7.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716412,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1,C17H14ClN5O3S2,CHEMBL1290000,100.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,250.0,100.0,350.0,350.0,600.0,2.544068044,2.544068044,2.0,6.455931956,6.455931956,7.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716511,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cccc(S(N)(=O)=O)n1,C18H14F3N5O3S2,CHEMBL1290098,100.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,300.0,100.0,400.0,400.0,700.0,2.602059991,2.602059991,2.0,6.397940009,6.397940009,7.0,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716512,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccnc(S(N)(=O)=O)c1,C18H14F3N5O3S2,CHEMBL1290099,80.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,460.0,80.0,540.0,540.0,1000.0,2.73239376,2.73239376,1.903089987,6.26760624,6.26760624,7.096910013,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,80.0,80.0,80.0,80.0,7.096910013008056,7.096910013008056,7.096910013008056,7.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716620,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(Cl)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1,C17H14ClN5O3S2,CHEMBL1290206,50.0,2000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,975.0,50.0,1025.0,1025.0,2000.0,3.010723865,3.010723865,1.698970004,5.989276135,5.989276135,7.301029996,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,50.0,50.0,50.0,50.0,7.301029995663981,7.301029995663981,7.301029995663981,7.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
716621,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 687028, Entry 1: 687031, ","Entry 0: Antagonist activity at human AR expressed in human HeLa cells co-transfected with MMTV-Luc-Hyg after 48 hrs by transient-luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human bicalutamide-resistant LNCAP cells assessed as inhibition of cell proliferation after 6 days, ",0,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1291499, Entry 1: CHEMBL1291551, ","Entry 0: 10.1016/j.bmc.2010.10.023, Entry 1: 10.1016/j.bmc.2010.10.023, ","Entry 0: 21050768, Entry 1: 21050768, ","Entry 0: CHEMBL1287756, Entry 1: CHEMBL1287756, ","Entry 0: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., Entry 1: Design and synthesis of an androgen receptor pure antagonist (CH5137291) for the treatment of castration-resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., Entry 1: A series of 5,5-dimethylthiohydantoin derivatives were synthesized and evaluated for androgen receptor pure antagonistic activities for the treatment of castration-resistant prostate cancer. Since CH4933468, which we reported previously, had a problem with agonist metabolites, novel thiohydantoin derivatives were identified by applying two strategies. One was the replacement of the alkylsulfonamide moiety by a phenylsulfonamide to avoid the production of agonist metabolites. The other was the replacement of the phenyl ring with a pyridine ring to improve in vivo potency and reduce hERG affinity. Pharmacological assays indicated that CH5137291 (17b) was a potent AR pure antagonist which did not produce the agonist metabolite. Moreover, CH5137291 completely inhibited in vivo tumor growth of LNCaP-BC2, a castration-resistant prostate cancer model., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cncc(S(N)(=O)=O)c1,C18H14F3N5O3S2,CHEMBL1290207,30.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,485.0,30.0,515.0,515.0,1000.0,2.711807229,2.711807229,1.477121255,6.288192771,6.288192771,7.522878745,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
795901,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Nc1nc(-c2ccc3ccccc3c2)cs1,C13H10N2S,CHEMBL1372017,9160.0,10600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,720.0,9160.0,9880.0,9880.0,10600.0,3.994756945,3.994756945,3.961895474,5.005243055,5.005243055,5.038104526,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9880.0,9880.0,9160.0,10600.0,5.005243055412372,5.005243055412372,5.03810452633215,4.97469413473523,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
815584,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Fc1ccc(-c2csc(N3CCOCC3)n2)cc1,C13H13FN2OS,CHEMBL1391700,410.0,650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,120.0,410.0,530.0,530.0,650.0,2.72427587,2.72427587,2.612783857,6.27572413,6.27572413,6.387216143,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,530.0,530.0,410.0,650.0,6.275724130399211,6.275724130399211,6.3872161432802645,6.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
827233,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,Fc1ccc(-c2csc(-c3ccncc3)n2)cc1,C14H9FN2S,CHEMBL1403349,1270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1270.0,1270.0,1270.0,1270.0,3.103803721,3.103803721,3.103803721,5.896196279,5.896196279,5.896196279,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1270.0,1270.0,1270.0,1270.0,5.896196279044043,5.896196279044043,5.896196279044043,5.896196279044043,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
839984,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1ccc(-c2csc(-c3ccncc3)n2)cc1,C14H10N2S,CHEMBL1416100,630.0,1200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,285.0,630.0,915.0,915.0,1200.0,2.961421094,2.961421094,2.799340549,6.038578906,6.038578906,6.200659451,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,915.0,915.0,630.0,1200.0,6.0385789059335515,6.0385789059335515,6.200659450546418,5.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
887544,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CS(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C14H15NO3S,CHEMBL1463660,6110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6110.0,6110.0,6110.0,6110.0,3.78604121,3.78604121,3.78604121,5.21395879,5.21395879,5.21395879,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6110.0,6110.0,6110.0,6110.0,5.213958789757446,5.213958789757446,5.213958789757446,5.213958789757446,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
912491,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,Fc1ccc(-c2csc(N3CCSCC3)n2)cc1,C13H13FN2S2,CHEMBL1488607,1590.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1590.0,1590.0,1590.0,1590.0,3.201397124,3.201397124,3.201397124,5.798602876,5.798602876,5.798602876,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1590.0,1590.0,1590.0,1590.0,5.798602875679548,5.798602875679548,5.798602875679548,5.798602875679548,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
972965,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,c1ccc(-c2csc(N3CCSCC3)n2)cc1,C13H14N2S2,CHEMBL1549081,620.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,620.0,620.0,620.0,620.0,2.792391689,2.792391689,2.792391689,6.207608311,6.207608311,6.207608311,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,620.0,620.0,620.0,620.0,6.2076083105017466,6.2076083105017466,6.2076083105017466,6.2076083105017466,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
996164,nM,IC50,,BAO_0000190,IC50,1446997,Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days,0,B,,CHEMBL3374324,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1.O=C([O-])c1cc2ccccc2c(Cc2c(O)c(C(=O)O)cc3ccccc23)c1O,C49H43N3O6,CHEMBL1572280,400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,400.0,400.0,400.0,400.0,2.602059991,2.602059991,2.602059991,6.397940009,6.397940009,6.397940009,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,400.0,400.0,400.0,400.0,6.3979400086720375,6.3979400086720375,6.3979400086720375,6.3979400086720375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1046340,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, Entry 2: 2227453, Entry 3: 2227484, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, Entry 2: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of PSA expression, Entry 3: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of DNA binding domain of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay, ","0,1,2","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, Entry 2: CHEMBL5140966, Entry 3: CHEMBL5140997, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 25062331, Entry 1: 25062331, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,c1ccc(-c2csc(N3CCOCC3)n2)cc1,C13H14N2OS,CHEMBL1623389,280.0,280.0,330.0,330.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,25.0,280.0,305.0,305.0,330.0,2.484299839,2.484299839,2.447158031,6.515700161,6.515700161,6.552841969,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,296.6666666666667,280.0,280.0,330.0,6.527731248074749,6.552841968657781,6.552841968657781,6.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1117936,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(COc1ccc(C#N)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C19H14F3N3O3,CHEMBL1738889,3.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3.8,3.8,3.8,3.8,0.579783597,0.579783597,0.579783597,8.420216403,8.420216403,8.420216403,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3.8,3.8,3.8,3.8,8.42021640338319,8.42021640338319,8.42021640338319,8.42021640338319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1117983,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 791027, Entry 1: 791030, Entry 2: 791031, Entry 3: 933429, ","Entry 0: Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis, Entry 1: Displacement of [3H]DHT from human androgen receptor expressed in Escherichia coli BL21 cells, Entry 2: Displacement of 5-iodoacetamidofluorescein labeled SRC23 peptide CKENALLRYLLDKDD human androgen receptor AF2 site expressed in Escherichia coli BL21 cells by fluorescence polarization assay, Entry 3: Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL1925688, Entry 1: CHEMBL1925691, Entry 2: CHEMBL1925692, Entry 3: CHEMBL2318841, ","Entry 0: 10.1021/jm201098n, Entry 1: 10.1021/jm201098n, Entry 2: 10.1021/jm201098n, Entry 3: 10.1021/jm3015712, ","Entry 0: 22047606, Entry 1: 22047606, Entry 2: 22047606, Entry 3: 23301637, ","Entry 0: CHEMBL1921777, Entry 1: CHEMBL1921777, Entry 2: CHEMBL1921777, Entry 3: CHEMBL2311268, ","Entry 0: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 1: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 2: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 3: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 1: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 2: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 3: The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (  J. Med. Chem.     2011 .  54  ,   8563  ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines., ",,Cc1ccc(OCCn2c(SCCOc3ccccc3)nc3ccccc32)cc1,C24H24N2O2S,CHEMBL1738936,10000.0,13100.0,13100.0,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,16474.29816,10000.0,21550.0,13100.0,50000.0,4.333447274,4.117271296,4.0,4.666552726,4.882728704,5.0,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1117984,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 791027, Entry 1: 791030, Entry 2: 791031, ","Entry 0: Transcriptional activity at human androgen receptor BF3 site stably transfected in eGFP-expressing human LNCAP cells after 5 days by fluorometric analysis, Entry 1: Displacement of [3H]DHT from human androgen receptor expressed in Escherichia coli BL21 cells, Entry 2: Displacement of 5-iodoacetamidofluorescein labeled SRC23 peptide CKENALLRYLLDKDD human androgen receptor AF2 site expressed in Escherichia coli BL21 cells by fluorescence polarization assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL1925688, Entry 1: CHEMBL1925691, Entry 2: CHEMBL1925692, ","Entry 0: 10.1021/jm201098n, Entry 1: 10.1021/jm201098n, Entry 2: 10.1021/jm201098n, ","Entry 0: 22047606, Entry 1: 22047606, Entry 2: 22047606, ","Entry 0: CHEMBL1921777, Entry 1: CHEMBL1921777, Entry 2: CHEMBL1921777, ","Entry 0: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 1: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., Entry 2: Targeting the binding function 3 (BF3) site of the human androgen receptor through virtual screening., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 1: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., Entry 2: The androgen receptor (AR) is the best studied drug target for the treatment of prostate cancer. While there are a number of drugs that target the AR, they all work through the same mechanism of action and are prone to the development of drug resistance. There is a large unmet need for novel AR inhibitors which work through alternative mechanism(s). Recent studies have identified a novel site on the AR called binding function 3 (BF3) that is involved into AR transcriptional activity. In order to identify inhibitors that target the BF3 site, we have conducted a large-scale in silico screen followed by experimental evaluation. A number of compounds were identified that effectively inhibited the AR transcriptional activity with no obvious cytotoxicity. The mechanism of action of these compounds was validated by biochemical assays and X-ray crystallography. These findings lay a foundation for the development of alternative or supplementary therapies capable of combating prostate cancer even in its antiandrogen resistant forms., ",,Cc1ccc(OCCn2c(SCCC(=O)O)nc3ccccc32)cc1,C19H20N2O3S,CHEMBL1738937,10000.0,50000.0,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18856.18083,10000.0,36666.66667,50000.0,50000.0,4.56427143,4.698970004,4.0,4.43572857,4.301029996,5.0,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1149151,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 752066, Entry 1: 752067, Entry 2: 752068, Entry 3: 752069, ","Entry 0: Antagonist activity at wild type androgen receptor expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 1: Antagonist activity at androgen receptor T877A mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 2: Antagonist activity at androgen receptor W741L mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 3: Antagonist activity at androgen receptor W741C mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1786230, Entry 1: CHEMBL1786231, Entry 2: CHEMBL1786232, Entry 3: CHEMBL1786233, ","Entry 0: 10.1021/jm2000097, Entry 1: 10.1021/jm2000097, Entry 2: 10.1021/jm2000097, Entry 3: 10.1021/jm2000097, ","Entry 0: 21506597, Entry 1: 21506597, Entry 2: 21506597, Entry 3: 21506597, ","Entry 0: CHEMBL1782015, Entry 1: CHEMBL1782015, Entry 2: CHEMBL1782015, Entry 3: CHEMBL1782015, ","Entry 0: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 1: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 2: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 3: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 1: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 2: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 3: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., ",,C[C@](O)(CS(=O)(=O)c1cccc2ccccc12)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C22H17F3N2O4S,CHEMBL1782494,3000.0,3000.0,3000.0,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1149152,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 752066, Entry 1: 752067, Entry 2: 752068, Entry 3: 752069, ","Entry 0: Antagonist activity at wild type androgen receptor expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 1: Antagonist activity at androgen receptor T877A mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 2: Antagonist activity at androgen receptor W741L mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 3: Antagonist activity at androgen receptor W741C mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1786230, Entry 1: CHEMBL1786231, Entry 2: CHEMBL1786232, Entry 3: CHEMBL1786233, ","Entry 0: 10.1021/jm2000097, Entry 1: 10.1021/jm2000097, Entry 2: 10.1021/jm2000097, Entry 3: 10.1021/jm2000097, ","Entry 0: 21506597, Entry 1: 21506597, Entry 2: 21506597, Entry 3: 21506597, ","Entry 0: CHEMBL1782015, Entry 1: CHEMBL1782015, Entry 2: CHEMBL1782015, Entry 3: CHEMBL1782015, ","Entry 0: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 1: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 2: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 3: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 1: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 2: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 3: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., ",,C[C@](O)(CS(=O)(=O)c1ccccc1Cc1ccccc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C25H21F3N2O4S,CHEMBL1782495,3000.0,3000.0,3000.0,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1149153,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 752066, Entry 1: 752067, Entry 2: 752068, Entry 3: 752069, ","Entry 0: Antagonist activity at wild type androgen receptor expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 1: Antagonist activity at androgen receptor T877A mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 2: Antagonist activity at androgen receptor W741L mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, Entry 3: Antagonist activity at androgen receptor W741C mutant expressed in african green monkey CV1 cells assessed as inhibition of dihydrotestosterone-induced transcriptional activity by luciferase reporter gene assay, ",0,"Entry 0: F, Entry 1: F, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1786230, Entry 1: CHEMBL1786231, Entry 2: CHEMBL1786232, Entry 3: CHEMBL1786233, ","Entry 0: 10.1021/jm2000097, Entry 1: 10.1021/jm2000097, Entry 2: 10.1021/jm2000097, Entry 3: 10.1021/jm2000097, ","Entry 0: 21506597, Entry 1: 21506597, Entry 2: 21506597, Entry 3: 21506597, ","Entry 0: CHEMBL1782015, Entry 1: CHEMBL1782015, Entry 2: CHEMBL1782015, Entry 3: CHEMBL1782015, ","Entry 0: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 1: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 2: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., Entry 3: Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 1: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 2: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., Entry 3: Several new androgen receptor antagonists were synthesized and found to have varying activities across typically anti-androgen resistant mutants (Thr877  Ala and Trp741  Leu) and markedly improved potency over previously reported pan-antagonists. X-ray crystallography of a new anti-androgen in an androgen receptor mutant (Thr877  Ala) shows that the receptor can accommodate the added bulk presented by phenyl to naphthyl substitution, casting doubt on previous reports of predicted binding orientation and the causes of antagonism in bulky-B-ring antagonists., ",,C[C@](O)(CS(=O)(=O)c1ccccc1-c1ccccc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C24H19F3N2O4S,CHEMBL1782496,3000.0,3000.0,3000.0,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1150311,nM,IC50,,BAO_0000190,IC50,942995,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of transcriptional activity by luciferase and beta-galactosidase reporter gene assay,0,B,,CHEMBL2343831,10.1016/j.bmc.2013.01.060,23462715,CHEMBL2331115,Development of silicon-containing bis-phenol derivatives as androgen receptor antagonists: selectivity switching by C/Si exchange.,PUBLICATION,"We previously reported that bis-phenol derivatives, including LG190178 (3a), possess not only vitamin D receptor (VDR) agonistic activity, but also androgen receptor (AR) antagonistic activity. Here, we describe the design, synthesis and evaluation of silicon-containing bis-phenol derivatives, with the objective of obtaining increased selectivity toward VDR or AR. We found that replacement of the quaternary carbon in the bis-phenol skeleton with silicon increased AR-antagonistic activity and reduced VDR-agonistic activity, that is, the AR selectivity of the silicon-containing compounds was higher than that of corresponding carbon compounds. To our knowledge, this is the first report of nuclear receptor (NR) selectivity switching by sila-substitution (C/Si exchange). Among the compounds synthesized, AR-selective ligand (S,R)-3b exhibited more potent anti-androgenic activity (IC50=0.072 M) than hydroxyflutamide, a well-known androgen antagonist (IC50=1.4 M), in SC-3 cell proliferation assay. These results suggest that sila-substitution is a useful approach for structural development of selective AR ligands.",,CC[Si](CC)(c1ccc(OCC(=O)C(C)(C)C)c(C)c1)c1ccc(OCC(=O)C(C)(C)C)c(C)c1,C30H44O4Si,CHEMBL1783642,6200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6200.0,6200.0,6200.0,6200.0,3.792391689,3.792391689,3.792391689,5.207608311,5.207608311,5.207608311,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6200.0,6200.0,6200.0,6200.0,5.2076083105017466,5.2076083105017466,5.2076083105017466,5.2076083105017466,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1163158,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 812094, Entry 1: 812095, ","Entry 0: Antagonist activity at androgen receptor in human LNCAP cells assessed as decrease in prostate specific antigen mRNA level after 20 hrs by real time RT-PCR analysis, Entry 1: Antagonist activity at androgen receptor in human LNCAP cells assessed as decrease in transmembrane protease serine 2 mRNA level after 20 hrs by real time RT-PCR analysis, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2013561, Entry 1: CHEMBL2013562, ","Entry 0: 10.1016/j.bmcl.2011.12.141, Entry 1: 10.1016/j.bmcl.2011.12.141, ","Entry 0: 22310230, Entry 1: 22310230, ","Entry 0: CHEMBL2010800, Entry 1: CHEMBL2010800, ","Entry 0: Methoxychalcone inhibitors of androgen receptor translocation and function., Entry 1: Methoxychalcone inhibitors of androgen receptor translocation and function., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity., Entry 1: Androgen receptor activity drives incurable castrate-resistant prostate cancer. All approved antiandrogens inhibit androgen receptor-driven transcription, and in addition the second-generation antiandrogen MDV3100 inhibits ligand-activated androgen receptor nuclear translocation, via an unknown mechanism. Here, we report methoxychalcones that lock the heat shock protein 90-androgen receptor complex in the cytoplasm in an androgen-non-responsive state, thus demonstrating a novel chemical scaffold for antiandrogen development and a unique mechanism of antiandrogen activity., ",,COc1ccccc1C(=O)/C=C/c1ccccc1[N+](=O)[O-],C16H13NO4,CHEMBL1802077,600.0,750.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,75.0,600.0,675.0,675.0,750.0,2.829303773,2.829303773,2.77815125,6.170696227,6.170696227,6.22184875,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,675.0,675.0,600.0,750.0,6.170696227168975,6.170696227168975,6.221848749616356,6.1249387366083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177477,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)COC(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C14H12F3NO3,CHEMBL1830768,70.0,113.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,21.5,70.0,91.5,91.5,113.0,1.961421094,1.961421094,1.84509804,7.038578906,7.038578906,7.15490196,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,113.0,113.0,113.0,113.0,6.94692155651658,6.94692155651658,6.94692155651658,6.94692155651658,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177478,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)COC(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C14H12F3NO3,CHEMBL1830769,42.0,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,14.0,42.0,56.0,56.0,70.0,1.748188027,1.748188027,1.62324929,7.251811973,7.251811973,7.37675071,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,70.0,70.0,70.0,70.0,7.154901959985743,7.154901959985743,7.154901959985743,7.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177479,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)COC(=O)[C@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C14H12F3NO3,CHEMBL1830770,1000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4500.0,1000.0,5500.0,5500.0,10000.0,3.740362689,3.740362689,3.0,5.259637311,5.259637311,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1177480,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CNC(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C14H13F3N2O2,CHEMBL1830771,82.0,2790.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1354.0,82.0,1436.0,1436.0,2790.0,3.15715444,3.15715444,1.913813852,5.84284556,5.84284556,7.086186148,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2790.0,2790.0,2790.0,2790.0,5.554395796726403,5.554395796726403,5.554395796726403,5.554395796726403,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177483,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, Entry 3: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, Entry 3: Antagonist activity at human androgen receptor by cell based assay, ","2,3","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, Entry 3: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, Entry 3: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, Entry 3: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, Entry 3: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 3: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C17H19F3N2O2,CHEMBL1830774,24.0,83.0,188.0,225.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,80.36479329,24.0,130.0,135.5,225.0,2.113943352,2.131939295,1.380211242,6.886056648,6.868060705,7.619788758,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,206.5,206.5,188.0,225.0,6.6850799440075805,6.6850799440075805,6.72584215073632,6.647817481888637,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177484,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, Entry 3: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, Entry 3: Antagonist activity at human androgen receptor by cell based assay, ","2,3","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, Entry 3: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, Entry 3: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, Entry 3: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, Entry 3: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 3: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CCCCN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C18H21F3N2O2,CHEMBL1830775,10.0,16.0,91.0,119.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,47.1009554,10.0,59.0,53.5,119.0,1.770852012,1.728353782,1.0,7.229147988,7.271646218,8.0,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,105.0,105.0,91.0,119.0,6.978810700930062,6.978810700930062,7.040958607678906,6.924453038607469,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177487,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CCCC(C)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C19H23F3N2O2,CHEMBL1830778,6.0,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,97.0,6.0,103.0,103.0,200.0,2.012837225,2.012837225,0.77815125,6.987162775,6.987162775,8.22184875,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,200.0,200.0,200.0,200.0,6.698970004336019,6.698970004336019,6.698970004336019,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177488,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CCC(C)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C18H21F3N2O2,CHEMBL1830779,32.0,132.0,9790.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4576.577178,32.0,3318.0,132.0,9790.0,3.520876382,2.120573931,1.505149978,5.479123618,6.879426069,7.494850022,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,9790.0,9790.0,9790.0,9790.0,5.009217308196862,5.009217308196862,5.009217308196862,5.009217308196862,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1177495,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 801332, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1947977, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.11.068, ","Entry 0: 21831636, Entry 1: 22197140, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1944520, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., ",,COC(=O)CN1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C17H17F3N2O4,CHEMBL1830786,303.0,494.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,95.5,303.0,398.5,398.5,494.0,2.600428326,2.600428326,2.481442629,6.399571674,6.399571674,6.518557371,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,494.0,494.0,494.0,494.0,6.306273051076353,6.306273051076353,6.306273051076353,6.306273051076353,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177498,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, Entry 3: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, Entry 3: Antagonist activity at human androgen receptor by cell based assay, ","2,3","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, Entry 3: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, Entry 3: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, Entry 3: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, Entry 3: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 3: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccccc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H19F3N2O2,CHEMBL1830789,11.0,30.0,38.0,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,33.37195679,11.0,44.75,34.0,100.0,1.65079304,1.531478917,1.041392685,7.34920696,7.468521083,7.958607315,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,69.0,69.0,38.0,100.0,7.161150909262744,7.161150909262744,7.42021640338319,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177649,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,COc1cccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)c1,C22H21F3N2O3,CHEMBL1830938,110.0,309.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,99.5,110.0,209.5,209.5,309.0,2.321184027,2.321184027,2.041392685,6.678815973,6.678815973,6.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,309.0,309.0,309.0,309.0,6.510041520575165,6.510041520575165,6.510041520575165,6.510041520575165,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177650,nM,IC50,,BAO_0000190,IC50,768070,Binding affinity to human androgen receptor,0,B,,CHEMBL1833026,10.1016/j.bmcl.2011.07.048,21831636,CHEMBL1828515,Pantolactams as androgen receptor antagonists for the topical suppression of sebum production.,PUBLICATION,"A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds.",,COc1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,C22H21F3N2O3,CHEMBL1830939,284.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,284.0,284.0,284.0,284.0,2.45331834,2.45331834,2.45331834,6.54668166,6.54668166,6.54668166,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,284.0,284.0,284.0,284.0,6.546681659952962,6.546681659952962,6.546681659952962,6.546681659952962,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177651,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, Entry 3: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, Entry 3: Antagonist activity at human androgen receptor by cell based assay, ","2,3","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, Entry 3: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, Entry 3: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, Entry 3: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, Entry 3: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 3: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccccc2F)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H18F4N2O2,CHEMBL1830940,44.0,92.0,112.0,174.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,46.63421491,44.0,105.5,102.0,174.0,2.02325246,2.008600172,1.643452676,6.97674754,6.991399828,7.356547324,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,143.0,143.0,112.0,174.0,6.844663962534939,6.844663962534939,6.950781977329818,6.7594507517174005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177652,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2cccc(F)c2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H18F4N2O2,CHEMBL1830941,48.0,61.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6.5,48.0,54.5,54.5,61.0,1.736396502,1.736396502,1.681241237,7.263603498,7.263603498,7.318758763,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,61.0,61.0,61.0,61.0,7.214670164989233,7.214670164989233,7.214670164989233,7.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177653,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccc(F)cc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H18F4N2O2,CHEMBL1830942,144.0,199.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,27.5,144.0,171.5,171.5,199.0,2.234264124,2.234264124,2.158362492,6.765735876,6.765735876,6.841637508,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,199.0,199.0,199.0,199.0,6.701146923590294,6.701146923590294,6.701146923590294,6.701146923590294,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177654,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccccc2O)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H19F3N2O3,CHEMBL1830943,13.0,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.0,13.0,15.0,15.0,17.0,1.176091259,1.176091259,1.113943352,7.823908741,7.823908741,7.886056648,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,17.0,17.0,17.0,17.0,7.769551078621726,7.769551078621726,7.769551078621726,7.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177655,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2cccc(O)c2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H19F3N2O3,CHEMBL1830944,11.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,294.5,11.0,305.5,305.5,600.0,2.485011215,2.485011215,1.041392685,6.514988785,6.514988785,7.958607315,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,600.0,600.0,600.0,600.0,6.221848749616356,6.221848749616356,6.221848749616356,6.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177656,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccc(O)cc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C21H19F3N2O3,CHEMBL1830945,17.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,7.5,17.0,24.5,24.5,32.0,1.389166084,1.389166084,1.230448921,7.610833916,7.610833916,7.769551079,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177657,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768070, Entry 2: 768071, Entry 3: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Binding affinity to human androgen receptor, Entry 2: Antagonist activity at human androgen receptor by cell based assay, Entry 3: Antagonist activity at human androgen receptor by cell based assay, ","2,3","Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833026, Entry 2: CHEMBL1833027, Entry 3: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, Entry 2: 10.1016/j.bmcl.2011.07.048, Entry 3: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, Entry 2: 21831636, Entry 3: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, Entry 2: CHEMBL1828515, Entry 3: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 2: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 3: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 2: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 3: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CSc1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)cc1,C22H21F3N2O2S,CHEMBL1830946,28.0,51.0,187.0,316.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,115.6816753,28.0,145.5,119.0,316.0,2.162862993,2.075546961,1.447158031,6.837137007,6.924453039,7.552841969,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,251.5,251.5,187.0,316.0,6.599462010608054,6.599462010608054,6.728158393463501,6.5003129173815966,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177660,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2ccncc2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C20H18F3N3O2,CHEMBL1830949,128.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,236.0,128.0,364.0,364.0,600.0,2.561101384,2.561101384,2.10720997,6.438898616,6.438898616,6.89279003,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,600.0,600.0,600.0,600.0,6.221848749616356,6.221848749616356,6.221848749616356,6.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177661,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CCOC(=O)c1ccc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)o1,C22H21F3N2O5,CHEMBL1830950,97.0,166.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,34.5,97.0,131.5,131.5,166.0,2.118925753,2.118925753,1.986771734,6.881074247,6.881074247,7.013228266,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,166.0,166.0,166.0,166.0,6.779891911959945,6.779891911959945,6.779891911959945,6.779891911959945,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177662,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,COC(=O)c1csc(CN2CC(C)(C)C(Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)n1,C20H18F3N3O4S,CHEMBL1830951,215.0,900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,342.5,215.0,557.5,557.5,900.0,2.746244872,2.746244872,2.33243846,6.253755128,6.253755128,6.66756154,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,900.0,900.0,900.0,900.0,6.045757490560675,6.045757490560675,6.045757490560675,6.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177663,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2nc3ccccc3s2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C22H18F3N3O2S,CHEMBL1830952,43.0,51.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,43.0,47.0,47.0,51.0,1.672097858,1.672097858,1.633468456,7.327902142,7.327902142,7.366531544,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,51.0,51.0,51.0,51.0,7.292429823902063,7.292429823902063,7.292429823902063,7.292429823902063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177665,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2noc(-c3ccccc3)n2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C23H19F3N4O3,CHEMBL1830954,40.0,84.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,22.0,40.0,62.0,62.0,84.0,1.792391689,1.792391689,1.602059991,7.207608311,7.207608311,7.397940009,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.0,84.0,84.0,84.0,7.075720713938118,7.075720713938118,7.075720713938118,7.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1177666,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 768070, Entry 1: 768071, ","Entry 0: Binding affinity to human androgen receptor, Entry 1: Antagonist activity at human androgen receptor by cell based assay, ",1,"Entry 0: B, Entry 1: F, ",,"Entry 0: CHEMBL1833026, Entry 1: CHEMBL1833027, ","Entry 0: 10.1016/j.bmcl.2011.07.048, Entry 1: 10.1016/j.bmcl.2011.07.048, ","Entry 0: 21831636, Entry 1: 21831636, ","Entry 0: CHEMBL1828515, Entry 1: CHEMBL1828515, ","Entry 0: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., Entry 1: Pantolactams as androgen receptor antagonists for the topical suppression of sebum production., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., Entry 1: A series of pantolactam based compounds were identified as potent antagonists for the androgen receptor (AR). Those that possessed properties suitable for topical delivery were evaluated in the validated Hamster Ear Model. Several compounds were found to be efficacious in reducing wax esters, a major component of sebum, initiating further preclinical work on these compounds., ",,CC1(C)CN(Cc2nc(-c3ccccc3)no2)C(=O)C1Oc1ccc(C#N)c(C(F)(F)F)c1,C23H19F3N4O3,CHEMBL1830955,54.0,159.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,52.5,54.0,106.5,106.5,159.0,2.027349608,2.027349608,1.73239376,6.972650392,6.972650392,7.26760624,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,159.0,159.0,159.0,159.0,6.798602875679548,6.798602875679548,6.798602875679548,6.798602875679548,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1248744,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 36122, Entry 1: 36125, Entry 2: 36129, ","Entry 0: Inhibitory activity against human Androgen receptor, Entry 1: Inhibition of antagonist activity towards Androgen receptor, Entry 2: Cross-reactivity as binding to human androgen receptor (hAR), ","0,1","Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL647748, Entry 1: CHEMBL649557, Entry 2: CHEMBL649561, ","Entry 0: 10.1021/jm950747d, Entry 1: 10.1016/s0960-894x(03)00256-7, Entry 2: 10.1016/s0960-894x(00)00011-1, ","Entry 0: 8627601, Entry 1: 12781198, Entry 2: 10743938, ","Entry 0: CHEMBL1129561, Entry 1: CHEMBL1144945, Entry 2: CHEMBL1133403, ","Entry 0: Synthesis and biological activity of novel nonsteroidal progesterone receptor antagonists based on cyclocymopol monomethyl ether., Entry 1: Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore., Entry 2: Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A novel class of nonsteroidal progesterone receptor antagonists has been synthesized and was shown to exhibit moderate binding affinity for hPR-A, the ability to inhibit the transcriptional activity of human progesterone receptor (hPR) in cell-based assays, and anti-progestational activity in a murine model. Cyclocymopol monomethyl ether, a component of the marine alga Cymopolia barbata was weakly active in random screening against PR. Investigations into the SAR surrounding the core of this natural product lead structure resulted in improved in vitro activity. In contrast to the cross-reactivity profiles observed with known steroidal antiprogestins, compounds of the general structural class described display a high degree of selectivity for the progesterone receptor and no functional activity on the glucocorticoid receptor., Entry 1: A series of 1,2-dihydrochromeno[3,4-f]quinoline derivatives was synthesized and tested in biological assays to evaluate the nonsteroidal progesterone receptor modulator pharmacophore (4) as antiprogestins. A number of potent analogues were identified by modification of the substituents at the D-ring., Entry 2: Synthesis and biological evaluation of 6-thiophene 1,2-dihydro or 1,2,3,4-tetrahydroquinoline derivatives resulted in a number of potent nonsteroidal antiprogestins., ",,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,C29H39NO3,CHEMBL1908373,269.0,269.0,269.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,269.0,269.0,269.0,269.0,2.42975228,2.42975228,2.42975228,6.57024772,6.57024772,6.57024772,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,269.0,269.0,269.0,269.0,6.570247719997592,6.570247719997592,6.570247719997592,6.570247719997592,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263690,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C#N)c2)C1(C)C,C18H21N3O2,CHEMBL1916236,175.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,175.0,175.0,175.0,175.0,2.243038049,2.243038049,2.243038049,6.756961951,6.756961951,6.756961951,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,175.0,175.0,175.0,175.0,6.756961951313706,6.756961951313706,6.756961951313706,6.756961951313706,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263691,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(Cl)c2)C1(C)C,C17H21ClN2O2,CHEMBL1916237,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32.0,32.0,32.0,32.0,1.505149978,1.505149978,1.505149978,7.494850022,7.494850022,7.494850022,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263692,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C)c2)C1(C)C,C18H24N2O2,CHEMBL1916238,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,70.0,70.0,70.0,70.0,1.84509804,1.84509804,1.84509804,7.15490196,7.15490196,7.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,70.0,70.0,70.0,70.0,7.154901959985743,7.154901959985743,7.154901959985743,7.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263693,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1(C)C,C18H21F3N2O2,CHEMBL1916239,126.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,126.0,126.0,126.0,126.0,2.100370545,2.100370545,2.100370545,6.899629455,6.899629455,6.899629455,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,126.0,126.0,126.0,126.0,6.8996294548824375,6.8996294548824375,6.8996294548824375,6.8996294548824375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263694,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)cc2Cl)C1(C)C,C17H21ClN2O2,CHEMBL1916240,161.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,161.0,161.0,161.0,161.0,2.206825876,2.206825876,2.206825876,6.793174124,6.793174124,6.793174124,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,161.0,161.0,161.0,161.0,6.79317412396815,6.79317412396815,6.79317412396815,6.79317412396815,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263695,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(C)n2)C1(C)C,C17H23N3O2,CHEMBL1916241,519.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,519.0,519.0,519.0,519.0,2.715167358,2.715167358,2.715167358,6.284832642,6.284832642,6.284832642,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,519.0,519.0,519.0,519.0,6.284832642151542,6.284832642151542,6.284832642151542,6.284832642151542,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263696,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2cnccn2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C20H21ClN4O2,CHEMBL1916242,82.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,82.0,82.0,82.0,82.0,1.913813852,1.913813852,1.913813852,7.086186148,7.086186148,7.086186148,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,82.0,82.0,82.0,82.0,7.086186147616283,7.086186147616283,7.086186147616283,7.086186147616283,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263697,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2cc[nH]n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C19H21ClN4O2,CHEMBL1916243,75.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,75.0,75.0,75.0,75.0,1.875061263,1.875061263,1.875061263,7.124938737,7.124938737,7.124938737,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,75.0,75.0,75.0,75.0,7.1249387366083,7.1249387366083,7.1249387366083,7.1249387366083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263698,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2cn[nH]c2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C19H21ClN4O2,CHEMBL1916244,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.0,42.0,42.0,42.0,1.62324929,1.62324929,1.62324929,7.37675071,7.37675071,7.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.0,42.0,42.0,42.0,7.376750709602099,7.376750709602099,7.376750709602099,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263699,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,Cn1cc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)cn1,C20H23ClN4O2,CHEMBL1916245,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263700,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,Cc1cc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)nn1C,C21H25ClN4O2,CHEMBL1914477,54.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,54.0,54.0,54.0,54.0,1.73239376,1.73239376,1.73239376,7.26760624,7.26760624,7.26760624,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,54.0,54.0,54.0,54.0,7.267606240177032,7.267606240177032,7.267606240177032,7.267606240177032,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263701,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,Cc1nnc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)o1,C19H21ClN4O3,CHEMBL1916246,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263702,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2cnc3ncccn23)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C22H22ClN5O2,CHEMBL1916247,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.0,16.0,16.0,16.0,1.204119983,1.204119983,1.204119983,7.795880017,7.795880017,7.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263703,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,Cc1nc2ncccn2c1C(=O)N[C@H]1C(C)(C)[C@H](Oc2ccc(C#N)c(Cl)c2)C1(C)C,C23H24ClN5O2,CHEMBL1916248,69.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,69.0,69.0,69.0,69.0,1.838849091,1.838849091,1.838849091,7.161150909,7.161150909,7.161150909,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,69.0,69.0,69.0,69.0,7.161150909262744,7.161150909262744,7.161150909262744,7.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263704,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,COCCn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,C22H27ClN4O3,CHEMBL1916249,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,136.0,136.0,136.0,136.0,2.133538908,2.133538908,2.133538908,6.866461092,6.866461092,6.866461092,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,136.0,136.0,136.0,136.0,6.866461091629782,6.866461091629782,6.866461091629782,6.866461091629782,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263705,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2ccn(CCO)n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C21H25ClN4O3,CHEMBL1916250,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,136.0,136.0,136.0,136.0,2.133538908,2.133538908,2.133538908,6.866461092,6.866461092,6.866461092,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,136.0,136.0,136.0,136.0,6.866461091629782,6.866461091629782,6.866461091629782,6.866461091629782,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263706,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2cnn(CCO)c2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C21H25ClN4O3,CHEMBL1916251,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,59.0,59.0,59.0,59.0,1.770852012,1.770852012,1.770852012,7.229147988,7.229147988,7.229147988,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,59.0,59.0,59.0,59.0,7.229147988357856,7.229147988357856,7.229147988357856,7.229147988357856,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263707,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CC1(C)[C@H](NC(=O)c2ccn(CCC#N)n2)C(C)(C)[C@H]1Oc1ccc(C#N)c(Cl)c1,C22H24ClN5O2,CHEMBL1916252,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,90.0,90.0,90.0,90.0,1.954242509,1.954242509,1.954242509,7.045757491,7.045757491,7.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,90.0,90.0,90.0,90.0,7.045757490560675,7.045757490560675,7.045757490560675,7.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263708,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CNC(=O)Cn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,C22H26ClN5O3,CHEMBL1916253,163.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,163.0,163.0,163.0,163.0,2.212187604,2.212187604,2.212187604,6.787812396,6.787812396,6.787812396,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,163.0,163.0,163.0,163.0,6.787812395596042,6.787812395596042,6.787812395596042,6.787812395596042,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263709,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,CN(C)C(=O)Cn1ccc(C(=O)N[C@H]2C(C)(C)[C@H](Oc3ccc(C#N)c(Cl)c3)C2(C)C)n1,C23H28ClN5O3,CHEMBL1916254,174.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,174.0,174.0,174.0,174.0,2.240549248,2.240549248,2.240549248,6.759450752,6.759450752,6.759450752,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,174.0,174.0,174.0,174.0,6.7594507517174005,6.7594507517174005,6.7594507517174005,6.7594507517174005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1263868,nM,IC50,,BAO_0000190,IC50,788156,Antagonist activity at human AR overexpressed in human LNCAP cells by luciferase reporter gene assay,0,F,,CHEMBL1919237,10.1021/jm201059s,21936524,CHEMBL1914419,Discovery of aryloxy tetramethylcyclobutanes as novel androgen receptor antagonists.,PUBLICATION,"An aryloxy tetramethylcyclobutane was identified as a novel template for androgen receptor (AR) antagonists via cell-based high-throughput screening. Follow-up to the initial ""hit"" established 5 as a viable lead. Further optimization to achieve full AR antagonism led to the discovery of 26 and 30, both of which demonstrated excellent in vivo tumor growth inhibition upon oral administration in a castration-resistant prostate cancer (CRPC) animal model.",,Cc1nc(O[C@H]2C(C)(C)[C@H](NC(=O)c3cnc4ncccn34)C2(C)C)ccc1C#N,C22H24N6O2,CHEMBL1916412,144.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,144.0,144.0,144.0,144.0,2.158362492,2.158362492,2.158362492,6.841637508,6.841637508,6.841637508,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,144.0,144.0,144.0,144.0,6.841637507904751,6.841637507904751,6.841637507904751,6.841637507904751,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271895,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(C)[nH]c(C)c1-c1ccc([N+](=O)[O-])cc1,C15H16N2O4,CHEMBL1934427,22.0,34.0,240.0,340.0,4200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1620.954089,22.0,967.2,240.0,4200.0,2.985516288,2.380211242,1.342422681,6.014483712,6.619788758,7.657577319,5,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,240.0,240.0,240.0,240.0,6.619788758288394,6.619788758288394,6.619788758288394,6.619788758288394,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271896,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(C)c1C,C16H18N2O4,CHEMBL1934428,30.0,47.0,210.0,500.0,6200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2407.221436,30.0,1397.4,210.0,6200.0,3.145320739,2.322219295,1.477121255,5.854679261,6.677780705,7.522878745,5,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271897,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(-c2ccccc2)c1C,C21H20N2O4,CHEMBL1934429,220.0,550.0,2100.0,4300.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3585.780808,220.0,3434.0,2100.0,10000.0,3.535800291,3.322219295,2.342422681,5.464199709,5.677780705,6.657577319,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,2100.0,2100.0,2100.0,2100.0,5.6777807052660805,5.6777807052660805,5.6777807052660805,5.6777807052660805,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271898,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,C22H22N2O4,CHEMBL1934430,5.2,5.5,160.0,340.0,3200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1235.103104,5.2,742.14,160.0,3200.0,2.87048584,2.204119983,0.716003344,6.12951416,6.795880017,8.283996656,5,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,160.0,160.0,160.0,160.0,6.795880017344075,6.795880017344075,6.795880017344075,6.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271899,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(CC2CCCCC2)c1C,C22H28N2O4,CHEMBL1934431,310.0,350.0,3700.0,3800.0,7200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2569.150832,310.0,3072.0,3700.0,7200.0,3.487421211,3.568201724,2.491361694,5.512578789,5.431798276,6.508638306,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,3700.0,3700.0,3700.0,3700.0,5.431798275933005,5.431798275933005,5.431798275933005,5.431798275933005,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271900,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(CCc2ccccc2)c1C,C23H24N2O4,CHEMBL1933081,52.0,150.0,970.0,4100.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3771.718632,52.0,3054.4,970.0,10000.0,3.484925911,2.986771734,1.716003344,5.515074089,6.013228266,7.283996656,5,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,970.0,970.0,970.0,970.0,6.013228265733755,6.013228265733755,6.013228265733755,6.013228265733755,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271901,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(C(=O)c2ccccc2)c1C,C22H20N2O5,CHEMBL1934432,85.0,150.0,1500.0,2400.0,7700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2804.149782,85.0,2367.0,1500.0,7700.0,3.374198258,3.176091259,1.929418926,5.625801742,5.823908741,7.070581074,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,1500.0,1500.0,1500.0,1500.0,5.823908740944319,5.823908740944319,5.823908740944319,5.823908740944319,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271902,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CCOC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(S(=O)(=O)c2ccccc2)c1C,C21H20N2O6S,CHEMBL1934433,62.0,130.0,4700.0,4700.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3672.368478,62.0,3918.4,4700.0,10000.0,3.593108768,3.672097858,1.792391689,5.406891232,5.327902142,7.207608311,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4700.0,4700.0,4700.0,4700.0,5.327902142064283,5.327902142064283,5.327902142064283,5.327902142064283,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271903,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,COC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,C21H20N2O4,CHEMBL1934434,3.8,5.0,150.0,300.0,740.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,273.0256955,3.8,239.76,150.0,740.0,2.37977673,2.176091259,0.579783597,6.62022327,6.823908741,8.420216403,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,150.0,150.0,150.0,150.0,6.823908740944319,6.823908740944319,6.823908740944319,6.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271904,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C(=O)O)c(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,C20H18N2O4,CHEMBL1934435,190.0,620.0,6500.0,8700.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4075.695769,190.0,5202.0,6500.0,10000.0,3.716170348,3.812913357,2.278753601,5.283829652,5.187086643,6.721246399,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,6500.0,6500.0,6500.0,6500.0,5.187086643357144,5.187086643357144,5.187086643357144,5.187086643357144,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1271905,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(CO)c(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,C20H20N2O3,CHEMBL1934436,92.0,300.0,660.0,3800.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3764.510146,92.0,2970.4,660.0,10000.0,3.472814936,2.819543936,1.963787827,5.527185064,6.180456064,7.036212173,5,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271906,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,CC(=O)c1c(-c2ccc([N+](=O)[O-])cc2)c(C)n(Cc2ccccc2)c1C,C21H20N2O3,CHEMBL1934437,130.0,390.0,900.0,4600.0,6500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2570.561028,130.0,2504.0,900.0,6500.0,3.398634325,2.954242509,2.113943352,5.601365675,6.045757491,6.886056648,5,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,900.0,900.0,900.0,900.0,6.045757490560675,6.045757490560675,6.045757490560675,6.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271907,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1cc(-c2ccc([N+](=O)[O-])cc2)c(C)n1Cc1ccccc1,C19H18N2O2,CHEMBL1934438,2.2,6.7,210.0,490.0,3100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1182.599331,2.2,761.78,210.0,3100.0,2.881829566,2.322219295,0.342422681,6.118170434,6.677780705,8.657577319,5,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271908,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,COC(=O)c1c(-c2ccccc2)c(C)n(Cc2ccccc2)c1C,C21H21NO2,CHEMBL1934439,65.0,130.0,1300.0,2600.0,3700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1414.830025,65.0,1559.0,1300.0,3700.0,3.192846115,3.113943352,1.812913357,5.807153885,5.886056648,7.187086643,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271909,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,COC(=O)c1c(-c2ccc(C#N)cc2)c(C)n(Cc2ccccc2)c1C,C22H20N2O2,CHEMBL1934440,23.0,27.0,120.0,270.0,710.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,256.1866507,23.0,230.0,120.0,710.0,2.361727836,2.079181246,1.361727836,6.638272164,6.920818754,7.638272164,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,120.0,120.0,120.0,120.0,6.920818753952375,6.920818753952375,6.920818753952375,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271910,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,COC(=O)c1c(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)n(Cc2ccccc2)c1C,C23H19F3N2O2,CHEMBL1934441,3.9,4.7,320.0,690.0,3300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1244.063994,3.9,863.72,320.0,3300.0,2.936372976,2.505149978,0.591064607,6.063627024,6.494850022,8.408935393,5,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,320.0,320.0,320.0,320.0,6.494850021680094,6.494850021680094,6.494850021680094,6.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271911,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccccc1,C21H17N3,CHEMBL1934442,1.4,3.0,40.0,41.0,380.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,144.4801218,1.4,93.08,40.0,380.0,1.968856375,1.602059991,0.146128036,7.031143625,7.397940009,8.853871964,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,40.0,40.0,40.0,40.0,7.3979400086720375,7.3979400086720375,7.3979400086720375,7.3979400086720375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271912,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cccnc1,C20H16N4,CHEMBL1934443,3.4,23.0,65.0,180.0,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,78.34228488,3.4,92.28,65.0,190.0,1.965107586,1.812913357,0.531478917,7.034892414,7.187086643,8.468521083,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,65.0,65.0,65.0,65.0,7.187086643357144,7.187086643357144,7.187086643357144,7.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271913,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1ccc(Cl)nc1,C20H15ClN4,CHEMBL1934444,9.0,24.0,45.0,100.0,910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,347.572496,9.0,217.6,45.0,910.0,2.337658891,1.653212514,0.954242509,6.662341109,7.346787486,8.045757491,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271914,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cncc(CO)c1,C21H18N4O,CHEMBL1934445,14.0,100.0,150.0,440.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,221.906647,14.0,260.8,150.0,600.0,2.416307587,2.176091259,1.146128036,6.583692413,6.823908741,7.853871964,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,150.0,150.0,150.0,150.0,6.823908740944319,6.823908740944319,6.823908740944319,6.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271915,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1Cc1cnc(Cl)c(CO)c1,C21H17ClN4O,CHEMBL1934446,25.0,37.0,100.0,110.0,280.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,91.16271168,25.0,110.4,100.0,280.0,2.042969073,2.0,1.397940009,6.957030927,7.0,7.602059991,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271916,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(-c2ccc(C#N)cc2)c(C#N)cn1Cc1cnc(Cl)c(CO)c1,C20H15ClN4O,CHEMBL1934447,320.0,490.0,810.0,1100.0,1400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,393.375139,320.0,824.0,810.0,1400.0,2.915927212,2.908485019,2.505149978,6.084072788,6.091514981,6.494850022,5,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,810.0,810.0,810.0,810.0,6.0915149811213505,6.0915149811213505,6.0915149811213505,6.0915149811213505,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1271917,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 796524, Entry 1: 796525, Entry 2: 796526, Entry 3: 796600, Entry 4: 796601, ","Entry 0: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 1: Displacement of [17-alpha-methyl-3H]-mibolerone from human androgen receptor T877A mutant expressed in HEK293 derived FreeStyle293F cells after 3 hrs, Entry 2: Antagonist activity at human androgen receptor expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Antagonist activity at human androgen receptor T877A mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, Entry 4: Antagonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as inhibition of DHT-induced luciferase activity after 24 hrs by reporter gene assay, ",2,"Entry 0: B, Entry 1: B, Entry 2: F, Entry 3: F, Entry 4: F, ",,"Entry 0: CHEMBL1937839, Entry 1: CHEMBL1937840, Entry 2: CHEMBL1937841, Entry 3: CHEMBL1937915, Entry 4: CHEMBL1937916, ","Entry 0: 10.1016/j.bmc.2011.10.067, Entry 1: 10.1016/j.bmc.2011.10.067, Entry 2: 10.1016/j.bmc.2011.10.067, Entry 3: 10.1016/j.bmc.2011.10.067, Entry 4: 10.1016/j.bmc.2011.10.067, ","Entry 0: 22094279, Entry 1: 22094279, Entry 2: 22094279, Entry 3: 22094279, Entry 4: 22094279, ","Entry 0: CHEMBL1932924, Entry 1: CHEMBL1932924, Entry 2: CHEMBL1932924, Entry 3: CHEMBL1932924, Entry 4: CHEMBL1932924, ","Entry 0: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., Entry 4: Design, synthesis, and biological evaluation of 4-phenylpyrrole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 1: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 2: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 3: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., Entry 4: A series of 4-phenylpyrrole derivatives D were designed, synthesized, and evaluated for their potential as novel orally available androgen receptor antagonists therapeutically effective against castration-resistant prostate cancers. 4-Phenylpyrrole compound 1 exhibited androgen receptor (AR) antagonistic activity against T877A and W741C mutant-type ARs as well as wild-type AR. An arylmethyl group incorporated into compound 1 contributed to enhancement of antagonistic activity. Compound 4n, 1-{[6-chloro-5-(hydroxymethyl)pyridin-3-yl]methyl}-4-(4-cyanophenyl)-2,5-dimethyl-1H-pyrrole-3-carbonitrile exhibited inhibitory effects on tumor cell growth against the bicalutamide-resistant LNCaP-cxD2 cell line as well as the androgen receptor-dependent JDCaP cell line in a mouse xenograft model. These results demonstrate that this series of pyrrole compounds are novel androgen receptor antagonists with efficacy against prostate cancer cells, including castration-resistant prostate cancers such as bicalutamide-resistant prostate cancer., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)cn1Cc1cnc(Cl)c(CO)c1,C20H15ClN4O,CHEMBL1934448,78.0,160.0,170.0,760.0,910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,347.1792621,78.0,415.6,170.0,910.0,2.618675539,2.230448921,1.892094603,6.381324461,6.769551079,7.107905397,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278010,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC1(C)CNC(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C14H13F3N2O2,CHEMBL1946622,105.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,105.0,105.0,105.0,105.0,2.021189299,2.021189299,2.021189299,6.978810701,6.978810701,6.978810701,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,105.0,105.0,105.0,105.0,6.978810700930062,6.978810700930062,6.978810700930062,6.978810700930062,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278194,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC(=O)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C17H17F3N2O3,CHEMBL1946805,266.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,266.0,266.0,266.0,266.0,2.424881637,2.424881637,2.424881637,6.575118363,6.575118363,6.575118363,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,266.0,266.0,266.0,266.0,6.575118363368933,6.575118363368933,6.575118363368933,6.575118363368933,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278195,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,Cc1nnc(CN2CC(C)(C)[C@@H](Oc3ccc(C#N)c(C(F)(F)F)c3)C2=O)o1,C18H17F3N4O3,CHEMBL1946806,633.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,633.0,633.0,633.0,633.0,2.80140371,2.80140371,2.80140371,6.19859629,6.19859629,6.19859629,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,633.0,633.0,633.0,633.0,6.198596289982645,6.198596289982645,6.198596289982645,6.198596289982645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278196,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC(c1nnc(-c2cccc(F)c2)o1)N1CC(C)(C)C(Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C24H20F4N4O3,CHEMBL1946807,77.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,77.0,77.0,77.0,77.0,1.886490725,1.886490725,1.886490725,7.113509275,7.113509275,7.113509275,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,77.0,77.0,77.0,77.0,7.113509274827518,7.113509274827518,7.113509274827518,7.113509274827518,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278198,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC1(C)CN(Cc2nnc(-c3ccccc3)o2)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C23H19F3N4O3,CHEMBL1946809,71.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,71.0,71.0,71.0,71.0,1.851258349,1.851258349,1.851258349,7.148741651,7.148741651,7.148741651,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,71.0,71.0,71.0,71.0,7.1487416512809245,7.1487416512809245,7.1487416512809245,7.1487416512809245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278201,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 801332, Entry 1: 2227430, ","Entry 0: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, Entry 1: Antagonist activity at Androgen receptor (unknown origin), ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL1947977, Entry 1: CHEMBL5140943, ","Entry 0: 10.1016/j.bmcl.2011.11.068, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 22197140, Entry 1: 35786895, ","Entry 0: CHEMBL1944520, Entry 1: CHEMBL5137058, ","Entry 0: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC1(C)CN(CCC#N)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C17H16F3N3O2,CHEMBL1946811,131.0,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,131.0,131.0,131.0,131.0,2.117271296,2.117271296,2.117271296,6.882728704,6.882728704,6.882728704,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,131.0,131.0,131.0,131.0,6.882728704344236,6.882728704344236,6.882728704344236,6.882728704344236,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278202,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC1(C)CN(CCO)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C16H17F3N2O3,CHEMBL1946812,263.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,263.0,263.0,263.0,263.0,2.419955748,2.419955748,2.419955748,6.580044252,6.580044252,6.580044252,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,263.0,263.0,263.0,263.0,6.580044251510242,6.580044251510242,6.580044251510242,6.580044251510242,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278570,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 801332, Entry 1: 801332, ","Entry 0: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, Entry 1: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1947977, Entry 1: CHEMBL1947977, ","Entry 0: 10.1016/j.bmcl.2011.11.068, Entry 1: 10.1016/j.bmcl.2011.11.068, ","Entry 0: 22197140, Entry 1: 22197140, ","Entry 0: CHEMBL1944520, Entry 1: CHEMBL1944520, ","Entry 0: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., Entry 1: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., Entry 1: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., ",,CC(CO)N1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C17H19F3N2O3,CHEMBL1947177,337.0,371.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.0,337.0,354.0,354.0,371.0,2.549003262,2.549003262,2.527629901,6.450996738,6.450996738,6.472370099,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,354.0,354.0,337.0,371.0,6.450996737974212,6.450996737974212,6.4723700991286615,6.430626090384954,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278571,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC1(C)CN(C(C)(C)CO)C(=O)[C@@H]1Oc1ccc(C#N)c(C(F)(F)F)c1,C18H21F3N2O3,CHEMBL1947178,761.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,761.0,761.0,761.0,761.0,2.881384657,2.881384657,2.881384657,6.118615343,6.118615343,6.118615343,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,761.0,761.0,761.0,761.0,6.118615343229427,6.118615343229427,6.118615343229427,6.118615343229427,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278572,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 801332, Entry 1: 801332, ","Entry 0: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, Entry 1: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL1947977, Entry 1: CHEMBL1947977, ","Entry 0: 10.1016/j.bmcl.2011.11.068, Entry 1: 10.1016/j.bmcl.2011.11.068, ","Entry 0: 22197140, Entry 1: 22197140, ","Entry 0: CHEMBL1944520, Entry 1: CHEMBL1944520, ","Entry 0: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., Entry 1: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., Entry 1: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., ",,CC(O)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C17H19F3N2O3,CHEMBL1947179,216.0,977.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,380.5,216.0,596.5,596.5,977.0,2.775610448,2.775610448,2.334453751,6.224389552,6.224389552,6.665546249,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,596.5,596.5,216.0,977.0,6.22438955199364,6.22438955199364,6.665546248849069,6.010105436281227,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278576,nM,IC50,,BAO_0000190,IC50,801332,Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry,0,F,,CHEMBL1947977,10.1016/j.bmcl.2011.11.068,22197140,CHEMBL1944520,Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer.,PUBLICATION,"High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities.",,CC(CO)CN1CC(C)(C)[C@@H](Oc2ccc(C#N)c(C(F)(F)F)c2)C1=O,C18H21F3N2O3,CHEMBL1947183,371.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,371.0,371.0,371.0,371.0,2.56937391,2.56937391,2.56937391,6.43062609,6.43062609,6.43062609,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,371.0,371.0,371.0,371.0,6.430626090384954,6.430626090384954,6.430626090384954,6.430626090384954,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1278578,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 801332, Entry 1: 2227430, ","Entry 0: Antagonist activity at androgen receptor expressed in human LNAR cells assessed as inhibition of R1881-induced luciferase activity by spectrophotometry, Entry 1: Antagonist activity at Androgen receptor (unknown origin), ","0,1","Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL1947977, Entry 1: CHEMBL5140943, ","Entry 0: 10.1016/j.bmcl.2011.11.068, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 22197140, Entry 1: 35786895, ","Entry 0: CHEMBL1944520, Entry 1: CHEMBL5137058, ","Entry 0: Discovery of 3-aryloxy-lactam analogs as potent androgen receptor full antagonists for treating castration resistant prostate cancer., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: High throughput cell-based screening led to the identification of 3-aryloxy lactams as potent androgen receptor (AR) antagonists. Refinement of these leads to improve the ADME profile and remove residual agonism led to the discovery of 12, a potent full antagonist with greater oral bioavailability. Improvements in the ADME profile were realized by designing more ligand-efficient molecules with reduced molecular weights and lower lipophilicities., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC1(C)CN(CCC#N)C(=O)[C@@H]1Oc1ccc(C#N)c(Cl)c1,C16H16ClN3O2,CHEMBL1947185,68.0,68.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,68.0,68.0,68.0,68.0,1.832508913,1.832508913,1.832508913,7.167491087,7.167491087,7.167491087,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,68.0,68.0,68.0,68.0,7.167491087293763,7.167491087293763,7.167491087293763,7.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283140,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NC(C)(C)C)cc1,C24H25ClN4O,CHEMBL1957607,110.0,770.0,970.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,367.4537008,110.0,616.6666667,770.0,970.0,2.790050474,2.886490725,2.041392685,6.209949526,6.113509275,6.958607315,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,770.0,770.0,770.0,770.0,6.113509274827518,6.113509274827518,6.113509274827518,6.113509274827518,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283141,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, Entry 6: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, Entry 3: 2227432, Entry 4: 2227433, Entry 5: 2227434, Entry 6: 2227435, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 3: Binding affinity to wild-type Androgen receptor (unknown origin), Entry 4: Binding affinity to bicalutamide-resistant Androgen receptor T877A mutant (unknown origin), Entry 5: Antagonist activity at wild-type Androgen receptor (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, Entry 6: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, Entry 3: B, Entry 4: B, Entry 5: B, Entry 6: B, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, Entry 3: CHEMBL5140945, Entry 4: CHEMBL5140946, Entry 5: CHEMBL5140947, Entry 6: CHEMBL5140948, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, Entry 3: 10.1021/acs.jmedchem.2c00716, Entry 4: 10.1021/acs.jmedchem.2c00716, Entry 5: 10.1021/acs.jmedchem.2c00716, Entry 6: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, Entry 3: 35786895, Entry 4: 35786895, Entry 5: 35786895, Entry 6: 35786895, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, Entry 3: CHEMBL5137058, Entry 4: CHEMBL5137058, Entry 5: CHEMBL5137058, Entry 6: CHEMBL5137058, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., Entry 4: Therapeutic Strategies to Target the Androgen Receptor., Entry 5: Therapeutic Strategies to Target the Androgen Receptor., Entry 6: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, Entry 6: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 4: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 5: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 6: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NCC(C)(C)O)cc1,C24H25ClN4O2,CHEMBL1957608,34.0,160.0,340.0,590.0,590.0,1100.0,1100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,390.9824361,34.0,559.1428571,590.0,1100.0,2.747522781,2.770852012,1.531478917,6.252477219,6.229147988,7.468521083,7,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,160.0,160.0,160.0,160.0,6.795880017344075,6.795880017344075,6.795880017344075,6.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283142,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)N2CCOCC2)cc1,C24H23ClN4O2,CHEMBL1957609,510.0,2400.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4101.38459,510.0,4303.333333,2400.0,10000.0,3.633804988,3.380211242,2.707570176,5.366195012,5.619788758,6.292429824,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,2400.0,2400.0,2400.0,2400.0,5.619788758288394,5.619788758288394,5.619788758288394,5.619788758288394,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283143,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(C(=O)NCC(C)(C)O)cc1,C23H23ClN4O3,CHEMBL1957610,180.0,1100.0,1800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,663.3919572,180.0,1026.666667,1100.0,1800.0,3.011429462,3.041392685,2.255272505,5.988570538,5.958607315,6.744727495,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1100.0,1100.0,1100.0,1100.0,5.958607314841775,5.958607314841775,5.958607314841775,5.958607314841775,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283144,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)cc2)c(C)c1Cc1ccc(F)cc1,C19H16FN3,CHEMBL1957611,91.0,170.0,700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,270.395184,91.0,320.3333333,170.0,700.0,2.505602133,2.230448921,1.959041392,6.494397867,6.769551079,7.040958608,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283145,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(F)cc1,C19H15ClFN3,CHEMBL1957612,0.47,75.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4696.355324,0.47,3358.49,75.0,10000.0,3.52614406,1.875061263,-0.327902142,5.47385594,7.124938737,9.327902142,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,75.0,75.0,75.0,75.0,7.1249387366083,7.1249387366083,7.1249387366083,7.1249387366083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283146,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(C(F)(F)F)c2)c(C)c1Cc1ccc(F)cc1,C20H15F4N3,CHEMBL1957613,1.4,110.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4687.997629,1.4,3370.466667,110.0,10000.0,3.527690036,2.041392685,0.146128036,5.472309964,6.958607315,8.853871964,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283147,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)cc2Cl)c(C)c1Cc1ccc(F)cc1,C19H15ClFN3,CHEMBL1957614,820.0,1500.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4176.452508,820.0,4106.666667,1500.0,10000.0,3.613489453,3.176091259,2.913813852,5.386510547,5.823908741,6.086186148,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,1500.0,1500.0,1500.0,1500.0,5.823908740944319,5.823908740944319,5.823908740944319,5.823908740944319,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283148,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(F)cc1,C18H13ClFN3O,CHEMBL1957615,110.0,110.0,670.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,263.9865316,110.0,296.6666667,110.0,670.0,2.472268752,2.041392685,2.041392685,6.527731248,6.958607315,6.958607315,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283149,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1-c1ccc(F)cc1,C18H13ClFN3,CHEMBL1957616,180.0,270.0,6200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2816.881649,180.0,2216.666667,270.0,6200.0,3.345700391,2.431363764,2.255272505,5.654299609,6.568636236,6.744727495,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,270.0,270.0,270.0,270.0,6.568636235841013,6.568636235841013,6.568636235841013,6.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283150,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1CCc1ccc(F)cc1,C20H17ClFN3,CHEMBL1957617,53.0,140.0,1100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,474.3859188,53.0,431.0,140.0,1100.0,2.63447727,2.146128036,1.72427587,6.36552273,6.853871964,7.27572413,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283151,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1C(O)c1ccc(F)cc1,C19H15ClFN3O,CHEMBL1957618,26.0,48.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,68.00653563,26.0,84.66666667,48.0,180.0,1.927712462,1.681241237,1.414973348,7.072287538,7.318758763,7.585026652,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283152,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccccc1C(N)=O,C20H17ClN4O,CHEMBL1957619,4200.0,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2734.146221,4200.0,8066.666667,10000.0,10000.0,3.906694111,4.0,3.62324929,5.093305889,5.0,5.37675071,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1283153,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1cccc(C(N)=O)c1,C20H17ClN4O,CHEMBL1957620,260.0,700.0,1900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,693.0768756,260.0,953.3333333,700.0,1900.0,2.979244778,2.84509804,2.414973348,6.020755222,6.15490196,6.585026652,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,700.0,700.0,700.0,700.0,6.154901959985743,6.154901959985743,6.154901959985743,6.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283154,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(N)=O)cc1,C20H17ClN4O,CHEMBL1957621,16.0,140.0,420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,168.9812613,16.0,192.0,140.0,420.0,2.283301229,2.146128036,1.204119983,6.716698771,6.853871964,7.795880017,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283155,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,CNC(=O)c1ccc(Cc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)cc1,C21H19ClN4O,CHEMBL1957622,27.0,110.0,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,581.5227138,27.0,479.0,110.0,1300.0,2.680335513,2.041392685,1.431363764,6.319664487,6.958607315,7.568636236,3,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283255,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)N(C)C)cc1,C22H21ClN4O,CHEMBL1957721,920.0,4000.0,6300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2204.056866,920.0,3740.0,4000.0,6300.0,3.572871602,3.602059991,2.963787827,5.427128398,5.397940009,6.036212173,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4000.0,4000.0,4000.0,4000.0,5.3979400086720375,5.3979400086720375,5.3979400086720375,5.3979400086720375,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283256,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Cc1ccc(C(=O)NCCO)cc1,C22H21ClN4O2,CHEMBL1957722,160.0,2100.0,2700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1083.98442,160.0,1653.333333,2100.0,2700.0,3.218360422,3.322219295,2.204119983,5.781639578,5.677780705,6.795880017,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2100.0,2100.0,2100.0,2100.0,5.6777807052660805,5.6777807052660805,5.6777807052660805,5.6777807052660805,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283257,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(C(=O)N2CCOCC2)cc1,C23H21ClN4O3,CHEMBL1957723,720.0,1300.0,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,967.5168675,720.0,1673.333333,1300.0,3000.0,3.223582462,3.113943352,2.857332496,5.776417538,5.886056648,6.142667504,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283258,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,CC(=O)Nc1ccc(Oc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)nc1,C19H16ClN5O2,CHEMBL1957724,1600.0,5400.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3434.465833,1600.0,5666.666667,5400.0,10000.0,3.753327667,3.73239376,3.204119983,5.246672333,5.26760624,5.795880017,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5400.0,5400.0,5400.0,5400.0,5.267606240177032,5.267606240177032,5.267606240177032,5.267606240177032,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1283259,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(NC(=O)C(C)(C)C)cn1,C22H22ClN5O2,CHEMBL1957725,190.0,4000.0,4300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1870.77524,190.0,2830.0,4000.0,4300.0,3.451786436,3.602059991,2.278753601,5.548213564,5.397940009,6.721246399,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4000.0,4000.0,4000.0,4000.0,5.3979400086720375,5.3979400086720375,5.3979400086720375,5.3979400086720375,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1283260,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 805648, Entry 1: 805650, Entry 2: 805651, ","Entry 0: Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, Entry 1: Antagonist activity at androgen receptor expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, Entry 2: Antagonist activity at androgen receptor T877A mutant expressed in Cos7 cells assessed as inhibition of dihydrotestosterone-induced luciferase activity after 24 hrs by reporter gene assay, ",1,"Entry 0: B, Entry 1: F, Entry 2: F, ",,"Entry 0: CHEMBL1960482, Entry 1: CHEMBL1960484, Entry 2: CHEMBL1960485, ","Entry 0: 10.1016/j.bmc.2012.02.005, Entry 1: 10.1016/j.bmc.2012.02.005, Entry 2: 10.1016/j.bmc.2012.02.005, ","Entry 0: 22391033, Entry 1: 22391033, Entry 2: 22391033, ","Entry 0: CHEMBL1955860, Entry 1: CHEMBL1955860, Entry 2: CHEMBL1955860, ","Entry 0: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 1: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., Entry 2: A series of 4-arylmethyl-1-phenylpyrazole and 4-aryloxy-1-phenylpyrazole compounds B were designed, synthesized, and evaluated for their potential as new-generation androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a bulky amide substituent (R(2)) to the terminal aryl ring of the 4-arylmethyl group favored the reduction of agonistic activity and improved the pharmacokinetic (PK) properties. Similarly, introduction of a bulky substituent in the 4-aryloxy derivatives also resulted in improved PK properties. Compounds 28 h and 44b exhibited potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft model. On the contrary, bicalutamide showed only partial suppression of tumor growth. These results suggest that the novel pyrazole derivatives are new-generation AR antagonists, different from the 'first-generation' antagonists such as bicalutamide in a CRPC treatment model., ",,CC(=O)Nc1ccc(Oc2c(C)nn(-c3ccc(C#N)c(Cl)c3)c2C)cn1,C19H16ClN5O2,CHEMBL1957726,350.0,1200.0,7100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3001.758744,350.0,2883.333333,1200.0,7100.0,3.459894853,3.079181246,2.544068044,5.540105147,5.920818754,6.455931956,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,1200.0,1200.0,1200.0,1200.0,5.920818753952375,5.920818753952375,5.920818753952375,5.920818753952375,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1299182,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccc2c(c1)OC(c1ccccc1O)CC2=O,C16H14O4,CHEMBL1977891,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1303106,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccc(O)cc1)c1cc(Cl)ccc1O,C15H11ClO3,CHEMBL1981815,5920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5920.0,5920.0,5920.0,5920.0,3.772321707,3.772321707,3.772321707,5.227678293,5.227678293,5.227678293,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5920.0,5920.0,5920.0,5920.0,5.22767829327708,5.22767829327708,5.22767829327708,5.22767829327708,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1332411,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3ccccc32)cc1C(F)(F)F,C22H14F3N3O,CHEMBL2011362,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,170.0,170.0,170.0,170.0,2.230448921,2.230448921,2.230448921,6.769551079,6.769551079,6.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332416,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,CC(C)n1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,C18H14F3N3O,CHEMBL2011367,373.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,373.0,373.0,373.0,373.0,2.571708832,2.571708832,2.571708832,6.428291168,6.428291168,6.428291168,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,373.0,373.0,373.0,373.0,6.428291168191312,6.428291168191312,6.428291168191312,6.428291168191312,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332418,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,CCn1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,C17H12F3N3O,CHEMBL2011369,293.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,293.0,293.0,293.0,293.0,2.46686762,2.46686762,2.46686762,6.53313238,6.53313238,6.53313238,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,293.0,293.0,293.0,293.0,6.533132379645891,6.533132379645891,6.533132379645891,6.533132379645891,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332420,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3cccnc32)cc1C(F)(F)F,C21H13F3N4O,CHEMBL2011371,60.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.6,60.6,60.6,60.6,1.782472624,1.782472624,1.782472624,7.217527376,7.217527376,7.217527376,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.6,60.6,60.6,60.6,7.217527375833714,7.217527375833714,7.217527375833714,7.217527375833714,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332421,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3ccccc3)c3ncccc32)cc1C(F)(F)F,C21H13F3N4O,CHEMBL2011372,588.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,588.0,588.0,588.0,588.0,2.769377326,2.769377326,2.769377326,6.230622674,6.230622674,6.230622674,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,588.0,588.0,588.0,588.0,6.230622673923862,6.230622673923862,6.230622673923862,6.230622673923862,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332422,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3ccccn3)c3ccccc32)cc1C(F)(F)F,C21H13F3N4O,CHEMBL2011373,301.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,301.0,301.0,301.0,301.0,2.478566496,2.478566496,2.478566496,6.521433504,6.521433504,6.521433504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,301.0,301.0,301.0,301.0,6.521433504406157,6.521433504406157,6.521433504406157,6.521433504406157,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332423,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3cccnc3)c3ccccc32)cc1C(F)(F)F,C21H13F3N4O,CHEMBL2011374,389.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,389.0,389.0,389.0,389.0,2.589949601,2.589949601,2.589949601,6.410050399,6.410050399,6.410050399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,389.0,389.0,389.0,389.0,6.410050398674292,6.410050398674292,6.410050398674292,6.410050398674292,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332425,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 812472, Entry 1: 812472, ","Entry 0: Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881, Entry 1: Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2014258, Entry 1: CHEMBL2014258, ","Entry 0: 10.1016/j.bmcl.2012.01.116, Entry 1: 10.1016/j.bmcl.2012.01.116, ","Entry 0: 22377517, Entry 1: 22377517, ","Entry 0: CHEMBL2010717, Entry 1: CHEMBL2010717, ","Entry 0: Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists., Entry 1: Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR., Entry 1: Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR., ",,CC(c1ccccc1)n1c(=O)n(-c2ccc(C#N)c(C(F)(F)F)c2)c2ccccc21,C23H16F3N3O,CHEMBL2011376,292.0,363.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.5,292.0,327.5,327.5,363.0,2.515211304,2.515211304,2.465382851,6.484788696,6.484788696,6.534617149,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,327.5,327.5,292.0,363.0,6.484788695672198,6.484788695672198,6.534617148551582,6.440093374963888,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332426,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,N#Cc1ccc(-n2c(=O)n(Cc3nc(-c4ccccn4)no3)c3ccccc32)cc1Cl,C22H13ClN6O2,CHEMBL2011377,126.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,126.0,126.0,126.0,126.0,2.100370545,2.100370545,2.100370545,6.899629455,6.899629455,6.899629455,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,126.0,126.0,126.0,126.0,6.8996294548824375,6.8996294548824375,6.8996294548824375,6.8996294548824375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332427,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 812472, Entry 1: 812472, ","Entry 0: Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881, Entry 1: Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881, ","0,1","Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2014258, Entry 1: CHEMBL2014258, ","Entry 0: 10.1016/j.bmcl.2012.01.116, Entry 1: 10.1016/j.bmcl.2012.01.116, ","Entry 0: 22377517, Entry 1: 22377517, ","Entry 0: CHEMBL2010717, Entry 1: CHEMBL2010717, ","Entry 0: Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists., Entry 1: Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR., Entry 1: Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR., ",,CC(c1nc(-c2ccccn2)no1)n1c(=O)n(-c2ccc(C#N)c(Cl)c2)c2ccccc21,C23H15ClN6O2,CHEMBL2011378,178.0,189.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.5,178.0,183.5,183.5,189.0,2.263636069,2.263636069,2.250420002,6.736363931,6.736363931,6.749579998,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,183.5,183.5,178.0,189.0,6.7363639314118915,6.7363639314118915,6.749579997691106,6.723538195826756,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332428,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,CNC(=O)c1ccc(-c2ccc3c(c2)C(C)(C)C(=O)N3c2ccc(C#N)c(C(F)(F)F)c2)cc1F,C26H19F4N3O2,CHEMBL2011379,197.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,197.0,197.0,197.0,197.0,2.294466226,2.294466226,2.294466226,6.705533774,6.705533774,6.705533774,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,197.0,197.0,197.0,197.0,6.705533773838407,6.705533773838407,6.705533773838407,6.705533773838407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332429,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,CNC(=O)c1ccc(-c2ccc3c(c2)C(C)(C)C(=O)N3c2ccc(C#N)c(OC)c2)cc1F,C26H22FN3O3,CHEMBL2011380,165.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,165.0,165.0,165.0,165.0,2.217483944,2.217483944,2.217483944,6.782516056,6.782516056,6.782516056,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,165.0,165.0,165.0,165.0,6.782516055786093,6.782516055786093,6.782516055786093,6.782516055786093,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1332430,nM,IC50,,BAO_0000190,IC50,812472,Antagonist activity at androgen receptor in human LNAR cells expressing ARE-PSA-LUC by luminescence analysis in presence of R1881,0,F,,CHEMBL2014258,10.1016/j.bmcl.2012.01.116,22377517,CHEMBL2010717,Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.,PUBLICATION,"Oxobenzimidazoles (e.g., 1), a novel series of androgen receptor (AR) antagonists, were discovered through de novo design guided by structure-based drug design. The compounds in this series were reasonably permeable and metabolically stable, but suffered from poor solubility. The incorporation of three dimensional structural features led to improved solubility. In addition, the observation of a 'flipped' binding mode of an oxobenzimidazole analog in an AR ligand binding domain (LBD) model, led to the design and discovery of the novel oxindole series (e.g., 2) that is a potent full antagonist of AR.",,COc1cc(N2C(=O)C(C)(C)c3cc(-c4cccnc4OC)ccc32)ccc1C#N,C24H21N3O3,CHEMBL2011381,79.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,79.6,79.6,79.6,79.6,1.900913068,1.900913068,1.900913068,7.099086932,7.099086932,7.099086932,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,79.6,79.6,79.6,79.6,7.099086932262331,7.099086932262331,7.099086932262331,7.099086932262331,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1339203,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 815556, Entry 1: 1989103, Entry 2: 2014924, Entry 3: 2014930, ","Entry 0: Antagonist activity at androgen receptor expressed in HeLa-AR3A-PSA-(ARE)4-Luc13 cells assessed as rightward shift of DHT-induced response incubated for 20 hrs at 37 degC by luciferase reporter gene assay, Entry 1: Antagonistic activity at AR in human 22Rv1 cells assessed as reduction in cell number by CCK8 assay, Entry 2: Displacement of [3H]-R1881 from androgen receptor (unknown origin) expressed in human HeLa cells harboring AR3A-PSA-(ARE)4-Luc13 incubated for 2 hrs by scintillation counting, Entry 3: Antagonist activity at androgen receptor (unknown origin) expressed in human HeLa cells harboring AR3A-PSA-(ARE)4-Luc13 in presence of DHT by BrightGlo luciferase assay, ","0,3","Entry 0: F, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2025085, Entry 1: CHEMBL4622650, Entry 2: CHEMBL4668502, Entry 3: CHEMBL4668508, ","Entry 0: 10.1016/j.bmcl.2012.03.085, Entry 1: 10.1021/acs.jmedchem.0c00939, Entry 2: 10.1021/acs.jmedchem.9b02138, Entry 3: 10.1021/acs.jmedchem.9b02138, ","Entry 0: 22507964, Entry 1: 32847363, Entry 2: 32463235, Entry 3: 32463235, ","Entry 0: CHEMBL2021904, Entry 1: CHEMBL4619820, Entry 2: CHEMBL4665678, Entry 3: CHEMBL4665678, ","Entry 0: Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer., Entry 1: Development of Novel AKR1C3 Inhibitors as New Potential Treatment for Castration-Resistant Prostate Cancer., Entry 2: Overview of AKR1C3: Inhibitor Achievements and Disease Insights., Entry 3: Overview of AKR1C3: Inhibitor Achievements and Disease Insights., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: Castrate resistant prostate cancer (CRPC) is associated with increased androgen receptor (AR) signaling often brought about by elevated intratumoral androgen biosynthesis and AR amplification. Inhibition of androgen biosynthesis and/or AR antagonism should be efficacious in the treatment of CRPC. AKR1C3 catalyzes the formation of potent AR ligands from inactive precursors and is one of the most upregulated genes in CRPC. AKR1C3 inhibitors should not inhibit the related isoforms, AKR1C1 and AKR1C2 that are involved in 5-dihydrotestosterone inactivation in the prostate. We have previously developed a series of flufenamic acid analogs as potent and selective AKR1C3 inhibitors [Adeniji, A. O. et al., J. Med. Chem.2012, 55, 2311]. Here we report the X-ray crystal structure of one lead compound 3-((4-(trifluoromethyl)phenyl) amino)benzoic acid (1) in complex with AKR1C3. Compound 1 adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms. We exploited the observation that some flufenamic acid analogs also act as AR antagonists and synthesized a second generation inhibitor, 3-((4-nitronaphthalen-1-yl)amino)benzoic acid (2). Compound 2 retained nanomolar potency and selective inhibition of AKR1C3 but also acted as an AR antagonist. It inhibited 5-dihydrotestosterone stimulated AR reporter gene activity with an IC(50)=4.7 M and produced a concentration dependent reduction in androgen receptor levels in prostate cancer cells. The in vitro and cell-based effects of compound 2 make it a promising lead for development of dual acting agent for CRPC. To illuminate the structural basis of AKR1C3 inhibition, we also report the crystal structure of the AKR1C3NADP(+)2 complex, which shows that compound 2 forms a unique double-decker structure with AKR1C3., Entry 1: Aldo-keto reductase (AKR) 1C3 catalyzes the synthesis of active androgens that promote the progression of prostate cancer. AKR1C3 also contributes to androgen-independent cell proliferation and survival through the metabolism of prostaglandins and reactive aldehydes. Because of its elevation in castration-resistant prostate cancer (CRPC) tissues, AKR1C3 is a promising therapeutic target for CRPC. In this study, we found a novel potent AKR1C3 inhibitor, <i>N</i>-(4-fluorophenyl)-8-hydroxy-2-imino-2<i>H</i>-chromene-3-carboxamide (<b>2d</b>), and synthesized its derivatives with IC<sub>50</sub> values of 25-56 nM and >220-fold selectivity over other AKRs (1C1, 1C2, and 1C4). The structural factors for the inhibitory potency were elucidated by crystallographic study of AKR1C3 complexes with <b>2j</b> and <b>2l</b>. The inhibitors suppressed proliferation of prostate cancer 22Rv1 and PC3 cells through both androgen-dependent and androgen-independent mechanisms. Additionally, <b>2j</b> and <b>2l</b> prevented prostate tumor growth in a xenograft mouse model. Furthermore, the inhibitors significantly augmented apoptotic cell death induced by anti-CRPC drugs (abiraterone or enzalutamide)., Entry 2: Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone receptors and cell proliferation. Because of the overexpression in metabolic diseases and various hormone-dependent and -independent carcinomas, as well as the emergence of clinical drug resistance, an increasing number of studies have investigated AKR1C3 inhibitors. Here, we briefly review the physiological and pathological function of AKR1C3 and then summarize the recent development of selective AKR1C3 inhibitors. We propose our viewpoints on the current problems associated with AKR1C3 inhibitors with the aim of providing a reference for future drug discovery and potential therapeutic perspectives on novel, potent, selective AKR1C3 inhibitors., Entry 3: Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone receptors and cell proliferation. Because of the overexpression in metabolic diseases and various hormone-dependent and -independent carcinomas, as well as the emergence of clinical drug resistance, an increasing number of studies have investigated AKR1C3 inhibitors. Here, we briefly review the physiological and pathological function of AKR1C3 and then summarize the recent development of selective AKR1C3 inhibitors. We propose our viewpoints on the current problems associated with AKR1C3 inhibitors with the aim of providing a reference for future drug discovery and potential therapeutic perspectives on novel, potent, selective AKR1C3 inhibitors., ",,O=C(O)c1cccc(Nc2ccc([N+](=O)[O-])c3ccccc23)c1,C17H12N2O4,CHEMBL2023820,4700.0,4700.0,8000.0,21000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,6718.258703,4700.0,9600.0,6350.0,21000.0,3.982271233,3.802773725,3.672097858,5.017728767,5.197226275,5.327902142,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,12850.0,12850.0,4700.0,21000.0,4.891096872332686,4.891096872332686,5.327902142064283,4.6777807052660805,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
1342875,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccccc1)c1cc(Cl)ccc1O,C15H11ClO2,CHEMBL2030817,1510.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1510.0,1510.0,1510.0,1510.0,3.178976947,3.178976947,3.178976947,5.821023053,5.821023053,5.821023053,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1510.0,1510.0,1510.0,1510.0,5.82102305270683,5.82102305270683,5.82102305270683,5.82102305270683,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1352960,nM,IC50,,BAO_0000190,IC50,36116,In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active.,0,F,,CHEMBL648081,10.1016/s0960-894x(99)00118-3,10230628,CHEMBL1132082,"Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one.",PUBLICATION,"A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone.",,CC[C@H]1CNc2cc3oc(=O)cc(C(F)(F)F)c3cc2[C@@H]1CC,C17H18F3NO2,CHEMBL2052002,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1364622,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 841247, Entry 1: 841248, Entry 2: 2227476, Entry 3: 2227477, ","Entry 0: Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, Entry 1: Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, Entry 2: Antagonist activity at wild-type human Androgen receptor measured by TR-FRET assay, Entry 3: Antagonist activity at human Androgen receptor T877A mutant measured by TR-FRET assay, ",1,"Entry 0: F, Entry 1: F, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2089650, Entry 1: CHEMBL2089651, Entry 2: CHEMBL5140989, Entry 3: CHEMBL5140990, ","Entry 0: 10.1021/jm201438f, Entry 1: 10.1021/jm201438f, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 22280402, Entry 1: 22280402, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL2086322, Entry 1: CHEMBL2086322, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., Entry 1: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., Entry 1: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,COc1cc(/C=N/NC(=O)c2cc3c(ccc4ccccc43)o2)cc(OC)c1O,C22H18N2O5,CHEMBL2086964,26300.0,26300.0,33200.0,33200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3450.0,26300.0,29750.0,29750.0,33200.0,4.47348697,4.47348697,4.419955748,4.52651303,4.52651303,4.580044252,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,26300.0,26300.0,26300.0,26300.0,4.580044251510242,4.580044251510242,4.580044251510242,4.580044251510242,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1364623,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 841247, Entry 1: 841248, ","Entry 0: Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, Entry 1: Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2089650, Entry 1: CHEMBL2089651, ","Entry 0: 10.1021/jm201438f, Entry 1: 10.1021/jm201438f, ","Entry 0: 22280402, Entry 1: 22280402, ","Entry 0: CHEMBL2086322, Entry 1: CHEMBL2086322, ","Entry 0: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., Entry 1: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., Entry 1: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., ",,O=C(N/N=C/c1cc(Br)ccc1O)c1cc2ccccc2cc1O,C18H13BrN2O3,CHEMBL2086965,12400.0,13300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,450.0,12400.0,12850.0,12850.0,13300.0,4.108903128,4.108903128,4.093421685,4.891096872,4.891096872,4.906578315,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,13300.0,13300.0,13300.0,13300.0,4.876148359032914,4.876148359032914,4.876148359032914,4.876148359032914,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1364624,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 841247, Entry 1: 841248, ","Entry 0: Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, Entry 1: Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2089650, Entry 1: CHEMBL2089651, ","Entry 0: 10.1021/jm201438f, Entry 1: 10.1021/jm201438f, ","Entry 0: 22280402, Entry 1: 22280402, ","Entry 0: CHEMBL2086322, Entry 1: CHEMBL2086322, ","Entry 0: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., Entry 1: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., Entry 1: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., ",,O=C(N/N=C/c1cc2ccccc2cc1O)c1cc2ccccc2cc1O,C22H16N2O3,CHEMBL2086966,11100.0,15900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2400.0,11100.0,13500.0,13500.0,15900.0,4.130333768,4.130333768,4.045322979,4.869666232,4.869666232,4.954677021,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,15900.0,15900.0,15900.0,15900.0,4.798602875679548,4.798602875679548,4.798602875679548,4.798602875679548,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1364625,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 841247, Entry 1: 841248, ","Entry 0: Antagonist activity at wild type AR LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, Entry 1: Antagonist activity at wild type AR T877A mutant LBD assessed as inhibition of DHT-induced fluorescent labeled D11-FxxLF recruitment after 2 to 4 hrs by TR-FRET assay, ",1,"Entry 0: F, Entry 1: F, ",,"Entry 0: CHEMBL2089650, Entry 1: CHEMBL2089651, ","Entry 0: 10.1021/jm201438f, Entry 1: 10.1021/jm201438f, ","Entry 0: 22280402, Entry 1: 22280402, ","Entry 0: CHEMBL2086322, Entry 1: CHEMBL2086322, ","Entry 0: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., Entry 1: ""True"" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., Entry 1: Prostate cancer (PCa) therapy typically involves administration of ""classical"" antiandrogens, competitive inhibitors of androgen receptor (AR) ligands, dihydrotestosterone (DHT) and testosterone (tes), for the ligand-binding pocket (LBP) in the ligand-binding domain (LBD) of AR. Prolonged LBP-targeting leads to resistance, and alternative therapies are urgently required. We report the identification and characterization of a novel series of diarylhydrazides as selective disruptors of AR interaction with coactivators through application of structure and ligand-based virtual screening. Compounds demonstrate full (""true"") antagonism in AR with low micromolar potency, selectivity over estrogen receptors  and  and glucocorticoid receptor, and partial antagonism of the progesterone receptor. MDG506 (5) demonstrates low cellular toxicity in PCa models and dose responsive reduction of classical antiandrogen-induced prostate specific antigen expression. These data provide compelling evidence for such non-LBP intervention as an alternative approach or in combination with classical PCa therapy., ",,CCCOc1ccc(/C=N/NC(=O)c2cc3c(ccc4ccccc43)o2)cc1,C23H20N2O3,CHEMBL2086967,17900.0,28100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5100.0,17900.0,23000.0,23000.0,28100.0,4.361727836,4.361727836,4.252853031,4.638272164,4.638272164,4.747146969,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,28100.0,28100.0,28100.0,28100.0,4.55129368009492,4.55129368009492,4.55129368009492,4.55129368009492,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1378008,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](O)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,C26H32N2O,CHEMBL2105738,1108.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1108.0,1108.0,1108.0,1108.0,3.04453976,3.04453976,3.04453976,5.95546024,5.95546024,5.95546024,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1108.0,1108.0,1108.0,1108.0,5.955460239607589,5.955460239607589,5.955460239607589,5.955460239607589,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1384562,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CC[C@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,C16H16F3NO2,CHEMBL2112311,2.0,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.0,2.0,6.0,6.0,10.0,0.77815125,0.77815125,0.301029996,8.22184875,8.22184875,8.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2.0,2.0,2.0,2.0,8.698970004336019,8.698970004336019,8.698970004336019,8.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1384563,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 36116, Entry 1: 36117, ","Entry 0: In vitro antagonistic activity against human androgen receptor using cotransfection assay in CV-1 cells; Not active., Entry 1: In vitro binding affinity at human androgen receptor transfected into COS cells., ",0,"Entry 0: F, Entry 1: B, ",,"Entry 0: CHEMBL648081, Entry 1: CHEMBL648082, ","Entry 0: 10.1016/s0960-894x(99)00118-3, Entry 1: 10.1016/s0960-894x(99)00118-3, ","Entry 0: 10230628, Entry 1: 10230628, ","Entry 0: CHEMBL1132082, Entry 1: CHEMBL1132082, ","Entry 0: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., Entry 1: Nonsteroidal androgen receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., Entry 1: A series of 2H-pyrano[3,2-g]quinolin-2-ones was prepared and tested for the ability to modulate the transcriptional activity of the human androgen receptor (hAR). The parent compound, 4-(trifluoromethyl)-2H-pyrano[3,2-g]quinolin-2-one, displayed moderate interaction with hAR, but substituted analogues were potent hAR modulators in vitro as measured by an hAR cotransfection assay in CV-1 cells and bound to hAR with high affinity in a whole cell assay. Several analogues were able to activate hAR-mediated gene transcription more potently and efficaciously than dihydrotestosterone., ",,CC[C@@H]1c2cc3c(C(F)(F)F)cc(=O)oc3cc2NC[C@H]1C,C16H16F3NO2,CHEMBL2112312,0.3,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.85,0.3,5.15,5.15,10.0,0.711807229,0.711807229,-0.522878745,8.288192771,8.288192771,9.522878745,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.3,0.3,0.3,0.3,9.522878745280337,9.522878745280337,9.522878745280337,9.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1384600,nM,IC50,,BAO_0000190,IC50,36103,Antagonistic activity against human androgen receptor (hAR) expressed in CV-1 cell lines,0,F,,CHEMBL648068,10.1016/s0960-894x(99)00119-5,10230629,CHEMBL1132083,"Switching androgen receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone.",PUBLICATION,"New nonsteroidal human androgen receptor (hAR) agonists were developed from an hAR antagonist pharmacophore, 2(1H)-piperidino[3,2-g]quinolinone. (+/-)-trans-7,8-Diethyl-4-trifluoromethyl-2(H)-piperidino-[3,2-g]quinoli none was synthesized and demonstrated potent hAR agonist activity (EC50=3 nM) in the cell-based cotransfection assay and high binding affinity (Ki=16 nM) in the competitive receptor binding assay.",,CC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1O,C11H11F3N2O5,CHEMBL2112349,15.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,15.0,15.0,15.0,15.0,1.176091259,1.176091259,1.176091259,7.823908741,7.823908741,7.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,15.0,15.0,15.0,15.0,7.823908740944319,7.823908740944319,7.823908740944319,7.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1385498,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,C[C@@H]1CNc2cc3nc(O)cc(C(F)(F)F)c3cc2[C@@H]1CCC(F)(F)F,C17H16F6N2O,CHEMBL2113247,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,63.0,63.0,63.0,63.0,1.799340549,1.799340549,1.799340549,7.200659451,7.200659451,7.200659451,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,63.0,63.0,63.0,63.0,7.200659450546419,7.200659450546419,7.200659450546419,7.200659450546419,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1385499,nM,IC50,,BAO_0000190,IC50,36105,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells using cotransfection assay,0,F,,CHEMBL648070,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC(C)C[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@@H]1C,C18H21F3N2O,CHEMBL2113248,29.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,29.0,29.0,29.0,29.0,1.462397998,1.462397998,1.462397998,7.537602002,7.537602002,7.537602002,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,29.0,29.0,29.0,29.0,7.5376020021010435,7.5376020021010435,7.5376020021010435,7.5376020021010435,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1385512,nM,IC50,,BAO_0000190,IC50,36106,Antagonistic activity against human androgen receptor (hAR) in CV-1 cells was determined as a function of maximal inhibition of dihydrotestosterone using cotransfection assay,0,F,,CHEMBL648071,10.1016/s0960-894x(99)00186-9,10340624,CHEMBL1132051,"4-Alkyl- and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgen receptor agonists.",PUBLICATION,"A series of human androgen receptor (hAR) agonists based on 4-alkyl-; 4,4-dialkyl-; and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinoline was synthesized and evaluated in competitive receptor binding assays and an androgen receptor cotransfection assay in a mammalian cell background. A number of compounds in this series demonstrated activity equal to or better than dihydrotestosterone in both assays and represent a novel class of compounds for use in androgen replacement therapy.",,CC[C@H]1c2cc3c(C(F)(F)F)cc(O)nc3cc2NC[C@H]1C,C16H17F3N2O,CHEMBL2113261,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1385544,nM,IC50,,BAO_0000190,IC50,446573,Antagonist activity at human androgen receptor by luciferase reporter gene assay,0,F,,CHEMBL896867,10.1021/jm070231h,17887661,CHEMBL1148826,Substituted 6-(1-pyrrolidine)quinolin-2(1H)-ones as novel selective androgen receptor modulators.,PUBLICATION,"The androgen receptor is a ligand inducible transcription factor that is involved in a broad range of physiological functions. Here we describe the discovery of a new class of orally available selective androgen receptor modulators. The lead compound, 6-[(2R,5R)-2-methyl-5-((R)-2,2,2-trifluoro-1-hydroxyethyl)pyrrolidin-1-yl]-4-trifluoromethylquinolin-2(1H)-one (6a), showed excellent anabolic activity in muscle with reduced effect on the prostate in a rat model of hypogonadism. The compound also improved bone strength in a rat model of post-menopausal osteoporosis.",,C[C@@H]1CC[C@H]([C@H](O)C(F)(F)F)N1c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C17H16F6N2O2,CHEMBL2113293,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1442756,nM,IC50,,BAO_0000190,IC50,873657,Antagonist activity against androgen receptor expressed in CHOK1 cells after 10 to 30 mins by luciferase reporter gene assay,0,F,,CHEMBL2188773,10.1021/jm300806c,22866979,CHEMBL2177005,Mineralocorticoid receptor antagonists for the treatment of hypertension and diabetic nephropathy.,PUBLICATION,,,CCOC(=O)C1=C(C)NC(C)=C(C(C)=O)[C@H]1c1cccc2c(=O)cc(C)oc12,C22H23NO5,CHEMBL2181926,4440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4440.0,4440.0,4440.0,4440.0,3.64738297,3.64738297,3.64738297,5.35261703,5.35261703,5.35261703,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4440.0,4440.0,4440.0,4440.0,5.35261702988538,5.35261702988538,5.35261702988538,5.35261702988538,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1442757,nM,IC50,,BAO_0000190,IC50,1658408,Antagonist activity at GAL4-fused human AR LBD (667 to 919 residues) expressed in CHO-K1 cells assessed as inhibition of dihydrotestosterone-induced transactivation activity after 5 to 6 hrs by luciferase reporter gene assay,0,B,,CHEMBL4008020,10.1021/acs.jmedchem.6b01065,28051871,CHEMBL4007392,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,PUBLICATION,"Steroidal mineralocorticoid receptor (MR) antagonists are used for treatment of a range of human diseases, but they present challenging issues of complex chemical synthesis, undesirable physical properties, and poor selectivity along with unwanted side effects. Therefore, there is a great interest in the discovery of non-steroidal ligands able to bind to the ligand-binding domain of the MR and recruit different co-regulators to produce tissue-specific therapeutic effects. Several academic groups and pharmaceutical companies have been developing a series of non-steroidal ligands that consist of different chemical scaffolds, yielding MR antagonists currently evaluated in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic nephropathy. The main focus of this Perspective is to review the reported structure-activity relationships of the different series of compounds, as well as the structural studies that contribute to a better understanding of the receptor active site and are also helpful for optimization processes.",,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C(N)=O)=C(C)N2,C21H22N4O3,CHEMBL2181927,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1442758,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1678006, Entry 1: 1678019, ","Entry 0: Antagonist activity at human GAL4-DBD fused AR ligand binding domain transfected in human Huh7 cells co-expressing GAL4-RE-Luc assessed as reduction in dihydrotestosterone-induced luciferase activity after 16 hrs by luciferase reporter gene assay, Entry 1: Binding affinity to AR (unknown origin), ",0,"Entry 0: A, Entry 1: A, ",,"Entry 0: CHEMBL4028149, Entry 1: CHEMBL4028162, ","Entry 0: 10.1021/acs.jmedchem.7b01515, Entry 1: 10.1021/acs.jmedchem.7b01515, ","Entry 0: 29300474, Entry 1: 29300474, ","Entry 0: CHEMBL4024791, Entry 1: CHEMBL4024791, ","Entry 0: Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists., Entry 1: Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset., Entry 1: A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset., ",,C[C@@H]1CN(c2ccc3c(n2)NC(=O)CO3)[C@H](c2ccccc2)CO1,C18H19N3O3,CHEMBL2181928,10000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1443444,nM,IC50,,BAO_0000190,IC50,887117,Antagonist activity at androgen receptor by cellular reporter gene assay,0,F,,CHEMBL2214342,10.1016/j.bmcl.2012.09.077,23079530,CHEMBL2203135,Novel progesterone receptor modulators: 4-aryl-phenylsulfonamides.,PUBLICATION,"We have developed a new series of progesterone receptor modulators based upon the 4-aryl-phenylsulfonamide. Initial work in the series afforded potent compounds with good properties, however an advanced intermediate proved to be genotoxic in a non-GLP Ames assay following metabolic activation. We subsequently solved this problem and identified advanced leads which demonstrated oral efficacy in rhesus monkey pharmacodynamic and kinetics models.",,CCS(=O)(=O)Nc1cc(F)c(-c2ccc(C#N)n2C)c(F)c1,C14H13F2N3O2S,CHEMBL2203836,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,100.0,100.0,100.0,100.0,2.0,2.0,2.0,7.0,7.0,7.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1501264,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,O=C(/C=C/c1ccccc1O)c1cc(Cl)ccc1O,C15H11ClO3,CHEMBL2297673,1000.0,3740.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1370.0,1000.0,2370.0,2370.0,3740.0,3.374748346,3.374748346,3.0,5.625251654,5.625251654,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2370.0,2370.0,1000.0,3740.0,5.6252516539898965,5.6252516539898965,6.0,5.42712839779952,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1501271,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccc(/C=C/C(=O)c2cc(Cl)ccc2O)cc1OC,C17H15ClO4,CHEMBL2297680,5250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5250.0,5250.0,5250.0,5250.0,3.720159303,3.720159303,3.720159303,5.279840697,5.279840697,5.279840697,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5250.0,5250.0,5250.0,5250.0,5.279840696594043,5.279840696594043,5.279840696594043,5.279840696594043,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1515635,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 933427, Entry 1: 933428, Entry 2: 933429, Entry 3: 2227453, Entry 4: 2227480, ","Entry 0: Inhibition of BF3 site of androgen receptor in enzalutamide-resistant human LNCAP cells assessed as reduction in PSA level after 3 days, Entry 1: Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB assessed as reduction in PSA level after 3 days, Entry 2: Inhibition of BF3 site of androgen receptor in human LNCAP cells expressing ARR2PB after 3 days by eGFP transcriptional assay, Entry 3: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of PSA expression, Entry 4: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of Binding Function 3 (BF3) of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay, ",3,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, ",,"Entry 0: CHEMBL2318839, Entry 1: CHEMBL2318840, Entry 2: CHEMBL2318841, Entry 3: CHEMBL5140966, Entry 4: CHEMBL5140993, ","Entry 0: 10.1021/jm3015712, Entry 1: 10.1021/jm3015712, Entry 2: 10.1021/jm3015712, Entry 3: 10.1021/acs.jmedchem.2c00716, Entry 4: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 23301637, Entry 1: 23301637, Entry 2: 23301637, Entry 3: 35786895, Entry 4: 35786895, ","Entry 0: CHEMBL2311268, Entry 1: CHEMBL2311268, Entry 2: CHEMBL2311268, Entry 3: CHEMBL5137058, Entry 4: CHEMBL5137058, ","Entry 0: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., Entry 1: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., Entry 2: Targeting the binding function 3 (BF3) site of the androgen receptor through virtual screening. 2. development of 2-((2-phenoxyethyl) thio)-1H-benzimidazole derivatives., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., Entry 4: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (  J. Med. Chem.     2011 .  54  ,   8563  ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines., Entry 1: The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (  J. Med. Chem.     2011 .  54  ,   8563  ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines., Entry 2: The human androgen receptor (AR) is a proven therapeutic target in prostate cancer. All current antiandrogens, such as Bicalutamide, Flutamide, Nilutamide, and Enzalutamide, target the buried hydrophobic androgen binding pocket of this protein. However, effective resistance mechanisms against these therapeutics exist such as mutations occurring at the target site. To overcome these limitations, the surface pocket of the AR called binding function 3 (BF3) was characterized as an alternative target for small molecule therapeutics. A number of AR inhibitors directly targeting the BF3 were previously identified by us (  J. Med. Chem.     2011 .  54  ,   8563  ). In the current study, based on the prior results, we have developed structure-activity relationships that allowed designing a series of 2-((2-phenoxyethyl)thio)-1H-benzimidazole and 2-((2-phenoxyethyl)thio)-1H-indole as lead BF3 inhibitors. Some of the developed BF3 ligands demonstrated significant antiandrogen potency against LNCaP and Enzalutamide-resistant prostate cancer cell lines., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 4: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,NS(=O)(=O)c1cccc2cc(SCCOc3ccccc3)[nH]c12,C16H16N2O3S2,CHEMBL2316547,530.0,1500.0,1500.0,1600.0,6400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2083.877156,530.0,2306.0,1500.0,6400.0,3.362859303,3.176091259,2.72427587,5.637140697,5.823908741,6.27572413,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,1600.0,1600.0,1600.0,1600.0,5.795880017344075,5.795880017344075,5.795880017344075,5.795880017344075,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527185,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,N#Cc1ccc(N2CCC(O)(Cc3ccccc3)C2)cc1Cl,C18H17ClN2O,CHEMBL2337505,59.0,420.0,450.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,336.1996245,59.0,482.25,435.0,1000.0,2.683272236,2.638489257,1.770852012,6.316727764,6.361510743,7.229147988,4,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,710.0,710.0,420.0,1000.0,6.1487416512809245,6.1487416512809245,6.376750709602099,6.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527186,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,N#Cc1ccc(N2CCC(O)C2)cc1Cl,C11H11ClN2O,CHEMBL2337506,30.0,82.0,120.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4296.759477,30.0,2558.0,101.0,10000.0,3.40790054,2.004321374,1.477121255,5.59209946,6.995678626,7.522878745,4,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5041.0,5041.0,82.0,10000.0,5.297483302561849,5.297483302561849,7.086186147616283,5.0,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
1527187,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,N#Cc1ccc(N2CCC(O)(c3ccccc3)C2)cc1Cl,C17H15ClN2O,CHEMBL2337507,130.0,250.0,370.0,380.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,101.8270593,130.0,282.5,310.0,380.0,2.451018452,2.491361694,2.113943352,6.548981548,6.508638306,6.886056648,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,315.0,315.0,250.0,380.0,6.501689446210399,6.501689446210399,6.6020599913279625,6.42021640338319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527188,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,N#Cc1ccc(N2CCC(O)(c3ccc(F)cc3)C2)cc1Cl,C17H14ClFN2O,CHEMBL2337508,36.0,65.0,68.0,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,54.98806689,36.0,87.25,66.5,180.0,1.940765436,1.822821645,1.556302501,7.059234564,7.177178355,7.443697499,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,122.5,122.5,65.0,180.0,6.911863911299449,6.911863911299449,7.187086643357144,6.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527189,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(F)cc1,C18H16ClFN2O,CHEMBL2337509,8.0,8.1,17.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4325.350989,8.0,2508.275,12.55,10000.0,3.39937515,1.098643726,0.903089987,5.60062485,7.901356274,8.096910013,4,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5004.05,5004.05,8.1,10000.0,5.3006783595270575,5.3006783595270575,8.09151498112135,5.0,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
1527190,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(C(N)=O)cc1,C19H18ClN3O2,CHEMBL2337510,9.0,17.0,27.0,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.31614794,9.0,23.75,22.0,42.0,1.375663614,1.342422681,0.954242509,7.624336386,7.657577319,8.045757491,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,29.5,29.5,17.0,42.0,7.530177984021837,7.530177984021837,7.769551078621726,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527191,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)cc1,C20H20ClN3O2,CHEMBL2337511,8.6,10.0,18.0,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,9.293411645,8.6,17.15,14.0,32.0,1.234264124,1.146128036,0.934498451,7.765735876,7.853871964,8.065501549,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,21.0,21.0,10.0,32.0,7.6777807052660805,7.6777807052660805,8.0,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527192,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)nc1,C19H19ClN4O2,CHEMBL2337512,16.0,68.0,100.0,120.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,39.29376541,16.0,76.0,84.0,120.0,1.880813592,1.924279286,1.204119983,7.119186408,7.075720714,7.795880017,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,94.0,94.0,68.0,120.0,7.026872146400302,7.026872146400302,7.167491087293763,6.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527193,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, Entry 4: 2227432, Entry 5: 2227444, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, Entry 4: Binding affinity to wild-type Androgen receptor (unknown origin), Entry 5: Binding affinity to bicalutamide-resistant Androgen receptor T878A mutant (unknown origin), ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, Entry 5: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, Entry 4: CHEMBL5140945, Entry 5: CHEMBL5140957, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, Entry 4: 10.1021/acs.jmedchem.2c00716, Entry 5: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, Entry 4: 35786895, Entry 5: 35786895, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, Entry 4: CHEMBL5137058, Entry 5: CHEMBL5137058, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 4: Therapeutic Strategies to Target the Androgen Receptor., Entry 5: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 4: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 5: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@H]2C)cn1,C19H19ClN4O2,CHEMBL2337513,25.0,44.0,99.0,100.0,830.0,1700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,618.6627155,25.0,466.3333333,99.5,1700.0,2.66869646,1.997823081,1.397940009,6.33130354,7.002176919,7.602059991,6,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,72.0,72.0,44.0,100.0,7.142667503568732,7.142667503568732,7.356547323513813,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527194,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(C(=O)N(C)C)nc1,C20H21ClN4O2,CHEMBL2337514,1100.0,1700.0,3000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3559.845502,1100.0,3950.0,2350.0,10000.0,3.596597096,3.371067862,3.041392685,5.403402904,5.628932138,5.958607315,4,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5850.0,5850.0,1700.0,10000.0,5.23284413391782,5.23284413391782,5.769551078621726,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
1527195,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@@]2(O)CCN(c3ccc(C#N)c(Cl)c3)[C@@H]2C)cn1,C19H19ClN4O2,CHEMBL2337515,97.0,1600.0,1600.0,6400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2375.997514,97.0,2424.25,1600.0,6400.0,3.384577404,3.204119983,1.986771734,5.615422596,5.795880017,7.013228266,4,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4000.0,4000.0,1600.0,6400.0,5.3979400086720375,5.3979400086720375,5.795880017344075,5.1938200260161125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527196,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@@]1(O)c1ccc(N2CCCC2=O)nc1,C21H21ClN4O2,CHEMBL2337516,11.0,13.0,87.0,160.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,61.4384855,11.0,67.75,50.0,160.0,1.8309093,1.698970004,1.041392685,7.1690907,7.301029996,7.958607315,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,86.5,86.5,13.0,160.0,7.062983892535186,7.062983892535186,7.886056647693163,6.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527197,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(OC)c3)[C@H]2C)cn1,C20H22N4O3,CHEMBL2337517,62.0,120.0,240.0,730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,263.1387467,62.0,288.0,180.0,730.0,2.459392488,2.255272505,1.792391689,6.540607512,6.744727495,7.207608311,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,425.0,425.0,120.0,730.0,6.371611069949688,6.371611069949688,6.920818753952375,6.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527198,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)cc3)[C@H]2C)cn1,C19H20N4O2,CHEMBL2337518,400.0,1400.0,5300.0,7600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2913.224159,400.0,3675.0,3350.0,7600.0,3.565257343,3.525044807,2.602059991,5.434742657,5.474955193,6.397940009,4,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4500.0,4500.0,1400.0,7600.0,5.346787486224656,5.346787486224656,5.853871964321762,5.119186407719209,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1527199,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 944550, Entry 1: 944551, Entry 2: 944552, Entry 3: 944553, ","Entry 0: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 1: Antagonist activity at wild type Androgen receptor (unknown origin) expressed in human Cos-7 cells co-expressing pGL3-MMTV-luc vector assessed as luciferase activity by reporter gene assay, Entry 2: Inhibition of Androgen receptor T877A mutant (unknown origin) expressed in Freestyle293F cells, Entry 3: Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, ","1,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL2339066, Entry 1: CHEMBL2339067, Entry 2: CHEMBL2339068, Entry 3: CHEMBL2339069, ","Entry 0: 10.1016/j.bmc.2012.11.001, Entry 1: 10.1016/j.bmc.2012.11.001, Entry 2: 10.1016/j.bmc.2012.11.001, Entry 3: 10.1016/j.bmc.2012.11.001, ","Entry 0: 23199477, Entry 1: 23199477, Entry 2: 23199477, Entry 3: 23199477, ","Entry 0: CHEMBL2331321, Entry 1: CHEMBL2331321, Entry 2: CHEMBL2331321, Entry 3: CHEMBL2331321, ","Entry 0: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 1: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 2: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., Entry 3: Design, synthesis, and biological evaluation of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives as novel androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 1: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 2: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., Entry 3: We designed and synthesized a series of 3-aryl-3-hydroxy-1-phenylpyrrolidine derivatives D and evaluated their potential as novel androgen receptor (AR) antagonists therapeutically effective against castration-resistant prostate cancer (CRPC). Introduction of a methyl group at the 2-position (R(2)) of the pyrrolidine ring increased the AR binding affinity. The (2S,3R) configuration of the pyrrolidine ring was favorable for the AR antagonistic activity. It was found that introduction of an amide substituent (R(1)) and a pyridin-3-yl group (Q) was effective for reducing the AR agonistic activity which appeared during the optimization of lead compound 6. Compound 54 showed potent antitumor effects against a CRPC model of LNCaP-hr cell line in a mouse xenograft, in which bicalutamide exhibited only partial suppression of tumor growth. Thus, the pyrrolidine derivatives such as 54 are novel AR antagonists, and their properties having efficacy against CRPC are distinct from those of a representative first-generation antagonist, bicalutamide., ",,CNC(=O)c1ccc([C@]2(O)CCN(c3ccc(C#N)c(F)c3)[C@H]2C)cn1,C19H19FN4O2,CHEMBL2337519,290.0,830.0,1700.0,1700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,601.1239473,290.0,1130.0,1265.0,1700.0,3.053078443,3.102090526,2.462397998,5.946921557,5.897909474,6.537602002,4,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1265.0,1265.0,830.0,1700.0,5.897909474488164,5.897909474488164,6.080921907623926,5.769551078621726,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1528790,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",pIC50,"Entry 0: 950670, Entry 1: 2227402, Entry 2: 2227449, ","Entry 0: Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis, Entry 1: Binding affinity to Androgen receptor (unknown origin), Entry 2: Antagonist activity at Androgen receptor (unknown origin) assessed as downregulation of AR, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL2352673, Entry 1: CHEMBL5140915, Entry 2: CHEMBL5140962, ","Entry 0: 10.1016/j.bmcl.2013.02.056, Entry 1: 10.1021/acs.jmedchem.2c00716, Entry 2: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 23466225, Entry 1: 35786895, Entry 2: 35786895, ","Entry 0: CHEMBL2346572, Entry 1: CHEMBL5137058, Entry 2: CHEMBL5137058, ","Entry 0: Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,N#Cc1ccc(CN2CCN(c3ccc4nnc(C(F)(F)F)n4n3)CC2)cc1,C18H16F3N7,CHEMBL2346967,1513.56,1584.89,79433.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,36714.69033,1513.56,27510.42333,1584.89,79432.82,4.439497273,3.199999125,3.179999642,4.560502727,5.800000875,5.820000358,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,79433.0,79433.0,79433.0,79433.0,4.0999990348465305,4.0999990348465305,4.0999990348465305,4.0999990348465305,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1528799,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",mix,"Entry 0: 950670, Entry 1: 2014757, Entry 2: 2227449, ","Entry 0: Inhibition of androgen receptor-mediated cellular downregulation in human LNCAP cells assessed as decrease in nuclear receptor level after 20 to 22 hrs by laser-scanning fluorescence microplate cytometeric analysis, Entry 1: Induction of androgen receptor degradation in human LNCaP cells, Entry 2: Antagonist activity at Androgen receptor (unknown origin) assessed as downregulation of AR, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL2352673, Entry 1: CHEMBL4668335, Entry 2: CHEMBL5140962, ","Entry 0: 10.1016/j.bmcl.2013.02.056, Entry 1: 10.1021/acs.jmedchem.0c00093, Entry 2: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 23466225, Entry 1: 32352776, Entry 2: 35786895, ","Entry 0: CHEMBL2346572, Entry 1: CHEMBL4665673, Entry 2: CHEMBL5137058, ","Entry 0: Discovery of AZD3514, a small-molecule androgen receptor downregulator for treatment of advanced prostate cancer., Entry 1: Monomeric Targeted Protein Degraders., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Removal of the basic piperazine nitrogen atom, introduction of a solubilising end group and partial reduction of the triazolopyridazine moiety in the previously-described lead androgen receptor downregulator 6-[4-(4-cyanobenzyl)piperazin-1-yl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazine (1) addressed hERG and physical property issues, and led to clinical candidate 6-(4-{4-[2-(4-acetylpiperazin-1-yl)ethoxy]phenyl}piperidin-1-yl)-3-(trifluoromethyl)-7,8-dihydro[1,2,4]triazolo[4,3-b]pyridazine (12), designated AZD3514, that is being evaluated in a Phase I clinical trial in patients with castrate-resistant prostate cancer., Entry 1: The discovery and development of targeted protein degraders have become important areas of research in the field of medicinal chemistry. Inducing degradation of a target protein presents several advantages relative to simple inhibition including a potential for extended duration of action and more profound pharmacology. While engineered heterodimeric molecules have recently been a major focus within industry and academia, this Perspective highlights examples of targeted protein degradation observed for smaller, monomeric molecules. Methods and tools for evaluating protein degradation as well as a discussion of physical properties of monomeric vs engineered heterodimeric degraders are presented., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC(=O)N1CCN(CCOc2ccc(C3CCN(C4=Nn5c(nnc5C(F)(F)F)CC4)CC3)cc2)CC1,C25H32F3N7O2,CHEMBL2346976,1778.28,1778.28,1780.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.810815776,1778.28,1778.853333,1778.28,1780.0,3.250140142,3.250000144,3.250000144,5.749859858,5.749999856,5.749999856,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1780.0,1780.0,1780.0,1780.0,5.749579997691106,5.749579997691106,5.749579997691106,5.749579997691106,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563158,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(C(F)(F)F)cc2)oc2cccc(O)c12,C16H9F3O3,CHEMBL2386392,1230.27,1240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4.865,1230.27,1235.135,1235.135,1240.0,3.091714428,3.091714428,3.090000434,5.908285572,5.908285572,5.909999566,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1235.135,1235.135,1230.27,1240.0,5.908285571512955,5.908285571512955,5.90999956608739,5.906578314837765,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563159,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(F)cc2)oc2cccc(O)c12,C15H9FO3,CHEMBL2386393,330.0,331.13,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.565,330.0,330.565,330.565,331.13,2.519256869,2.519256869,2.51851394,6.480743131,6.480743131,6.48148606,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,330.565,330.565,330.0,331.13,6.480743131138247,6.480743131138247,6.481486060122113,6.480001470881152,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563160,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccccc2)oc2cccc(F)c12,C15H9FO2,CHEMBL2386394,770.0,776.25,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3.125,770.0,773.125,773.125,776.25,2.888249717,2.888249717,2.886490725,6.111750283,6.111750283,6.113509275,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,773.125,773.125,770.0,776.25,6.1117502830268045,6.1117502830268045,6.113509274827518,6.109998386815364,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563161,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc([N+](=O)[O-])cc2)oc2cccc(O)c12,C15H9NO5,CHEMBL2386395,360.0,363.08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.54,360.0,361.54,361.54,363.08,2.558156354,2.558156354,2.556302501,6.441843646,6.441843646,6.443697499,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,361.53999999999996,361.53999999999996,360.0,363.08,6.441843646313426,6.441843646313426,6.443697499232713,6.439997673226633,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563162,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,N#Cc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C16H9NO3,CHEMBL2386396,250.0,251.19,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.595,250.0,250.595,250.595,251.19,2.398972401,2.398972401,2.397940009,6.601027599,6.601027599,6.602059991,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,250.595,250.595,250.0,251.19,6.6010275985217275,6.6010275985217275,6.6020599913279625,6.599997654072044,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563163,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,CN(C)c1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C17H15NO3,CHEMBL2386397,850.0,851.14,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.57,850.0,850.57,850.57,851.14,2.929710061,2.929710061,2.929418926,6.070289939,6.070289939,6.070581074,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,850.5699999999999,850.5699999999999,850.0,851.14,6.070289939120491,6.070289939120491,6.070581074285707,6.069998998990925,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563165,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,Nc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C15H11NO3,CHEMBL2386399,1990.0,1995.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2.63,1990.0,1992.63,1992.63,1995.26,3.299426665,3.299426665,3.298853076,5.700573335,5.700573335,5.701146924,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1992.63,1992.63,1990.0,1995.26,5.700573335457106,5.700573335457106,5.701146923590294,5.700000503883016,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563167,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,CSc1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C16H12O3S,CHEMBL2386401,1070.0,1071.52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.76,1070.0,1070.76,1070.76,1071.52,3.029692139,3.029692139,3.029383778,5.970307861,5.970307861,5.970616222,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1070.76,1070.76,1070.0,1071.52,5.970307860966378,5.970307860966378,5.97061622231479,5.9699997184078955,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563170,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(Cl)cc2)oc2cccc(F)c12,C15H8ClFO2,CHEMBL2386404,360.0,363.08,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.54,360.0,361.54,361.54,363.08,2.558156354,2.558156354,2.556302501,6.441843646,6.441843646,6.443697499,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,361.53999999999996,361.53999999999996,360.0,363.08,6.441843646313426,6.441843646313426,6.443697499232713,6.439997673226633,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563171,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,O=c1cc(-c2ccc(F)cc2)oc2cccc(F)c12,C15H8F2O2,CHEMBL2386405,190.0,190.55,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.275,190.0,190.275,190.275,190.55,2.279381731,2.279381731,2.278753601,6.720618269,6.720618269,6.721246399,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.275,190.275,190.0,190.55,6.720618269386569,6.720618269386569,6.721246399047171,6.719991046891814,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563172,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,N#Cc1ccc(-c2cc(=O)c3c(F)cccc3o2)cc1,C16H8FNO2,CHEMBL2386406,1200.0,1202.26,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1.13,1200.0,1201.13,1201.13,1202.26,3.079590014,3.079590014,3.079181246,5.920409986,5.920409986,5.920818754,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1201.13,1201.13,1200.0,1202.26,5.920409985746755,5.920409985746755,5.920818753952375,5.920001601921648,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1563174,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",mix,"Entry 0: 962459, Entry 1: 962459, ","Entry 0: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor LBD expressed in human MDA-kb2 cells by luciferase reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2390352, Entry 1: CHEMBL2390352, ","Entry 0: 10.1016/j.bmc.2013.03.060, Entry 1: 10.1016/j.bmc.2013.03.060, ","Entry 0: 23611768, Entry 1: 23611768, ","Entry 0: CHEMBL2385078, Entry 1: CHEMBL2385078, ","Entry 0: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., Entry 1: The systematic structure-activity relationship to predict how flavones bind to human androgen receptor for their antagonistic activity., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., Entry 1: Although flavones act as potent androgen receptor (AR) antagonists, it remains unclear how flavones interact with AR. The aim of this in silico study was to investigate the molecular recognition processes of newly synthesized 5,4'-difluoroflavone with the highest activity (IC50 value=0.19 M) in the AR-ligand binding domain (AR-LBD). The results demonstrated that at its 4'-position of 5,4'-difluoroflavone the substituents may face Arg752 and that in AR-LBD, the submolecular bulk of substituents is unfavorable for AR antagonists and the negative electrostatic interaction site prefers the stronger hydrogen bond capability of substituents of AR antagonists. The prediction model is a valuable tool for designing a novel AR antagonist., ",,NC(=O)c1ccc(-c2cc(=O)c3c(O)cccc3o2)cc1,C16H11NO4,CHEMBL2386408,3548.13,3580.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.935,3548.13,3564.065,3564.065,3580.0,3.551945616,3.551945616,3.549999524,5.448054384,5.448054384,5.450000476,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3564.065,3564.065,3548.13,3580.0,5.4480543840729,5.4480543840729,5.450000476425332,5.446116973356125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1567843,nM,IC50,,BAO_0000190,IC50,966507,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,0,B,,CHEMBL2399205,10.1016/j.bmcl.2013.04.065,23727044,CHEMBL2396586,Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.,PUBLICATION,"In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.",,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(C#N)cc3)nc2C)c1,C20H18N4O3S,CHEMBL2397333,6260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6260.0,6260.0,6260.0,6260.0,3.796574333,3.796574333,3.796574333,5.203425667,5.203425667,5.203425667,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6260.0,6260.0,6260.0,6260.0,5.20342566678957,5.20342566678957,5.20342566678957,5.20342566678957,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1567844,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 966507, Entry 1: 2227483, ","Entry 0: Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay, Entry 1: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of Binding Function 3 (BF3) of AR measured by luciferase assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL2399205, Entry 1: CHEMBL5140996, ","Entry 0: 10.1016/j.bmcl.2013.04.065, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 23727044, Entry 1: 35786895, ","Entry 0: CHEMBL2396586, Entry 1: CHEMBL5137058, ","Entry 0: Discovery of non-LBD inhibitor for androgen receptor by structure-guide design., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(Cl)c(Cl)c3)nc2C)c1,C19H17Cl2N3O3S,CHEMBL2397334,2650.0,6260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1805.0,2650.0,4455.0,4455.0,6260.0,3.648847708,3.648847708,3.423245874,5.351152292,5.351152292,5.576754126,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,2650.0,2650.0,2650.0,2650.0,5.576754126063192,5.576754126063192,5.576754126063192,5.576754126063192,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1567845,nM,IC50,,BAO_0000190,IC50,966507,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,0,B,,CHEMBL2399205,10.1016/j.bmcl.2013.04.065,23727044,CHEMBL2396586,Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.,PUBLICATION,"In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.",,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3cc(Cl)cc(Cl)c3)nc2C)c1,C19H17Cl2N3O3S,CHEMBL2397335,13190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,13190.0,13190.0,13190.0,13190.0,4.120244796,4.120244796,4.120244796,4.879755204,4.879755204,4.879755204,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,13190.0,13190.0,13190.0,13190.0,4.879755204453635,4.879755204453635,4.879755204453635,4.879755204453635,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1567846,nM,IC50,,BAO_0000190,IC50,966507,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,0,B,,CHEMBL2399205,10.1016/j.bmcl.2013.04.065,23727044,CHEMBL2396586,Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.,PUBLICATION,"In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.",,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc(F)c(Cl)c3)nc2C)c1,C19H17ClFN3O3S,CHEMBL2397336,5070.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5070.0,5070.0,5070.0,5070.0,3.705007959,3.705007959,3.705007959,5.294992041,5.294992041,5.294992041,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5070.0,5070.0,5070.0,5070.0,5.294992040666664,5.294992040666664,5.294992040666664,5.294992040666664,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1567847,nM,IC50,,BAO_0000190,IC50,966507,Inhibition of androgen receptor in human LNCAP cells after 1 day by luciferase reporter gene assay,0,B,,CHEMBL2399205,10.1016/j.bmcl.2013.04.065,23727044,CHEMBL2396586,Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.,PUBLICATION,"In this study, we synthesized the BF-3 binding small molecules, a series of pyridazinone-based compounds, as a novel class of non-LBP antiandrogens for treating prostate cancer by inhibiting androgen receptor. The new class compound was discovered to inhibitor the viability of AR-dependent human prostate LNCap cells and AR activity combining with the computational method. It showed a good physicochemical and PK property.",,CCS(=O)(=O)Nc1cccc(-c2cc(=O)n(-c3ccc4ccccc4c3)nc2C)c1,C23H21N3O3S,CHEMBL2397337,9760.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9760.0,9760.0,9760.0,9760.0,3.989449818,3.989449818,3.989449818,5.010550182,5.010550182,5.010550182,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9760.0,9760.0,9760.0,9760.0,5.010550182333308,5.010550182333308,5.010550182333308,5.010550182333308,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1570948,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CCC(CC)(c1ccc(N)c(C)c1)c1ccc(O)c(C)c1,C19H25NO,CHEMBL2403348,5400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5400.0,5400.0,5400.0,5400.0,3.73239376,3.73239376,3.73239376,5.26760624,5.26760624,5.26760624,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5400.0,5400.0,5400.0,5400.0,5.267606240177032,5.267606240177032,5.267606240177032,5.267606240177032,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1570949,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CC[Si](CC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,C18H24O2Si,CHEMBL2403349,1900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1900.0,1900.0,1900.0,1900.0,3.278753601,3.278753601,3.278753601,5.721246399,5.721246399,5.721246399,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1900.0,1900.0,1900.0,1900.0,5.721246399047171,5.721246399047171,5.721246399047171,5.721246399047171,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1570950,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CCCC[Si](CCCC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,C22H32O2Si,CHEMBL2403350,8200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8200.0,8200.0,8200.0,8200.0,3.913813852,3.913813852,3.913813852,5.086186148,5.086186148,5.086186148,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8200.0,8200.0,8200.0,8200.0,5.086186147616283,5.086186147616283,5.086186147616283,5.086186147616283,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1570955,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CCC(CC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,C19H24O2,CHEMBL2403355,4500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4500.0,4500.0,4500.0,4500.0,3.653212514,3.653212514,3.653212514,5.346787486,5.346787486,5.346787486,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4500.0,4500.0,4500.0,4500.0,5.346787486224656,5.346787486224656,5.346787486224656,5.346787486224656,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1570956,nM,IC50,,BAO_0000190,IC50,971947,Antagonist activity at human pSG5-AR assessed as inhibition of dihydrotestosterone-induced effect by reporter gene assay,0,B,,CHEMBL2405557,10.1016/j.bmcl.2013.05.067,23768907,CHEMBL2401681,Structure-activity relationships of bisphenol A analogs at estrogen receptors (ERs): discovery of an ER-selective antagonist.,PUBLICATION,"Our multi-template approach for drug discovery, focusing on protein targets with similar fold structures, has yielded lead compounds for various targets. We have also shown that a diphenylmethane skeleton can serve as a surrogate for a steroid skeleton. Here, on the basis of those ideas, we hypothesized that the diphenylmethane derivative bisphenol A (BPA) would bind to the ligand-binding domain of estrogen receptors (ERs) in a similar manner to estradiol and act as a steroid surrogate. To test this idea, we synthesized a series of BPA analogs and evaluated their structure-activity relationships, focusing on agonistic/antagonistic activities at ERs and ER/ER subtype selectivity. Among the compounds examined, 18 was found to be a potent ER-antagonist with high selectivity over ER and androgen receptor under our assay conditions. A computational docking study suggested that 18 would bind to the antagonistic conformation of ER. ER-selective antagonists, such as 18, are candidate agents for treatment of breast cancer.",,CCCC(CCC)(c1ccc(O)c(C)c1)c1ccc(O)c(C)c1,C21H28O2,CHEMBL2403356,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1592038,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1621736, Entry 1: 1621737, Entry 2: 1621750, ","Entry 0: Antagonist activity at wild type AR in human PC3 cells assessed as suppression of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay, Entry 1: Antagonist activity at AR T877A mutant (unknown origin) transfected in human PC3 cells assessed as inhibition of DHT-induced receptor transcriptional activation after 24 hrs by PSA-luciferase reporter gene assay, Entry 2: Antagonist activity at AR F876L mutant (unknown origin) expressed in human PC3 cells assessed as inhibition of DHT-induced receptor transactivation after 24 hrs by PSA-luciferase reporter gene assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3864019, Entry 1: CHEMBL3864020, Entry 2: CHEMBL3864033, ","Entry 0: 10.1021/acsmedchemlett.6b00180, Entry 1: 10.1021/acsmedchemlett.6b00180, Entry 2: 10.1021/acsmedchemlett.6b00180, ","Entry 0: 27994731, Entry 1: 27994731, Entry 2: 27994731, ","Entry 0: CHEMBL3862039, Entry 1: CHEMBL3862039, Entry 2: CHEMBL3862039, ","Entry 0: Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor., Entry 1: Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor., Entry 2: Identification of Triptophenolide from Tripterygium wilfordii as a Pan-antagonist of Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: A compound, triptophenolide, derived from Tripterygium wilfordii was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant androgen receptors. Triptophenolide exhibits its antiandrogenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor., Entry 1: A compound, triptophenolide, derived from Tripterygium wilfordii was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant androgen receptors. Triptophenolide exhibits its antiandrogenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor., Entry 2: A compound, triptophenolide, derived from Tripterygium wilfordii was identified as an antiandrogen. Triptophenolide inhibits the activity of both wild-type and F876L mutant androgen receptors. Triptophenolide exhibits its antiandrogenic activity through competitive binding with androgen in the hormone-binding pocket, decreasing the expression of androgen receptor, and reducing the nuclear translocation of androgen receptor., ",,CC(C)c1ccc2c(c1O)CC[C@H]1C3=C(CC[C@]21C)C(=O)OC3,C20H24O3,CHEMBL3039217,260.0,388.0,480.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.21455906,260.0,376.0,388.0,480.0,2.575187845,2.588831726,2.414973348,6.424812155,6.411168274,6.585026652,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,260.0,260.0,260.0,260.0,6.585026652029182,6.585026652029182,6.585026652029182,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1594580,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,N#Cc1ccc(N2[C@@H]3CC[C@H]2C[C@@H](O)C3)cc1Cl,C14H15ClN2O,CHEMBL3084689,31.7,31.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,31.7,31.7,31.7,31.7,1.501059262,1.501059262,1.501059262,7.498940738,7.498940738,7.498940738,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,31.7,31.7,31.7,31.7,7.498940737782249,7.498940737782249,7.498940737782249,7.498940737782249,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1603490,nM,IC50,,BAO_0000190,IC50,1275503,Antagonist activity at human androgen receptor ligand binding domain expressed in human Huh7 cells after 16 hrs by luciferase reporter gene assay,0,B,,CHEMBL3090518,10.1016/j.bmcl.2013.09.099,24157365,CHEMBL3085697,Design and synthesis of aryl sulfonamide-based nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Hit-to-lead medicinal chemistry efforts are described starting from a screening hit 1, leading to a new class of aryl sulfonamide-based MR antagonist, exemplified by 17, that possesses favourable MR binding affinity, selectivity profile against closely related NHRs, physicochemical properties and metabolic stability.",,Cc1cn(-c2ccc(CNS(=O)(=O)c3cc(F)ccc3F)cc2)c(C)n1,C18H17F2N3O2S,CHEMBL3086027,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1733375,nM,IC50,,BAO_0000190,IC50,1336860,Inhibition of androgen receptor (unknown origin),0,B,,CHEMBL3241718,10.1016/j.bmcl.2014.02.057,24630411,CHEMBL3232811,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,PUBLICATION,"Novel potent and selective mineralocorticoid receptor antagonists were identified, utilizing heterocyclic amide replacements in the oxazolidinedione series. Structure-activity relationship (SAR) efforts focused on improving lipophilic ligand efficiency (LLE) while maintaining nuclear hormone receptor selectivity and reasonable pharmacokinetic profiles.",,COc1cc(OC)cc(-c2nnc([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccccc4)C3=O)o2)c1,C28H25N3O6,CHEMBL3234858,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1733380,nM,IC50,,BAO_0000190,IC50,1336860,Inhibition of androgen receptor (unknown origin),0,B,,CHEMBL3241718,10.1016/j.bmcl.2014.02.057,24630411,CHEMBL3232811,Mineralocorticoid receptor antagonists: identification of heterocyclic amide replacements in the oxazolidinedione series.,PUBLICATION,"Novel potent and selective mineralocorticoid receptor antagonists were identified, utilizing heterocyclic amide replacements in the oxazolidinedione series. Structure-activity relationship (SAR) efforts focused on improving lipophilic ligand efficiency (LLE) while maintaining nuclear hormone receptor selectivity and reasonable pharmacokinetic profiles.",,C[C@H](c1ccccc1)N1C(=O)O[C@](Cc2ccccc2)(c2nnc(C3(c4ccccc4)CC3)o2)C1=O,C29H25N3O4,CHEMBL3234863,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748732,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1cc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C24H25N3O3,CHEMBL3263750,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748733,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,CCOc1cc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C25H27N3O3,CHEMBL3263751,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748734,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C23H24N4O3,CHEMBL3263752,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748736,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C22H23N5O3,CHEMBL3263754,9050.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9050.0,9050.0,9050.0,9050.0,3.956648579,3.956648579,3.956648579,5.043351421,5.043351421,5.043351421,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9050.0,9050.0,9050.0,9050.0,5.043351420794797,5.043351420794797,5.043351420794797,5.043351420794797,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748737,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1cc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C23H24N4O3,CHEMBL3263755,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748738,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,Cc1nc(N2N=C(c3ccc(C(=O)O)cc3)C[C@@H]2C2CCCC2)ccc1C#N,C22H22N4O2,CHEMBL3263756,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748739,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,CCOc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C24H26N4O3,CHEMBL3263757,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748740,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(Cl)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)O,C22H21ClN4O3,CHEMBL3263758,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748742,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(N)=O,C23H25N5O2,CHEMBL3263760,3250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3250.0,3250.0,3250.0,3250.0,3.511883361,3.511883361,3.511883361,5.488116639,5.488116639,5.488116639,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3250.0,3250.0,3250.0,3250.0,5.488116639021126,5.488116639021126,5.488116639021126,5.488116639021126,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1748743,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,CNC(=O)c1ccc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)nc1OC,C24H27N5O2,CHEMBL3263761,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748744,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)N(C)C,C25H29N5O2,CHEMBL3263762,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748745,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(N)=O,C22H24N6O2,CHEMBL3263763,7780.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7780.0,7780.0,7780.0,7780.0,3.890979597,3.890979597,3.890979597,5.109020403,5.109020403,5.109020403,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7780.0,7780.0,7780.0,7780.0,5.1090204030103115,5.1090204030103115,5.1090204030103115,5.1090204030103115,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748746,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,CNC(=O)c1ccc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)nc1OC,C23H26N6O2,CHEMBL3263764,8520.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8520.0,8520.0,8520.0,8520.0,3.930439595,3.930439595,3.930439595,5.069560405,5.069560405,5.069560405,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8520.0,8520.0,8520.0,8520.0,5.0695604052333,5.0695604052333,5.0695604052333,5.0695604052333,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748747,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)N(C)C,C24H28N6O2,CHEMBL3263765,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748748,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)NS(C)(=O)=O,C24H27N5O4S,CHEMBL3263766,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748749,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)n3)[C@@H](C3CCCC3)C2)ccc1C(=O)NS(C)(=O)=O,C23H26N6O4S,CHEMBL3263767,9940.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9940.0,9940.0,9940.0,9940.0,3.997386384,3.997386384,3.997386384,5.002613616,5.002613616,5.002613616,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9940.0,9940.0,9940.0,9940.0,5.002613615602686,5.002613615602686,5.002613615602686,5.002613615602686,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1748750,nM,IC50,,BAO_0000190,IC50,1349007,Antagonist activity at androgen receptor (unknown origin) by Gal4-based cellular assay,0,B,,CHEMBL3266005,10.1021/jm500206r,24738581,CHEMBL3259597,"Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.",PUBLICATION,"A novel series of nonsteroidal mineralocorticoid receptor (MR) antagonists identified as part of our strategy to follow up on the clinical candidate PF-03882845 (2) is reported. Optimization departed from the previously described pyrazoline 3a and focused on improving the selectivity for MR versus the progesterone receptor (PR) as an approach to avoid potential sex-hormone-related adverse effects and improving biopharmaceutical properties. From this effort, (R)-14c was identified as a potent nonsteroidal MR antagonist (IC50 = 4.5 nM) with higher than 500-fold selectivity versus PR and other related nuclear hormone receptors, with improved solubility as compared to 2 and pharmacokinetic properties suitable for oral administration. (R)-14c was evaluated in vivo using the increase of urinary Na(+)/K(+) ratio in rat as a mechanism biomarker of MR antagonism. Treatment with (R)-14c by oral administration resulted in significant increases in urinary Na(+)/K(+) ratio and demonstrated this novel compound acts as an MR antagonist.",,COc1nc(C2=NN(c3ccc(C#N)c(C)c3)[C@@H](C3CCCC3)C2)ccc1C(=O)Nc1nnn[nH]1,C24H25N9O2,CHEMBL3263768,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1782695,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CN(Cc1ccc(Br)o1)C(=O)c1cc2ccc(F)cc2[nH]1,C15H12BrFN2O2,CHEMBL3318054,8090.0,15670.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3790.0,8090.0,11880.0,11880.0,15670.0,4.074816441,4.074816441,3.907948522,4.925183559,4.925183559,5.092051478,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11880.0,11880.0,8090.0,15670.0,4.925183559354825,4.925183559354825,5.092051478387727,4.80493100353141,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1782696,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc(CN(C)C(=O)c2cc3cc(F)ccc3[nH]2)o1,C16H15FN2O2,CHEMBL3318055,6560.0,9440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1440.0,6560.0,8000.0,8000.0,9440.0,3.903089987,3.903089987,3.816903839,5.096910013,5.096910013,5.183096161,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8000.0,8000.0,6560.0,9440.0,5.096910013008056,5.096910013008056,5.1830961606243395,5.025028005701931,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1782697,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,N#CCCN(Cc1ccccc1)C(=O)c1cc2ccccc2[nH]1,C19H17N3O,CHEMBL3318056,4580.0,7510.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1465.0,4580.0,6045.0,6045.0,7510.0,3.781396305,3.781396305,3.660865478,5.218603695,5.218603695,5.339134522,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,6045.0,6045.0,4580.0,7510.0,5.2186036948032095,5.2186036948032095,5.33913452199613,5.124360062995832,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
1782698,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,COCCN(Cc1ccco1)C(=O)c1cc2cc(F)ccc2[nH]1,C17H17FN2O3,CHEMBL3318057,6470.0,6620.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,75.0,6470.0,6545.0,6545.0,6620.0,3.815909651,3.815909651,3.810904281,5.184090349,5.184090349,5.189095719,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6545.0,6545.0,6470.0,6620.0,5.184090349113226,5.184090349113226,5.189095719331299,5.1791420105603,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1782699,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CC(C)N(Cc1ccco1)C(=O)c1cc2cc(C(F)(F)F)ccc2[nH]1,C18H17F3N2O2,CHEMBL3318058,5200.0,5290.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,45.0,5200.0,5245.0,5245.0,5290.0,3.719745493,3.719745493,3.716003344,5.280254507,5.280254507,5.283996656,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5245.0,5245.0,5200.0,5290.0,5.280254507470423,5.280254507470423,5.2839966563652006,5.276544327964814,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1782700,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,O=C(c1cc2ccc(F)cc2[nH]1)N(Cc1ccco1)Cc1ccco1,C19H15FN2O3,CHEMBL3317457,4040.0,5480.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,720.0,4040.0,4760.0,4760.0,5480.0,3.677606953,3.677606953,3.606381365,5.322393047,5.322393047,5.393618635,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4760.0,4760.0,4040.0,5480.0,5.3223930472795065,5.3223930472795065,5.393618634889395,5.261219441515631,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782701,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CN(Cc1ccc(Br)s1)C(=O)c1cc2ccc(F)cc2[nH]1,C15H12BrFN2OS,CHEMBL3318059,3060.0,3530.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,235.0,3060.0,3295.0,3295.0,3530.0,3.517855419,3.517855419,3.485721426,5.482144581,5.482144581,5.514278574,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3295.0,3295.0,3060.0,3530.0,5.482144581069972,5.482144581069972,5.51427857351842,5.452225294612178,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782702,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CN(Cc1cccs1)C(=O)c1cc2ccc(F)cc2[nH]1,C15H13FN2OS,CHEMBL3318060,3380.0,5450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1035.0,3380.0,4415.0,4415.0,5450.0,3.644930708,3.644930708,3.5289167,5.355069292,5.355069292,5.4710833,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4415.0,4415.0,3380.0,5450.0,5.355069292086412,5.355069292086412,5.471083299722345,5.2636034977233574,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782703,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc(CN(C(=O)c2cc3ccccc3[nH]2)C(C)C)o1,C18H20N2O2,CHEMBL3318061,3320.0,3420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,3320.0,3370.0,3370.0,3420.0,3.527629901,3.527629901,3.521138084,5.472370099,5.472370099,5.478861916,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3370.0,3370.0,3320.0,3420.0,5.4723700991286615,5.4723700991286615,5.478861916295964,5.465973893943865,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782704,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc2cc(C(=O)N(Cc3ccc(C)o3)C(C)C)[nH]c2c1,C19H22N2O2,CHEMBL3318062,1650.0,2890.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,620.0,1650.0,2270.0,2270.0,2890.0,3.356025857,3.356025857,3.217483944,5.643974143,5.643974143,5.782516056,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2270.0,2270.0,1650.0,2890.0,5.6439741428068775,5.6439741428068775,5.782516055786093,5.539102157243452,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782705,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc2[nH]c(C(=O)N(Cc3ccc(C)o3)C(C)C)cc2c1,C19H22N2O2,CHEMBL3318063,1770.0,2670.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,450.0,1770.0,2220.0,2220.0,2670.0,3.346352974,3.346352974,3.247973266,5.653647026,5.653647026,5.752026734,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2220.0,2220.0,1770.0,2670.0,5.653647025549361,5.653647025549361,5.752026733638194,5.573488738635425,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782706,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc2[nH]c(C(=O)N(Cc3ccco3)C(C)C)cc2c1,C18H20N2O2,CHEMBL3318064,1200.0,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,1200.0,1250.0,1250.0,1300.0,3.096910013,3.096910013,3.079181246,5.903089987,5.903089987,5.920818754,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1250.0,1250.0,1200.0,1300.0,5.903089986991944,5.903089986991944,5.920818753952375,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782707,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc(CN(C(=O)c2cc3cc(F)ccc3[nH]2)C(C)C)o1,C18H19FN2O2,CHEMBL3318065,1100.0,1380.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,140.0,1100.0,1240.0,1240.0,1380.0,3.093421685,3.093421685,3.041392685,5.906578315,5.906578315,5.958607315,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1240.0,1240.0,1100.0,1380.0,5.906578314837765,5.906578314837765,5.958607314841775,5.860120913598763,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782708,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc2cc(C(=O)N(Cc3ccco3)C(C)C)[nH]c2c1,C18H20N2O2,CHEMBL3318066,850.0,1020.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,85.0,850.0,935.0,935.0,1020.0,2.970811611,2.970811611,2.929418926,6.029188389,6.029188389,6.070581074,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,935.0,935.0,850.0,1020.0,6.029188389127482,6.029188389127482,6.070581074285707,5.991399828238082,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782709,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc(CN(C(=O)c2cc3cccc(F)c3[nH]2)C(C)C)o1,C18H19FN2O2,CHEMBL3318067,1000.0,1200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,100.0,1000.0,1100.0,1100.0,1200.0,3.041392685,3.041392685,3.0,5.958607315,5.958607315,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1100.0,1100.0,1000.0,1200.0,5.958607314841775,5.958607314841775,6.0,5.920818753952375,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782710,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, Entry 2: 1460103, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, Entry 2: Inhibition of androgen receptor binding function 3 in human enzalutamide-resistant MR49F cells assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, Entry 2: CHEMBL3369088, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, Entry 2: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, Entry 2: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, Entry 2: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 2: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 2: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,Cc1ccc(CN(C(=O)c2cc3ccc(F)cc3[nH]2)C(C)C)o1,C18H19FN2O2,CHEMBL3318068,700.0,840.0,2180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,667.1331701,700.0,1240.0,840.0,2180.0,3.093421685,2.924279286,2.84509804,5.906578315,6.075720714,6.15490196,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,770.0,770.0,700.0,840.0,6.113509274827518,6.113509274827518,6.154901959985743,6.075720713938118,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782711,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CC(C)N(Cc1ccco1)C(=O)c1cc2cc(F)ccc2[nH]1,C17H17FN2O2,CHEMBL3318069,500.0,600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,500.0,550.0,550.0,600.0,2.740362689,2.740362689,2.698970004,6.259637311,6.259637311,6.301029996,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,550.0,550.0,500.0,600.0,6.259637310505756,6.259637310505756,6.301029995663981,6.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1782712,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1460096, Entry 1: 1460097, ","Entry 0: Inhibition of androgen receptor binding function 3 in eGFP-expressing human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in androgen receptor transcriptional activity after 3 days, Entry 1: Inhibition of androgen receptor binding function 3 in human LNCAP cells containing androgen-responsive probasin-derived promoter assessed as reduction in PSA expression after 3 days by prostate surface antigen assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3368856, Entry 1: CHEMBL3368857, ","Entry 0: 10.1021/jm500684r, Entry 1: 10.1021/jm500684r, ","Entry 0: 25025737, Entry 1: 25025737, ","Entry 0: CHEMBL3351962, Entry 1: CHEMBL3351962, ","Entry 0: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., Entry 1: Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., Entry 1: To overcome resistance to conventional anti-androgens of human androgen receptor (AR), the allosteric site of the AR binding function 3 (BF3) was investigated as an alternative target for small molecule therapeutics. A library of 1H-indole-2-carboxamides were discovered as BF3 inhibitors and exhibited strong antiproliferative activity against LNCaP and enzalutamide-resistant prostate cancer cell lines. Several of the lead compounds may prove of particular benefit as a novel alternative treatment for castration-resistant prostate cancers., ",,CC(C)N(Cc1ccco1)C(=O)c1cc2ccc(F)cc2[nH]1,C17H17FN2O2,CHEMBL3318070,430.0,530.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,430.0,480.0,480.0,530.0,2.681241237,2.681241237,2.633468456,6.318758763,6.318758763,6.366531544,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,480.0,480.0,430.0,530.0,6.318758762624412,6.318758762624412,6.366531544420414,6.275724130399211,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786041,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,CNc1nc(-c2ccc3ccccc3c2)cs1,C14H12N2S,CHEMBL3323467,3170.0,3910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,370.0,3170.0,3540.0,3540.0,3910.0,3.549003262,3.549003262,3.501059262,5.450996738,5.450996738,5.498940738,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3540.0,3540.0,3170.0,3910.0,5.450996737974212,5.450996737974212,5.498940737782249,5.407823242604133,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786042,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Oc1ccc2nc(N3CCOCC3)sc2c1,C11H12N2O2S,CHEMBL3323468,7410.0,8080.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,335.0,7410.0,7745.0,7745.0,8080.0,3.889021422,3.889021422,3.869818208,5.110978578,5.110978578,5.130181792,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7745.0,7745.0,7410.0,8080.0,5.110978577904775,5.110978577904775,5.130181792020672,5.092588639225414,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1786043,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,Oc1ccc(-c2ccc3ccccc3n2)cc1,C15H11NO,CHEMBL3323469,9840.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9840.0,9840.0,9840.0,9840.0,3.992995098,3.992995098,3.992995098,5.007004902,5.007004902,5.007004902,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9840.0,9840.0,9840.0,9840.0,5.007004901568658,5.007004901568658,5.007004901568658,5.007004901568658,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1786044,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1ccc(-c2ccc(N3CCOCC3)s2)cc1,C14H15NOS,CHEMBL3323470,510.0,520.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,5.0,510.0,515.0,515.0,520.0,2.711807229,2.711807229,2.707570176,6.288192771,6.288192771,6.292429824,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,515.0,515.0,510.0,520.0,6.288192770958809,6.288192770958809,6.292429823902063,6.2839966563652006,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786045,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,FC(F)(F)c1cccc(-c2csc(N3CCOCC3)n2)c1,C14H13F3N2OS,CHEMBL3323471,580.0,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,15.0,580.0,595.0,595.0,610.0,2.774516966,2.774516966,2.763427994,6.225483034,6.225483034,6.236572006,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,595.0,595.0,580.0,610.0,6.22548303427145,6.22548303427145,6.236572006437063,6.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786046,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Cc1ccc(C)c(-c2csc(N3CCOCC3)n2)c1,C15H18N2OS,CHEMBL3323472,520.0,620.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,520.0,570.0,570.0,620.0,2.755874856,2.755874856,2.716003344,6.244125144,6.244125144,6.283996656,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,570.0,570.0,520.0,620.0,6.2441251443275085,6.2441251443275085,6.2839966563652006,6.2076083105017466,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786047,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1ccc(-c2csc(N3CCCCC3)n2)cc1,C14H16N2S,CHEMBL3323473,690.0,1030.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,170.0,690.0,860.0,860.0,1030.0,2.934498451,2.934498451,2.838849091,6.065501549,6.065501549,6.161150909,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,860.0,860.0,690.0,1030.0,6.0655015487564325,6.0655015487564325,6.161150909262744,5.987162775294828,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786048,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1ccc(-c2cc(N3CCOCC3)cs2)cc1,C14H15NOS,CHEMBL3323474,840.0,1240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,200.0,840.0,1040.0,1040.0,1240.0,3.017033339,3.017033339,2.924279286,5.982966661,5.982966661,6.075720714,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1040.0,1040.0,840.0,1240.0,5.982966660701219,5.982966660701219,6.075720713938118,5.906578314837765,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786049,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Nc1ccccc1-c1csc(N2CCOCC2)n1,C13H15N3OS,CHEMBL3323475,1380.0,2030.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,325.0,1380.0,1705.0,1705.0,2030.0,3.231724383,3.231724383,3.139879086,5.768275617,5.768275617,5.860120914,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1705.0,1705.0,1380.0,2030.0,5.768275616671484,5.768275616671484,5.860120913598763,5.692503962086787,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786050,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,N#Cc1ccc(-c2ccc(N3CCOCC3)s2)cc1,C15H14N2OS,CHEMBL3323476,890.0,1440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,275.0,890.0,1165.0,1165.0,1440.0,3.066325925,3.066325925,2.949390007,5.933674075,5.933674075,6.050609993,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1165.0,1165.0,890.0,1440.0,5.933674074637962,5.933674074637962,6.050609993355088,5.841637507904751,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786051,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,FC(F)(F)[C@H]1CN(c2nc(-c3ccccc3)cs2)CCO1,C14H13F3N2OS,CHEMBL3323477,160.0,1650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,745.0,160.0,905.0,905.0,1650.0,2.956648579,2.956648579,2.204119983,6.043351421,6.043351421,6.795880017,2,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,905.0,905.0,160.0,1650.0,6.043351420794797,6.043351420794797,6.795880017344075,5.782516055786093,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786052,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1ccc(-c2csc(N3CCOCC3)n2)c(Cl)c1,C13H12Cl2N2OS,CHEMBL3323478,1320.0,1660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,170.0,1320.0,1490.0,1490.0,1660.0,3.173186268,3.173186268,3.120573931,5.826813732,5.826813732,5.879426069,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1490.0,1490.0,1320.0,1660.0,5.826813731587726,5.826813731587726,5.87942606879415,5.779891911959945,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786053,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1ccc(-c2csc(N3CCOCC3)n2)cc1Cl,C13H12Cl2N2OS,CHEMBL3323479,2960.0,3320.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,180.0,2960.0,3140.0,3140.0,3320.0,3.496929648,3.496929648,3.471291711,5.503070352,5.503070352,5.528708289,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3140.0,3140.0,2960.0,3320.0,5.503070351926785,5.503070351926785,5.528708288941061,5.478861916295964,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786054,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,OCc1sc(N2CCOCC2)nc1-c1ccccc1,C14H16N2O2S,CHEMBL3323480,5040.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5040.0,5040.0,5040.0,5040.0,3.702430536,3.702430536,3.702430536,5.297569464,5.297569464,5.297569464,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5040.0,5040.0,5040.0,5040.0,5.297569463554475,5.297569463554475,5.297569463554475,5.297569463554475,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1786055,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Oc1ccc(-c2nc(-c3c[nH]c4ccccc34)cs2)cc1,C17H12N2OS,CHEMBL3323481,5050.0,6460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,705.0,5050.0,5755.0,5755.0,6460.0,3.760045328,3.760045328,3.703291378,5.239954672,5.239954672,5.296708622,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5755.0,5755.0,5050.0,6460.0,5.239954672034189,5.239954672034189,5.296708621881339,5.189767482004916,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1786056,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,CCc1sc(N2CCOCC2)nc1-c1ccccc1,C15H18N2OS,CHEMBL3323482,5800.0,8430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1315.0,5800.0,7115.0,7115.0,8430.0,3.852174904,3.852174904,3.763427994,5.147825096,5.147825096,5.236572006,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7115.0,7115.0,5800.0,8430.0,5.147825095579697,5.147825095579697,5.236572006437063,5.074172425375258,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1786057,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, Entry 2: 2227453, Entry 3: 2227484, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, Entry 2: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of PSA expression, Entry 3: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of DNA binding domain of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay, ","0,1,2","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, Entry 2: CHEMBL5140966, Entry 3: CHEMBL5140997, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 25062331, Entry 1: 25062331, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Brc1ncn(-c2csc(N3CCOCC3)n2)c1Br,C10H10Br2N4OS,CHEMBL3323483,100.0,100.0,170.0,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,100.0,135.0,135.0,170.0,2.130333768,2.130333768,2.0,6.869666232,6.869666232,7.0,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,123.33333333333333,100.0,100.0,170.0,6.908919530652668,7.0,7.0,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786058,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,COc1c(-c2csc(N3CCOCC3)n2)ccc(F)c1F,C14H14F2N2O2S,CHEMBL3323484,180.0,250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,180.0,215.0,215.0,250.0,2.33243846,2.33243846,2.255272505,6.66756154,6.66756154,6.744727495,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,215.0,215.0,180.0,250.0,6.667561540084395,6.667561540084395,6.7447274948966935,6.6020599913279625,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786059,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Cc1scc(-c2csc(N3CCOCC3)n2)c1C,C13H16N2OS2,CHEMBL3323485,250.0,430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,90.0,250.0,340.0,340.0,430.0,2.531478917,2.531478917,2.397940009,6.468521083,6.468521083,6.602059991,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,250.0,430.0,6.468521082957745,6.468521082957745,6.6020599913279625,6.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786060,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,c1cc(-c2csc(N3CCOCC3)n2)cs1,C11H12N2OS2,CHEMBL3323486,220.0,260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20.0,220.0,240.0,240.0,260.0,2.380211242,2.380211242,2.342422681,6.619788758,6.619788758,6.657577319,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,240.0,240.0,220.0,260.0,6.619788758288394,6.619788758288394,6.657577319177793,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786061,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Oc1c(F)cccc1-c1csc(N2CCOCC2)n1,C13H13FN2O2S,CHEMBL3323487,150.0,270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,60.0,150.0,210.0,210.0,270.0,2.322219295,2.322219295,2.176091259,6.677780705,6.677780705,6.823908741,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,150.0,270.0,6.6777807052660805,6.6777807052660805,6.823908740944319,6.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786062,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,COc1cc(F)ccc1-c1csc(N2CCOCC2)n1,C14H15FN2O2S,CHEMBL3323488,230.0,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,35.0,230.0,265.0,265.0,300.0,2.423245874,2.423245874,2.361727836,6.576754126,6.576754126,6.638272164,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,265.0,265.0,230.0,300.0,6.576754126063192,6.576754126063192,6.638272163982407,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786063,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1ncn(-c2csc(N3CCOCC3)n2)c1Br,C10H10BrClN4OS,CHEMBL3323489,330.0,440.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,55.0,330.0,385.0,385.0,440.0,2.58546073,2.58546073,2.51851394,6.41453927,6.41453927,6.48148606,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,385.0,385.0,330.0,440.0,6.414539270491499,6.414539270491499,6.481486060122113,6.356547323513812,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786064,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1ncn(-c2csc(N3CCOCC3)n2)c1Cl,C10H10Cl2N4OS,CHEMBL3323490,570.0,680.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,55.0,570.0,625.0,625.0,680.0,2.795880017,2.795880017,2.755874856,6.204119983,6.204119983,6.244125144,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,625.0,625.0,570.0,680.0,6.204119982655925,6.204119982655925,6.2441251443275085,6.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786065,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Oc1c(-c2csc(N3CCOCC3)n2)ccc(F)c1F,C13H12F2N2O2S,CHEMBL3323491,700.0,800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,50.0,700.0,750.0,750.0,800.0,2.875061263,2.875061263,2.84509804,6.124938737,6.124938737,6.15490196,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,750.0,750.0,700.0,800.0,6.1249387366083,6.1249387366083,6.154901959985743,6.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786066,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1cn(-c2csc(N3CCOCC3)n2)cn1,C10H11ClN4OS,CHEMBL3323492,720.0,960.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,120.0,720.0,840.0,840.0,960.0,2.924279286,2.924279286,2.857332496,6.075720714,6.075720714,6.142667504,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,840.0,840.0,720.0,960.0,6.075720713938118,6.075720713938118,6.142667503568732,6.017728766960432,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786067,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Oc1cc(F)ccc1-c1csc(N2CCOCC2)n1,C13H13FN2O2S,CHEMBL3323493,810.0,1190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,190.0,810.0,1000.0,1000.0,1190.0,3.0,3.0,2.908485019,6.0,6.0,6.091514981,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,810.0,1190.0,6.0,6.0,6.0915149811213505,5.924453038607469,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786068,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1c(Br)ncn1-c1csc(N2CCOCC2)n1,C10H10BrClN4OS,CHEMBL3323494,1280.0,1450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,85.0,1280.0,1365.0,1365.0,1450.0,3.135132651,3.135132651,3.10720997,5.864867349,5.864867349,5.89279003,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1365.0,1365.0,1280.0,1450.0,5.864867348623225,5.864867348623225,5.892790030352131,5.838631997765025,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786069,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Ic1ncn(-c2csc(N3CCOCC3)n2)c1I,C10H10I2N4OS,CHEMBL3323495,1730.0,1810.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,40.0,1730.0,1770.0,1770.0,1810.0,3.247973266,3.247973266,3.238046103,5.752026734,5.752026734,5.761953897,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1770.0,1770.0,1730.0,1810.0,5.752026733638194,5.752026733638194,5.761953896871205,5.7423214251308154,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786070,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,c1ccc(-c2csc(N3CCOCC3)n2)nc1,C12H13N3OS,CHEMBL3323496,2580.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2580.0,2580.0,2580.0,2580.0,3.411619706,3.411619706,3.411619706,5.588380294,5.588380294,5.588380294,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2580.0,2580.0,2580.0,2580.0,5.58838029403677,5.58838029403677,5.58838029403677,5.58838029403677,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786071,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Clc1ncn(-c2csc(N3CCOCC3)n2)c1I,C10H10ClIN4OS,CHEMBL3323497,2610.0,4020.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,705.0,2610.0,3315.0,3315.0,4020.0,3.520483533,3.520483533,3.416640507,5.479516467,5.479516467,5.583359493,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3315.0,3315.0,2610.0,4020.0,5.4795164672592085,5.4795164672592085,5.583359492661719,5.39577394691553,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786072,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Brc1cn(-c2csc(N3CCOCC3)n2)cn1,C10H11BrN4OS,CHEMBL3323498,1740.0,2800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,530.0,1740.0,2270.0,2270.0,2800.0,3.356025857,3.356025857,3.240549248,5.643974143,5.643974143,5.759450752,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2270.0,2270.0,1740.0,2800.0,5.6439741428068775,5.6439741428068775,5.7594507517174005,5.552841968657781,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786073,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,c1cc(-c2csc(N3CCOCC3)n2)ccn1,C12H13N3OS,CHEMBL3323499,2940.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2940.0,2940.0,2940.0,2940.0,3.46834733,3.46834733,3.46834733,5.53165267,5.53165267,5.53165267,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2940.0,2940.0,2940.0,2940.0,5.531652669587842,5.531652669587842,5.531652669587842,5.531652669587842,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786074,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,COc1c(F)cc(O)cc1-c1csc(N2CCOCC2)n1,C14H15FN2O3S,CHEMBL3323500,3020.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3020.0,3020.0,3020.0,3020.0,3.480006943,3.480006943,3.480006943,5.519993057,5.519993057,5.519993057,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3020.0,3020.0,3020.0,3020.0,5.519993057042849,5.519993057042849,5.519993057042849,5.519993057042849,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786075,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,CS(=O)(=O)c1c(F)cccc1-c1csc(N2CCOCC2)n1,C14H15FN2O3S2,CHEMBL3323501,3560.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3560.0,3560.0,3560.0,3560.0,3.551449998,3.551449998,3.551449998,5.448550002,5.448550002,5.448550002,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3560.0,3560.0,3560.0,3560.0,5.448550002027125,5.448550002027125,5.448550002027125,5.448550002027125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786076,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1446996, Entry 1: 1446997, ","Entry 0: Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay, Entry 1: Inhibition of androgen receptor in human LNCaP cells assessed as inhibition of prostate-specific antigen secretion into media after 3 days, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3374323, Entry 1: CHEMBL3374324, ","Entry 0: 10.1021/jm500802j, Entry 1: 10.1021/jm500802j, ","Entry 0: 25062331, Entry 1: 25062331, ","Entry 0: CHEMBL3352043, Entry 1: CHEMBL3352043, ","Entry 0: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., Entry 1: Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., Entry 1: The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7., ",,Cc1ncn(-c2csc(N3CCOCC3)n2)c1C,C12H16N4OS,CHEMBL3323502,2420.0,3560.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,570.0,2420.0,2990.0,2990.0,3560.0,3.475671188,3.475671188,3.383815366,5.524328812,5.524328812,5.616184634,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2990.0,2990.0,2420.0,3560.0,5.52432881167557,5.52432881167557,5.616184634019569,5.448550002027125,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1786077,nM,IC50,,BAO_0000190,IC50,1446996,Inhibition of androgen receptor transcriptional activity in human LNCaP cells after 3 days by eGFP assay,0,B,,CHEMBL3374323,10.1021/jm500802j,25062331,CHEMBL3352043,Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.,PUBLICATION,"The human androgen receptor (AR) is considered as a master regulator in the development and progression of prostate cancer (PCa). As resistance to clinically used anti-AR drugs remains a major challenge for the treatment of advanced PCa, there is a pressing need for new anti-AR therapeutic avenues. In this study, we identified a binding site on the DNA binding domain (DBD) of the receptor and utilized virtual screening to discover a set of micromolar hits for the target. Through further exploration of the most potent hit (1), a structural analogue (6) was identified demonstrating 10-fold improved anti-AR potency. Further optimization resulted in a more potent synthetic analogue (25) with anti-AR potency comparable to a newly FDA-approved drug Enzalutamide. Site-directed mutagenesis demonstrated that the developed inhibitors do interact with the intended target site. Importantly, the AR DBD inhibitors could effectively inhibit the growth of Enzalutamide-resistant cells as well as block the transcriptional activity of constitutively active AR splice variants, such as V7.",,Cc1sc(N2CCOCC2)nc1-c1ccccc1,C14H16N2OS,CHEMBL3323503,1460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1460.0,1460.0,1460.0,1460.0,3.164352856,3.164352856,3.164352856,5.835647144,5.835647144,5.835647144,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1460.0,1460.0,1460.0,1460.0,5.835647144215563,5.835647144215563,5.835647144215563,5.835647144215563,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837632,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,N#Cc1ccc(N2[C@H]3CC[C@H]2CC(O)C3)cc1C(F)(F)F,C15H15F3N2O,CHEMBL3410850,39.8,39.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,39.8,39.8,39.8,39.8,1.599883072,1.599883072,1.599883072,7.400116928,7.400116928,7.400116928,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,39.8,39.8,39.8,39.8,7.400116927926312,7.400116927926312,7.400116927926312,7.400116927926312,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837633,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,CC1(O)C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,C16H17F3N2O,CHEMBL3410851,29.3,29.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,29.3,29.3,29.3,29.3,1.46686762,1.46686762,1.46686762,7.53313238,7.53313238,7.53313238,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,29.3,29.3,29.3,29.3,7.533132379645891,7.533132379645891,7.533132379645891,7.533132379645891,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837634,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,N#Cc1ccc(N2C3CCC2CC(=O)C3)cc1C(F)(F)F,C15H13F3N2O,CHEMBL3410852,66.0,66.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,66.0,66.0,66.0,66.0,1.819543936,1.819543936,1.819543936,7.180456064,7.180456064,7.180456064,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,66.0,66.0,66.0,66.0,7.180456064458132,7.180456064458132,7.180456064458132,7.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837635,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,N#Cc1ccc(N2[C@H]3CC[C@H]2CC(NCc2ccccc2)C3)cc1C(F)(F)F,C22H22F3N3,CHEMBL3410853,233.0,233.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,233.0,233.0,233.0,233.0,2.367355921,2.367355921,2.367355921,6.632644079,6.632644079,6.632644079,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,233.0,233.0,233.0,233.0,6.632644078973981,6.632644078973981,6.632644078973981,6.632644078973981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837636,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,CS(=O)(=O)NC1C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,C16H18F3N3O2S,CHEMBL3410854,2650.0,2650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2650.0,2650.0,2650.0,2650.0,3.423245874,3.423245874,3.423245874,5.576754126,5.576754126,5.576754126,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2650.0,2650.0,2650.0,2650.0,5.576754126063192,5.576754126063192,5.576754126063192,5.576754126063192,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837637,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, ","Entry 0: 25646649, Entry 1: 25646649, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., ",,CCS(=O)(=O)NC1C[C@@H]2CC[C@@H](C1)N2c1ccc(C#N)c(C(F)(F)F)c1,C17H20F3N3O2S,CHEMBL3410855,2040.0,2040.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2040.0,2040.0,2040.0,2040.0,3.309630167,3.309630167,3.309630167,5.690369833,5.690369833,5.690369833,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2040.0,2040.0,2040.0,2040.0,5.690369832574102,5.690369832574102,5.690369832574102,5.690369832574102,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1837638,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1468250, Entry 1: 1468251, Entry 2: 2227383, ","Entry 0: Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, Entry 1: Displacement of [3H]R1881 from pSG5-tagged human androgen receptor expressed in COS1 cells assessed as relative binding inhibition, Entry 2: Binding affinity to human Androgen receptor, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3411793, Entry 1: CHEMBL3411794, Entry 2: CHEMBL5140896, ","Entry 0: 10.1021/jm501995n, Entry 1: 10.1021/jm501995n, Entry 2: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 25646649, Entry 1: 25646649, Entry 2: 35786895, ","Entry 0: CHEMBL3407333, Entry 1: CHEMBL3407333, Entry 2: CHEMBL5137058, ","Entry 0: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 1: Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 1: To circumvent antiandrogen resistance in prostate cancer, antiandrogens effective for both the androgen receptor (AR) and AR mutants are required. The AR antagonists in this study originate from previous findings, which showed that subtle differences in substitution pattern lead to a conformational change that alters the ligand activity, rendering an agonist to an antagonist. We have identified small yet potent tropanol-based ligands possessing significant antiandrogenic activity with both wild-type AR and the two most common AR ligand binding domain (LBD) mutants., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1c(N2C3CCC2CC(C)(O)C3)ccc(C#N)c1Cl,C16H19ClN2O,CHEMBL3410856,1.0,2.11,2.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.523259018,1.0,1.74,2.11,2.11,0.240549248,0.324282455,0.0,8.759450752,8.675717545,9.0,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1.0,1.0,1.0,1.0,9.0,9.0,9.0,9.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946588,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(Cl)ccc3[nH]2)C1=O,C25H19ClFN3O3,CHEMBL3578271,3100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3100.0,3100.0,3100.0,3100.0,3.491361694,3.491361694,3.491361694,5.508638306,5.508638306,5.508638306,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3100.0,3100.0,3100.0,3100.0,5.508638306165727,5.508638306165727,5.508638306165727,5.508638306165727,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946591,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(C(F)(F)F)ccc3[nH]2)C1=O,C26H19F4N3O3,CHEMBL3578274,3000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3000.0,3000.0,3000.0,3000.0,3.477121255,3.477121255,3.477121255,5.522878745,5.522878745,5.522878745,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3000.0,3000.0,3000.0,3000.0,5.522878745280337,5.522878745280337,5.522878745280337,5.522878745280337,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946593,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(NS(C)(=O)=O)ccc3[nH]2)C1=O,C26H23FN4O5S,CHEMBL3578276,13000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,13000.0,13000.0,13000.0,13000.0,4.113943352,4.113943352,4.113943352,4.886056648,4.886056648,4.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,13000.0,13000.0,13000.0,13000.0,4.886056647693163,4.886056647693163,4.886056647693163,4.886056647693163,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1946600,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(-c4cc[nH]n4)ccc3[nH]2)C1=O,C28H22FN5O3,CHEMBL3576885,3100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3100.0,3100.0,3100.0,3100.0,3.491361694,3.491361694,3.491361694,5.508638306,5.508638306,5.508638306,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3100.0,3100.0,3100.0,3100.0,5.508638306165727,5.508638306165727,5.508638306165727,5.508638306165727,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946602,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,Cc1nocc1-c1ccc2[nH]c([C@@]3(Cc4ccccc4)OC(=O)N([C@H](C)c4ccc(F)cc4)C3=O)nc2c1,C29H23FN4O4,CHEMBL3578284,3400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3400.0,3400.0,3400.0,3400.0,3.531478917,3.531478917,3.531478917,5.468521083,5.468521083,5.468521083,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3400.0,3400.0,3400.0,3400.0,5.468521082957745,5.468521082957745,5.468521082957745,5.468521082957745,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946603,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(N4CCOCC4)ccc3[nH]2)C1=O,C29H27FN4O4,CHEMBL3578285,7700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7700.0,7700.0,7700.0,7700.0,3.886490725,3.886490725,3.886490725,5.113509275,5.113509275,5.113509275,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7700.0,7700.0,7700.0,7700.0,5.113509274827518,5.113509274827518,5.113509274827518,5.113509274827518,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1946604,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3cc(-c4cccnc4)ccc3[nH]2)C1=O,C30H23FN4O3,CHEMBL3578286,3700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3700.0,3700.0,3700.0,3700.0,3.568201724,3.568201724,3.568201724,5.431798276,5.431798276,5.431798276,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3700.0,3700.0,3700.0,3700.0,5.431798275933005,5.431798275933005,5.431798275933005,5.431798275933005,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1946613,nM,IC50,,BAO_0000190,IC50,1497343,Antagonist activity at human androgen receptor expressed in CHOK1 cells assessed as inhibition of D(-)-norgestrel-induced protein interaction with steroid receptor co-activator peptide after 24 hrs by beta-galactosidase reporter gene assay,0,B,,CHEMBL3579176,10.1021/acsmedchemlett.5b00010,25941555,CHEMBL3576820,Discovery of benzimidazole oxazolidinediones as novel and selective nonsteroidal mineralocorticoid receptor antagonists.,PUBLICATION,"Elaboration of the oxazolidinedione series led to replacement of the exocyclic amides with substituted benzimidazoles. The structure-activity relationship (SAR) exploration resulted in the discovery of potent and selective nonsteroidal mineralocorticoid receptor (MR) antagonists with significantly improved microsomal stability and pharmacokinetic (PK) profile relative to the HTS hit 1a. One compound 2p possessed comparable efficacy as spironolactone (SPL) at 100 mg/kg (p.o.) in the rat natriuresis model. As such, this series was validated as a lead series for further optimization.",,C[C@H](c1ccc(F)cc1)N1C(=O)O[C@](Cc2ccccc2)(c2nc3c(NS(C)(=O)=O)cccc3[nH]2)C1=O,C26H23FN4O5S,CHEMBL3578295,11000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11000.0,11000.0,11000.0,11000.0,4.041392685,4.041392685,4.041392685,4.958607315,4.958607315,4.958607315,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11000.0,11000.0,11000.0,11000.0,4.958607314841775,4.958607314841775,4.958607314841775,4.958607314841775,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1958610,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1511238, Entry 1: 1511239, Entry 2: 1511240, ","Entry 0: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK2 gene expression by Array Plate assay, Entry 1: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK3 gene expression by Array Plate assay, Entry 2: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay, ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3607996, Entry 1: CHEMBL3607997, Entry 2: CHEMBL3607998, ","Entry 0: 10.1021/acs.jmedchem.5b00867, Entry 1: 10.1021/acs.jmedchem.5b00867, Entry 2: 10.1021/acs.jmedchem.5b00867, ","Entry 0: 26305181, Entry 1: 26305181, Entry 2: 26305181, ","Entry 0: CHEMBL3603831, Entry 1: CHEMBL3603831, Entry 2: CHEMBL3603831, ","Entry 0: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 1: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 2: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 1: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 2: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., ",,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4C=CCC(=O)[C@@]43C)[C@]1(O)CC[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,C30H40O8,CHEMBL3605560,2400.0,3280.0,3520.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,481.4792023,2400.0,3066.666667,3280.0,3520.0,3.486666573,3.515873844,3.380211242,5.513333427,5.484126156,5.619788758,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2840.0,2840.0,2400.0,3280.0,5.546681659952962,5.546681659952962,5.619788758288394,5.484126156288321,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1958612,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1511238, Entry 1: 1511239, Entry 2: 1511240, ","Entry 0: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK2 gene expression by Array Plate assay, Entry 1: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK3 gene expression by Array Plate assay, Entry 2: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay, ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3607996, Entry 1: CHEMBL3607997, Entry 2: CHEMBL3607998, ","Entry 0: 10.1021/acs.jmedchem.5b00867, Entry 1: 10.1021/acs.jmedchem.5b00867, Entry 2: 10.1021/acs.jmedchem.5b00867, ","Entry 0: 26305181, Entry 1: 26305181, Entry 2: 26305181, ","Entry 0: CHEMBL3603831, Entry 1: CHEMBL3603831, Entry 2: CHEMBL3603831, ","Entry 0: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 1: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 2: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 1: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 2: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., ",,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4CC=CC(=O)[C@@]43C)[C@]1(O)[C@@H](OC(C)=O)C[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,C32H42O10,CHEMBL3605562,1790.0,2720.0,3580.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,730.9506747,1790.0,2696.666667,2720.0,3580.0,3.430827267,3.434568904,3.252853031,5.569172733,5.565431096,5.747146969,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2255.0,2255.0,1790.0,2720.0,5.64685345378602,5.64685345378602,5.747146969020107,5.565431095965802,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1958613,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1511238, Entry 1: 1511239, Entry 2: 1511240, ","Entry 0: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK2 gene expression by Array Plate assay, Entry 1: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK3 gene expression by Array Plate assay, Entry 2: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay, ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3607996, Entry 1: CHEMBL3607997, Entry 2: CHEMBL3607998, ","Entry 0: 10.1021/acs.jmedchem.5b00867, Entry 1: 10.1021/acs.jmedchem.5b00867, Entry 2: 10.1021/acs.jmedchem.5b00867, ","Entry 0: 26305181, Entry 1: 26305181, Entry 2: 26305181, ","Entry 0: CHEMBL3603831, Entry 1: CHEMBL3603831, Entry 2: CHEMBL3603831, ","Entry 0: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 1: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 2: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 1: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 2: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., ",,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4C=CCC(=O)[C@@]43C)[C@]1(O)[C@@H](OC(C)=O)C[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,C32H42O10,CHEMBL3605563,620.0,1200.0,1420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,337.4413529,620.0,1080.0,1200.0,1420.0,3.033423755,3.079181246,2.792391689,5.966576245,5.920818754,6.207608311,3,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,910.0,910.0,620.0,1200.0,6.040958607678906,6.040958607678906,6.2076083105017466,5.920818753952375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1958614,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1511238, Entry 1: 1511239, Entry 2: 1511240, ","Entry 0: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK2 gene expression by Array Plate assay, Entry 1: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced KLK3 gene expression by Array Plate assay, Entry 2: Inhibition of androgen receptor in human LNCAP cells assessed as inhibition of DHT-induced SPDEF gene expression by Array Plate assay, ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3607996, Entry 1: CHEMBL3607997, Entry 2: CHEMBL3607998, ","Entry 0: 10.1021/acs.jmedchem.5b00867, Entry 1: 10.1021/acs.jmedchem.5b00867, Entry 2: 10.1021/acs.jmedchem.5b00867, ","Entry 0: 26305181, Entry 1: 26305181, Entry 2: 26305181, ","Entry 0: CHEMBL3603831, Entry 1: CHEMBL3603831, Entry 2: CHEMBL3603831, ","Entry 0: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 1: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., Entry 2: Discovery of Potent 17-Hydroxywithanolides for Castration-Resistant Prostate Cancer by High-Throughput Screening of a Natural Products Library for Androgen-Induced Gene Expression Inhibitors., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 1: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., Entry 2: Prostate cancer (PC) is the second most prevalent cancer among men in Western societies, and those who develop metastatic castration-resistant PC (CRPC) invariably succumb to the disease. The need for effective treatments for CRPC is a pressing concern, especially due to limited durable responses with currently employed therapies. Here, we demonstrate the successful application of a high-throughput gene-expression profiling assay directly targeting genes of the androgen receptor pathway to screen a natural products library leading to the identification of 17-hydroxywithanolides 1-5, of which physachenolide D (5) exhibited potent and selective in vitro activity against two PC cell lines, LNCaP and PC-3. Epoxidation of 5 afforded physachenolide C (6) with higher potency and stability. Structure-activity relationships for withanolides as potential anti-PC agents are presented together with in vivo efficacy studies on compound 6, suggesting that 17-hydroxywithanolides are promising candidates for further development as CRPC therapeutics., ",,CC(=O)OC[C@]12CC[C@H]3[C@@H](CC=C4CC=CC(=O)[C@@]43C)[C@]1(O)CC[C@@]2(O)[C@@](C)(O)[C@H]1CC(C)=C(C)C(=O)O1,C30H40O8,CHEMBL3605564,580.0,750.0,770.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,85.24474568,580.0,700.0,750.0,770.0,2.84509804,2.875061263,2.763427994,6.15490196,6.124938737,6.236572006,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,665.0,665.0,580.0,750.0,6.1771783546968955,6.1771783546968955,6.236572006437063,6.1249387366083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966803,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@@H]1O)[C@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@H]12,C17H15IN2O4,CHEMBL3623114,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966804,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1C(=O)O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C19H15F3N2O5,CHEMBL3623115,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
1966805,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CC(C)OC(=O)[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H21F3N2O5,CHEMBL3623116,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966806,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CN(C(=O)[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12)c1ccccc1,C26H22F3N3O4,CHEMBL3623117,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34.0,34.0,34.0,34.0,1.531478917,1.531478917,1.531478917,7.468521083,7.468521083,7.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,34.0,34.0,34.0,34.0,7.468521082957745,7.468521082957745,7.468521082957745,7.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966807,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1N)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C18H16F3N3O3,CHEMBL3623118,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966808,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CCC(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C21H20F3N3O4,CHEMBL3623119,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23.0,23.0,23.0,23.0,1.361727836,1.361727836,1.361727836,7.638272164,7.638272164,7.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966809,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CNS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C19H19F3N4O5S,CHEMBL3623120,34.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,34.0,34.0,34.0,34.0,1.531478917,1.531478917,1.531478917,7.468521083,7.468521083,7.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,34.0,34.0,34.0,34.0,7.468521082957745,7.468521082957745,7.468521082957745,7.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966810,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CC(C)NC(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C22H23F3N4O4,CHEMBL3623121,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966811,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CN1CCN(OC(=O)N[C@@H]2C[C@]3(C)O[C@]2(C)[C@@H]2C(=O)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)[C@@H]23)CC1,C24H26F3N5O5,CHEMBL3623122,6.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6.0,6.0,6.0,6.0,0.77815125,0.77815125,0.77815125,8.22184875,8.22184875,8.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,6.0,6.0,6.0,6.0,8.221848749616356,8.221848749616356,8.221848749616356,8.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966812,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1NS(C)(=O)=O)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C19H18F3N3O5S,CHEMBL3623123,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966813,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1NS(=O)(=O)c1ccccc1)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C24H20F3N3O5S,CHEMBL3623124,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1.0,1.0,1.0,1.0,0.0,0.0,0.0,9.0,9.0,9.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1.0,1.0,1.0,1.0,9.0,9.0,9.0,9.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966814,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1NS(=O)(=O)c1ccccc1F)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C24H19F4N3O5S,CHEMBL3623125,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966815,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,C[C@]12O[C@@](C)(C[C@H]1NS(=O)(=O)c1cccnc1)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C23H19F3N4O5S,CHEMBL3623126,7.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7.0,7.0,7.0,7.0,0.84509804,0.84509804,0.84509804,8.15490196,8.15490196,8.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,7.0,7.0,7.0,7.0,8.154901959985743,8.154901959985743,8.154901959985743,8.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
1966816,nM,IC50,,BAO_0000190,IC50,1519755,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of DHT-induced PSA expression by alkaline phosphatase reporter gene assay,0,B,,CHEMBL3624234,10.1021/acsmedchemlett.5b00173,26288692,CHEMBL3621143,"Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.",PUBLICATION,"BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.",,CCS(=O)(=O)N[C@@H]1C[C@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C20H20F3N3O5S,CHEMBL3623127,16.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16.0,16.0,16.0,16.0,1.204119983,1.204119983,1.204119983,7.795880017,7.795880017,7.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,16.0,16.0,16.0,16.0,7.795880017344075,7.795880017344075,7.795880017344075,7.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038880,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCC1CCc2cc3c(C(F)(F)F)cc(=O)[nH]c3cc2N1,C15H15F3N2O,CHEMBL3706874,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,14.0,14.0,14.0,14.0,1.146128036,1.146128036,1.146128036,7.853871964,7.853871964,7.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,14.0,14.0,14.0,14.0,7.853871964321762,7.853871964321762,7.853871964321762,7.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038881,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C13H13F3N2O,CHEMBL3706875,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32.0,32.0,32.0,32.0,1.505149978,1.505149978,1.505149978,7.494850022,7.494850022,7.494850022,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038882,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C10H7F3N2O,CHEMBL3706876,28.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,28.0,28.0,28.0,28.0,1.447158031,1.447158031,1.447158031,7.552841969,7.552841969,7.552841969,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,28.0,28.0,28.0,28.0,7.552841968657781,7.552841968657781,7.552841968657781,7.552841968657781,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038883,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C11H9F3N2O,CHEMBL3706877,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038884,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C12H11F3N2O,CHEMBL3706878,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,35.0,35.0,35.0,35.0,1.544068044,1.544068044,1.544068044,7.455931956,7.455931956,7.455931956,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,35.0,35.0,35.0,35.0,7.455931955649724,7.455931955649724,7.455931955649724,7.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038885,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCCCNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C14H15F3N2O,CHEMBL3706879,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,67.0,67.0,67.0,67.0,1.826074803,1.826074803,1.826074803,7.173925197,7.173925197,7.173925197,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,67.0,67.0,67.0,67.0,7.173925197299173,7.173925197299173,7.173925197299173,7.173925197299173,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038886,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CC(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C13H13F3N2O,CHEMBL3706880,56.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,56.0,56.0,56.0,56.0,1.748188027,1.748188027,1.748188027,7.251811973,7.251811973,7.251811973,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,56.0,56.0,56.0,56.0,7.251811972993799,7.251811972993799,7.251811972993799,7.251811972993799,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038887,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CC(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C14H15F3N2O,CHEMBL3706881,74.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,74.0,74.0,74.0,74.0,1.86923172,1.86923172,1.86923172,7.13076828,7.13076828,7.13076828,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,74.0,74.0,74.0,74.0,7.130768280269024,7.130768280269024,7.130768280269024,7.130768280269024,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038888,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CC(C)(C)CNc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C15H17F3N2O,CHEMBL3706882,98.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,98.0,98.0,98.0,98.0,1.991226076,1.991226076,1.991226076,7.008773924,7.008773924,7.008773924,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,98.0,98.0,98.0,98.0,7.008773924307505,7.008773924307505,7.008773924307505,7.008773924307505,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038889,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C15H17F3N2O,CHEMBL3706883,209.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,209.0,209.0,209.0,209.0,2.320146286,2.320146286,2.320146286,6.679853714,6.679853714,6.679853714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,209.0,209.0,209.0,209.0,6.679853713888946,6.679853713888946,6.679853713888946,6.679853713888946,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038890,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,C=CC(C)(C)Nc1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C15H15F3N2O,CHEMBL3706884,122.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,122.0,122.0,122.0,122.0,2.086359831,2.086359831,2.086359831,6.913640169,6.913640169,6.913640169,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,122.0,122.0,122.0,122.0,6.913640169325252,6.913640169325252,6.913640169325252,6.913640169325252,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038891,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NC3CCC3)cc2[nH]1,C14H13F3N2O,CHEMBL3706885,43.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,43.0,43.0,43.0,43.0,1.633468456,1.633468456,1.633468456,7.366531544,7.366531544,7.366531544,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,43.0,43.0,43.0,43.0,7.366531544420414,7.366531544420414,7.366531544420414,7.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038892,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NC3CCCC3)cc2[nH]1,C15H15F3N2O,CHEMBL3706886,149.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,149.0,149.0,149.0,149.0,2.173186268,2.173186268,2.173186268,6.826813732,6.826813732,6.826813732,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,149.0,149.0,149.0,149.0,6.826813731587726,6.826813731587726,6.826813731587726,6.826813731587726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038893,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NC3CCCCC3)cc2[nH]1,C16H17F3N2O,CHEMBL3706887,507.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,507.0,507.0,507.0,507.0,2.705007959,2.705007959,2.705007959,6.294992041,6.294992041,6.294992041,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,507.0,507.0,507.0,507.0,6.294992040666664,6.294992040666664,6.294992040666664,6.294992040666664,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038894,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)F)cc2[nH]1,C12H8F6N2O,CHEMBL3706888,21.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,21.0,21.0,21.0,21.0,1.322219295,1.322219295,1.322219295,7.677780705,7.677780705,7.677780705,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,21.0,21.0,21.0,21.0,7.6777807052660805,7.6777807052660805,7.6777807052660805,7.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038895,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)C(F)(F)F)cc2[nH]1,C13H8F8N2O,CHEMBL3706889,58.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,58.0,58.0,58.0,58.0,1.763427994,1.763427994,1.763427994,7.236572006,7.236572006,7.236572006,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,58.0,58.0,58.0,58.0,7.236572006437063,7.236572006437063,7.236572006437063,7.236572006437063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038897,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NCc3ccccc3)cc2[nH]1,C17H13F3N2O,CHEMBL3706891,294.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,294.0,294.0,294.0,294.0,2.46834733,2.46834733,2.46834733,6.53165267,6.53165267,6.53165267,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,294.0,294.0,294.0,294.0,6.531652669587842,6.531652669587842,6.531652669587842,6.531652669587842,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038898,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CN(C)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C12H11F3N2O,CHEMBL3706892,1160.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1160.0,1160.0,1160.0,1160.0,3.064457989,3.064457989,3.064457989,5.935542011,5.935542011,5.935542011,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1160.0,1160.0,1160.0,1160.0,5.935542010773082,5.935542010773082,5.935542010773082,5.935542010773082,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038899,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCN(CC)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C14H15F3N2O,CHEMBL3706893,591.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,591.0,591.0,591.0,591.0,2.771587481,2.771587481,2.771587481,6.228412519,6.228412519,6.228412519,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,591.0,591.0,591.0,591.0,6.228412519118745,6.228412519118745,6.228412519118745,6.228412519118745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038900,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C14H12F6N2O,CHEMBL3706894,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.0,42.0,42.0,42.0,1.62324929,1.62324929,1.62324929,7.37675071,7.37675071,7.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.0,42.0,42.0,42.0,7.376750709602099,7.376750709602099,7.376750709602099,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038901,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCCN(CC(F)(F)F)c1ccc2c(C(F)(F)F)cc(=O)[nH]c2c1,C15H14F6N2O,CHEMBL3706895,549.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,549.0,549.0,549.0,549.0,2.739572344,2.739572344,2.739572344,6.260427656,6.260427656,6.260427656,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,549.0,549.0,549.0,549.0,6.2604276555499085,6.2604276555499085,6.2604276555499085,6.2604276555499085,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038902,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,C11H9F3N2O,CHEMBL3706896,76.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,76.0,76.0,76.0,76.0,1.880813592,1.880813592,1.880813592,7.119186408,7.119186408,7.119186408,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,76.0,76.0,76.0,76.0,7.119186407719209,7.119186407719209,7.119186407719209,7.119186407719209,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038903,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,C12H11F3N2O,CHEMBL3706897,23.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,23.0,23.0,23.0,23.0,1.361727836,1.361727836,1.361727836,7.638272164,7.638272164,7.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,23.0,23.0,23.0,23.0,7.638272163982407,7.638272163982407,7.638272163982407,7.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038904,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,C13H13F3N2O,CHEMBL3706898,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038905,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCC(C)c1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1N,C14H15F3N2O,CHEMBL3706899,14.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,14.0,14.0,14.0,14.0,1.146128036,1.146128036,1.146128036,7.853871964,7.853871964,7.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,14.0,14.0,14.0,14.0,7.853871964321762,7.853871964321762,7.853871964321762,7.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038906,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCCNc1cc2[nH]c(=O)cc(C(F)(F)F)c2cc1C,C14H15F3N2O,CHEMBL3706900,674.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,674.0,674.0,674.0,674.0,2.828659897,2.828659897,2.828659897,6.171340103,6.171340103,6.171340103,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,674.0,674.0,674.0,674.0,6.17134010346468,6.17134010346468,6.17134010346468,6.17134010346468,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038907,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,Cc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(C)C,C15H17F3N2O,CHEMBL3706901,301.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,301.0,301.0,301.0,301.0,2.478566496,2.478566496,2.478566496,6.521433504,6.521433504,6.521433504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,301.0,301.0,301.0,301.0,6.521433504406157,6.521433504406157,6.521433504406157,6.521433504406157,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038908,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NC,C13H13F3N2O,CHEMBL3706902,504.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,504.0,504.0,504.0,504.0,2.702430536,2.702430536,2.702430536,6.297569464,6.297569464,6.297569464,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,504.0,504.0,504.0,504.0,6.297569463554475,6.297569463554475,6.297569463554475,6.297569463554475,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038909,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCc1cc2c(C(F)(F)F)cc(=O)[nH]c2cc1NCC(F)(F)F,C14H12F6N2O,CHEMBL3706903,216.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,216.0,216.0,216.0,216.0,2.334453751,2.334453751,2.334453751,6.665546249,6.665546249,6.665546249,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,216.0,216.0,216.0,216.0,6.665546248849069,6.665546248849069,6.665546248849069,6.665546248849069,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038910,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(NCC(F)(F)F)cc2o1,C12H7F6NO2,CHEMBL3706904,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50.0,50.0,50.0,50.0,1.698970004,1.698970004,1.698970004,7.301029996,7.301029996,7.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,50.0,50.0,50.0,50.0,7.301029995663981,7.301029995663981,7.301029995663981,7.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038911,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2ccc(N(CC(F)(F)F)CC(F)(F)F)cc2o1,C14H8F9NO2,CHEMBL3706905,63.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,63.0,63.0,63.0,63.0,1.799340549,1.799340549,1.799340549,7.200659451,7.200659451,7.200659451,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,63.0,63.0,63.0,63.0,7.200659450546419,7.200659450546419,7.200659450546419,7.200659450546419,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038912,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CCNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C12H11F3N2O,CHEMBL3706906,111.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,111.0,111.0,111.0,111.0,2.045322979,2.045322979,2.045322979,6.954677021,6.954677021,6.954677021,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,111.0,111.0,111.0,111.0,6.954677021213342,6.954677021213342,6.954677021213342,6.954677021213342,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038913,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)F)ccc2[nH]1,C12H8F6N2O,CHEMBL3706907,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,18.0,18.0,18.0,18.0,1.255272505,1.255272505,1.255272505,7.744727495,7.744727495,7.744727495,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,18.0,18.0,18.0,18.0,7.7447274948966935,7.7447274948966935,7.7447274948966935,7.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038914,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2cc(NCC(F)(F)C(F)(F)F)ccc2[nH]1,C13H8F8N2O,CHEMBL3706908,17.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,17.0,17.0,17.0,17.0,1.230448921,1.230448921,1.230448921,7.769551079,7.769551079,7.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,17.0,17.0,17.0,17.0,7.769551078621726,7.769551078621726,7.769551078621726,7.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038915,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,O=c1cc(C(F)(F)F)c2cc(NC3CCCC3)ccc2[nH]1,C15H15F3N2O,CHEMBL3706909,42.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,42.0,42.0,42.0,42.0,1.62324929,1.62324929,1.62324929,7.37675071,7.37675071,7.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,42.0,42.0,42.0,42.0,7.376750709602099,7.376750709602099,7.376750709602099,7.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038916,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CC(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C14H15F3N2O,CHEMBL3706910,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038917,nM,IC50,,BAO_0000190,IC50,438255,Antagonist activity at human androgen receptor expressed in CV1 cells,0,F,,CHEMBL887361,10.1016/j.bmcl.2007.01.007,17257838,CHEMBL1144605,Discovery of an androgen receptor modulator pharmacophore based on 2-quinolinones.,PUBLICATION,A series of alkylamino-2-quinolinone compounds (3) was discovered as androgen receptor modulators based on an early linear tricyclic quinoline pharmacophore (1). The series demonstrated selective high binding affinity to androgen receptor and potent receptor modulating activities in the cotransfection assays.,,CC(C)(C)CNc1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C15H17F3N2O,CHEMBL3706911,27.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.0,27.0,27.0,27.0,1.431363764,1.431363764,1.431363764,7.568636236,7.568636236,7.568636236,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.0,27.0,27.0,27.0,7.568636235841013,7.568636235841013,7.568636235841013,7.568636235841013,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038932,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(Cc3ccccc3)CC(F)(F)F)ccc2[nH]1,C19H14F6N2O,CHEMBL3706926,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2038933,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(Cc3cccs3)CC(F)(F)F)ccc2[nH]1,C17H12F6N2OS,CHEMBL3706927,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2038934,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CCOC(=O)CN(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H14F6N2O3,CHEMBL3706928,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038935,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=C(N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1)C(F)(F)F,C14H7F9N2O2,CHEMBL3706929,4.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4.1,4.1,4.1,4.1,0.612783857,0.612783857,0.612783857,8.387216143,8.387216143,8.387216143,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4.1,4.1,4.1,4.1,8.387216143280265,8.387216143280265,8.387216143280265,8.387216143280265,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2038936,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,O=c1cc(C(F)(F)F)c2cc(N(Cc3ccoc3)CC(F)(F)F)ccc2[nH]1,C17H12F6N2O2,CHEMBL3706930,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2038937,nM,IC50,,BAO_0000190,IC50,441969,Antagonist activity at human AR,0,F,,CHEMBL891113,10.1016/j.bmcl.2007.01.001,17267219,CHEMBL1147033,Novel selective androgen receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones.,PUBLICATION,A series of selective androgen receptor modulators (SARMs) with a wide spectrum of receptor modulating activities was developed based on optimization of the 4-substituted 6-bisalkylamino-2-quinolinones (3). Significance of the trifluoromethyl group on the side chains and its interactions with amino acid residues within the androgen receptor (AR) ligand binding domain are discussed. A representative analog (9) was tested orally in a rodent model of hypogonadism and demonstrated desirable tissue selectivity.,,CC(=O)C(C)N(CC(F)(F)F)c1ccc2[nH]c(=O)cc(C(F)(F)F)c2c1,C16H14F6N2O2,CHEMBL3706931,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2078081,nM,IC50,,BAO_0000190,IC50,1566741,Antagonist activity against androgen receptor (unknown origin),0,B,,CHEMBL3788113,10.1016/j.bmcl.2016.02.088,26965862,CHEMBL3784967,7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.,PUBLICATION,"The clinically used androgen receptor (AR) antagonists (bicalutamide, flutamide and nilutamide) bind with low affinity to AR and can induce escape mechanisms. Furthermore, under AR gene amplification or mutation conditions they demonstrate agonist activity and fail to inhibit AR, causing relapse into castration resistant prostate cancer (CRPC). Discovery of new scaffolds distinct from the 4-cyano/nitro-3-(trifluoromethyl)phenyl group common to currently used antiandrogens is urgently needed to avoid cross-resistance with these compounds. In this study, a series of twenty-nine 7-substituted umbelliferone derivatives was prepared and their antiproliferative activities were evaluated. The most active compound 7a demonstrated submicromolar inhibitory activity in the human prostate cancer cell line (22Rv1); IC50=0.93 M which represents a 50 fold improvement over the clinical antiandrogen bicalutamide (IC50=46 M) and a more than 30 fold improvement over enzalutamide (IC50=32 M). Interestingly, this compound showed even better activity against the human breast cancer cell line (MCF-7); IC50=0.47 M. Molecular modelling studies provided a plausible theoretical explanation for our findings.",,CCOC(=O)C(CC)Oc1ccc2c(C)cc(=O)oc2c1,C16H18O5,CHEMBL3787387,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2078082,nM,IC50,,BAO_0000190,IC50,1566741,Antagonist activity against androgen receptor (unknown origin),0,B,,CHEMBL3788113,10.1016/j.bmcl.2016.02.088,26965862,CHEMBL3784967,7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.,PUBLICATION,"The clinically used androgen receptor (AR) antagonists (bicalutamide, flutamide and nilutamide) bind with low affinity to AR and can induce escape mechanisms. Furthermore, under AR gene amplification or mutation conditions they demonstrate agonist activity and fail to inhibit AR, causing relapse into castration resistant prostate cancer (CRPC). Discovery of new scaffolds distinct from the 4-cyano/nitro-3-(trifluoromethyl)phenyl group common to currently used antiandrogens is urgently needed to avoid cross-resistance with these compounds. In this study, a series of twenty-nine 7-substituted umbelliferone derivatives was prepared and their antiproliferative activities were evaluated. The most active compound 7a demonstrated submicromolar inhibitory activity in the human prostate cancer cell line (22Rv1); IC50=0.93 M which represents a 50 fold improvement over the clinical antiandrogen bicalutamide (IC50=46 M) and a more than 30 fold improvement over enzalutamide (IC50=32 M). Interestingly, this compound showed even better activity against the human breast cancer cell line (MCF-7); IC50=0.47 M. Molecular modelling studies provided a plausible theoretical explanation for our findings.",,Cc1cc(=O)oc2cc(OCC(=O)C(C)(C)C)ccc12,C16H18O4,CHEMBL3785926,3760.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3760.0,3760.0,3760.0,3760.0,3.575187845,3.575187845,3.575187845,5.424812155,5.424812155,5.424812155,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3760.0,3760.0,3760.0,3760.0,5.424812155072339,5.424812155072339,5.424812155072339,5.424812155072339,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2078083,nM,IC50,,BAO_0000190,IC50,1566741,Antagonist activity against androgen receptor (unknown origin),0,B,,CHEMBL3788113,10.1016/j.bmcl.2016.02.088,26965862,CHEMBL3784967,7-Substituted umbelliferone derivatives as androgen receptor antagonists for the potential treatment of prostate and breast cancer.,PUBLICATION,"The clinically used androgen receptor (AR) antagonists (bicalutamide, flutamide and nilutamide) bind with low affinity to AR and can induce escape mechanisms. Furthermore, under AR gene amplification or mutation conditions they demonstrate agonist activity and fail to inhibit AR, causing relapse into castration resistant prostate cancer (CRPC). Discovery of new scaffolds distinct from the 4-cyano/nitro-3-(trifluoromethyl)phenyl group common to currently used antiandrogens is urgently needed to avoid cross-resistance with these compounds. In this study, a series of twenty-nine 7-substituted umbelliferone derivatives was prepared and their antiproliferative activities were evaluated. The most active compound 7a demonstrated submicromolar inhibitory activity in the human prostate cancer cell line (22Rv1); IC50=0.93 M which represents a 50 fold improvement over the clinical antiandrogen bicalutamide (IC50=46 M) and a more than 30 fold improvement over enzalutamide (IC50=32 M). Interestingly, this compound showed even better activity against the human breast cancer cell line (MCF-7); IC50=0.47 M. Molecular modelling studies provided a plausible theoretical explanation for our findings.",,Cc1cc(=O)oc2cc(OC(C)C(=O)c3ccccc3)ccc12,C19H16O4,CHEMBL3787517,5090.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5090.0,5090.0,5090.0,5090.0,3.706717782,3.706717782,3.706717782,5.293282218,5.293282218,5.293282218,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5090.0,5090.0,5090.0,5090.0,5.293282217663241,5.293282217663241,5.293282217663241,5.293282217663241,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2095597,nM,IC50,,BAO_0000190,IC50,1591302,Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay,0,B,,CHEMBL3829948,10.1016/j.bmcl.2016.06.001,27301368,CHEMBL3826911,"Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.",PUBLICATION,"Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target. Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations. Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified.",,CC(O)(CSc1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C19H13F9N2O4S,CHEMBL3828139,710.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,710.0,710.0,710.0,710.0,2.851258349,2.851258349,2.851258349,6.148741651,6.148741651,6.148741651,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,710.0,710.0,710.0,710.0,6.1487416512809245,6.1487416512809245,6.1487416512809245,6.1487416512809245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2095612,nM,IC50,,BAO_0000190,IC50,1591302,Antagonist activity at GAL4 DBD-fused androgen receptor LBD (unknown origin) transfected in UAS-bla GripTite 293 cells assessed as inhibition of R1881-induced receptor activation after 16 to 24 hrs by beta-lactamase reporter gene assay,0,B,,CHEMBL3829948,10.1016/j.bmcl.2016.06.001,27301368,CHEMBL3826911,"Rational design and synthesis of novel anti-prostate cancer agents bearing a 3,5-bis-trifluoromethylphenyl moiety.",PUBLICATION,"Prostate cancer is a major cause of male death worldwide and the identification of new and improved treatments is constantly required. Among the available options, different non-steroidal androgen receptor (AR) antagonists are approved also to treat castration-resistant forms. Most of these drugs show limited application due to the development of resistant mutants of their biological target. Following docking-based studies on a homology model for the AR open antagonist conformation, a series of novel 3,5-bis-trifluoromethylphenyl compounds was designed with the aim to improve the antiproliferative activity of anti-androgen drugs bicalutamide and enzalutamide. The new structural modifications might impede the receptor to adopt its closed agonist conformation also in the presence of adaptive mutations. Among the novel compounds synthesised, several displayed significantly improved in vitro activity in comparison with the parent structures, with IC50 values in the low micromolar range against four different prostate cancer cell lines (LNCaP, VCaP, DU-145, 22Rv1). Selected hits demonstrated full AR antagonistic behaviour and promising candidates for further development were identified.",,CC(O)(CS(=O)(=O)c1cc(C(F)(F)F)cc(C(F)(F)F)c1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C19H13F9N2O6S,CHEMBL3827008,3100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3100.0,3100.0,3100.0,3100.0,3.491361694,3.491361694,3.491361694,5.508638306,5.508638306,5.508638306,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3100.0,3100.0,3100.0,3100.0,5.508638306165727,5.508638306165727,5.508638306165727,5.508638306165727,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2102524,nM,IC50,427293.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)no1,C22H22N4O3,CHEMBL3893153,650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,650.0,650.0,650.0,650.0,2.812913357,2.812913357,2.812913357,6.187086643,6.187086643,6.187086643,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,650.0,650.0,650.0,650.0,6.187086643357144,6.187086643357144,6.187086643357144,6.187086643357144,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2102691,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,N#Cc1ccc(N2C[C@H]3[C@H]4CC[C@H](C4)[C@@]3(C(N)=O)S2(=O)=O)cc1C(F)(F)F,C17H16F3N3O3S,CHEMBL3893320,55.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,55.0,55.0,55.0,55.0,1.740362689,1.740362689,1.740362689,7.259637311,7.259637311,7.259637311,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,55.0,55.0,55.0,55.0,7.259637310505756,7.259637310505756,7.259637310505756,7.259637310505756,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2104848,nM,IC50,325897.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(=O)NC)cc3)C2=S)cc1C(F)(F)F,C25H23F3N4O2S,CHEMBL3895477,92.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,92.0,92.0,92.0,92.0,1.963787827,1.963787827,1.963787827,7.036212173,7.036212173,7.036212173,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,92.0,92.0,92.0,92.0,7.036212172654444,7.036212172654444,7.036212172654444,7.036212172654444,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2104975,nM,IC50,427290.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(Cl)c(F)c4)CC3)ccnc12,C23H19ClFN3O2,CHEMBL3895604,61.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,61.0,61.0,61.0,61.0,1.785329835,1.785329835,1.785329835,7.214670165,7.214670165,7.214670165,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,61.0,61.0,61.0,61.0,7.214670164989233,7.214670164989233,7.214670164989233,7.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2107655,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@@H]3C=C[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C17H15F3N2O2S,CHEMBL3898284,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2108355,nM,IC50,427265.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1nocc1C(=O)NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1,C21H22FN3O3,CHEMBL3898984,210.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,210.0,210.0,210.0,210.0,2.322219295,2.322219295,2.322219295,6.677780705,6.677780705,6.677780705,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2109177,nM,IC50,427278.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)cc1,C22H20BrFN2O2,CHEMBL3899806,477.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,477.0,477.0,477.0,477.0,2.678518379,2.678518379,2.678518379,6.321481621,6.321481621,6.321481621,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,477.0,477.0,477.0,477.0,6.321481620959886,6.321481620959886,6.321481620959886,6.321481620959886,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2110199,nM,IC50,325899.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)C2=S)cc1C(F)(F)F,C25H24F3N5O3S2,CHEMBL3900828,138.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,138.0,138.0,138.0,138.0,2.139879086,2.139879086,2.139879086,6.860120914,6.860120914,6.860120914,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,138.0,138.0,138.0,138.0,6.860120913598763,6.860120913598763,6.860120913598763,6.860120913598763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2111681,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,CNC(=O)[C@@]12[C@@H](CN(c3ccc(C#N)c(C(F)(F)F)c3)S1(=O)=O)[C@H]1C[C@H](F)[C@@H]2C1,C18H17F4N3O3S,CHEMBL3902310,57.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,57.0,57.0,57.0,57.0,1.755874856,1.755874856,1.755874856,7.244125144,7.244125144,7.244125144,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,57.0,57.0,57.0,57.0,7.2441251443275085,7.2441251443275085,7.2441251443275085,7.2441251443275085,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2112411,nM,IC50,325866.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(OC(=O)CCl)cc3)C2=S)cc1C(F)(F)F,C21H15ClF3N3O3S,CHEMBL3903040,131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,131.0,131.0,131.0,131.0,2.117271296,2.117271296,2.117271296,6.882728704,6.882728704,6.882728704,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,131.0,131.0,131.0,131.0,6.882728704344236,6.882728704344236,6.882728704344236,6.882728704344236,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2113605,nM,IC50,325865.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(N)cc3)C2=S)cc1C(F)(F)F,C19H15F3N4OS,CHEMBL3904234,273.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,273.0,273.0,273.0,273.0,2.436162647,2.436162647,2.436162647,6.563837353,6.563837353,6.563837353,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,273.0,273.0,273.0,273.0,6.5638373529592435,6.5638373529592435,6.5638373529592435,6.5638373529592435,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2113925,nM,IC50,427273.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1cccc(F)c1,C22H20BrFN2O2,CHEMBL3904554,93.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,93.0,93.0,93.0,93.0,1.968482949,1.968482949,1.968482949,7.031517051,7.031517051,7.031517051,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,93.0,93.0,93.0,93.0,7.031517051446065,7.031517051446065,7.031517051446065,7.031517051446065,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2115098,nM,IC50,427267.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccon1,C20H20FN3O3,CHEMBL3905727,740.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,740.0,740.0,740.0,740.0,2.86923172,2.86923172,2.86923172,6.13076828,6.13076828,6.13076828,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,740.0,740.0,740.0,740.0,6.130768280269024,6.130768280269024,6.130768280269024,6.130768280269024,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2116399,nM,IC50,427288.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)c(Cl)c4)CC3)ccnc12,C23H19ClFN3O2,CHEMBL3907028,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,67.0,67.0,67.0,67.0,1.826074803,1.826074803,1.826074803,7.173925197,7.173925197,7.173925197,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,67.0,67.0,67.0,67.0,7.173925197299173,7.173925197299173,7.173925197299173,7.173925197299173,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2116675,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1627005, Entry 1: 1627005, ","Entry 0: Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation, Entry 1: Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3869526, Entry 1: CHEMBL3869526, ","Entry 0: 10.1016/j.bmcl.2016.10.059, Entry 1: 10.1016/j.bmcl.2016.10.059, ","Entry 0: 27836399, Entry 1: 27836399, ","Entry 0: CHEMBL3868609, Entry 1: CHEMBL3868609, ","Entry 0: [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists., Entry 1: [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing., Entry 1: This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing., ",,C[C@@]12[C@@H]3CC[C@@H](C3O)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C17H17F3N2O3S,CHEMBL3907304,327.0,444.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,58.5,327.0,385.5,385.5,444.0,2.586024382,2.586024382,2.514547753,6.413975618,6.413975618,6.485452247,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,385.5,385.5,327.0,444.0,6.4139756176130245,6.4139756176130245,6.485452247339714,6.35261702988538,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2119856,nM,IC50,325869.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C23H20F3N3OS,CHEMBL3910485,194.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,194.0,194.0,194.0,194.0,2.28780173,2.28780173,2.28780173,6.71219827,6.71219827,6.71219827,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,194.0,194.0,194.0,194.0,6.7121982700697735,6.7121982700697735,6.7121982700697735,6.7121982700697735,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2120670,nM,IC50,427269.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1cc[nH]n1,C20H21FN4O2,CHEMBL3911299,420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,420.0,420.0,420.0,420.0,2.62324929,2.62324929,2.62324929,6.37675071,6.37675071,6.37675071,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,420.0,420.0,420.0,420.0,6.376750709602099,6.376750709602099,6.376750709602099,6.376750709602099,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2122925,nM,IC50,427275.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)cc1F,C23H22BrFN2O2,CHEMBL3913554,68.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,68.0,68.0,68.0,68.0,1.832508913,1.832508913,1.832508913,7.167491087,7.167491087,7.167491087,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,68.0,68.0,68.0,68.0,7.167491087293763,7.167491087293763,7.167491087293763,7.167491087293763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2123043,nM,IC50,427276.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)cc1,C23H20BrN3O2,CHEMBL3913672,261.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,261.0,261.0,261.0,261.0,2.416640507,2.416640507,2.416640507,6.583359493,6.583359493,6.583359493,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,261.0,261.0,261.0,261.0,6.583359492661719,6.583359492661719,6.583359492661719,6.583359492661719,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2123465,nM,IC50,427280.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1cccc(F)c1,C22H21FN2O2,CHEMBL3914094,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32.0,32.0,32.0,32.0,1.505149978,1.505149978,1.505149978,7.494850022,7.494850022,7.494850022,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2125875,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1642258, Entry 1: 1642259, Entry 2: 1642260, ","Entry 0: Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 1: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG, Berlin, Germany), which contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant W741C (Haapala et al., Lab Invest. 81(12): 1647-51, 2001), and with a reporter plasmid based on pGL4.14 (#E6691, Promega) with the luciferase-gene (from Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-8, 1987). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 2: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG Berlin, Germany) that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant E709Y (Georget et al., Mol. Endocrinol. 20(4): 724-734, 2006), and with the MMTV-luciferase plasmid (see above, transactivation assay for the androgen receptor mutant W741C). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3888981, Entry 1: CHEMBL3888982, Entry 2: CHEMBL3888983, ",,,"Entry 0: CHEMBL3886907, Entry 1: CHEMBL3886907, Entry 2: CHEMBL3886907, ","Entry 0: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 1: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 2: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, ","Entry 0: PATENT, Entry 1: PATENT, Entry 2: PATENT, ",,"Entry 0: US-9428460-B2, Entry 1: US-9428460-B2, Entry 2: US-9428460-B2, ",O=C(NC[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1ccc(F)c(F)c1,C23H22F2N2O2,CHEMBL3916504,56.0,72.0,105.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,20.401525,56.0,77.66666667,72.0,105.0,1.890234666,1.857332496,1.748188027,7.109765334,7.142667504,7.251811973,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,64.0,64.0,56.0,72.0,7.1938200260161125,7.1938200260161125,7.251811972993799,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2126733,nM,IC50,427262.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccc(F)cc1,C23H22F2N2O2,CHEMBL3917362,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,240.0,240.0,240.0,240.0,2.380211242,2.380211242,2.380211242,6.619788758,6.619788758,6.619788758,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,240.0,240.0,240.0,240.0,6.619788758288394,6.619788758288394,6.619788758288394,6.619788758288394,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2126743,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,N#Cc1ccc(N2C[C@H]3[C@H]4CC[C@H](C4)[C@H]3S2(=O)=O)cc1C(F)(F)F,C16H15F3N2O2S,CHEMBL3917372,130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,130.0,130.0,130.0,130.0,2.113943352,2.113943352,2.113943352,6.886056648,6.886056648,6.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,130.0,130.0,130.0,130.0,6.886056647693163,6.886056647693163,6.886056647693163,6.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2128599,nM,IC50,325873.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc([N+](=O)[O-])cc3)C2=S)cc1C(F)(F)F,C21H15F3N4O3S,CHEMBL3919228,498.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,498.0,498.0,498.0,498.0,2.697229343,2.697229343,2.697229343,6.302770657,6.302770657,6.302770657,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,498.0,498.0,498.0,498.0,6.302770657240282,6.302770657240282,6.302770657240282,6.302770657240282,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2129618,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@@H](CN(c3ccc(C#N)c(C(F)(F)F)c3)S1(=O)=O)[C@H]1C[C@H](O)[C@@H]2C1,C17H17F3N2O3S,CHEMBL3920247,106.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,106.0,106.0,106.0,106.0,2.025305865,2.025305865,2.025305865,6.974694135,6.974694135,6.974694135,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,106.0,106.0,106.0,106.0,6.97469413473523,6.97469413473523,6.97469413473523,6.97469413473523,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2130086,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1642258, Entry 1: 1642259, Entry 2: 1642260, ","Entry 0: Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 1: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG, Berlin, Germany), which contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant W741C (Haapala et al., Lab Invest. 81(12): 1647-51, 2001), and with a reporter plasmid based on pGL4.14 (#E6691, Promega) with the luciferase-gene (from Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-8, 1987). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 2: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG Berlin, Germany) that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant E709Y (Georget et al., Mol. Endocrinol. 20(4): 724-734, 2006), and with the MMTV-luciferase plasmid (see above, transactivation assay for the androgen receptor mutant W741C). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3888981, Entry 1: CHEMBL3888982, Entry 2: CHEMBL3888983, ",,,"Entry 0: CHEMBL3886907, Entry 1: CHEMBL3886907, Entry 2: CHEMBL3886907, ","Entry 0: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 1: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 2: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, ","Entry 0: PATENT, Entry 1: PATENT, Entry 2: PATENT, ",,"Entry 0: US-9428460-B2, Entry 1: US-9428460-B2, Entry 2: US-9428460-B2, ",N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4cccc(F)c4)CC3)ccnc12,C23H20FN3O2,CHEMBL3920715,9.0,30.0,52.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,17.55625878,9.0,30.33333333,30.0,52.0,1.481920138,1.477121255,0.954242509,7.518079862,7.522878745,8.045757491,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.5,19.5,9.0,30.0,7.709965388637482,7.709965388637482,8.045757490560675,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2130686,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,CNC(=O)[C@@]12[C@@H]3CC[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C18H18F3N3O3S,CHEMBL3921315,44.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,44.0,44.0,44.0,44.0,1.643452676,1.643452676,1.643452676,7.356547324,7.356547324,7.356547324,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,44.0,44.0,44.0,44.0,7.356547323513813,7.356547323513813,7.356547323513813,7.356547323513813,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2131201,nM,IC50,427283.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1ccc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4ccccc34)CC2)cc1,C24H23N3O2,CHEMBL3921830,330.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,330.0,330.0,330.0,330.0,2.51851394,2.51851394,2.51851394,6.48148606,6.48148606,6.48148606,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,330.0,330.0,330.0,330.0,6.481486060122113,6.481486060122113,6.481486060122113,6.481486060122113,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2135729,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@@H]3CC[C@@H](C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C17H17F3N2O2S,CHEMBL3926358,73.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,73.0,73.0,73.0,73.0,1.86332286,1.86332286,1.86332286,7.13667714,7.13667714,7.13667714,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,73.0,73.0,73.0,73.0,7.136677139879544,7.136677139879544,7.136677139879544,7.136677139879544,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2136534,nM,IC50,,BAO_0000190,IC50,1624955,Antagonist activity at human AR expressed in HEK293 cells measured after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL3867367,10.1021/acsmedchemlett.6b00184,27994732,CHEMBL3865849,Development of N-(4-Phenoxyphenyl)benzenesulfonamide Derivatives as Novel Nonsteroidal Progesterone Receptor Antagonists.,PUBLICATION,"We report here development of N-(4-phenoxyphenyl)benzenesulfonamide derivatives as a novel class of nonsteroidal progesterone receptor (PR) antagonists. PR plays key roles in various physiological systems, including the female reproductive system, and PR antagonists are candidates for clinical treatment of multiple diseases, including uterine leiomyoma, endometriosis, breast cancer, and some psychiatric disorders. We found that the benzenesulfonanilide skeleton functions as a novel scaffold for PR antagonists, and we adopted 3-chlorobenzenesulfonyl derivative 20a as a lead compound for structural development. Among the synthesized compounds, 3-trifluoromethyl derivative 32 exhibited the most potent PR-antagonistic activity, with high binding affinity for PR and selectivity over androgen receptor (AR). It is structurally distinct from other nonsteroidal PR antagonists, including cyanopyrrole derivatives, and further modification is expected to afford novel selective PR modulators.",,O=S(=O)(Nc1ccc(Oc2ccccc2)cc1)c1cccc(C(F)(F)F)c1,C19H14F3NO3S,CHEMBL3927163,5300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5300.0,5300.0,5300.0,5300.0,3.72427587,3.72427587,3.72427587,5.27572413,5.27572413,5.27572413,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5300.0,5300.0,5300.0,5300.0,5.275724130399211,5.275724130399211,5.275724130399211,5.275724130399211,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2136602,nM,IC50,427277.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(C(F)(F)F)c(F)c1,C23H19BrF4N2O2,CHEMBL3927231,463.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,463.0,463.0,463.0,463.0,2.665580991,2.665580991,2.665580991,6.334419009,6.334419009,6.334419009,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,463.0,463.0,463.0,463.0,6.334419008982047,6.334419008982047,6.334419008982047,6.334419008982047,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2137397,nM,IC50,427291.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4cc(F)cc(F)c4)CC3)ccnc12,C23H19F2N3O2,CHEMBL3928026,39.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,39.0,39.0,39.0,39.0,1.591064607,1.591064607,1.591064607,7.408935393,7.408935393,7.408935393,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,39.0,39.0,39.0,39.0,7.4089353929735005,7.4089353929735005,7.4089353929735005,7.4089353929735005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2138395,nM,IC50,427274.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)c(F)c1,C22H19BrF2N2O2,CHEMBL3929024,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,170.0,170.0,170.0,170.0,2.230448921,2.230448921,2.230448921,6.769551079,6.769551079,6.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2140131,nM,IC50,427287.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)no1,C21H20N4O3,CHEMBL3930760,18.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,18.0,18.0,18.0,18.0,1.255272505,1.255272505,1.255272505,7.744727495,7.744727495,7.744727495,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,18.0,18.0,18.0,18.0,7.7447274948966935,7.7447274948966935,7.7447274948966935,7.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2141018,nM,IC50,325871.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCN(C)CC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C23H21F3N4OS,CHEMBL3931647,638.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,638.0,638.0,638.0,638.0,2.804820679,2.804820679,2.804820679,6.195179321,6.195179321,6.195179321,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,638.0,638.0,638.0,638.0,6.195179321278838,6.195179321278838,6.195179321278838,6.195179321278838,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2141835,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2227423, Entry 1: 2227424, ","Entry 0: Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay, Entry 1: Antagonist activity at Androgen receptor in human LNCaP cells measured by SEAP reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL5140936, Entry 1: CHEMBL5140937, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CCS(=O)(=O)N[C@@H]1C[C@@]2(C)O[C@]1(C)[C@@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@@H]12,C20H20F3N3O5S,CHEMBL3932464,16.0,153.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,68.5,16.0,84.5,84.5,153.0,1.926856709,1.926856709,1.204119983,7.073143291,7.073143291,7.795880017,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,84.5,84.5,16.0,153.0,7.073143291050307,7.073143291050307,7.795880017344075,6.815308569182402,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2142154,nM,IC50,427286.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)cc4)CC3)ccnc12,C23H20FN3O2,CHEMBL3932783,140.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,140.0,140.0,140.0,140.0,2.146128036,2.146128036,2.146128036,6.853871964,6.853871964,6.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2142228,nM,IC50,325882.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccccc3C)C2=S)cc1C(F)(F)F,C21H16F3N3OS,CHEMBL3932857,258.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,258.0,258.0,258.0,258.0,2.411619706,2.411619706,2.411619706,6.588380294,6.588380294,6.588380294,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,258.0,258.0,258.0,258.0,6.58838029403677,6.58838029403677,6.58838029403677,6.58838029403677,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2143118,nM,IC50,427268.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(F)cccc34)CC2)no1,C21H22FN3O3,CHEMBL3933747,480.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,480.0,480.0,480.0,480.0,2.681241237,2.681241237,2.681241237,6.318758763,6.318758763,6.318758763,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,480.0,480.0,480.0,480.0,6.318758762624412,6.318758762624412,6.318758762624412,6.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2144150,nM,IC50,325880.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(CCl)(CCl)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C20H14Cl2F3N3OS,CHEMBL3934779,521.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,521.0,521.0,521.0,521.0,2.716837723,2.716837723,2.716837723,6.283162277,6.283162277,6.283162277,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,521.0,521.0,521.0,521.0,6.283162276700476,6.283162276700476,6.283162276700476,6.283162276700476,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2144613,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@@H]3CC[C@@H](C3=O)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C17H15F3N2O3S,CHEMBL3935242,67.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,67.0,67.0,67.0,67.0,1.826074803,1.826074803,1.826074803,7.173925197,7.173925197,7.173925197,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,67.0,67.0,67.0,67.0,7.173925197299173,7.173925197299173,7.173925197299173,7.173925197299173,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2146087,nM,IC50,325894.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(=O)NCCO)cc3)C2=S)cc1C(F)(F)F,C25H23F3N4O3S,CHEMBL3936716,732.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,732.0,732.0,732.0,732.0,2.864511081,2.864511081,2.864511081,6.135488919,6.135488919,6.135488919,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,732.0,732.0,732.0,732.0,6.135488918941608,6.135488918941608,6.135488918941608,6.135488918941608,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2146302,nM,IC50,427279.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccc(F)c(Cl)c1,C22H19BrClFN2O2,CHEMBL3936931,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,190.0,190.0,190.0,190.0,2.278753601,2.278753601,2.278753601,6.721246399,6.721246399,6.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.0,190.0,190.0,190.0,6.721246399047171,6.721246399047171,6.721246399047171,6.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2146812,nM,IC50,427264.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(N[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1ccc(F)c(F)c1,C22H20F2N2O2,CHEMBL3937441,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,45.0,45.0,45.0,45.0,1.653212514,1.653212514,1.653212514,7.346787486,7.346787486,7.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2147722,nM,IC50,325879.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(C(F)(F)F)cc3)C2=S)cc1C(F)(F)F,C20H13F6N3OS,CHEMBL3938351,143.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,143.0,143.0,143.0,143.0,2.155336037,2.155336037,2.155336037,6.844663963,6.844663963,6.844663963,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,143.0,143.0,143.0,143.0,6.844663962534939,6.844663962534939,6.844663962534939,6.844663962534939,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2148307,nM,IC50,325892.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(N)=O)cc3)C2=S)cc1C(F)(F)F,C23H19F3N4O2S,CHEMBL3938936,224.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,224.0,224.0,224.0,224.0,2.350248018,2.350248018,2.350248018,6.649751982,6.649751982,6.649751982,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,224.0,224.0,224.0,224.0,6.649751981665837,6.649751981665837,6.649751981665837,6.649751981665837,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2148643,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@H]3C[C@H]([C@H](O)C3)[C@@H]1CN(c1ccc(C#N)c(C(F)(F)F)c1)S2(=O)=O,C17H17F3N2O3S,CHEMBL3939272,430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,430.0,430.0,430.0,430.0,2.633468456,2.633468456,2.633468456,6.366531544,6.366531544,6.366531544,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,430.0,430.0,430.0,430.0,6.366531544420414,6.366531544420414,6.366531544420414,6.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2149394,nM,IC50,325868.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C21H16F3N3OS,CHEMBL3940023,124.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,124.0,124.0,124.0,124.0,2.093421685,2.093421685,2.093421685,6.906578315,6.906578315,6.906578315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,124.0,124.0,124.0,124.0,6.906578314837765,6.906578314837765,6.906578314837765,6.906578314837765,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2149675,nM,IC50,325876.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(O)cc3)C(C)(C)C2=S)cc1C(F)(F)F,C19H14F3N3OS2,CHEMBL3940304,278.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,278.0,278.0,278.0,278.0,2.444044796,2.444044796,2.444044796,6.555955204,6.555955204,6.555955204,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,278.0,278.0,278.0,278.0,6.555955204081924,6.555955204081924,6.555955204081924,6.555955204081924,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2151069,nM,IC50,325881.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(CF)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C20H15F4N3OS,CHEMBL3941698,126.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,126.0,126.0,126.0,126.0,2.100370545,2.100370545,2.100370545,6.899629455,6.899629455,6.899629455,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,126.0,126.0,126.0,126.0,6.8996294548824375,6.8996294548824375,6.8996294548824375,6.8996294548824375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2156715,nM,IC50,325875.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(O)cc3)C2=S)cc1C(F)(F)F,C20H14F3N3O2S,CHEMBL3947344,162.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,162.0,162.0,162.0,162.0,2.209515015,2.209515015,2.209515015,6.790484985,6.790484985,6.790484985,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,162.0,162.0,162.0,162.0,6.790484985457369,6.790484985457369,6.790484985457369,6.790484985457369,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2157405,nM,IC50,427272.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4ccccc34)CC2)no1,C21H23N3O3,CHEMBL3948034,210.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,210.0,210.0,210.0,210.0,2.322219295,2.322219295,2.322219295,6.677780705,6.677780705,6.677780705,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2157582,nM,IC50,325891.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CO)cc3)C2=S)cc1C(F)(F)F,C21H16F3N3O2S,CHEMBL3948211,311.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,311.0,311.0,311.0,311.0,2.492760389,2.492760389,2.492760389,6.507239611,6.507239611,6.507239611,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,311.0,311.0,311.0,311.0,6.507239610973162,6.507239610973162,6.507239610973162,6.507239610973162,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2158547,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,C[C@@]12[C@@H](CN(c3ccc(C#N)c(C(F)(F)F)c3)S1(=O)=O)[C@H]1C[C@H](F)[C@@H]2C1,C17H16F4N2O2S,CHEMBL3949176,91.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,91.0,91.0,91.0,91.0,1.959041392,1.959041392,1.959041392,7.040958608,7.040958608,7.040958608,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,91.0,91.0,91.0,91.0,7.040958607678906,7.040958607678906,7.040958607678906,7.040958607678906,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2163299,nM,IC50,427282.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(Br)cccc23)CC1)c1ccon1,C20H20BrN3O3,CHEMBL3953928,630.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,630.0,630.0,630.0,630.0,2.799340549,2.799340549,2.799340549,6.200659451,6.200659451,6.200659451,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,630.0,630.0,630.0,630.0,6.200659450546418,6.200659450546418,6.200659450546418,6.200659450546418,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2164384,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1621343, Entry 1: 2230827, ","Entry 0: Displacement of [3H]mibolerone from androgen receptor (unknown origin) in membranes after 24 hrs by HAP adsorption assay, Entry 1: Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL3863626, Entry 1: CHEMBL5144599, ","Entry 0: 10.1016/j.bmcl.2016.09.058, Entry 1: 10.1016/j.bmcl.2021.128441, ","Entry 0: 27717544, Entry 1: 34767912, ","Entry 0: CHEMBL3862016, Entry 1: CHEMBL5143530, ","Entry 0: Targeting prostate cancer with compounds possessing dual activity as androgen receptor antagonists and HDAC6 inhibitors., Entry 1: Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: While enzalutamide and abiraterone are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC), approximately 20-40% of patients have no response to these agents. It has been stipulated that the lack of response and the development of secondary resistance to these drugs may be due to the presence of AR splice variants. HDAC6 has a role in regulating the androgen receptor (AR) by modulating heat shock protein 90 (Hsp90) acetylation, which controls the nuclear localization and activation of the AR in androgen-dependent and independent scenarios. With dual-acting AR-HDAC6 inhibitors it should be possible to target patients who don't respond to enzalutamide. Herein, we describe the design, synthesis and biological evaluation of dual-acting compounds which target AR and are also specific towards HDAC6. Our efforts led to compound 10 which was found to have potent dual activity (HDAC6 IC50=0.0356M and AR binding IC50=<0.03M). Compound 10 was further evaluated for antagonist and other cell-based activities, in vitro stability and pharmacokinetics., Entry 1: The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window., ",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2ccccc2N)c(F)c1,C26H19F4N5O2S,CHEMBL3955013,330.0,1700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,685.0,330.0,1015.0,1015.0,1700.0,3.006466042,3.006466042,2.51851394,5.993533958,5.993533958,6.48148606,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1700.0,1700.0,1700.0,1700.0,5.769551078621726,5.769551078621726,5.769551078621726,5.769551078621726,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2165118,nM,IC50,325872.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc(C#N)cc3)C2=S)cc1C(F)(F)F,C22H15F3N4OS,CHEMBL3955747,469.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,469.0,469.0,469.0,469.0,2.671172843,2.671172843,2.671172843,6.328827157,6.328827157,6.328827157,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,469.0,469.0,469.0,469.0,6.328827157284917,6.328827157284917,6.328827157284917,6.328827157284917,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2165452,nM,IC50,325886.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc4ccccc4c3)C2=S)cc1C(F)(F)F,C24H16F3N3OS,CHEMBL3956081,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2167620,nM,IC50,325863.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C20H16F3N3OS,CHEMBL3958249,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,125.0,125.0,125.0,125.0,2.096910013,2.096910013,2.096910013,6.903089987,6.903089987,6.903089987,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,125.0,125.0,125.0,125.0,6.903089986991944,6.903089986991944,6.903089986991944,6.903089986991944,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2168116,nM,IC50,325895.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(=O)OC)cc3)C2=S)cc1C(F)(F)F,C25H22F3N3O3S,CHEMBL3958745,432.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,432.0,432.0,432.0,432.0,2.635483747,2.635483747,2.635483747,6.364516253,6.364516253,6.364516253,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,432.0,432.0,432.0,432.0,6.364516253185088,6.364516253185088,6.364516253185088,6.364516253185088,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2168429,nM,IC50,427292.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,N#Cc1cccc2c(O[C@H]3CC[C@H](CNC(=O)c4ccon4)CC3)ccnc12,C21H20N4O3,CHEMBL3959058,720.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,720.0,720.0,720.0,720.0,2.857332496,2.857332496,2.857332496,6.142667504,6.142667504,6.142667504,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,720.0,720.0,720.0,720.0,6.142667503568732,6.142667503568732,6.142667503568732,6.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2169307,nM,IC50,325862.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccc3)C2=S)cc1C(F)(F)F,C19H14F3N3OS,CHEMBL3959936,149.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,149.0,149.0,149.0,149.0,2.173186268,2.173186268,2.173186268,6.826813732,6.826813732,6.826813732,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,149.0,149.0,149.0,149.0,6.826813731587726,6.826813731587726,6.826813731587726,6.826813731587726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2169626,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1642258, Entry 1: 1642259, Entry 2: 1642260, ","Entry 0: Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 1: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG, Berlin, Germany), which contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant W741C (Haapala et al., Lab Invest. 81(12): 1647-51, 2001), and with a reporter plasmid based on pGL4.14 (#E6691, Promega) with the luciferase-gene (from Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-8, 1987). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 2: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG Berlin, Germany) that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant E709Y (Georget et al., Mol. Endocrinol. 20(4): 724-734, 2006), and with the MMTV-luciferase plasmid (see above, transactivation assay for the androgen receptor mutant W741C). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3888981, Entry 1: CHEMBL3888982, Entry 2: CHEMBL3888983, ",,,"Entry 0: CHEMBL3886907, Entry 1: CHEMBL3886907, Entry 2: CHEMBL3886907, ","Entry 0: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 1: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 2: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, ","Entry 0: PATENT, Entry 1: PATENT, Entry 2: PATENT, ",,"Entry 0: US-9428460-B2, Entry 1: US-9428460-B2, Entry 2: US-9428460-B2, ",N#Cc1cccc2c(O[C@H]3CC[C@H](NC(=O)c4ccc(F)c(F)c4)CC3)ccnc12,C23H19F2N3O2,CHEMBL3960255,14.0,72.0,92.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,33.07902995,14.0,59.33333333,72.0,92.0,1.773298748,1.857332496,1.146128036,7.226701252,7.142667504,7.853871964,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,43.0,43.0,14.0,72.0,7.366531544420414,7.366531544420414,7.853871964321762,7.142667503568732,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2170536,nM,IC50,325884.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3cc(C)ccn3)C2=S)cc1C(F)(F)F,C19H15F3N4OS,CHEMBL3961165,457.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,457.0,457.0,457.0,457.0,2.6599162,2.6599162,2.6599162,6.3400838,6.3400838,6.3400838,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,457.0,457.0,457.0,457.0,6.34008379993015,6.34008379993015,6.34008379993015,6.34008379993015,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2171655,nM,IC50,325883.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccn3)C2=S)cc1C(F)(F)F,C18H13F3N4OS,CHEMBL3962284,723.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,723.0,723.0,723.0,723.0,2.859138297,2.859138297,2.859138297,6.140861703,6.140861703,6.140861703,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,723.0,723.0,723.0,723.0,6.140861702705469,6.140861702705469,6.140861702705469,6.140861702705469,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2172985,nM,IC50,325878.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccccc3C(=O)O)C2=S)cc1C(F)(F)F,C20H14F3N3O3S,CHEMBL3963614,523.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,523.0,523.0,523.0,523.0,2.718501689,2.718501689,2.718501689,6.281498311,6.281498311,6.281498311,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,523.0,523.0,523.0,523.0,6.281498311132726,6.281498311132726,6.281498311132726,6.281498311132726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2175076,nM,IC50,325896.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCCC(N)=O)cc3)C2=S)cc1C(F)(F)F,C24H21F3N4O2S,CHEMBL3965705,112.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,112.0,112.0,112.0,112.0,2.049218023,2.049218023,2.049218023,6.950781977,6.950781977,6.950781977,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,112.0,112.0,112.0,112.0,6.950781977329818,6.950781977329818,6.950781977329818,6.950781977329818,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2175866,nM,IC50,325898.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(N4CCNCC4)cc3)C2=S)cc1C(F)(F)F,C24H22F3N5OS,CHEMBL3966495,718.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,718.0,718.0,718.0,718.0,2.856124444,2.856124444,2.856124444,6.143875556,6.143875556,6.143875556,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,718.0,718.0,718.0,718.0,6.1438755557577,6.1438755557577,6.1438755557577,6.1438755557577,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2176268,nM,IC50,427289.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1ccc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(C#N)cccc34)CC2)cc1F,C24H22FN3O2,CHEMBL3966897,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,45.0,45.0,45.0,45.0,1.653212514,1.653212514,1.653212514,7.346787486,7.346787486,7.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2176514,nM,IC50,427263.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)N[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)no1,C20H20BrN3O3,CHEMBL3967143,20.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20.0,20.0,20.0,20.0,1.301029996,1.301029996,1.301029996,7.698970004,7.698970004,7.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,20.0,20.0,20.0,20.0,7.698970004336019,7.698970004336019,7.698970004336019,7.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2176607,nM,IC50,325893.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(CCC(=O)NC)cc3)C2=S)cc1C(F)(F)F,C24H21F3N4O2S,CHEMBL3967236,234.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,234.0,234.0,234.0,234.0,2.369215857,2.369215857,2.369215857,6.630784143,6.630784143,6.630784143,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,234.0,234.0,234.0,234.0,6.6307841425898575,6.6307841425898575,6.6307841425898575,6.6307841425898575,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2179934,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1642258, Entry 1: 1642259, Entry 2: 1642260, ","Entry 0: Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 1: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG, Berlin, Germany), which contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant W741C (Haapala et al., Lab Invest. 81(12): 1647-51, 2001), and with a reporter plasmid based on pGL4.14 (#E6691, Promega) with the luciferase-gene (from Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-8, 1987). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., Entry 2: Transactivation Assay: PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979) were plated out at a density of 10000 cells per well of a 96-well cell culture plate in RMPI 1640 medium (F1235, Biochrom AG Berlin, Germany) that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). On the next day the cells were transiently transfected with the pSG5-vector (#216201 Stratagene), which contained the sequence of the androgen receptor mutant E709Y (Georget et al., Mol. Endocrinol. 20(4): 724-734, 2006), and with the MMTV-luciferase plasmid (see above, transactivation assay for the androgen receptor mutant W741C). The cells were treated with the test substances in concentrations from 110^8 to 110^10 M in the presence of 110^10 M R1881 and were incubated overnight at 37 C. and 5% CO2. After 24 hours, 100 l of Steady Glo Lysis and Detection reagent (E2550, Promega) was added per well and the luminescence was read in a Victor3 Luminometer (PerkinElmer) for 1 second per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance)., ","0,1","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL3888981, Entry 1: CHEMBL3888982, Entry 2: CHEMBL3888983, ",,,"Entry 0: CHEMBL3886907, Entry 1: CHEMBL3886907, Entry 2: CHEMBL3886907, ","Entry 0: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 1: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, Entry 2: N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products, ","Entry 0: PATENT, Entry 1: PATENT, Entry 2: PATENT, ",,"Entry 0: US-9428460-B2, Entry 1: US-9428460-B2, Entry 2: US-9428460-B2, ",O=C(NC[C@H]1CC[C@H](Oc2ccnc3ccccc23)CC1)c1cccc(F)c1,C23H23FN2O2,CHEMBL3970563,175.0,194.0,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,18.44511378,175.0,196.3333333,194.0,220.0,2.29299404,2.28780173,2.243038049,6.70700596,6.71219827,6.756961951,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,184.5,184.5,175.0,194.0,6.734003629504921,6.734003629504921,6.756961951313706,6.7121982700697735,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2181903,nM,IC50,325870.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCCCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C24H22F3N3OS,CHEMBL3972532,232.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,232.0,232.0,232.0,232.0,2.365487985,2.365487985,2.365487985,6.634512015,6.634512015,6.634512015,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,232.0,232.0,232.0,232.0,6.634512015109101,6.634512015109101,6.634512015109101,6.634512015109101,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2182633,nM,IC50,325877.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)N(c3ccc(O)cc3)C(C)(C)C2=O)cc1C(F)(F)F,C19H14F3N3O3,CHEMBL3973262,369.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,369.0,369.0,369.0,369.0,2.567026366,2.567026366,2.567026366,6.432973634,6.432973634,6.432973634,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,369.0,369.0,369.0,369.0,6.432973633840939,6.432973633840939,6.432973633840939,6.432973633840939,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2182934,nM,IC50,427266.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,O=C(NC[C@H]1CC[C@H](Oc2ccnc3c(F)cccc23)CC1)c1ccno1,C20H20FN3O3,CHEMBL3973563,460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,460.0,460.0,460.0,460.0,2.662757832,2.662757832,2.662757832,6.337242168,6.337242168,6.337242168,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,460.0,460.0,460.0,460.0,6.337242168318426,6.337242168318426,6.337242168318426,6.337242168318426,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2185427,nM,IC50,325874.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3ccc(-c4ccccc4)cc3)C2=S)cc1C(F)(F)F,C26H18F3N3OS,CHEMBL3976056,283.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,283.0,283.0,283.0,283.0,2.451786436,2.451786436,2.451786436,6.548213564,6.548213564,6.548213564,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,283.0,283.0,283.0,283.0,6.54821356447571,6.54821356447571,6.54821356447571,6.54821356447571,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2186422,nM,IC50,325867.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCCC3)N(c3ccc(C)cc3)C2=S)cc1C(F)(F)F,C22H18F3N3OS,CHEMBL3977051,147.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,147.0,147.0,147.0,147.0,2.167317335,2.167317335,2.167317335,6.832682665,6.832682665,6.832682665,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,147.0,147.0,147.0,147.0,6.8326826652518236,6.8326826652518236,6.8326826652518236,6.8326826652518236,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2191980,nM,IC50,427281.0,BAO_0000190,IC50,1642258,"Transactivation Assay: For determining the androgen receptor-dependent transcription, a cellular assay system was used, consisting of PC-3 cells (Kaighn et al., Invest. Urol. 17: 16-23, 1979), which express the human androgen receptor stably and recombinantly (full length, wild-type form, see Swiss-Prot Acc. No. P10275, Entry Version 159, Sequence Version 2). In addition, these PC3 cells contain a stably integrated reporter gene plasmid, which is based on the commercially available plasmid pGL4.14 (#E6691, Promega Corporation, Madison, Wis., USA) and contains the luciferase gene from the American firefly (Photinus pyralis) under the control of the MMTV promoter (Cato et al., EMBO J. 6: 363-368, 1987). These cells were propagated in routine cell culture at 37 C. and 5% CO2 in a medium containing 90% RPMI 1640 (Invitrogen GmbH, Darmstadt, Germany), 100 U penicillin, 100 g/ml streptomycin (Invitrogen), 4 mM L-glutamine (Invitrogen), 10% fetal calf serum (FCS Serum Gold, PAA Laboratories GmbH, Clbe, Germany), 600 g/ml Geneticin (G418-sulphate, Invitrogen) and 10 g/ml puromycin (Sigma Aldrich GmbH, Germany). For carrying out the transactivation assays, approx. 1000 cells per well were plated out in a 384-well cell culture plate in a medium that contained activated charcoal-treated calf serum (FCS Serum Gold, PAA Laboratories) at a concentration of 5% (v/v). The test substances were added in a concentration series from 5.1210^12 to 110^5 M in the presence of 110^1 R1881 (methyltrienolone). The test plates were incubated overnight at 37 C. and 5% CO2. After 16 hours, 15 l of Steady Glo Lysis and Detection reagent (E2550, Promega Corporation, Madison, Wis., USA) was added per well and the luminescence was read in a Topcount Luminometer (PerkinElmer, Waltham, Mass., USA) for 4 seconds per well. The luminescence values obtained were normalized, wherein 100% corresponded to the effect of the unstimulated control (without R1881), and 0% corresponded to the effect of the stimulated control (R1881 plus DMSO instead of test substance).",0,B,,CHEMBL3888981,,,CHEMBL3886907,"N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides as androgen receptor antagonists, production and use thereof as medicinal products",PATENT,,US-9428460-B2,Cc1cc(C(=O)NC[C@H]2CC[C@H](Oc3ccnc4c(Br)cccc34)CC2)no1,C21H22BrN3O3,CHEMBL3982609,690.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,690.0,690.0,690.0,690.0,2.838849091,2.838849091,2.838849091,6.161150909,6.161150909,6.161150909,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,690.0,690.0,690.0,690.0,6.161150909262744,6.161150909262744,6.161150909262744,6.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2194077,nM,IC50,325885.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C3(CCC3)N(c3cc(C)n[nH]3)C2=S)cc1C(F)(F)F,C18H14F3N5OS,CHEMBL3984706,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1000.0,1000.0,1000.0,1000.0,3.0,3.0,3.0,6.0,6.0,6.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1000.0,1000.0,1000.0,1000.0,6.0,6.0,6.0,6.0,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2194502,nM,IC50,325864.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=O)C(C)(C)N(c3ccc(O)cc3)C2=S)cc1C(F)(F)F,C19H14F3N3O2S,CHEMBL3985131,137.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,137.0,137.0,137.0,137.0,2.136720567,2.136720567,2.136720567,6.863279433,6.863279433,6.863279433,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,137.0,137.0,137.0,137.0,6.863279432843593,6.863279432843593,6.863279432843593,6.863279432843593,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2196480,nM,IC50,,BAO_0000190,IC50,1627005,Antagonist activity at androgen receptor in human MDA-MB-453 cells assessed as inhibition of testosterone-induced transactivation,0,B,,CHEMBL3869526,10.1016/j.bmcl.2016.10.059,27836399,CHEMBL3868609,[2.2.1]-Bicyclic sultams as potent androgen receptor antagonists.,PUBLICATION,"This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.",,N#Cc1ccc(N2C[C@@H]3[C@@H]([C@@H]4C=C[C@H]3C4)S2(=O)=O)cc1C(F)(F)F,C16H13F3N2O2S,CHEMBL3987109,219.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,219.0,219.0,219.0,219.0,2.340444115,2.340444115,2.340444115,6.659555885,6.659555885,6.659555885,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,219.0,219.0,219.0,219.0,6.6595558851598815,6.6595558851598815,6.6595558851598815,6.6595558851598815,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2199890,nM,IC50,,BAO_0000190,IC50,1648028,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,0,B,,CHEMBL3997084,10.1016/j.bmcl.2017.01.065,28162857,CHEMBL3994642,"Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents.",PUBLICATION,"The structural modification and molecular docking-based screening approaches on thiazole-based isoindolinediones were imposed to find the novel 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives. The best fit compounds (6a-n) were synthesized and evaluated their antiproliferative activities on the prostate cancer cell lines (PC-3 & LNCaP). Among them, the compound, 6m exhibited good activity, particularly on LNCaP (IC50=5.961.6M), moderately active against PC-3 cell lines as compared to bicalutamide. The compound, 6m decreased the androgen-mediated transcription of ARE-mRNA in PSA, TMPRSS2, c-myc and cyclin D1 than R-bicalutamide. The compounds, 6e and 6f were reconfirmed through single crystal XRD analysis. The ADME profiling of the test compounds was evaluated to find the drug-likeness and pharmacokinetic parameters. These findings may provide vital information for the development of anti-prostate cancer agents.",,COc1ccc(-c2csc(N3C(=O)c4ccc(F)cc4C3=O)n2)cc1,C18H11FN2O3S,CHEMBL4059979,8170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8170.0,8170.0,8170.0,8170.0,3.912222057,3.912222057,3.912222057,5.087777943,5.087777943,5.087777943,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8170.0,8170.0,8170.0,8170.0,5.087777943467585,5.087777943467585,5.087777943467585,5.087777943467585,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2200182,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1662819, Entry 1: 1662820, Entry 2: 2227383, ","Entry 0: Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method, Entry 1: Agonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells after 24 hrs by MMTV-promoter driven luciferase reporter gene assay, Entry 2: Binding affinity to human Androgen receptor, ",1,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4012500, Entry 1: CHEMBL4012501, Entry 2: CHEMBL5140896, ","Entry 0: 10.1016/j.bmcl.2017.03.038, Entry 1: 10.1016/j.bmcl.2017.03.038, Entry 2: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 28363748, Entry 1: 28363748, Entry 2: 35786895, ","Entry 0: CHEMBL4011613, Entry 1: CHEMBL4011613, Entry 2: CHEMBL5137058, ","Entry 0: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 1: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 1: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1c(N2CC[C@](C)(O)[C@@H]2C)ccc(C#N)c1Cl,C14H17ClN2O,CHEMBL4060271,0.2,0.49,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.330689515,0.2,0.563333333,0.49,1.0,-0.24923455,-0.30980392,-0.698970004,9.24923455,9.30980392,9.698970004,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.49,0.49,0.49,0.49,9.309803919971486,9.309803919971486,9.309803919971486,9.309803919971486,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2202256,nM,IC50,,BAO_0000190,IC50,1678006,Antagonist activity at human GAL4-DBD fused AR ligand binding domain transfected in human Huh7 cells co-expressing GAL4-RE-Luc assessed as reduction in dihydrotestosterone-induced luciferase activity after 16 hrs by luciferase reporter gene assay,0,A,,CHEMBL4028149,10.1021/acs.jmedchem.7b01515,29300474,CHEMBL4024791,"Identification of Morpholino-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-ones as Nonsteroidal Mineralocorticoid Antagonists.",PUBLICATION,"A novel series of morpholine-based nonsteroidal mineralocorticoid receptor antagonists is reported. Starting from a pyrrolidine HTS hit 9 that possessed modest potency but excellect selectivity versus related nuclear hormone receptors, a series of libraries led to identification of morpholine lead 10. After further optimization, cis disubstituted morpholine 22 was discovered, which showed a 45-fold boost in binding affinity and corresponding functional potency compared to 13. While 22 had high clearance in rat, it provided sufficient exposure at high doses to favorably assess in vivo efficacy (increased urinary Na+/K+ ratio) and safety. In contrast to rat, the dog and human MetID and PK profiles of 22 were adequate, suggesting that it could be suitable as a potential clinical asset.",,O=C1COc2ccc(N3CCOC[C@H]3c3ccccc3)cc2N1,C18H18N2O3,CHEMBL4062345,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2207919,nM,IC50,,BAO_0000190,IC50,1658408,Antagonist activity at GAL4-fused human AR LBD (667 to 919 residues) expressed in CHO-K1 cells assessed as inhibition of dihydrotestosterone-induced transactivation activity after 5 to 6 hrs by luciferase reporter gene assay,0,B,,CHEMBL4008020,10.1021/acs.jmedchem.6b01065,28051871,CHEMBL4007392,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,PUBLICATION,"Steroidal mineralocorticoid receptor (MR) antagonists are used for treatment of a range of human diseases, but they present challenging issues of complex chemical synthesis, undesirable physical properties, and poor selectivity along with unwanted side effects. Therefore, there is a great interest in the discovery of non-steroidal ligands able to bind to the ligand-binding domain of the MR and recruit different co-regulators to produce tissue-specific therapeutic effects. Several academic groups and pharmaceutical companies have been developing a series of non-steroidal ligands that consist of different chemical scaffolds, yielding MR antagonists currently evaluated in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic nephropathy. The main focus of this Perspective is to review the reported structure-activity relationships of the different series of compounds, as well as the structural studies that contribute to a better understanding of the receptor active site and are also helpful for optimization processes.",,CCOc1nccc2c1[C@H](c1ccc(C#N)cc1OC)C(C#N)=C(C)N2,C20H18N4O2,CHEMBL4068008,2800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2800.0,2800.0,2800.0,2800.0,3.447158031,3.447158031,3.447158031,5.552841969,5.552841969,5.552841969,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2800.0,2800.0,2800.0,2800.0,5.552841968657781,5.552841968657781,5.552841968657781,5.552841968657781,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2208857,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1662819, Entry 1: 1662820, ","Entry 0: Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method, Entry 1: Agonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells after 24 hrs by MMTV-promoter driven luciferase reporter gene assay, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4012500, Entry 1: CHEMBL4012501, ","Entry 0: 10.1016/j.bmcl.2017.03.038, Entry 1: 10.1016/j.bmcl.2017.03.038, ","Entry 0: 28363748, Entry 1: 28363748, ","Entry 0: CHEMBL4011613, Entry 1: CHEMBL4011613, ","Entry 0: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 1: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 1: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., ",,C[C@@H]1N(c2ccc(C#N)c(Cl)c2)CC[C@]1(C)O,C13H15ClN2O,CHEMBL4068946,0.32,0.52,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.1,0.32,0.42,0.42,0.52,-0.37675071,-0.37675071,-0.494850022,9.37675071,9.37675071,9.494850022,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.52,0.52,0.52,0.52,9.2839966563652,9.2839966563652,9.2839966563652,9.2839966563652,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2209567,nM,IC50,,BAO_0000190,IC50,1648028,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,0,B,,CHEMBL3997084,10.1016/j.bmcl.2017.01.065,28162857,CHEMBL3994642,"Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents.",PUBLICATION,"The structural modification and molecular docking-based screening approaches on thiazole-based isoindolinediones were imposed to find the novel 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives. The best fit compounds (6a-n) were synthesized and evaluated their antiproliferative activities on the prostate cancer cell lines (PC-3 & LNCaP). Among them, the compound, 6m exhibited good activity, particularly on LNCaP (IC50=5.961.6M), moderately active against PC-3 cell lines as compared to bicalutamide. The compound, 6m decreased the androgen-mediated transcription of ARE-mRNA in PSA, TMPRSS2, c-myc and cyclin D1 than R-bicalutamide. The compounds, 6e and 6f were reconfirmed through single crystal XRD analysis. The ADME profiling of the test compounds was evaluated to find the drug-likeness and pharmacokinetic parameters. These findings may provide vital information for the development of anti-prostate cancer agents.",,O=C1c2ccc(F)cc2C(=O)N1c1nc(-c2ccc(F)cc2)cs1,C17H8F2N2O2S,CHEMBL4069656,21510.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,21510.0,21510.0,21510.0,21510.0,4.33264041,4.33264041,4.33264041,4.66735959,4.66735959,4.66735959,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,21510.0,21510.0,21510.0,21510.0,4.667359589612538,4.667359589612538,4.667359589612538,4.667359589612538,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2210336,nM,IC50,,BAO_0000190,IC50,1648028,Antagonist activity at AR T877A mutant in human LNCAP cells assessed as inhibition of DHT-induced proliferation after 48 hrs by MTT assay,0,B,,CHEMBL3997084,10.1016/j.bmcl.2017.01.065,28162857,CHEMBL3994642,"Design, synthesis and biological evaluation of 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives as anti-prostate cancer agents.",PUBLICATION,"The structural modification and molecular docking-based screening approaches on thiazole-based isoindolinediones were imposed to find the novel 2-(4-phenylthiazol-2-yl) isoindoline-1,3-dione derivatives. The best fit compounds (6a-n) were synthesized and evaluated their antiproliferative activities on the prostate cancer cell lines (PC-3 & LNCaP). Among them, the compound, 6m exhibited good activity, particularly on LNCaP (IC50=5.961.6M), moderately active against PC-3 cell lines as compared to bicalutamide. The compound, 6m decreased the androgen-mediated transcription of ARE-mRNA in PSA, TMPRSS2, c-myc and cyclin D1 than R-bicalutamide. The compounds, 6e and 6f were reconfirmed through single crystal XRD analysis. The ADME profiling of the test compounds was evaluated to find the drug-likeness and pharmacokinetic parameters. These findings may provide vital information for the development of anti-prostate cancer agents.",,Cc1ccc(-c2csc(N3C(=O)c4ccccc4C3=O)n2)cc1,C18H12N2O2S,CHEMBL4070425,29040.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,29040.0,29040.0,29040.0,29040.0,4.462996612,4.462996612,4.462996612,4.537003388,4.537003388,4.537003388,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,29040.0,29040.0,29040.0,29040.0,4.537003387971944,4.537003387971944,4.537003387971944,4.537003387971944,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2228825,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1671470, Entry 1: 2214674, Entry 2: 2227402, ","Entry 0: Displacement of [3H]mibolerone from human AR after 3 hrs, Entry 1: Inhibition of Androgen receptor (unknown origin), Entry 2: Binding affinity to Androgen receptor (unknown origin), ",1,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4021499, Entry 1: CHEMBL5127806, Entry 2: CHEMBL5140915, ","Entry 0: 10.1016/j.bmc.2017.04.018, Entry 1: 10.1016/j.ejmech.2022.114119, Entry 2: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 28454849, Entry 1: 35063736, Entry 2: 35786895, ","Entry 0: CHEMBL4020736, Entry 1: CHEMBL5126525, Entry 2: CHEMBL5137058, ","Entry 0: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate., Entry 1: Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: We previously reported that 4-(pyrrolidin-1-yl)benzonitrile derivative 1b was a selective androgen receptor modulator (SARM) that exhibited anabolic effects on organs such as muscles and the central nervous system (CNS), but neutral effects on the prostate. From further modification, we identified that 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2a showed strong AR binding affinity with improved metabolic stabilities. Based on these results, we tried to enhance the AR agonistic activities by modifying the substituents of the 5-oxopyrrolidine ring. As a consequence, we found that 4-[(2S,3S)-2-ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile (2f) had ideal SARM profiles in Hershberger assay and sexual behavior induction assay. Furthermore, 2f showed good pharmacokinetic profiles in rats, dogs, monkeys, excellent nuclear selectivity and acceptable toxicological profiles. We also determined its binding mode by obtaining the co-crystal structures with AR., Entry 1: Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC[C@H]1[C@@H](O)CC(=O)N1c1ccc(C#N)c(C(F)(F)F)c1,C14H13F3N2O2,CHEMBL4088914,3.6,3.6,4.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3.6,3.6,3.6,3.6,0.556302501,0.556302501,0.556302501,8.443697499,8.443697499,8.443697499,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3.6,3.6,3.6,3.6,8.443697499232712,8.443697499232712,8.443697499232712,8.443697499232712,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2229939,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 1662819, Entry 1: 1662820, Entry 2: 1671470, Entry 3: 2214674, ","Entry 0: Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method, Entry 1: Agonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells after 24 hrs by MMTV-promoter driven luciferase reporter gene assay, Entry 2: Displacement of [3H]mibolerone from human AR after 3 hrs, Entry 3: Inhibition of Androgen receptor (unknown origin), ",1,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL4012500, Entry 1: CHEMBL4012501, Entry 2: CHEMBL4021499, Entry 3: CHEMBL5127806, ","Entry 0: 10.1016/j.bmcl.2017.03.038, Entry 1: 10.1016/j.bmcl.2017.03.038, Entry 2: 10.1016/j.bmc.2017.04.018, Entry 3: 10.1016/j.ejmech.2022.114119, ","Entry 0: 28363748, Entry 1: 28363748, Entry 2: 28454849, Entry 3: 35063736, ","Entry 0: CHEMBL4011613, Entry 1: CHEMBL4011613, Entry 2: CHEMBL4020736, Entry 3: CHEMBL5126525, ","Entry 0: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 1: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 2: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate., Entry 3: Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 1: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 2: We previously reported that 4-(pyrrolidin-1-yl)benzonitrile derivative 1b was a selective androgen receptor modulator (SARM) that exhibited anabolic effects on organs such as muscles and the central nervous system (CNS), but neutral effects on the prostate. From further modification, we identified that 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2a showed strong AR binding affinity with improved metabolic stabilities. Based on these results, we tried to enhance the AR agonistic activities by modifying the substituents of the 5-oxopyrrolidine ring. As a consequence, we found that 4-[(2S,3S)-2-ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile (2f) had ideal SARM profiles in Hershberger assay and sexual behavior induction assay. Furthermore, 2f showed good pharmacokinetic profiles in rats, dogs, monkeys, excellent nuclear selectivity and acceptable toxicological profiles. We also determined its binding mode by obtaining the co-crystal structures with AR., Entry 3: Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated., ",,Cc1c(N2CC[C@H](O)[C@@H]2C)ccc(C#N)c1Cl,C13H15ClN2O,CHEMBL4090028,0.19,0.72,1.0,0.72,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.229496732,0.19,0.5875,0.72,0.72,-0.230992129,-0.142667504,-0.721246399,9.230992129,9.142667504,9.721246399,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.72,0.72,0.72,0.72,9.142667503568731,9.142667503568731,9.142667503568731,9.142667503568731,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2230682,nM,IC50,,BAO_0000190,IC50,1726360,Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4141638,10.1016/j.ejmech.2017.10.031,29117897,CHEMBL4138152,Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.,PUBLICATION,"Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising invitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.",,N#Cc1ccc(N2C(=O)C3Cc4ccccc4N3C2=S)cc1C(F)(F)F,C18H10F3N3OS,CHEMBL4090771,18750.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,18750.0,18750.0,18750.0,18750.0,4.273001272,4.273001272,4.273001272,4.726998728,4.726998728,4.726998728,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,18750.0,18750.0,18750.0,18750.0,4.726998727936262,4.726998727936262,4.726998727936262,4.726998727936262,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2232446,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 1662819, Entry 1: 1662820, Entry 2: 1671470, Entry 3: 2214674, ","Entry 0: Displacement of [17-alpha-methyl-H-3] mibolerone from wild-type androgen receptor (unknown origin) expressed in Freestyle293F cells measured after 3 hrs dextran/charcoal based method, Entry 1: Agonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells after 24 hrs by MMTV-promoter driven luciferase reporter gene assay, Entry 2: Displacement of [3H]mibolerone from human AR after 3 hrs, Entry 3: Inhibition of Androgen receptor (unknown origin), ",1,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL4012500, Entry 1: CHEMBL4012501, Entry 2: CHEMBL4021499, Entry 3: CHEMBL5127806, ","Entry 0: 10.1016/j.bmcl.2017.03.038, Entry 1: 10.1016/j.bmcl.2017.03.038, Entry 2: 10.1016/j.bmc.2017.04.018, Entry 3: 10.1016/j.ejmech.2022.114119, ","Entry 0: 28363748, Entry 1: 28363748, Entry 2: 28454849, Entry 3: 35063736, ","Entry 0: CHEMBL4011613, Entry 1: CHEMBL4011613, Entry 2: CHEMBL4020736, Entry 3: CHEMBL5126525, ","Entry 0: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 1: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs). Part II: Optimization of 4-(pyrrolidin-1-yl)benzonitrile derivatives., Entry 2: Synthesis and biological evaluation of novel selective androgen receptor modulators (SARMs) Part III: Discovery of 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2f as a clinical candidate., Entry 3: Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021)., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 1: We recently reported a class of novel tissue-selective androgen receptor modulators (SARMs), represented by a naphthalene derivative A. However, their pharmacokinetic (PK) profiles were poor due to low metabolic stability. To improve the PK profiles, we modified the hydroxypyrrolidine and benzonitrile substituents of 4-(pyrrolidin-1-yl)benzonitrile derivative B, which had a comparable potency as that of compound A. This optimization led us to further modifications, which improved metabolic stability while maintaining potent androgen agonistic activity. Among the synthesized compounds, (2S,3S)-2,3-dimethyl-3-hydroxylpyrrolidine derivative 1c exhibited a suitable PK profile and improved metabolic stability. Compound 1c demonstrated significant efficacy in levator ani muscle without increasing the weight of the prostate in an in vivo study. In addition, compound 1c showed agonistic activity in the CNS, which was detected using sexual behavior induction assay., Entry 2: We previously reported that 4-(pyrrolidin-1-yl)benzonitrile derivative 1b was a selective androgen receptor modulator (SARM) that exhibited anabolic effects on organs such as muscles and the central nervous system (CNS), but neutral effects on the prostate. From further modification, we identified that 4-(5-oxopyrrolidine-1-yl)benzonitrile derivative 2a showed strong AR binding affinity with improved metabolic stabilities. Based on these results, we tried to enhance the AR agonistic activities by modifying the substituents of the 5-oxopyrrolidine ring. As a consequence, we found that 4-[(2S,3S)-2-ethyl-3-hydroxy-5-oxopyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile (2f) had ideal SARM profiles in Hershberger assay and sexual behavior induction assay. Furthermore, 2f showed good pharmacokinetic profiles in rats, dogs, monkeys, excellent nuclear selectivity and acceptable toxicological profiles. We also determined its binding mode by obtaining the co-crystal structures with AR., Entry 3: Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated., ",,Cc1c(N2CC[C@](C)(O)[C@@H]2C)ccc(C#N)c1F,C14H17FN2O,CHEMBL4092535,0.29,1.0,1.0,1.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.307439018,0.29,0.8225,1.0,1.0,-0.084864093,0.0,-0.537602002,9.084864093,9.0,9.537602002,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1.0,1.0,1.0,1.0,9.0,9.0,9.0,9.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2236812,nM,IC50,,BAO_0000190,IC50,1658408,Antagonist activity at GAL4-fused human AR LBD (667 to 919 residues) expressed in CHO-K1 cells assessed as inhibition of dihydrotestosterone-induced transactivation activity after 5 to 6 hrs by luciferase reporter gene assay,0,B,,CHEMBL4008020,10.1021/acs.jmedchem.6b01065,28051871,CHEMBL4007392,Modulating Mineralocorticoid Receptor with Non-steroidal Antagonists. New Opportunities for the Development of Potent and Selective Ligands without Off-Target Side Effects.,PUBLICATION,"Steroidal mineralocorticoid receptor (MR) antagonists are used for treatment of a range of human diseases, but they present challenging issues of complex chemical synthesis, undesirable physical properties, and poor selectivity along with unwanted side effects. Therefore, there is a great interest in the discovery of non-steroidal ligands able to bind to the ligand-binding domain of the MR and recruit different co-regulators to produce tissue-specific therapeutic effects. Several academic groups and pharmaceutical companies have been developing a series of non-steroidal ligands that consist of different chemical scaffolds, yielding MR antagonists currently evaluated in clinical studies for the treatment of congestive heart failure, hypertension, or diabetic nephropathy. The main focus of this Perspective is to review the reported structure-activity relationships of the different series of compounds, as well as the structural studies that contribute to a better understanding of the receptor active site and are also helpful for optimization processes.",,CCOc1ncc(C)c2c1[C@H](c1ccc(C#N)cc1OC)C(C#N)=C(C)N2,C21H20N4O2,CHEMBL4096901,2400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2400.0,2400.0,2400.0,2400.0,3.380211242,3.380211242,3.380211242,5.619788758,5.619788758,5.619788758,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2400.0,2400.0,2400.0,2400.0,5.619788758288394,5.619788758288394,5.619788758288394,5.619788758288394,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2254087,nM,IC50,325888.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C(C)(C)/C2=N/C(=S)NCC)cc1C(F)(F)F,C23H22F3N5S2,CHEMBL4114736,157.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,157.0,157.0,157.0,157.0,2.195899652,2.195899652,2.195899652,6.804100348,6.804100348,6.804100348,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,157.0,157.0,157.0,157.0,6.804100347590766,6.804100347590766,6.804100347590766,6.804100347590766,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2254134,nM,IC50,325890.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C(=S)Nc2ccc(C#N)c(C(F)(F)F)c2)cc1C(F)(F)F,C30H20F6N6S2,CHEMBL4114783,144.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,144.0,144.0,144.0,144.0,2.158362492,2.158362492,2.158362492,6.841637508,6.841637508,6.841637508,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,144.0,144.0,144.0,144.0,6.841637507904751,6.841637507904751,6.841637507904751,6.841637507904751,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2254152,nM,IC50,325887.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C)cc1C(F)(F)F,C22H19F3N4S,CHEMBL4114801,222.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,222.0,222.0,222.0,222.0,2.346352974,2.346352974,2.346352974,6.653647026,6.653647026,6.653647026,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,222.0,222.0,222.0,222.0,6.653647025549361,6.653647025549361,6.653647025549361,6.653647025549361,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2255046,nM,IC50,325889.0,BAO_0000190,IC50,1640502,"Reporter Assay: The compounds were subjected to tests using an artificial AR response reporter system in a hormone refractory prostate cancer cell line. In this system, the prostate cancer LNCaP cells were engineered to stably express about 5-fold higher level of AR than endogenous level. The exogenous AR has similar properties to endogenous AR in that both are stabilized by a synthetic androgen R1881. The AR-over expressed cells were also engineered to stably incorporate an AR response reporter and the reporter activity of these cells shows features of hormone refractory prostate cancer.",0,B,,CHEMBL3887225,,,CHEMBL3886221,Treatment of hyperproliferative disorders with diarylhydantoin compounds,PATENT,,US-9126941-B2,[C-]#[N+]c1ccc(N2C(=S)N(c3ccc(C)cc3)C3(CCC3)/C2=N/C(=S)Nc2ccccc2)cc1C(F)(F)F,C28H22F3N5S2,CHEMBL4115695,176.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,176.0,176.0,176.0,176.0,2.245512668,2.245512668,2.245512668,6.754487332,6.754487332,6.754487332,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,176.0,176.0,176.0,176.0,6.7544873321858505,6.7544873321858505,6.7544873321858505,6.7544873321858505,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2263018,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]32)cc1,C32H43NO2,CHEMBL4159987,165.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,165.0,165.0,165.0,165.0,2.217483944,2.217483944,2.217483944,6.782516056,6.782516056,6.782516056,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,165.0,165.0,165.0,165.0,6.782516055786093,6.782516055786093,6.782516055786093,6.782516055786093,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2264785,nM,IC50,,BAO_0000190,IC50,1736259,Antagonist activity at AR (unknown origin) expressed in human LNCaP cells assessed as reduction in R1881-induced response incubated for 20 hrs by luciferase reporter gene assay,0,A,,CHEMBL4151795,10.1021/acs.jmedchem.8b00743,30091920,CHEMBL4145686,Discovery of a Potent and Selective Steroidal Glucocorticoid Receptor Antagonist (ORIC-101).,PUBLICATION,"The glucocorticoid receptor (GR) has been linked to therapy resistance across a wide range of cancer types. Preclinical data suggest that antagonists of this nuclear receptor may enhance the activity of anticancer therapy. The first-generation GR antagonist mifepristone is currently undergoing clinical evaluation in various oncology settings. Structure-based modification of mifepristone led to the discovery of ORIC-101 (28), a highly potent steroidal GR antagonist with reduced androgen receptor (AR) agonistic activity amenable for dosing in androgen receptor positive tumors and with improved CYP2C8 and CYP2C9 inhibition profile to minimize drug-drug interaction potential. Unlike mifepristone, 28 could be codosed with chemotherapeutic agents readily metabolized by CYP2C8 such as paclitaxel. Furthermore, 28 demonstrated in vivo antitumor activity by enhancing response to chemotherapy in the GR+ OVCAR5 ovarian cancer xenograft model. Clinical evaluation of safety and therapeutic potential of 28 is underway.",,CC(C)N(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]32)cc1,C34H47NO2,CHEMBL4161754,484.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,484.0,484.0,484.0,484.0,2.684845362,2.684845362,2.684845362,6.315154638,6.315154638,6.315154638,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,484.0,484.0,484.0,484.0,6.315154638355588,6.315154638355588,6.315154638355588,6.315154638355588,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2264941,nM,IC50,,BAO_0000190,IC50,1726360,Antagonist activity at androgen receptor (unknown origin) expressed in African green monkey COS7 cells assessed as inhibition of R1881-induced protein activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4141638,10.1016/j.ejmech.2017.10.031,29117897,CHEMBL4138152,Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents.,PUBLICATION,"Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising invitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.",,CCOC(=O)Nc1cc2c(cc1F)CC1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=S)N1C2,C22H16F4N4O3S,CHEMBL4161910,7390.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7390.0,7390.0,7390.0,7390.0,3.868644438,3.868644438,3.868644438,5.131355562,5.131355562,5.131355562,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7390.0,7390.0,7390.0,7390.0,5.131355561605174,5.131355561605174,5.131355561605174,5.131355561605174,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2266100,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,C32H41NO2,CHEMBL4163069,129.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,129.0,129.0,129.0,129.0,2.11058971,2.11058971,2.11058971,6.88941029,6.88941029,6.88941029,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,129.0,129.0,129.0,129.0,6.889410289700751,6.889410289700751,6.889410289700751,6.889410289700751,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2276830,nM,IC50,,BAO_0000190,IC50,1735695,Antagonist activity at human CMX-AR expressed in HEK293 cells assessed as reduction in dihydrotestosterone-induced transactivation activity after 24 hrs by luciferase reporter gene assay,0,A,,CHEMBL4151231,10.1021/acsmedchemlett.8b00058,30034593,CHEMBL4145662,Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.,PUBLICATION,"The progesterone receptor (PR) plays an important role in various physiological systems, including female reproduction and the central nervous system, and PR antagonists are thought to be effective not only as contraceptive agents and abortifacients but also in the treatment of various diseases, including hormone-dependent cancers and endometriosis. Here, we identified phenanthridin-6(5H)-one derivatives as a new class of PR antagonists and investigated their structure-activity relationships. Among the synthesized compounds, 37, 40, and 46 exhibited very potent PR antagonistic activity with high selectivity for PR over other nuclear receptors. These compounds are structurally distinct from other nonsteroidal PR antagonists, including cyanoaryl derivatives, and should be useful for further studies of the clinical utility of PR antagonists.",,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c3ccc(F)cc3c(=O)n(C)c12,C18H12F7NO2,CHEMBL4173799,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2277230,nM,IC50,,BAO_0000190,IC50,1735695,Antagonist activity at human CMX-AR expressed in HEK293 cells assessed as reduction in dihydrotestosterone-induced transactivation activity after 24 hrs by luciferase reporter gene assay,0,A,,CHEMBL4151231,10.1021/acsmedchemlett.8b00058,30034593,CHEMBL4145662,Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.,PUBLICATION,"The progesterone receptor (PR) plays an important role in various physiological systems, including female reproduction and the central nervous system, and PR antagonists are thought to be effective not only as contraceptive agents and abortifacients but also in the treatment of various diseases, including hormone-dependent cancers and endometriosis. Here, we identified phenanthridin-6(5H)-one derivatives as a new class of PR antagonists and investigated their structure-activity relationships. Among the synthesized compounds, 37, 40, and 46 exhibited very potent PR antagonistic activity with high selectivity for PR over other nuclear receptors. These compounds are structurally distinct from other nonsteroidal PR antagonists, including cyanoaryl derivatives, and should be useful for further studies of the clinical utility of PR antagonists.",,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1ccccc12,C17H11F6NO2,CHEMBL4174199,20000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20000.0,20000.0,20000.0,20000.0,4.301029996,4.301029996,4.301029996,4.698970004,4.698970004,4.698970004,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,20000.0,20000.0,20000.0,20000.0,4.698970004336019,4.698970004336019,4.698970004336019,4.698970004336019,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2278280,nM,IC50,,BAO_0000190,IC50,1735695,Antagonist activity at human CMX-AR expressed in HEK293 cells assessed as reduction in dihydrotestosterone-induced transactivation activity after 24 hrs by luciferase reporter gene assay,0,A,,CHEMBL4151231,10.1021/acsmedchemlett.8b00058,30034593,CHEMBL4145662,Novel Nonsteroidal Progesterone Receptor (PR) Antagonists with a Phenanthridinone Skeleton.,PUBLICATION,"The progesterone receptor (PR) plays an important role in various physiological systems, including female reproduction and the central nervous system, and PR antagonists are thought to be effective not only as contraceptive agents and abortifacients but also in the treatment of various diseases, including hormone-dependent cancers and endometriosis. Here, we identified phenanthridin-6(5H)-one derivatives as a new class of PR antagonists and investigated their structure-activity relationships. Among the synthesized compounds, 37, 40, and 46 exhibited very potent PR antagonistic activity with high selectivity for PR over other nuclear receptors. These compounds are structurally distinct from other nonsteroidal PR antagonists, including cyanoaryl derivatives, and should be useful for further studies of the clinical utility of PR antagonists.",,Cc1cc(C(O)(C(F)(F)F)C(F)(F)F)cc2c1[nH]c(=O)c1cc(F)ccc12,C17H10F7NO2,CHEMBL4175249,1800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1800.0,1800.0,1800.0,1800.0,3.255272505,3.255272505,3.255272505,5.744727495,5.744727495,5.744727495,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1800.0,1800.0,1800.0,1800.0,5.7447274948966935,5.7447274948966935,5.7447274948966935,5.7447274948966935,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2317692,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccc2oc(-c3ccccc3OC)cc(=O)c2c1,C17H14O4,CHEMBL4278241,6190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6190.0,6190.0,6190.0,6190.0,3.791690649,3.791690649,3.791690649,5.208309351,5.208309351,5.208309351,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6190.0,6190.0,6190.0,6190.0,5.208309350979882,5.208309350979882,5.208309350979882,5.208309350979882,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2318088,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 1803383, Entry 1: 1803384, Entry 2: 1803387, ","Entry 0: Inhibition of R1881-induced full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct after 72 hrs by fluorescence assay, Entry 1: Inhibition of R1881-induced transcriptional activity of human AR V7 truncated mutant expressed in human PC3 cells harboring pGL3-ARR3tk-NLuc after 24 hrs by luciferase reporter gene assay, Entry 2: Inhibition of full length AR transcriptional activity in human LNCAP cells harboring AR2PB-eGFP construct assessed as reduction in R1881-induced secreted PSA level after 72 hrs by fluorescence assay, ","0,2","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL4275675, Entry 1: CHEMBL4275676, Entry 2: CHEMBL4275679, ","Entry 0: 10.1016/j.ejmech.2018.08.059, Entry 1: 10.1016/j.ejmech.2018.08.059, Entry 2: 10.1016/j.ejmech.2018.08.059, ","Entry 0: 30193215, Entry 1: 30193215, Entry 2: 30193215, ","Entry 0: CHEMBL4270637, Entry 1: CHEMBL4270637, Entry 2: CHEMBL4270637, ","Entry 0: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 1: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., Entry 2: Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 1: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., Entry 2: The androgen receptor (AR) is a hormone-activated transcription factor that regulates the development and progression of prostate cancer (PCa) and represents one of the most well-established drug targets. Currently clinically approved small molecule inhibitors of AR, such as enzalutamide, are built upon a common chemical scaffold that interacts with the AR by the same mechanism of action. These inhibitors eventually fail due to the emergence of drug-resistance in the form of AR mutations and expression of truncated AR splice variants (e.g. AR-V7) that are constitutively active, signalling the progression of the castration-resistant state of the disease. The urgent need therefore continues for novel classes of AR inhibitors that can overcome drug resistance, especially since AR signalling remains important even in late-stage advanced PCa. Previously, we identified a collection of 10-benzylidene-10H-anthracen-9-ones that effectively inhibit AR transcriptional activity, induce AR degradation and display some ability to block recruitment of hormones to the receptor. In the current work, we extended the analysis of the lead compounds, and used methods of both ligand- and structure-based drug design to develop a panel of novel 10-benzylidene-10H-anthracen-9-one derivatives capable of suppressing transcriptional activity and protein expression levels of both full length- and AR-V7 truncated forms of human androgen receptor. Importantly, the developed compounds efficiently inhibited the growth of AR-V7 dependent prostate cancer cell-lines which are completely resistant to all current anti-androgens., ",,O=C1c2ccccc2C(=Cc2cccc(O)c2)c2ccccc21,C21H14O2,CHEMBL4278637,316.2,350.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4557.041254,316.2,3555.4,350.0,10000.0,3.550888468,2.544068044,2.499961866,5.449111532,6.455931956,6.500038134,3,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,5158.1,5158.1,316.2,10000.0,5.2875102424564755,5.2875102424564755,6.50003813440381,5.0,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
2318400,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2cc(O)cc(O)c21,C15H12O5,CHEMBL4278949,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2318769,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2ccc(Cl)cc21,C15H11ClO3,CHEMBL4279318,1680.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1680.0,1680.0,1680.0,1680.0,3.225309282,3.225309282,3.225309282,5.774690718,5.774690718,5.774690718,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1680.0,1680.0,1680.0,1680.0,5.774690718274137,5.774690718274137,5.774690718274137,5.774690718274137,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2319292,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,CC(C)Oc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,C18H17BrO3,CHEMBL4279841,1000.0,9110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4055.0,1000.0,5055.0,5055.0,9110.0,3.70372116,3.70372116,3.0,5.29627884,5.29627884,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5055.0,5055.0,1000.0,9110.0,5.29627884007298,5.29627884007298,6.0,5.040481623027002,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
2321180,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccccc1/C=C/C(=O)c1cc(Cl)ccc1O,C16H13ClO3,CHEMBL4281732,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2322220,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2c(Br)cc(Br)cc21,C15H10Br2O3,CHEMBL4282772,3570.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3570.0,3570.0,3570.0,3570.0,3.552668216,3.552668216,3.552668216,5.447331784,5.447331784,5.447331784,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3570.0,3570.0,3570.0,3570.0,5.447331783887806,5.447331783887806,5.447331783887806,5.447331783887806,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2322680,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,COc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,C16H13BrO3,CHEMBL4283232,1000.0,4870.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1935.0,1000.0,2935.0,2935.0,4870.0,3.467608106,3.467608106,3.0,5.532391894,5.532391894,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2935.0,2935.0,1000.0,4870.0,5.532391894416366,5.532391894416366,6.0,5.3124710387853655,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2323799,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,CCCOc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,C18H17BrO3,CHEMBL4284351,3960.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3960.0,3960.0,3960.0,3960.0,3.597695186,3.597695186,3.597695186,5.402304814,5.402304814,5.402304814,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3960.0,3960.0,3960.0,3960.0,5.402304814074488,5.402304814074488,5.402304814074488,5.402304814074488,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2324585,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccccc1/C=C/C(=O)c1cc(F)ccc1O,C16H13FO3,CHEMBL4285137,5010.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5010.0,5010.0,5010.0,5010.0,3.699837726,3.699837726,3.699837726,5.300162274,5.300162274,5.300162274,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5010.0,5010.0,5010.0,5010.0,5.300162274132754,5.300162274132754,5.300162274132754,5.300162274132754,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2325016,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1cc(/C=C/C(=O)c2cc(Cl)ccc2O)ccc1O,C16H13ClO4,CHEMBL4285568,5950.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5950.0,5950.0,5950.0,5950.0,3.774516966,3.774516966,3.774516966,5.225483034,5.225483034,5.225483034,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5950.0,5950.0,5950.0,5950.0,5.22548303427145,5.22548303427145,5.22548303427145,5.22548303427145,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2326103,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COc1ccccc1/C=C/C(=O)c1cc(I)ccc1O,C16H13IO3,CHEMBL4286655,1720.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1720.0,1720.0,1720.0,1720.0,3.235528447,3.235528447,3.235528447,5.764471553,5.764471553,5.764471553,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1720.0,1720.0,1720.0,1720.0,5.764471553092451,5.764471553092451,5.764471553092451,5.764471553092451,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2327207,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,CCOc1ccccc1/C=C/C(=O)c1cc(Br)ccc1O,C17H15BrO3,CHEMBL4287759,5270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5270.0,5270.0,5270.0,5270.0,3.721810615,3.721810615,3.721810615,5.278189385,5.278189385,5.278189385,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5270.0,5270.0,5270.0,5270.0,5.278189384787454,5.278189384787454,5.278189384787454,5.278189384787454,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2328396,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,COCOc1ccccc1/C=C/C(=O)c1cc(F)ccc1O,C17H15FO4,CHEMBL4288948,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2329038,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1803354, Entry 1: 1803361, ","Entry 0: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced cell growth treated for every 2 days for 4 days by hemocytometry, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4275646, Entry 1: CHEMBL4275653, ","Entry 0: 10.1016/j.ejmech.2018.08.069, Entry 1: 10.1016/j.ejmech.2018.08.069, ","Entry 0: 30189396, Entry 1: 30189396, ","Entry 0: CHEMBL4270636, Entry 1: CHEMBL4270636, ","Entry 0: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., Entry 1: 5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., Entry 1: Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses., ",,COc1ccc(O)c(C(=O)/C=C/c2ccccc2OC)c1,C17H16O4,CHEMBL4289590,1000.0,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,4500.0,1000.0,5500.0,5500.0,10000.0,3.740362689,3.740362689,3.0,5.259637311,5.259637311,6.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,5500.0,5500.0,1000.0,10000.0,5.259637310505756,5.259637310505756,6.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,IC50
2329449,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2ccc(Br)cc21,C15H11BrO3,CHEMBL4290001,1770.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1770.0,1770.0,1770.0,1770.0,3.247973266,3.247973266,3.247973266,5.752026734,5.752026734,5.752026734,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1770.0,1770.0,1770.0,1770.0,5.752026733638194,5.752026733638194,5.752026733638194,5.752026733638194,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2329470,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccc2c(c1)OCO2)c1cc(Cl)ccc1O,C16H11ClO4,CHEMBL4290022,4360.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4360.0,4360.0,4360.0,4360.0,3.639486489,3.639486489,3.639486489,5.360513511,5.360513511,5.360513511,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4360.0,4360.0,4360.0,4360.0,5.360513510731414,5.360513510731414,5.360513510731414,5.360513510731414,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2332416,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccccc1O)c1cc(F)ccc1O,C15H11FO3,CHEMBL4292968,1420.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1420.0,1420.0,1420.0,1420.0,3.152288344,3.152288344,3.152288344,5.847711656,5.847711656,5.847711656,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1420.0,1420.0,1420.0,1420.0,5.847711655616943,5.847711655616943,5.847711655616943,5.847711655616943,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2332828,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2ccc(I)cc21,C15H11IO3,CHEMBL4293380,4260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4260.0,4260.0,4260.0,4260.0,3.629409599,3.629409599,3.629409599,5.370590401,5.370590401,5.370590401,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4260.0,4260.0,4260.0,4260.0,5.370590400897281,5.370590400897281,5.370590400897281,5.370590400897281,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2333264,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccccc1O)c1cc(Br)ccc1O,C15H11BrO3,CHEMBL4293816,8690.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8690.0,8690.0,8690.0,8690.0,3.939019776,3.939019776,3.939019776,5.060980224,5.060980224,5.060980224,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8690.0,8690.0,8690.0,8690.0,5.060980223551334,5.060980223551334,5.060980223551334,5.060980223551334,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2334012,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccccc1O)c1cc(I)ccc1O,C15H11IO3,CHEMBL4294564,1640.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1640.0,1640.0,1640.0,1640.0,3.214843848,3.214843848,3.214843848,5.785156152,5.785156152,5.785156152,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1640.0,1640.0,1640.0,1640.0,5.785156151952302,5.785156151952302,5.785156151952302,5.785156151952302,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2334442,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C(/C=C/c1ccccc1O)c1cc(Br)cc(Br)c1O,C15H10Br2O3,CHEMBL4294994,2870.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2870.0,2870.0,2870.0,2870.0,3.457881897,3.457881897,3.457881897,5.542118103,5.542118103,5.542118103,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2870.0,2870.0,2870.0,2870.0,5.542118103266008,5.542118103266008,5.542118103266008,5.542118103266008,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2334671,nM,IC50,,BAO_0000190,IC50,1803354,Antagonist activity at AR in human LNCAP cells assessed as reduction in DHT-induced transcriptional activation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4275646,10.1016/j.ejmech.2018.08.069,30189396,CHEMBL4270636,"5'-Chloro-2,2'-dihydroxychalcone and related flavanoids as treatments for prostate cancer.",PUBLICATION,"Several flavonoids and their biosynthetic precursor chalcones were designed and synthesized to improve the biological effects of the lead compound 2'-hydroxyflavonone against androgen receptor (AR)-dependent transcriptional stimulation. Newly synthesized chalcones 19 and 26 suppressed AR-dependent transcription as well as DHT-dependent growth stimulation at a low micromolar level. These compounds were also effective against ligand-independent constitutively active mutant AR derived from castration-resistant PCa (CRPC). Compounds 19 and 26 showed broad spectrum antiproliferative activity at 5-10M against multiple tumor cell lines including androgen-independent and taxane-resistant prostate cancer as well as a multidrug-resistant subline. Mode of action studies suggested that 19 induced sub-G1 accumulation in PC-3cells by disrupting the microtubule network without affecting cell cycle progression. Furthermore, the invivo effectiveness of chalcone 19 was confirmed in a xenograft model antitumor assay. Thus, chalcone 19 has the potential to be a bifunctional lead for treatment of AR-dependent PCa at lower doses as well as AR-independent PCa, including CRPC, at higher doses.",,O=C1CC(c2ccccc2O)Oc2cc(O)ccc21,C15H12O4,CHEMBL4295223,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2335156,nM,IC50,,BAO_0000190,IC50,2055578,Inhibition of androgen receptor (unknown origin),0,B,,CHEMBL4710579,10.1016/j.ejmech.2020.112667,32911308,CHEMBL4706566,New drug approvals for 2019: Synthesis and clinical applications.,PUBLICATION,"48 new drugs including 38 chemical entities (33 new chemical entities, 3 new diagnostic agents, and 2 payloads of antibody drug conjugates) and 10 biologics were approved by the U.S. Food and Drug Administration (FDA) during 2019. These marketed new drugs represent privileged structures and novel action of mechanism, and thus can be served as leads to discover new drugs with the similar biological targets and improved therapeutic efficacy. This review aims to provide an overview regarding the synthetic approaches of 33 new chemical entities approved by the FDA in 2019 and their clinical applications.",,CC(O)c1cc(C(=O)N[C@@H](C)Cn2ccc(-c3ccc(C#N)c(Cl)c3)n2)n[nH]1,C19H19ClN6O2,CHEMBL4297185,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26.0,26.0,26.0,26.0,1.414973348,1.414973348,1.414973348,7.585026652,7.585026652,7.585026652,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,26.0,26.0,26.0,26.0,7.585026652029182,7.585026652029182,7.585026652029182,7.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2335646,nM,IC50,,BAO_0000190,IC50,2227466,Antagonist activity at Androgen receptor (unknown origin) assessed as inhibition of activation function 1 (AF-1) of AR N-terminal transactivation domain (NTD),0,B,,CHEMBL5140979,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,CC(=O)OC[C@H](COc1ccc(C(C)(C)c2ccc(OC[C@@H](CCl)OC(C)=O)cc2)cc1)OC(C)=O,C27H33ClO8,CHEMBL4297675,9600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9600.0,9600.0,9600.0,9600.0,3.982271233,3.982271233,3.982271233,5.017728767,5.017728767,5.017728767,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9600.0,9600.0,9600.0,9600.0,5.017728766960432,5.017728766960432,5.017728766960432,5.017728766960432,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2343981,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H17F4N3O2,CHEMBL4436972,39.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,39.0,39.0,39.0,39.0,1.591064607,1.591064607,1.591064607,7.408935393,7.408935393,7.408935393,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,39.0,39.0,39.0,39.0,7.4089353929735005,7.4089353929735005,7.4089353929735005,7.4089353929735005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2345220,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H17F4N3O2,CHEMBL4438211,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,59.0,59.0,59.0,59.0,1.770852012,1.770852012,1.770852012,7.229147988,7.229147988,7.229147988,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,59.0,59.0,59.0,59.0,7.229147988357856,7.229147988357856,7.229147988357856,7.229147988357856,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2346325,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,CC(O)(CCc1ccc(N=C=S)cc1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C19H16F3N3O4S,CHEMBL4439316,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2346336,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2014924, Entry 1: 2014930, ","Entry 0: Displacement of [3H]-R1881 from androgen receptor (unknown origin) expressed in human HeLa cells harboring AR3A-PSA-(ARE)4-Luc13 incubated for 2 hrs by scintillation counting, Entry 1: Antagonist activity at androgen receptor (unknown origin) expressed in human HeLa cells harboring AR3A-PSA-(ARE)4-Luc13 in presence of DHT by BrightGlo luciferase assay, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4668502, Entry 1: CHEMBL4668508, ","Entry 0: 10.1021/acs.jmedchem.9b02138, Entry 1: 10.1021/acs.jmedchem.9b02138, ","Entry 0: 32463235, Entry 1: 32463235, ","Entry 0: CHEMBL4665678, Entry 1: CHEMBL4665678, ","Entry 0: Overview of AKR1C3: Inhibitor Achievements and Disease Insights., Entry 1: Overview of AKR1C3: Inhibitor Achievements and Disease Insights., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone receptors and cell proliferation. Because of the overexpression in metabolic diseases and various hormone-dependent and -independent carcinomas, as well as the emergence of clinical drug resistance, an increasing number of studies have investigated AKR1C3 inhibitors. Here, we briefly review the physiological and pathological function of AKR1C3 and then summarize the recent development of selective AKR1C3 inhibitors. We propose our viewpoints on the current problems associated with AKR1C3 inhibitors with the aim of providing a reference for future drug discovery and potential therapeutic perspectives on novel, potent, selective AKR1C3 inhibitors., Entry 1: Human aldo-keto reductase family 1 member C3 (AKR1C3) is known as a hormone activity regulator and prostaglandin F (PGF) synthase that regulates the occupancy of hormone receptors and cell proliferation. Because of the overexpression in metabolic diseases and various hormone-dependent and -independent carcinomas, as well as the emergence of clinical drug resistance, an increasing number of studies have investigated AKR1C3 inhibitors. Here, we briefly review the physiological and pathological function of AKR1C3 and then summarize the recent development of selective AKR1C3 inhibitors. We propose our viewpoints on the current problems associated with AKR1C3 inhibitors with the aim of providing a reference for future drug discovery and potential therapeutic perspectives on novel, potent, selective AKR1C3 inhibitors., ",,Oc1ccc2c(O)ncc(-c3cc(F)c(F)c(F)c3)c2c1,C15H8F3NO2,CHEMBL4439327,2100.0,80000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,38950.0,2100.0,41050.0,41050.0,80000.0,4.613313161,4.613313161,3.322219295,4.386686839,4.386686839,5.677780705,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,80000.0,80000.0,80000.0,80000.0,4.096910013008056,4.096910013008056,4.096910013008056,4.096910013008056,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2346711,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2c(-c3ccccc3)cccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C26H20F3N3O2,CHEMBL4439702,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2349866,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c2ccc(F)cc12,C21H17F4N3O2,CHEMBL4442857,157.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,157.0,157.0,157.0,157.0,2.195899652,2.195899652,2.195899652,6.804100348,6.804100348,6.804100348,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,157.0,157.0,157.0,157.0,6.804100347590766,6.804100347590766,6.804100347590766,6.804100347590766,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2350575,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2ccccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H18F3N3O2,CHEMBL4443566,142.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,142.0,142.0,142.0,142.0,2.152288344,2.152288344,2.152288344,6.847711656,6.847711656,6.847711656,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,142.0,142.0,142.0,142.0,6.847711655616943,6.847711655616943,6.847711655616943,6.847711655616943,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2351913,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1909470, Entry 1: 2101892, ","Entry 0: Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4411916, Entry 1: CHEMBL4810288, ","Entry 0: 10.1021/acs.jmedchem.8b00973, Entry 1: 10.1021/acs.jmedchem.1c00439, ","Entry 0: 30525603, Entry 1: 34269581, ","Entry 0: CHEMBL4411271, Entry 1: CHEMBL4808211, ","Entry 0: New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity., Entry 1: Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed., Entry 1: A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers., ",,C[C@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N3O2,CHEMBL4444904,85.0,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,85.0,85.0,85.0,85.0,1.929418926,1.929418926,1.929418926,7.070581074,7.070581074,7.070581074,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,85.0,85.0,85.0,85.0,7.070581074285707,7.070581074285707,7.070581074285707,7.070581074285707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2353480,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2ccccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H16F3N3O2,CHEMBL4446471,64.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,64.0,64.0,64.0,64.0,1.806179974,1.806179974,1.806179974,7.193820026,7.193820026,7.193820026,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,64.0,64.0,64.0,64.0,7.1938200260161125,7.1938200260161125,7.1938200260161125,7.1938200260161125,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2354548,nM,IC50,,BAO_0000190,IC50,1869960,Inhibition of human androgen receptor,0,B,,CHEMBL4371127,10.1021/acs.jmedchem.7b01788,29400967,CHEMBL4371002,Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.,PUBLICATION,"The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the methyl group while also acting as a functional mimetic of the carbonyl, carbinol, and nitrile moieties. In this context, fluorine substitution can influence the potency, conformation, metabolism, membrane permeability, and P-gp recognition of a molecule and temper inhibition of the hERG channel by basic amines. However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated molecular construction that broadens biological mimesis. In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a molecule are summarized.",,CC1(C)CCc2cc3c(cc2N1)NC(C#N)C=C3C(F)(F)F,C16H16F3N3,CHEMBL4447539,9.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9.0,9.0,9.0,9.0,0.954242509,0.954242509,0.954242509,8.045757491,8.045757491,8.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,9.0,9.0,9.0,9.0,8.045757490560675,8.045757490560675,8.045757490560675,8.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2354968,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C25H19ClFN3O2,CHEMBL4447959,203.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,203.0,203.0,203.0,203.0,2.307496038,2.307496038,2.307496038,6.692503962,6.692503962,6.692503962,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,203.0,203.0,203.0,203.0,6.692503962086787,6.692503962086787,6.692503962086787,6.692503962086787,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2355057,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(-n4cccc4)cc3)C[C@@]21C,C32H37NO2,CHEMBL4448048,354.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,354.0,354.0,354.0,354.0,2.549003262,2.549003262,2.549003262,6.450996738,6.450996738,6.450996738,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,354.0,354.0,354.0,354.0,6.450996737974212,6.450996737974212,6.450996737974212,6.450996737974212,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2355946,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,CCOC(=O)c1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c2ccccc12,C23H20F3N3O4,CHEMBL4448937,972.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,972.0,972.0,972.0,972.0,2.987666265,2.987666265,2.987666265,6.012333735,6.012333735,6.012333735,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,972.0,972.0,972.0,972.0,6.012333735073725,6.012333735073725,6.012333735073725,6.012333735073725,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2356961,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H17BrClN3O2,CHEMBL4449952,835.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,835.0,835.0,835.0,835.0,2.921686475,2.921686475,2.921686475,6.078313525,6.078313525,6.078313525,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,835.0,835.0,835.0,835.0,6.078313524516398,6.078313524516398,6.078313524516398,6.078313524516398,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2358804,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1cc(-c2ccccc2)c2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C25H19ClFN3O2,CHEMBL4451795,1032.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1032.0,1032.0,1032.0,1032.0,3.013679697,3.013679697,3.013679697,5.986320303,5.986320303,5.986320303,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1032.0,1032.0,1032.0,1032.0,5.986320302708807,5.986320302708807,5.986320302708807,5.986320302708807,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2359926,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C(C)C)cc3)C[C@@]21C,C32H43NO2,CHEMBL4452917,2246.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2246.0,2246.0,2246.0,2246.0,3.351409752,3.351409752,3.351409752,5.648590248,5.648590248,5.648590248,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2246.0,2246.0,2246.0,2246.0,5.648590248074561,5.648590248074561,5.648590248074561,5.648590248074561,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2360044,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N4CCCC4)cc3)C[C@@]21C,C32H41NO2,CHEMBL4453035,3146.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3146.0,3146.0,3146.0,3146.0,3.497758718,3.497758718,3.497758718,5.502241282,5.502241282,5.502241282,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3146.0,3146.0,3146.0,3146.0,5.502241281712732,5.502241281712732,5.502241281712732,5.502241281712732,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2363774,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N3O2,CHEMBL4456765,127.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,127.0,127.0,127.0,127.0,2.103803721,2.103803721,2.103803721,6.896196279,6.896196279,6.896196279,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,127.0,127.0,127.0,127.0,6.896196279044043,6.896196279044043,6.896196279044043,6.896196279044043,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2363790,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc(Br)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15BrF3N3O2,CHEMBL4456781,918.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,918.0,918.0,918.0,918.0,2.962842681,2.962842681,2.962842681,6.037157319,6.037157319,6.037157319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,918.0,918.0,918.0,918.0,6.037157318798758,6.037157318798758,6.037157318798758,6.037157318798758,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2367563,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CCC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C33H45NO2,CHEMBL4460554,175.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,175.0,175.0,175.0,175.0,2.243038049,2.243038049,2.243038049,6.756961951,6.756961951,6.756961951,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,175.0,175.0,175.0,175.0,6.756961951313706,6.756961951313706,6.756961951313706,6.756961951313706,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2367576,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C26H19F4N3O2,CHEMBL4460567,215.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,215.0,215.0,215.0,215.0,2.33243846,2.33243846,2.33243846,6.66756154,6.66756154,6.66756154,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,215.0,215.0,215.0,215.0,6.667561540084395,6.667561540084395,6.667561540084395,6.667561540084395,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2370567,nM,IC50,,BAO_0000190,IC50,1853777,Inhibition of R1881 induced-AR transcriptional activity in AR-positive human 22Rv1 cells harboring ARE14 construct after 24 hrs by luciferase assay,0,B,,CHEMBL4354401,10.1016/j.ejmech.2019.06.040,31271960,CHEMBL4351016,Synthesis of novel galeterone derivatives and evaluation of their invitro activity against prostate cancer cell lines.,PUBLICATION,"Prostate cancer is one of the main causes of male cancer-related deaths worldwide and the suppression of androgen receptor signalling is established as an effective strategy for the treatment. A series of galeterone analogues including several steroid-fused azacycles, as well as 17-(benzimidazol-1-ylimino), 16-(benzimidazol-2-ylamino), and 16-(benzothiazol-2-ylamino) steroid derivatives, were synthesized and tested against prostate cancer cell lines. Candidate compound 3f was shown to reduce AR-regulated transcription in a dose-dependent manner in nanomolar ranges and suppress expression of AR-regulated proteins Nkx3.1 and PSA in 22Rv1-ARE14 and VCaP cancer cell lines. Flexible docking study revealed similar position of 3f within AR binding site in comparison of galeterone even with stronger binding energy.",,CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@@H]3[C@@H]2CC[C@]2(C)c4c(C)nc5[nH]c6ccccc6c5c4C[C@@H]32)C1,C31H36N2O2,CHEMBL4463558,315.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,315.0,315.0,315.0,315.0,2.498310554,2.498310554,2.498310554,6.501689446,6.501689446,6.501689446,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,315.0,315.0,315.0,315.0,6.501689446210399,6.501689446210399,6.501689446210399,6.501689446210399,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2372435,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,C12H10F4N2O2,CHEMBL4465426,4400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4400.0,4400.0,4400.0,4400.0,3.643452676,3.643452676,3.643452676,5.356547324,5.356547324,5.356547324,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4400.0,4400.0,4400.0,4400.0,5.356547323513812,5.356547323513812,5.356547323513812,5.356547323513812,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2375888,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C32H43NO2,CHEMBL4468879,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2376614,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2cc(F)c(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H16F5N3O2,CHEMBL4469605,101.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,101.0,101.0,101.0,101.0,2.004321374,2.004321374,2.004321374,6.995678626,6.995678626,6.995678626,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,101.0,101.0,101.0,101.0,6.995678626217358,6.995678626217358,6.995678626217358,6.995678626217358,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2381102,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N3O2,CHEMBL4474096,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,85.0,85.0,85.0,85.0,1.929418926,1.929418926,1.929418926,7.070581074,7.070581074,7.070581074,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,85.0,85.0,85.0,85.0,7.070581074285707,7.070581074285707,7.070581074285707,7.070581074285707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2381124,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H15ClFN3O2,CHEMBL4474118,94.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,94.0,94.0,94.0,94.0,1.973127854,1.973127854,1.973127854,7.026872146,7.026872146,7.026872146,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,94.0,94.0,94.0,94.0,7.026872146400302,7.026872146400302,7.026872146400302,7.026872146400302,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2382569,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2c(F)cc(-c3ccc(F)cc3)cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C26H18F5N3O2,CHEMBL4475563,898.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,898.0,898.0,898.0,898.0,2.953276337,2.953276337,2.953276337,6.046723663,6.046723663,6.046723663,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,898.0,898.0,898.0,898.0,6.0467236633326955,6.0467236633326955,6.0467236633326955,6.0467236633326955,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2382771,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@@](O)(Cn1ccc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N3O2,CHEMBL4475765,598.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,598.0,598.0,598.0,598.0,2.776701184,2.776701184,2.776701184,6.223298816,6.223298816,6.223298816,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,598.0,598.0,598.0,598.0,6.223298816011589,6.223298816011589,6.223298816011589,6.223298816011589,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2383419,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]32)cc1,C33H45NO2,CHEMBL4476413,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2383499,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CCC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C31H41NO2,CHEMBL4476493,2955.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2955.0,2955.0,2955.0,2955.0,3.470557485,3.470557485,3.470557485,5.529442515,5.529442515,5.529442515,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2955.0,2955.0,2955.0,2955.0,5.529442514782726,5.529442514782726,5.529442514782726,5.529442514782726,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2384218,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N4CCN(S(C)(=O)=O)CC4)cc3)C[C@@]21C,C35H48N2O4S,CHEMBL4483408,359.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,359.0,359.0,359.0,359.0,2.555094449,2.555094449,2.555094449,6.444905551,6.444905551,6.444905551,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,359.0,359.0,359.0,359.0,6.444905551421681,6.444905551421681,6.444905551421681,6.444905551421681,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2384473,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H15ClFN3O2,CHEMBL4483663,142.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,142.0,142.0,142.0,142.0,2.152288344,2.152288344,2.152288344,6.847711656,6.847711656,6.847711656,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,142.0,142.0,142.0,142.0,6.847711655616943,6.847711655616943,6.847711655616943,6.847711655616943,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2384507,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(F)(F)F)[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]32)cc1,C30H36F3NO2,CHEMBL4483697,642.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,642.0,642.0,642.0,642.0,2.807535028,2.807535028,2.807535028,6.192464972,6.192464972,6.192464972,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,642.0,642.0,642.0,642.0,6.192464971931146,6.192464971931146,6.192464971931146,6.192464971931146,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2386176,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,COCC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C31H41NO3,CHEMBL4514765,5000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5000.0,5000.0,5000.0,5000.0,3.698970004,3.698970004,3.698970004,5.301029996,5.301029996,5.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5000.0,5000.0,5000.0,5000.0,5.301029995663981,5.301029995663981,5.301029995663981,5.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2386878,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(OC)cc3)C[C@@]21C,C29H36O3,CHEMBL4515467,561.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,561.0,561.0,561.0,561.0,2.748962861,2.748962861,2.748962861,6.251037139,6.251037139,6.251037139,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,561.0,561.0,561.0,561.0,6.251037138743839,6.251037138743839,6.251037138743839,6.251037138743839,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2392090,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2c(F)c(-c3ccccc3)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C26H19F4N3O2,CHEMBL4520679,1015.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1015.0,1015.0,1015.0,1015.0,3.006466042,3.006466042,3.006466042,5.993533958,5.993533958,5.993533958,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1015.0,1015.0,1015.0,1015.0,5.993533957750769,5.993533957750769,5.993533957750769,5.993533957750769,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2392776,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2cc(F)c(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H16ClF2N3O2,CHEMBL4521365,32.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32.0,32.0,32.0,32.0,1.505149978,1.505149978,1.505149978,7.494850022,7.494850022,7.494850022,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,32.0,32.0,32.0,32.0,7.494850021680094,7.494850021680094,7.494850021680094,7.494850021680094,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2397607,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H17ClFN3O2,CHEMBL4527176,37.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,37.0,37.0,37.0,37.0,1.568201724,1.568201724,1.568201724,7.431798276,7.431798276,7.431798276,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,37.0,37.0,37.0,37.0,7.431798275933005,7.431798275933005,7.431798275933005,7.431798275933005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2397672,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2c(F)cccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H17ClFN3O2,CHEMBL4527241,126.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,126.0,126.0,126.0,126.0,2.100370545,2.100370545,2.100370545,6.899629455,6.899629455,6.899629455,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,126.0,126.0,126.0,126.0,6.8996294548824375,6.8996294548824375,6.8996294548824375,6.8996294548824375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2398303,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN(C)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC3CC3)[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]32)cc1,C32H41NO2,CHEMBL4527872,1452.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1452.0,1452.0,1452.0,1452.0,3.161966616,3.161966616,3.161966616,5.838033384,5.838033384,5.838033384,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1452.0,1452.0,1452.0,1452.0,5.838033383635925,5.838033383635925,5.838033383635925,5.838033383635925,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2398520,nM,IC50,,BAO_0000190,IC50,1934449,Inhibition of AR transcriptional activity in human ARR2PB-eGFP expressing LNCaP cells after 3 days by fluorescence assay,0,B,,CHEMBL4480101,10.1016/j.bmcl.2016.07.067,27503683,CHEMBL4477262,Non-canonical modulators of nuclear receptors.,PUBLICATION,"Like G protein-coupled receptors (GPCRs) and protein kinases, nuclear receptors (NRs) are a rich source of pharmaceutical targets. Over 80 NR-targeting drugs have been approved for 18 NRs. The focus of drug discovery in NRs has hitherto been on identifying ligands that bind to the canonical ligand binding pockets of the C-terminal ligand binding domains (LBDs). Due to the development of drug resistance and selectivity concerns, there has been considerable interest in exploring other, non-canonical ligand binding sites. Unfortunately, the potencies of compounds binding at other sites have generally not been sufficient for clinical development. However, the situation has changed dramatically over the last 3years, as compounds with sufficient potency have been reported for several NR targets. Here we review recent developments in this area from a medicinal chemistry point of view in the hope of stimulating further interest in this area of research.",,c1ccc2c(c1)CC(c1c[nH]c3ccccc13)N2,C16H14N2,CHEMBL4528089,310.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,310.0,310.0,310.0,310.0,2.491361694,2.491361694,2.491361694,6.508638306,6.508638306,6.508638306,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,310.0,310.0,310.0,310.0,6.508638306165727,6.508638306165727,6.508638306165727,6.508638306165727,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2404755,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](OCc3ccc(Cl)cc3)C[C@@]21C,C29H35ClO3,CHEMBL4534324,85.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,85.0,85.0,85.0,85.0,1.929418926,1.929418926,1.929418926,7.070581074,7.070581074,7.070581074,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,85.0,85.0,85.0,85.0,7.070581074285707,7.070581074285707,7.070581074285707,7.070581074285707,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2410384,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2cc(F)c(-c3ccccc3)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C25H21ClFN3O2,CHEMBL4539953,244.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,244.0,244.0,244.0,244.0,2.387389826,2.387389826,2.387389826,6.612610174,6.612610174,6.612610174,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,244.0,244.0,244.0,244.0,6.61261017366127,6.61261017366127,6.61261017366127,6.61261017366127,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2412584,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(CN1CCc2cc(F)ccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H17ClFN3O2,CHEMBL4542153,130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,130.0,130.0,130.0,130.0,2.113943352,2.113943352,2.113943352,6.886056648,6.886056648,6.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,130.0,130.0,130.0,130.0,6.886056647693163,6.886056647693163,6.886056647693163,6.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2413124,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc(I)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F3IN3O2,CHEMBL4542693,985.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,985.0,985.0,985.0,985.0,2.99343623,2.99343623,2.99343623,6.00656377,6.00656377,6.00656377,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,985.0,985.0,985.0,985.0,6.006563769502388,6.006563769502388,6.006563769502388,6.006563769502388,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2416248,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC(C)(C)C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3[C@@H](c3ccc(N4CCOCC4)cc3)C[C@@]21C,C34H45NO3,CHEMBL4545820,208.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,208.0,208.0,208.0,208.0,2.318063335,2.318063335,2.318063335,6.681936665,6.681936665,6.681936665,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,208.0,208.0,208.0,208.0,6.681936665037238,6.681936665037238,6.681936665037238,6.681936665037238,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2418825,nM,IC50,,BAO_0000190,IC50,1869960,Inhibition of human androgen receptor,0,B,,CHEMBL4371127,10.1021/acs.jmedchem.7b01788,29400967,CHEMBL4371002,Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.,PUBLICATION,"The electronic properties and relatively small size of fluorine endow it with considerable versatility as a bioisostere and it has found application as a substitute for lone pairs of electrons, the hydrogen atom, and the methyl group while also acting as a functional mimetic of the carbonyl, carbinol, and nitrile moieties. In this context, fluorine substitution can influence the potency, conformation, metabolism, membrane permeability, and P-gp recognition of a molecule and temper inhibition of the hERG channel by basic amines. However, as a consequence of the unique properties of fluorine, it features prominently in the design of higher order structural metaphors that are more esoteric in their conception and which reflect a more sophisticated molecular construction that broadens biological mimesis. In this Perspective, applications of fluorine in the construction of bioisosteric elements designed to enhance the in vitro and in vivo properties of a molecule are summarized.",,CC1(C)CCc2cc3c(cc2N1)NC(F)C=C3C(F)(F)F,C15H16F4N2,CHEMBL4548397,22.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,22.0,22.0,22.0,22.0,1.342422681,1.342422681,1.342422681,7.657577319,7.657577319,7.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,22.0,22.0,22.0,22.0,7.657577319177793,7.657577319177793,7.657577319177793,7.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2425074,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2ccc([N+](=O)[O-])cc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F3N4O4,CHEMBL4554646,58.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,58.0,58.0,58.0,58.0,1.763427994,1.763427994,1.763427994,7.236572006,7.236572006,7.236572006,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,58.0,58.0,58.0,58.0,7.236572006437063,7.236572006437063,7.236572006437063,7.236572006437063,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2432766,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)CCOC)cc3)C[C@@]21C,C32H43NO3,CHEMBL4562338,1295.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1295.0,1295.0,1295.0,1295.0,3.112269768,3.112269768,3.112269768,5.887730232,5.887730232,5.887730232,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1295.0,1295.0,1295.0,1295.0,5.887730231582729,5.887730231582729,5.887730231582729,5.887730231582729,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2437904,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1cc(F)c2ccccc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H15ClFN3O2,CHEMBL4567476,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,45.0,45.0,45.0,45.0,1.653212514,1.653212514,1.653212514,7.346787486,7.346787486,7.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2441483,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CC#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,C30H39NO2,CHEMBL4571052,912.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,912.0,912.0,912.0,912.0,2.959994838,2.959994838,2.959994838,6.040005162,6.040005162,6.040005162,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,912.0,912.0,912.0,912.0,6.0400051616715835,6.0400051616715835,6.0400051616715835,6.0400051616715835,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2442111,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,CC(O)(CCc1ccc(N)cc1)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,C18H18F3N3O4,CHEMBL4571680,392.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,392.0,392.0,392.0,392.0,2.593286067,2.593286067,2.593286067,6.406713933,6.406713933,6.406713933,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,392.0,392.0,392.0,392.0,6.406713932979542,6.406713932979542,6.406713932979542,6.406713932979542,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2442737,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC(C)(NC(=O)Nc1ccc(F)c(C(F)(F)F)c1)C(=O)O,C12H12F4N2O3,CHEMBL4572306,3100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3100.0,3100.0,3100.0,3100.0,3.491361694,3.491361694,3.491361694,5.508638306,5.508638306,5.508638306,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3100.0,3100.0,3100.0,3100.0,5.508638306165727,5.508638306165727,5.508638306165727,5.508638306165727,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2447027,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CCN(CC)c1ccc([C@H]2C[C@@]3(C)[C@@H](CC[C@@]3(O)C#CC(C)(C)C)[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]32)cc1,C34H47NO2,CHEMBL4576596,263.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,263.0,263.0,263.0,263.0,2.419955748,2.419955748,2.419955748,6.580044252,6.580044252,6.580044252,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,263.0,263.0,263.0,263.0,6.580044251510242,6.580044251510242,6.580044251510242,6.580044251510242,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2453896,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2nc(C#N)ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H14F3N5O2,CHEMBL4583465,686.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,686.0,686.0,686.0,686.0,2.836324116,2.836324116,2.836324116,6.163675884,6.163675884,6.163675884,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,686.0,686.0,686.0,686.0,6.163675884293248,6.163675884293248,6.163675884293248,6.163675884293248,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2454958,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 1909470, Entry 1: 2101892, ","Entry 0: Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4411916, Entry 1: CHEMBL4810288, ","Entry 0: 10.1021/acs.jmedchem.8b00973, Entry 1: 10.1021/acs.jmedchem.1c00439, ","Entry 0: 30525603, Entry 1: 34269581, ","Entry 0: CHEMBL4411271, Entry 1: CHEMBL4808211, ","Entry 0: New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity., Entry 1: Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed., Entry 1: A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers., ",,CN(C[C@](C)(O)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1)c1ccc(C#N)c(-c2ccccc2)c1,C26H21F3N4O2,CHEMBL4584527,48.0,48.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,48.0,48.0,48.0,48.0,1.681241237,1.681241237,1.681241237,7.318758763,7.318758763,7.318758763,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,48.0,48.0,48.0,48.0,7.318758762624412,7.318758762624412,7.318758762624412,7.318758762624412,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2456418,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cccc(F)c21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H15ClFN3O2,CHEMBL4585987,234.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,234.0,234.0,234.0,234.0,2.369215857,2.369215857,2.369215857,6.630784143,6.630784143,6.630784143,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,234.0,234.0,234.0,234.0,6.6307841425898575,6.6307841425898575,6.6307841425898575,6.6307841425898575,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2457179,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2cc([N+](=O)[O-])ccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F3N4O4,CHEMBL4586748,88.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,88.0,88.0,88.0,88.0,1.944482672,1.944482672,1.944482672,7.055517328,7.055517328,7.055517328,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,88.0,88.0,88.0,88.0,7.055517327849832,7.055517327849832,7.055517327849832,7.055517327849832,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2459182,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1cc(C(=O)O)c2ccccc21)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H16F3N3O4,CHEMBL4588751,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2460935,nM,IC50,,BAO_0000190,IC50,1909470,Antagonist activity at human androgen receptor expressed in HEK293 cells assessed as inhibition of R1881-induced receptor transactivation after 24 hrs by luciferase reporter gene assay,0,B,,CHEMBL4411916,10.1021/acs.jmedchem.8b00973,30525603,CHEMBL4411271,"New Generation of Selective Androgen Receptor Degraders: Our Initial Design, Synthesis, and Biological Evaluation of New Compounds with Enzalutamide-Resistant Prostate Cancer Activity.",PUBLICATION,"In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel series of indolyl and indolinyl propanamides (series II and III) were discovered as selective androgen receptor degraders (SARDs). Initial studies of androgen receptor (AR) antagonist (1) and agonist (2) propanamides yielded a tertiary aniline (3) with novel SARD activity but poor metabolic stability. Cyclization to II and III produced submicromolar AR antagonism and protein degradation selective to AR and AR splice variant (AR SV). II and III maintained potency against enzalutamide-resistant (Enz-R) mutant ARs and PC cells and were efficacious in Enz-R xenografts, suggesting their potential to treat advanced PCs. Design, synthesis, and biological activity of novel SARDs that could potentially be used for the treatment of a wide spectrum of PCs including castration-resistant, Enz-R, and/or AR SV-dependent advanced PCs that are often untreatable with known hormone therapies are discussed.",,C[C@](O)(Cn1ccc2ccc(F)cc21)C(=O)Nc1ccc(C#N)c(Cl)c1,C19H15ClFN3O2,CHEMBL4590504,99.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,99.0,99.0,99.0,99.0,1.995635195,1.995635195,1.995635195,7.004364805,7.004364805,7.004364805,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,99.0,99.0,99.0,99.0,7.00436480540245,7.00436480540245,7.00436480540245,7.00436480540245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2461784,nM,IC50,,BAO_0000190,IC50,1904897,Antagonist activity at human androgen receptor in human LNCAP cells harboring firefly luciferase gene after 20 hrs by One-Glo luciferase reporter gene assay,0,B,,CHEMBL4407255,10.1021/acs.jmedchem.9b00711,31274313,CHEMBL4406804,Discovery of a Potent Steroidal Glucocorticoid Receptor Antagonist with Enhanced Selectivity against the Progesterone and Androgen Receptors (OP-3633).,PUBLICATION,"Structure-based modification of mifepristone (1) led to the discovery of novel mifepristone derivatives with improved selectivity profile. Addition of a methyl group at the C10 position of the steroid has a significant impact on progesterone receptor (PR) and androgen receptor (AR) activity. Within this series, OP-3633 (15) emerged as a glucocorticoid receptor (GR) antagonist with increased selectivity against PR and AR, improved cytochrome P450 inhibition profile, and significantly improved pharmacokinetic properties compared to 1. Furthermore, 15 demonstrated substantial inhibition of GR transcriptional activity in the GR positive HCC1806 triple negative breast cancer xenograft model. Overall, compound 15 is a promising GR antagonist candidate to clinically evaluate the impact of GR inhibition in reversal or prevention of therapy resistance.",,CN1CCN(c2ccc([C@H]3C[C@@]4(C)[C@@H](CC[C@@]4(O)C#CC(C)(C)C)[C@@H]4CCC5=CC(=O)CC[C@@H]5[C@H]43)cc2)CC1,C35H48N2O2,CHEMBL4591353,1005.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1005.0,1005.0,1005.0,1005.0,3.002166062,3.002166062,3.002166062,5.997833938,5.997833938,5.997833938,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1005.0,1005.0,1005.0,1005.0,5.997833938243493,5.997833938243493,5.997833938243493,5.997833938243493,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2487665,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(C#N)c(Br)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C16H11BrF3N5O2,CHEMBL4739997,181.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,181.0,181.0,181.0,181.0,2.257678575,2.257678575,2.257678575,6.742321425,6.742321425,6.742321425,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,181.0,181.0,181.0,181.0,6.7423214251308154,6.7423214251308154,6.7423214251308154,6.7423214251308154,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2488042,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1ccc(F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12F4N4O2,CHEMBL4740374,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2488410,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,N#Cc1ccc(NC(=O)CS(=O)(=O)c2ccc(F)cc2)cc1C(F)(F)F,C16H10F4N2O3S,CHEMBL4740742,248.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,248.0,248.0,248.0,248.0,2.394451681,2.394451681,2.394451681,6.605548319,6.605548319,6.605548319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,248.0,248.0,248.0,248.0,6.605548319173784,6.605548319173784,6.605548319173784,6.605548319173784,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2488612,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1S(C)(=O)=O,C13H12F4N2O4S,CHEMBL4740944,6300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6300.0,6300.0,6300.0,6300.0,3.799340549,3.799340549,3.799340549,5.200659451,5.200659451,5.200659451,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6300.0,6300.0,6300.0,6300.0,5.200659450546418,5.200659450546418,5.200659450546418,5.200659450546418,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2488689,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccnc(Cl)c1,C12H12ClFN4O2,CHEMBL4741021,2470.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2470.0,2470.0,2470.0,2470.0,3.392696953,3.392696953,3.392696953,5.607303047,5.607303047,5.607303047,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2470.0,2470.0,2470.0,2470.0,5.607303046740334,5.607303046740334,5.607303046740334,5.607303046740334,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2489237,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1ccc(C(F)(F)F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C16H12F6N4O2,CHEMBL4741569,205.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,205.0,205.0,205.0,205.0,2.311753861,2.311753861,2.311753861,6.688246139,6.688246139,6.688246139,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,205.0,205.0,205.0,205.0,6.688246138944246,6.688246138944246,6.688246138944246,6.688246138944246,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2489435,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,COC(=O)Nc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,C23H20F3N5O4,CHEMBL4741767,827.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,827.0,827.0,827.0,827.0,2.91750551,2.91750551,2.91750551,6.08249449,6.08249449,6.08249449,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,827.0,827.0,827.0,827.0,6.082494490447453,6.082494490447453,6.082494490447453,6.082494490447453,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2490052,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,CC(=O)c1cnn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c1,C17H15F3N4O3,CHEMBL4742694,758.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,758.0,758.0,758.0,758.0,2.879669206,2.879669206,2.879669206,6.120330794,6.120330794,6.120330794,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,758.0,758.0,758.0,758.0,6.120330794367947,6.120330794367947,6.120330794367947,6.120330794367947,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2490503,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)COC2=O,C21H14F3N3O3S,CHEMBL4743145,148.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,148.6,148.6,148.6,148.6,2.172018809,2.172018809,2.172018809,6.827981191,6.827981191,6.827981191,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,148.6,148.6,148.6,148.6,6.827981190575444,6.827981190575444,6.827981190575444,6.827981190575444,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2490583,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccc(C(F)(F)F)nc2)C1=O,C11H10F3N3O2,CHEMBL4743225,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2490660,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,CN1Cc2cc(N3C(=S)N(c4ccc(C#N)c(C(F)(F)F)c4)C(=O)C3(C)C)ccc2C1=O,C22H17F3N4O2S,CHEMBL4743302,590.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,590.2,590.2,590.2,590.2,2.770999205,2.770999205,2.770999205,6.229000795,6.229000795,6.229000795,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,590.2,590.2,590.2,590.2,6.229000794836059,6.229000794836059,6.229000794836059,6.229000794836059,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2490887,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(Cc2ccc(F)c(C(F)(F)F)c2)C1=O,C13H12F4N2O2,CHEMBL4743529,4200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4200.0,4200.0,4200.0,4200.0,3.62324929,3.62324929,3.62324929,5.37675071,5.37675071,5.37675071,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4200.0,4200.0,4200.0,4200.0,5.376750709602099,5.376750709602099,5.376750709602099,5.376750709602099,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2491754,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccc(C(F)(F)F)cc5)ccc4N3C2=S)cc1C(F)(F)F,C26H15F6N3OS,CHEMBL4744396,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2492332,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccc(F)c(C(F)F)c2)C1=O,C12H11F3N2O2,CHEMBL4744974,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2492567,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)CCOC2=O,C22H16F3N3O3S,CHEMBL4745209,195.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,195.5,195.5,195.5,195.5,2.291146762,2.291146762,2.291146762,6.708853238,6.708853238,6.708853238,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,195.5,195.5,195.5,195.5,6.708853238268114,6.708853238268114,6.708853238268114,6.708853238268114,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2493213,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ncc(N2C(=O)C3(COC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C20H11F3N4O4S,CHEMBL4745855,26735.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26735.0,26735.0,26735.0,26735.0,4.427080188,4.427080188,4.427080188,4.572919812,4.572919812,4.572919812,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,26735.0,26735.0,26735.0,26735.0,4.572919811563641,4.572919811563641,4.572919811563641,4.572919811563641,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2493801,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CN(C)C(=O)c1cc(N2C(=O)NC(C)(C)C2=O)ccc1F,C14H16FN3O3,CHEMBL4746443,9100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9100.0,9100.0,9100.0,9100.0,3.959041392,3.959041392,3.959041392,5.040958608,5.040958608,5.040958608,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9100.0,9100.0,9100.0,9100.0,5.040958607678906,5.040958607678906,5.040958607678906,5.040958607678906,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2494011,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ncc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C22H15F3N4O3S,CHEMBL4746653,63.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,63.8,63.8,63.8,63.8,1.804820679,1.804820679,1.804820679,7.195179321,7.195179321,7.195179321,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,63.8,63.8,63.8,63.8,7.195179321278838,7.195179321278838,7.195179321278838,7.195179321278838,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2494172,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2022761, Entry 1: 2101892, ","Entry 0: Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay, Entry 1: Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4676574, Entry 1: CHEMBL4810288, ","Entry 0: 10.1021/acs.jmedchem.0c00943, Entry 1: 10.1021/acs.jmedchem.1c00439, ","Entry 0: 33095584, Entry 1: 34269581, ","Entry 0: CHEMBL4673256, Entry 1: CHEMBL4808211, ","Entry 0: Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer., Entry 1: Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer., Entry 1: A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers., ",,C[C@](O)(Cn1cc(-c2ccc(F)cc2)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H16F4N4O2,CHEMBL4746814,969.0,969.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,969.0,969.0,969.0,969.0,2.986323777,2.986323777,2.986323777,6.013676223,6.013676223,6.013676223,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,969.0,969.0,969.0,969.0,6.013676222949234,6.013676222949234,6.013676222949234,6.013676222949234,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2494318,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,CC(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12F4N4O,CHEMBL4746960,462.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,462.0,462.0,462.0,462.0,2.664641976,2.664641976,2.664641976,6.335358024,6.335358024,6.335358024,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,462.0,462.0,462.0,462.0,6.335358024443875,6.335358024443875,6.335358024443875,6.335358024443875,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2494414,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,N#Cc1ccc(NC(=O)CCn2cc(F)cn2)cc1C(F)(F)F,C14H10F4N4O,CHEMBL4747056,2124.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2124.0,2124.0,2124.0,2124.0,3.327154512,3.327154512,3.327154512,5.672845488,5.672845488,5.672845488,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2124.0,2124.0,2124.0,2124.0,5.6728454875905685,5.6728454875905685,5.6728454875905685,5.6728454875905685,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2494857,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,O=C1NC2(CCCCC2)C(=O)N1c1ccc(F)c(C(F)(F)F)c1,C15H14F4N2O2,CHEMBL4747499,4200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4200.0,4200.0,4200.0,4200.0,3.62324929,3.62324929,3.62324929,5.37675071,5.37675071,5.37675071,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4200.0,4200.0,4200.0,4200.0,5.376750709602099,5.376750709602099,5.376750709602099,5.376750709602099,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2494902,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,Cc1ccc(N2C(=O)NC(C)(C)C2=O)cc1C(F)(F)F,C13H13F3N2O2,CHEMBL4747544,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2495025,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,Cc1cnn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)c1,C16H15F3N4O2,CHEMBL4747667,8087.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8087.0,8087.0,8087.0,8087.0,3.907787443,3.907787443,3.907787443,5.092212557,5.092212557,5.092212557,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8087.0,8087.0,8087.0,8087.0,5.0922125568893835,5.0922125568893835,5.0922125568893835,5.0922125568893835,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2495759,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccnc(C(F)(F)F)c2)C1=O,C11H10F3N3O2,CHEMBL4748422,4500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4500.0,4500.0,4500.0,4500.0,3.653212514,3.653212514,3.653212514,5.346787486,5.346787486,5.346787486,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4500.0,4500.0,4500.0,4500.0,5.346787486224656,5.346787486224656,5.346787486224656,5.346787486224656,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2495894,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1S(=O)(=O)c1ccccc1,C18H14F4N2O4S,CHEMBL4748557,4300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4300.0,4300.0,4300.0,4300.0,3.633468456,3.633468456,3.633468456,5.366531544,5.366531544,5.366531544,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4300.0,4300.0,4300.0,4300.0,5.366531544420414,5.366531544420414,5.366531544420414,5.366531544420414,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497023,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2ncc(NS(C)(=O)=O)s2)cc1)c1cc(Cl)c(OCCCl)c(C#N)c1,C23H23Cl2N3O4S2,CHEMBL4749686,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497025,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2cnc(NS(C)(=O)=O)nc2)cc1)c1cc(Cl)c(OCCCl)c(C#N)c1,C24H24Cl2N4O4S,CHEMBL4749688,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497316,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,Cc1nc(NS(C)(=O)=O)nc(COc2ccc(C(C)(C)c3cc(Cl)c(OCCCl)c(C#N)c3)cc2)c1C,C26H28Cl2N4O4S,CHEMBL4749979,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497440,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccc(Cl)c(C(F)(F)F)c2)C1=O,C12H10ClF3N2O2,CHEMBL4750103,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1300.0,1300.0,1300.0,1300.0,3.113943352,3.113943352,3.113943352,5.886056648,5.886056648,5.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497688,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccccc5)ccc4N3C2=S)cc1C(F)(F)F,C25H16F3N3OS,CHEMBL4750351,3438.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3438.0,3438.0,3438.0,3438.0,3.536305872,3.536305872,3.536305872,5.463694128,5.463694128,5.463694128,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3438.0,3438.0,3438.0,3438.0,5.463694127648966,5.463694127648966,5.463694127648966,5.463694127648966,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2497840,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,C19H11BrF3N3OS,CHEMBL4750503,4377.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4377.0,4377.0,4377.0,4377.0,3.641176547,3.641176547,3.641176547,5.358823453,5.358823453,5.358823453,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4377.0,4377.0,4377.0,4377.0,5.358823453386886,5.358823453386886,5.358823453386886,5.358823453386886,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2498983,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(C(F)(F)F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C16H12F6N4O2,CHEMBL4751646,71.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,71.0,71.0,71.0,71.0,1.851258349,1.851258349,1.851258349,7.148741651,7.148741651,7.148741651,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,71.0,71.0,71.0,71.0,7.1487416512809245,7.1487416512809245,7.1487416512809245,7.1487416512809245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2499814,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,Cc1cn(C[C@](C)(O)C(=O)Nc2ccc(C#N)c(C(F)(F)F)c2)nc1Cl,C16H14ClF3N4O2,CHEMBL4752477,332.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,332.0,332.0,332.0,332.0,2.521138084,2.521138084,2.521138084,6.478861916,6.478861916,6.478861916,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,332.0,332.0,332.0,332.0,6.478861916295964,6.478861916295964,6.478861916295964,6.478861916295964,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2500026,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C23H16F3N3O3S,CHEMBL4752689,80.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,80.7,80.7,80.7,80.7,1.906873535,1.906873535,1.906873535,7.093126465,7.093126465,7.093126465,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,80.7,80.7,80.7,80.7,7.09312646527793,7.09312646527793,7.09312646527793,7.09312646527793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2500230,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,CC(C)(C)OC(=O)Nc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,C26H26F3N5O4,CHEMBL4752893,1153.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1153.0,1153.0,1153.0,1153.0,3.061829307,3.061829307,3.061829307,5.938170693,5.938170693,5.938170693,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1153.0,1153.0,1153.0,1153.0,5.938170692705301,5.938170692705301,5.938170692705301,5.938170692705301,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2500328,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(Cl)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12ClF3N4O2,CHEMBL4752991,136.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,136.0,136.0,136.0,136.0,2.133538908,2.133538908,2.133538908,6.866461092,6.866461092,6.866461092,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,136.0,136.0,136.0,136.0,6.866461091629782,6.866461091629782,6.866461091629782,6.866461091629782,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2501214,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc([N+](=O)[O-])cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12F3N5O4,CHEMBL4753877,36.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,36.0,36.0,36.0,36.0,1.556302501,1.556302501,1.556302501,7.443697499,7.443697499,7.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,36.0,36.0,36.0,36.0,7.443697499232713,7.443697499232713,7.443697499232713,7.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2501411,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CNc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,C18H10BrF3N4OS,CHEMBL4754074,9862.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9862.0,9862.0,9862.0,9862.0,3.993964998,3.993964998,3.993964998,5.006035002,5.006035002,5.006035002,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9862.0,9862.0,9862.0,9862.0,5.006035001804881,5.006035001804881,5.006035001804881,5.006035001804881,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2501646,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ncc(N2C(=O)C3(CCCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C23H17F3N4O3S,CHEMBL4754309,93.3,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,93.3,93.3,93.3,93.3,1.969881644,1.969881644,1.969881644,7.030118356,7.030118356,7.030118356,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,93.3,93.3,93.3,93.3,7.0301183562535,7.0301183562535,7.0301183562535,7.0301183562535,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2502182,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)C(c2ccc(F)c(C(F)(F)F)c2)C1=O,C13H11F4NO2,CHEMBL4754845,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2503002,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,O=C1NC2(CCCC2)C(=O)N1c1ccc(F)c(C(F)(F)F)c1,C14H12F4N2O2,CHEMBL4755665,990.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,990.0,990.0,990.0,990.0,2.995635195,2.995635195,2.995635195,6.004364805,6.004364805,6.004364805,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,990.0,990.0,990.0,990.0,6.00436480540245,6.00436480540245,6.00436480540245,6.00436480540245,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2503080,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cnc(Cl)nc5)ccc4N3C2=S)cc1C(F)(F)F,C23H13ClF3N5OS,CHEMBL4755743,8075.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8075.0,8075.0,8075.0,8075.0,3.907142531,3.907142531,3.907142531,5.092857469,5.092857469,5.092857469,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8075.0,8075.0,8075.0,8075.0,5.0928574689968595,5.0928574689968595,5.0928574689968595,5.0928574689968595,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2503714,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2cnccn2)C1=O,C9H10N4O2,CHEMBL4756377,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2504022,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ncc(N2C(=O)C3(CCCC3)N(c3cnc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C21H14F3N5O3S,CHEMBL4756685,2219.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2219.0,2219.0,2219.0,2219.0,3.346157302,3.346157302,3.346157302,5.653842698,5.653842698,5.653842698,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2219.0,2219.0,2219.0,2219.0,5.653842697767992,5.653842697767992,5.653842697767992,5.653842697767992,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2504273,nM,IC50,,BAO_0000190,IC50,2031846,Antagonist activity at Androgen receptor (unknown origin) expressed in COS7 cells by dual luciferase reporter gene assay relative to control,0,B,,CHEMBL4686004,10.1016/j.ejmech.2020.112196,32169785,CHEMBL4680224,Discovery of pyridine tetrahydroisoquinoline thiohydantoin derivatives with low blood-brain barrier penetration as the androgen receptor antagonists.,PUBLICATION,"Prostate cancer (PC) is the most diagnosed type of malignancy in men and the major frequently cause of cancer-related death worldwide. The androgen receptor (AR) has become a promising drug target for the treatment of PC. Here, we reported the design, optimization and evaluation of pyridine tetrahydroisoquinoline thiohydantoin derivatives with improved activity and safety as potent AR antagonists. The most promising compound 42f exhibited potent inhibitory activity on AR and strongly blocked AR nuclear translocation. Moreover, 42f displayed promising invitro antitumor activity toward AR-dependent prostate cancer cell lines (LNCaP) and also demonstrated therapeutic effects in LNCaP xenograft tumor model in mice (TGI: 79%) with no apparent toxicity observed invivo. More importantly, 42f showed negligible penetration of the brain-blood barrier (BBB) compared with enzalutamide. These results provide a foundation for the development of a new class of androgen receptor antagonists for potential therapeutics against PC with lower seizurogenic risk for patients.",,CCOC(=O)Nc1cc2c(cc1F)CC1C(=O)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=S)N1C2,C21H15F4N5O3S,CHEMBL4756936,6170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6170.0,6170.0,6170.0,6170.0,3.790285164,3.790285164,3.790285164,5.209714836,5.209714836,5.209714836,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6170.0,6170.0,6170.0,6170.0,5.209714835966758,5.209714835966758,5.209714835966758,5.209714835966758,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2504676,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2ccnc(NS(C)(=O)=O)n2)cc1)c1cc(F)c(OCCCl)c(Cl)c1,C23H24Cl2FN3O4S,CHEMBL4757339,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2505039,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(Cl)c(Br)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H11BrClF3N4O2,CHEMBL4757702,138.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,138.0,138.0,138.0,138.0,2.139879086,2.139879086,2.139879086,6.860120914,6.860120914,6.860120914,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,138.0,138.0,138.0,138.0,6.860120913598763,6.860120913598763,6.860120913598763,6.860120913598763,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2505189,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccc(C(F)(F)F)nc5)ccc4N3C2=S)cc1C(F)(F)F,C25H14F6N4OS,CHEMBL4757852,2183.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2183.0,2183.0,2183.0,2183.0,3.339053736,3.339053736,3.339053736,5.660946264,5.660946264,5.660946264,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2183.0,2183.0,2183.0,2183.0,5.660946264290861,5.660946264290861,5.660946264290861,5.660946264290861,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2505378,nM,IC50,,BAO_0000190,IC50,2227466,Antagonist activity at Androgen receptor (unknown origin) assessed as inhibition of activation function 1 (AF-1) of AR N-terminal transactivation domain (NTD),0,B,,CHEMBL5140979,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,CC(C)(c1ccc(OCC(O)CO)cc1)c1ccc(OCC(O)CCl)cc1,C21H27ClO5,CHEMBL4758041,6000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6000.0,6000.0,6000.0,6000.0,3.77815125,3.77815125,3.77815125,5.22184875,5.22184875,5.22184875,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6000.0,6000.0,6000.0,6000.0,5.221848749616356,5.221848749616356,5.221848749616356,5.221848749616356,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2505456,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(-c2ccccc2)c(C#N)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C21H15F3N6O2,CHEMBL4758119,579.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,579.0,579.0,579.0,579.0,2.762678564,2.762678564,2.762678564,6.237321436,6.237321436,6.237321436,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,579.0,579.0,579.0,579.0,6.2373214362725635,6.2373214362725635,6.2373214362725635,6.2373214362725635,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2505614,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1CC#N,C14H11F4N3O2,CHEMBL4758277,290.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,290.0,290.0,290.0,290.0,2.462397998,2.462397998,2.462397998,6.537602002,6.537602002,6.537602002,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,290.0,290.0,290.0,290.0,6.537602002101044,6.537602002101044,6.537602002101044,6.537602002101044,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2506022,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(-c2ccccc2)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H17F3N4O2,CHEMBL4758685,1152.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1152.0,1152.0,1152.0,1152.0,3.061452479,3.061452479,3.061452479,5.938547521,5.938547521,5.938547521,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1152.0,1152.0,1152.0,1152.0,5.938547520912807,5.938547520912807,5.938547520912807,5.938547520912807,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2506807,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,CC1(C)C(=O)N(c2cnc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc2c(c1)COC2=O,C20H13F3N4O3S,CHEMBL4759470,941.1,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,941.1,941.1,941.1,941.1,2.973635773,2.973635773,2.973635773,6.026364227,6.026364227,6.026364227,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,941.1,941.1,941.1,941.1,6.026364226582593,6.026364226582593,6.026364226582593,6.026364226582593,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2506960,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,c1ccc(C2Nc3ccc4ccccc4c3C3C4CCC(C4)C23)cc1,C24H23N,CHEMBL4759623,5600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5600.0,5600.0,5600.0,5600.0,3.748188027,3.748188027,3.748188027,5.251811973,5.251811973,5.251811973,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5600.0,5600.0,5600.0,5600.0,5.251811972993799,5.251811972993799,5.251811972993799,5.251811972993799,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2507041,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cnc6ccccc6c5)ccc4N3C2=S)cc1C(F)(F)F,C28H17F3N4OS,CHEMBL4759704,8953.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8953.0,8953.0,8953.0,8953.0,3.951968584,3.951968584,3.951968584,5.048031416,5.048031416,5.048031416,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8953.0,8953.0,8953.0,8953.0,5.048031415507089,5.048031415507089,5.048031415507089,5.048031415507089,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2507169,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C22H14F3N3O4S,CHEMBL4759832,238.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,238.8,238.8,238.8,238.8,2.378034322,2.378034322,2.378034322,6.621965678,6.621965678,6.621965678,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,238.8,238.8,238.8,238.8,6.6219656775426685,6.6219656775426685,6.6219656775426685,6.6219656775426685,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2507178,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C22H14F3N3O3S,CHEMBL4759841,216.7,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,216.7,216.7,216.7,216.7,2.335858911,2.335858911,2.335858911,6.664141089,6.664141089,6.664141089,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,216.7,216.7,216.7,216.7,6.664141088680182,6.664141088680182,6.664141088680182,6.664141088680182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2507478,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,Brc1ccc(C2Nc3ccc4ccccc4c3C3C=CCC32)cc1,C22H18BrN,CHEMBL4760141,150.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,150.0,150.0,150.0,150.0,2.176091259,2.176091259,2.176091259,6.823908741,6.823908741,6.823908741,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,150.0,150.0,150.0,150.0,6.823908740944319,6.823908740944319,6.823908740944319,6.823908740944319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2508528,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CSc1nc(C)c(COc2ccc(C(C)(C)c3cc(Cl)c(OCCCl)c(C#N)c3)cc2)o1,C24H24Cl2N2O3S,CHEMBL4761191,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2509294,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)S(=O)(=O)Nc1nc(COc2ccc(C(C)(C)c3cc(Cl)c(OCCCl)c(C#N)c3)cc2)co1,C25H27Cl2N3O5S,CHEMBL4761957,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2509754,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C21H12F3N3O3S,CHEMBL4762417,669.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,669.6,669.6,669.6,669.6,2.825815445,2.825815445,2.825815445,6.174184555,6.174184555,6.174184555,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,669.6,669.6,669.6,669.6,6.174184555014796,6.174184555014796,6.174184555014796,6.174184555014796,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2510441,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2nc(NS(C)(=O)=O)cs2)cc1)c1cc(Cl)c(OCCCl)c(C#N)c1,C23H23Cl2N3O4S2,CHEMBL4763104,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2510473,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,O=C1N[C@H](c2ccccc2)C(=O)N1c1ccc(F)c(C(F)F)c1,C16H11F3N2O2,CHEMBL4763136,5300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5300.0,5300.0,5300.0,5300.0,3.72427587,3.72427587,3.72427587,5.27572413,5.27572413,5.27572413,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5300.0,5300.0,5300.0,5300.0,5.275724130399211,5.275724130399211,5.275724130399211,5.275724130399211,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2511213,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2cccnc2)C1=O,C10H11N3O2,CHEMBL4763876,9600.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9600.0,9600.0,9600.0,9600.0,3.982271233,3.982271233,3.982271233,5.017728767,5.017728767,5.017728767,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9600.0,9600.0,9600.0,9600.0,5.017728766960432,5.017728766960432,5.017728766960432,5.017728766960432,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2512329,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ncc(N2C(=O)C3(CCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C21H13F3N4O4S,CHEMBL4764992,516.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,516.2,516.2,516.2,516.2,2.712818,2.712818,2.712818,6.287182,6.287182,6.287182,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,516.2,516.2,516.2,516.2,6.28718199979215,6.28718199979215,6.28718199979215,6.28718199979215,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2512812,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,CC(C)(C)OC(=O)Nc1cnn(C[C@](C)(O)C(=O)Nc2cnc(C#N)c(C(F)(F)F)c2)c1,C19H21F3N6O4,CHEMBL4776221,6108.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6108.0,6108.0,6108.0,6108.0,3.785899028,3.785899028,3.785899028,5.214100972,5.214100972,5.214100972,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6108.0,6108.0,6108.0,6108.0,5.214100971615617,5.214100971615617,5.214100971615617,5.214100971615617,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2513724,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)CNC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,C13H12F4N2O2,CHEMBL4777133,6900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6900.0,6900.0,6900.0,6900.0,3.838849091,3.838849091,3.838849091,5.161150909,5.161150909,5.161150909,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6900.0,6900.0,6900.0,6900.0,5.161150909262744,5.161150909262744,5.161150909262744,5.161150909262744,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2514102,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)CN(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1,C12H12F4N2O,CHEMBL4777511,8100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,8100.0,8100.0,8100.0,8100.0,3.908485019,3.908485019,3.908485019,5.091514981,5.091514981,5.091514981,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,8100.0,8100.0,8100.0,8100.0,5.0915149811213505,5.0915149811213505,5.0915149811213505,5.0915149811213505,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2514610,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1ccc(-c2ccccc2)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H17F3N4O2,CHEMBL4778019,4770.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4770.0,4770.0,4770.0,4770.0,3.678518379,3.678518379,3.678518379,5.321481621,5.321481621,5.321481621,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4770.0,4770.0,4770.0,4770.0,5.321481620959886,5.321481620959886,5.321481620959886,5.321481620959886,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2514776,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,O=C1C2CCCN2C(=O)N1c1ccc(F)c(C(F)(F)F)c1,C13H10F4N2O2,CHEMBL4778185,3500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3500.0,3500.0,3500.0,3500.0,3.544068044,3.544068044,3.544068044,5.455931956,5.455931956,5.455931956,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3500.0,3500.0,3500.0,3500.0,5.455931955649724,5.455931955649724,5.455931955649724,5.455931955649724,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2514889,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccnc3ccccc23)C1=O,C14H13N3O2,CHEMBL4778298,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1300.0,1300.0,1300.0,1300.0,3.113943352,3.113943352,3.113943352,5.886056648,5.886056648,5.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2515141,nM,IC50,,BAO_0000190,IC50,2012438,Antagonist activity at recombinant androgen receptor (unknown origin) transfected in human LNCaP cells co-transfected with PSA and luciferase incubated for 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4666016,10.1016/j.ejmech.2019.01.036,30711833,CHEMBL4665623,Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.,PUBLICATION,"Prostate cancer (PCa) is the most frequently diagnosed male malignant tumor and remains the second leading cause of male cancer mortality in the western countries. The second-generation antiandrogen enzalutamide (ENZa) can prolong survival time for patients with mCRPC. However, the overexpression of glucocorticoids receptor (GR) in mCRPC cells causes the resistance of antiandrogen and leads to the failure of androgen receptor (AR) targeting therapy. Herein, based on the chemical structures of antiandrogen and crystal structure of GR, we set up to develop GR/AR (GR and AR) dual antagonist by virtual screening and biological evaluation. We identified Z19 as a dual AR/GR antagonist. Z19 inhibited the transcription activity of both AR and GR, reducing both protein and mRNA level of the downstream proteins of GR and AR signaling, and provided a potential lead compound for the development of novel treatment agents of prostate cancer. Our work demonstrates that rational drug design is an efficient strategy in development of the GR/AR dual antagonist for the treatment of prostate cancer.",,CCOC(=O)c1ccc(NC(=O)c2cccc(S(=O)(=O)N3CCCc4ccccc43)c2)s1,C23H22N2O5S2,CHEMBL4778550,2030.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2030.0,2030.0,2030.0,2030.0,3.307496038,3.307496038,3.307496038,5.692503962,5.692503962,5.692503962,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2030.0,2030.0,2030.0,2030.0,5.692503962086787,5.692503962086787,5.692503962086787,5.692503962086787,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2515386,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(C#N)cn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C15H11F3N6O2,CHEMBL4778795,59.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,59.0,59.0,59.0,59.0,1.770852012,1.770852012,1.770852012,7.229147988,7.229147988,7.229147988,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,59.0,59.0,59.0,59.0,7.229147988357856,7.229147988357856,7.229147988357856,7.229147988357856,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2515565,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CN1C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)C1(C)C,C13H12F4N2O2,CHEMBL4778974,1300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1300.0,1300.0,1300.0,1300.0,3.113943352,3.113943352,3.113943352,5.886056648,5.886056648,5.886056648,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1300.0,1300.0,1300.0,1300.0,5.886056647693163,5.886056647693163,5.886056647693163,5.886056647693163,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2516065,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cccn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H13F3N4O2,CHEMBL4779474,1442.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1442.0,1442.0,1442.0,1442.0,3.15896526,3.15896526,3.15896526,5.84103474,5.84103474,5.84103474,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1442.0,1442.0,1442.0,1442.0,5.84103473961659,5.84103473961659,5.84103473961659,5.84103473961659,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2516118,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(Cl)c1,C14H12ClFN4O2,CHEMBL4779527,427.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,427.0,427.0,427.0,427.0,2.630427875,2.630427875,2.630427875,6.369572125,6.369572125,6.369572125,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,427.0,427.0,427.0,427.0,6.369572124974976,6.369572124974976,6.369572124974976,6.369572124974976,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2517140,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCCOC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C23H16F3N3O4S,CHEMBL4780549,140.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,140.9,140.9,140.9,140.9,2.148910993,2.148910993,2.148910993,6.851089007,6.851089007,6.851089007,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.9,140.9,140.9,140.9,6.851089006890644,6.851089006890644,6.851089006890644,6.851089006890644,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2518299,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2cccc(C(F)(F)F)c2)C1=O,C12H11F3N2O2,CHEMBL4781708,6000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6000.0,6000.0,6000.0,6000.0,3.77815125,3.77815125,3.77815125,5.22184875,5.22184875,5.22184875,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6000.0,6000.0,6000.0,6000.0,5.221848749616356,5.221848749616356,5.221848749616356,5.221848749616356,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2518317,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4ccccc4N3C2=S)cc1C(F)(F)F,C19H12F3N3OS,CHEMBL4781726,2837.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2837.0,2837.0,2837.0,2837.0,3.452859336,3.452859336,3.452859336,5.547140664,5.547140664,5.547140664,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2837.0,2837.0,2837.0,2837.0,5.547140664204147,5.547140664204147,5.547140664204147,5.547140664204147,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2518787,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1NC(=O)N(c2ccc(F)c(C(F)F)c2)C1=O,C11H9F3N2O2,CHEMBL4782196,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2519017,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccncc2)C1=O,C10H11N3O2,CHEMBL4782426,3800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3800.0,3800.0,3800.0,3800.0,3.579783597,3.579783597,3.579783597,5.420216403,5.420216403,5.420216403,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3800.0,3800.0,3800.0,3800.0,5.42021640338319,5.42021640338319,5.42021640338319,5.42021640338319,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2519377,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,Clc1ccc(C2Nc3ccc4ccccc4c3C3C4CCC(C4)C23)cc1,C24H22ClN,CHEMBL4782786,7450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7450.0,7450.0,7450.0,7450.0,3.872156273,3.872156273,3.872156273,5.127843727,5.127843727,5.127843727,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7450.0,7450.0,7450.0,7450.0,5.127843727251707,5.127843727251707,5.127843727251707,5.127843727251707,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2519515,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@@](Cn1cc(N)cn1)(OC(=O)CCl)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C17H15ClF3N5O3,CHEMBL4782924,901.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,901.0,901.0,901.0,901.0,2.954724791,2.954724791,2.954724791,6.045275209,6.045275209,6.045275209,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,901.0,901.0,901.0,901.0,6.045275209020937,6.045275209020937,6.045275209020937,6.045275209020937,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2519583,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(-c2ccc(F)cc2)c(F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H15F5N4O2,CHEMBL4782992,285.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,285.0,285.0,285.0,285.0,2.45484486,2.45484486,2.45484486,6.54515514,6.54515514,6.54515514,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,285.0,285.0,285.0,285.0,6.54515513999149,6.54515513999149,6.54515513999149,6.54515513999149,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2520835,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(C#N)c(Br)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C15H10BrF3N6O2,CHEMBL4784244,5481.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5481.0,5481.0,5481.0,5481.0,3.738859802,3.738859802,3.738859802,5.261140198,5.261140198,5.261140198,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5481.0,5481.0,5481.0,5481.0,5.2611401979278,5.2611401979278,5.2611401979278,5.2611401979278,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2523096,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1CCc1ccccc1,C20H18F4N2O2,CHEMBL4786505,2400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2400.0,2400.0,2400.0,2400.0,3.380211242,3.380211242,3.380211242,5.619788758,5.619788758,5.619788758,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2400.0,2400.0,2400.0,2400.0,5.619788758288394,5.619788758288394,5.619788758288394,5.619788758288394,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2523402,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)C(=O)NC(=O)N1c1ccc(F)c(C(F)(F)F)c1,C12H10F4N2O2,CHEMBL4786811,2800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2800.0,2800.0,2800.0,2800.0,3.447158031,3.447158031,3.447158031,5.552841969,5.552841969,5.552841969,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2800.0,2800.0,2800.0,2800.0,5.552841968657781,5.552841968657781,5.552841968657781,5.552841968657781,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2523812,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5ccn(C6CC6)n5)ccc4N3C2=S)cc1C(F)(F)F,C25H18F3N5OS,CHEMBL4787221,4527.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4527.0,4527.0,4527.0,4527.0,3.655810494,3.655810494,3.655810494,5.344189506,5.344189506,5.344189506,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4527.0,4527.0,4527.0,4527.0,5.3441895055047475,5.3441895055047475,5.3441895055047475,5.3441895055047475,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2524222,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1cnc2c(c1)COC2=O,C20H13F3N4O3S,CHEMBL4787631,2292.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2292.0,2292.0,2292.0,2292.0,3.360214613,3.360214613,3.360214613,5.639785387,5.639785387,5.639785387,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2292.0,2292.0,2292.0,2292.0,5.639785386704648,5.639785386704648,5.639785386704648,5.639785386704648,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2524588,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)CC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,C13H11F4NO2,CHEMBL4787997,910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,910.0,910.0,910.0,910.0,2.959041392,2.959041392,2.959041392,6.040958608,6.040958608,6.040958608,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,910.0,910.0,910.0,910.0,6.040958607678906,6.040958607678906,6.040958607678906,6.040958607678906,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2525301,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CSc4cc(Br)ccc4N3C2=S)cc1C(F)(F)F,C18H9BrF3N3OS2,CHEMBL4788710,18140.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,18140.0,18140.0,18140.0,18140.0,4.258637283,4.258637283,4.258637283,4.741362717,4.741362717,4.741362717,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,18140.0,18140.0,18140.0,18140.0,4.741362717275924,4.741362717275924,4.741362717275924,4.741362717275924,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2525460,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,Cc1noc(C)c1-c1ccc2c(c1)CCC1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=S)N21,C24H17F3N4O2S,CHEMBL4788869,5978.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5978.0,5978.0,5978.0,5978.0,3.776555911,3.776555911,3.776555911,5.223444089,5.223444089,5.223444089,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5978.0,5978.0,5978.0,5978.0,5.223444089296738,5.223444089296738,5.223444089296738,5.223444089296738,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2525849,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2cnc(NS(C)(=O)=O)o2)cc1)c1cc(Cl)c(OCCCl)c(C#N)c1,C23H23Cl2N3O5S,CHEMBL4789258,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2526500,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2ccnc(NS(C)(=O)=O)n2)cc1)c1cc(Cl)c(OCCCl)c(Cl)c1,C23H24Cl3N3O4S,CHEMBL4789909,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2526751,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,CCOC(=O)C1Nc2ccc3ccccc3c2C2C=CCC12,C19H19NO2,CHEMBL4790160,820.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,820.0,820.0,820.0,820.0,2.913813852,2.913813852,2.913813852,6.086186148,6.086186148,6.086186148,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,820.0,820.0,820.0,820.0,6.086186147616283,6.086186147616283,6.086186147616283,6.086186147616283,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2526860,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)OC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,C12H9F4NO3,CHEMBL4790269,2100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2100.0,2100.0,2100.0,2100.0,3.322219295,3.322219295,3.322219295,5.677780705,5.677780705,5.677780705,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2100.0,2100.0,2100.0,2100.0,5.6777807052660805,5.6777807052660805,5.6777807052660805,5.6777807052660805,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2527132,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(C(F)(F)F)cn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C15H11F6N5O2,CHEMBL4790541,208.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,208.0,208.0,208.0,208.0,2.318063335,2.318063335,2.318063335,6.681936665,6.681936665,6.681936665,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,208.0,208.0,208.0,208.0,6.681936665037238,6.681936665037238,6.681936665037238,6.681936665037238,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2529075,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCCC3)N(c3ccc4c(c3)CCOC4=O)C2=S)cc1C(F)(F)F,C24H18F3N3O3S,CHEMBL4792484,134.6,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,134.6,134.6,134.6,134.6,2.12904506,2.12904506,2.12904506,6.87095494,6.87095494,6.87095494,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,134.6,134.6,134.6,134.6,6.870954940112042,6.870954940112042,6.870954940112042,6.870954940112042,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2529529,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@@](O)(Cn1cc(F)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12F4N4O2,CHEMBL4792938,192.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,192.0,192.0,192.0,192.0,2.283301229,2.283301229,2.283301229,6.716698771,6.716698771,6.716698771,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,192.0,192.0,192.0,192.0,6.716698771296451,6.716698771296451,6.716698771296451,6.716698771296451,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2529661,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,O=C1CNC(=O)N1c1ccc(F)c(C(F)(F)F)c1,C10H6F4N2O2,CHEMBL4793070,260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,260.0,260.0,260.0,260.0,2.414973348,2.414973348,2.414973348,6.585026652,6.585026652,6.585026652,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,260.0,260.0,260.0,260.0,6.585026652029182,6.585026652029182,6.585026652029182,6.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2529749,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(CO)NC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C1=O,C12H10F4N2O3,CHEMBL4793158,4800.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4800.0,4800.0,4800.0,4800.0,3.681241237,3.681241237,3.681241237,5.318758763,5.318758763,5.318758763,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4800.0,4800.0,4800.0,4800.0,5.318758762624412,5.318758762624412,5.318758762624412,5.318758762624412,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2530033,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1ccc(-c2ccc(F)cc2)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C21H16F4N4O2,CHEMBL4793442,1069.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1069.0,1069.0,1069.0,1069.0,3.028977705,3.028977705,3.028977705,5.971022295,5.971022295,5.971022295,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1069.0,1069.0,1069.0,1069.0,5.971022294791222,5.971022294791222,5.971022294791222,5.971022294791222,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2530788,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C#Cc1ccc(-c2cnn(C[C@](C)(O)C(=O)Nc3ccc(C#N)c(C(F)(F)F)c3)c2)cc1,C23H17F3N4O2,CHEMBL4794197,276.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,276.0,276.0,276.0,276.0,2.440909082,2.440909082,2.440909082,6.559090918,6.559090918,6.559090918,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,276.0,276.0,276.0,276.0,6.559090917934783,6.559090917934783,6.559090917934783,6.559090917934783,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2531058,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(Br)c(F)n1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C14H10BrF4N5O2,CHEMBL4794467,35.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,35.0,35.0,35.0,35.0,1.544068044,1.544068044,1.544068044,7.455931956,7.455931956,7.455931956,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,35.0,35.0,35.0,35.0,7.455931955649724,7.455931955649724,7.455931955649724,7.455931955649724,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2531230,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3(CCCCC3)N(c3ccc4c(c3)COC4=O)C2=S)cc1C(F)(F)F,C24H18F3N3O3S,CHEMBL4794639,95.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,95.2,95.2,95.2,95.2,1.978636948,1.978636948,1.978636948,7.021363052,7.021363052,7.021363052,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,95.2,95.2,95.2,95.2,7.021363051615525,7.021363051615525,7.021363051615525,7.021363051615525,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2532125,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)CC(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)N1,C13H12F4N2O2,CHEMBL4795534,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2532923,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,Clc1ccc(C2Nc3ccc4ccccc4c3C3C=CCC32)cc1,C22H18ClN,CHEMBL4796332,1920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1920.0,1920.0,1920.0,1920.0,3.283301229,3.283301229,3.283301229,5.716698771,5.716698771,5.716698771,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1920.0,1920.0,1920.0,1920.0,5.716698771296451,5.716698771296451,5.716698771296451,5.716698771296451,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2533925,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(Br)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12BrF3N4O2,CHEMBL4797334,427.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,427.0,427.0,427.0,427.0,2.630427875,2.630427875,2.630427875,6.369572125,6.369572125,6.369572125,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,427.0,427.0,427.0,427.0,6.369572124974976,6.369572124974976,6.369572124974976,6.369572124974976,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2534306,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2031517, Entry 1: 2031518, ","Entry 0: Displacement of fluormone-AL green from GST-tagged androgen receptor LBD (unknown origin) measured after 4 hrs by fluorescence polarization assay, Entry 1: Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4685675, Entry 1: CHEMBL4685676, ","Entry 0: 10.1016/j.ejmech.2020.112156, Entry 1: 10.1016/j.ejmech.2020.112156, ","Entry 0: 32114360, Entry 1: 32114360, ","Entry 0: CHEMBL4680213, Entry 1: CHEMBL4680213, ","Entry 0: Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation., Entry 1: Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics., Entry 1: Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics., ",,Clc1ccccc1C1Nc2ccc3ccccc3c2C2C=CCC21,C22H18ClN,CHEMBL4797715,2400.0,4020.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,810.0,2400.0,3210.0,3210.0,4020.0,3.506505032,3.506505032,3.380211242,5.493494968,5.493494968,5.619788758,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2400.0,2400.0,2400.0,2400.0,5.619788758288394,5.619788758288394,5.619788758288394,5.619788758288394,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2534845,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,Clc1ccc(C2Nc3ccc4ccccc4c3C3OCCCC23)c(Cl)c1,C22H19Cl2NO,CHEMBL4798254,20350.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,20350.0,20350.0,20350.0,20350.0,4.308564414,4.308564414,4.308564414,4.691435586,4.691435586,4.691435586,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,20350.0,20350.0,20350.0,20350.0,4.691435586438761,4.691435586438761,4.691435586438761,4.691435586438761,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2535197,nM,IC50,,BAO_0000190,IC50,2031518,Antagonist activity at androgen receptor in human LNCaP cells transfected with ARR2 PB-eGFP assessed as inhibition of DHT-induced transcriptional activity measured after 3 days by fluorescence assay,0,B,,CHEMBL4685676,10.1016/j.ejmech.2020.112156,32114360,CHEMBL4680213,"Novel androgen receptor antagonist identified by structure-based virtual screening, structural optimization, and biological evaluation.",PUBLICATION,"Androgen receptor (AR) plays important roles in the development of prostate cancer (PCa), and therefore it has been regarded as the most important therapeutic target for both hormone-sensitive prostate cancer (HSPC) and advanced PCa. In this study, a novel hit (C18) with IC of 2.4M against AR transcriptional activity in LNCaP cell was identified through structure-based virtual screening based on molecular docking and free energy calculations. The structure-activity relationship analysis and structural optimization of C18 resulted in the discovery of a structural analogue (AT2), a more potent AR antagonist with 16-fold improved anti-AR potency. Further assays indicated that AT2 was capable of effectively inhibiting the transcriptional function of AR and blocking the nuclear translocation of AR like the second-generation AR antagonists. The antagonists discovered in this study may be served as the promising lead compounds for the development of AR-driven PCa therapeutics.",,Fc1ccccc1C1Nc2ccc3ccccc3c2C2C=CCC21,C22H18FN,CHEMBL4798606,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2535434,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(I)cn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12F3IN4O2,CHEMBL4798843,2038.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2038.0,2038.0,2038.0,2038.0,3.30920418,3.30920418,3.30920418,5.69079582,5.69079582,5.69079582,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2038.0,2038.0,2038.0,2038.0,5.690795820329592,5.690795820329592,5.690795820329592,5.690795820329592,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2535536,nM,IC50,,BAO_0000190,IC50,2034916,Antagonist activity at androgen receptor (unknown origin) expressed in HEK293 cells using DHT as substrate preincubated for 30 mins followed by substrate addition measured after 24 hrs by Steady-Glo luciferase assay,0,B,,CHEMBL4689074,10.1016/j.bmc.2020.115953,33388655,CHEMBL4680336,"Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer.",PUBLICATION,"Prostate cancer (PC) is the most common malignancy in men worldwide. Here, two series of novel thiohydantoin derivatives of enzalutamide as potent androgen receptor (AR) antagonists were designed and synthesized. Among them, compound 31c was identified as an AR antagonist which is 2.3-fold more potent than enzalutamide. Molecular docking studies were performed to explain the improved potency of 31c at AR. In cell proliferation assays, 31c exhibited similar anti-proliferative activities with enzalutamide against hormone sensitive LNCaP cells and AR-overexpressing LNCaP/AR cells. These data indicate that 31c can be a good lead compound for further structure optimization for the treatment of prostate cancer.",,N#Cc1ccc(N2C(=O)C3CCc4cc(-c5cccnc5)ccc4N3C2=S)cc1C(F)(F)F,C24H15F3N4OS,CHEMBL4798945,3906.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3906.0,3906.0,3906.0,3906.0,3.591732239,3.591732239,3.591732239,5.408267761,5.408267761,5.408267761,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3906.0,3906.0,3906.0,3906.0,5.408267761048164,5.408267761048164,5.408267761048164,5.408267761048164,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2535766,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CCN1C(=O)N(c2ccc(F)c(C(F)(F)F)c2)C(=O)C1(C)C,C14H14F4N2O2,CHEMBL4799175,140.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,140.0,140.0,140.0,140.0,2.146128036,2.146128036,2.146128036,6.853871964,6.853871964,6.853871964,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2535830,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)(c1ccc(OCc2cnc(Cl)o2)cc1)c1cc(Cl)c(OCCCl)c(C#N)c1,C22H19Cl3N2O3,CHEMBL4799239,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2536020,nM,IC50,,BAO_0000190,IC50,2027527,Inhibition of wild-type androgen receptor in human LAPC4 cells assessed as inhibition of DHT-induced luciferase activity measured after 24 hrs by luciferase reporter assay,0,B,,CHEMBL4681685,10.1021/acs.jmedchem.6b01410,27933964,CHEMBL4680100,Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).,PUBLICATION,"The aryl hydantoin 1 (Ro 13-3978) was identified in the early 1980s as a promising antischistosomal lead compound. However, this series of aryl hydantoins produced antiandrogenic side effects in the host, a not unexpected outcome given their close structural similarity to the antiandrogenic drug nilutamide. Building on the known SAR of this compound series, we now describe a number of analogs of 1 designed to maximize structural diversity guided by incorporation of substructures and functional groups known to diminish ligand-androgen receptor interactions. These analogs had calculated polar surface area (PSA), measured LogD, aqueous kinetic solubility, and estimated plasma protein binding values in ranges predictive of good ADME profiles. The principal SAR insight was that the hydantoin core of 1 is required for high antischistosomal activity. We identified several compounds with high antischistosomal efficacy that were less antiandrogenic than 1. These data provide direction for the ongoing optimization of antischistosomal hydantoins.",,CC1(C)NC(=O)N(c2ccc(F)c(C#N)c2)C1=O,C12H10FN3O2,CHEMBL4799429,3700.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3700.0,3700.0,3700.0,3700.0,3.568201724,3.568201724,3.568201724,5.431798276,5.431798276,5.431798276,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3700.0,3700.0,3700.0,3700.0,5.431798275933005,5.431798275933005,5.431798275933005,5.431798275933005,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2536709,nM,IC50,,BAO_0000190,IC50,2075804,Modulation of AR in human LNCAP cells transfected with PSA reporter gene assessed as inhibition of R1881-induced PSA luciferase activity pretreated for 1 hr followed by R1881 addition and measured after 24 hrs by luciferase assay,0,B,,CHEMBL4731338,10.1021/acsmedchemlett.0c00452,33214809,CHEMBL4725453,Modulation of Androgen Receptor for Therapeutic Application in Cancer and Viral Infection.,PUBLICATION,"The current drug discovery paradigm has failed to address the treatment need for diseases of high priority to developing countries. Cutaneous leishmaniasis is a good example of such diseases with virtually no new effective drug developed in the past 70 years. The past two decades had witnessed relatively increased attention toward neglected diseases by stimulating pharmaceutical industries through introductions of Priority Review Vouchers (PRVs) and Product Development Partnerships (PDPs). However, the lion's share of resources allocated for research and development by PRVs and PDPs is directed toward research organizations and pharmaceutical industries in developed countries. This new approach has also not led to the development of drugs for most neglected diseases including cutaneous leishmaniasis. Improving the medical discovery capacity of countries where these diseases are prevalent and enabling exploration of the hitherto untapped natural resources are an effective and sustainable solution.",,CC(C)S(=O)(=O)c1nc(COc2ccc(C(C)(C)c3cc(Cl)c(OCCCl)c(C#N)c3)cc2)co1,C25H26Cl2N2O5S,CHEMBL4800118,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2536954,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@](O)(Cn1cc(F)cn1)C(=O)Nc1cc(C(F)(F)F)c(C#N)cc1I,C15H11F4IN4O2,CHEMBL4800363,5450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5450.0,5450.0,5450.0,5450.0,3.736396502,3.736396502,3.736396502,5.263603498,5.263603498,5.263603498,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5450.0,5450.0,5450.0,5450.0,5.2636034977233574,5.2636034977233574,5.2636034977233574,5.2636034977233574,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2537163,nM,IC50,,BAO_0000190,IC50,2022761,Antagonist activity at recombinant human AR expressed in HEK293 cells assessed as inhibition of R1881-induced transcriptional activity measured after 24 hrs by dual luciferase reporter gene assay,0,B,,CHEMBL4676574,10.1021/acs.jmedchem.0c00943,33095584,CHEMBL4673256,Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.",,C[C@@]1(Cn2cc(F)cn2)OC(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C1=O,C16H10F4N4O3,CHEMBL4800572,1131.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1131.0,1131.0,1131.0,1131.0,3.053462605,3.053462605,3.053462605,5.946537395,5.946537395,5.946537395,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1131.0,1131.0,1131.0,1131.0,5.946537395074545,5.946537395074545,5.946537395074545,5.946537395074545,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2539686,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc(F)c2[nH]cc(-c3ccc4ccccc4n3)c2c1,C17H10F2N2,CHEMBL4845915,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2540752,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1ccc2c(-c3ccc4ccccc4n3)c[nH]c2c1F,C18H13FN2,CHEMBL4846981,2170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2170.0,2170.0,2170.0,2170.0,3.336459734,3.336459734,3.336459734,5.663540266,5.663540266,5.663540266,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2170.0,2170.0,2170.0,2170.0,5.663540266151471,5.663540266151471,5.663540266151471,5.663540266151471,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2540853,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc2c(-c3ccc4c(-c5cncs5)cccc4n3)c[nH]c2c(F)c1F,C20H10F3N3S,CHEMBL4847082,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,70.0,70.0,70.0,70.0,1.84509804,1.84509804,1.84509804,7.15490196,7.15490196,7.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,70.0,70.0,70.0,70.0,7.154901959985743,7.154901959985743,7.154901959985743,7.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2542352,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2119486, Entry 1: 2227453, ","Entry 0: Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method, Entry 1: Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of PSA expression, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4828552, Entry 1: CHEMBL5140966, ","Entry 0: 10.1021/acs.jmedchem.1c00681, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 34661404, Entry 1: 35786895, ","Entry 0: CHEMBL4825767, Entry 1: CHEMBL5137058, ","Entry 0: Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC(C)NC(=O)c1cccc2nc(-c3cn(COP(=O)([O-])[O-])c4c(F)c(F)c(F)cc34)ccc12.[Na+].[Na+],C22H17F3N3Na2O5P,CHEMBL4848581,660.0,660.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,660.0,660.0,660.0,660.0,2.819543936,2.819543936,2.819543936,6.180456064,6.180456064,6.180456064,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,660.0,660.0,660.0,660.0,6.180456064458132,6.180456064458132,6.180456064458132,6.180456064458132,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2542773,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,O=C(NCC1CC1)c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12,C22H16F3N3O,CHEMBL4849002,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,180.0,180.0,180.0,180.0,2.255272505,2.255272505,2.255272505,6.744727495,6.744727495,6.744727495,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,180.0,180.0,180.0,180.0,6.7447274948966935,6.7447274948966935,6.7447274948966935,6.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2542794,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,O=C(NCC(F)F)c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12,C20H12F5N3O,CHEMBL4849023,40.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,40.0,40.0,40.0,40.0,1.602059991,1.602059991,1.602059991,7.397940009,7.397940009,7.397940009,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,40.0,40.0,40.0,40.0,7.3979400086720375,7.3979400086720375,7.3979400086720375,7.3979400086720375,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2544745,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1ccc2c(-c3ccc4ccccc4n3)c[nH]c2c1F,C17H10F2N2,CHEMBL4850974,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,190.0,190.0,190.0,190.0,2.278753601,2.278753601,2.278753601,6.721246399,6.721246399,6.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.0,190.0,190.0,190.0,6.721246399047171,6.721246399047171,6.721246399047171,6.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2546198,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(CN1CCOCC1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C16H18F3N3O3,CHEMBL4852427,1018.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1018.0,1018.0,1018.0,1018.0,3.007747778,3.007747778,3.007747778,5.992252222,5.992252222,5.992252222,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1018.0,1018.0,1018.0,1018.0,5.99225222199926,5.99225222199926,5.99225222199926,5.99225222199926,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2546313,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1c(F)ccc2c(-c3ccc4ccccc4n3)c[nH]c12,C18H13FN2,CHEMBL4852542,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,170.0,170.0,170.0,170.0,2.230448921,2.230448921,2.230448921,6.769551079,6.769551079,6.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2546473,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4ccc(Cl)cc4n3)c[nH]c12,C18H13ClN2,CHEMBL4852702,1650.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1650.0,1650.0,1650.0,1650.0,3.217483944,3.217483944,3.217483944,5.782516056,5.782516056,5.782516056,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1650.0,1650.0,1650.0,1650.0,5.782516055786093,5.782516055786093,5.782516055786093,5.782516055786093,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2546647,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc2c(-c3ccc4ccccc4n3)c[nH]c2c(F)c1F,C17H9F3N2,CHEMBL4852876,90.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,90.0,90.0,90.0,90.0,1.954242509,1.954242509,1.954242509,7.045757491,7.045757491,7.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,90.0,90.0,90.0,90.0,7.045757490560675,7.045757490560675,7.045757490560675,7.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2546721,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2110649, Entry 1: 2110650, ","Entry 0: Antagonist activity at AR in human LNCaP cells transfected with PSA assessed as inhibition of R1881-induced PSA luciferase activity pretreated with compound followed by R1881 addition and measured after 48 hrs by luciferase assay, Entry 1: Inhibition of R1881-stimulated AR transcription driven human LNCaP cells proliferation preincubated for 1 hr followed by R1881 addition and measured after 4 days by Alamar blue assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4819499, Entry 1: CHEMBL4819500, ","Entry 0: 10.1021/acs.jnatprod.0c00921, Entry 1: 10.1021/acs.jnatprod.0c00921, ","Entry 0: 33124806, Entry 1: 33124806, ","Entry 0: CHEMBL4818988, Entry 1: CHEMBL4818988, ","Entry 0: Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer., Entry 1: Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Synthetic analogues of the marine natural product sintokamides have been prepared in order to investigate the structure-activity relationships for the androgen receptor N-terminal domain (AR NTD) antagonist activity of the sintokamide scaffold. An <i>in vitro</i> LNCaP cell-based transcriptional activity assay with an androgen-driven luciferase (Luc) reporter was used to monitor the potency of analogues. The data have shown that the chlorine atoms on the leucine side chains are essential for potent activity. Analogues missing the nonchlorinated methyl groups of the leucine side chains (C-1 and C-17) are just as active and in some cases more active than the natural products. Analogues with the natural <i>R</i> configuration at C-10 and the unnatural <i>R</i> configuration at C-4 are most potent. Replacing the natural propionamide N-terminus cap with the more sterically hindered pivaloylamide N-terminus cap leads to enhanced potency. The tetramic acid fragment and the methyl ether on the tetramic acid fragment are essential for activity. The SAR optimized analogue <b>76</b> is more selective, easier to synthesize, more potent, and presumed to be more resistant to proteolysis than the natural sintokamides., Entry 1: Synthetic analogues of the marine natural product sintokamides have been prepared in order to investigate the structure-activity relationships for the androgen receptor N-terminal domain (AR NTD) antagonist activity of the sintokamide scaffold. An <i>in vitro</i> LNCaP cell-based transcriptional activity assay with an androgen-driven luciferase (Luc) reporter was used to monitor the potency of analogues. The data have shown that the chlorine atoms on the leucine side chains are essential for potent activity. Analogues missing the nonchlorinated methyl groups of the leucine side chains (C-1 and C-17) are just as active and in some cases more active than the natural products. Analogues with the natural <i>R</i> configuration at C-10 and the unnatural <i>R</i> configuration at C-4 are most potent. Replacing the natural propionamide N-terminus cap with the more sterically hindered pivaloylamide N-terminus cap leads to enhanced potency. The tetramic acid fragment and the methyl ether on the tetramic acid fragment are essential for activity. The SAR optimized analogue <b>76</b> is more selective, easier to synthesize, more potent, and presumed to be more resistant to proteolysis than the natural sintokamides., ",,CCC(=O)N[C@H](C[C@H](C)C(Cl)(Cl)Cl)C(=O)N1C(=O)C=C(OC)[C@@H]1C[C@H](C)C(Cl)Cl,C18H25Cl5N2O4,CHEMBL4852950,6500.0,14000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,3750.0,6500.0,10250.0,10250.0,14000.0,4.010723865,4.010723865,3.812913357,4.989276135,4.989276135,5.187086643,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6500.0,6500.0,6500.0,6500.0,5.187086643357144,5.187086643357144,5.187086643357144,5.187086643357144,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2546762,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc(Cl)cc2c(-c3ccc4ccccc4n3)c[nH]c12,C17H10ClFN2,CHEMBL4852991,130.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,130.0,130.0,130.0,130.0,2.113943352,2.113943352,2.113943352,6.886056648,6.886056648,6.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,130.0,130.0,130.0,130.0,6.886056647693163,6.886056647693163,6.886056647693163,6.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2547200,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1nncc1-c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N5O2,CHEMBL4853429,317.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,317.0,317.0,317.0,317.0,2.501059262,2.501059262,2.501059262,6.498940738,6.498940738,6.498940738,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,317.0,317.0,317.0,317.0,6.498940737782249,6.498940737782249,6.498940737782249,6.498940737782249,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2547916,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,CC(C)(C)NC(=O)c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12,C22H18F3N3O,CHEMBL4854145,740.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,740.0,740.0,740.0,740.0,2.86923172,2.86923172,2.86923172,6.13076828,6.13076828,6.13076828,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,740.0,740.0,740.0,740.0,6.130768280269024,6.130768280269024,6.130768280269024,6.130768280269024,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2549841,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1ccc2c(-c3ccc4ccccc4n3)c[nH]c2c1Cl,C17H10ClFN2,CHEMBL4856070,30.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30.0,30.0,30.0,30.0,1.477121255,1.477121255,1.477121255,7.522878745,7.522878745,7.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,30.0,30.0,30.0,30.0,7.522878745280337,7.522878745280337,7.522878745280337,7.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2550356,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4cccc(Cl)c4n3)c[nH]c12,C18H13ClN2,CHEMBL4856585,200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,200.0,200.0,200.0,200.0,2.301029996,2.301029996,2.301029996,6.698970004,6.698970004,6.698970004,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,200.0,200.0,200.0,200.0,6.698970004336019,6.698970004336019,6.698970004336019,6.698970004336019,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2550954,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4cccc(F)c4n3)c[nH]c12,C18H13FN2,CHEMBL4857183,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,100.0,100.0,100.0,100.0,2.0,2.0,2.0,7.0,7.0,7.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2551137,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1cncn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C14H12F3N5O2,CHEMBL4857366,1091.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1091.0,1091.0,1091.0,1091.0,3.037824751,3.037824751,3.037824751,5.962175249,5.962175249,5.962175249,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1091.0,1091.0,1091.0,1091.0,5.962175249411658,5.962175249411658,5.962175249411658,5.962175249411658,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2553885,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cc(Cl)c2[nH]cc(-c3ccc4ccccc4n3)c2c1,C18H13ClN2,CHEMBL4860114,1900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1900.0,1900.0,1900.0,1900.0,3.278753601,3.278753601,3.278753601,5.721246399,5.721246399,5.721246399,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1900.0,1900.0,1900.0,1900.0,5.721246399047171,5.721246399047171,5.721246399047171,5.721246399047171,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2555044,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1ccc(-c2ccc(F)cc2)c1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C22H17F4N3O2,CHEMBL4861273,226.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,226.0,226.0,226.0,226.0,2.354108439,2.354108439,2.354108439,6.645891561,6.645891561,6.645891561,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,226.0,226.0,226.0,226.0,6.645891560852599,6.645891560852599,6.645891560852599,6.645891560852599,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2555049,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1cc(-c2ccc(F)cc2)nn1)C(=O)Nc1cnc(C#N)c(C(F)(F)F)c1,C19H14F4N6O2,CHEMBL4861278,217.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,217.0,217.0,217.0,217.0,2.336459734,2.336459734,2.336459734,6.663540266,6.663540266,6.663540266,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,217.0,217.0,217.0,217.0,6.663540266151471,6.663540266151471,6.663540266151471,6.663540266151471,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2555143,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2110649, Entry 1: 2110650, ","Entry 0: Antagonist activity at AR in human LNCaP cells transfected with PSA assessed as inhibition of R1881-induced PSA luciferase activity pretreated with compound followed by R1881 addition and measured after 48 hrs by luciferase assay, Entry 1: Inhibition of R1881-stimulated AR transcription driven human LNCaP cells proliferation preincubated for 1 hr followed by R1881 addition and measured after 4 days by Alamar blue assay, ",0,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL4819499, Entry 1: CHEMBL4819500, ","Entry 0: 10.1021/acs.jnatprod.0c00921, Entry 1: 10.1021/acs.jnatprod.0c00921, ","Entry 0: 33124806, Entry 1: 33124806, ","Entry 0: CHEMBL4818988, Entry 1: CHEMBL4818988, ","Entry 0: Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer., Entry 1: Structure-Activity Relationships for the Marine Natural Product Sintokamides: Androgen Receptor N-Terminus Antagonists of Interest for Treatment of Metastatic Castration-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Synthetic analogues of the marine natural product sintokamides have been prepared in order to investigate the structure-activity relationships for the androgen receptor N-terminal domain (AR NTD) antagonist activity of the sintokamide scaffold. An <i>in vitro</i> LNCaP cell-based transcriptional activity assay with an androgen-driven luciferase (Luc) reporter was used to monitor the potency of analogues. The data have shown that the chlorine atoms on the leucine side chains are essential for potent activity. Analogues missing the nonchlorinated methyl groups of the leucine side chains (C-1 and C-17) are just as active and in some cases more active than the natural products. Analogues with the natural <i>R</i> configuration at C-10 and the unnatural <i>R</i> configuration at C-4 are most potent. Replacing the natural propionamide N-terminus cap with the more sterically hindered pivaloylamide N-terminus cap leads to enhanced potency. The tetramic acid fragment and the methyl ether on the tetramic acid fragment are essential for activity. The SAR optimized analogue <b>76</b> is more selective, easier to synthesize, more potent, and presumed to be more resistant to proteolysis than the natural sintokamides., Entry 1: Synthetic analogues of the marine natural product sintokamides have been prepared in order to investigate the structure-activity relationships for the androgen receptor N-terminal domain (AR NTD) antagonist activity of the sintokamide scaffold. An <i>in vitro</i> LNCaP cell-based transcriptional activity assay with an androgen-driven luciferase (Luc) reporter was used to monitor the potency of analogues. The data have shown that the chlorine atoms on the leucine side chains are essential for potent activity. Analogues missing the nonchlorinated methyl groups of the leucine side chains (C-1 and C-17) are just as active and in some cases more active than the natural products. Analogues with the natural <i>R</i> configuration at C-10 and the unnatural <i>R</i> configuration at C-4 are most potent. Replacing the natural propionamide N-terminus cap with the more sterically hindered pivaloylamide N-terminus cap leads to enhanced potency. The tetramic acid fragment and the methyl ether on the tetramic acid fragment are essential for activity. The SAR optimized analogue <b>76</b> is more selective, easier to synthesize, more potent, and presumed to be more resistant to proteolysis than the natural sintokamides., ",,COC1=CC(=O)N(C(=O)[C@@H](CCC(Cl)(Cl)Cl)NC(=O)C(C)(C)C)[C@@H]1CCC(Cl)(Cl)Cl,C18H24Cl6N2O4,CHEMBL4861372,10000.0,12000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,10000.0,11000.0,11000.0,12000.0,4.041392685,4.041392685,4.0,4.958607315,4.958607315,5.0,2,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2556635,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1cnc(C(F)(F)F)n1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H11F6N5O2,CHEMBL4862864,1013.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1013.0,1013.0,1013.0,1013.0,3.005609445,3.005609445,3.005609445,5.994390555,5.994390555,5.994390555,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1013.0,1013.0,1013.0,1013.0,5.994390554639719,5.994390554639719,5.994390554639719,5.994390554639719,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2558638,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4ccc(F)cc4n3)c[nH]c12,C18H13FN2,CHEMBL4864867,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2559636,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, Entry 5: BAO_0000190, ",IC50,"Entry 0: 2111612, Entry 1: 2111616, Entry 2: 2111624, Entry 3: 2111625, Entry 4: 2127795, Entry 5: 2127796, ","Entry 0: Displacement of [3H]methyltrienolone from wild-type androgen receptor in human LNCaP cells incubated for 24 hrs by scintillation counting analysis, Entry 1: Antagonist activity at VP16-AR wild-type (unknown origin) transfected in human HepG2 cells cotransfected with ARE-LUC incubated for 48 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay, Entry 2: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay, Entry 3: Antagonist activity at AR wild-type (unknown origin) transfected in human LNCAP cells cotransfected with ARE-LUC incubated for 20 to 24 hrs in presence of AR agonist R1881 by steady-glo luciferase reporter gene assay, Entry 4: Antagonist activity at AR F877L mutant (unknown origin) transfected in human LNCAP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay, Entry 5: Antagonist activity at wild type androgen receptor in castration-resistant human LNCaP cells assessed as inhibition of R1881-stimulated receptor transcriptional activation measured after 20 to 24 hrs by Steady-Glo luciferase assay, ","1,3,5","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, Entry 5: B, ",,"Entry 0: CHEMBL4820462, Entry 1: CHEMBL4820466, Entry 2: CHEMBL4820474, Entry 3: CHEMBL4820475, Entry 4: CHEMBL4837140, Entry 5: CHEMBL4837141, ","Entry 0: 10.1021/acs.jmedchem.0c01563, Entry 1: 10.1021/acs.jmedchem.0c01563, Entry 2: 10.1021/acs.jmedchem.0c01563, Entry 3: 10.1021/acs.jmedchem.0c01563, Entry 4: 10.1021/acsmedchemlett.1c00032, Entry 5: 10.1021/acsmedchemlett.1c00032, ","Entry 0: 33470111, Entry 1: 33470111, Entry 2: 33470111, Entry 3: 33470111, Entry 4: 34422225, Entry 5: 34422225, ","Entry 0: CHEMBL4819022, Entry 1: CHEMBL4819022, Entry 2: CHEMBL4819022, Entry 3: CHEMBL4819022, Entry 4: CHEMBL4834497, Entry 5: CHEMBL4834497, ","Entry 0: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 1: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 2: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 3: Discovery of JNJ-63576253: A Clinical Stage Androgen Receptor Antagonist for F877L Mutant and Wild-Type Castration-Resistant Prostate Cancer (mCRPC)., Entry 4: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., Entry 5: Spirocyclic Thiohydantoin Antagonists of F877L and Wild-Type Androgen Receptor for Castration-Resistant Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, Entry 5: PUBLICATION, ","Entry 0: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 1: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 2: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 3: Persistent androgen receptor (AR) activation drives therapeutic resistance to second-generation AR pathway inhibitors and contributes to the progression of advanced prostate cancer. One resistance mechanism is point mutations in the ligand binding domain of AR that can transform antagonists into agonists. The AR F877L mutation, identified in patients treated with enzalutamide or apalutamide, confers resistance to both enzalutamide and apalutamide. Compound <b>4</b> (JNJ-pan-AR) was identified as a pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. Metabolite identification studies revealed a latent bioactivation pathway associated with <b>4</b>. Subsequent lead optimization of <b>4</b> led to amelioration of this pathway and nomination of <b>5</b> (JNJ-63576253) as a clinical stage, next-generation AR antagonist for the treatment of castration-resistant prostate cancer (CRPC)., Entry 4: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., Entry 5: Androgen receptor (AR) transcriptional reactivation plays a key role in the development and progression of lethal castration-resistant prostate cancer (CRPC). Recurrent alterations in the AR enable persistent AR pathway signaling and drive resistance to the treatment of second-generation antiandrogens. AR F877L, a point mutation in the ligand binding domain of the AR, was identified in patients who acquired resistance to enzalutamide or apalutamide. In parallel to our previous structure-activity relationship (SAR) studies of compound <b>4</b> (JNJ-pan-AR) and clinical stage compound <b>5</b> (JNJ-63576253), we discovered additional AR antagonists that provide opportunities for future development. Here we report a highly potent series of spirocyclic thiohydantoins as AR antagonists for the treatment of the F877L mutant and wild-type CRPC., ",,CN1CCC(Oc2ccc(N3C(=S)N(c4cnc(C#N)c(C(F)(F)F)c4)C(=O)C34CCC4)cc2)CC1,C25H24F3N5O2S,CHEMBL4865865,19.0,98.0,98.0,127.0,191.0,191.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,59.57814663,19.0,120.6666667,112.5,191.0,2.081587316,2.051152522,1.278753601,6.918412684,6.948847478,7.721246399,6,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,138.66666666666666,127.0,98.0,191.0,6.858027924092919,6.896196279044043,7.008773924307505,6.718966632752273,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2562272,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1cc(-c2ccc(F)cc2)nn1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C20H15F4N5O2,CHEMBL4868501,383.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,383.0,383.0,383.0,383.0,2.583198774,2.583198774,2.583198774,6.416801226,6.416801226,6.416801226,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,383.0,383.0,383.0,383.0,6.416801226031377,6.416801226031377,6.416801226031377,6.416801226031377,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2562535,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4c(C(F)(F)F)cccc4n3)c[nH]c12,C19H13F3N2,CHEMBL4868764,240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,240.0,240.0,240.0,240.0,2.380211242,2.380211242,2.380211242,6.619788758,6.619788758,6.619788758,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,240.0,240.0,240.0,240.0,6.619788758288394,6.619788758288394,6.619788758288394,6.619788758288394,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2562715,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,CNC(=O)c1cccc2nc(-c3c[nH]c4c(C)cccc34)ccc12,C20H17N3O,CHEMBL4868944,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,230.0,230.0,230.0,230.0,2.361727836,2.361727836,2.361727836,6.638272164,6.638272164,6.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,230.0,230.0,230.0,230.0,6.638272163982407,6.638272163982407,6.638272163982407,6.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2563162,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2ccc(-c3c[nH]c4c(C)cccc34)nc12,C19H16N2,CHEMBL4869391,180.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,180.0,180.0,180.0,180.0,2.255272505,2.255272505,2.255272505,6.744727495,6.744727495,6.744727495,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,180.0,180.0,180.0,180.0,6.7447274948966935,6.7447274948966935,6.7447274948966935,6.7447274948966935,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2563909,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc(Cl)c2[nH]cc(-c3ccc4ccccc4n3)c2c1,C17H10ClFN2,CHEMBL4870138,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,100.0,100.0,100.0,100.0,2.0,2.0,2.0,7.0,7.0,7.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2564160,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4ccccc4n3)c[nH]c12,C18H14N2,CHEMBL4870389,60.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,60.0,60.0,60.0,60.0,1.77815125,1.77815125,1.77815125,7.22184875,7.22184875,7.22184875,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,60.0,60.0,60.0,60.0,7.221848749616356,7.221848749616356,7.221848749616356,7.221848749616356,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2564384,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1cncc1Br)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C15H12BrF3N4O2,CHEMBL4870613,1019.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1019.0,1019.0,1019.0,1019.0,3.008174184,3.008174184,3.008174184,5.991825816,5.991825816,5.991825816,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1019.0,1019.0,1019.0,1019.0,5.991825815993574,5.991825815993574,5.991825815993574,5.991825815993574,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2564432,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,OC(c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12)C(F)(F)F,C19H10F6N2O,CHEMBL4870661,32000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,32000.0,32000.0,32000.0,32000.0,4.505149978,4.505149978,4.505149978,4.494850022,4.494850022,4.494850022,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,32000.0,32000.0,32000.0,32000.0,4.494850021680094,4.494850021680094,4.494850021680094,4.494850021680094,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2565220,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc2c(-c3ccc4c(C(F)(F)F)cccc4n3)c[nH]c2c(F)c1F,C18H8F6N2,CHEMBL4871449,550.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,550.0,550.0,550.0,550.0,2.740362689,2.740362689,2.740362689,6.259637311,6.259637311,6.259637311,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,550.0,550.0,550.0,550.0,6.259637310505756,6.259637310505756,6.259637310505756,6.259637310505756,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2565511,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cccc2c(-c3ccc4cccc(Br)c4n3)c[nH]c12,C18H13BrN2,CHEMBL4871740,160.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,160.0,160.0,160.0,160.0,2.204119983,2.204119983,2.204119983,6.795880017,6.795880017,6.795880017,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,160.0,160.0,160.0,160.0,6.795880017344075,6.795880017344075,6.795880017344075,6.795880017344075,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2566304,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,O=C(NC1CC1)c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12,C21H14F3N3O,CHEMBL4872533,70.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,70.0,70.0,70.0,70.0,1.84509804,1.84509804,1.84509804,7.15490196,7.15490196,7.15490196,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,70.0,70.0,70.0,70.0,7.154901959985743,7.154901959985743,7.154901959985743,7.154901959985743,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2569041,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(Cn1ccnc1)C(=O)Nc1ccc(C#N)c(Cl)c1,C14H13ClN4O2,CHEMBL4875270,1856.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1856.0,1856.0,1856.0,1856.0,3.268577972,3.268577972,3.268577972,5.731422028,5.731422028,5.731422028,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1856.0,1856.0,1856.0,1856.0,5.731422028117157,5.731422028117157,5.731422028117157,5.731422028117157,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2569505,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Clc1cccc2c(-c3ccc4ccccc4n3)c[nH]c12,C17H11ClN2,CHEMBL4875734,100.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,100.0,100.0,100.0,100.0,2.0,2.0,2.0,7.0,7.0,7.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2569680,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Fc1cc2c(-c3ccc4c(-c5nccs5)cccc4n3)c[nH]c2c(F)c1F,C20H10F3N3S,CHEMBL4875909,500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,500.0,500.0,500.0,500.0,2.698970004,2.698970004,2.698970004,6.301029996,6.301029996,6.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,500.0,500.0,500.0,500.0,6.301029995663981,6.301029995663981,6.301029995663981,6.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2570029,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,CNC(=O)c1cccc2nc(-c3c[nH]c4c(F)c(F)c(F)cc34)ccc12,C19H12F3N3O,CHEMBL4876258,110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,110.0,110.0,110.0,110.0,2.041392685,2.041392685,2.041392685,6.958607315,6.958607315,6.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2570238,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Clc1cc(Cl)c2[nH]cc(-c3ccc4ccccc4n3)c2c1,C17H10Cl2N2,CHEMBL4876467,1500.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1500.0,1500.0,1500.0,1500.0,3.176091259,3.176091259,3.176091259,5.823908741,5.823908741,5.823908741,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1500.0,1500.0,1500.0,1500.0,5.823908740944319,5.823908740944319,5.823908740944319,5.823908740944319,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2570875,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cc(F)cc2c(-c3ccc4ccccc4n3)c[nH]c12,C18H13FN2,CHEMBL4877104,230.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,230.0,230.0,230.0,230.0,2.361727836,2.361727836,2.361727836,6.638272164,6.638272164,6.638272164,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,230.0,230.0,230.0,230.0,6.638272163982407,6.638272163982407,6.638272163982407,6.638272163982407,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2571008,nM,IC50,,BAO_0000190,IC50,2119486,Antagonist activity at androgen receptor in human LNCaP cells harboring eGFP/ARRIPB incubated for 3 days by fluorescence method,0,B,,CHEMBL4828552,10.1021/acs.jmedchem.1c00681,34661404,CHEMBL4825767,"Development of 2-(5,6,7-Trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer.",PUBLICATION,"Prostate cancer (PCa) patients undergoing androgen deprivation therapy almost invariably develop castration-resistant prostate cancer (CRPC). Targeting the androgen receptor (AR) Binding Function-3 (BF3) site offers a promising option to treat CRPC. However, BF3 inhibitors have been limited by poor potency or inadequate metabolic stability. Through extensive medicinal chemistry, molecular modeling, and biochemistry, we identified 2-(5,6,7-trifluoro-1<i>H</i>-Indol-3-yl)-quinoline-5-carboxamide (VPC-13789), a potent AR BF3 antagonist with markedly improved pharmacokinetic properties. We demonstrate that VPC-13789 suppresses AR-mediated transcription, chromatin binding, and recruitment of coregulatory proteins. This novel AR antagonist selectively reduces the growth of both androgen-dependent and enzalutamide-resistant PCa cell lines. Having demonstrated <i>in vitro</i> efficacy, we developed an orally bioavailable prodrug that reduced PSA production and tumor volume in animal models of CRPC with no observed toxicity. VPC-13789 is a potent, selective, and orally bioavailable antiandrogen with a distinct mode of action that has a potential as novel CRPC therapeutics.",,Cc1cc(C)c2[nH]cc(-c3ccc4ccccc4n3)c2c1,C19H16N2,CHEMBL4877237,1590.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1590.0,1590.0,1590.0,1590.0,3.201397124,3.201397124,3.201397124,5.798602876,5.798602876,5.798602876,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1590.0,1590.0,1590.0,1590.0,5.798602875679548,5.798602875679548,5.798602875679548,5.798602875679548,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2571011,nM,IC50,,BAO_0000190,IC50,2101892,Antagonist activity at human androgen receptor expressed in HEK-293 cells harboring GRE-LUC and CMV-renilla luciferase assessed as inhibition of transactivation incubated for 24 hrs in presence of R1881 by dual luciferase assay,0,B,,CHEMBL4810288,10.1021/acs.jmedchem.1c00439,34269581,CHEMBL4808211,Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate Cancer.,PUBLICATION,"A series of propanamide derivatives were designed, synthesized, and pharmacologically characterized as selective androgen receptor degraders (SARDs) and pan-antagonists that exert a broad-scope androgen receptor (AR) antagonism. Incorporating different basic heteromonocyclic B-ring structural elements in the common A-ring-linkage-B-ring nonsteroidal antiandrogen general pharmacophore contributed to a novel scaffold of small molecules with SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-69 (<b>11</b>), UT-155 (<b>12</b>), and UT-34 (<b>13</b>). Compound <b>26f</b> exhibited inhibitory and degradation effects in vitro in a wide array of wtAR, point mutant, and truncation mutant-driven prostate cancers (PCs). Further, <b>26f</b> inhibited tumor cell growth in a xenograft model composed of enzalutamide-resistant (EnzR) LNCaP cells. These results demonstrate an advancement toward the development of novel SARDs and pan-antagonists with efficacy against EnzR prostate cancers.",,C[C@](O)(CN(c1ccccc1)c1ccc(F)cc1)C(=O)Nc1ccc(C#N)c(C(F)(F)F)c1,C24H19F4N3O2,CHEMBL4877240,172.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,172.0,172.0,172.0,172.0,2.235528447,2.235528447,2.235528447,6.764471553,6.764471553,6.764471553,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,172.0,172.0,172.0,172.0,6.764471553092451,6.764471553092451,6.764471553092451,6.764471553092451,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2714048,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cc1cccc(C(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c1,C18H12F3NO3,CHEMBL5069607,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2714313,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Oc1ccc2c(C(F)(F)F)cc(=O)oc2c1)C1CCCCC1,C17H15F3O4,CHEMBL5069872,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2715926,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Oc1ccccc1/C=N/c1ccc2oc(-c3ccccc3)nc2c1,C20H14N2O2,CHEMBL5071469,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2716139,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3c(F)cccc3Cl)cc2o1,C17H9ClF4O3,CHEMBL5071682,780.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,780.0,780.0,780.0,780.0,2.892094603,2.892094603,2.892094603,6.107905397,6.107905397,6.107905397,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,780.0,780.0,780.0,780.0,6.107905397309519,6.107905397309519,6.107905397309519,6.107905397309519,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2716369,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,COC(=O)c1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C19H13F3O5,CHEMBL5071912,30740.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,30740.0,30740.0,30740.0,30740.0,4.487703863,4.487703863,4.487703863,4.512296137,4.512296137,4.512296137,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,30740.0,30740.0,30740.0,30740.0,4.512296136836274,4.512296136836274,4.512296136836274,4.512296136836274,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2718454,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,N#Cc1ccc(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C20H16N2O3S,CHEMBL5074003,2250.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2250.0,2250.0,2250.0,2250.0,3.352182518,3.352182518,3.352182518,5.647817482,5.647817482,5.647817482,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2250.0,2250.0,2250.0,2250.0,5.647817481888637,5.647817481888637,5.647817481888637,5.647817481888637,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2718626,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1ccccc1,C19H17NO3S,CHEMBL5074175,110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,110.0,110.0,110.0,110.0,2.041392685,2.041392685,2.041392685,6.958607315,6.958607315,6.958607315,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,110.0,110.0,110.0,110.0,6.958607314841775,6.958607314841775,6.958607314841775,6.958607314841775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2718769,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CC(=O)N1c2cc(S(=O)(=O)Nc3ccc(OCc4ccccc4)cc3)c(Br)cc2CC1C,C24H23BrN2O4S,CHEMBL5074318,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2718836,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,C[C@H](Oc1cc(Cl)ccc1Cl)C(=O)Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1,C19H12Cl2F3NO4,CHEMBL5074385,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2719218,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1ccc(Br)cc1,C19H16BrNO3S,CHEMBL5074767,1550.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1550.0,1550.0,1550.0,1550.0,3.190331698,3.190331698,3.190331698,5.809668302,5.809668302,5.809668302,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1550.0,1550.0,1550.0,1550.0,5.809668301829708,5.809668301829708,5.809668301829708,5.809668301829708,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2719691,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1ccc(F)cc1,C19H16FNO3S,CHEMBL5075240,2270.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2270.0,2270.0,2270.0,2270.0,3.356025857,3.356025857,3.356025857,5.643974143,5.643974143,5.643974143,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2270.0,2270.0,2270.0,2270.0,5.6439741428068775,5.6439741428068775,5.6439741428068775,5.6439741428068775,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2720031,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CCCCS(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C17H21NO3S,CHEMBL5075580,7050.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7050.0,7050.0,7050.0,7050.0,3.848189117,3.848189117,3.848189117,5.151810883,5.151810883,5.151810883,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7050.0,7050.0,7050.0,7050.0,5.151810883008602,5.151810883008602,5.151810883008602,5.151810883008602,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2720400,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(c1ccccc1)c1ccc(/N=C/c2ccccc2O)cc1,C20H15NO2,CHEMBL5075949,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2720622,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CC1NC(=O)NC(=O)C1S(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C18H19N3O5S,CHEMBL5076171,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2720703,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc([N+](=O)[O-])cc3)cc2o1,C17H10F3NO5,CHEMBL5076252,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2721069,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,CCOC(=O)C(CC)Oc1ccc2c(C(F)(F)F)cc(=O)oc2c1,C16H15F3O5,CHEMBL5076618,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2721298,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Oc1ccccc1/C=N/c1ccc(Cl)c(Cl)c1,C13H9Cl2NO,CHEMBL5076847,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2721324,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3Cl)cc2o1,C17H10ClF3O3,CHEMBL5076873,410.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,410.0,410.0,410.0,410.0,2.612783857,2.612783857,2.612783857,6.387216143,6.387216143,6.387216143,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,410.0,410.0,410.0,410.0,6.3872161432802645,6.3872161432802645,6.3872161432802645,6.3872161432802645,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2721855,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=[N+]([O-])c1ccccc1S(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C19H16N2O5S,CHEMBL5077404,4160.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4160.0,4160.0,4160.0,4160.0,3.619093331,3.619093331,3.619093331,5.380906669,5.380906669,5.380906669,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4160.0,4160.0,4160.0,4160.0,5.380906669373258,5.380906669373258,5.380906669373258,5.380906669373258,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2721994,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=[N+]([O-])c1cccc(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)c1,C19H16N2O5S,CHEMBL5077543,1590.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1590.0,1590.0,1590.0,1590.0,3.201397124,3.201397124,3.201397124,5.798602876,5.798602876,5.798602876,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1590.0,1590.0,1590.0,1590.0,5.798602875679548,5.798602875679548,5.798602875679548,5.798602875679548,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2722088,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3cc4c(cc3Cl)OCO4)cc2o1,C18H10ClF3O5,CHEMBL5077637,1470.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1470.0,1470.0,1470.0,1470.0,3.167317335,3.167317335,3.167317335,5.832682665,5.832682665,5.832682665,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1470.0,1470.0,1470.0,1470.0,5.8326826652518236,5.8326826652518236,5.8326826652518236,5.8326826652518236,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2722111,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Cc1ccc(Cl)cc1)Nc1ccc(OCc2ccccc2)cc1,C20H18ClNO3S,CHEMBL5077660,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2723169,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,Cc1ccc(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C20H19NO3S,CHEMBL5078718,11520.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,11520.0,11520.0,11520.0,11520.0,4.061452479,4.061452479,4.061452479,4.938547521,4.938547521,4.938547521,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,11520.0,11520.0,11520.0,11520.0,4.938547520912807,4.938547520912807,4.938547520912807,4.938547520912807,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2723227,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1)c1ccccc1Cl,C17H9ClF3NO3,CHEMBL5078776,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2723348,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,Cc1cc(C)c(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)c(C)c1,C22H23NO3S,CHEMBL5078897,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2723389,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc(OC(F)(F)F)cc3)cc2o1,C18H10F6O4,CHEMBL5078938,25060.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25060.0,25060.0,25060.0,25060.0,4.398981067,4.398981067,4.398981067,4.601018933,4.601018933,4.601018933,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25060.0,25060.0,25060.0,25060.0,4.6010189333418685,4.6010189333418685,4.6010189333418685,4.6010189333418685,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2723651,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cc1cccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c1,C18H13F3O3,CHEMBL5079200,1400.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1400.0,1400.0,1400.0,1400.0,3.146128036,3.146128036,3.146128036,5.853871964,5.853871964,5.853871964,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1400.0,1400.0,1400.0,1400.0,5.853871964321762,5.853871964321762,5.853871964321762,5.853871964321762,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2724149,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc(C(F)(F)F)cc3)cc2o1,C18H10F6O3,CHEMBL5079698,890.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,890.0,890.0,890.0,890.0,2.949390007,2.949390007,2.949390007,6.050609993,6.050609993,6.050609993,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,890.0,890.0,890.0,890.0,6.050609993355088,6.050609993355088,6.050609993355088,6.050609993355088,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2724278,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cc1ccc(OC(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c(C)c1,C19H14F3NO4,CHEMBL5079827,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2724344,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1)c1ccccc1F,C17H9F4NO3,CHEMBL5079893,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2725675,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=[N+]([O-])c1ccc(CS(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C20H18N2O5S,CHEMBL5081224,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2726033,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1ccc(C(F)(F)F)cc1,C20H16F3NO3S,CHEMBL5081582,1770.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1770.0,1770.0,1770.0,1770.0,3.247973266,3.247973266,3.247973266,5.752026734,5.752026734,5.752026734,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1770.0,1770.0,1770.0,1770.0,5.752026733638194,5.752026733638194,5.752026733638194,5.752026733638194,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2726081,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 2172739, Entry 1: 2172740, Entry 2: 2172741, ","Entry 0: Binding affinity to GST-tagged AR ligand binding domain (unknown origin) measured after 4 hrs by fluorescence polarization assay, Entry 1: Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay, Entry 2: Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP assessed as decrease in PSA level, ","1,2","Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL5057873, Entry 1: CHEMBL5057874, Entry 2: CHEMBL5057875, ","Entry 0: 10.1021/acs.jmedchem.1c01287, Entry 1: 10.1021/acs.jmedchem.1c01287, Entry 2: 10.1021/acs.jmedchem.1c01287, ","Entry 0: 34809430, Entry 1: 34809430, Entry 2: 34809430, ","Entry 0: CHEMBL5055679, Entry 1: CHEMBL5055679, Entry 2: CHEMBL5055679, ","Entry 0: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., Entry 1: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., Entry 2: Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., Entry 1: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., Entry 2: Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists., ",,O=c1cc(C(F)(F)F)c2ccc(/N=C/c3ccccc3O)cc2o1,C17H10F3NO3,CHEMBL5081630,1660.0,3710.0,5570.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,1596.8789,1660.0,3646.666667,3710.0,5570.0,3.561896067,3.56937391,3.220108088,5.438103933,5.43062609,5.779891912,3,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,4640.0,4640.0,3710.0,5570.0,5.333482019445119,5.333482019445119,5.430626090384954,5.254144804826271,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2727003,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CC(C)CS(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C17H21NO3S,CHEMBL5082552,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2727413,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc(F)cc3)cc2o1,C17H10F4O3,CHEMBL5082962,470.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,470.0,470.0,470.0,470.0,2.672097858,2.672097858,2.672097858,6.327902142,6.327902142,6.327902142,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,470.0,470.0,470.0,470.0,6.327902142064283,6.327902142064283,6.327902142064283,6.327902142064283,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2727853,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,CC(=O)c1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C19H13F3O4,CHEMBL5083402,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2727862,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1)c1nc2ncccn2n1,C16H8F3N5O3,CHEMBL5083411,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2728337,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccncc3)cc2o1,C16H10F3NO3,CHEMBL5083886,1900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1900.0,1900.0,1900.0,1900.0,3.278753601,3.278753601,3.278753601,5.721246399,5.721246399,5.721246399,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1900.0,1900.0,1900.0,1900.0,5.721246399047171,5.721246399047171,5.721246399047171,5.721246399047171,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2728577,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3cccc(Br)c3)cc2o1,C17H10BrF3O3,CHEMBL5084126,2280.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2280.0,2280.0,2280.0,2280.0,3.357934847,3.357934847,3.357934847,5.642065153,5.642065153,5.642065153,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2280.0,2280.0,2280.0,2280.0,5.642065152999546,5.642065152999546,5.642065152999546,5.642065152999546,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2729090,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cn1cc(C(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c(I)n1,C15H9F3IN3O3,CHEMBL5084639,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2729101,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cc1ccc(/N=C/c2ccccc2O)cc1Br,C14H12BrNO,CHEMBL5084650,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2729123,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CC(=O)Nc1ccc(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C21H20N2O4S,CHEMBL5084672,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2729517,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2160327, Entry 1: 2160328, ","Entry 0: Antagonist activity at human AR AF2 assessed as inhibition of fluorescent-labelled D11-FxxLF peptide Co-activator to receptor by TR-FRET assay, Entry 1: Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL5045077, Entry 1: CHEMBL5045078, ","Entry 0: 10.1021/acs.jmedchem.1c01938, Entry 1: 10.1021/acs.jmedchem.1c01938, ","Entry 0: 35077161, Entry 1: 35077161, ","Entry 0: CHEMBL5042532, Entry 1: CHEMBL5042532, ","Entry 0: Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2., Entry 1: Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment., Entry 1: Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment., ",,CN(C)S(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C15H18N2O3S,CHEMBL5085066,470.0,18050.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,8790.0,470.0,9260.0,9260.0,18050.0,3.966610987,3.966610987,2.672097858,5.033389013,5.033389013,6.327902142,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,18050.0,18050.0,18050.0,18050.0,4.7435227937583235,4.7435227937583235,4.7435227937583235,4.7435227937583235,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2729601,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1)c1ccccc1,C17H10F3NO3,CHEMBL5085150,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2729663,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1ccc(Cl)cc1,C19H16ClNO3S,CHEMBL5085212,5020.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5020.0,5020.0,5020.0,5020.0,3.700703717,3.700703717,3.700703717,5.299296283,5.299296283,5.299296283,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5020.0,5020.0,5020.0,5020.0,5.29929628285498,5.29929628285498,5.29929628285498,5.29929628285498,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2730773,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cn1cc(C(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cn1,C15H10F3N3O3,CHEMBL5086322,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2731054,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CCS(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C15H17NO3S,CHEMBL5086603,7900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,7900.0,7900.0,7900.0,7900.0,3.897627091,3.897627091,3.897627091,5.102372909,5.102372909,5.102372909,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,7900.0,7900.0,7900.0,7900.0,5.102372908709558,5.102372908709558,5.102372908709558,5.102372908709558,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2731826,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,COC(=O)C(CC(C)C)Oc1ccc2c(C(F)(F)F)cc(=O)oc2c1,C17H17F3O5,CHEMBL5087375,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2731939,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cc1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C18H13F3O3,CHEMBL5087488,610.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,610.0,610.0,610.0,610.0,2.785329835,2.785329835,2.785329835,6.214670165,6.214670165,6.214670165,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,610.0,610.0,610.0,610.0,6.214670164989233,6.214670164989233,6.214670164989233,6.214670164989233,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2731990,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CCOC(=O)c1cn[nH]c1S(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C19H19N3O5S,CHEMBL5087539,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2732241,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc(-c4ccccc4)cc3)cc2o1,C23H15F3O3,CHEMBL5087790,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2732427,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc(Cl)cc3)cc2o1,C17H10ClF3O3,CHEMBL5087976,1040.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1040.0,1040.0,1040.0,1040.0,3.017033339,3.017033339,3.017033339,5.982966661,5.982966661,5.982966661,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1040.0,1040.0,1040.0,1040.0,5.982966660701219,5.982966660701219,5.982966660701219,5.982966660701219,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2732934,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,COc1ccc([N+](=O)[O-])cc1COc1ccc2c(C(F)(F)F)cc(=O)oc2c1,C18H12F3NO6,CHEMBL5088483,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2732993,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,COC(=O)c1sccc1S(=O)(=O)Nc1ccc(OCc2ccccc2)cc1,C19H17NO5S2,CHEMBL5088542,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2733086,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3Br)cc2o1,C17H10BrF3O3,CHEMBL5088635,940.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,940.0,940.0,940.0,940.0,2.973127854,2.973127854,2.973127854,6.026872146,6.026872146,6.026872146,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,940.0,940.0,940.0,940.0,6.026872146400302,6.026872146400302,6.026872146400302,6.026872146400302,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2733261,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,CC(=O)c1ccc(S(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C21H19NO4S,CHEMBL5088810,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2733446,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=C(Nc1ccc2c(C(F)(F)F)cc(=O)oc2c1)c1cccc(Cl)c1,C17H9ClF3NO3,CHEMBL5088995,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2733983,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,CCn1cc(C(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c(C)n1,C17H14F3N3O3,CHEMBL5089532,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2734571,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,Cn1c(=O)n(C)c2cc(S(=O)(=O)Nc3ccc(OCc4ccccc4)cc3)ccc21,C22H21N3O4S,CHEMBL5090120,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2735118,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Nc1ccc(OCc2ccccc2)cc1)c1cc(Cl)ccc1Cl,C19H15Cl2NO3S,CHEMBL5090667,3370.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,3370.0,3370.0,3370.0,3370.0,3.527629901,3.527629901,3.527629901,5.472370099,5.472370099,5.472370099,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,3370.0,3370.0,3370.0,3370.0,5.4723700991286615,5.4723700991286615,5.4723700991286615,5.4723700991286615,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2735136,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,O=S(=O)(Cc1ccccc1)Nc1ccc(OCc2ccccc2)cc1,C20H19NO3S,CHEMBL5090685,5730.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5730.0,5730.0,5730.0,5730.0,3.758154622,3.758154622,3.758154622,5.241845378,5.241845378,5.241845378,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5730.0,5730.0,5730.0,5730.0,5.24184537803261,5.24184537803261,5.24184537803261,5.24184537803261,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2735619,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,CC(C)c1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C20H17F3O3,CHEMBL5091168,9260.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9260.0,9260.0,9260.0,9260.0,3.966610987,3.966610987,3.966610987,5.033389013,5.033389013,5.033389013,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9260.0,9260.0,9260.0,9260.0,5.033389013318065,5.033389013318065,5.033389013318065,5.033389013318065,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2736135,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,NC(=O)c1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C18H12F3NO4,CHEMBL5091684,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2736158,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccn3)cc2o1,C16H10F3NO3,CHEMBL5091707,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2736223,nM,IC50,,BAO_0000190,IC50,2160328,Antagonist activity against human androgen receptor expressed in human LNCap cells trasfected with ARR2PB-eGFP cells incubated for 3 days by fluorescence based AR transcription assay,0,B,,CHEMBL5045078,10.1021/acs.jmedchem.1c01938,35077161,CHEMBL5042532,Discovery of <i>N</i>-(4-(Benzyloxy)-phenyl)-sulfonamide Derivatives as Novel Antagonists of the Human Androgen Receptor Targeting the Activation Function 2.,PUBLICATION,"Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of <i>N</i>-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC<sub>50</sub> = 0.47 M) and peptide displacement activity (IC<sub>50</sub> = 18.05 M). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.",,COc1ccc(CS(=O)(=O)Nc2ccc(OCc3ccccc3)cc2)cc1,C21H21NO4S,CHEMBL5091772,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2736546,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3cccnc3)cc2o1,C16H10F3NO3,CHEMBL5092095,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2738181,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3F)cc2o1,C17H10F4O3,CHEMBL5093730,920.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,920.0,920.0,920.0,920.0,2.963787827,2.963787827,2.963787827,6.036212173,6.036212173,6.036212173,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,920.0,920.0,920.0,920.0,6.036212172654444,6.036212172654444,6.036212172654444,6.036212172654444,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2738324,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,N#Cc1cccc(/N=C/c2ccccc2O)c1,C14H10N2O,CHEMBL5093873,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2738854,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc4ccccc4c3)cc2o1,C21H13F3O3,CHEMBL5094403,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2738914,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,Cn1cc(C(=O)Nc2ccc3c(C(F)(F)F)cc(=O)oc3c2)c(Br)n1,C15H9BrF3N3O3,CHEMBL5094463,50000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50000.0,50000.0,50000.0,50000.0,4.698970004,4.698970004,4.698970004,4.301029996,4.301029996,4.301029996,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,50000.0,50000.0,50000.0,50000.0,4.301029995663981,4.301029995663981,4.301029995663981,4.301029995663981,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2738979,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,O=c1cc(C(F)(F)F)c2ccc(OCc3ccc4c(c3)OCO4)cc2o1,C18H11F3O5,CHEMBL5094528,9370.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9370.0,9370.0,9370.0,9370.0,3.971739591,3.971739591,3.971739591,5.028260409,5.028260409,5.028260409,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9370.0,9370.0,9370.0,9370.0,5.028260409112222,5.028260409112222,5.028260409112222,5.028260409112222,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2739070,nM,IC50,,BAO_0000190,IC50,2172740,Inhibition of AR transcriptional activity in human LNCaP cells harboring ARR2PB-eGFP incubated for 72 hrs by fluorescence assay,0,B,,CHEMBL5057874,10.1021/acs.jmedchem.1c01287,34809430,CHEMBL5055679,Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.,PUBLICATION,"Androgen receptor (AR) has proved to be a vital drug target for treating prostate cancer. Here, we reported the discovery of a novel AR antagonist <b>92</b> targeting the AR ligand-binding pocket, but distinct from the marketed drug enzalutamide (Enz), <b>92</b> demonstrated inhibition on the AR ligand-binding domain (LBD) dimerization, which is a novel mechanism reported for the first time. First, a novel hit (<b>26</b>, IC<sub>50</sub> = 5.57 M) was identified through virtual screening based on a theoretical AR LBD dimer bound with the Enz model. Then, guided by molecular modeling, <b>92</b> was discovered with 32.7-fold improved AR antagonistic activity (IC<sub>50</sub> = 0.17 M). Besides showing high bioactivity and safety, <b>92</b> can inhibit AR nuclear translocation. Furthermore, <b>92</b> inhibited the formation of the AR LBD dimer, possibly through attenuating the hydrogen-bonding network between the two monomers. This interesting finding would pave the way for the discovery of a new class of AR antagonists.",,COc1ccc(COc2ccc3c(C(F)(F)F)cc(=O)oc3c2)cc1,C18H13F3O4,CHEMBL5094619,1620.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1620.0,1620.0,1620.0,1620.0,3.209515015,3.209515015,3.209515015,5.790484985,5.790484985,5.790484985,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1620.0,1620.0,1620.0,1620.0,5.790484985457369,5.790484985457369,5.790484985457369,5.790484985457369,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2740585,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(NC(=O)c2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C19H10F3N5O,CHEMBL5169354,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2740801,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCCC(=O)NO,C18H19F3N4O3S,CHEMBL5169570,1170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1170.0,1170.0,1170.0,1170.0,3.068185862,3.068185862,3.068185862,5.931814138,5.931814138,5.931814138,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1170.0,1170.0,1170.0,1170.0,5.931814138253839,5.931814138253839,5.931814138253839,5.931814138253839,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2740862,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2ccccc2N)nc1,C25H19F3N6O2S,CHEMBL5169631,750.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,750.0,750.0,750.0,750.0,2.875061263,2.875061263,2.875061263,6.124938737,6.124938737,6.124938737,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,750.0,750.0,750.0,750.0,6.1249387366083,6.1249387366083,6.1249387366083,6.1249387366083,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2741144,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CCCNC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C21H16F4N4O,CHEMBL5169913,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2741319,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cn1,C31H23F3N6O2S,CHEMBL5170088,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2741516,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNS(=O)(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C18H12F4N4O2S,CHEMBL5170285,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2742027,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1C12CC(CC(=O)Nc3ccccc3N)(C1)C2,C26H24F3N5O2S,CHEMBL5170796,190.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,190.0,190.0,190.0,190.0,2.278753601,2.278753601,2.278753601,6.721246399,6.721246399,6.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,190.0,190.0,190.0,190.0,6.721246399047171,6.721246399047171,6.721246399047171,6.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2743118,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(C(=O)Nc3ccc(F)nc3)n2)cc1C(F)(F)F,C17H9F4N5O,CHEMBL5171887,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2743142,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(C(=O)Nc3ccc(F)cn3)n2)cc1C(F)(F)F,C17H9F4N5O,CHEMBL5171911,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2744049,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,Cc1cn(-c2ccc(C#N)c(C(F)(F)F)c2)nc1CNC(=O)c1ccc(C#N)cc1,C21H14F3N5O,CHEMBL5172818,14900.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,14900.0,14900.0,14900.0,14900.0,4.173186268,4.173186268,4.173186268,4.826813732,4.826813732,4.826813732,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,14900.0,14900.0,14900.0,14900.0,4.826813731587726,4.826813731587726,4.826813731587726,4.826813731587726,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2744175,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(C(=O)Nc3ccncc3)n2)cc1C(F)(F)F,C17H10F3N5O,CHEMBL5172944,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2744233,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)nc1,C31H23F3N6O2S,CHEMBL5173002,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2744595,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](NC(=O)c3ccnnc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,C31H35N5O,CHEMBL5173364,1348.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1348.0,1348.0,1348.0,1348.0,3.129689892,3.129689892,3.129689892,5.870310108,5.870310108,5.870310108,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1348.0,1348.0,1348.0,1348.0,5.870310107800699,5.870310107800699,5.870310107800699,5.870310107800699,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2745172,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCCCCC(=O)NO,C20H23F3N4O3S,CHEMBL5173941,390.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,390.0,390.0,390.0,390.0,2.591064607,2.591064607,2.591064607,6.408935393,6.408935393,6.408935393,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,390.0,390.0,390.0,390.0,6.4089353929735005,6.4089353929735005,6.4089353929735005,6.4089353929735005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2745385,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)cn3)n2)cc1Cl,C17H11ClFN5O,CHEMBL5174154,170.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,170.0,170.0,170.0,170.0,2.230448921,2.230448921,2.230448921,6.769551079,6.769551079,6.769551079,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,170.0,170.0,170.0,170.0,6.769551078621726,6.769551078621726,6.769551078621726,6.769551078621726,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2745946,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,Cc1cncc(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6ccnnc6)CC[C@]5(C)[C@H]4CC[C@]23C)c1,C30H36N4O,CHEMBL5174715,1641.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1641.0,1641.0,1641.0,1641.0,3.215108581,3.215108581,3.215108581,5.784891419,5.784891419,5.784891419,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1641.0,1641.0,1641.0,1641.0,5.7848914189469065,5.7848914189469065,5.7848914189469065,5.7848914189469065,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2746308,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc([N+](=O)[O-])cc3)n2)cc1C(F)(F)F,C19H12F3N5O3,CHEMBL5175077,80.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,80.0,80.0,80.0,80.0,1.903089987,1.903089987,1.903089987,7.096910013,7.096910013,7.096910013,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,80.0,80.0,80.0,80.0,7.096910013008056,7.096910013008056,7.096910013008056,7.096910013008056,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2746460,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,CNC(=O)c1ccc(C(=O)NCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1F,C21H15F4N5O2,CHEMBL5175229,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2746463,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(NC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C18H10F4N4O,CHEMBL5175232,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2747241,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1Cc1ccc(C(=O)Nc2ccccc2N)cc1,C27H22F3N5O2S,CHEMBL5176010,280.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,280.0,280.0,280.0,280.0,2.447158031,2.447158031,2.447158031,6.552841969,6.552841969,6.552841969,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,280.0,280.0,280.0,280.0,6.552841968657781,6.552841968657781,6.552841968657781,6.552841968657781,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2747766,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CCNC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C20H14F4N4O,CHEMBL5176535,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2748310,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 2194588, Entry 1: 2194597, Entry 2: 2194598, Entry 3: 2194599, Entry 4: 2194600, ","Entry 0: Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay, Entry 1: Antagonist activity at androgen receptor F877L mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 2: Antagonist activity at androgen receptor F877L/T877A dual mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 3: Antagonist activity at androgen receptor F877L mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, Entry 4: Antagonist activity at androgen receptor F876L/T877A mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, ","0,3","Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, ",,"Entry 0: CHEMBL5106948, Entry 1: CHEMBL5106957, Entry 2: CHEMBL5106958, Entry 3: CHEMBL5106959, Entry 4: CHEMBL5106960, ","Entry 0: 10.1021/acs.jmedchem.2c00912, Entry 1: 10.1021/acs.jmedchem.2c00912, Entry 2: 10.1021/acs.jmedchem.2c00912, Entry 3: 10.1021/acs.jmedchem.2c00912, Entry 4: 10.1021/acs.jmedchem.2c00912, ","Entry 0: 36154033, Entry 1: 36154033, Entry 2: 36154033, Entry 3: 36154033, Entry 4: 36154033, ","Entry 0: CHEMBL5104187, Entry 1: CHEMBL5104187, Entry 2: CHEMBL5104187, Entry 3: CHEMBL5104187, Entry 4: CHEMBL5104187, ","Entry 0: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 1: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 2: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 3: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 4: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 1: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 2: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 3: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 4: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., ",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)cc3)n2)cc1C(F)(F)F,C19H12F4N4O,CHEMBL5177079,120.0,250.0,250.0,910.0,910.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,347.8160433,120.0,488.0,250.0,910.0,2.688419822,2.397940009,2.079181246,6.311580178,6.602059991,6.920818754,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,515.0,515.0,120.0,910.0,6.288192770958809,6.288192770958809,6.920818753952375,6.040958607678906,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2750215,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, ",IC50,"Entry 0: 2207001, Entry 1: 2207015, Entry 2: 2207016, ","Entry 0: Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay, Entry 1: Antagonist activity at androgen receptor T877A mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay, Entry 2: Antagonist activity at androgen receptor F876L mutant (unknown origin) expressed in HEK293 cells incubated for 24 hrs by luciferase reporter assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, ",,"Entry 0: CHEMBL5119709, Entry 1: CHEMBL5119723, Entry 2: CHEMBL5119724, ","Entry 0: 10.1021/acs.jmedchem.2c01164, Entry 1: 10.1021/acs.jmedchem.2c01164, Entry 2: 10.1021/acs.jmedchem.2c01164, ","Entry 0: 36070471, Entry 1: 36070471, Entry 2: 36070471, ","Entry 0: CHEMBL5113526, Entry 1: CHEMBL5113526, Entry 2: CHEMBL5113526, ","Entry 0: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer., Entry 1: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer., Entry 2: Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, ","Entry 0: Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients., Entry 1: Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients., Entry 2: Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients., ",,Cc1cn(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6ccncc6)CC[C@]5(C)[C@H]4CC[C@]23C)cn1,C29H36N4O,CHEMBL5178984,208.8,246.6,268.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,24.54872705,208.8,241.2,246.6,268.2,2.382377303,2.391993072,2.319730494,6.617622697,6.608006928,6.680269506,3,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,208.8,208.8,208.8,208.8,6.680269505669775,6.680269505669775,6.680269505669775,6.680269505669775,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2750404,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)nc1,C29H21F3N6O2S2,CHEMBL5179173,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2751704,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(C(=O)NCCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C21H14F3N5O,CHEMBL5180473,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2751811,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2ccccc2N)cc1,C26H20F3N5O2S,CHEMBL5180580,980.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,980.0,980.0,980.0,980.0,2.991226076,2.991226076,2.991226076,6.008773924,6.008773924,6.008773924,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,980.0,980.0,980.0,980.0,6.008773924307505,6.008773924307505,6.008773924307505,6.008773924307505,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2752231,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](NC(=O)c3ccnnc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3ccnc3)=CC[C@@H]12,C27H33N5O,CHEMBL5181000,980.8,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,980.8,980.8,980.8,980.8,2.991580457,2.991580457,2.991580457,6.008419543,6.008419543,6.008419543,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,980.8,980.8,980.8,980.8,6.00841954282566,6.00841954282566,6.00841954282566,6.00841954282566,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2753598,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C19H12F4N4O,CHEMBL5182367,760.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,760.0,760.0,760.0,760.0,2.880813592,2.880813592,2.880813592,6.119186408,6.119186408,6.119186408,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,760.0,760.0,760.0,760.0,6.119186407719209,6.119186407719209,6.119186407719209,6.119186407719209,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2755121,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,Cc1cn(-c2ccc(C#N)c(C(F)(F)F)c2)nc1CNC(=O)c1ccc(F)cc1,C20H14F4N4O,CHEMBL5183890,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2756312,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(NC(=O)Nc3ccc(F)cc3)n2)cc1C(F)(F)F,C18H11F4N5O,CHEMBL5185081,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2756339,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,O=C(Cc1ccn(-c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)n1)Nc1ccc(F)nc1,C17H11F4N5O3,CHEMBL5185108,360.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,360.0,360.0,360.0,360.0,2.556302501,2.556302501,2.556302501,6.443697499,6.443697499,6.443697499,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,360.0,360.0,360.0,360.0,6.443697499232713,6.443697499232713,6.443697499232713,6.443697499232713,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2756627,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,O=C(Cc1ccn(-c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)n1)Nc1ccc(F)cc1,C18H12F4N4O3,CHEMBL5185396,340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,340.0,340.0,340.0,340.0,2.531478917,2.531478917,2.531478917,6.468521083,6.468521083,6.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,340.0,340.0,6.468521082957745,6.468521082957745,6.468521082957745,6.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2756973,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](NC(=O)c3ccncc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3cnc4ccccc43)=CC[C@@H]12,C32H36N4O,CHEMBL5185742,1551.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1551.0,1551.0,1551.0,1551.0,3.190611798,3.190611798,3.190611798,5.809388202,5.809388202,5.809388202,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1551.0,1551.0,1551.0,1551.0,5.809388202186395,5.809388202186395,5.809388202186395,5.809388202186395,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2757444,nM,IC50,,BAO_0000190,IC50,2227423,Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay,0,B,,CHEMBL5140936,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,C[C@@]12O[C@@](C)(C[C@H]1O)[C@@H]1C(=O)N(c3ccc(C#N)c(I)c3)C(=O)[C@@H]12,C17H15IN2O4,CHEMBL5186213,19.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,19.0,19.0,19.0,19.0,1.278753601,1.278753601,1.278753601,7.721246399,7.721246399,7.721246399,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,19.0,19.0,19.0,19.0,7.721246399047171,7.721246399047171,7.721246399047171,7.721246399047171,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2757448,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,Cc1cn(-c2ccc(C#N)c(C(F)(F)F)c2)nc1CNC(=O)c1ccc([N+](=O)[O-])cc1,C20H14F3N5O3,CHEMBL5186217,450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,450.0,450.0,450.0,450.0,2.653212514,2.653212514,2.653212514,6.346787486,6.346787486,6.346787486,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,450.0,450.0,450.0,450.0,6.346787486224656,6.346787486224656,6.346787486224656,6.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2757587,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2227423, Entry 1: 2227424, ","Entry 0: Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay, Entry 1: Antagonist activity at Androgen receptor in human LNCaP cells measured by SEAP reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL5140936, Entry 1: CHEMBL5140937, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CCCCc1ccc(OC(=O)N2C[C@@H]3C[C@H]2[C@@H]2C(=O)N(c4ccc([N+](=O)[O-])c5ccccc45)C(=O)N32)cc1,C28H26N4O6,CHEMBL5186356,60.0,4750.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,2345.0,60.0,2405.0,2405.0,4750.0,3.381115081,3.381115081,1.77815125,5.618884919,5.618884919,7.22184875,2,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2405.0,2405.0,60.0,4750.0,5.618884919290149,5.618884919290149,7.221848749616356,5.323306390375134,INACTIVE,INACTIVE,ACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2757631,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,CC(C)(O)c1ccc(C(=O)NCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C22H19F3N4O2,CHEMBL5186400,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2757811,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)cn3)n2)cc1C(F)(F)F,C18H11F4N5O,CHEMBL5186580,340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,340.0,340.0,340.0,340.0,2.531478917,2.531478917,2.531478917,6.468521083,6.468521083,6.468521083,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,340.0,340.0,340.0,340.0,6.468521082957745,6.468521082957745,6.468521082957745,6.468521082957745,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2758259,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,Cc1ccc(NC(=O)Cc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C20H15F3N4O,CHEMBL5187028,4530.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,4530.0,4530.0,4530.0,4530.0,3.656098202,3.656098202,3.656098202,5.343901798,5.343901798,5.343901798,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,4530.0,4530.0,4530.0,4530.0,5.343901797987169,5.343901797987169,5.343901797987169,5.343901797987169,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2760109,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)c(F)c3)n2)cc1C(F)(F)F,C19H11F5N4O,CHEMBL5188878,210.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,210.0,210.0,210.0,210.0,2.322219295,2.322219295,2.322219295,6.677780705,6.677780705,6.677780705,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,210.0,210.0,210.0,210.0,6.6777807052660805,6.6777807052660805,6.6777807052660805,6.6777807052660805,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2761220,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2227423, Entry 1: 2227424, ","Entry 0: Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay, Entry 1: Antagonist activity at Androgen receptor in human LNCaP cells measured by SEAP reporter gene assay, ","0,1","Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL5140936, Entry 1: CHEMBL5140937, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC(C)N1C[C@@]2(C)O[C@](C)(C1)[C@H]1C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]12,C21H22F3N3O3,CHEMBL5189989,32.0,125.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,46.5,32.0,78.5,78.5,125.0,1.894869657,1.894869657,1.505149978,7.105130343,7.105130343,7.494850022,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,78.5,78.5,32.0,125.0,7.105130343254747,7.105130343254747,7.494850021680094,6.903089986991944,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2762425,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(C(=O)NCCCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C22H16F3N5O,CHEMBL5191194,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2763342,nM,IC50,,BAO_0000190,IC50,2227480,Antagonist activity at Androgen receptor in human LNCaP cells assessed as inhibition of Binding Function 3 (BF3) of AR measured by enhanced green fluorescent protein transcriptional (eGFPT) assay,0,B,,CHEMBL5140993,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,CC(C)C(NC(=O)c1cc2ccc(F)cc2[nH]1)c1ccco1,C17H17FN2O2,CHEMBL5192111,430.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,430.0,430.0,430.0,430.0,2.633468456,2.633468456,2.633468456,6.366531544,6.366531544,6.366531544,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,430.0,430.0,430.0,430.0,6.366531544420414,6.366531544420414,6.366531544420414,6.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2763643,nM,IC50,,BAO_0000190,IC50,2227415,Partial agonist activity at human Androgen receptor,0,B,,CHEMBL5140928,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,C[C@@]1(c2ccc(O)cc2)NC(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C1=O,C18H12F3N3O3,CHEMBL5192412,0.9,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,0.9,0.9,0.9,0.9,-0.045757491,-0.045757491,-0.045757491,9.045757491,9.045757491,9.045757491,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,0.9,0.9,0.9,0.9,9.045757490560675,9.045757490560675,9.045757490560675,9.045757490560675,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2764021,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2cc(-c3ccccc3)c(CNC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C25H16F4N4O,CHEMBL5192790,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2764146,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 2227432, Entry 1: 2227433, Entry 2: 2227434, Entry 3: 2227435, ","Entry 0: Binding affinity to wild-type Androgen receptor (unknown origin), Entry 1: Binding affinity to bicalutamide-resistant Androgen receptor T877A mutant (unknown origin), Entry 2: Antagonist activity at wild-type Androgen receptor (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, Entry 3: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL5140945, Entry 1: CHEMBL5140946, Entry 2: CHEMBL5140947, Entry 3: CHEMBL5140948, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1nn(-c2ccc(C#N)c(Cl)c2)c(C)c1Oc1ccc(C(=O)NC(C)(C)C)cn1,C22H22ClN5O2,CHEMBL5192915,190.0,340.0,430.0,1000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,306.6757245,190.0,490.0,385.0,1000.0,2.69019608,2.58546073,2.278753601,6.30980392,6.41453927,6.721246399,4,ACTIVE,ACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,430.0,430.0,430.0,430.0,6.366531544420414,6.366531544420414,6.366531544420414,6.366531544420414,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2764308,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(C(=O)Nc3ccc(F)cc3)n2)cc1C(F)(F)F,C18H10F4N4O,CHEMBL5193077,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2764362,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2cc(-c3cccs3)ccc2N)cn1,C29H21F3N6O2S2,CHEMBL5193131,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2764640,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1cc(NC(=O)Cc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)ccc1F,C20H11F4N5O,CHEMBL5193409,6340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,6340.0,6340.0,6340.0,6340.0,3.802089258,3.802089258,3.802089258,5.197910742,5.197910742,5.197910742,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,6340.0,6340.0,6340.0,6340.0,5.1979107421182675,5.1979107421182675,5.1979107421182675,5.1979107421182675,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2765329,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2cc(C(F)(F)F)c(CNC(=O)c3ccc(F)cc3)n2)cc1C(F)(F)F,C20H11F7N4O,CHEMBL5194098,16240.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,16240.0,16240.0,16240.0,16240.0,4.210586025,4.210586025,4.210586025,4.789413975,4.789413975,4.789413975,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,16240.0,16240.0,16240.0,16240.0,4.789413975094844,4.789413975094844,4.789413975094844,4.789413975094844,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2765513,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCCCC(=O)NO,C19H21F3N4O3S,CHEMBL5194282,1450.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1450.0,1450.0,1450.0,1450.0,3.161368002,3.161368002,3.161368002,5.838631998,5.838631998,5.838631998,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1450.0,1450.0,1450.0,1450.0,5.838631997765025,5.838631997765025,5.838631997765025,5.838631997765025,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2765696,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CCNC(=O)c3ccc([N+](=O)[O-])cc3)n2)cc1C(F)(F)F,C20H14F3N5O3,CHEMBL5194465,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2765770,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc(F)nc3)n2)cc1C(F)(F)F,C18H11F4N5O,CHEMBL5194539,780.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,780.0,780.0,780.0,780.0,2.892094603,2.892094603,2.892094603,6.107905397,6.107905397,6.107905397,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,780.0,780.0,780.0,780.0,6.107905397309519,6.107905397309519,6.107905397309519,6.107905397309519,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2765995,nM,IC50,,BAO_0000190,IC50,2227423,Antagonist activity at Androgen receptor in human MDA-MB-453 cells measured by SEAP reporter gene assay,0,B,,CHEMBL5140936,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,CNC(=O)[C@]12C(=O)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)[C@H]1[C@H]1C[C@H](F)[C@@H]2C1,C19H15F4N3O3,CHEMBL5194764,91.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,91.0,91.0,91.0,91.0,1.959041392,1.959041392,1.959041392,7.040958608,7.040958608,7.040958608,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,91.0,91.0,91.0,91.0,7.040958607678906,7.040958607678906,7.040958607678906,7.040958607678906,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2766016,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc(Cl)cc3)n2)cc1C(F)(F)F,C19H12ClF3N4O,CHEMBL5194785,1150.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1150.0,1150.0,1150.0,1150.0,3.06069784,3.06069784,3.06069784,5.93930216,5.93930216,5.93930216,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1150.0,1150.0,1150.0,1150.0,5.939302159646388,5.939302159646388,5.939302159646388,5.939302159646388,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2767103,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc([N+](=O)[O-])cc3)n2)cc1C(F)(F)F,C19H12F3N5O3,CHEMBL5195872,1850.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1850.0,1850.0,1850.0,1850.0,3.267171728,3.267171728,3.267171728,5.732828272,5.732828272,5.732828272,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1850.0,1850.0,1850.0,1850.0,5.732828271596986,5.732828271596986,5.732828271596986,5.732828271596986,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2767537,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(C(=O)NCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C20H12F3N5O,CHEMBL5196306,300.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,300.0,300.0,300.0,300.0,2.477121255,2.477121255,2.477121255,6.522878745,6.522878745,6.522878745,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,300.0,300.0,300.0,300.0,6.522878745280337,6.522878745280337,6.522878745280337,6.522878745280337,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2768328,nM,IC50,,BAO_0000190,pIC50,2227440,Antagonist activity at Androgen receptor (unknown origin) in African green monkey COS-1 cells,0,B,,CHEMBL5140953,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,N#Cc1ccc(C2=NO[C@H]3CCCC[C@@H]23)cc1C(F)(F)F,C15H13F3N2O,CHEMBL5197097,27.54,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,27.54,27.54,27.54,27.54,1.439963936,1.439963936,1.439963936,7.560036064,7.560036064,7.560036064,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,27.54,27.54,27.54,27.54,7.560036064079095,7.560036064079095,7.560036064079095,7.560036064079095,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2768515,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,COc1ccc(NC(=O)Cc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C20H15F3N4O2,CHEMBL5197284,9200.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9200.0,9200.0,9200.0,9200.0,3.963787827,3.963787827,3.963787827,5.036212173,5.036212173,5.036212173,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9200.0,9200.0,9200.0,9200.0,5.036212172654444,5.036212172654444,5.036212172654444,5.036212172654444,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2768955,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,Cc1cn(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6cccnc6)CC[C@]5(C)[C@H]4CC[C@]23C)cn1,C29H36N4O,CHEMBL5197724,1285.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,1285.0,1285.0,1285.0,1285.0,3.108903128,3.108903128,3.108903128,5.891096872,5.891096872,5.891096872,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,1285.0,1285.0,1285.0,1285.0,5.891096872332687,5.891096872332687,5.891096872332687,5.891096872332687,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2769835,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)Nc3ccc(F)cc3)n2)cc1C(F)(F)F,C19H13F4N5O,CHEMBL5198604,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2770356,nM,IC50,,BAO_0000190,IC50,2227415,Partial agonist activity at human Androgen receptor,0,B,,CHEMBL5140928,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,N#Cc1ccc(N2C(=O)N[C@@](CO)(c3ccccc3)C2=O)cc1C(F)(F)F,C18H12F3N3O3,CHEMBL5199125,13.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,13.0,13.0,13.0,13.0,1.113943352,1.113943352,1.113943352,7.886056648,7.886056648,7.886056648,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,13.0,13.0,13.0,13.0,7.886056647693163,7.886056647693163,7.886056647693163,7.886056647693163,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2771523,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](NC(=O)c3ccnnc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3ccnn3)=CC[C@@H]12,C26H32N6O,CHEMBL5200292,9145.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,9145.0,9145.0,9145.0,9145.0,3.96118371,3.96118371,3.96118371,5.03881629,5.03881629,5.03881629,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,9145.0,9145.0,9145.0,9145.0,5.038816290187564,5.038816290187564,5.038816290187564,5.038816290187564,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2771538,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)cc3)n2)cc1Cl,C18H12ClFN4O,CHEMBL5200307,220.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,220.0,220.0,220.0,220.0,2.342422681,2.342422681,2.342422681,6.657577319,6.657577319,6.657577319,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,220.0,220.0,220.0,220.0,6.657577319177793,6.657577319177793,6.657577319177793,6.657577319177793,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2771754,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc(C(F)(F)F)cc3)n2)cc1C(F)(F)F,C20H12F6N4O,CHEMBL5200523,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2771928,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,Cc1cn(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6ccnnc6)CC[C@]5(C)[C@H]4CC[C@]23C)cn1,C28H35N5O,CHEMBL5200697,244.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,244.0,244.0,244.0,244.0,2.387389826,2.387389826,2.387389826,6.612610174,6.612610174,6.612610174,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,244.0,244.0,244.0,244.0,6.61261017366127,6.61261017366127,6.61261017366127,6.61261017366127,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2772332,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 2194588, Entry 1: 2194597, Entry 2: 2194598, Entry 3: 2194599, Entry 4: 2194600, ","Entry 0: Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay, Entry 1: Antagonist activity at androgen receptor F877L mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 2: Antagonist activity at androgen receptor F877L/T877A dual mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 3: Antagonist activity at androgen receptor F877L mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, Entry 4: Antagonist activity at androgen receptor F876L/T877A mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, ",,"Entry 0: CHEMBL5106948, Entry 1: CHEMBL5106957, Entry 2: CHEMBL5106958, Entry 3: CHEMBL5106959, Entry 4: CHEMBL5106960, ","Entry 0: 10.1021/acs.jmedchem.2c00912, Entry 1: 10.1021/acs.jmedchem.2c00912, Entry 2: 10.1021/acs.jmedchem.2c00912, Entry 3: 10.1021/acs.jmedchem.2c00912, Entry 4: 10.1021/acs.jmedchem.2c00912, ","Entry 0: 36154033, Entry 1: 36154033, Entry 2: 36154033, Entry 3: 36154033, Entry 4: 36154033, ","Entry 0: CHEMBL5104187, Entry 1: CHEMBL5104187, Entry 2: CHEMBL5104187, Entry 3: CHEMBL5104187, Entry 4: CHEMBL5104187, ","Entry 0: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 1: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 2: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 3: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 4: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 1: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 2: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 3: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 4: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., ",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)nc3)n2)cc1Cl,C17H11ClFN5O,CHEMBL5201101,69.0,170.0,270.0,270.0,460.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,129.6432027,69.0,247.8,270.0,460.0,2.394101302,2.431363764,1.838849091,6.605898698,6.568636236,7.161150909,5,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,69.0,69.0,69.0,69.0,7.161150909262744,7.161150909262744,7.161150909262744,7.161150909262744,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2772837,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, ",IC50,"Entry 0: 2227432, Entry 1: 2227433, Entry 2: 2227434, Entry 3: 2227435, ","Entry 0: Binding affinity to wild-type Androgen receptor (unknown origin), Entry 1: Binding affinity to bicalutamide-resistant Androgen receptor T877A mutant (unknown origin), Entry 2: Antagonist activity at wild-type Androgen receptor (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, Entry 3: Antagonist activity at Androgen receptor T877A mutant (unknown origin) expressed in African green monkey COS-7 cells measured as gene transcription level, ",2,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, ",,"Entry 0: CHEMBL5140945, Entry 1: CHEMBL5140946, Entry 2: CHEMBL5140947, Entry 3: CHEMBL5140948, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, Entry 2: 10.1021/acs.jmedchem.2c00716, Entry 3: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, Entry 2: 35786895, Entry 3: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, Entry 2: CHEMBL5137058, Entry 3: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., Entry 2: Therapeutic Strategies to Target the Androgen Receptor., Entry 3: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 2: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 3: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,Cc1c(C#N)c(-c2ccc(C#N)cc2)c(C)n1-c1cnc(Cl)c(CO)c1,C20H15ClN4O,CHEMBL5201606,25.0,37.0,100.0,110.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,37.40989174,25.0,68.0,68.5,110.0,1.832508913,1.835690571,1.397940009,7.167491087,7.164309429,7.602059991,4,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,100.0,100.0,100.0,100.0,7.0,7.0,7.0,7.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2772933,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,C[C@]12CC[C@H](NC(=O)c3ccncc3)CC1=CC[C@@H]1[C@@H]2CC[C@]2(C)C(n3ccnc3)=CC[C@@H]12,C28H34N4O,CHEMBL5201702,511.2,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,511.2,511.2,511.2,511.2,2.708590845,2.708590845,2.708590845,6.291409155,6.291409155,6.291409155,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,511.2,511.2,511.2,511.2,6.2914091548496565,6.2914091548496565,6.2914091548496565,6.2914091548496565,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2773162,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CNC(=O)c3ccc(F)cn3)n2)cc1C(F)(F)F,C18H11F4N5O,CHEMBL5201931,5820.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,5820.0,5820.0,5820.0,5820.0,3.764922985,3.764922985,3.764922985,5.235077015,5.235077015,5.235077015,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,5820.0,5820.0,5820.0,5820.0,5.235077015350112,5.235077015350112,5.235077015350112,5.235077015350112,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2773871,nM,IC50,,BAO_0000190,IC50,2214674,Inhibition of Androgen receptor (unknown origin),0,B,,CHEMBL5127806,10.1016/j.ejmech.2022.114119,35063736,CHEMBL5126525,Overview of the development of selective androgen receptor modulators (SARMs) as pharmacological treatment for osteoporosis (1998-2021).,PUBLICATION,"Osteoporosis is a common disease in which the risk of fracture increases due to decreased bone mass and qualitative skeletal changes. Selective androgen receptor modulators (SARMs) are agonists with tissue selectivity, which act as partial or weak androgen receptor (AR) agonists in androgenic tissues, but mainly as complete AR agonists in synthetic metabolic tissues. In the recent 20 years, many scaffolds of SARMs have been reported, among which several molecules are promising and are undergoing clinical trial evaluation. However, it is still a challenge to discover SARMs with high activity and reduced side effects. In this review, not only are structure of SARMs reported in the literatures systematically collected and classified but also the structure-activity relationships (SAR) are systematically summarized. Furthermore, the advances in SARMs as potential treatment for osteoporosis are also updated.",,CN1C(=O)C=C[C@]2(C)[C@H]3CC[C@]4(C)C(C(=O)Nc5ccccc5C(F)(F)F)CC[C@H]4[C@@H]3CC[C@@H]12,C27H33F3N2O2,CHEMBL5202640,38.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,38.0,38.0,38.0,38.0,1.579783597,1.579783597,1.579783597,7.420216403,7.420216403,7.420216403,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,38.0,38.0,38.0,38.0,7.42021640338319,7.42021640338319,7.42021640338319,7.42021640338319,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2774525,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, Entry 2: BAO_0000190, Entry 3: BAO_0000190, Entry 4: BAO_0000190, ",IC50,"Entry 0: 2194588, Entry 1: 2194597, Entry 2: 2194598, Entry 3: 2194599, Entry 4: 2194600, ","Entry 0: Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay, Entry 1: Antagonist activity at androgen receptor F877L mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 2: Antagonist activity at androgen receptor F877L/T877A dual mutant (unknown origin) expressed in PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by dual luciferase assay, Entry 3: Antagonist activity at androgen receptor F877L mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, Entry 4: Antagonist activity at androgen receptor F876L/T877A mutant in human PC-3 cells assessed as inhibition of transcriptional activity measured after 24 hrs by luminescence based microplate reader assay, ",0,"Entry 0: B, Entry 1: B, Entry 2: B, Entry 3: B, Entry 4: B, ",,"Entry 0: CHEMBL5106948, Entry 1: CHEMBL5106957, Entry 2: CHEMBL5106958, Entry 3: CHEMBL5106959, Entry 4: CHEMBL5106960, ","Entry 0: 10.1021/acs.jmedchem.2c00912, Entry 1: 10.1021/acs.jmedchem.2c00912, Entry 2: 10.1021/acs.jmedchem.2c00912, Entry 3: 10.1021/acs.jmedchem.2c00912, Entry 4: 10.1021/acs.jmedchem.2c00912, ","Entry 0: 36154033, Entry 1: 36154033, Entry 2: 36154033, Entry 3: 36154033, Entry 4: 36154033, ","Entry 0: CHEMBL5104187, Entry 1: CHEMBL5104187, Entry 2: CHEMBL5104187, Entry 3: CHEMBL5104187, Entry 4: CHEMBL5104187, ","Entry 0: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 1: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 2: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 3: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., Entry 4: Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, Entry 2: PUBLICATION, Entry 3: PUBLICATION, Entry 4: PUBLICATION, ","Entry 0: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 1: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 2: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 3: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., Entry 4: The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy., ",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccc(F)nc3)n2)cc1C(F)(F)F,C18H11F4N5O,CHEMBL5203294,140.0,1120.0,1120.0,1310.0,1310.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,438.3149553,140.0,1000.0,1120.0,1310.0,3.0,3.049218023,2.146128036,6.0,5.950781977,6.853871964,5,INACTIVE,INACTIVE,ACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,140.0,140.0,140.0,140.0,6.853871964321762,6.853871964321762,6.853871964321762,6.853871964321762,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2774866,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2cc(-c3ccccc3)ccc2N)cc1,C32H24F3N5O2S,CHEMBL5203635,10000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10000.0,10000.0,10000.0,10000.0,4.0,4.0,4.0,5.0,5.0,5.0,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,10000.0,10000.0,10000.0,10000.0,5.0,5.0,5.0,5.0,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2775345,nM,IC50,,BAO_0000190,IC50,2227418,Agonist activity at Androgen receptor in human 22Rv1 cells cotransfected with pARE-LUC measured by luciferase assay,0,B,,CHEMBL5140931,10.1021/acs.jmedchem.2c00716,35786895,CHEMBL5137058,Therapeutic Strategies to Target the Androgen Receptor.,PUBLICATION,"The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target.",,CCCN(CC(F)(F)F)c1cc(Br)c(C#N)s1,C10H10BrF3N2S,CHEMBL5204114,10.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,10.0,10.0,10.0,10.0,1.0,1.0,1.0,8.0,8.0,8.0,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,10.0,10.0,10.0,10.0,8.0,8.0,8.0,8.0,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2775408,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1CCCC(=O)NO,C17H17F3N4O3S,CHEMBL5204177,390.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,390.0,390.0,390.0,390.0,2.591064607,2.591064607,2.591064607,6.408935393,6.408935393,6.408935393,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,390.0,390.0,390.0,390.0,6.4089353929735005,6.4089353929735005,6.4089353929735005,6.4089353929735005,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2776192,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CCCNC(=O)c3ccc([N+](=O)[O-])cc3)n2)cc1C(F)(F)F,C21H16F3N5O3,CHEMBL5204961,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2776344,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(-n2ccc(CC(=O)Nc3ccncc3)n2)cc1C(F)(F)F,C18H12F3N5O,CHEMBL5205113,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2777325,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,N#Cc1ccc(NC(=O)Cc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)cc1,C20H12F3N5O,CHEMBL5206094,50.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,50.0,50.0,50.0,50.0,1.698970004,1.698970004,1.698970004,7.301029996,7.301029996,7.301029996,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,50.0,50.0,50.0,50.0,7.301029995663981,7.301029995663981,7.301029995663981,7.301029995663981,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2777465,nM,IC50,,BAO_0000190,IC50,2230827,Anti-androgenic activity at androgen receptor (unknown origin) expressed in HEK293 cells by BRET assay,0,B,,CHEMBL5144599,10.1016/j.bmcl.2021.128441,34767912,CHEMBL5143530,Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat.,PUBLICATION,"The combination of androgen receptor antagonists with histone deacetylase inhibitors (HDACi) has been shown to be more effective than antiandrogens alone in halting growth of prostate cancer cell lines. Here we have designed, synthesized and assessed a series of antiandrogen/HDACi hybrids by combining structural features of enzalutamide with either SAHA or entinostat. The hybrids are demonstrated to maintain bifunctionality using a fluorometric HDAC assay and a bioluminescence resonance energy transfer (BRET) antiandrogen assay. Antiproliferative assays showed that hybrids bearing o-aminoanilide-based HDACi motifs outperformed hydroxamic acid based HDACi's. The hybrids demonstrated selectivity for epithelial cell lines vs. stromal cell lines, suggesting a potentially useful therapeutic window.",,CC1(C)C(=O)N(c2ccc(C#N)c(C(F)(F)F)c2)C(=S)N1c1ccc(C(=O)Nc2ccccc2N)cn1,C25H19F3N6O2S,CHEMBL5206234,2340.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2340.0,2340.0,2340.0,2340.0,3.369215857,3.369215857,3.369215857,5.630784143,5.630784143,5.630784143,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2340.0,2340.0,2340.0,2340.0,5.6307841425898575,5.6307841425898575,5.6307841425898575,5.6307841425898575,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2777867,nM,IC50,,BAO_0000190,IC50,2239506,Inhibition of full length human AR stably expressed in human HEK293 cells assessed as luciferase activity incubated for 24 hrs by microplate luminometer luciferase assay,0,B,,CHEMBL5153402,10.1039/d2md00206j,36439976,CHEMBL5150054,"Pyrazole-containing pharmaceuticals: target, pharmacological activity, and their SAR studies.",PUBLICATION,"Pyrazole is a five-membered heterocycle bearing two adjacent nitrogen atoms. Both pharmaceutical agents and natural products with pyrazole as a nucleus have exhibited a broad spectrum of biological activities. In the last few decades, more than 40 pyrazole-containing drugs have been approved by the FDA for the treatment of a broad range of clinical conditions including celecoxib (anti-inflammatory), CDPPB (antipsychotic), difenamizole (analgesic), <i>etc.</i> Owing to the unique physicochemical properties of the pyrazole core, pyrazole-containing drugs may exert better pharmacokinetics and pharmacological effects compared with drugs containing similar heterocyclic rings. The purpose of this paper is to provide an overview of all the existing drugs bearing a pyrazole nucleus that have been approved or in clinical trials, involving their pharmacological activities and SAR studies.",,CC(Cn1ccc(-c2ccc(C#N)c(Cl)c2)n1)NC(=O)c1cc(C(C)O)[nH]n1,C19H19ClN6O2,CHEMBL5206636,26.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,26.0,26.0,26.0,26.0,1.414973348,1.414973348,1.414973348,7.585026652,7.585026652,7.585026652,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,26.0,26.0,26.0,26.0,7.585026652029182,7.585026652029182,7.585026652029182,7.585026652029182,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2777869,nM,IC50,,BAO_0000190,IC50,2207001,Antagonist activity at DHT-induced Androgen receptor transcriptional activity in human HEK293 cells measured after 24 hrs by Steady-Glo reagent based assay,0,B,,CHEMBL5119709,10.1021/acs.jmedchem.2c01164,36070471,CHEMBL5113526,"Design, Synthesis, and Biological Evaluation of Androgen Receptor Degrading and Antagonizing Bifunctional Steroidal Analogs for the Treatment of Advanced Prostate Cancer.",PUBLICATION,"Metastatic castration-resistant prostate cancer (mCRPC) with high mortality has seriously threatened men's health. Bifunctional agents simultaneously degrade and antagonize androgen receptor (AR), display robust AR signaling pathway blockade, and show the therapeutic prospect for mCRPC. Herein, systemic structural modifications on the C-3, C-6, and C-17 positions of galeterone led to the discovery of <b>67-b</b> with the dual functions of AR antagonism and degradation. <i>In vitro</i>, <b>67-b</b> exhibited excellent antiproliferative activity and potent AR degradation activity in different PCa cells (LNCaP and 22RV1), as well as outstanding antagonistic activity against wild-type and mutant (W741L, T877A, and F876L) ARs. <i>In vivo</i>, <b>67-b</b> effectively inhibited the growth of hormone-sensitive organs in the Hershberger assay and exhibited tumor regression in the enzalutamide-resistant (c4-2b-ENZ) xenograft model. These results confirmed <b>67-b</b> to be a promising AR degrader and antagonist for the treatment of mCRPC patients.",,COc1cncc(C2=CC[C@H]3[C@@H]4CC=C5C[C@@H](NC(=O)c6ccnnc6)CC[C@]5(C)[C@H]4CC[C@]23C)c1,C30H36N4O2,CHEMBL5206638,914.5,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,914.5,914.5,914.5,914.5,2.96118371,2.96118371,2.96118371,6.03881629,6.03881629,6.03881629,1,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,914.5,914.5,914.5,914.5,6.038816290187564,6.038816290187564,6.038816290187564,6.038816290187564,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2779438,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,CC(O)c1cc(C(=O)NCc2ccn(-c3ccc(C#N)c(C(F)(F)F)c3)n2)n[nH]1,C18H15F3N6O2,CHEMBL5208207,25000.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,25000.0,25000.0,25000.0,25000.0,4.397940009,4.397940009,4.397940009,4.602059991,4.602059991,4.602059991,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,25000.0,25000.0,25000.0,25000.0,4.6020599913279625,4.6020599913279625,4.6020599913279625,4.6020599913279625,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,IC50
2779456,nM,IC50,,BAO_0000190,IC50,2194588,Antagonist activity at androgen receptor (unknown origin) in human LNCap-ARR2PB-eGFP cells by measuring fluorescence intensity measured after 3 days by transcriptional assay,0,B,,CHEMBL5106948,10.1021/acs.jmedchem.2c00912,36154033,CHEMBL5104187,"Discovery of 2-(1-(3-Chloro-4-cyanophenyl)-1<i>H</i>-pyrazol-3-yl)acetamides as Potent, Selective, and Orally Available Antagonists Targeting the Androgen Receptor.",PUBLICATION,"The androgen receptor (AR) antagonists are efficient therapeutics for the treatment of prostate cancer (PCa). All the approved AR antagonists to date are targeted to the ligand-binding pocket (LBP) of AR and have suffered from various drug resistances, whereas AR antagonist targeting non-LBP site of AR is conceived as a promising strategy. Through the scaffold hopping of AR LBP antagonists, the 2-chloro-4-(1<i>H</i>-pyrazol-1-yl)benzonitrile was designed as a new core structure for AR antagonists. A total of 46 compounds were synthesized and biologically evaluated to disclose compounds <b>2f</b>, <b>2k</b>, and <b>4c</b>, exhibiting potent AR antagonistic activities (IC<sub>50</sub> up to 69 nM), force against antiandrogen resistance, and untraditional targeting site of probably AR binding function 3. Therein, <b>4c</b> exhibited effective tumor growth inhibition in LNCaP xenograft study upon oral administration. This work provides a novel chemical scaffold for AR antagonists and offers new perspective for the development of PCa therapy.",,O=C(Cc1ccn(-c2ccc([N+](=O)[O-])c(C(F)(F)F)c2)n1)Nc1ccc(F)cn1,C17H11F4N5O3,CHEMBL5208225,2570.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,0.0,2570.0,2570.0,2570.0,2570.0,3.409933123,3.409933123,3.409933123,5.590066877,5.590066877,5.590066877,1,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,2570.0,2570.0,2570.0,2570.0,5.590066876668706,5.590066876668706,5.590066876668706,5.590066876668706,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,INACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
2779535,nM,IC50,,"Entry 0: BAO_0000190, Entry 1: BAO_0000190, ",IC50,"Entry 0: 2227383, Entry 1: 2227458, ","Entry 0: Binding affinity to human Androgen receptor, Entry 1: Antagonist activity at Androgen receptor in human MDA-kb2 cells, ",1,"Entry 0: B, Entry 1: B, ",,"Entry 0: CHEMBL5140896, Entry 1: CHEMBL5140971, ","Entry 0: 10.1021/acs.jmedchem.2c00716, Entry 1: 10.1021/acs.jmedchem.2c00716, ","Entry 0: 35786895, Entry 1: 35786895, ","Entry 0: CHEMBL5137058, Entry 1: CHEMBL5137058, ","Entry 0: Therapeutic Strategies to Target the Androgen Receptor., Entry 1: Therapeutic Strategies to Target the Androgen Receptor., ","Entry 0: PUBLICATION, Entry 1: PUBLICATION, ","Entry 0: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., Entry 1: The androgen receptor (AR) plays a key role in the maintenance of muscle and bone and the support of male sexual-related functions, as well as in the progression of prostate cancer. Accordingly, AR-targeted therapies have been developed for the treatment of related human diseases and conditions. AR agonists are an important class of drugs in the treatment of bone loss and muscle atrophy. AR antagonists have also been developed for the treatment of prostate cancer, including metastatic castration-resistant prostate cancer (mCRPC). Additionally, selective AR degraders (SARDs) have been reported. More recently, heterobifunctional degrader molecules of AR have been developed, and four such compounds are now in clinical development for the treatment of human prostate cancer. This review attempts to summarize the different types of compounds designed to target AR and the current frontiers of research on this important therapeutic target., ",,CC(c1ccccc1)N(C)c1ccc(C#N)c(C(F)(F)F)n1,C16H14F3N3,CHEMBL5208304,20.0,45.0,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,12.5,20.0,32.5,32.5,45.0,1.511883361,1.511883361,1.301029996,7.488116639,7.488116639,7.698970004,2,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,45.0,45.0,45.0,45.0,7.346787486224656,7.346787486224656,7.346787486224656,7.346787486224656,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,ACTIVE,IC50
